

Contemporary Endocrinology
Series Editor: Leonid Poretsky

Stephen J. Winters
Ilpo T. Huhtaniemi *Editors*

Male Hypogonadism

Basic, Clinical and Therapeutic Principles

Second Edition

 Humana Press

Contemporary Endocrinology

Series Editor

Leonid Poretsky
Division of Endocrinology
Lenox Hill Hospital,
New York, New York, USA

More information about this series at <http://www.springer.com/series/7680>

Stephen J. Winters MD
Ilpo T. Huhtaniemi MD, PhD
Editors

Male Hypogonadism

Basic, Clinical and Therapeutic
Principles

Second Edition

 Humana Press

Editors

Stephen J. Winters, MD
Department of Medicine, Division of
Endocrinology, Metabolism and Diabetes
University of Louisville
Louisville, KY, USA

Ilpo T. Huhtaniemi, MD, PhD
Institute of Reproductive
and Developmental Biology,
Department of Surgery and Cancer
Imperial College London
London, UK

Contemporary Endocrinology

ISBN 978-3-319-53296-7

ISBN 978-3-319-53298-1 (eBook)

DOI 10.1007/978-3-319-53298-1

Library of Congress Control Number: 2017931052

1st edition: © Springer Science+Business Media New York 2004

2nd edition: © Springer International Publishing AG 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by Springer Nature

The registered company is Springer International Publishing AG

The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Series Editor Foreword

Controversies regarding the treatment of male hypogonadism using testosterone recently attracted much public attention. Indeed, comprehensive knowledge of male hypogonadism still leaves a lot to be desired, even among health professionals. The current volume of the Contemporary Endocrinology book series goes a long way to help correct this knowledge deficit by addressing the subject in a truly comprehensive way.

The international group of experts assembled by Drs. Winters and Huh-taniemi examines the problem from fetal life to puberty to advanced age, from brain dysfunction to dysfunction of the testis itself, and from the genetic influences to those of the environment. Fertility issues are addressed, as well as the relevant aspects of obesity, cancer, and the metabolic syndrome.

The chapters are written to stand on their own as complete reviews of a particular topic and are assembled logically to produce a comprehensive picture of the entire subject. As intended by the editors and the authors, this volume is appropriate for a wide audience of readers—from medical students to advanced investigators in the areas of male hypogonadism.

The editors and the authors are to be congratulated on their accomplishment, which will benefit both current and future generations of physicians dealing with this increasingly important problem.

New York, NY, USA

Leonid Poretsky, MD

Preface to the Second Edition

The first edition of *Male Hypogonadism: Basic, Clinical and Therapeutic Principles* was published in 2004. Since then, our understanding of the biology and clinical management of hypogonadal men has increased substantially. Much has been learned about the cellular and molecular biology of male reproduction and about testosterone treatment from carefully performed clinical studies.

This second edition builds on the first, but has changed with some new chapters and new authors, and it is now co-edited by Stephen J. Winters and Ilpo T. Huhtaniemi. The monograph is again intended for the wide audience of scientists and clinicians who are interested in the reproductive endocrinology of males and the disorders that cause its dysfunction. Accordingly, the goal of this monograph is to link the recent advances in our understanding of the biology of hypothalamic–pituitary–testicular function to improved care for our patients. The chapters were contributed by authors from around the world, and from various scientific and clinical disciplines, who have devoted their careers to the study of the biology and pathophysiology of the male.

The format of this monograph remains unchanged. Chapters 1–3 review the neuroendocrine control of testicular function, provide an overview of the steroidogenic function of Leydig cells from the fetus to adulthood, and summarize what is known about spermatogenesis and spermiogenesis. Chapters 4–12 discuss clinical disorders that cause gonadotropin deficiency and testicular failure. Chapters 13–17 summarize how exercise, the environment, obesity, and aging influence how the testis functions, and Chaps. 18–20 present current views of the benefits and risks of androgen replacement therapy and the approach to stimulating spermatogenesis in gonadotropin-deficient men. We have tried to minimize the overlap and differences of opinion, but perhaps some is beneficial.

We thank Springer Science for supporting the publication of the second edition of *Male Hypogonadism: Basic, Clinical and Therapeutic Principles*, and we thank the authors, some for a second time, who devoted a great deal of effort to prepare these informative and well-written chapters. We learned a great deal of modern medicine from reading these reviews and hope that our readers will do likewise.

Louisville, USA
London, UK

Stephen J. Winters, MD
Ilpo T. Huhtaniemi, MD, PhD

Contents

1	Neuroendocrine Control of Human Testicular Function	1
	Joseph P. Moore Jr. and Stephen J. Winters	
2	The Human Leydig Cell	25
	Peter J. O'Shaughnessy	
3	Human Spermatogenesis and Its Regulation	49
	Haiqi Chen, Dolores Mruk, Xiang Xiao and C. Yan Cheng	
4	Normal and Delayed Puberty	73
	Sasha Howard and Leo Dunkel	
5	Congenital Hypogonadotropic Hypogonadism in Males: Clinical Features and Pathophysiology	95
	Ravikumar Balasubramanian and William F. Crowley Jr.	
6	Male Hypogonadism Resulting from Mutations in the Genes for the Gonadotropin Subunits and Their Receptors.	127
	Ilpo T. Huhtaniemi	
7	Hypogonadism in Males with Congenital Adrenal Hyperplasia	153
	Nike M.M.L. Stikkelbroeck and Hedi L. Claahsen-van der Grinten	
8	Male Hypogonadism Due to Disorders of the Pituitary and Suprasellar Region	169
	Rosario Pivonello, Ciro Salzano, Mariano Galdiero and Annamaria Colao	
9	Klinefelter Syndrome and Other Forms of Primary Testicular Failure.	187
	John K. Amory and William J. Bremner	
10	The Undescended Testis	197
	Peter A. Lee, Christopher P. Houk and Jorma Toppari	

11 Male Hypogonadism and Liver Disease	219
Samuel M. Kim, Swaytha Yalamanchi and Adrian S. Dobs	
12 Male Hypogonadism Due to Cancer and Cancer Treatments	235
Rod T. Mitchell, Jan-Bernd Stukenborg and Kirsi Jahnukainen	
13 Exercise and Male Hypogonadism: Testosterone, the Hypothalamic-Pituitary-Testicular Axis, and Exercise Training	257
Anthony C. Hackney, Travis Anderson and Jennifer Dobridge	
14 Environmental Causes of Testicular Dysfunction	281
Richard M. Sharpe	
15 Sex Hormone-Binding Globulin and the Metabolic Syndrome	305
Geoffrey L. Hammond	
16 An Ensemble Perspective of Aging-Related Hypoandrogenemia in Men.	325
Peter Y. Liu, Paul Takahashi and Johannes D. Veldhuis	
17 Obesity and Aging in Late-Onset Hypogonadism	349
Giulia Rastrelli and Frederick C.W. Wu	
18 Androgen Replacement Therapy in Hypogonadal Men.	367
Jonas Čeponis, Ronald S. Swerdloff and Christina Wang	
19 Androgen Therapy for Hypogonadism in Men with Chronic Illnesses.	399
Wenyi Zhang, Moizza Shabbir and Peter Y. Liu	
20 Stimulation of Spermatogenesis in Hypogonadotropic Men.	423
Julia Rohayem and Eberhard Nieschlag	
Index	437

Contributors

John K. Amory MD, MPH Department of Medicine, University of Washington, Seattle, WA, USA

Travis Anderson MA Department of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, USA

Ravikumar Balasubramanian MBBS, PhD, MRCP (UK) Medicine, Reproductive Endocrine Unit, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

William J. Bremner MD, PhD Department of Medicine, University of Washington, Seattle, WA, USA

Haiqi Chen PhD Center for Biomedical Research Population Council, New York, NY, USA

C. Yan Cheng PhD Center for Biomedical Research Population Council, New York, NY, USA

Hedi L. Claahsen-van der Grinten MD, PhD Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Annamaria Colao MD, PhD Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Federico II University of Naples, Naples, Italy

William F. Crowley Jr. MD Medicine, Reproductive Endocrine Unit, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

Jonas Čeponis MD, PhD Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania

Jennifer Dobridge MA Department of Exercise and Sport Science, University of North Carolina, Chapel Hill, NC, USA

Adrian S. Dobs MD Division of Endocrinology, Department of Medicine and Oncology, Diabetes, and Metabolism, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Leo Dunkel MD, PhD Barts and the London School of Medicine and Dentistry, Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK

Mariano Galdiero MD I.O.S. & Coleman Srl, Acerra, Naples, Italy

Anthony C. Hackney PhD, DSc Department of Exercise and Sport Science; Department of Nutrition, Schools of Public Health & Medicine, University of North Carolina, Chapel Hill, NC, USA

Geoffrey L. Hammond PhD Cellular & Physiological Sciences, Life Sciences Center, The University of British Columbia, Vancouver, BC, Canada

Christopher P. Houk MD Department of Pediatrics, Medical College of Georgia, Georgia Rege University, Augusta, GA, USA

Sasha Howard MD Barts and the London School of Medicine and Dentistry, Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK

Iipo T. Huhtaniemi MD, PhD Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer, Imperial College London, London, UK

Kirsi Jahnukainen MD, PhD Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

Samuel M. Kim MD Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Peter A. Lee MD, PhD The Milton S. Hershey Medical Center, Hershey, PA, USA

Peter Y. Liu MBBS, PhD, FRACP Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute (LA BioMed), Torrance, CA, USA

Rod T. Mitchell BSc, MBChB, PhD MRC Centre for Reproductive Health, Queens Medical Research Institute, University of Edinburgh, Edinburgh, Lothian, Scotland, UK

Dolores Mruk PhD Center for Biomedical Research Population Council, New York, NY, USA

Joseph P. Moore Jr. PhD School of Medicine, Anatomical Sciences and Neurobiology, University of Louisville, Louisville, KY, USA

Eberhard Nieschlag Centre of Reproductive Medicine and Andrology, University of Münster, Münster, Germany

Peter J. O'Shaughnessy BSc, PhD College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

Rosario Pivonello MD, PhD Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Federico II University of Naples, Naples, Italy

Giulia Rastrelli MD, PhD Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy

Julia Rohayem Centre of Reproductive Medicine and Andrology, University of Münster, Münster, Germany

Ciro Salzano MD Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Federico II University of Naples, Naples, Italy

Moizza Shabbir BA Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute (LA BioMed), Torrance, CA, USA

Richard M. Sharpe BSc, MSc, PhD MRC Centre for Reproductive Health, the Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

Nike M.M.L. Stikkelbroeck MD, PhD Division of Endocrinology, Radboud University Medical Centre, Internal Medicine, Nijmegen, The Netherlands

Jan-Bernd Stukenborg MSc, PhD Department of Women’s and Children’s Health, Karolinska Institutet and University Hospital, Nordfertil Research Lab Stockholm, Stockholm, Sweden

Ronald S. Swerdloff MD Harbor UCLA Medical Center Los Angeles, Biomedical Research Institute, Torrance, CA, USA

Paul Takahashi MD Department of Medicine, Mayo Clinic, Rochester, MN, USA

Jorma Toppari MD, PhD Department of Physiology, Institute of Biomedicine, University of Turku, Department of Pediatrics, Turku University Hospital, Turku, Finland

Johannes D. Veldhuis MD Department of Internal Medicine, Department of Endocrinology, Endocrine Research Unit, Mayo Clinic College of Medicine, Mayo Clinic Rochester, Rochester, MN, USA

Christina Wang MD Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, UCLA Clinical and Translational Science Institute, Torrance, CA, USA

Stephen J. Winters MD Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Louisville, Louisville, KY, USA

Frederick C.W. Wu MD University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

Xiang Xiao PhD Department of Reproductive Physiology, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, China

Swaytha Yalamanchi MD Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Wenyi Zhang MD Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute (LA BioMed), Torrance, CA, USA

Neuroendocrine Control of Human Testicular Function

1

Joseph P. Moore Jr. PhD and Stephen J. Winters MD

Contents

Overview	1
GnRH Synthesis and Secretion	1
Gonadotrophs and GnRH Receptors	4
The Gonadotropic Hormones	6
Pulsatile Gonadotropin Secretion	7
LH Control of Testosterone Synthesis	8
Estrogens in Males	9
Testicular Control of Gonadotropin Secretion	10
Inhibin, Activin and FSH	12
Neuroendocrine Mechanisms for the Differential Control of FSH and LH	15
Conclusion	16
References	16

pituitary, GnRH stimulates the synthesis and secretion of the pituitary gonadotropic hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH are released into the circulation in bursts and activate G-protein coupled receptors on Leydig and Sertoli cells, respectively, that stimulate testosterone production and spermatogenesis. The system is tightly regulated and is maintained at a proper set-point by the negative feedback effects of testicular steroids and inhibin-B. Testicular function is also influenced by multiple internal (paracrine and autocrine) and external (endocrine) environmental factors.

Overview

The major regulator of testicular function is gonadotropin-releasing hormone (GnRH) produced in neurons scattered throughout the anterior hypothalamus. When it reaches the anterior

GnRH Synthesis and Secretion

GnRH is the primary neuronal link to reproduction. GnRH, a C-terminal amidated decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂), is found in a small number of neurons that are located diffusely throughout the medial basal and preoptic areas of the anterior hypothalamus in primates [1]. GnRH neurons send axons through subventricular and periventricular pathways to terminate in the capillary space within the median eminence located in the floor of the third ventricle. GnRH from these axons enters the capillaries and is transported in the hypothalamic portal blood to the cells of the anterior pituitary. The median eminence is located outside the blood

J.P. Moore Jr. (✉)
School of Medicine, Anatomical Sciences and Neurobiology, University of Louisville, 511 South Floyd St., Room 111, Louisville, KY 40202, USA
e-mail: jpmoor03@louisville.edu

S.J. Winters
Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Louisville, 550 S. Jackson St., ACB-A3G11, Louisville, KY 40202, USA
e-mail: sjwint01@louisville.edu

brain barrier and is accessible to regulatory factors within the systemic circulation.

The amount of GnRH that is secreted is influenced by many factors. GnRH mRNA levels are determined by the rate of transcription of the pro-GnRH gene which is known to be controlled by the POU-homeodomain protein, Oct-1, adhesion-related kinase (Ark), and by retinoid-X receptors, among many other regulatory factors [2]. Studies in GT1-7 cells, a GnRH-producing murine neuronal cell line, suggest that mRNA stability also plays an important role in maintaining GnRH gene expression. GnRH mRNA levels increase in the hypothalamus of adult male monkeys following bilateral orchidectomy [3], indicating that the testis secretes endocrine hormones, presumably testosterone, that suppress GnRH gene expression. Transcription of GnRH mRNA produces a pro-GnRH precursor, and yet another level of control within GnRH neurons involves the posttranslational processing of the inactive precursor to the active decapeptide. Subsequent to its secretion, peptidases in the median eminence and pituitary inactivate GnRH and have been demonstrated to produce a biologically active fragment that can antagonize the effects of active GnRH [4] and thereby further regulate the actions of GnRH. The current GnRH analogs used clinically are not degraded in the same manner adding to the potency of their effectiveness. Recent work analyzing developmental changes in the promoter regions of the GnRH gene of the mouse and rhesus monkey has demonstrated that alterations in chromatin interactions and DNA methylation are coincident with changes in GnRH mRNA levels and supports potential epigenetic regulation of GnRH expression [5, 6].

GnRH, like most hypophysiotropic peptides, is released into the portal blood in bursts. Measurement of GnRH concentrations within third ventricular cerebral spinal fluid in non-human primates revealed that GnRH is released in a pulsatile manner and is followed by a coincident pulse in systemic LH [7]. The average concentration of GnRH in hypothalamic portal blood (in rams) is approximately 20 pg/ml (0.02 nM), and levels in conscious sheep ranged from nadir values of <5 pg/ml to pulse peak values of about

30 pg/ml [8]. In those studies, the amplitudes of GnRH pulses in intact, castrated and testosterone-replaced castrated rams were roughly equivalent; by contrast, GnRH pulse frequency was higher in castrates than in intact animals and was reduced by testosterone replacement. The implication of those observations is that GnRH secretion rises with testosterone deficiency primarily because GnRH pulse frequency is accelerated.

Throughout the past decade, the primary discovery for the regulation of GnRH synthesis and secretion has been on unraveling the critical role of the kisspeptin-GPR54 system. Kisspeptin is encoded by the *Kiss1* gene, located on chromosome 1q32.1, and is the natural ligand of the previously orphaned receptor—GPR54 [9, 10]. In 2003, mutations in GPR54 were identified in two separate consanguineous families with selective congenital hypogonadotropic hypogonadism [11, 12]. Genetic knockout studies in mice confirmed that the kisspeptin protein and GPR54 receptor were essential for sexual maturation and fertility [11, 13]. Kisspeptin neurons are located in the infundibular nucleus and preoptic area within the human hypothalamus, and they synapse with the dendrites, axons, and/or cell bodies of GnRH neurons which express the GPR54 receptor [14, 15]. Intravenous injection of kisspeptin increases LH pulse amplitude and frequency in healthy and hypogonadal men [16, 17]. Infusion of a kisspeptin antagonist into the hypothalamus of rhesus monkeys reduced mean GnRH and GnRH pulses and blocked kisspeptin-stimulated GnRH secretion [18, 19]. Ongoing investigations are providing strong evidence that kisspeptin neurons play an important role in modulating GnRH responses to circulating gonadal steroids, stress indices and nutritional status.

GnRH pulse frequency is controlled by the “GnRH pulse generator,” the term used to describe the highly synchronized firing of GnRH neurons in the mediobasal hypothalamus (MBH). The idea that changes in cell membrane potentials predispose to bursts of GnRH release follows from the finding that bursts of electrical activity in the MBH in the non-human primate coincided with pulses of LH secretion [20]. The coincident

firing of multiple GnRH-expressing neurons may reflect communication by gap junctions, through interneurons, or second messengers. Recently, clustered GnRH neurons in the preoptic area of the hypothalamus have been shown to possess intermingled dendrite bundles with shared synapses [21]. The identification of GnRH receptors on GnRH neurons, and the observation that adding GnRH to GnRH neuronal cultures depresses GnRH pulsatile release, provides a possible framework for intraneuronal communication by GnRH itself [22]. Experiments using various 5' deletion constructs of the GnRH promoter-luciferase vector suggest that episodic GnRH gene expression is a promoter-dependent event that is mediated by Oct-1 and specific GATA-binding elements [23, 24].

Kisspeptin neurons have been shown to play a role in the pulsatile pattern of GnRH secretion in primates. Kisspeptin neurons are localized within the same hypothalamic regions, outside of GnRH neuronal locations, where lesions in rhesus monkeys were originally demonstrated to suppress LH secretion [25, 26]. Pulsatile administration of kisspeptin to juvenile male monkeys stimulates a pulsatile pattern of gonadotropin release that mimics LH secretion in pubertal males and can be blocked with a GnRH antagonist [27]. Delivery of a single i.v. bolus of kisspeptin to healthy men induces an immediate pulse in circulating LH and effectively resets the GnRH pulse generator delaying subsequent endogenous pulses to the naturally occurring interval [28]. Most convincingly, measurements within the median eminence of female rhesus monkeys revealed that kisspeptin is secreted in a pulsatile manner with an interpulse interval of 60 min and that most kisspeptin pulses are accompanied by a simultaneous increase in GnRH [29]. Elaborate studies in ruminants and rodents have confirmed the important regulatory role for kisspeptin on GnRH pulsatility.

The prevailing model by which kisspeptin neurons can regulate pulsatile activity of GnRH neurons comes from the recent discovery of a subset of kisspeptin neurons that co-express the neuropeptides neurokinin B (NKB), and dynorphin (DYN) thereby known as KNDy neurons.




Fig. 1.1 Model depicting the role of ARC KNDy neurons in the generation of pulsatile GnRH release. KNDy neurons in the ARC nucleus form an interconnected population with their axons and/or dendrites. In the presence of low levels of Dyn, individual KNDy neurons (insert, 1–3) begin constitutively increasing NKB secretion leading to a synchronous excitation and Kiss release which stimulates GnRH secretion (*graphs* in insert). Moments later, Dyn levels begin to increase and apply a brake to NKB, Kiss and GnRH secretion. Increased local concentration of Dyn will inhibit KNDy neurons, resulting in an interpulse interval, until a lower threshold is reached and the cycle can reset

KNDy neurons form an interconnected reciprocal network in the arcuate nucleus of rats and sheep [30, 31]. The synchronous activity of KNDy neurons is thought to be controlled by excitatory actions of NKB and the inhibitory signaling of DYN which can autoregulate KNDy neurons through DYN and NKB receptors. As illustrated in Fig. 1.1, a pulse of GnRH is initiated by a constitutive increase in NKB secretion which synchronizes a further increase in NKB by the network of KNDy neurons. The synchronized increase in NKB initiates a pulse of kisspeptin which stimulates the rapid secretion of GnRH. NKB also stimulates the secretion of DYN from KNDy neurons which initially limits kisspeptin secretion, and, within minutes inhibits KNDy neuronal activity, and effectively terminates GnRH release. The inhibitory tone of DYN signaling will gradually suppress DYN secretion and allow for constitutive NKB release to initiate the next pulse of GnRH secretion. Although this




Fig. 1.2 Diagram showing activation of GnRH neurons by neurotransmitters and the relation to the anterior pituitary

model has not been directly tested in humans, it is supported by finding inactivating mutations in kisspeptin and NKB receptors that result in hypogonadotropic hypogonadism in men [12, 32].

As shown in Fig. 1.2, the release of GnRH is influenced by multiple neurotransmitters including glutamate, gamma-aminobutyric acid (GABA), neuropeptide Y, opiates, dopamine, norepinephrine, cAMP and nitric oxide [33]. The presence of receptors on GnRH neurons for most of these substances implies that they influence GnRH neurons directly. NMDA receptors that mediate glutamate activation of GnRH may involve the nitric oxide signaling pathway. Neurotransmitters with receptors that are not expressed on GnRH neurons may regulate GnRH via synaptic connections between GnRH neurons and other interneurons. Regulation of GnRH secretion may also occur directly on neuronal axon terminals that abut on capillaries in the median eminence.

A second form of GnRH, GnRH-2 [34, 35] that was initially identified in non-vertebrates, is also found in the primate brain [36]. GnRH-2 appears to activate a unique GnRH-II receptor [37], but this receptor does not appear to be expressed in humans [38]. Thus, the significance

of GnRH-2 in humans is not yet known, and there is little evidence for a role in reproduction.

There has been resurgence in research on a gonadotropin-inhibiting hormone (GnIH) which appears to have a functional role in regulating GnRH neurons and gonadotropin secretion in seasonal breeders and lower mammals (for review, see [39]). However, the role of the primate GnIH ortholog, RFRP-3, has not been elucidated. In a recent study in rhesus macaque, an antagonist to RFRP-3 was demonstrated to prevent the decline in circulating testosterone levels that accompanies acute fasting [40]. This result suggests the possibility that a GnIH hormone exists in primates and may have a role in modulating reproductive function in response to varying metabolic states. Further research is necessary to validate this hypothesis.

Gonadotrophs and GnRH Receptors

Gonadotrophs account for 6–10% of the cells of the normal anterior pituitary [41]. Gonadotrophs may be small and round, or larger and ovoid, and are difficult to identify by morphological criteria. Instead, immunostaining using specific antibodies for LH- β and FSH- β proteins are used to identify gonadotrophs. In primates [42], as in rodents [41], the great majority of gonadotrophs are bihormonal, i.e., they express both LH- β and FSH- β subunit genes. A small fraction of cells appear to express LH or FSH selectively, and some gonadotrophs also produce growth hormone. The proportions of each of the hormone-producing gonadotrophs are developmentally regulated [43]; however, the biological significance of these observations remains unclear.

GnRH activates gonadotrophs through both short-term and long-term mechanisms that are illustrated in Fig. 1.3. Upon reaching the pituitary, GnRH binds to and activates a cell-surface G-protein coupled receptor (GnRH-R) [44]. This receptor is a structurally unique member of the seven-transmembrane G-protein-linked receptor family that lacks the long C-terminal intracellular tail that is typical of most G-protein-coupled receptors. This tail is important in the rapid




Fig. 1.3 Signaling mechanisms initiated by activation of the GnRH receptor stimulate gonadotropin synthesis and secretion

desensitization of other G-protein-coupled receptors, whereas down-regulation of the GnRH receptor by GnRH is a relatively delayed event that occurs over hours rather than minutes. Binding of GnRH to its receptor facilitates binding of a G-protein to the receptor's third intracellular loop. The bound G-protein exchanges GDP for GTP and dissociates into its constituent α and $\beta\gamma$ subunits. The α -subunits are unique to each G-protein, whereas the β - and γ -subunits of the different G-proteins are similar. The dissociated G-protein α -subunit activates downstream signaling pathways [45]. $G_{\alpha_{q/11}}$, the major G-protein that associates with the GnRH-R, activates membrane-associated phospholipase C to hydrolyze membrane phosphoinositides and increase intracellular inositol phosphates (Ips) including

inositol triphosphate ($I_{1,4,5}P_3$). $I_{1,4,5}P_3$ rapidly mobilizes calcium from intracellular stores, and L-type voltage-gated calcium channels open following which extracellular calcium enters the cell [45]. The rise in intracellular free calcium is primarily responsible for the immediate release of LH and FSH [46]. GnRH receptors also interact with other G-proteins including G_{α_i} and G_{α_s} . The GnRH receptor can couple to G_{α_s} in rat pituitary cells [47] and subsequently activate cAMP production and the PKA signaling pathway [48]. Interaction with G_{α_i} occurs primarily in non-pituitary tissues.

The long-term stimulatory effects of GnRH are to increase transcription of the genes for the gonadotropin subunits and the GnRH receptor, among other genes. These effects occur primarily

through liberation of membrane diacylglycerol (DAG) that in turn activates protein kinase C. The subsequent phosphorylation of subfamilies of mitogen-activated protein kinases (MAP kinases), including members of the ERK and JNK families, initiates nuclear translocation of proteins that bind directly to the 5' regulatory regions of gonadotropin subunit and the GnRH-receptor genes or serve as cofactors for promoter activation [49]. Increased intracellular calcium also causes increased activation of calmodulin-dependent protein kinases which contributes to the transcriptional effects of GnRH [50].

GnRH receptors are up-regulated by pulsatile GnRH [51]. Accordingly, when pulsatile GnRH secretion increases, as in castration or primary testicular failure, GnRH receptors increase. Gonadotrophs become more responsive to GnRH, and the LH response to GnRH stimulation is amplified [52]. With continuous GnRH treatment on the other hand, GnRH receptors decline, followed by suppression of LH- β and FSH- β mRNAs. This "homologous desensitization" of the GnRH-R is regulated by several serine-threonine protein kinases including protein kinase A (PKA) and protein kinase C (PKC), as well as by G-protein-coupled receptor kinases (GRKs) which combine to cause a reduction in the efficiency with which Ins(1,4,5)P₃ mobilizes Ca²⁺ from intracellular storage [53]. GnRH receptors also decline with GnRH deficiency.

GnRH receptors undergo a low level of agonist-independent constitutive internalization which is not influenced by binding to GnRH agonists [54]. Accordingly, a wide variety of postreceptor modifications have been proposed for the observed receptor desensitization that disconnects GnRH binding from LH secretion after prolonged exposure [55]. The primate GnRH-R is different than other mammalian GnRH-R due to the presence of a primate-specific Lys191 [56], the lack of a second glycosylation site near the NH₂ terminus [57] as well as the absence of any COOH tail [58]. These differences lead to a comparatively significant reduction in the percentage of membrane-bound receptors and suggest that differential expression of intracellular chaperones or

membrane scaffolding proteins may play an important role in GnRH signaling and desensitization. Evidence for this is the recent discovery that the proto-oncogene SET, also called I2PP2A (inhibitor 2 of protein phosphatase 2A), interacts with the first and third intracellular loops of the GnRH receptor and leads to inhibition of calcium signaling while increasing the cAMP signaling pathway [59].

The Gonadotropic Hormones

LH and FSH are members of the glycoprotein family of hormones that also includes thyrotroph-stimulating hormone (TSH) and chorionic gonadotropin (hCG). These heterodimers are composed of a common α -subunit and unique β -subunits. The subunits have N-linked oligosaccharide chains that are associated with asparagine residues. Each subunit is encoded by a unique gene that is found on a separate chromosome: The human α -subunit gene is on 6p21.1–23, LH- β is on 19q13.3, and FSH- β is on 11p13 (see Chap. 6).

The production of LH and FSH is directly influenced by the level of the gonadotropin subunit mRNAs. This relationship seems especially strong for FSH- β mRNA and FSH secretion. Each of the gonadotropin subunit mRNAs is increased by GnRH, and stimulation of the β -subunit genes by GnRH is primarily transcriptional. Complexes of transcription factors including SF-1, EGR-1, and SP1 are activators of the LH β -subunit gene [60], whereas the AP1 proteins fos/jun are important for up-regulation of FSH- β transcription by GnRH [61]. GnRH stimulation must be pulsatile for LH- β and FSH- β mRNA levels to be increased. Transcriptional regulatory proteins that control α -subunit expression include cAMP response element binding protein (CREB), MAP kinase/ERK1 and GATA-binding proteins [62]. α -Subunit gene expression is increased robustly both by pulsatile and by continuous GnRH, and GnRH not only stimulates α -subunit transcription but also prolongs the half-life of the α -subunit mRNA [63]. Thus, the requirements for α -subunit mRNA up-regulation by GnRH

seem less stringent than are those for the β -subunit genes. These factors partly explain why α -subunit is synthesized in excess of β -subunits and why β -subunits are rate limiting for gonadotropin synthesis.

Proteins that are destined for secretion are synthesized on ribosomes bound to the endoplasmic reticulum. During the translational process, preformed oligosaccharide chains are linked to the side chain amino group of asparagines on the gonadotropin subunits. As translation continues, sugar moieties are trimmed, and the subunits change configuration allowing for their combination. A region of the β -subunit, termed the "seatbelt," wraps around the α -subunit loop 2 [64]. Dimeric LH and FSH are segregated in the ER and are transferred to the Golgi where they are concentrated in secretory granules. These protein-rich vesicles subsequently fuse with the plasma membrane following stimulation by GnRH. This process is termed "exocytosis." There is evidence that granules containing FSH are also exported directly to the plasma membrane independent of GnRH pulsatile stimulation. This mode of secretion allows for FSH secretion between pulses. Gonadotrophs also secrete uncombined α -subunit both in pulsatile fashion and continuously.

Pulsatile Gonadotropin Secretion

Experiments in ovariectomized rhesus monkeys rendered gonadotropin-deficient with hypothalamic lesions lead to the proposal that an intermittent pattern of GnRH secretion was necessary for normal LH secretion [65]. In those animals, GnRH administered in pulses stimulated LH secretion, but GnRH administered continuously was much less effective. The pulsatile nature of LH secretion was subsequently established in all species, including man [66]. Accordingly, LH secretion is stimulated when GnRH is administered in pulses to gonadotropin-deficient patients but not when administered continuously [67, 68]. An understanding of these physiological principles leads to the use of pulsatile GnRH as a treatment to stimulate fertility and to the

development of long-acting GnRH analogs that initially stimulate LH/FSH secretion but then deplete membrane GnRH-R and inhibit gonadotropin production to produce a biochemical gonadectomy that is used as a treatment for patients with prostate cancer and other androgen-dependent disorders [69].

With current assays, GnRH is undetectable in the peripheral circulation. Therefore, GnRH secretion cannot be studied directly in humans. Instead, changes in circulating LH levels are used as a surrogate marker for the activity of the GnRH pulse generator. LH secretion is determined by the frequency, amplitude, and duration of its secretory pulses. Presumably because of its longer circulating half-life, FSH pulses are less clearly defined in peripheral blood than are LH pulses because FSH pulses are clearly evident in jugular blood (in ewes) where clearance effects are minimized [70].

Cultured pituitary cells that are perfused with pulses of GnRH are a powerful model yielding important information on the actions of GnRH and other factors that regulate gonadotropin secretion under controlled conditions. Using this experimental approach, episodes of LH as well as FSH secretion are distinct and short-lived with a rapid upstroke and abrupt termination. LH pulse amplitude is directly proportional to the dose of GnRH administered, and the median duration of an LH pulse about 25 min.

In contrast to the regularity of LH pulses produced by a constant dose of GnRH *in vitro*, Fig. 1.4 illustrates that LH pulses in the peripheral circulation in man vary in amplitude and that interpulse intervals are inconstant. LH pulses *in vivo* are also characterized by a less rapid upstroke and a slower decline from the peak than are pulses *in vitro*. This presumably reflects dilution of secreted hormone by plasma in the general circulation and the influence of clearance of LH by the liver and kidney. Whether LH is released in the basal interval between GnRH-initiated secretory episodes has been debated, but this mode of secretion is small and is probably not biologically important.

Hormone pulse detection has been standardized by the development of computer algorithms




Fig. 1.4 Circulating LH and alpha subunit levels in a normal adult man. Blood samples were drawn every 10 min for 12 h beginning at 0800 h and measured for LH using Nichols Allegro LH 2-site assay, and a specific assay double antibody immunoassay for α -subunit

[71]. Using this approach, objective assessment of the frequency and amplitude characteristics of hormone pulses has been possible. Pulses of LH secretion occur throughout the day and night in normal adult men. However, estimates of the frequency of LH (GnRH) pulses in men have varied based on the intensity and duration of the blood sampling protocol, the assay used to measure LH and the algorithm used to identify pulses. Most investigators have proposed an average frequency of 1 LH pulse every 1–2 h for normal men, but interestingly there is a large between-individual variation [72]. Because of variability in pulse amplitude and frequency, the distinction between true and artifactual pulses can be difficult. One approach is to co-analyze LH and uncombined α -subunit pulses [31] because α -subunit is released into the circulation by GnRH together with LH and FSH (Fig. 1.4). According to this logic, concordant LH and α -subunit fluctuations presumably reflect true GnRH pulsatile signals. There is generally a positive relationship between LH pulse amplitude and the preceding interpulse interval in part because a longer interval allows for the circulating level to decline to a lower baseline value.

In addition to moment-to-moment pulsatile pattern of LH secretion, there is a diurnal rhythm in circulating LH as well as testosterone levels in pubertal boys with increased LH pulsatile amplitude during sleep and increased testosterone

levels in the early morning hours [73]. The diurnal variation in plasma testosterone in adults is coincident with diurnal rhythms for LH [74, 75]. The diurnal testosterone variation in men is disrupted by fragmented sleep [76], while LH rhythms are not affected [75] and therefore the mechanism for this alteration has not been established. The diurnal variation in testosterone is blunted in older men [77] and in young men with testicular failure [78].

LH Control of Testosterone Synthesis

Testosterone, a C₁₉ 3-keto, 17 β -hydroxy Δ^4 steroid, is synthesized from cholesterol through a series of cytochrome P450- and dehydrogenase-dependent enzymatic reactions [79]. The conversion of cholesterol to pregnenolone occurs within mitochondria and is catalyzed by P450_{sc}, the cytochrome P450 side chain cleavage enzyme. Pregnenolone exits the mitochondria and can be converted to testosterone by two alternative routes that are referred to as the Δ^4 -pathway or the Δ^5 -pathway, based on whether the steroid intermediates are 3-keto, Δ^4 steroids (Δ^4) or 3-hydroxy, Δ^5 steroids (Δ^5). Classical experiments using human testicular microsomes incubated with radiolabeled steroids revealed that the Δ^5 -pathway predominates in the human testis. In that pathway, C₁₇ hydroxylation of pregnenolone to form 17 α -hydroxypregnenolone is followed by cleavage of the C₁₇–C₂₀ bond of 17 α -hydroxypregnenolone to produce dehydroepiandrosterone (DHEA). Oxidation of the 3 β -hydroxy group and isomerization of the C₅–C₆ double bond of DHEA by 3 β -hydroxysteroid dehydrogenase/ Δ^5 – Δ^4 isomerase (3 β HSD) forms androstenedione. The C₁₇ keto group of androstenedione is oxidized to a hydroxyl group by 17 β -hydroxysteroid dehydrogenase type III (17 β HSD)-producing testosterone (see Chap. 3).

LH stimulates testosterone biosynthesis in Leydig cells through a G-protein-associated seven-transmembrane receptor [80]. LH binding to the receptor initiates a signaling cascade by activating Gs that stimulates adenylate cyclase activity and increases intracellular cAMP levels

to activate cAMP-dependent protein kinase A (PKA). cAMP-dependent PKA stimulates testosterone synthesis in at least two ways. An acute response, within minutes of hormonal stimulation, is characterized by an increase in cholesterol transport into the mitochondria and is mediated by the steroidogenic acute regulatory (StAR) protein [81]. StAR acts on the outer mitochondrial membrane, where it undergoes conformational changes through interactions with protonated phospholipids causing opening and closing of a sterol-binding pocket, permitting uptake and discharge of cholesterol [82]. The chronic response to LH, which requires several hours to days, involves transcriptional activation of the genes encoding the steroidogenic enzymes of the testosterone biosynthetic pathway, P450_{scc}, P450_{c17}, 3 β HSD and 17 β HSD.

Other factors that stimulate testosterone synthesis directly include PRL, GH, T3, PACAP, VIP and inhibin, whereas glucocorticoids, estradiol, activin, AVP, CRF and IL-1 have been reported to reduce testosterone production by Leydig cells. Although controversial for many years, experiments with recombinant FSH suggest that FSH is not an important regulator of Leydig cell function [83, 84]. However, it can indirectly stimulate Leydig cells through a Sertoli cell-mediated paracrine loop. In an elegant experiment, however, selective genetic ablation of Sertoli cells in neonatal or adult mice resulted in a significant decrease in Leydig cell number with normal mean testosterone levels but fewer high level pulses of circulating testosterone and higher levels of LH [85], suggesting that a Sertoli cell factor may regulate pulsatile testosterone biosynthesis.

The blood production rate of testosterone in normal adult men has been estimated to range from 5000 to 7500 $\mu\text{g}/24\text{ h}$ [86], and levels of total testosterone among normal men range from 250 to 1000 ng/dl (10–40 nmol/L) in most assays. The level of testosterone in adult men declines by more than 95% if the testes are removed. The remainder of the circulating testosterone is derived from the production of androstenedione and dehydroepiandrosterone (DHEA) by the adrenal cortex. Intratesticular testosterone concentrations in normal men are 100-fold higher than are serum

levels [87]. The higher concentration is due to local production as well as sequestration by the Sertoli cell-derived androgen binding protein [88]. High intratesticular concentrations of testosterone are believed to be important for spermatogenesis; however, concentrations tenfold above serum levels are sufficient for normal spermatogenesis [89, 90].

Estrogens in Males

Normal men produce about 40 μg of estradiol and 60 μg of estrone per day. Estradiol is produced from testosterone, and estrone from androstenedione, by aromatase P450, the product of the *CYP19* gene [91]. This microsomal enzyme oxidizes the C19 angular methyl group to produce a phenolic A ring. Aromatase mRNA is expressed in adult Leydig cells where it is activated by LH/hCG [92]. However, most of the estrogen in men is derived from aromatase in adipose and skin stromal cells, aortic smooth muscle cells, kidney, skeletal cells and the brain. The promoter sequences of the extra-gonadal and testicular P450 aromatase genes are distinct and tissue-specific due to differential splicing, but the translated protein appears to be the same in all tissues. There is evidence in vitro that cytokines such as IL-6 stimulate aromatase in stromal cells, but the factors that regulate extra-testicular aromatase are not well understood.

Estrogens are known to exert important physiological effects on reproduction as well as other organ systems in men. The two forms of the estrogen receptor, ER- α and ER- β , are each known to play a role in reproduction [93]. ER- α is the dominant form in the pituitary and hypothalamus, whereas both ER- α and ER- β are found in the testis, prostate and epididymis [94]. Studies in one man with an inactivating ER- α mutation and four men deficient in aromatase (Table 1.1) reveal effects of estrogens on bone metabolism, insulin sensitivity, hepatic lipid metabolism and reproduction. Studies in normal men using pharmacologic inhibitors and steroid add-back protocols support these findings [95]. Dilatation and atrophy of the seminiferous tubules in ER- α -deficient mice

Table 1.1 Hormone levels in a man with a mutation of the ER α (1), and four men deficient in aromatase (2–5)

	Age (yrs)	Testosterone	Estradiol (pg/ml)	LH (mIU/ml)	FSH (mIU/ml)	Testis size	Sperm count	Reference
1	28	44 (ng/dL)	119	37 (2.0–20)	33 (2.0–15)	20–25 mL	25 mil/ml	[176]
2	24	2015 (ng/dL)	<7	26.1 (2.0–9.9)	28.3 (5.0–9.9)	R 6 × 3.5 L 5.5 × 3.2 cm	ND	[177]
3	31	523 (ng/dL)	<10	5.6 (1.4–8.9)	17.1 (1.7–6.9)	8 mL	1 mil/ml	[178]
4	27	829 (ng/dL)	<20	8.3 (1.2–8.6)	18.8 (1.3–19.3)	Ambiguous genitalia 20 mL	56 mil/ml	[110]
5	24	20.15 (nmol/L)	UD	4.8 (<11.1)	14.4 (<20.3)	15 mL	129 mil/ml	[109]

LH and FSH levels in parentheses are the normal ranges reported in those references

UD Undetectable

[96] imply an effect of estrogen to regulate aquaporin expression in the efferent ductules of the testis. Aromatase-deficient mice, although fertile in early life, develop infertility. Thus, estradiol is essential for male reproduction.

Testicular Control of Gonadotropin Secretion

Gonadotropin secretion, while up-regulated by GnRH, is maintained at physiological levels through testicular negative feedback mechanisms summarized in Fig. 1.5. Accordingly, plasma LH and FSH levels decrease following the administration of testosterone or estradiol and rise when negative feedback is disrupted by castration.


The process of negative feedback control of LH and FSH by gonadal steroids in males is partly species-specific. There is considerable evidence in primates that androgens suppress LH synthesis and secretion primarily through an action on the GnRH pulse generator. For example, LH pulse frequency and amplitude are elevated in castrates and are suppressed by testosterone replacement [97]. Furthermore, when male rhesus monkeys were rendered gonadotropin-deficient with radio-frequency lesions, and stimulated with pulses of GnRH, LH secretion increased little after bilateral orchidectomy until GnRH pulse frequency was increased [98]. In addition, expression of the mRNAs for GnRH [3], as well as pituitary GnRH receptors, and the gonadotropin subunit

genes are increased in orchidectomized monkeys [99]. Moreover, when pituitary cells from adult male monkeys were stimulated with pulses of GnRH, no inhibition of GnRH-induced LH secretion by testosterone or DHT was found. In pituitary cells from rats, on the other hand, the gonadotroph is a direct site of testosterone negative feedback control since GnRH-stimulated LH pulses were suppressed in amplitude by testosterone, and α -subunit gene expression was reduced (Fig. 1.6 [100]).

GnRH-deficient men represent a human model to examine the effects of testicular steroids on the hypothalamus and pituitary. When such patients were treated with fixed doses of GnRH [101], testosterone suppressed LH secretion less than in normal men implying that testosterone controls GnRH secretion. Moreover, suppression by testosterone was blocked by the aromatase inhibitor testolactone [101], and in separate experiments, dihydrotestosterone had no effect [102]. Together these data imply that the pituitary effect of testosterone to inhibit LH was through bioconversion to estradiol.

Whether it is testosterone, itself, and/or the estradiol derived from testosterone by aromatase in the central nervous system, pituitary system, or peripheral tissues that controls LH secretion, has been a subject of considerable interest. The finding that dihydrotestosterone (DHT), a non-aromatizable androgen, decreases LH pulse frequency strongly supports a role for androgens in the regulation of the GnRH pulse generator.

Fig. 1.5 Diagram of the negative feedback control of gonadotropin secretion by testicular hormones




Furthermore, LH pulse frequency is increased in patients with non-functional androgen receptors (AR) in the complete androgen insensitivity syndrome, indicating that AR signaling regulates GnRH pulse frequency [103].

Estradiol also plays an important physiological role in the negative feedback control of gonadotropin secretion in men. This control mechanism was suggested by pharmacological studies using the estrogen antagonist clomiphene [104], or the aromatase inhibitor, testolactone [105]. When those drugs were administered to normal men, circulating LH and FSH levels rose together with plasma testosterone concentrations. This finding was confirmed and extended in

studies using the aromatase inhibitor, anastrozole [106, 107]. Variable LH and FSH levels in an adult man with an inactivating mutation of the ER- α and four men with mutations of the CYP19 aromatase gene (reviewed [108–110]) are shown in Table 1.1. Estradiol treatment also decreases the LH response to GnRH stimulation in men [111] and in primate pituitary cells perfused with pulses of GnRH (Fig. 1.6, [100]) indicating an additional direct negative feedback effect of estradiol on the pituitary.

GnRH neurons appear by autoradiography and immunocytochemistry to lack both androgen and estrogen receptors and numerous animal models have shown that kisspeptin neurons

Fig. 1.6 Effects of testosterone or estradiol on GnRH-stimulated LH secretion from pituitary cell cultures from adult male monkeys and rats. From Kawakami and Winters [100]. Reprinted with permission from Endocrine Society




mediate the negative feedback effects of gonadal steroid hormones (for review, see [112]). Both estrogen and androgen receptors are localized to kisspeptin neurons in the hypothalamus of male mice [113]. Furthermore, testosterone administration to castrated male monkeys decreased kisspeptin mRNA in the medial basal hypothalamus coincident with suppression of circulating levels of LH [114]. A comparison of kisspeptin neurons in the hypothalamus of young and elderly men dying a sudden death revealed an age-related increase in the number of kisspeptin neurons and fibers and an enhancement of afferent contacts they established onto GnRH neurons [115]. These studies support the concept that kisspeptin neurons mediate the negative feedback effects of testosterone in primates including man and are consistent with studies showing that androgen negative feedback responsiveness increases with aging [116]. However, many other hypothalamic neuromodulators are responsive to castration and testosterone replacement, and therefore, the role of kisspeptin neurons may be partial with regard to steroid hormone negative feedback.

Inhibin, Activin and FSH

Although LH and FSH are both produced within the same cell type, the synthesis and secretion of the gonadotropins are, in some circumstances, differentially regulated. Both LH and FSH are stimulated by GnRH and are suppressed by gonadal steroid hormones. However, FSH levels may rise selectively in men with seminiferous tubular failure, and FSH synthesis, and secretion, can be selectively regulated through the actions of two paracrine factors, pituitary activin and follistatin, and by testicular inhibin-B. Activin selectively up-regulates FSH secretion by stimulating FSH- β gene expression [117] with negligible effects on LH synthesis. Inhibin and follistatin prevent activin from binding to its receptor through separate mechanisms, effectively antagonizing the stimulatory effects of activin on FSH synthesis.

Activin, a member of the TGF- β family of growth factors, is a dimeric peptide consisting of two similar subunits that were designated as β -subunits because the identification of activin followed the cloning of inhibin, an α - β

Fig. 1.7 A diagram for activin signaling through Smad proteins



heterodimer. There are at least four forms of the β subunit: β_A , β_B , β_C and β_D . Activin-B ($\beta_B\beta_B$) is the predominant form in the pituitary, whereas most other tissues produce activin-A. Activin functions in neural and mesodermal morphogenesis, wound healing, vascular remodeling and inflammation, as well as in reproduction [118–121]. Activins (and follistatin) primarily function as local paracrine or autocrine factors with no observable changes in the general circulation except in pregnancy and advanced stages in cancer patients [122, 123]. Therefore, activin-stimulated FSH synthesis and secretion is tightly and selectively regulated within the pituitary milieu.

Like other members of the TGF β superfamily, activins signal through a serine-threonine receptor hetero-oligomeric complex that activates intracellular SMAD proteins (Fig. 1.7, [124]). Initially, the activin ligand binds to a specific type II receptor subunit, either ActRII or IIB [125–127]. Subsequent to ligand binding, the type II subunit pairs with a type I receptor subunit (either

ActRI or IB) and forms a heteromeric complex at the cell surface [128–130]. The serine/threonine kinase of the type II subunit is responsible for phosphorylation of the type I subunit, thereby initiating postreceptor signaling/phosphorylation of SMAD2 and SMAD3 proteins which then dissociate from the receptor complex, bind SMAD-4 and translocate from cytoplasm to nucleus. Activated SMAD complexes interact with cofactor proteins and bind to SMAD binding elements on gene promoters, including FSH- β , driving immediate gene activation.

The actions of activin are antagonized by follistatin that binds to and neutralizes the bioactivity of activin, as well as by inhibin that competes with activin for binding to the activin RII receptor [131]. Inhibin is an antagonist of activin because it fails to initiate intracellular SMAD signaling. Inhibin has a lower affinity for Act RII than activin, and betaglycan, a membrane proteoglycan, appears to function as an accessory receptor binding protein to potentiate

inhibin binding, as well as for TGF- β and bone morphogenic protein [132]. Follistatin is structurally unrelated to activin and inhibin, but like activin, is found in all tissues examined. In the rat pituitary, follistatin is up-regulated by activin, GnRH and PACAP, and is suppressed by testosterone and by follistatin itself, no doubt through binding to activin. In primate pituitary cultures, on the other hand, GnRH is ineffective, and testosterone, as well as activin, increases follistatin expression [133]. Pituitary follistatin influences the FSH and LH response to castration. Follistatin expression increases following orchidectomy in adult male rats [134], and there is a reciprocal relationship over time between follistatin and FSH- β gene expression implying that follistatin attenuates the FSH castration response in that species. In male primates including man, by contrast, the level of follistatin mRNA is relatively unaffected by bilateral orchidectomy, and FSH- β mRNA increases about 50-fold (Fig. 1.8, [99]). Thus, follistatin appears to function as a brake on FSH production in male rodents but not in primates.

Inhibin is produced by Sertoli cells and by fetal Leydig cells and plays a fundamental role in the selective regulation of FSH [135, 136]. Inhibin also regulates ovarian steroidogenesis and follicular development while its paracrine function in testis is not well understood. The term inhibin was first applied in 1932 [137] to the aqueous extract of bull testis that prevented the development of castration cells within the anterior pituitary, and was distinguished from androin, that was present in the ether-extract and stimulated prostate growth, and is now known as testosterone.

Inhibin is a heterodimer of an α -subunit (20 kDa) and one of two β -subunits, β_A and β_B (13 kDa). Of these, only the β_B subunit is expressed by the testis in most species, and therefore testicular inhibin is inhibin-B. The inhibin α -subunit is expressed in Sertoli cells and somewhat in Leydig cells and is up-regulated by FSH. The β_B subunit is expressed in Sertoli cells and germ cells, but the factors regulating the β_B subunit gene are not well understood. The level of inhibin/activin β_B mRNA in the rat testis is




Fig. 1.8 A comparison of the effects of orchidectomy on gonadotropin subunit and follistatin mRNA levels in adult male rats and monkeys. From Winters et al. [99]. Reprinted with permission from Endocrine Society

unaffected by hypophysectomy or by FSH treatment [138]. Transcription factors of the GATA-binding protein family regulate both the inhibin β - and α -subunit promoters [139]. Exogenous testosterone treatment results in suppression of FSH and a parallel decrease in circulating inhibin-B [140].

Conversely, inhibin-B levels increase in men treated with FSH for infertility [140, 141]. Control of inhibin β_B by a germ cell factor is suggested by the decline in plasma inhibin-B levels, but not inhibin- α subunit levels, that follows destruction of germ cells by cancer chemotherapy

[142]. Inhibin-B is a marker of Sertoli cell function and is positively correlated with sperm count and testicular volume [143].

Inhibin-B is a selective negative regulator of FSH. While initially shown *in vitro* using pituitary cells from rodents [144], subsequent experiments in adult male monkeys revealed suppression of circulating FSH with no effect on the levels of LH or testosterone [145]. Inhibin can also augment the suppressive effect of testosterone on FSH synthesis, because inhibin suppresses FSH secretion [146]. On the other hand, very large doses of FSH are required to increase circulating inhibin-B levels [147]. Consequently, plasma inhibin-B and FSH concentrations are inversely related among normal men and are more strongly inversely correlated when values from men with varying degrees of primary testicular failure are included in the analysis [147, 148]. The relationship between inhibin-B and FSH differs from that between LH and testosterone which is bidirectional, *i.e.*, LH stimulates testosterone, and testosterone suppresses LH, such that there is no comparable strong correlation between circulating LH and testosterone levels among normal men. The different relationships between plasma LH with testosterone compared to FSH with inhibin-B levels were clearly demonstrated in experiments conducted by Ramaswamy *et al.* [149]. These investigators removed one testis from adult male rhesus monkeys following which the plasma levels of both testosterone and inhibin-B decreased. The decline in testosterone was brief and was restored to normal by a rise in LH, whereas inhibin-B levels remained at approximately 50% of baseline values for up to 6 weeks even though FSH levels rose. Thus, LH and testosterone form a classical feed-forward/feedback loop whereas inhibin-B controls FSH but is less dependent on FSH stimulation.

Inhibin-B levels increase during the neonatal phase of development, sometimes called mini-puberty, and again at puberty. Although plasma LH and FSH levels rise at these developmental stages, the number of Sertoli cells also increases. Furthermore, studies in adult monkeys showed a strong positive correlation between

circulating inhibin-B levels and Sertoli cell number [150]. Thus, circulating inhibin-B appears to reflect the number and function of Sertoli cells and is less dependent on FSH stimulation.

Activin, inhibin and follistatin may also act locally in the testes to regulate reproductive function. Activin receptor gene expression has been detected in Sertoli cells, primary spermatocytes and round spermatids, and radiolabeled activin-A binding has been demonstrated in the latter cell types [138, 151, 152]. Both proposed inhibin receptors, betaglycan and InhBP/p120 are present in rat Leydig cells [132, 153], and betaglycan is expressed in germ cells [154]. In general, activin treatment reduces hCG-driven Leydig cell production of androgens [155] while inhibin action can prevent activin effects [155], and has been shown to stimulate testosterone release in some [156] but not all [157] studies. In terms of actions on gamete production, activin and inhibin tend to have opposing actions with activin stimulating [158] and inhibin reducing [159, 160] spermatogenesis. Inhibin- α -deficient mice have large testes and develop gonadal stromal tumors that appear to occur due to activin excess [161] and over-expression of the α -subunit in transgenic mice results in hypospermatogenesis [162]. Thus, the balance of activin and inhibin (and potentially follistatin), directly in the testes, may impact both endocrine signals via altered testosterone production as well as gamete maturation.

Neuroendocrine Mechanisms for the Differential Control of FSH and LH

In addition to the selective regulation of FSH- β mRNA levels by pituitary activin and follistatin and by testicular inhibin-B, there may be other mechanisms for the differential secretion of FSH and LH. Results from studies in rats [163] and rat pituitary cell cultures [164] revealed that the frequency of GnRH pulses regulates LH- β and FSH- β mRNA levels differently, with very rapid GnRH pulse frequencies (every 15–30 min) favoring LH- β over FSH- β gene expression.

Variation in GnRH pulse frequency has been shown to activate distinct signaling pathways to affect gonadotropin subunit transcription (for review see [165]). LH- β transcription is dependent on early growth response-1 protein (Egr-1). Egr-1 expression has been shown to increase with high-frequency GnRH, while the Egr-1 corepressor, Nab-2, is increased during low-frequency GnRH delivery [166]. Other recent studies have revealed that PKA can selectively stimulate FSH- β in response to GnRH at both fast and slow pulse frequencies [167]. Low-frequency GnRH pulses stimulate PKA activity and increase FOS and JUN proto-oncogenes which stimulate the FSH- β gene promoter [167]. High-frequency GnRH stimulates corepressors of FOS and JUN (ICER, SKIL and TGIF-1) which negatively regulate the FSH- β promoter [168, 169].

Up-regulation of pituitary follistatin by rapid GnRH pulse frequencies [164] with blockade of activin-stimulated FSH- β gene expression may also occur. Follistatin mRNA levels are inversely correlated with GnRH pulse frequency, with rapid frequencies supporting maximal follistatin expression and slower frequencies causing a selective rise in FSH- β mRNA without an increase in follistatin [163].

While GnRH pulse frequency seems to differentially regulate FSH and LH in rodents, its importance in men is less certain. For example, in men with congenital hypogonadotropic hypogonadism (e.g., Kallmann syndrome) who were treated long term with pulsatile GnRH, increasing the frequency of GnRH stimulation from every 2 h to every 30 min for 7 days increased serum LH levels threefold, but FSH levels rose by 50% [170]. In a second study in a similar patient population, increasing the GnRH pulse frequency from every 1.5 h to every 0.5 h suppressed plasma FSH but plasma LH levels were unchanged [171]. In both studies, changes in testosterone, estradiol and inhibin-B levels as a consequence of increased GnRH may have influenced the results.

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide that stimulates α -subunit transcription, and lengthens LH- β mRNA transcripts and presumably prolongs

half-life, but suppresses FSH- β mRNA levels in part by stimulating follistatin transcription [172]. These observations in vitro suggest PACAP could play a role in the differential production of FSH and LH. Recent analysis of transgenic mice that over-express PACAP in the pituitary has provided in vivo evidence for an autocrine/paracrine role for PACAP in the differential regulation of the gonadotropins during sexual maturation [173]. PACAP can directly affect gonadotrophs as well as modulate the effects of GnRH through interactions of intracellular signaling mechanisms (for review, see Halvorson, 2014 [174]). PACAP can stimulate gonadotropin synthesis and secretion from human gonadotrophinomas [175]. The role of PACAP in the physiological regulation of gonadotropins in humans has not been fully established to date and will require future investigation.

Conclusion

This chapter provides background information on the normal function of the hypothalamic-pituitary-testicular unit in men. The recent growth of understanding of this system through the application of molecular and cellular methods is impressive. In the following chapters, conditions that disrupt these normal processes are discussed.

References

1. Goldsmith PCTK, Song T, Kim EJ, Boggan JE. Location of the neuroendocrine gonadotropin-releasing hormone neurons in the monkey hypothalamus by retrograde tracing and immunostaining. *J Neuroendocrinol.* 1990;2:157–68.
2. Jin JM, Yang WX. Molecular regulation of hypothalamus-pituitary-gonads axis in males. *Gene.* 2014;551:15–25.
3. El Majdoubi M, Sahu A, Plant TM. Changes in hypothalamic gene expression associated with the arrest of pulsatile gonadotropin-releasing hormone release during infancy in the agonadal male rhesus monkey (*Macaca mulatta*). *Endocrinology.* 2000;141:3273–7.
4. Wu TJ, Mani SK, Glucksman MJ, Roberts JL. Stimulation of luteinizing hormone-releasing

- hormone (LHRH) gene expression in GT1-7 cells by its metabolite, LHRH-(1-5). *Endocrinology*. 2005;146:280–6.
5. Iyer AK, Brayman MJ, Mellon PL. Dynamic chromatin modifications control GnRH gene expression during neuronal differentiation and protein kinase C signal transduction. *Mol Endocrinol*. 2011;25:460–73.
 6. Kurian JR, Keen KL, Terasawa E. Epigenetic changes coincide with in vitro primate GnRH neuronal maturation. *Endocrinology*. 2010;151:5359–68.
 7. Van Vugt DA, Diefenbach WD, Alston E, Ferin M. Gonadotropin-releasing hormone pulses in third ventricular cerebrospinal fluid of ovariectomized rhesus monkeys: correlation with luteinizing hormone pulses. *Endocrinology*. 1985;117:1550–8.
 8. Caraty A, Locatelli A. Effect of time after castration on secretion of LHRH and LH in the ram. *J Reprod Fertil*. 1988;82:263–9.
 9. Kotani M, Dethoux M, Vandenberghe A, Comuni D, Vanderwinden JM, Le Poul E, Brezillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, Blanpain C, Schiffmann SN, Vassart G, Parmentier M. The metastasis suppressor gene *KiSS-1* encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. *J Biol Chem*. 2001;276:34631–6.
 10. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. *KiSS-1*, a novel human malignant melanoma metastasis-suppressor gene. *J Natl Cancer Inst*. 1996;88:1731–7.
 11. Seminara SB, Messenger S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O’Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH. The GPR54 gene as a regulator of puberty. *N Engl J Med*. 2003;349:1614–27.
 12. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the *KiSS1*-derived peptide receptor GPR54. *Proc Natl Acad Sci U S A*. 2003;100:10972–6.
 13. d’Anglemont de Tassigny X, Fagg LA, Dixon JP, Day K, Leitch HG, Hendrick AG, Zahn D, Franceschini I, Caraty A, Carlton MB, Aparicio SA, Colledge WH. Hypogonadotropic hypogonadism in mice lacking a functional *Kiss1* gene. *Proc Natl Acad Sci U S A* 2007;104:10714–19.
 14. Messenger S, Chatzidaki EE, Ma D, Hendrick AG, Zahn D, Dixon J, Thresher RR, Malinge I, Lomet D, Carlton MB, Colledge WH, Caraty A, Aparicio SA. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. *Proc Natl Acad Sci U S A*. 2005;102:1761–6.
 15. Hrabovszky E, Ciofi P, Vida B, Horvath MC, Keller E, Caraty A, Bloom SR, Ghatei MA, Dhillon WS, Liposits Z, Kallo I. The kisspeptin system of the human hypothalamus: sexual dimorphism and relationship with gonadotropin-releasing hormone and neurokinin B neurons. *Eur J Neurosci*. 2010;31:1984–98.
 16. George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. *Clin Endocrinol*. 2013;79:100–4.
 17. George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. *J Clin Endocrinol Metab*. 2011;96:E1228–36.
 18. Shahab M, Mastronardi C, Seminara SB, Crowley WF, Ojeda SR, Plant TM. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. *Proc Natl Acad Sci U S A*. 2005;102:2129–34.
 19. Roseweir AK, Kauffman AS, Smith JT, Guerriero KA, Morgan K, Pielecka-Fortuna J, Pineda R, Gottsch ML, Tena-Sempere M, Moenter SM, Terasawa E, Clarke IJ, Steiner RA, Millar RP. Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation. *J Neurosci Official J Soc Neurosci*. 2009;29:3920–9.
 20. Knobil E. The electrophysiology of the GnRH pulse generator in the rhesus monkey. *J Steroid Biochem*. 1989;33:669–71.
 21. Campbell RE, Gaidamaka G, Han SK, Herbison AE. Dendro-dendritic bundling and shared synapses between gonadotropin-releasing hormone neurons. *Proc Natl Acad Sci U S A*. 2009;106:10835–40.
 22. Krsmanovic LZ, Martinez-Fuentes AJ, Arora KK, Mores N, Tomic M, Stojilkovic SS, Catt KJ. Local regulation of gonadotroph function by pituitary gonadotropin-releasing hormone. *Endocrinology*. 2000;141:1187–95.
 23. Vazquez-Martinez R, Leclerc GM, Wierman ME, Boockfor FR. Episodic activation of the rat GnRH promoter: role of the homeoprotein oct-1. *Mol Endocrinol*. 2002;16:2093–100.
 24. Leclerc GM, Bose SK, Boockfor FR. Specific GATA-binding elements in the GnRH promoter are required for gene expression pulse activity: role of GATA-4 and GATA-5 in this intermittent process. *Neuroendocrinology*. 2008;88:1–16.
 25. Plant TM, Krey LC, Moossy J, McCormack JT, Hess DL, Knobil E. The arcuate nucleus and the control of gonadotropin and prolactin secretion in the female rhesus monkey (*Macaca mulatta*). *Endocrinology*. 1978;102:52–62.
 26. Ramaswamy S, Guerriero KA, Gibbs RB, Plant TM. Structural interactions between kisspeptin and GnRH neurons in the mediobasal hypothalamus of the male rhesus monkey (*Macaca mulatta*)

- as revealed by double immunofluorescence and confocal microscopy. *Endocrinology*. 2008;149:4387–95.
27. Plant TM, Ramaswamy S, Dipietro MJ. Repetitive activation of hypothalamic G protein-coupled receptor 54 with intravenous pulses of kisspeptin in the juvenile monkey (*Macaca mulatta*) elicits a sustained train of gonadotropin-releasing hormone discharges. *Endocrinology*. 2006;147:1007–13.
 28. Chan YM, Butler JP, Pinnell NE, Pralong FP, Crowley WF Jr, Ren C, Chan KK, Seminara SB. Kisspeptin resets the hypothalamic GnRH clock in men. *J Clin Endocrinol Metab*. 2011;96:E908–15.
 29. Keen KL, Wegner FH, Bloom SR, Ghatei MA, Terasawa E. An increase in kisspeptin-54 release occurs with the pubertal increase in luteinizing hormone-releasing hormone-1 release in the stalk-median eminence of female rhesus monkeys in vivo. *Endocrinology*. 2008;149:4151–7.
 30. Krajewski SJ, Burke MC, Anderson MJ, McMullen NT, Rance NE. Forebrain projections of arcuate neurokinin B neurons demonstrated by anterograde tract-tracing and monosodium glutamate lesions in the rat. *Neuroscience*. 2010;166:680–97.
 31. Burke MC, Letts PA, Krajewski SJ, Rance NE. Coexpression of dynorphin and neurokinin B immunoreactivity in the rat hypothalamus: morphologic evidence of interrelated function within the arcuate nucleus. *J Comp Neurol*. 2006;498:712–26.
 32. Guran T, Tolhurst G, Bereket A, Rocha N, Porter K, Turan S, Gribble FM, Kotan LD, Akcay T, Atay Z, Canan H, Serin A, O'Rahilly S, Reimann F, Semple RK, Topaloglu AK. Hypogonadotropic hypogonadism due to a novel missense mutation in the first extracellular loop of the neurokinin B receptor. *J Clin Endocrinol Metab*. 2009;94:3633–9.
 33. Urbanski HF, Kohama SG, Garyfallou VT. Mechanisms mediating the response of GnRH neurones to excitatory amino acids. *Rev Reprod*. 1996;1:173–81.
 34. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. *Proc Natl Acad Sci U S A*. 1998;95:305–9.
 35. Sherwood NM, Lovejoy DA, Coe IR. Origin of mammalian gonadotropin-releasing hormones. *Endocr Rev*. 1993;14:241–54.
 36. Lescheid DW, Terasawa E, Ablner LA, Urbanski HF, Warby CM, Millar RP, Sherwood NM. A second form of gonadotropin-releasing hormone (GnRH) with characteristics of chicken GnRH-II is present in the primate brain. *Endocrinology*. 1997;138:5618–29.
 37. Neill JD, Duck LW, Sellers JC, Musgrove LC. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. *Biochem Biophys Res Commun*. 2001;282:1012–8.
 38. van Biljon W, Wykes S, Scherer S, Krawetz SA, Hapgood J. Type II gonadotropin-releasing hormone receptor transcripts in human sperm. *Biol Reprod*. 2002;67:1741–9.
 39. Vega MG, Zarek SM, Bhagwat M, Segars JH. Gonadotropin surge-inhibiting/attenuating factors: a review of current evidence, potential applications, and future directions for research. *Mol Reprod Dev*. 2015;82:2–16.
 40. Batool A, Naz R, Wazir M, Azam A, Ullah R, Wahab F, Shahab M. Acute fasting-induced repression of the hypothalamic-pituitary-gonadal axis is reversed by RF-9 administration in the adult male macaque. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme* 2014;46:927–832.
 41. Childs GV. Division of labor among gonadotropes. *Vitam Horm*. 1995;50:215–86.
 42. Okada Y, Fujii Y, Moore JP Jr, Winters SJ. Androgen receptors in gonadotrophs in pituitary cultures from adult male monkeys and rats. *Endocrinology*. 2003;144:267–73.
 43. Meeran D, Urbanski HF, Gregory SJ, Townsend J, Tortorese DJ. Developmental changes in the hormonal identity of gonadotroph cells in the rhesus monkey pituitary gland. *J Clin Endocrinol Metab*. 2003;88:2934–42.
 44. Shacham S, Harris D, Ben-Shlomo H, Cohen I, Bonfil D, Przedeki F, Lewy H, Ashkenazi IE, Seger R, Naor Z. Mechanism of GnRH receptor signaling on gonadotropin release and gene expression in pituitary gonadotrophs. *Vitam Horm*. 2001;63:63–90.
 45. Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. *Endocr Rev*. 1994;15:462–99.
 46. Conn PM, Janovick JA, Stanislaus D, Kuphal D, Jennes L. Molecular and cellular bases of gonadotropin-releasing hormone action in the pituitary and central nervous system. *Vitam Horm*. 1995;50:151–214.
 47. Stanislaus D, Ponder S, Ji TH, Conn PM. Gonadotropin-releasing hormone receptor couples to multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and overexpression of G proteins. *Biol Reprod*. 1998;59:579–86.
 48. Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM, Webster NJ. Involvement of both G (q11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells. *J Biol Chem*. 2002;277:32099–108.
 49. Weck J, Anderson AC, Jenkins S, Fallest PC, Shupnik MA. Divergent and composite gonadotropin-releasing hormone-responsive elements in the rat luteinizing hormone subunit genes. *Mol Endocrinol*. 2000;14:472–85.
 50. Haisenleder DJ, Yasin M, Marshall JC. Gonadotropin subunit and gonadotropin-releasing hormone receptor gene expression are regulated by

- alterations in the frequency of calcium pulsatile signals. *Endocrinology*. 1997;138:5227–30.
51. Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. *Endocrinology*. 1993;133:931–4.
 52. Clayton RN, Catt KJ. Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. *Endocr Rev*. 1981;2:186–209.
 53. McArdle CA, Counis R. GnRH and PACAP action in gonadotropes: cross-talk between phosphoinositidase C and adenylyl cyclase mediated signaling pathways. *Trends Endocrinol Metab*. 1996;7:168–75.
 54. Pawson AJ, Faccenda E, Maudsley S, Lu ZL, Naor Z, Millar RP. Mammalian type I gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization. *Endocrinology*. 2008;149:1415–22.
 55. McArdle CA, Davidson JS, Willars GB. The tail of the gonadotrophin-releasing hormone receptor: desensitization at, and distal to G protein-coupled receptors. *Mol Cell Endocrinol*. 1999;151:129–36.
 56. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. *Traffic*. 2004;5:821–37.
 57. McArdle CA, Forrest-Owen W, Willars G, Davidson J, Poch A, Kratzmeier M. Desensitization of gonadotropin-releasing hormone action in the gonadotrope-derived alpha T3-1 cell line. *Endocrinology*. 1995;136:4864–71.
 58. Pawson AJ, Katz A, Sun YM, Lopes J, Illing N, Millar RP, Davidson JS. Contrasting internalization kinetics of human and chicken gonadotropin-releasing hormone receptors mediated by C-terminal tail. *J Endocrinol*. 1998;156:R9–12.
 59. Avet C, Garrel G, Denoyelle C, Laverriere JN, Counis R, Cohen-Tannoudji J, Simon V. SET protein interacts with intracellular domains of the gonadotropin-releasing hormone receptor and differentially regulates receptor signaling to cAMP and calcium in gonadotrope cells. *J Biol Chem*. 2013;288:2641–54.
 60. Kaiser UB, Halvorson LM, Chen MT. Sp1, steroidogenic factor 1 (SF-1), and early growth response protein 1 (egr-1) binding sites form a tripartite gonadotropin-releasing hormone response element in the rat luteinizing hormone-beta gene promoter: an integral role for SF-1. *Mol Endocrinol*. 2000;14:1235–45.
 61. Strahl BD, Huang HJ, Sebastian J, Ghosh BR, Miller WL. Transcriptional activation of the ovine follicle-stimulating hormone beta-subunit gene by gonadotropin-releasing hormone: involvement of two activating protein-1-binding sites and protein kinase C. *Endocrinology*. 1998;139:4455–65.
 62. Maurer RA, Kim KE, Schoderbek WE, Roberston MS, Glenn DJ. Regulation of glycoprotein hormone alpha-subunit gene expression. *Recent Prog Horm Res*. 1999;54:455–84.
 63. Chedrese PJ, Kay TW, Jameson JL. Gonadotropin-releasing hormone stimulates glycoprotein hormone alpha-subunit messenger ribonucleic acid (mRNA) levels in alpha T3 cells by increasing transcription and mRNA stability. *Endocrinology*. 1994;134:2475–81.
 64. Xing Y, Williams C, Campbell RK, Cook S, Knoppers M, Addona T, Altarocca V, Moyle WR. Threading of a glycosylated protein loop through a protein hole: implications for combination of human chorionic gonadotropin subunits. *Protein Sci*. 2001;10:226–35.
 65. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypophysal gonadotropin-releasing hormone. *Science*. 1978;202:631–3.
 66. Nankin HR, Troen P. Repetitive luteinizing hormone elevations in serum of normal men. *J Clin Endocrinol Metab*. 1971;33:558–60.
 67. Crowley WF Jr, McArthur JW. Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH). *J Clin Endocrinol Metab*. 1980;51:173–5.
 68. Brodie TD, Crowley WF Jr. Neuroendocrine control of reproduction and its therapeutic manipulation with GnRH and its analogs. *Int J Fertil*. 1985;30:66–70 74–65.
 69. Labrie F. Endocrine therapy for prostate cancer. *Endocrinol Metab Clin North Am*. 1991;20:845–72.
 70. Padmanabhan V, McFadden K, Mauger DT, Karsch FJ, Midgley AR Jr. Neuroendocrine control of follicle-stimulating hormone (FSH) secretion. I. Direct evidence for separate episodic and basal components of FSH secretion. *Endocrinology*. 1997;138:424–32.
 71. Veldhuis JD, Johnson ML. Testing pulse detection algorithms with simulations of episodically pulsatile substrate, metabolite, or hormone release. *Methods Enzymol*. 1994;240:377–415.
 72. Spratt DI, Carr DB, Merriam GR, Scully RE, Rao PN, Crowley WF Jr. The spectrum of abnormal patterns of gonadotropin-releasing hormone secretion in men with idiopathic hypogonadotropic hypogonadism: clinical and laboratory correlations. *J Clin Endocrinol Metab*. 1987;64:283–91.
 73. Boyar RM, Rosenfeld RS, Kapen S, Finkelstein JW, Roffwarg HP, Weitzman ED, Hellman L. Human puberty. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. *J Clin Invest*. 1974;54:609–18.
 74. Liu PY, Iranmanesh A, Keenan DM, Pincus SM, Veldhuis JD. A noninvasive measure of negative-feedback strength, approximate entropy, unmasks strong diurnal variations in the regularity of LH secretion. *Am J Physiol Endocrinol Metab*. 2007;293:E1409–15.

75. Schmid SM, Hallschmid M, Fau-Jauch-Chara K, Jauch-Chara K, Fau-Lehnert H, Lehnert H, Fau-Schultes B, Schultes B. Sleep timing may modulate the effect of sleep loss on testosterone. *J Clin Endocrinol Metab.* 2001;86:1134–9.
76. Luboshitzky R, Zabari Z, Shen-Orr Z, Herer P, Lavie P. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. *J Clin Endocrinol Metab.* 2001;86:1134–9.
77. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. *J Clin Endocrinol Metab.* 1983;56:1278–81.
78. Winters SJ. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. *J Androl.* 1991;12:185–90.
79. Payne AH, Youngblood GL. Regulation of expression of steroidogenic enzymes in Leydig cells. *Biol Reprod.* 1995;52:217–25.
80. Dufau ML. The luteinizing hormone receptor. *Annu Rev Physiol.* 1998;60:461–96.
81. Stocco DM. StAR protein and the regulation of steroid hormone biosynthesis. *Annu Rev Physiol.* 2001;63:193–213.
82. Miller WL. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. *Biochim Biophys Acta.* 2007;1771:663–76.
83. Mannaerts B, de Leeuw R, Geelen J, Van Ravestein A, Van Wezenbeek P, Schuurs A, Kloosterboer H. Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone. *Endocrinology.* 1991;129:2623–30.
84. Majumdar SS, Winters SJ, Plant TM. A study of the relative roles of follicle-stimulating hormone and luteinizing hormone in the regulation of testicular inhibin secretion in the rhesus monkey (*Macaca mulatta*). *Endocrinology.* 1997;138:1363–73.
85. Rebourcet D, O'Shaughnessy PJ, Monteiro A, Milne L, Cruickshanks L, Jeffrey N, Guillou F, Freeman TC, Mitchell RT, Smith LB. Sertoli cells maintain Leydig cell number and peritubular myoid cell activity in the adult mouse testis. *PLoS ONE.* 2014;9:e105687.
86. Vierhapper H, Nowotny P, Waldhausl W. production rates of testosterone in patients with Cushing's syndrome. *Metabolism.* 2000;49:229–31.
87. Jarow JP, Zirkin BR. The androgen microenvironment of the human testis and hormonal control of spermatogenesis. *Ann N Y Acad Sci.* 2005;1061:208–20.
88. Joseph DR. Structure, function, and regulation of androgen-binding protein/sex hormone-binding globulin. *Vitam Horm.* 1994;49:197–280.
89. Coviello AD, Bremner WJ, Matsumoto AM, Herbst KL, Amory JK, Anawalt BD, Yan X, Brown TR, Wright WW, Zirkin BR, Jarow JP. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. *J Androl.* 2004;25:931–8.
90. Page ST, Kalthorn TF, Bremner WJ, Anawalt BD, Matsumoto AM, Amory JK. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. *J Androl.* 2007;28:734–41.
91. Jones ME, Simpson ER. Oestrogens in male reproduction. *Baillieres Best Pract Res Clin Endocrinol Metab.* 2000;14:505–16.
92. Brodie A, Inkster S, Yue W. Aromatase expression in the human male. *Mol Cell Endocrinol.* 2001;178:23–8.
93. Couse JF, Curtis Hewitt S, Korach KS. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. *J Steroid Biochem Mol Biol.* 2000;74:287–96.
94. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor- alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. *Endocrinology.* 1997;138:4613–21.
95. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallas JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med.* 2013;369:1011–22.
96. Robertson KM, O'Donnell L, Jones ME, Meachem SJ, Boon WC, Fisher CR, Graves KH, McLachlan RI, Simpson ER. Impairment of spermatogenesis in mice lacking a functional aromatase (*cyp 19*) gene. *Proc Natl Acad Sci U S A.* 1999;96:7986–91.
97. Plant TM. Effects of orchidectomy and testosterone replacement treatment on pulsatile luteinizing hormone secretion in the adult rhesus monkey (*Macaca mulatta*). *Endocrinology.* 1982;110:1905–13.
98. Plant TM, Dubey AK. Evidence from the rhesus monkey (*Macaca mulatta*) for the view that negative feedback control of luteinizing hormone secretion by the testis is mediated by a deceleration of hypothalamic gonadotropin-releasing hormone pulse frequency. *Endocrinology.* 1984;115:2145–53.
99. Winters SJ, Kawakami S, Sahu A, Plant TM. Pituitary follistatin and activin gene expression, and the testicular regulation of FSH in the adult Rhesus monkey (*Macaca mulatta*). *Endocrinology.* 2001;142:2874–8.
100. Kawakami S, Winters SJ. Regulation of luteinizing hormone secretion and subunit messenger ribonucleic acid expression by gonadal steroids in perfused pituitary cells from male monkeys and rats. *Endocrinology.* 1999;140:3587–93.
101. Finkelstein JS, Whitcomb RW, O'Dea LS, Longcope C, Schoenfeld DA, Crowley WF Jr. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone

- administration in normal and gonadotropin-releasing hormone-deficient men. *J Clin Endocrinol Metab.* 1991;73:609–20.
102. Bagatell CJ, Dahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. *J Androl.* 1994;15:15–21.
103. Naftolin F, Pujol-Amat P, Corker CS, Shane JM, Polani PE, Kohlinsky S, Yen SS, Bobrow M. Gonadotropins and gonadal steroids in androgen insensitivity (testicular feminization) syndrome: effects of castration and sex steroid administration. *Am J Obstet Gynecol.* 1983;147:491–6.
104. Winters SJ, Troen P. Evidence for a role of endogenous estrogen in the hypothalamic control of gonadotropin secretion in men. *J Clin Endocrinol Metab.* 1985;61:842–5.
105. Marynick SP, Loriaux DL, Sherins RJ, Pita JC Jr, Lipsitt MB. Evidence that testosterone can suppress pituitary gonadotropin secretion independently of peripheral aromatization. *J Clin Endocrinol Metab.* 1979;49:396–8.
106. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF Jr. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. *J Clin Endocrinol Metab.* 2000;85:3027–35.
107. Veldhuis JD, Iranmanesh A. Short-term aromatase-enzyme blockade unmasks impaired feedback adaptations in luteinizing hormone and testosterone secretion in older men. *J Clin Endocrinol Metab.* 2005;90:211–8.
108. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. *J Clin Endocrinol Metab.* 1999;84:4677–94.
109. Chen Z, Wang O, Nie M, Elison K, Zhou D, Li M, Jiang Y, Xia W, Meng X, Chen S, Xing X. Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism. *Mol Cell Endocrinol.* 2015;399:32–42.
110. Baykan EK, Erdogan M, Ozen S, Darcan S, Saygili LF. Aromatase deficiency, a rare syndrome: case report. *J Clin Res Pediatr Endocrinol.* 2013;5:129–32.
111. Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. *J Clin Invest.* 1973;52:2617–28.
112. Popa SM, Clifton DK, Steiner RA. The role of kisspeptins and GPR54 in the neuroendocrine regulation of reproduction. *Annu Rev Physiol.* 2008;70:213–38.
113. Smith JT, Dungan HM, Stoll EA, Gottsch ML, Braun RE, Eacker SM, Clifton DK, Steiner RA. Differential regulation of KiSS-1 mRNA expression by sex steroids in the brain of the male mouse. *Endocrinology.* 2005;146:2976–84.
114. Shibata M, Friedman RL, Ramaswamy S, Plant TM. Evidence that down regulation of hypothalamic KiSS-1 expression is involved in the negative feedback action of testosterone to regulate luteinizing hormone secretion in the adult male rhesus monkey (*Macaca mulatta*). *J Neuroendocrinol.* 2007;19:432–8.
115. Molnar CS, Vida B, Sipos MT, Ciofi P, Borsary BA, Racz K, Herczeg L, Bloom SR, Ghatei MA, Dhillon WS, Liposits Z, Hrabovszky E. Morphological evidence for enhanced kisspeptin and neuropeptide Y signaling in the infundibular nucleus of the aging man. *Endocrinology.* 2012;153:5428–39.
116. Winters SJ, Atkinson L. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. *Testosterone Study Group Clin Endocrinol.* 1997;47:317–22.
117. Mather JP, Moore A, Li RH. Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. *Proc Soc Exp Biol Med.* 1997;215:209–22.
118. McDowell N, Gurdon JB. Activin as a morphogen in *Xenopus* mesoderm induction. *Semin Cell Dev Biol.* 1999;10:311–7.
119. Munz B, Tretter YP, Hertel M, Engelhardt F, Alzheimer C, Werner S. The roles of activins in repair processes of the skin and the brain. *Mol Cell Endocrinol.* 2001;180:169–77.
120. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM. Evidence for activin A and follistatin involvement in the systemic inflammatory response. *Mol Cell Endocrinol.* 2001;180:155–62.
121. Plendl J. Angiogenesis and vascular regression in the ovary. *Anat Histol Embryol.* 2000;29:257–66.
122. Woodruff TK, Sluss P, Wang E, Janssen I, Mersol-Barg MS. Activin A and follistatin are dynamically regulated during human pregnancy. *J Endocrinol.* 1997;152:167–74.
123. Loomans HA, Andl CD. Intertwining of activin A and TGFbeta signaling: dual roles in cancer progression and cancer cell invasion. *Cancers.* 2014;7:70–91.
124. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. *Science.* 2002;296:1646–7.
125. Pangas SA, Woodruff TK. Activin signal transduction pathways. *Trends Endocrinol Metab.* 2000;11:309–14.
126. Mathews LS, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. *Cell.* 1991;65:973–82.
127. Mathews LS, Vale WW, Kintner CR. Cloning of a second type of activin receptor and functional characterization in *Xenopus* embryos. *Science.* 1992;255:1702–5.

128. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. *Nature*. 1994;370:341-7.
129. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. *Cell*. 1993;75:671-80.
130. Tsuchida K, Lewis KA, Mathews LS, Vale WW. Molecular characterization of rat transforming growth factor-beta type II receptor. *Biochem Biophys Res Commun*. 1993;191:790-5.
131. DePaolo LV. Inhibins, activins, and follistatins: the saga continues. *Proc Soc Exp Biol Med*. 1997;214:328-39.
132. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. *Nature*. 2000;404:411-4.
133. Kawakami S, Fujii Y, Okada Y, Winters SJ. Paracrine regulation of FSH by follistatin in folliculostellate cell-enriched primate pituitary cell cultures. *Endocrinology*. 2002;143:2250-8.
134. Kaiser UB, Chin WW. Regulation of follistatin messenger ribonucleic acid levels in the rat pituitary. *J Clin Invest*. 1993;91:2523-31.
135. Marchetti C, Hamdane M, Mitchell V, Mayo K, Devisme L, Rigot JM, Beauvillain JC, Hermand E, Defossez A. Immunolocalization of inhibin and activin alpha and betaB subunits and expression of corresponding messenger RNAs in the human adult testis. *Biol Reprod*. 2003;68:230-5.
136. Burger HG, Robertson DM. Editorial: inhibin in the male—Progress at last. *Endocrinology*. 1997;138:1361-2.
137. McCullagh D. Dual endocrine activity of the testes. *Science*. 1932;76:19-20.
138. de Winter JP, Themmen AP, Hoogerbrugge JW, Klaij IA, Grootegoed JA, de Jong FH. Activin receptor mRNA expression in rat testicular cell types. *Mol Cell Endocrinol*. 1992;83:R1-8.
139. Feng ZM, Wu AZ, Zhang Z, Chen CL. GATA-1 and GATA-4 transactivate inhibin/activin beta-B-subunit gene transcription in testicular cells. *Mol Endocrinol*. 2000;14:1820-35.
140. Anderson RA, Wallace EM, Groome NP, Bellis AJ, Wu FC. Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone. *Hum Reprod*. 1997;12:746-51.
141. Adamopoulos D, Kapolla N, Nicopoulou S, Pappa A, Koukkou E, Gregoriou A. Assessment of Sertoli cell functional reserve and its relationship to sperm parameters. *Int J Androl*. 2003;26:215-25.
142. Wallace EM, Groome NP, Riley SC, Parker AC, Wu FC. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: a prospective longitudinal study. *J Clin Endocrinol Metab*. 1997;82:3111-5.
143. Pierik FH, Vreeburg JT, Stijnen T, De Jong FH, Weber RF. Serum inhibin B as a marker of spermatogenesis. *J Clin Endocrinol Metab*. 1998;83:3110-4.
144. de Kretser DM, Robertson DM. The isolation and physiology of inhibin and related proteins. *Biol Reprod*. 1989;40:33-47.
145. Ramaswamy S, Pohl CR, McNeilly AS, Winters SJ, Plant TM. The time course of follicle-stimulating hormone suppression by recombinant human inhibin A in the adult male rhesus monkey (*Macaca mulatta*). *Endocrinology*. 1998;139:3409-15.
146. Carroll RS, Corrigan AZ, Gharib SD, Vale W, Chin WW. Inhibin, activin, and follistatin: regulation of follicle-stimulating hormone messenger ribonucleic acid levels. *Mol Endocrinol*. 1989;3:1969-76.
147. Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. *J Clin Endocrinol Metab*. 1996;81:3341-5.
148. Bohring C, Krause W. Serum levels of inhibin B in men of different age groups. *Aging Male Official J Int Soc Study Aging Male*. 2003;6:73-8.
149. Ramaswamy S, Marshall GR, McNeilly AS, Plant TM. Dynamics of the follicle-stimulating hormone (FSH)-inhibin B feedback loop and its role in regulating spermatogenesis in the adult male rhesus monkey (*Macaca mulatta*) as revealed by unilateral orchidectomy. *Endocrinology*. 2000;141:18-27.
150. Ramaswamy S, Marshall GR, McNeilly AS, Plant TM. Evidence that in a physiological setting Sertoli cell number is the major determinant of circulating concentrations of inhibin B in the adult male rhesus monkey (*Macaca mulatta*). *J Androl*. 1999;20:430-4.
151. Kaipia A, Parvinen M, Toppari J. Localization of activin receptor (ActR-IIB2) mRNA in the rat seminiferous epithelium. *Endocrinology*. 1993;132:477-9.
152. Krummen LA, Moore A, Woodruff TK, Covello R, Taylor R, Working P, Mather JP. Localization of inhibin and activin binding sites in the testis during development by in situ ligand binding. *Biol Reprod*. 1994;50:734-44.
153. Chong H, Pangas SA, Bernard DJ, Wang E, Gitch J, Chen W, Draper LB, Cox ET, Woodruff TK. Structure and expression of a membrane component of the inhibin receptor system. *Endocrinology*. 2000;141:2600-7.
154. MacConell LA, Leal AM, Vale WW. The distribution of betaglycan protein and mRNA in rat brain, pituitary, and gonads: implications for a role for betaglycan in inhibin-mediated reproductive functions. *Endocrinology*. 2002;143:1066-75.

155. Lin T, Calkins JK, Morris PL, Vale W, Bardin CW. Regulation of Leydig cell function in primary culture by inhibin and activin. *Endocrinology*. 1989;125:2134–40.
156. Hsueh AJ, Dahl KD, Vaughan J, Tucker E, Rivier J, Bardin CW, Vale W. Heterodimers and homodimers of inhibin subunits have different paracrine action in the modulation of luteinizing hormone-stimulated androgen biosynthesis. *Proc Natl Acad Sci U S A*. 1987;84:5082–6.
157. Risbridger GP, Clements J, Robertson DM, Drummond AE, Muir J, Burger HG, de Kretser DM. Immuno- and bioactive inhibin and inhibin alpha-subunit expression in rat Leydig cell cultures. *Mol Cell Endocrinol*. 1989;66:119–22.
158. Mather JP, Attie KM, Woodruff TK, Rice GC, Phillips DM. Activin stimulates spermatogonial proliferation in germ-Sertoli cell cocultures from immature rat testis. *Endocrinology*. 1990;127:3206–14.
159. van Dissel-Emiliani FM, Grootenhuis AJ, de Jong FH, de Rooij DG. Inhibin reduces spermatogonial numbers in testes of adult mice and Chinese hamsters. *Endocrinology*. 1989;125:1899–903.
160. Hakovirta H, Kaipia A, Soder O, Parvinen M. Effects of activin-A, inhibin-A, and transforming growth factor-beta 1 on stage-specific deoxyribonucleic acid synthesis during rat seminiferous epithelial cycle. *Endocrinology*. 1993;133:1664–8.
161. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. *Proc Natl Acad Sci U S A*. 1994;91:8817–21.
162. McMullen ML, Cho BN, Yates CJ, Mayo KE. Gonadal pathologies in transgenic mice expressing the rat inhibin alpha-subunit. *Endocrinology*. 2001;142:5005–14.
163. Kirk SE, Dalkin AC, Yasin M, Haisenleder DJ, Marshall JC. Gonadotropin-releasing hormone pulse frequency regulates expression of pituitary follistatin messenger ribonucleic acid: a mechanism for differential gonadotrope function. *Endocrinology*. 1994;135:876–80.
164. Besecke LM, Guendner MJ, Schneyer AL, Bauer-Dantoin AC, Jameson JL, Weiss J. Gonadotropin-releasing hormone regulates follicle-stimulating hormone- beta gene expression through an activin/follistatin autocrine or paracrine loop. *Endocrinology*. 1996;137:3667–73.
165. Thompson IR, Kaiser UB. GnRH pulse frequency-dependent differential regulation of LH and FSH gene expression. *Mol Cell Endocrinol*. 2014;385:28–35.
166. Lawson MA, Tsutsumi R, Zhang H, Talukdar I, Butler BK, Santos SJ, Mellon PL, Webster NJ. Pulse sensitivity of the luteinizing hormone beta promoter is determined by a negative feedback loop involving early growth response-1 and Ngfi-A binding protein 1 and 2. *Mol Endocrinol*. 2007;21:1175–91.
167. Thompson IR, Ciccone NA, Xu S, Zaytseva S, Carroll RS, Kaiser UB. GnRH pulse frequency-dependent stimulation of FSHbeta transcription is mediated via activation of PKA and CREB. *Mol Endocrinol*. 2013;27:606–18.
168. Mistry DS, Tsutsumi R, Fernandez M, Sharma S, Cardenas SA, Lawson MA, Webster NJ. Gonadotropin-releasing hormone pulse sensitivity of follicle-stimulating hormone-beta gene is mediated by differential expression of positive regulatory activator protein 1 factors and corepressors SKIL and TGIF1. *Mol Endocrinol*. 2011;25:1387–403.
169. Ciccone NA, Xu S, Lacza CT, Carroll RS, Kaiser UB. Frequency-dependent regulation of follicle-stimulating hormone beta by pulsatile gonadotropin-releasing hormone is mediated by functional antagonism of bZIP transcription factors. *Mol Cell Biol*. 2010;30:1028–40.
170. Spratt DI, Finkelstein JS, Butler JP, Badger TM, Crowley WF Jr. Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men. *J Clin Endocrinol Metab*. 1987;64:1179–86.
171. Gross KM, Matsumoto AM, Berger RE, Bremner WJ. Increased frequency of pulsatile luteinizing hormone-releasing hormone administration selectively decreases follicle-stimulating hormone levels in men with idiopathic azoospermia. *Fertil Steril*. 1986;45:392–6.
172. Tsujii T, Ishizaka K, Winters SJ. Effects of pituitary adenylate cyclase-activating polypeptide on gonadotropin secretion and subunit messenger ribonucleic acids in perfused rat pituitary cells. *Endocrinology*. 1994;135:826–33.
173. Moore JP Jr, Yang RQ, Winters SJ. Targeted pituitary overexpression of pituitary adenylate-cyclase activating polypeptide alters postnatal sexual maturation in male mice. *Endocrinology*. 2012;153:1421–34.
174. Halvorson LM. PACAP modulates GnRH signaling in gonadotropes. *Mol Cell Endocrinol*. 2014;385:45–55.
175. Petersen B, Buchfelder M, Fahlbusch R, Adams EF. Pituitary adenylate cyclase-activating polypeptide directly stimulates LH and FSH secretion by human pituitary gonadotrophinomas. *Exp Clin Endocrinol Diab Official J Ger Soc Endocrinol Ger Diab Assoc* 1996;104:250–55.
176. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. *N Engl J Med*. 1994;331:1056–61.

-
177. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. *J Clin Endocrinol Metab.* 1995;80:3689–98.
178. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. *N Engl J Med.* 1997;337:91–5.

Peter J. O'Shaughnessy BSc, PhD

Contents

Introduction	25
Leydig Cell Development.....	25
Fetal Leydig Cells.....	27
Neonatal Leydig Cells	27
Adult Leydig Cells	27
Steroidogenic Function of Leydig Cells	28
Androgen Synthesis via the Canonical Pathway	29
Androgen Synthesis via the Alternative Pathway.....	29
Estrogen Synthesis by Human Leydig Cells	30
Androgen Secretion by the Leydig Cells/Testis	30
Other Functions of the Leydig Cell	30
Regulation of Leydig Cell Development and Function	31
Leydig Cell Development.....	31
Regulation of Leydig Cell Activity.....	32
Clinical Aspects	34
Leydig Cell Aging	34
Leydig Cell Tumors.....	36
Leydig Cell Toxicology.....	38
Conclusions—Future Work	38
References	39

Introduction

In all mammals, Leydig cells are the main source of the androgens required for development of the male phenotype, for germ cell production, and for male sex drive. The Leydig cells are essential, therefore, for masculinization, fertility, and reproductive health and, recent evidence would also suggest, for general adult wellbeing in the male [1]. In this chapter, the development, steroidogenic function and regulation of human Leydig cells will be summarized. Clinical aspects of aging and pathology related to Leydig cells will also be reviewed. The data presented is based, where possible, on information from the human, but there is a much larger database of rodent studies available and data from these studies is included where relevant.

Leydig Cell Development

Leydig cells were first described by the German histologist Franz Leydig in 1850 as prominent clusters of cells lying between the seminiferous tubules in a variety of mammals [2]. Subsequently, Leydig cells have been shown to be the major functional cell type in the interstitial compartment of the testis, separated from the seminiferous tubules by the peritubular myoid cells (Fig. 2.1). Human Leydig cells are ovoid or polygonal in shape with eosinophilic cytoplasm, a euchromatic

P.J. O'Shaughnessy (✉)
College of Medical Veterinary and Life Sciences,
University of Glasgow, Bearsden Rd.,
Glasgow G61 1QH, UK
e-mail: peter.oshaughnessy@glasgow.ac.uk




Fig. 2.1 Fetal testis. **a** Fetal mouse: low magnification of a semi-thin section showing seminiferous tubules (*ST*) and interstitial tissue (*I*). **b** Fetal mouse: higher magnification of (**a**) showing gonocytes (*G*) in the central part of the sex cord with the Sertoli cells (*S*) around the periphery. The peritubular myoid cells (*PMC*) form a concentric layer around the cord, and Leydig cells (*L*) are present within the interstitium. **c** Fetal human: immunohistochemically

labeled for the androgen receptor (*AR*) which is clearly expressed in *PMC* and in some interstitial cells. **d** Fetal human: immunohistochemically labeled for 3 β -hydroxysteroid dehydrogenase (*HSD3B*) which is localized exclusively in the Leydig cells. In all photomicrographs, the bar represents 50 μ m. Adapted from O'Shaughnessy and Fowler [22]. (c) Society for Reproduction and Fertility (2011). Reproduced with permission

round eccentric nucleus with a peripheral distribution of heterochromatin, and a conspicuous nucleolus. The predominant cytoplasmic organelle is the smooth endoplasmic reticulum (*SER*), which is characteristically abundant in steroidogenic cells, with mitochondria and lipid droplets also numerous (Fig. 2.2). Crystals of Reinke are variably found in normal adult human Leydig cells, although their composition and significance remains unknown.

In all mammalian species so far studied, two populations of Leydig cells have been identified. A fetal population that arises soon after testis differentiation, and an adult population which develops before puberty [3]. Until recently, it was thought that the fetal population regressed as the adult population developed, but evidence

from the mouse suggests that the fetal cells remain present in the adult at about 10% of the total Leydig cell number [4]. In humans, blood levels of testosterone peak three times during development [5], and it has been suggested that this is evidence for three populations of Leydig cells in humans [6]. The first peak occurs at 12–14 weeks of gestation, during the fetal differentiation of Leydig cells [7, 8]. Testosterone levels then decline and are low for the remainder of gestation and the very early neonatal period. There is a second peak of testosterone, with associated high levels of *INSL3*, at 2 months postpartum that has been associated with the “extra” population of Leydig cells in the human (termed neonatal Leydig cells—see below) [9–




Fig. 2.2 Pubertal adult human Leydig cells. This electron micrograph of a resin section shows part of two adult human Leydig cells. Lipid droplets (*L*) can be seen along with numerous mitochondria (example is indicated with an *arrowhead*) and abundant smooth endoplasmic reticulum. Reproduced from Prince [200] with permission from the publisher John Wiley and Sons

11]. This post-natal testosterone surge is often referred to as “minipuberty” and may act to increase reproductive growth and alter neurobehavioral development in boys [12]. Beyond the neonatal period, Leydig cell numbers regress, although whether the fetal cells degenerate or remain in a morphologically unrecognized state is not clear. Either way, the interstitium contains few steroidogenically active cells during infancy [3]. The adult generation of Leydig cells starts to differentiate prepubertally but is not complete until adulthood [13] with serum levels of testosterone averaging 6 ng/ml (20 nmol/L) during adulthood [14]. Finally, there is a decline in testosterone secretion with aging, which is variable in its magnitude and time of onset. This age-related decline is multifactorial (see below), but it is likely to be associated with decreased testosterone production by the Leydig cells.

Fetal Leydig Cells

The testes begin to develop in the human fetus at around 6 weeks of gestation, with migration of the preSertoli cells from the coelomic epithelium and formation of the sex cords [15]. Fetal Leydig cells can be identified in the interstitial compartment by about eight weeks of gestation [16]. Studies in the mouse indicate that the fetal Leydig cells originate

from two lineages: one arising from the coelomic epithelium and the other from cells associated with the vasculature along the gonad/mesonephros border [17]. Fetal Leydig cell numbers increase exponentially during the first half of the second trimester reaching a maximum number of about 2×10^6 around 18 weeks [7] before declining again toward birth [7, 18]. Testosterone is first detectable in the testis as early as 6–7 weeks of gestation [19] and rises toward the prenatal peak at 12–14 weeks [7, 20]. This peak in testosterone is due to the increasing number of fetal Leydig cells and to increasing levels of chorionic gonadotrophin (hCG) [21] which acts through the LHCGR to stimulate Leydig cell function. Testosterone levels decline in the second half of gestation as hCG levels drop markedly and Leydig cell numbers decline [8, 20]. Surviving Leydig cells in the second half of gestation are partly dependent on pituitary LH [22] for activity.

Neonatal Leydig Cells

Shortly after birth in the human, levels of LH rise and the number of Leydig cells increases leading to a neonatal surge in plasma testosterone levels at 2–3 months of age. At this stage, Leydig cells contain abundant smooth endoplasmic reticulum and mitochondria, as well as varying amounts of lipid droplets [13, 23, 24]. After the neonatal stage, Leydig cell numbers regress rapidly and become very scarce until six to eight years of age when they begin to increase toward adult levels. Well-differentiated Leydig cells are absent from the interstitial space during the quiescent phase, and in their place are partially differentiated Leydig cells and fibroblast-like cells. At this stage, Leydig cells are dispersed in a loose connective tissue matrix, and contain elongated nuclei with scarcely visible cytoplasm. It has been proposed that these partially differentiated Leydig cells and primitive fibroblasts are precursors of adult Leydig cells [25–27] although studies in the mouse would suggest other origins (see below). As suggested above, it has been proposed that the neonatal Leydig cells represent a third population of Leydig cells in the human, alongside the fetal




Fig. 2.3 Steroidogenic pathways leading to formation of dihydrotestosterone (DHT). The canonical pathways through Δ^4 and Δ^5 steroids are shown on the left with the alternative (backdoor) pathway on the right. Enzymes shaded in *gray* are required for the canonical pathway (with a number also required for the alternative pathway). Enzymes shaded in *yellow* are specific to the alternative

pathway. Abbreviations; 5 α DHP, dihydroprogesterone; 17OH-DHP, 17 α -hydroxydihydroprogesterone; DHEA dehydroepiandrosterone; DHT, dihydrotestosterone. This Figure was published in Knobil and Neill's *Physiology of Reproduction*, Vol 1, PJ O'Shaughnessy, Testicular Development, Pages 567–594, Copyright Elsevier (2015). Reprinted with permission

and adult populations [6]. Given that fetal Leydig cells persist in the mouse, however, a simpler explanation would be that this neonatal peak of testosterone is due to re-activation of the fetal Leydig cells by the increase in LH levels which occurs at this time [4].

Adult Leydig Cells

The precursor cells for the adult Leydig cell population begin their transformation at 6–8 years of age, and the number of adult Leydig cells increases during puberty reaching a maximum reported as 8×10^8 per testis in the young adult [13]. At this time, a third rise in testosterone concentrations occurs, and levels remain high into middle/old age. Thereafter, Leydig cell numbers may decline in men as they age past 60 years, but there is current uncertainty about this as discussed below (see Leydig cell aging). Either way, between ages 20 and 60, there is a relatively stable equilibrium in the number of Leydig cells, which make up about 4% of the volume of the mature testis [28].

Steroidogenic Function of Leydig Cells

The main function of Leydig cells is to synthesize and secrete androgens, primarily testosterone. In humans, testosterone is synthesized mainly through the Δ^5 pathway via dehydroepiandrosterone (DHEA) and androstenedione (Fig. 2.3) [29]. This requires the activities of four enzymes: cholesterol side chain cleavage (CYP11A1), 17 α -hydroxylase/C₁₇₋₂₀ lyase (CYP17A1), 3 β -hydroxysteroid dehydrogenase/ Δ^{5-4} isomerase (HSD3B3), and 17 β -hydroxysteroid dehydrogenase type 3 (HSD17B3) [30]. Leydig cells are the only cells in the testis which express CYP11A1, HSD3B3, and CYP17A1 and are, therefore, the sole site for cholesterol conversion to C₁₉ steroids. In contrast, data from the mouse show that the HSD17B3 enzyme is expressed only in the Sertoli cells of the fetal/neonatal testis [31, 32] which means that fetal Leydig cells primarily secrete androstenedione (the Δ^4 pathway predominates in rodents) and Sertoli cells are required for testosterone synthesis. In the adult mouse, HSD17B3 is

expressed solely in the Leydig cells and the Leydig cells alone produce testosterone [31, 32]. Whether this pattern of HSD17B3 expression and steroid synthesis is specific to the mouse or is also relevant to the human remains to be determined. During fetal development, testosterone from the fetal Leydig cells will masculinize the internal ducts and glands but masculinization of the external genitalia depends on the formation of DHT in the genital tubercle [33]. Formation of DHT can be from testosterone through the action of SRD5A2, as shown in Fig. 2.3, but an alternative pathway has also been described which bypasses testosterone, and this pathway may be equally important for fetal masculinization in the human [34].

Androgen Synthesis via the Canonical Pathway

Androgen synthesis from cholesterol depends initially upon the transport of cholesterol from intracellular sources to the inner mitochondrial membrane, and subsequent loading of cholesterol into the catalytic site of CYP11A1 [35]. Cholesterol is hydrophobic and cannot cross the aqueous intermembrane space of mitochondria to reach the CYP11A1 enzyme rapidly enough by simple diffusion to support acute steroid synthesis [36]. To overcome this problem, the cholesterol is transferred into the mitochondria through the transduceosome which includes the steroid acute regulator (STAR) protein, translocator protein, and voltage-dependent anion channel [37]. In the inner mitochondrial membrane, cholesterol is converted by CYP11A1 to pregnenolone and isocaproaldehyde [38] which is unstable and quickly oxidized to isocaproic acid. This reaction requires a mitochondrial electron transfer system of adrenodoxin and adrenodoxin reductase to convey electrons from NADPH to CYP11A1 [35].

Pregnenolone can act as substrate for testosterone synthesis through two different routes in the canonical pathway—the Δ^4 and Δ^5 pathways—so called because of the position of one of the double bonds on the steroid backbone. The particular

pathway taken is species-dependent and is regulated by the relative affinities of the converting enzymes for different substrates. In humans, the pathway is predominantly Δ^5 because CYP17A1 has a higher binding affinity for pregnenolone than HSD3B [39]. In rodents, CYP17A1 has a higher affinity for progesterone, and the Δ^4 pathway predominates [40]. In human Leydig cells, therefore, the pathway is predominantly through pregnenolone, 17α -hydroxypregnenolone, DHEA, androstenedione, and testosterone.

The enzymes involved in the canonical pathway are located in the mitochondria (CYP11A1, HSD3B2) and in the smooth endoplasmic reticulum (CYP17A1, HSD17B3) [30, 41]. In humans, there are two genes encoding HSD3B (types I and II) and both enzymes show the same activity although only HSD3B2 is expressed in the Leydig cells [42, 43]. The CYP17A1 enzyme carries out two steps in the bioconversion of pregnenolone and progesterone to the C_{19} steroids, DHEA, and androstenedione, respectively, with 17α -hydroxypregnenolone or 17α -hydroxyprogesterone as transient intermediates, although human CYP17A1 fails to show detectable activity with 17α -hydroxyprogesterone as substrate [40]. The final step in the formation of testosterone is the conversion of androstenedione to testosterone, catalyzed by HSD17B3. This enzyme is part of a family of 14 enzymes that show related activities [44], and in humans, HSD17B1 and HSD17B5 (a member of the aldo/keto reductase superfamily, also known as AKR1C3) are also able to carry out the same reaction [44]. It is clear, however, that in the human fetal testis at least, the HSD17B3 is predominant since XY individuals lacking functional HSD17B3 activity have a significantly reduced ratio of testosterone/androstenedione and fail to masculinize externally during fetal development [45]. Interestingly, testosterone levels rise at puberty in these individuals and virilization does occur leading to the suggestion that HSD17B5 may be of importance in the adult Leydig cells [46].

Androgen Synthesis via the Alternative Pathway

Individuals who are genetic males but with disorders of activity in the enzymes of the canonical pathway will show disordered sex development (DSD) with incompletely masculinized external genitalia. Some cases of DSD (with normal androgen receptor signaling) cannot be explained by alterations in the canonical pathway, however, suggesting that other pathways/mechanisms are involved in androgen synthesis and masculinization [47]. In 2003, Wilson and colleagues described an alternative “backdoor” pathway of androgen synthesis in the testes of the pouch young tamar wallaby [48] (Fig. 2.3), and this pathway was subsequently shown to be active in the prepubertal mouse testis [49]. The importance of this pathway to human masculinization became apparent when unrelated individuals with DSD were shown to have disorders in one or more of the enzymes involved in the alternative pathway [34]. The non-functional/partially functional enzymes in these individuals were AKR1C4 and/or AKR1C2 which are both required for the alternative pathway but will not affect the canonical pathway (Fig. 2.3). Barring some other unknown mutation in these individuals, this would suggest that *both* canonical and alternative pathways to DHT synthesis are required during human male fetal development to ensure normal masculinization. Transcripts encoding enzymes involved in the alternative pathway have been shown to be present in the fetal human testis [34], and it has been assumed that testes secrete DHT via this pathway [34]. This is not clear, however, since earlier studies have reported little or no DHT synthesis by the human fetal testis [50, 51] suggesting that all DHT synthesis must take place at the target organ. It is also not clear whether the testes are the only organs involved in the alternative pathway since the fetal human liver also expresses at least some of the same enzymes [52]. Further studies are needed, therefore, to identify which tissues are involved in the alternative pathway,

and to measure the levels of the different pathway intermediates in the fetal circulation.

Estrogen Synthesis by Human Leydig Cells

Estrogens are formed by aromatization of androstenedione or testosterone by the enzyme CYP19A1. In the testis of most species, aromatase activity is detectable in Leydig cells, Sertoli cells, and germ cells [53], and the relative contributions of each of these testicular cell types to testicular aromatase activity varies with age and between species. In the rat and mouse, Sertoli cells contribute to testicular aromatase activity in immature animals while germ cells are a significant site of activity in the adult [53]. Sertoli cells from juvenile Rhesus monkeys are reported to express aromatase activity, [54] although, in humans, Leydig cells appear to be the only source of testicular estrogens at all ages [55, 56].

Androgen Secretion by the Leydig Cells/Testis

Once synthesized, the lipophilic androgens move out of the Leydig cells by passive diffusion, down the concentration gradient. Within the testis, testosterone and precursors diffuse freely into the interstitial space and enter the testicular blood capillaries that are immediately adjacent to Leydig cells [57]. Interestingly, it is this process of testosterone release into the testicular vascular bed which might be altered in Klinefelter syndrome leading to reduced circulating testosterone levels [58]. Once they are part of the systemic circulation, secreted testosterone binds to plasma proteins and is present in both bound and unbound forms. In adult humans, more than 95% of testosterone is complexed with proteins, both the high affinity ($K_D = 1 \text{ nM}$) sex hormone binding globulin (SHBG) and the low affinity ($K_D = 1000 \text{ nM}$) albumin. The proportion of testosterone that is unbound or loosely bound

represents the biologically active fraction, which freely diffuses from capillaries into cells. The SHBG-bound fraction is thought to act as a reservoir for the steroid, although SHBG-bound steroids may also enter cells via endocytic receptors on the surface of target cells and contribute to hormone action [58]. Increasing levels of SHBG during aging contributes to reduced free plasma testosterone during this period (see below, Leydig cell aging).

Other Functions of the Leydig Cell

The principal function of the Leydig cells is to produce androgen, but the cells are also the only source of INSL3 during fetal development [59, 60]. This hormone is essential, along with androgen, for inducing normal testicular descent although INSL3-receptors (RXFP2) are found on Leydig cells and on germ cells, and there is evidence that INSL3 can act to reduce germ cell apoptosis [61]. Any role that INSL3 plays in Leydig cell function, however, is likely to be restricted to the period around early puberty [61]. In order to identify other functions of the Leydig cells, Leydig cell-specific transcripts in the adult rat have been identified on the assumption that at least some of these transcripts are likely to be involved in cell-specific functions [62, 63]. Apart from transcripts encoding components of the steroidogenic apparatus, the most common predicted function of translated proteins from these cell-specific transcripts is endogenous and xeno-toxicant metabolism and reduction in oxidative stress [62]. The Leydig cells may, therefore, play a significant role in protecting the adult testis from damage caused by toxicants or by stress.

Regulation of Leydig Cell Development and Function

Leydig Cell Development

Most information available on the control of Leydig cell development comes from rodent

models, and there is no reason to doubt that these fundamentals are significantly different in the human, but caution needs to be maintained when extrapolating between species.

Initial development of the fetal Leydig cells is dependent upon the Sertoli cells and, in particular, upon Desert Hedgehog (DHH) and Platelet-derived Growth Factor- α (PDGFA) released by the Sertoli cells [64–66]. In the absence of DHH in mice, there is a marked reduction in fetal Leydig cell numbers, reduced androgen levels and failure of masculinization, with a similar phenotype also seen in humans with a mutation in DHH [67, 68]. Similarly, reduced fetal Leydig cell numbers are seen in mice lacking PDGFA [69], and it is likely that the effect of both DHH and PDGFA is to promote expansion of the fetal Leydig cell precursor population [69]. In contrast, both NOTCH and WNT4 signaling act to inhibit fetal Leydig cell differentiation and WNT4 appears to be important in preventing Leydig cell development in the fetal ovary [70, 71]. Interestingly, downregulation of Wilm's tumor gene (WT1) may also be required for fetal Leydig cell development, with over-expression in fetal Leydig cells leading to development of a Sertoli cell-like phenotype [72, 73]. A number of homeoproteins (ARX, LHX9, PBX1, and RHOX4) are expressed in interstitial cells, and they have been shown to be involved in testis development. Only ARX has, so far, been linked directly to fetal Leydig cell development [74], however, possibly through an action on the progenitor cells [75]. In rodents, secretion of LH by the fetal pituitary is not required for fetal Leydig cell activity [76, 77], and once formed, the cells appear to function largely independently of the fetal Sertoli cells [78]. Similarly, fetal Leydig cell activity in humans is not dependent on fetal pituitary LH [79] but, unlike rodents, activation of the LHCGR is essential [80], indicating that hCG is required in humans to stimulate Leydig cell activity in utero [22].

The adult Leydig cells develop from peritubular precursors [81–83] which may be stem cells [84]. After initial differentiation, the cells undergo one or two mitotic divisions to reach the

final population size [85]. The initial process of adult Leydig cell differentiation is completely dependent on the Sertoli cells [78] since Sertoli cell ablation in the neonatal mouse leads to general failure of adult Leydig cell differentiation except in regions where Sertoli cells or Sertoli-like cells have survived ablation [78]. This failure of adult Leydig cell development is associated with apparent loss of Leydig cell precursor cells, although it is likely that the Sertoli cells are also directly involved in stimulating Leydig cell differentiation since DHH appears to be required for normal adult Leydig cell development, perhaps through inducing stem cell commitment [64, 86, 87]. The Sertoli cell-derived factor anti-Müllerian hormone (AMH) may also be involved in the regulation of adult Leydig cell development with a pubertal decrease in AMH required for normal maturation [88]. It has been shown that the orphan nuclear receptor NR2F2 is necessary for adult Leydig cell development, possibly through development of the progenitors and through maturation of the differentiated cells [89]. PDGFA is also involved in the differentiation process although the origin of this factor in the post-natal testis is not clear [90–93]. In addition to the requirement for Sertoli cells, it is clear that adult Leydig cell development is critically dependent on LH. Progenitor Leydig cells do not express the LH receptor [94], and initial Leydig cell differentiation is LH-independent [95, 96] but, in the absence of LH or the LH receptor, there is a marked reduction in the number of Leydig cells that develop in the adult [97]. Similarly, in mice with enhanced chronic exposure to LH activity, there is hyperplasia of the adult Leydig cell population [98]. Overall, therefore, the data suggest that initial Leydig cell differentiation is Sertoli cell-dependent/LH-independent, but that further development of the cells is critically dependent on LH.

One other factor of importance in Leydig cell development is androgen. In mice lacking androgen receptors, there is failure of normal adult Leydig cell development, with a reduction in Leydig cell number, and those cells which do develop lack many transcripts/proteins which are

associated with the adult cell population [99, 100]. In mice with a more specific deletion of androgen receptors only in the Leydig cell, there is also inhibition of cell maturation although the effect is less marked than with complete androgen receptor deletion [101]. Leydig cell numbers are unaffected in Leydig cell-specific knockouts and so androgen effects on Leydig cell development appear to be a mix of direct effects on the cells and indirect effects through other cells which express androgen receptors such as the peritubular myoid cells and Sertoli cells. In humans lacking functional androgen receptors, Leydig cell dysfunction appears to be less marked than in the mouse, with circulating testosterone levels in the normal range, albeit with high circulating LH levels [102–105]. This difference may be accounted for by loss of CYP17A1 in mice lacking androgen receptors [106], as the CYP17A1 enzyme levels appear to be normal, or possibly increased, in androgen-insensitive humans [107]. Interestingly, in both mouse and human, loss of androgen receptors leads to late-onset Leydig cell apoptosis, an event that is very rare in normal Leydig cell populations [101]. Androgenic stimulation also appears to be required by the adult Leydig cell stem cells during fetal life to ensure normal stem cell numbers in the adult [108] which may explain evidence suggesting that reduced fetal androgen exposure is associated with lower adult male androgen levels [109].

Regulation of Leydig Cell Activity

The main regulator of Leydig cell activity is LH, and two types of responses to LH are seen. The first, acute response triggers a rapid production of steroid within minutes [110] through the binding of LH to the receptor, stimulation of adenylate cyclase, and the formation of the second messenger adenosine 3',5'-cyclic monophosphate (cAMP) (Fig. 2.4). Increased cAMP causes subsequent phosphorylation of proteins via protein kinase A or C [111, 112] in a cascade of events leading to increased STAR phosphorylation and expression and increased testosterone synthesis.




Fig. 2.4 Mechanisms of hormone-mediated steroid production in Leydig cells. LH is the major endocrine regulator of Leydig cell steroidogenesis, and binding of LH to the LH receptor (LHR also termed LHCGR) leads to activation of adenylate cyclase (AC). Osteocalcin (Os) also activates adenylate cyclase through binding to GPCR6A. Activation of adenylate cyclase leads to an increase in cAMP which, in turn, causes influx of Ca²⁺ into the cells and induces activation of various kinases including protein kinase A (PKA). This leads to activation

of transcription factors (e.g. CREB, GATA4, NUR77) and induced expression of genes involved in steroid hormone synthesis, including STAR. Increased cAMP also activates the MAP kinase pathway via activation of the epidermal growth factors receptor (EGFR) which leads to increased expression and phosphorylation of STAR. The overall effect in the short term is to increase testosterone synthesis by the Leydig cells and, in the longer term, to increase transcription of the steroidogenic enzymes

The increase in cAMP also leads to the activation of a Ca²⁺-signaling pathway [113] and increased NR4A1-mediated hormone-stimulated STAR expression [114]. In addition, LH-induced cAMP signaling in the Leydig cell transactivates the epidermal growth factor receptor (EGFR) leading to activation and expression of STAR protein [115] (Fig. 2.4). The second effect of LH is a long-term trophic effect on the Leydig cells mediated through transcriptional regulation. LH signaling acts through phosphorylation of transcription factors to enhance transcription from cyclic AMP-response elements (CREs) in the promoters for several LH target genes including STAR, CYP11A1, and HSD3B [110, 116]. Some target genes lack a consensus CRE, and expression is modulated by interaction between different transcription factors such as NR5A1 [117]. Overall, in the longer term, LH acts to maintain the steroidogenic enzyme activity of the Leydig

cell and the steroidogenic apparatus. This can be seen clearly in animals which lack LH stimulation either through gene mutation/manipulation or after treatment such as hypophysectomy. In *hpg* or *LHRKO* mice, which both lack LH stimulation; the Leydig cells are smaller and contain large lipid droplets; steroidogenic enzyme transcript level/activity is markedly reduced and androgen output in response to trophic stimulation is very low [95–97, 118].

In addition to LH, adrenocorticotrophic hormone (ACTH) can act to regulate fetal Leydig cell function in the mouse, although it does not appear to have any effect on adult Leydig cells [119]. Isolated fetal/neonatal mouse testes or Leydig cells will respond rapidly in vitro to physiological levels of ACTH with a marked rise in testosterone, similar to that seen in response to LH [119, 120]. It is not clear that ACTH plays a physiological role in development of the fetal

Leydig cells in mice, however, since androgen levels are normal in mice lacking ACTH or ACTH and LH [121]. It remains to be seen whether ACTH is of importance to fetal Leydig cell function in species, such as the human, which require trophic endocrine support for normal fetal androgen production. Responsiveness of fetal Leydig cells to ACTH in the mouse does raise one interesting aspect of these cells and that is their similarity to adrenocortical cells. It has been reported that at least some of the fetal Leydig cells may derive from the same progenitor population as the adrenocortical cells [122], and at least some of the cells show distinct similarities both in hormone responsiveness and steroidogenic enzyme expression [123–125]. Whether these are a subpopulation of normal fetal Leydig cells or ectopic adrenal cells which have been shown to give rise to adrenal rest tumors in the testis [126] remains to be seen.

In rodents, the fetal Leydig cells are also responsive to a variety of local and endocrine factors such as pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and natriuretic peptides [127–129]. Since fetal Leydig cells in rodents do not specifically require LH, it is possible that activation of the cells *in vivo* is through multiple redundant mechanisms involving LH, ACTH, and activating peptides. A redundant mechanism such as this may have evolved to ensure that sufficient Leydig cell activation occurs to induce fetal masculinization. Whether human fetal Leydig cells are also sensitive to multiple agonists is not known, although it is clear that human fetal androgen production is critically dependent on LHCG stimulation [80].

Recently, the bone protein osteocalcin has been reported to act as a trophic hormone on adult Leydig cells via the GPRC6A receptor [130, 131] (Fig. 2.4). Osteocalcin was shown to have a direct effect on testosterone synthesis by adult Leydig cells, and circulating testosterone levels and seminal vesicle weights were significantly reduced in mice lacking osteocalcin [130]. These effects were less marked than in mice lacking LH, but the fertility of the osteocalcin-deficient mice was reduced

indicating that osteocalcin is required for optimal reproductive function. Evidence from two human patients with primary testicular failure linked to mutations in GPRC6A is also supportive of the hypothesis that osteocalcin can regulate testicular function [131]. The link between steroid hormones and bone mass has been known for a number of years but these data show that the skeleton can regulate Leydig cell function in a classic endocrine feedback loop [132].

In addition to the direct effects of LH, ACTH, and osteocalcin on Leydig cell function, follicle stimulating hormone (FSH) may play an indirect stimulatory role in the regulation of Leydig cells. Evidence for an effect of FSH comes from gonadotrophin-deficient mice and rats treated with FSH, and from differences in Leydig cell function between control mice and animals lacking FSH stimulation [133–137]. In addition to mice, there is also evidence that FSH can stimulate Leydig cell function indirectly in other species including humans [18, 138–140]. FSH receptors are restricted to the Sertoli cells [141], and so FSH effects on the Leydig cells must be mediated through Sertoli-secreted factors. The effects of FSH are fairly rapid, however, with a response seen in *hpg* mice in less than 4 h [135] suggesting that whatever paracrine factors are involved they must be acting directly on the Leydig cells. These effects of FSH are consistent with recent studies which show that ablation of the Sertoli cells in the adult mouse causes a marked reduction in Leydig cell number within 30 days [142], demonstrating that Sertoli cell factors are required for maintenance of the adult Leydig cell population. The identity of these factors remains unknown but an obvious candidate is DHH which is closely involved in Leydig cell development and continues to be secreted specifically by the Sertoli cells into adulthood.

Clinical Aspects

Leydig Cell Aging

Most studies show that plasma levels of total testosterone in men fall between 1% and 2% per




Fig. 2.5 Age-dependent changes in male hormone levels. These graphs show the relationship between age and hormone levels in men. Mean hormone values at 5-year age bands are shown based on data from 3220 men. Men with known pituitary or testicular diseases or current use of medications that could affect pituitary or testicular function or sex-steroid clearance were excluded. Total testosterone and free testosterone were significantly lower and luteinizing hormone (LH) and sex hormone binding globulin (SHBG) significantly higher in the older age groups. There was an apparent inflection point around 70 year for LH. Data shown in these figures are from [145] with permission of the authors

year beginning at about age 40, although free testosterone declines more rapidly ($\sim 3\%$ per year) as levels of SHBG increase at the same time [143–145] (Fig. 2.5). This decline in testosterone is multifactorial but can be divided into primary/compensated hypogonadism (low/normal testosterone with high LH) which is primarily linked to aging and secondary hypogonadism (low testosterone with low LH) which does not appear to be age-related but is clearly linked to obesity [146]. Metabolic clearance of testosterone slows with age [147] (which would

tend to increase circulating testosterone), and so the increased LH seen in primary/compensated hypogonadism is evidence that the primary endocrine failure associated with aging is likely to be at the level of the testis [148]. Also, it has been shown that the circulating androgen response to increased LH declines with age in humans [148, 149] as might be expected from primary testicular failure.

Age-related declines in testicular testosterone output could be caused by decreased Leydig cell numbers and/or reduced steroidogenic ability. There are a number of studies which report that Leydig cell numbers decline with age in the human population [150–153], although a more recent study found no age-related change in Leydig cell number [154]. Counting cell numbers in the testis is prone to technical problems which may have affected the older studies while the number of men over 60 in the more recent report [154] was only 4, so whether Leydig cell number declines with aging will remain uncertain until further studies are carried out.

Whether or not Leydig cell numbers decline with age, there is good evidence for degenerative changes in the cells including cytoplasmic or intranuclear crystalline inclusions, lipofuscin granules, diminished smooth endoplasmic reticulum, and smaller and fewer mitochondria when compared to young men [155–157]. Older men with higher serum LH and lower serum testosterone levels also have a large number of abnormal Leydig cells, suggesting that Leydig cell structural changes are related to changes in steroidogenic function [155]. Studies of intratesticular steroid levels in aging men do not show a specific lesion in the steroidogenic pathway but overall levels are lower, and there is evidence of reduced mitochondrial steroid production [158]. Using rat models in which the primary aging deficit is at the level of the Leydig cells, it has been shown that Leydig cell aging in the rat is associated with multiple defects in the steroidogenic machinery from reduced LH-dependent cAMP production to reduced steroidogenic enzyme levels [159]. This deterioration of Leydig

cell function may be related to alterations in the redox balance of the cells leading to increased superoxide content with aging [159]. It is also likely, however, that other factors also contribute to the decline in Leydig cell function with age, as newly formed Leydig cells in testes from aged Norway rats show a rapid decline in steroidogenic function [160]. This does not appear to be due to changes in LH but may be caused by alterations in the levels of other trophic factors, changes in cell–cell signaling in the testis or vascular re-modeling associated with aging.

Leydig Cell Tumors

Leydig cell tumors were first identified by Sacchi in 1895, and are the most common interstitial tumors although they are rare overall and account for only 1–3% of testicular tumors [161–163]. Most Leydig cell tumors are unilateral (only 3% are bilateral [164]) and can appear at any age, although there is a peak incidence before puberty (between 5 and 10 years) and a second larger peak between 30 and 60 years. The tumors produce androgens, mainly testosterone, but serum estrogen levels may be elevated either through direct production of estrogen by the tumor or by peripheral aromatization of secreted androgen [165]. In boys, Leydig cell tumors are uniformly benign, hormonally active tumors, and account for about 10% of cases of precocious puberty [166]. In adults, most Leydig cell tumors are benign, and patients present with a painless testicular mass which may be palpable but is usually an incidental finding on scrotal ultrasonography for other conditions [167]. Small non-palpable Leydig cell tumors which are not visible on ultrasonograms can be seen by magnetic resonance imaging [168]. Where there is significant estrogen production, gynecomastia may be present along with loss of libido, erectile dysfunction, impotence, and infertility [165]. In adults, approximately 10% of Leydig cell tumors are malignant [162, 163] with regional lymph nodes, liver, lungs, and bone, the most common sites of metastases [162].

Macroscopically, the lesions associated with Leydig cell tumors are generally small, yellow to brown, well circumscribed and rarely hemorrhagic or necrotic. Microscopically, four different cell types can be found, ranging from large polygonal cells to spindle-shaped sarcomatoid cells [165, 169]. The cells have round nuclei with eosinophilic granular cytoplasm containing lipid vacuoles, lipofuscin granules, and Reinke's crystals present in about one third of the cases [170] (Fig. 2.6). Ultrastructurally, the cells show features expected of steroid-secreting cells, including abundant smooth endoplasmic reticulum.

Classically, the primary treatment for Leydig cell tumors has been radical orchiectomy, and it remains in use for malignant cases. Testis-sparing surgery, with enucleation of the mass, has proved to be a feasible and safe choice, however, and is increasingly being reported for benign cases. A recent study of patients with Leydig cell tumors found a 100% disease-free survival with no local recurrences or metastases following testis-sparing surgery [171]. Testis-sparing surgery should also be considered for children who present with the clinical and biochemical findings typical of Leydig cell tumors, and an ultrasonographically defined encapsulated intratesticular mass [172]. Malignant Leydig cell tumors are radio-resistant and chemo-resistant, and have a poor prognosis with median survival time of 2 years [173].

The etiology of Leydig cell tumors remains uncertain, particularly in adults, but somatic activating mutations of the LHCGR have been found in a number of these tumors in boys [174]. This is consistent with the gonadotropin-independent nature of these tumors and with the development of fetal Leydig cell tumors in mice exposed to persistently high levels of hCG [175]. Other somatic mutations are also likely to be involved although a link to activating mutations in genes such as the Gs α -subunit of the stimulatory G protein (GNAS) have not been shown [174]. Leydig cell tumors in adults may be derived from the adult population of Leydig cells which would be consistent with the presence of Reinke's crystals in some tumors as fetal Leydig cells lack these structures [176]. This




Fig. 2.6 Leydig cell tumors. Histologic sections of Leydig cell tumors. **a** Leydig cell tumor cells have abundant, eosinophilic cytoplasm with regular round nuclei, distinct cell borders and fibrovascular septa between the tumor cells. **b** Periodic acid Schiff stain which highlights the cytoplasmic lipofuscin granules in the tumor cells, a diagnostic clue to Leydig cell tumors. **c** Higher power photomicrograph showing intracytoplasmic Reinke crystals in a Leydig cell tumor (*arrows*). The crystals appear as refractile, cylindrical, rectangular, or rhomboid structures, and their identification is helpful for distinguishing Leydig cell tumors from other similar

lesions (hematoxylin-eosin). **d** Leydig cell tumors typically show strong, diffuse cytoplasmic reactivity for α -inhibin (INHA) which is shown here as a brown stain. INHA is a sensitive and specific marker that can be used to separate testicular sex cord–stromal tumors, including Leydig cell tumors, from germ cell tumors, Reprinted from Al-Agha & Axiotis, An In-Depth Look at Leydig Cell Tumor of the Testis. Arch Pathol Lab Med. 2007; Vol 131 (issue 2): pp 311–317 with permission from Archives of Pathology & Laboratory Medicine. Copyright 2007 College of American Pathologists [165]

may mean that the etiology of adult tumors differs from tumors in boys. The tyrosine kinase inhibitor imatinib has been reported to show chemotherapeutic activity in animal models [177], but this activity has not been demonstrated in an adult human trial [178].

Leydig cell hyperplasia shares the same clinical presentation as a Leydig cell tumor, including painful gynecomastia and decreased libido in adults, precocious puberty in children, and infertility or palpable testicular masses [179]. It should be noted, however, that many cases of

apparent Leydig cell hyperplasia reported in the literature, in both humans and rodent models, are due to loss of germ cells (e.g., through cryptorchidism) causing shrinkage of the seminiferous tubules and an apparent increase in relative interstitial volume. Stereological measurement of Leydig cell numbers in these cases will often show no change in Leydig cell number per testis [180]. It is significant, therefore, that reported clinical Leydig cell hyperplasia is always associated with spermatogenic failure [179]. However, there is no doubt that true Leydig cell

hyperplasia can occur if LH (or hCG) levels are elevated [179], and the hyperplastic Leydig cells are generally arranged in diffuse, multifocal, small nodules and show frequent mitoses, necrosis, and vascular invasion. Hyperplastic Leydig cells usually infiltrate between seminiferous tubules while benign Leydig cell tumors form nodules that compress surrounding tubules.

Leydig Cell Toxicology

As described above, the Leydig cells express a number of metabolic enzymes which might be expected to inactivate xenotoxins and thereby protect the spermatogenic and steroidogenic function of the testis [62]. At the same time, however, the Leydig cells themselves are the potential target of a number of possible toxicants. This is an area which has seen a marked increase in publication activity in the last 10 years, with a considerable number of potential toxicants identified, and some of the better characterized/most relevant substances include phthalates, bisphenol A, statins, and ethanol. Phthalates are present in food packaging, cosmetics, and medical devices such as tubings and catheters, and so human exposure is significant with particular concern about fetal exposure [181]. Inhibitory effects of phthalates on rodent Leydig cell development and function are well documented, particularly with respect to the fetal Leydig cells, and may be related to altered expression of NR2F2 [182]. Changes to fetal Leydig cell development would be likely to affect normal masculinization of the fetus and are, therefore, potentially serious, but the effects of phthalates may be species-dependent with no clear effect seen in human fetal testis organ culture [181, 183], although there may be effects on adult human Leydig cells [184]. Bisphenol A is ubiquitous in the environment and is used primarily to manufacture polycarbonate plastic or as a non-polymer additive to other plastics and to epoxy resins. Bisphenol A has estrogenic activity and is classed as an endocrine disrupting compound, but it is also reported to directly inhibit fetal Leydig cell function in both rats and humans [185, 186]

and is of ongoing concern. Statins act to inhibit cholesterol synthesis, and are taken daily by an estimated 20 million men, many of whom are more than 60 years old, and so with aging Leydig cells. Leydig cells need cholesterol as substrate for androgen synthesis (Fig. 2.3), some of which comes from circulating lipoproteins and some from *de novo* synthesis. A recent meta-analysis reported that statins reduce circulating testosterone concentration in men [187] which would be consistent with reported inhibitory effects in vitro on rat Leydig cells [188, 189], although no studies have yet been reported using isolated human Leydig cells. Long-term abuse of ethanol reduces circulating testosterone levels which may be a combination of direct effects on the Leydig cells [190, 191] with changes in circulating LH. Most studies report normal or elevated LH following alcohol abuse but the gonadotrophin response to pituitary stimulation is reduced suggesting altered hypothalamic pituitary function [190, 192, 193]. Finally, it has been shown that the alkylating agent ethane dimethane sulfonate (EDS) can act as a specific cytotoxicant in Leydig cells. This effect is species-specific with complete Leydig cell ablation seen in rats within 24 h but with little effect seen in the mouse, dog, and monkey [194]. It is still not known why the cytotoxic effect is specific to Leydig cells in the rat, but EDS has proven particularly useful in the study of Leydig cell biology [194].

Conclusions—Future Work

The importance of testosterone to adult male health is increasingly recognized, with an established link now made between low testosterone and the onset of conditions such as obesity, metabolic syndrome, and type 2 diabetes [1, 195–197]. It is clear, therefore, that we need to understand how Leydig cells are regulated in the adult human, and why testosterone levels are low in some individuals. In general, our knowledge and understanding of testis biology and Leydig cell function are expanding quickly due largely to the availability of transgenic mouse models which allow hormonal control and cell–cell

interactions to be dissected and examined. With the important exception of fetal development, specific studies on the human Leydig cell are limited, however, and it is clear that more human-specific information is needed, particularly for important areas such as Leydig cell aging and toxicology. There has been increased availability of human fetal tissues for research in recent years which means that our understanding of this phase of human testicular development is improving, although use of human fetal material remains controversial in the USA (<http://tinyurl.com/hrxj29r>). It is known that fetal programming can have a marked effect on adult health [198], and there is evidence that low testosterone in the fetus is associated with reduced adult testosterone levels [109, 199] perhaps through changes in Leydig stem cell development [108]. The recent identification of factors which appear to be required for Leydig stem cell differentiation in the rat [87] highlights an area which is likely to be of considerable focus in coming years as interest develops in the manipulation of this process.

Acknowledgements Support from the BBSRC (BB/J015105) and MRC (MR/L01001) during the preparation of this manuscript is acknowledged.

References

1. Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. *Rev Endocr Metab Disord*. 2015;16:249–68. doi:10.1007/s11154-015-9323-2.
2. Christensen A. A history of Leydig cell research. In: Payne AH, Hardy MP, editors. *The Leydig cell in health and disease*. Totowa: Humana Press; 2007. p. 3–30.
3. Teerds KJ, Huhtaniemi IT Morphological and functional maturation of Leydig cells: from rodent models to primates. *Hum Reprod Update* 2015;21: 310–28. doi:10.1093/humupd/dmv008 dmv008 [pii].
4. Shima Y, Matsuzaki S, Miyabayashi K, Otake H, Baba T, Kato S, Huhtaniemi I, Morohashi K. Fetal Leydig cells persist as an androgen-independent subpopulation in the postnatal testis. *Mol Endocrinol*. 2015;29:1581–93. doi:10.1210/me.2015-1200.
5. Forest MG, De Peretti E, Bertrand J. Hypothalamic-pituitarygonadal relationships in man from birth to puberty. *Clin Endocrinol (Oxf)*. 1976;5:551–69.
6. Prince FP. The triphasic nature of Leydig cell development in humans, and comments on nomenclature. *J Endocrinol*. 2001;168:213–6.
7. O’Shaughnessy PJ, Baker PJ, Monteiro A, Cassie S, Bhattacharya S, Fowler PA. Developmental changes in human fetal testicular cell numbers and messenger ribonucleic acid levels during the second trimester. *J Clin Endocrinol Metab*. 2007;92: 4792–801.
8. Fowler PA, Bhattacharya S, Gromoll J, Monteiro A, O’Shaughnessy PJ. Maternal smoking and developmental changes in luteinizing hormone (LH) and the LH receptor in the fetal testis. *J Clin Endocrinol Metab*. 2009;94:4688–95.
9. Winter JS, Hughes IA, Reyes FI, Faiman C. Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal steroid concentrations in man from birth to two years of age. *J Clin Endocrinol Metab*. 1976;42:679–86.
10. Winter JS, Faiman C, Hobson WC, Prasad AV, Reyes FI. Pituitary-gonadal relations in infancy. I. Patterns of serum gonadotropin concentrations from birth to four years of age in man and chimpanzee. *J Clin Endocrinol Metab*. 1975;40:545–51.
11. Bay K, Virtanen HE, Hartung S, Ivell R, Main KM, Skakkebaek NE, Andersson AM, Toppari J Insulin-like factor 3 levels in cord blood and serum from children: effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. *J Clin Endocrinol Metab* 2007;92:4020–027. doi:10.1210/jc.2007-0974 jc.2007-0974 [pii].
12. Kuiri-Hanninen T, Sankilampi U, Dunkel L Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. *Horm Res Paediatr* 2014;82: 73–80. doi:10.1159/000362414 000362414 [pii].
13. Nistal M, Paniagua R, Regadera J, Santamaria L, Amat P. A quantitative morphological-study of human Leydig-cells from birth to adulthood. *Cell Tissue Res*. 1986;246:229–36.
14. Carlstrom K, Eriksson A, Stege R, Rannevik G. Relationship between serum testosterone and sex hormone-binding globulin in adult men with intact or absent gonadal function. *Int J Androl*. 1990;13:67–73.
15. Gondos B. Development and differentiation of the testis and male reproductive tract. In: Steinberger A, Steinberger B, editors. *Testicular development, structure and function*. New York: Raven Press; 1980. p. 3–20.
16. Voutilainen R. Differentiation of the fetal gonad. *Horm Res*. 1992;38(Suppl 2):66–71.
17. DeFalco T, Takahashi S, Capel B Two distinct origins for Leydig cell progenitors in the fetal testis. *Dev Biol* 2011;352:14–26. doi:10.1016/j.ydbio.2011.01.011 S0012-1606(11)00027-3 [pii].
18. O’Shaughnessy PJ. Testicular development. In: Plant Tony, Zeleznik Anthony, editors. *Knobil*

- and Neill's physiology of reproduction. Amsterdam: Academic Press; 2015. p. 567–94.
19. Tapanainen J, Kellokumpulehtinen P, Pelliniemi L, Huhtaniemi I. Age-related-changes in endogenous steroids of human-fetal testis during early and mid-pregnancy. *J Clin Endocrinol Metab.* 1981;52: 98–102.
 20. Clements JA, Reyes FI, Winter JS, Faiman C. Studies on human sexual development. III. Fetal pituitary and serum, and amniotic fluid concentrations of LH, CG, and FSH. *J Clin Endocrinol Metab.* 1976;42:9–19.
 21. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro- α C and follistatin during pregnancy. *Hum Reprod.* 1998;13:3530–6.
 22. O'Shaughnessy P, Fowler PA. Endocrinology of the mammalian fetal testis. *Reproduction.* 2011;141: 37–46.
 23. Huhtaniemi I, Pelliniemi LJ. Fetal Leydig cells: cellular origin, morphology, life span, and special functional features. *Proc Soc Exp Biol Med.* 1992;201:125–40.
 24. Pelliniemi LJ, Niei M. Fine structure of the human foetal testis. I. The interstitial tissue. *Z Zellforsch Mikrosk Anat.* 1969;99:507–22.
 25. Chemes H, Cigorraga S, Bergada C, Schteingart H, Rey R, Pellizzari E. Isolation of human leydig-cell mesenchymal precursors from patients with the androgen insensitivity syndrome—testosterone production and response to human chorionic-gonadotropin stimulation in culture. *Biol Reprod.* 1992;46:793–801.
 26. Prince FP. Ultrastructure of immature leydig-cells in the human prepubertal testis. *Anat Rec.* 1984;209:165–76.
 27. Chemes HE, Gottlieb SE, Pasqualini T, Domenichini E, Rivarola MA, Bergada C. Response to acute hCG stimulation and steroidogenic potential of Leydig cell fibroblastic precursors in humans. *J Androl.* 1985;6:102–12.
 28. de Kretser D, Kerr JB. The cytology of the testis. In: Ernst K, Neil JD, editors. *The physiology of reproduction.* New York: Raven Press; 1994. p. 1177–290.
 29. Luu-The V. Assessment of steroidogenesis and steroidogenic enzyme functions. *J Steroid Biochem Mol Biol* 2013;137:176–82. doi:10.1016/j.jsbmb.2013.05.017 S0960-0760(13)00112-X [pii].
 30. Payne AH, O'Shaughnessy PJ. Structure, function and regulation of steroidogenic enzymes in the Leydig cell. In: Payne AH, Hardy MP, Russell LD, editors. *The Leydig cell.* Vienna, USA: Cache River Press; 1996. p. 259–85.
 31. Shima Y, Miyabayashi K, Haraguchi S, Arakawa T, Otake H, Baba T, Matsuzaki S, Shishido Y, Akiyama H, Tachibana T, Tsutsui K, Morohashi KI. Contribution of Leydig and Sertoli Cells to testosterone production in mouse fetal testes. *Mol Endocrinol* 2012;27:63–73. doi:10.1210/me.2012-1256me.2012-1256 [pii].
 32. O'Shaughnessy PJ, Baker PJ, Heikkila M, Vainio S, McMahon AP. Localization of 17 β -hydroxysteroid dehydrogenase/17-ketosteroid reductase isoform expression in the developing mouse testis— androstenedione is the major androgen secreted by fetal/neonatal leydig cells. *Endocrinology.* 2000; 141:2631–7.
 33. Wilson JD, George FW, Griffin JE. The hormonal-control of sexual development. *Science.* 1981;211:1278–84.
 34. Fluck CE, Meyer-Boni M, Pandey AV, Kempna P, Miller WL, Schoenle EJ, Biason-Lauber A. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. *Am J Hum Genet* 2011;89:201–18. doi:10.1016/j.ajhg.2011.06.009 S0002-9297(11)00262-X [pii].
 35. Papadopoulos V, Miller WL. Role of mitochondria in steroidogenesis. *Best Pract Res Clin Endocrinol Metab* 2012;26:771–90. doi:10.1016/j.beem.2012.05.002 S1521-690X(12)00063-2 [pii].
 36. Stocco DM, Clark BJ. Regulation of the acute production of steroids in steroidogenic cells. *Endocr Rev.* 1996;17:221–44.
 37. Papadopoulos V, Aghazadeh Y, Fan J, Campioli E, Zirkin B, Midzak A. Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis. *Mol Cell Endocrinol* 2015;408:90–8. doi:10.1016/j.mce.2015.03.014 S0303-7207(15) 00145-8 [pii].
 38. Burstein S, Gut M. Intermediates in the conversion of cholesterol to pregnenolone: kinetics and mechanism. *Steroids* 1976;28:115–31. 0039-128X(76) 90131-8 [pii].
 39. Biason-Lauber A, Miller WL, Pandey AV, Fluck CE of marsupials and men: "Backdoor" dihydrotestosterone synthesis in male sexual differentiation. *Mol Cell Endocrinol* 2013;371:124–32. doi:10.1016/j.mce.2013.01.017 S0303-7207(13) 00040-3 [pii].
 40. Brock BJ, Waterman MR. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. *Biochemistry.* 1999;38:1598–606. doi:10.1021/bi9821059 [doi];bi9821059 [pii].
 41. Thomas JL, Bose HS. Regulation of human 3- β -hydroxysteroid dehydrogenase type-2 (3- β -HSD2) by molecular chaperones and the mitochondrial environment affects steroidogenesis. *J Steroid Biochem Mol Biol* 2015;151:74–84. doi:10.1016/j.jsbmb.2014.11.018 S0960-0760(14) 00283-0 [pii].
 42. Dupont E, Zhao HF, Rheaume E, Simard J, Luuthe V, Labrie F, Pelletier G. Localization of 3 β -hydroxysteroid dehydrogenase D5-D4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization. *Endocrinology.* 1990;127:1394–403.

43. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH Molecular biology of the 3 β -hydroxysteroid dehydrogenase/ Δ 5- Δ 4 isomerase gene family. *Endocr Rev*. 2005.
44. Saloniemi T, Jokela H, Strauss L, Pakarinen P, Poutanen M The diversity of sex steroid action: novel functions of hydroxysteroid (17 β) dehydrogenases as revealed by genetically modified mouse models. *J Endocrinol* 2012;212:27–40. doi:10.1530/JOE-11-0315 JOE-11-0315 [pii].
45. Boehmer AL, Brinkmann AO, Sandkuijl LA, Halley DJ, Niermeijer MF, Andersson S, de Jong FH, Kayserili H, de Vroede MA, Otten BJ, Rouwe CW, Mendonca BB, Rodrigues C, Bode HH, de Ruiter PE, Delemarre-van de Waal HA, Drop SL. 17 β -hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. *J Clin Endocrinol Metab*. 1999;84:4713–21. doi:10.1210/jcem.84.12.6174.
46. Werner R, Kulle A, Sommerfeld I, Riepe FG, Wudy S, Hartmann MF, Merz H, Dohnert U, Bertelloni S, Holterhus PM, Hiort O Testosterone synthesis in patients with 17 β -hydroxysteroid dehydrogenase 3 deficiency. *Sex Dev* 2012;6:161–68. doi:10.1159/000336605 000336605 [pii].
47. Mendonca BB, Arnhold IJP, Domenice S, Costa EMF 46,XY Disorders of Sexual Development. NBK279170 2000 [bookaccession].
48. Wilson JD, Auchus RJ, Leihy MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G, Renfree MB. 5 α -androstan-3 α ,17 β -diol is formed in tamar wallaby pouch young testes by a pathway involving 5 α -pregnan-3 α ,17 α -diol-20-one as a key intermediate. *Endocrinology*. 2003;144:575–80.
49. Mahendroo M, Wilson JD, Richardson JA, Auchus RJ. Steroid 5 α -reductase 1 promotes 5 α -androstan-3 α ,17 β -diol synthesis in immature mouse testes by two pathways. *Mol Cell Endocrinol*. 2004;222:113–20. doi:10.1016/j.mce.2004.04.009.
50. Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual differentiation in the human embryo. *J Clin Endocrinol Metab*. 1974;38:113–25. doi:10.1210/jcem-38-1-113.
51. George FW, Carr BR, Noble JF, Wilson JD. 5 α -reduced androgens in the human-fetal testis. *J Clin Endocrinol Metab*. 1987;64:628–30.
52. O'Shaughnessy PJ, Monteiro A, Bhattacharya S, Fraser MJ, Fowler PA Steroidogenic enzyme expression in the human fetal liver and potential role in the endocrinology of pregnancy. *Mol Hum Reprod* 2013;19:177–87. doi:10.1093/molehr/gas059 gas059 [pii].
53. Carreau S, Bouraima-Lelong H, Delalande C Estrogen, a female hormone involved in spermatogenesis. *Adv Med Sci* 2012;57: 31–6. doi:10.2478/v10039-012-0005-y D8734766262701R4 [pii].
54. Majumdar SS, Winters SJ, Plant TM. Procedures for the isolation and culture of Sertoli cells from the testes of infant, juvenile, and adult rhesus monkeys (*Macaca mulatta*). *Biol Reprod*. 1998;58:633–40.
55. Inkster S, Yue W, Brodie A. Human testicular aromatase: immunocytochemical and biochemical studies. *J Clin Endocrinol Metab*. 1995;80:1941–7. doi:10.1210/jcem.80.6.7539819.
56. Carreau S. Leydig cell aromatase. In: Payne AH, Hardy MP, editors. *The Leydig cell in health and disease*. Totowa: Humana; 2007. p. 189–95.
57. Winters SJ, Takahashi J, Troen P. Secretion of testosterone and its delta4 precursor steroids into spermatic vein blood in men with varicocele-associated infertility. *J Clin Endocrinol Metab*. 1999;84:997–1001. doi:10.1210/jcem.84.3.5548.
58. Tuttmann F, Damm OS, Luetjens CM, Baldi M, Zitzmann M, Kliesch S, Nieschlag E, Gromoll J, Wistuba J, Simoni M. Intratesticular testosterone is increased in men with Klinefelter syndrome and may not be released into the bloodstream owing to altered testicular vascularization—a preliminary report. *Andrology*. 2014;2:275–81. doi:10.1111/j.2047-2927.2014.00190.x.
59. Virtanen HE, Toppari J. Embryology and physiology of testicular development and descent. *Pediatr Endocrinol Rev*. 2014;11(Suppl 2):206–13.
60. Bay K, Cohen AS, Jorgensen FS, Jorgensen C, Lind AM, Skakkebaek NE, Andersson AM. Insulin-like factor 3 levels in second-trimester amniotic fluid. *J Clin Endocrinol Metab*. 2008;93:4048–51.
61. Ivell R, Heng K, Anand-Ivell R. Insulin-Like Factor 3 and the HPG Axis in the Male. *Front Endocrinol (Lausanne)*. 2014;5:6. doi:10.3389/fendo.2014.00006.
62. O'Shaughnessy PJ, Monteiro A, Fowler PA, Morris ID Identification of Leydig cell-specific mRNA transcripts in the adult rat testis. *Reproduction* 2014;147:671–82. doi:10.1530/REP-13-0603 REP-13-0603 [pii].
63. Zhang YF, Yuan KM, Liang Y, Chu YH, Lian QQ, Ge YF, Zhen W, Sottas CM, Su ZJ, Ge RS Alterations of gene profiles in Leydig-cell-regenerating adult rat testis after ethane dimethane sulfonate-treatment. *Asian J Androl* 2015;17:253–60. doi:10.4103/1008-682X.136447 136447 [pii].
64. Clark AM, Garland KK, Russell LD. Desert hedgehog (*Dhh*) gene is required in the mouse testis for formation of adult-type Leydig cells and normal development of peritubular cells and seminiferous tubules. *Biol Reprod*. 2000;63:1825–38.
65. Pierucci-Alves F, Clark AM, Russell LD. A developmental study of the desert hedgehog-null mouse testis. *Biol Reprod*. 2001;65:1392–402.
66. Yao HH, Whoriskey W, Capel B. Desert Hedgehog/Patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. *Genes Dev*. 2002;16:1433–40.
67. Umehara F, Tate G, Itoh K, Yamaguchi N, Douchi T, Mitsuya T, Osame M A novel mutation of desert hedgehog in a patient with 46,XY partial gonadal dysgenesis accompanied by minifascicular

- neuropathy. *Am J Hum Genet* 2000;67:1302–305. doi:[10.1016/S0002-9297\(07\)62958-9](https://doi.org/10.1016/S0002-9297(07)62958-9) S0002-9297(07)62958-9 [pii].
68. Canto P, Soderlund D, Reyes E, Mendez JP. Mutations in the desert hedgehog (DHH) gene in patients with 46, XY complete pure gonadal dysgenesis. *J Clin Endocrinol Metab.* 2004;89:4480–3.
 69. Brennan J, Tilmann C, Capel B. Pdgfr- α mediates testis cord organization and fetal Leydig cell development in the XY gonad. *Genes Dev.* 2003;17:800–10.
 70. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. *Nature.* 1999;397:405–9.
 71. Tang H, Brennan J, Karl J, Hamada Y, Raetzman L, Capel B Notch signaling maintains Leydig progenitor cells in the mouse testis. *Development* 2008;135:3745–753. doi:[10.1242/dev.024786](https://doi.org/10.1242/dev.024786) dev.024786 [pii].
 72. Wen Q, Zheng QS, Li XX, Hu ZY, Gao F, Cheng CY, Liu YX Wt1 dictates the fate of fetal and adult Leydig cells during development in the mouse testis. *Am J Physiol Endocrinol Metab* 2014;307:E1131-143. doi:[10.1152/ajpendo.00425.2014](https://doi.org/10.1152/ajpendo.00425.2014) [pii].
 73. Zhang L, Chen M, Wen Q, Li Y, Wang Y, Wang Y, Qin Y, Cui X, Yang L, Huff V, Gao F Reprogramming of Sertoli cells to fetal-like Leydig cells by Wt1 ablation. *Proc Natl Acad Sci U S A* 2015;112:4003–008. doi:[10.1073/pnas.1422371112](https://doi.org/10.1073/pnas.1422371112) 1422371112 [pii].
 74. Kitamura K, Yanazawa M, Sugiyama N, Miura H, Iizuka-Kogo A, Kusaka M, Omichi K, Suzuki R, Kato-Fukui Y, Kamiirisa K, Matsuo M, Kamijo S, Kasahara M, Yoshioka H, Ogata T, Fukuda T, Kondo I, Kato M, Dobyns WB, Yokoyama M, Morohashi K. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. *Nat Genet.* 2002;32:359–69.
 75. Miyabayashi K, Katoh-Fukui Y, Ogawa H, Baba T, Shima Y, Sugiyama N, Kitamura K, Morohashi K. Aristaless related homeobox gene, Arx, is implicated in mouse fetal Leydig cell differentiation possibly through expressing in the progenitor cells. *PLoS ONE.* 2013;8:e68050. doi:[10.1371/journal.pone.0068050](https://doi.org/10.1371/journal.pone.0068050) PONE-D-13-03678 [pii].
 76. O'Shaughnessy PJ, Baker P, Sohnius U, Haavisto A-M, Charlton HM, Huhtaniemi I. Fetal development of Leydig cell activity in the mouse is independent of pituitary gonadotroph function. *Endocrinology.* 1998;139:1141–6.
 77. Zhang F-P, Poutanen M, Wilbertz J, Huhtaniemi I. Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. *Mol Endocrinol.* 2001;15:172–83.
 78. Rebourcet D, O'Shaughnessy PJ, Pitetti JL, Monteiro A, O'Hara L, Milne L, Tsai YT, Cruickshanks L, Riethmacher D, Guillou F, Mitchell RT, van't Hof R, Freeman TC, Nef S, Smith LB Sertoli cells control peritubular myoid cell fate and support adult Leydig cell development in the prepubertal testis. *Development* 2014;141:2139–149. doi:[10.1242/dev.107029](https://doi.org/10.1242/dev.107029) 141/10/2139 [pii].
 79. Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL. Hypogonadism caused by a single amino acid substitution in the b-subunit of luteinizing hormone. *N Eng J Med.* 1992;326:179–83.
 80. Kremer H, Kraaij R, Toledo SPA, Post M, Fridman JB, Hayashida CY, van Reen M, Milgrom E, Ropers HH, Mariman E, Themmen APN, Brunner HG. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. *Nat Genet.* 1995;9:160–4.
 81. Ariyaratne HB, Mendis-Handagama SM, Hales DB, Mason JI. Studies of the onset of Leydig precursor cell differentiation in the prepubertal rat testis. *Biol Reprod.* 2000;63:165–71.
 82. Landreh L, Stukenborg JB, Soder O, Svechnikov K Phenotype and steroidogenic potential of PDGFR α -positive rat neonatal peritubular cells. *Mol Cell Endocrinol* 2013;372:96–104. doi:[10.1016/j.mce.2013.03.019](https://doi.org/10.1016/j.mce.2013.03.019) S0303-7207(13)00115-9 [pii].
 83. O'Shaughnessy PJ, Morris ID, Baker PJ. Leydig cell re-generation and expression of cell signaling molecules in the germ cell-free testis. *Reproduction.* 2008;135:851–8.
 84. Ge RS, Dong Q, Sottas CM, Papadopoulos V, Zirkin BR, Hardy MP In search of rat stem Leydig cells: Identification, isolation, and lineage-specific development. *Proc Natl Acad Sci U S A.* 2006.
 85. Hardy MP, Zirkin BR, Ewing LL. Kinetic studies on the development of the adult population of Leydig cells in testes of the pubertal rat. *Endocrinology.* 1989;124:762–70.
 86. Park SY, Tong M, Jameson JL Distinct roles for steroidogenic factor 1 and desert hedgehog pathways in fetal and adult Leydig cell development. *Endocrinology* 2007.
 87. Li X, Wang Z, Jiang Z, Guo J, Zhang Y, Li C, Chung J, Folmer J, Liu J, Lian Q, Ge R, Zirkin BR, Chen H Regulation of seminiferous tubule-associated stem Leydig cells in adult rat testes. *Proc Natl Acad Sci U S A.* 2016 doi:[10.1073/pnas.1519395113](https://doi.org/10.1073/pnas.1519395113) 1519395113 [pii].
 88. Racine C, Rey R, Forest MG, Louis F, Ferre A, Huhtaniemi I, Josso N, di Clemente N. Receptors for anti-mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. *Proc Natl Acad Sci U S A.* 1995;95:594–9.
 89. Qin J, Tsai MJ, Tsai SY. Essential roles of COUP-TFII in Leydig cell differentiation and male fertility. *PLoS ONE.* 2008;3:e3285.
 90. Gnassi L, Basciani S, Mariani S, Arizzi M, Spera G, Wang C, Bondjers C, Karlsson L, Betsholtz C. Leydig cell loss and spermatogenic arrest in

- platelet-derived growth factor (PDGF)-A-deficient mice. *J Cell Biol.* 2000;149:1019–26.
91. Schmahl J, Rizzolo K, Soriano P The PDGF signaling pathway controls multiple steroid-producing lineages. *Genes Dev* 2008;22:3255–267. doi:[10.1101/gad.1723908](https://doi.org/10.1101/gad.1723908) 22/23/3255 [pii].
 92. Basciani S, Mariani S, Spera G, Gnassi L Role of platelet-derived growth factors in the testis. *Endocr Rev* 2010;31:916–39. doi:[10.1210/er.2010-0004](https://doi.org/10.1210/er.2010-0004) [pii].
 93. Gnassi L, Emidi A, Jannini EA, Carosa E, Maroder M, Arizzi M, Ulisse S, Spera G. Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action. *J Cell Biol.* 1995;131:1105–21.
 94. Mendis-Handagama SM, Ariyaratne HB. Differentiation of the adult Leydig cell population in the postnatal testis. *Biol Reprod.* 2001;65:660–71.
 95. Zhang FP, Pakarainen T, Zhu F, Poutanen M, Huhtaniemi I. Molecular characterization of postnatal development of testicular steroidogenesis in luteinizing hormone receptor knockout mice. *Endocrinology.* 2004;145:1453–63.
 96. Baker PJ, Johnston H, Abel MH, Charlton HM, O'Shaughnessy PJ. Differentiation of adult-type Leydig cells occurs in gonadotrophin-deficient mice. *Reprod Biol Endocrinol.* 2003;1:4.
 97. Baker PJ, O'Shaughnessy PJ. Role of gonadotrophins in regulating numbers of Leydig and Sertoli cells during fetal and postnatal development in mice. *Reproduction.* 2001;122:227–34.
 98. McGee SR, Narayan P Precocious puberty and Leydig cell hyperplasia in male mice with a gain of function mutation in the LH receptor gene. *Endocrinology* 2013;154:3900–913. doi:[10.1210/en.2012-2179](https://doi.org/10.1210/en.2012-2179) [pii].
 99. O'Shaughnessy PJ, Johnston H, Willerton L, Baker PJ. Failure of normal adult Leydig cell development in androgen-receptor-deficient mice. *J Cell Sci.* 2002;115:3491–6.
 100. De Gendt K, Atanassova N, Tan KA, De Franca LR, Parreira GG, McKinnell C, Sharpe RM, Saunders PT, Mason J, Hartung S, Ivell R, Denoet E, Verhoeven G. Development and function of the adult generation of Leydig cells in mice with Sertoli cell-selective (SCARKO) or total (ARKO) ablation of the androgen receptor. *Endocrinology.* 2005;146:4117–26.
 101. O'Hara L, McInnes K, Simitsidellis I, Morgan S, Atanassova N, Slowikowska-Hilczer J, Kula K, Szarras-Czapnik M, Milne L, Mitchell RT, Smith LB Autocrine androgen action is essential for Leydig cell maturation and function, and protects against late-onset Leydig cell apoptosis in both mice and men. *FASEB J* 2015;29:894–910. doi:[10.1096/fj.14-255729](https://doi.org/10.1096/fj.14-255729) [pii].
 102. Boyar RM, Moore RJ, Rosner W, Aiman J, Chipman J, Madden JD, Marks JF, Griffin JE. Studies of gonadotropin-gonadal dynamics in patients with androgen insensitivity. *J Clin Endocrinol Metab.* 1978;47:1116–22. doi:[10.1210/jcem-47-5-1116](https://doi.org/10.1210/jcem-47-5-1116).
 103. Judd HL, Hamilton CR, Barlow JJ, Yen SS, Kliman B. Androgen and gonadotropin dynamics in testicular feminization syndrome. *J Clin Endocrinol Metab.* 1972;34:229–34. doi:[10.1210/jcem-34-1-229](https://doi.org/10.1210/jcem-34-1-229).
 104. Nusynowitz ML, Strader WJ III. Regulation of gonadotropin response in testicular feminization syndrome. *Am J Med Sci.* 1975;270:491–6.
 105. Tremblay RR, Foley TP Jr, Corvol P, Park IJ, Kowarski A, Blizzard RM, Jones HW Jr, Migeon CJ. Plasma concentration of testosterone, dihydrotestosterone, testosterone-oestradiol binding globulin, and pituitary gonadotrophins in the syndrome of male pseudo-hermaphroditism with testicular feminization. *Acta Endocrinol (Copenh).* 1972;70:331–41.
 106. Murphy L, O'Shaughnessy PJ. Testicular steroidogenesis in the testicular feminized (Tfm) mouse: loss of 17 α -hydroxylase activity. *J Endocrinol.* 1991;131:443–9.
 107. Wilson SC, Oakey RE, Scott JS. Steroid metabolism in testes of patients with incomplete masculinization due to androgen insensitivity or 17 β -hydroxysteroid dehydrogenase deficiency and normally differentiated males. *J Steroid Biochem.* 1988;29:649–55.
 108. Kilcoyne KR, Smith LB, Atanassova N, MacPherson S, McKinnell C, van den Driesche S, Jobling MS, Chambers TJ, De GK, Verhoeven G, O'Hara L, Platts S, Renato de FL, Lara NL, Anderson RA, Sharpe RM Fetal programming of adult Leydig cell function by androgenic effects on stem/progenitor cells. *Proc Natl Acad Sci U S A* 2014;111:E1924–932. doi:[10.1073/pnas.1320735111](https://doi.org/10.1073/pnas.1320735111) [pii].
 109. Eisenberg ML, Jensen TK, Walters RC, Skakkebaek NE, Lipshultz LI The relationship between anogenital distance and reproductive hormone levels in adult men. *J Urol* 2012;187:594–98. doi:[10.1016/j.juro.2011.10.041](https://doi.org/10.1016/j.juro.2011.10.041) [pii].
 110. Smith LB, Walker WH. Hormone signalling in the testis. In: Plant TM, Zeleznick AJ, editors. *Knobil and Neill's physiology of reproduction.* Amsterdam: Elsevier; 2015. p. 637–90.
 111. Hansson V, Skälhegg BS, Tasken K Cyclic-AMP-dependent protein kinase (PKA) in testicular cells. Cell specific expression, differential regulation and targeting of subunits of PKA. *J Steroid Biochem Mol Biol* 2000;73:81–92. doi:[S0960-0760\(00\)00057-1](https://doi.org/10.1016/S0960-0760(00)00057-1) [pii].
 112. Manna PR, Huhtaniemi IT, Stocco DM Mechanisms of protein kinase C signaling in the modulation of 3',5'-cyclic adenosine monophosphate-mediated steroidogenesis in mouse gonadal cells. *Endocrinology* 2009;150:3308–317. doi:[10.1210/en.2008-1668](https://doi.org/10.1210/en.2008-1668) [pii].
 113. Costa RR, Varanda WA, Franci CR A calcium-induced calcium release mechanism supports luteinizing hormone-induced testosterone

- secretion in mouse Leydig cells. *Am J Physiol Cell Physiol* 2010;299:C316-23. doi:[10.1152/ajpcell.00521.2009](https://doi.org/10.1152/ajpcell.00521.2009) ajpcell.00521.2009 [pii].
114. Abdou HS, Villeneuve G, Tremblay JJ The calcium signaling pathway regulates leydig cell steroidogenesis through a transcriptional cascade involving the nuclear receptor NR4A1 and the steroidogenic acute regulatory protein. *Endocrinology* 2013;154:511–20. doi:[10.1210/en.2012-1767](https://doi.org/10.1210/en.2012-1767) en.2012-1767 [pii].
 115. Evaul K, Hammes SR Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells. *J Biol Chem* 2008;283:27525–7533. doi:[10.1074/jbc.M803867200](https://doi.org/10.1074/jbc.M803867200) M803867200 [pii].
 116. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolsheimer E, Jacobsen E, Kadam S, Ecker JR, Emerson B, Hogenesch JB, Unterman T, Young RA, Montminy M Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. *Proc Natl Acad Sci U S A* 2005;102:4459–464. doi:[10.1073/pnas.0501076102](https://doi.org/10.1073/pnas.0501076102) 0501076102 [pii].
 117. Manna PR, Eubank DW, Lalli E, Sassone-Corsi P, Stocco DM. Transcriptional regulation of the mouse steroidogenic acute regulatory protein gene by the cAMP response-element binding protein and steroidogenic factor 1. *J Mol Endocrinol.* 2003;30:381–97.
 118. Scott IS, Charlton HM, Cox BS, Grocock CA, Sheffield JW, O'Shaughnessy PJ. Effect of LH injections on testicular steroidogenesis, cholesterol side-chain cleavage P450 messenger RNA content and leydig cell morphology in hypogonadal mice. *J Endocrinol.* 1990;125:131–8.
 119. O'Shaughnessy PJ, Fleming LM, Jackson G, Hochgeschwender U, Reed P, Baker PJ. Adrenocorticotrophic hormone directly stimulates testosterone production by the fetal and neonatal mouse testis. *Endocrinology.* 2003;144:3279–84.
 120. Johnston H, King PJ, O'Shaughnessy PJ. Effects of ACTH and expression of the melanocortin-2 receptor in the neonatal mouse testis. *Reproduction.* 2007;133:1181–7.
 121. O'Shaughnessy PJ, Morris ID, Huhtaniemi I, Baker PJ, Abel MH. Role of androgen and gonadotrophins in the development and function of the Sertoli cells and Leydig cells: Data from mutant and genetically modified mice. *Mol Cell Endocrinol.* 2009;306:2–8.
 122. Hatano O, Takakusu A, Nomura M, Morohashi K. Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1. *Genes Cells.* 1996;1:663–71.
 123. Hu L, Monteiro A, Johnston H, King P, O'Shaughnessy PJ. Expression of Cyp21a1 and Cyp11b1 in the fetal mouse testis. *Reproduction.* 2007;134:585–91.
 124. O'Shaughnessy PJ, Baker PJ, Johnston H. The foetal Leydig cell—differentiation, function and regulation. *Int J Androl.* 2006;29:90–5.
 125. Val P, Jeays-Ward K, Swain A. Identification of a novel population of adrenal-like cells in the mammalian testis. *Dev Biol.* 2006;299:250–6.
 126. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM, Sweep FC, Hermus AR Testicular adrenal rest tumours in congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab* 2009;23:209–20. doi:[10.1016/j.beem.2008.09.007](https://doi.org/10.1016/j.beem.2008.09.007) S1521-690X(08)00105-X [pii].
 127. El Gehani F, Tena-Sempere M, Ruskoaho H, Huhtaniemi I. Natriuretic peptides stimulate steroidogenesis in the fetal rat testis. *Biol Reprod.* 2001;65:595–600.
 128. El Gehani F, Tena-Sempere M, Huhtaniemi I. Evidence that pituitary adenylate cyclase-activating polypeptide is a potent regulator of fetal rat testicular steroidogenesis. *Biol Reprod.* 2000;63:1482–9.
 129. El Gehani F, Tena-Sempere M, Huhtaniemi I. Vasoactive intestinal peptide stimulates testosterone production by cultured fetal rat testicular cells. *Mol Cell Endocrinol.* 1998;140:175–8.
 130. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G Endocrine regulation of male fertility by the skeleton. *Cell* 2011;144: 796–809. doi:[10.1016/j.cell.2011.02.004](https://doi.org/10.1016/j.cell.2011.02.004) S0092-8674(11)00118-8 [pii].
 131. Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, Srinivas P, Chamouni A, Lugani F, Lejeune H, Kumar TR, Plotton I, Karsenty G Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. *J Clin Invest* 2013;123:2421–433. doi:[10.1172/JCI65952](https://doi.org/10.1172/JCI65952) 65952 [pii].
 132. Karsenty G, Oury F Regulation of male fertility by the bone-derived hormone osteocalcin. *Mol Cell Endocrinol* 2014;382:521–26. doi:[10.1016/j.mce.2013.10.008](https://doi.org/10.1016/j.mce.2013.10.008) S0303-7207(13)00448-6 [pii].
 133. Chen YI, Payne AH, Kelch RP. FSH stimulation of Leydig cell function in the hypophysectomized immature rat. *Proc Soc Exp Biol Med.* 1976;153:473–5.
 134. Lapolt PS, Tilly JL, Aihara T, Nishimori K, Hsueh AJW. Gonadotropin-induced up-regulation and down-regulation of ovarian follicle-stimulating-hormone (fsh) receptor gene- expression in immature rats—effects of pregnant mares serum gonadotropin, human chorionic-gonadotropin, and recombinant fsh. *Endocrinology.* 1992;130:1289–95.
 135. Sadate-Ngatchou PI, Pouchnik DJ, Griswold MD. Follicle-stimulating hormone induced changes in

- gene expression of murine testis. *Mol Endocrinol*. 2004;18:2805–16.
136. Baker PJ, Pakarinen P, Huhtaniemi IT, Abel MH, Charlton HM, Kumar TR, O'Shaughnessy PJ. Failure of normal leydig cell development in follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSH β -deficient mice: role for constitutive FSH receptor activity. *Endocrinology*. 2003;144:138–45.
 137. Abel M, Baban D, Lee S, Charlton H, O'Shaughnessy P. Effects of follicle stimulating hormone on testicular mRNA transcript levels in the hypogonadal mouse. *J Mol Endocrinol*. 2009;42:291–303.
 138. Young J, Couzinet B, Chanson P, Brailly S, Loumaye E, Schaison G. Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions. *J Clin Endocrinol Metab*. 2000;85:3239–44.
 139. Lofrano-Porto A, Casulari LA, Nascimento PP, Giacomini L, Naves LA, da Motta LD, Layman LC. Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation. *Fertil Steril*. 2008;90:1169–74.
 140. Levalle O, Zylbersztein C, Aszpis S, Aquilano D, Terradas C, Colombani M, Aranda C, Scaglia H. Recombinant human follicle-stimulating hormone administration increases testosterone production in men, possibly by a Sertoli cell-secreted nonsteroid factor. *J Clin Endocrinol Metab*. 1998;83:3973–6.
 141. Heckert LL, Griswold MD. The expression of the follicle-stimulating hormone receptor in spermatogenesis. *Recent Prog Horm Res*. 2002;57:129–48.
 142. Rebourcet D, O'Shaughnessy PJ, Monteiro A, Milne L, Cruickshanks L, Jeffrey N, Guillou F, Freeman TC, Mitchell RT, Smith LB. Sertoli cells maintain Leydig cell number and peritubular myoid cell activity in the adult mouse testis. *PLoS ONE*. 2014;9:e105687. doi:10.1371/journal.pone.0105687 PONE-D-14-19027 [pii].
 143. Huhtaniemi I Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. *Asian J Androl* 2014;16:192–202. doi:10.4103/1008-682X.122336 122336 [pii].
 144. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. *J Clin Endocrinol Metab* 2007;92:549–55. doi:10.1210/jc.2006-1859 jc.2006-1859 [pii].
 145. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. *J Clin Endocrinol Metab* 2008;93: 2737–745. doi:10.1210/jc.2007-1972 jc.2007-1972 [pii].
 146. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Aging Study. *J Clin Endocrinol Metab* 2010;95:1810–818. doi:10.1210/jc.2009-1796 jc.2009-1796 [pii].
 147. Coviello AD, Lakshman K, Mazer NA, Bhasin S Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. *J Clin Endocrinol Metab* 2006; 91:4669–675. doi:10.1210/jc.2006-0822 jc.2006-0822 [pii].
 148. Veldhuis JD, Liu PY, Keenan DM, Takahashi PY Older men exhibit reduced efficacy of and heightened potency downregulation by intravenous pulses of recombinant human LH: a study in 92 healthy men. *Am J Physiol Endocrinol Metab* 2012;302: E117-22. doi:10.1152/ajpendo.00450.2011 ajpendo.00450.2011 [pii].
 149. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. *J Clin Endocrinol Metab*. 1987;65:1118–26. doi:10.1210/jcem-65-6-1118.
 150. Neaves WB, Johnson L, Porter JC, Parker CR Jr, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. *J Clin Endocrinol Metab*. 1984;59:756–63. doi:10.1210/jcem-59-4-756.
 151. Kaler LW, Neaves WB. Attrition of the human Leydig cell population with advancing age. *Anat Rec*. 1978;192:513–8. doi:10.1002/ar.1091920405.
 152. Harbitz TB. Morphometric studies of the Leydig cells in elderly men with special reference to the histology of the prostate. An analysis in an autopsy series. *Acta Pathol Microbiol Scand A*. 1973;81:301–14.
 153. Paniagua R, Martin A, Nistal M, Amat P. Testicular involution in elderly men: comparison of histologic quantitative studies with hormone patterns. *Fertil Steril*. 1987;47:671–9.
 154. Petersen PM, Seieroe K, Pakkenberg B. The total number of Leydig and Sertoli cells in the testes of men across various age groups—a stereological study. *J Anat*. 2015;226:175–9. doi:10.1111/joa.12261.
 155. Paniagua R, Nistal M, Saez FJ, Fraile B. Ultrastructure of the aging human testis. *J Electron Microscop Tech*. 1991;19:241–60.

156. Nistal M, Santamaria L, Paniagua R, Regadera J, Codesal J. Multinucleate leydig-cells in normal human testes. *Andrologia*. 1986;18:268–72.
157. Mori H, Hiromoto N, Nakahara M, Shiraiishi T. Stereological analysis of Leydig cell ultrastructure in aged humans. *J Clin Endocrinol Metab*. 1982;55:634–41. doi:[10.1210/jcem-55-4-634](https://doi.org/10.1210/jcem-55-4-634).
158. Takahashi J, Higashi Y, LaNasa JA, Yoshida K, Winters SJ, Oshima H, Troen P. Studies of the human testis. XVIII. Simultaneous measurement of nine intratesticular steroids: evidence for reduced mitochondrial function in testis of elderly men. *J Clin Endocrinol Metab*. 1983;56:1178–87. doi:[10.1210/jcem-56-6-1178](https://doi.org/10.1210/jcem-56-6-1178).
159. Beattie MC, Adekola L, Papadopoulos V, Chen H, Zirkin BR Leydig cell aging and hypogonadism. *Exp Gerontol*. 2015 doi:[10.1016/j.exger.2015.02.014](https://doi.org/10.1016/j.exger.2015.02.014) S0531–5565(15)00076-5 [pii].
160. Chen H, Guo J, Ge R, Lian Q, Papadopoulos V, Zirkin BR Steroidogenic fate of the Leydig cells that repopulate the testes of young and aged Brown Norway rats after elimination of the preexisting Leydig cells. *Exp Gerontol* 2015;72:8–15. doi:[10.1016/j.exger.2015.08.014](https://doi.org/10.1016/j.exger.2015.08.014) S0531-5565(15)30038-3 [pii].
161. Woodward PJ, Sohaey R, O'Donoghue MJ, Green DE. From the archives of the AFIP: tumors and tumorlike lesions of the testis: radiologic-pathologic correlation. *Radiographics*. 2002;22:189–216. doi:[10.1148/radiographics.22.1.g02ja14189](https://doi.org/10.1148/radiographics.22.1.g02ja14189).
162. Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. *Am J Surg Pathol*. 1985;9:177–92.
163. Maizlin ZV, Belenky A, Kunichezky M, Sandbank J, Strauss S Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance. *J Ultrasound Med* 2004;23:959–64. 23/7/959 [pii].
164. Cortez JC, Kaplan GW. Gonadal stromal tumors, gonadoblastomas, epidermoid cysts, and secondary tumors of the testis in children. *Urol Clin North Am*. 1993;20:15–26.
165. Al-Agha OM, Axiotis CA An in-depth look at Leydig cell tumor of the testis. *Arch Pathol Lab Med* 2007;131:311–17. doi:[10.1043/1543-2165\(2007\)131\[311:AILALC\]2.0.CO;2](https://doi.org/10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2) RS6-0240 [pii].
166. Ducharme JR, Collu R. Pubertal development: normal, precocious and delayed. *Clin Endocrinol Metab*. 1982;11:57–87.
167. Leonhartsberger N, Ramoner R, Aigner F, Stoehr B, Pichler R, Zangerl F, Fritzer A, Steiner H. Increased incidence of Leydig cell tumours of the testis in the era of improved imaging techniques. *BJU Int*. 2011;108:1603–7. doi:[10.1111/j.1464-410X.2011.10177.x](https://doi.org/10.1111/j.1464-410X.2011.10177.x).
168. Lock G, Schmidt C, Helmich F, Stolle E, Dieckmann KP Early experience with contrast-enhanced ultrasound in the diagnosis of testicular masses: a feasibility study. *Urology* 2011;77:1049–053. doi:[10.1016/j.urology.2010.12.035](https://doi.org/10.1016/j.urology.2010.12.035) S0090-4295 (10)02173-4 [pii].
169. Richmond I, Banerjee SS, Eyden BP, Sissons MC. Sarcomatoid Leydig cell tumour of testis. *Histopathology*. 1995;27:578–80.
170. Ritchie JP. Neoplasms of the testis. In: Walsh P, Reitik A, Vaughan E, Wein A, editors. *Campbell's Urology*. Philadelphia: WB Saunders; 1992. p. 1222–63.
171. Bozzini G, Picozzi S, Gadda F, Colombo R, Decobelli O, Palou J, Colpi G, Carmignani L Long-term follow-up using testicle-sparing surgery for Leydig cell tumor. *Clin Genitourin Cancer* 2013;11:321–24. doi:[10.1016/j.clgc.2012.12.008](https://doi.org/10.1016/j.clgc.2012.12.008) S1558-7673(12)00247-9 [pii].
172. Chandak P, Shah A, Taghizadeh A, Tiptaft R, Dasgupta P. Testis-sparing surgery for benign and malignant testicular tumours. *Int J Clin Pract*. 2003;57:912–3.
173. Bertram KA, Bratloff B, Hodges GF, Davidson H. Treatment of malignant Leydig cell tumor. *Cancer*. 1991;68:2324–9.
174. Olivier P, Simoneau-Roy J, Francoeur D, Sartelet H, Parma J, Vassart G, Van VG Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. *J Pediatr* 2012;161:1147–52. doi:[10.1016/j.jpeds.2012.05.039](https://doi.org/10.1016/j.jpeds.2012.05.039) S0022-3476(12)00556-2 [pii].
175. Ahtiainen P, Rulli SB, Shariatmadari R, Pelliniemi LJ, Toppari J, Poutanen M, Huh-taniemi IT Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. *Oncogene* 2005;24:7301–309. doi:[10.1038/sj.onc.1208893](https://doi.org/10.1038/sj.onc.1208893) 1208893 [pii].
176. Makabe S, Naguro T, Heyn R, Motta PM. Ultrastructure of human Leydig cells at early gonadal embryogenesis. *Ital J Anat Embryol*. 1995;100(Suppl 1):525–33.
177. Basciani S, Brama M, Mariani S, De LG, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnassi L Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. *Cancer Res* 2005;65:1897–903. doi:[10.1158/0008-5472.CAN-04-2181](https://doi.org/10.1158/0008-5472.CAN-04-2181) 65/5/1897 [pii].
178. Froehner M, Beuthien-Baumann B, Dittert DD, Schuler U, Wirth MP. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. *Cancer Chemother Pharmacol*. 2006;58:716–8. doi:[10.1007/s00280-005-0181-6](https://doi.org/10.1007/s00280-005-0181-6).
179. Naughton CK, Nadler RB, Basler JW, Humphrey PA. Leydig cell hyperplasia. *Br J Urol*. 1998;81:282–9.
180. Tash JA, McCallum S, Hardy MP, Knudsen B, Schlegel PN. Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia. *J Urol*. 2002;168:1068–70. doi:[10.1097/01.ju](https://doi.org/10.1097/01.ju)

- 0000026414.68954.d1 S0022-5347(05)64576-4 [pii].
181. Habert R, Livera G, Rouiller-fabre V. Man is not a big rat: concerns with traditional human risk assessment of phthalates based on their anti-androgenic effects observed in the rat foetus. *Basic Clin Androl.* 2014;24:14. doi:[10.1186/2051-4190-24-14](https://doi.org/10.1186/2051-4190-24-14) 27 [pii].
 182. van den Driesche S, Walker M, McKinnell C, Scott HM, Eddie SL, Mitchell RT, Seckl JR, Drake AJ, Smith LB, Anderson RA, Sharpe RM. Proposed role for COUP-TFII in regulating fetal Leydig cell steroidogenesis, perturbation of which leads to masculinization disorders in rodents. *PLoS ONE.* 2012;7:e37064. doi:[10.1371/journal.pone.0037064](https://doi.org/10.1371/journal.pone.0037064) PONE-D-12-03035 [pii].
 183. Svechnikov K, Savchuk I, Morvan ML, Antignac JP, Le BB, Soder O Phthalates exert multiple effects on Leydig cell steroidogenesis. *Horm Res Paediatr.* 2015; 000440619 doi:[10.1159/000440619](https://doi.org/10.1159/000440619).
 184. Desdoits-Lethimonier C, Albert O, Le BB, Perdu E, Zalko D, Courant F, Lesne L, Guille F, Dejuq-Rainsford N, Jegou B Human testis steroidogenesis is inhibited by phthalates. *Hum Reprod* 2012;27:1451–459. doi:[10.1093/humrep/des069](https://doi.org/10.1093/humrep/des069) des069 [pii].
 185. N'Tumba-Byn T, Moison D, Lacroix M, Lecureuil C, Lesage L, Prud'homme SM, Pozzi-Gaudin S, Frydman R, Benachi A, Livera G, Rouiller-fabre V, Habert R. Differential effects of bisphenol A and diethylstilbestrol on human, rat and mouse fetal leydig cell function. *PLoS ONE.* 2012;7:e51579. doi:[10.1371/journal.pone.0051579](https://doi.org/10.1371/journal.pone.0051579) PONE-D-12-19171 [pii].
 186. Ben MM, Lesne L, Desdoits-Lethimonier C, Coiffec I, Lassarguere J, Lavoue V, Deceuninck Y, Antignac JP, Le BB, Perdu E, Zalko D, Pineau C, Chevrier C, Dejuq-Rainsford N, Mazaud-Guittot S, Jegou B. An investigation of the endocrine-disruptive effects of bisphenol a in human and rat fetal testes. *PLoS ONE.* 2015;10:e0117226. doi:[10.1371/journal.pone.0117226](https://doi.org/10.1371/journal.pone.0117226) PONE-D-14-40771 [pii].
 187. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. *BMC Med* 2013;11:57. doi:[10.1186/1741-7015-11-57](https://doi.org/10.1186/1741-7015-11-57) 1741–7015-11-57 [pii].
 188. Klinefelter GR, Laskey JW, Amann RP Statin drugs markedly inhibit testosterone production by rat Leydig cells in vitro: implications for men. *Reprod Toxicol* 2014;45:52–8. doi:[10.1016/j.reprotox.2013.12.010](https://doi.org/10.1016/j.reprotox.2013.12.010) S0890-6238(14)00007-0 [pii].
 189. Beverly BE, Lambright CS, Furr JR, Sampson H, Wilson VS, McIntyre BS, Foster PM, Travlos G, Gray LE, Jr Simvastatin and dipentyl phthalate lower ex vivo testicular testosterone production and exhibit additive effects on testicular testosterone and gene expression via distinct mechanistic pathways in the fetal rat. *Toxicol Sci* 2014;141:524–37. doi:[10.1093/toxsci/kfu149](https://doi.org/10.1093/toxsci/kfu149) kfu149 [pii].
 190. Van Thiel DH, Lester R, Sherins RJ. Hypogonadism in alcoholic liver disease: evidence for a double defect. *Gastroenterology.* 1974;67:1188–99.
 191. Maneesh M, Dutta S, Chakrabarti A, Vasudevan DM. Alcohol abuse-duration dependent decrease in plasma testosterone and antioxidants in males. *Indian J Physiol Pharmacol.* 2006;50:291–6.
 192. Santori C, Ceccanti M, Diacinti D, Attilia ML, Toppo L, D'Erasmus E, Romagnoli E, Mascia ML, Cipriani C, Prastaro A, Carnevale V, Minisola S Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. *J Endocrinol Invest* 2008;31:321–26. doi:[10.1007/BF03346365](https://doi.org/10.1007/BF03346365) 4564 [pii].
 193. Muthusami KR, Chinnaswamy P Effect of chronic alcoholism on male fertility hormones and semen quality. *Fertil Steril* 2005;84:919–24. doi:[10.1016/j.fertnstert.2005.04.025](https://doi.org/10.1016/j.fertnstert.2005.04.025) S0015-0282(05)01251-3 [pii].
 194. Smith LB, O'Shaughnessy PJ, Rebourcet D. Cell-specific ablation in the testis: what have we learned? *Andrology.* 2015;3:1035–49. doi:[10.1111/andr.12107](https://doi.org/10.1111/andr.12107).
 195. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. *J Clin Endocrinol Metab.* 2007;92:3568–72.
 196. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab.* 2008;93:68–75.
 197. Saad F, Gooren LJ The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. *J Obes* 2011.
 198. Barker DJ. The origins of the developmental origins theory. *J Intern Med.* 2007;261:412–7.
 199. Vanbillemont G, Lapauw B, Bogaert V, De Naeyer H, De Bacquer D, Ruige J, Kaufman JM, Taes YE. Birth weight in relation to sex steroid status and body composition in young healthy male siblings. *J Clin Endocrinol Metab.* 2010;95:1587–94.
 200. Prince FP Mitochondrial cristae diversity in human Leydig cells: a revised look at cristae morphology in these steroid-producing cells. *Anat Rec* 1999; 254:534–41. doi:[10.1002/\(SICI\)1097-0185\(19990401\)254:4<534::AID-AR8>3.0.CO;2-#](https://doi.org/10.1002/(SICI)1097-0185(19990401)254:4<534::AID-AR8>3.0.CO;2-#).

Human Spermatogenesis and Its Regulation

3

Haiqi Chen PhD, Dolores Mruk PhD, Xiang Xiao PhD
and C. Yan Cheng PhD

Contents

Introduction.....	49
Structure and Composition of the Seminiferous Epithelium.....	50
Sertoli Cells and the Blood–Testis Barrier (BTB)....	52
Cell–Cell Interactions in the Testis.....	53
Spermatogonia and Self-renewal.....	54
Spermatocytes and Meiosis.....	56
Spermatids and Spermiogenesis.....	58
Cycle of the Seminiferous Epithelium.....	58
Factors that Regulate Spermatogenesis.....	59
Hormonal Regulation.....	59
Small Non-coding RNAs (sncRNAs).....	62
Obesity.....	63
Summary.....	64
References.....	64

Introduction

In human spermatogenesis, undifferentiated spermatogonia derived from spermatogonial stem cells give rise to diploid spermatocytes which undergo meiosis I/II to produce haploid spermatids [1–3]. Spermatids, in turn, undergo spermiogenesis to form functional spermatozoa [3–5]. After puberty at ~12 years of age, a healthy man produces upwards of 200 million sperm daily from his 20 s through 50 s [6, 7], which declines gradually with a reduction of ~50% by his 80 s [8, 9]. Spermatogenesis is composed of a series of cellular events which includes (i) self-renewal of spermatogonial stem cells and spermatogonia via mitosis, (ii) transformation and differentiation of spermatocytes, (iii) generation of haploid spermatids via meiosis I/II, and (iv) final morphological maturation of spermatids to become spermatozoa via spermiogenesis. These processes thus involve multiple cellular events in the testis and are under complex controls by regulatory hormonal and signaling axes. The most important of these regulatory pathways is the hypothalamic–pituitary–testicular axis involving both FSH and LH, and testosterone and estradiol-17 β as key regulators [10–14]. Since the subject of hormonal regulation of spermatogenesis in men has been extensively reviewed [10–15], we focus our discussion herein on other topics in which advances have been made in recent years.

H. Chen · D. Mruk · C.Y. Cheng (✉)
Center for Biomedical Research Population Council,
1230 York Ave., New York, NY 10065, USA
e-mail: y-cheng@popcbr.rockefeller.edu

H. Chen
e-mail: hqchen1990@gmail.com

D. Mruk
e-mail: mruk@popcbr.rockefeller.edu

X. Xiao
Department of Reproductive Physiology,
Zhejiang Academy of Medical Sciences, Hangzhou,
Zhejiang, China
e-mail: xxiao@zjams.cn

A better understanding of human spermatogenesis is necessary since about 15% of married couples are infertile, and half of these cases are attributed to male factors, indicating that about 7% of men in the general population are infertile [16]. In this context, it is of interest to note that male reproductive health can be considerably altered by the environment and life style factors [17–21]. Semen quality is believed to be declining [22–25], illustrating the global trend of impaired male reproductive health. While 6–18% of non-obstructive azoospermia or severe oligozoospermia cases can be attributed to Y chromosome microdeletions [26], as many as 25–40% of infertile men have no identifiable cause for hypospermatogenesis [27, 28]. In fact, infertility is an emerging global public health issue right after cancer and cardiovascular diseases. Interestingly, experiments using mouse genetic models, including knockout/knockin/gene-trapped, transgenic, and chemical-induced point mutant mice, have identified more than 400 genes pertinent to spermatogenesis [28, 29], and the use of proteomics, epigenomics, and genomics have identified >2300 genes pertinent to spermatogenesis and/or testis function. However, how this information applies to humans remains largely unknown [30]. Future directions in “omics” research pertinent to human spermatogenesis have been recently reviewed [30, 31]; herein, we focus on the local regulation of spermatogenesis and highlight areas of research which can serve as helpful examples to guide future investigations.

Structure and Composition of the Seminiferous Epithelium

In adult humans, as in rodents, the functional unit that produces sperm via spermatogenesis is the seminiferous tubule. Spermatogenesis is supported by testosterone produced by Leydig cells in the interstitium, and by estradiol-17 β produced by Sertoli and germ cells [10–15], although there is evidence that human Leydig cells also produce estradiol-17 β [32]. In men, each testis has ~400–600 seminiferous tubules, the length of all the

tubules combined per pair of testes is ~400 meters, and each tubule has a diameter of ~200 μm [3, 33]. Spermatogenesis occurs as shown in the cross section of a tubule (Fig. 3.1), consisting of Sertoli cells and germ cells at different stages of development. These germ cells include undifferentiated spermatogonia, dark type A spermatogonia, pale type A spermatogonia, type B spermatogonia; preleptotene, leptotene, zygotene and pachytene primary spermatocytes, and secondary spermatocytes; as well as Sa, Sb, Sc, Sd1, and Sd2 spermatids until Sd2 transform into spermatozoa [34]. Sertoli and germ cells near the base of the seminiferous epithelium are in close contact with the basement membrane, which is a modified form of extracellular matrix and is composed of mostly collagen (type IV) and laminins, heparin sulfate proteoglycan, and nidogen/entactin [35, 36]. Behind the basement membrane is the type 1 collagen layer, to be followed by the myoid cell layer, lymph, and then lymphatic endothelium. Collectively, they constitute the tunica propria [35, 36] (Fig. 3.1). During spermatogenesis, germ cells, in particular post-meiotic spermatids, rely almost solely on Sertoli cells for structural, nutritional, and paracrine support since haploid spermatids are metabolically quiescent cells with relatively little cytosol to support their cellular functions [37, 38]. Thus, the Sertoli cell is known as the “mother” or “nurse” cell, with each Sertoli cell supporting ~30–50 developing germ cells based on morphometric analysis in the rat testis [39].

In humans, Sertoli cells undergo mitotic proliferation in two separate phases. The first phase takes place shortly after birth during the neonatal-infantile period when the Sertoli cell population increases via mitotic proliferation [40]. During puberty, Sertoli cells again rapidly divide mitotically [40], giving rise to ~500 $\times 10^6$ Sertoli cells per testis (each adult human testis weighs ~18–19 gm). The Sertoli cell number declines to ~300 $\times 10^6$ by 50–85 years of age, associated with a reduction in daily sperm output [8]. Each testis has ~4.5 $\times 10^6$ Sertoli cells in mice [41] and 30–40 $\times 10^6$ Sertoli cells in rats [42–44] compared to 500 $\times 10^6$ in men [8], and a daily sperm




Fig. 3.1 Structure and cellular composition of the seminiferous epithelium in the human testis. The seminiferous epithelium, as seen in this schematic drawing of a cross section of a seminiferous tubule, is composed of Sertoli and germ cells. The BTB is constituted by actin-based tight junctions, basal ectoplasmic specialization (ES), and gap junctions, as well as the intermediate filament-based desmosome. As one of the tightest blood–tissue barriers in the human body, the BTB divides the seminiferous epithelium into the adluminal (apical) and basal compartments. Spermatogonia (both type A, B and undifferentiated) and preleptotene spermatocytes reside in the basal compartment, whereas the other primary and secondary spermatocytes and post-meiotic spermatids are found in

the apical compartment. The most notable junction in the mammalian testis including humans is the ES, which is typified by the presence of actin microfilament bundles sandwiched in-between cisternae of endoplasmic reticulum and the apposing Sertoli cell–cell plasma membranes. The ES at the BTB is called basal ES while the ES at the Sertoli–spermatid interface is designated apical ES. Since developing germ cells (e.g., preleptotene spermatocytes) and developing spermatids are being transported across the seminiferous epithelium, Sertoli cell–Sertoli cell and Sertoli–germ cell junctions are continuously remodeling throughout the 6 stages of the epithelial cycle of spermatogenesis in the human testis

production of 8x [41], 70x [45], and 200x10⁶ [46], respectively. The number of Sertoli cells is determined by FSH, thyroid hormones, growth hormone, and several paracrine growth factors [40]. Outside the tubules in the interstitial space lay the Leydig cells, fibroblasts, and some

macrophages and microvessels (Fig. 3.1). Leydig cells produce testosterone (T) under the influence of luteinizing hormone (LH) since LH receptors are limited to Leydig cells in human and rodent testes. Interestingly, the T level in the interstitial fluid and seminiferous tubule fluid is at least

70- and 50-fold higher than the T level in the systemic circulation in the rat [47]. In humans, the intratesticular T (e.g., interstitial fluid) level is also 100-fold higher than the systemic circulation [48–50], illustrating a considerably higher T level is maintained in the testis to support spermatogenesis.

Sertoli Cells and the Blood–Testis Barrier (BTB)

The seminiferous epithelium of the mammalian testis is further divided into two functional compartments: (1) the basal, and (2) the adluminal (apical) compartments (Fig. 3.1), due to the presence of the Sertoli cell blood–testis barrier (BTB) located near the basement membrane. The BTB is constituted by coexisting actin-based basal ectoplasmic specialization (basal ES) and tight junction (TJ), as well as coexisting basal ES and gap junction, and intermediate filament-based desmosome [51, 52]. As such, undifferentiated spermatogonia, both type A and B spermatogonia, and preleptotene spermatocytes differentiated from type B spermatogonia reside in the basal compartment. More advanced primary spermatocytes, secondary spermatocytes, and all haploid spermatids including spermatozoa reside in the adluminal compartment (Fig. 3.1).

Briefly, the BTB provides a unique microenvironment in the adluminal compartment for meiosis I/II and post-meiotic spermatid development so that these events are segregated from the systemic circulation, behind an immunological barrier. Studies have shown, however, that the BTB contributes minor significance to the immune privilege of the testis since germ cells residing in the basal compartment are equally immunogenic, containing multiple testis-specific antigens [53, 54]. Instead, the testis immune privilege is maintained mostly by Sertoli cells through their secretory immunosuppressive biomolecules: cytokines, bioactive lipids and peptides, and androgens from Leydig cells [55]. The BTB in humans is established at puberty by ~12–13 years of age when Sertoli cells cease to

divide and become fully differentiated, concomitant with the onset of meiosis I/II [40]. It is of interest to note that human Sertoli cells, similar to Sertoli cells in rodents, can be de-differentiated, becoming mitotically active when they are exposed to fetal bovine serum [40], such as cultured in media containing 5–10% fetal bovine serum (v/v) [56]. Under such conditions, Sertoli cells can be maintained through multiple passes in vitro without detectable changes in their functional and physiological properties [57].

BTB function in rodents is dependent on testosterone [58–61]. However, treatment of normal men with testosterone plus levonorgestrel (LNG), which is capable of suppressing spermatogenesis and causing azoospermia or oligospermia with suppression of intratesticular androgen levels, did not affect BTB function since the distribution of claudin-3 remained relatively unaltered [62]. However, in a more recent study in which healthy men were treated with T plus LNG together with the GnRH antagonist acyline or the 5 α -reductase inhibitor dutasteride (in order to provide added suppression of spermatogenesis), there was considerable down-regulation of claudin-11, connexin-43, and vinculin at the BTB compared to men treated with T + LNG alone [63]. Collectively, these findings suggest that human BTB is regulated in a manner similar to rodents. Some species differences exist, however, such as the extent of androgen-dependency, since it appears that a considerable reduction in the intratesticular T level is necessary to suppress the BTB integrity in humans.

Due to the limited access to normal human testes for functional analysis, it is difficult to compare the regulation of the human BTB integrity with that of rodents. With advances in cell and tissue culture techniques, however, human Sertoli cells, using media containing fetal bovine serum, have been cultured and maintained successfully for several weeks in vitro [56, 57, 64–66], with a functional tight junction-permeability barrier [56, 64]. Using this approach, the organization of F-actin that supports BTB integrity has been investigated at the human Sertoli cell BTB. It is now known that

human Sertoli cell F-actin organization is maintained, similar to that of rodents, by actin binding proteins, including Arp2/3 (actin related protein 2/3) complex and Eps8 (epidermal growth factor receptor pathway substrate 8) that confers branched actin network and bundled actin microfilaments, respectively [57]. Furthermore, exposure of human Sertoli cells to environmental toxicants, such as CdCl₂, or bisphenol A (BPA), rapidly perturbs F-actin organization in these cells. Changes in the distribution of cell adhesion proteins at the BTB, including the TJ-protein ZO-1, and the basal ES proteins N-cadherin and β -catenin, from the cell surface to the cell cytosol [57], likely reflect degradation via an endosome-dependent degradation pathway. These changes disrupt integrity and function of the BTB. It is expected that much information will be obtained using this *in vitro* system to gain insight into the biology of the human BTB.

Cell–Cell Interactions in the Testis

Due to the presence of the BTB, germ cell development, in particular post-meiotic spermatid development, relies almost exclusively on the structural, nutritional, and paracrine support of Sertoli cells. This is mediated via cell junctions at the Sertoli–germ cell interface, involving multiple genes and their proteins [37, 38, 67, 68] (Fig. 3.2). Even though undifferentiated spermatogonia [e.g., spermatogonial stem cells (SSCs)], type A and type B spermatogonia, and preleptotene spermatocytes reside outside the BTB, they also rely on the Sertoli cell for functional and structural support through the expression of unique genes (Fig. 3.2). This is particularly true for SSCs which are located at the stem cell niches—usually at the base of the seminiferous epithelium wherein three seminiferous tubules meet, adjacent to the microvessels in the interstitium. In short, SSCs rely on Sertoli cells for structural and functional support, besides biomolecules from the microvessels [69, 70].

Sertoli cells also modulate spermatogenesis through cross talk with Leydig cells. Sertoli cells stimulate Leydig cell differentiation but inhibit




Fig. 3.2 Cell–cell interaction within the testis and its functional relationship to the hypothalamic–pituitary–testicular axis. The classic hormonal regulatory axis that exerts its regulatory effects on the testis through the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn regulates the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Testosterone produced by interstitial Leydig cells provides the feedback loop to modulate the production of GnRH from the hypothalamus and thereby LH and FSH from the pituitary gland. In humans and primates in contrast to rodents, testosterone has no direct feedback effect on the pituitary [240]. Inhibin produced by Sertoli cells provides selective feedback to the production of FSH. There is cross talk among germ cells (including spermatogonial stem cells) and Sertoli cells in the seminiferous epithelium, as well as Leydig cells and peritubular myoid cells in the interstitium. Studies have shown an array of growth factors, genes and hormones are involved. Abbreviations: CSF1, colony stimulating factor 1; BMP4, bone morphogenetic protein 4; GDF9, growth differentiation factor-9; GnRH, gonadotropin-releasing hormone; P-Mod-S, peritubular myoid cell modulates Sertoli cell factor; TGF- β 1, transforming growth factor-1; Wt1, Wilms’ tumor 1

Leydig cell steroidogenesis [71–73]. One of the paracrine factors produced by Sertoli cells that modulates Leydig cell function has been partially characterized [74]. Studies using genetic models

have shown that Sertoli cells maintain Leydig cell number (both fetal and adult Leydig cells) and support Leydig cell development [75, 76], as well as determine Leydig cell differentiation status and cell fate through the *Wtl* gene [77]. On the other hand, Sertoli cells also interact with germ cells to support spermatogenesis through multiple paracrine factors [37, 78, 79] (Fig. 3.2).


There is also functional cross talk between Sertoli cells and the tunica propria, in particular peritubular myoid cells (Fig. 3.2). For instance, Sertoli cells work in concert with peritubular myoid cells in the production and deposition of extracellular matrix (ECM) components [80] to produce and maintain the basement membrane, which is a modified form of ECM [35, 36]. Studies have also suggested that peritubular myoid cells modulate Sertoli cell function wherein myoid cells produce a paracrine factor known as P-Mod-S that regulates Sertoli cell function [81]. However, the identity of this factor remains to be clarified. Another report has shown that while peritubular myoid cells do not secrete clusterin or α_2 -macroglobulin (a wide-spectrum protease inhibitor [82]), co-cultures of myoid cells with Sertoli cell promote Sertoli cell α_2 -macroglobulin and clusterin secretion [83]. It must be noted, however, that unlike Sertoli cells, which can be maintained in culture in serum-free medium (e.g., F12/DMEM with several growth factors [84]) for up to ~ 2 -wk, peritubular myoid cell cultures require the presence of serum proteins, such as ~ 5 –10% fetal calf serum for their survival [83].

The most conclusive study thus far to illustrate the importance of peritubular myoid cells in spermatogenesis is the generation of a peritubular myoid cell-specific androgen receptor (AR) knockout (PTM-ARKO) mouse model [85]. PTM-ARKO male mice have reduced seminiferous tubule fluid production and are azoospermic and infertile, with reduced expression of certain androgen-dependent Sertoli cell genes [85]. These findings illustrate that ARs in Sertoli cells fail to assume the function of ARs in myoid cells to sustain spermatogenesis. Furthermore, these findings demonstrate that Sertoli cell androgen-dependent gene expression is

modulated by peritubular myoid cells, unequivocally demonstrating that Sertoli and peritubular myoid cells are functionally connected. Interestingly, studies using *Amh-Cre* to induce expression of the Diphtheria toxin receptor in Sertoli cells to cause controlled, cell-specific, and acute ablation of the Sertoli cell population in adult mice have shown that Sertoli cells also control peritubular myoid cell fate, including its differentiation status and cell population [76]. Using this approach, Sertoli cells were shown to modulate testicular vascular network development, including modulating circulating testosterone levels in adult mice [86]. It should be noted that much of the information stated above and depicted in Fig. 3.2 is derived from studies in rodents. Clearly, further studies are needed to understand the cell–cell interactions between Sertoli cells, Leydig cells, and peritubular myoid cells in the human testis.

Spermatogonia and Self-renewal

Spermatogonia are the progenitor cells of all germ cells and are designated type A and type B [87, 88]. In humans, type A spermatogonia are further categorized into progenitor dark type A spermatogonia (A_d) and pale type A spermatogonia (A_p) which are capable of undergoing mitotic proliferation for self-renewal [89] (Fig. 3.3). A_p are the predominant spermatogonia that survive radio- and chemotherapy while A_d are largely eliminated during such treatment, illustrating that A_p are the potential spermatogonial stem cells [90]. At present, it is generally accepted that A_d constitute a pool of reserve spermatogonia which remain quiescent but can give rise to A_p when needed and are considered to be the ‘true’ spermatogonial stem cells in humans [4, 91]. The molecular basis for the regulation of human spermatogonia remains largely unknown. cKIT, a transmembrane protein tyrosine kinase receptor (also known as stem cell factor receptor or CD117), and its ligand cKIT ligand (also known as stem cell factor (SCF)) are known to be involved in the differentiation of spermatogonia in humans, rodents, and primates



◀ **Fig. 3.3** Comparison of germ cell development in the human *versus* the rat testis. While the development of germ cells through spermatogenesis is similar between the two species, there are some notable differences such as during spermatogonial self-renewal and differentiation. In the rat, A single spermatogonia (A_s) divide and form A paired spermatogonia (A_{pr}), which further divide to form A aligned spermatogonia (A_{al}). The differentiating A_{al} undergo 5 cell divisions (A_{1-4} and In) to form type B spermatogonia. In humans, both Adark spermatogonia (A_d) and Apale spermatogonia (A_p) are capable of undergoing self-renewal through mitosis, and A_p also give rise to type B spermatogonia, the latter of which are then differentiate to form preleptotene spermatocytes. In the human testis, preleptotene spermatocytes formed in

[91]. cKIT is expressed in spermatogonia, round spermatids, and spermatozoa as well as in Leydig cells whereas its ligand or SCF is primarily expressed in Sertoli cells in humans [92]. However, cKIT is not expressed in spermatocytes or elongating spermatids [93]. Expression of cKIT in type A spermatogonia varies across the seminiferous tubules, being highest in proliferating A_p spermatogonia and type B spermatogonia [93–95], illustrating the involvement of cKIT/SCF in spermatogonial self-renewal and differentiation. The reduced staining of cKIT in type A spermatogonia has been shown in men with subfertility, and its reduced expression is associated with an increase in apoptosis in type A spermatogonia [96].

GFRA1, $\alpha 6$ -INTEGRIN, PLZF, GPR125, SALL4, and THY1 are undifferentiated spermatogonia markers in mouse, monkey, and man, whereas UTF1 (undifferentiated embryonic cell transcription factor 1) and FGFR3 (fibroblast growth factor receptor 3, also known as CD333) are molecular markers specific for human type A spermatogonia [91]. The molecular basis for the transition of undifferentiated spermatogonia to type A spermatogonia has been established in rodents and involves retinoic acid (RA), the active metabolite of vitamin A, which is also involved in the initiation of meiosis [97]. Indeed, treatment of mice with the pan-retinoic acid receptor antagonist, BMS-189453 that blocks the action of RA in the mouse testis, leads to reversible infertility due to meiotic arrest [98, 99]. The notion that RA is involved in

stage III (concomitant with spermiation that takes place at late stage II) of the epithelial cycle are transported across the BTB to enter the adluminal compartment to prepare for meiosis I/II which takes place at stage VI of the epithelial cycle, and Sa spermatids, the equivalent of round spermatids in the rat, are found in stage I. In the rat, a single diploid A_s can give rise to 4096 haploid sperm; whereas in the human, only 16 sperm are derived from one type A spermatogonium. The number of different types of germ cells that can be derived from a single committed type A spermatogonium is indicated. This figure was prepared based on the information of earlier reports [1, 51, 127] and in the model of rat spermatogenesis it is noted that A_{pr} and A_{al} spermatogonia have been shown to be able to revert to A_s [241]

spermatogenesis in humans is based on findings that bisdichloroacetyl diamine WIN 18,446, an inhibitor of retinoic acid synthesis, inhibits ALDH1A2 and induces reversible infertility in mice, rats, monkeys, and men [100–103]. More study is needed to define the role of retinoic acid in human spermatogonial differentiation.

Spermatogonial differentiation is a gonadotropin-dependent event in primates [104] since FSH treatment increases the number of A_p and type B spermatogonia in monkeys [105, 106]. Emerging evidence suggests that FSH plays a role in spermatogonial differentiation in men [107]. However, in normal adult men, gonadotropins (FSH and LH) serve as spermatogonial survival factors by regulating the intrinsic apoptotic pathway to promote germ cell survival but have no effect on germ cell proliferation [108].

Spermatocytes and Meiosis

Spermatocytes, namely leptotene, zygotene, pachytene, and diplotene spermatocytes are found in the human seminiferous epithelium [109] following the initiation of meiosis in humans at puberty [110] (Figs. 3.3 and 3.4). Diplotene spermatocytes undergo meiosis I to form secondary spermatocytes (with haploid number of chromosomes but $2n$ content of DNA), which rapidly progress to meiosis II so that a single secondary spermatocyte produces two haploid round Sa spermatids. In this context,




Fig. 3.4 A schematic drawing illustrating the six stages of the epithelial cycle (I-VI) in the human testis, and the associated germ cell types in the seminiferous epithelium in each of these stages. It is noted that spermiation takes place in late stage II, and preleptotene spermatocytes arise in stage III, which are being transported across the BTB in stage III. Meiosis takes place at stage VI of the cycle, and

the entire epithelial cycle takes 16 days to complete. The duration of each stage, from I to VI, is also annotated. This drawing was prepared and modified from earlier reports [4, 34, 242], and recent advances in the staging of human spermatogenesis have recently been discussed [243]

it is of interest to note that, unlike other somatic cells, neither spermatocytes nor spermatids metabolize glucose; instead, they rely on lactate supplied by Sertoli cells as their energy source [111, 112]. In brief, glucose is taken up by Sertoli cells via the specific glucose transporter GLUT1 and is processed into lactate glycolytically [113] by testis-specific lactate dehydrogenase C4 (LDHC4). Lactate is transported out of

Sertoli cells by a monocarboxylate transporter MCT1 and taken up by meiotic and post-meiotic germ cells via their specific monocarboxylate transporter, MCT2 [111]. Studies have shown that energy metabolism of Sertoli and germ cells is regulated by FSH, steroids, insulin and paracrine factors, and their disruption leads to male infertility [112, 114]. It is also noted that defects in meiosis, such as meiotic maturation arrest

(or early maturation arrest) is found in ~10% of men with non-obstructive azoospermia (NOA), with the histopathological features of reduced tubule diameter, reduce germ cell number, and degenerating spermatocytes [115].

Spermatids and Spermiogenesis

The process during which spermatids undergo extensive morphological transformation through round Sa spermatids, Sb1, Sb2, Sc, Sd1, and Sd2, and eventually to spermatozoa is known as spermiogenesis [116] (Figs. 3.3 and 3.4). During this process, no further cellular divisions occur, newly formed round spermatids from secondary spermatocytes are characterized by a small spherical nucleus with the usual array of cytoplasmic organelles, including the Golgi apparatus, mitochondria, and centrioles [116]. Each spermatid undergoes considerable morphological changes that begin with a large granule called the acrosomic granule which is generated by several small proacrosomic granules in the area of the Golgi apparatus that grows over the nucleus. As spermiogenesis continues, the acrosome transforms further, and nuclear chromatin condensation begins [117]. At the final steps, the spermatid nucleus completes its chromatin condensation, and the majority of the cytoplasm eventually detaches from the spermatid to form the residual body, which is engulfed by the Sertoli cell and processed into a phagosome. The phagosome is then transported to the base of the Sertoli cell for lysosomal degradation [118]. In humans, spermiogenesis can be disrupted, leading to: (i) late maturation arrest, manifested by an arrest in development in early spermatids with dark round nuclei, and (ii) hypospermatogenesis, with an arrest in further development of condensed oval spermatids [115]. Mature spermatozoa, once formed, are released into the tubule lumen via the final cellular process of spermatogenesis at spermiation [5, 119]. While the molecular mechanism underlying spermiation remains relatively unexplored, studies in rodents have shown that spermiation is tightly regulated by the spatiotemporal expression of signaling

molecules such as p-FAK-Tyr⁴⁰⁷, as well as actin binding/regulatory proteins (e.g., the Arp2/3 complex, Eps8), involving degeneration of apical ES and generation of laminin fragments [5, 119]. However, this process is poorly understood in humans except that it is likely dependent on FSH and testosterone. So far, human male infertility has not been attributed to defects of spermiation alone [3].

Cycle of the Seminiferous Epithelium

In human as well as rodent testes, the distinctive cellular associations in the seminiferous epithelium along the tubule can be defined into different stages which appear cyclically throughout spermatogenesis, known as the epithelial cycle of spermatogenesis [88, 120, 121]. In the testis of rats, mice, and humans, an epithelial cycle is composed of I-XIV, I-XII, and I-VI stages, respectively [4, 122, 123]. It is of interest to note that spermiation and meiosis I/II take place at stage VIII and XIV, VIII and XII and II and VI, in the rat, mouse, and human testis, respectively. It takes about 16 days to complete an epithelial cycle in the human [124] versus 8.6 days in the mouse [125] and 12.8 days in the rat [126]. This is the time it takes for a given spot in a seminiferous tubule at a specific stage of the epithelial cycle, such as at stage II, when observed under the stereomicroscope, to undergo cyclic staging and become stage II again. However, the duration of spermatogenesis, i.e., from type A spermatogonia to spermatozoa, is ~68 days (4.2 cycles) in humans versus ~35 days (4 cycles) and ~58 days (4.5 cycles) in mice and rats as noted in Fig. 3.4 for humans (for reviews, see [1, 127, 128]). This is the time it takes for a single human diploid Ap spermatogonium (progenitor germ cell, wherein Ad spermatogonium is the regenerative reserve stem cell) to develop into multiple haploid spermatozoa which requires ~4.2 cycles. In this context, it is noted that the staging of the epithelial cycle is largely defined according to changes in the Golgi region of developing spermatids, namely the acrosome, when it is visualized by the periodic acid Schiff's reaction (PAS). In mouse, rat, and

human, spermatids can be divided into 16, 19, and 6 steps, respectively, throughout spermiogenesis before they develop and transform into spermatozoa. The classification of human spermatids into 6 steps of Sa, Sb1, Sb2, Sc, Sd1, and Sd2 was based on the use of osmium-dichromate as fixative for the human testis, which was then stained with osmium and examined by transmission electron microscopy [117].

Factors that Regulate Spermatogenesis

Numerous factors are known to affect human spermatogenesis. Below, we highlight regulators that are well established or are rapidly developing in the field.

Hormonal Regulation

Hormonal regulation of spermatogenesis in humans is a complex biological event involving both testosterone and estradiol-17 β [10, 13, 14, 129, 130] and is tightly regulated by the hypothalamic–pituitary–testicular axis by follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that exert their effects on Sertoli and Leydig cells, respectively. Besides these hormones, inhibins, activins, follistatin, and other paracrine factors are also involved. Since the hormonal regulation of spermatogenesis in humans has been eminently reviewed recently [11, 13, 131–136], interested readers are encouraged to seek further information from these earlier reviews. Below is a summary of recent findings pertinent to the hormonal regulation of human spermatogenesis.

FSH

FSH is an important regulator of spermatogenesis through effects on Sertoli cells where FSH receptors are expressed. FSH activates at least five signaling pathways in Sertoli cells: cAMP-PKA, MAPK, PI3 K-AKT, intracellular Ca, and phospholipase A2 [137–139]. Gene expression profiles indicate that FSH regulates a

panoply of Sertoli cell genes. FSH promotes Sertoli cell proliferation before puberty, while after puberty, FSH activates Sertoli cell to support germ cell development. Despite the important role of FSH in spermatogenesis, this hormone, unlike testosterone (see below), is not considered essential to, but rather fine-tunes spermatogenesis. For instance, deletion of the FSH- β subunit in mice led to infertility in FSH-deficient females due to a block in folliculogenesis, but FSH-deficient males were fertile even though the testes of these mice were reduced in size [140, 141]. Furthermore, men with inactivating mutations of the FSH- β gene or the FSH receptor have impaired spermatogenesis but generally remain fertile—an observation explained in part by the finding that the FSH receptor possesses low-level constitutive activity in the absence of FSH [129, 142–144] (see Chap. 6). On the other hand, it is of interest to note that men with congenital complete hypogonadotropic hypogonadism (CHH) are usually treated with hCG (human chorionic gonadotrophin) together with FSH to induce testis development, spermatogenesis, and fertility (see Chap. 20). Also, men with idiopathic oligoasthenozoospermia treated with recombinant FSH for 3 months were found to have considerable improvement in seminal parameters vs. untreated controls [145, 146].

LH

The primary function of LH is to stimulate the production of testosterone by Leydig cells [147]. LHCG-receptor (luteinizing hormone/choriogonadotropin receptor, also called LHCG-R or LHR) expression begins in fetal Leydig cells [148]. Human males with inactivating mutations of the LHCG-R develop ambiguous genitalia and are testosterone-deficient indicating that hCG/LH signaling is essential for testosterone production in the fetus and adult [149–151]. LH stimulates testosterone production by stimulating the expression of key steroidogenic enzyme genes as well as transcription factors that are required for testosterone biosynthesis to support spermatogenesis and other male reproductive function [152]. Ligand

binding to the LHCG-R stimulates adenylate cyclase, increases cAMP production and phosphorylates target proteins through protein kinases A and C, activates ERK1 and 2, and increases calcium signaling [148]. Interestingly, accumulating evidence supports the notion that steroidogenesis in human fetal testes is highly sensitive to environmental toxicants or elected lifestyle (e.g., cigarette smoking) which are disruptive to LH-mediated testosterone production by Leydig cells [17, 153].

Intratesticular Testosterone (ITT) Microenvironment

Testicular aspirations of normal men have shown that T is the predominant intratesticular sex steroid [48, 49, 154]. ITT concentration in men averages 609 ± 50 ng/ml, which is much higher than the average serum T level of 3.7 ± 0.3 ng/ml [48–50]. This gradient between the testis and serum is similar to findings in rodents, wherein ITT in rat testes is ~ 100 -fold higher than the serum T level [47, 155]. Collectively, these findings support the notion that a high ITT level is necessary to maintain spermatogenesis. For instance, the high level of T in the testis is known to support spermatid adhesion, spermiogenesis, and BTB function in rodent testes [5, 51, 156]. In this context, it is of interest to note that the ITT concentration at ~ 2000 nM versus ~ 12 nM of T in serum in normal men is considerably higher than that of SHBG/ABP (sex hormone binding globulin/androgen binding protein, ~ 50 nM; note: SHBG/ABP reduces androgen bioavailability), suggesting that most ITT is bioavailable [154]. Studies by Jarow et al. found that $\sim 70\%$ of the total ITT is bioactive based on a novel androgen bioactivity assay [154]. Interestingly, neither ITT concentrations nor intratesticular bioactive androgen levels were strongly correlated with serum T concentration (correlation coefficients, $r = 0.38$) nor serum bioactive androgen level ($r = 0.46$). Yet SHBG/ABP levels in the testis and serum in humans were strongly correlated [48, 154]. These data thus fail to explain the disparity between intratesticular and serum bioactive androgen levels [48, 154, 157]. In contrast, Roth et al. found that T levels in testicular aspirations

(i.e., to obtain ITT) and serum of fertile men in samples obtained simultaneously were strongly and positively correlated ($r = 0.67$) [158]. The different results in the two studies may be due to different assay approaches. In this context, it is of interest to note that a recent report has shown that high ITT is not necessary to support spermatogenesis in humans [159], and proposed that the ITT level may be high only because T is synthesized locally by Leydig cells in the interstitial space of the testis. Thus, the physiological significance of the ITT level to support spermatogenesis requires additional further studies.

Importantly, the earlier report of Roth et al. also demonstrated considerable variations in ITT levels in fertile men which correlated very strongly with serum LH levels ($r = 0.87$). It was hypothesized that LH secretory pulsatility might cause pulsatility in ITT concentrations [158]. In fact, ITT pulsatility was suggested by an earlier study that quantified T and estradiol concentrations over 4 h in cannulated gonadal veins of men with varicocele [32]. While the importance of ITT pulsatility to spermatogenesis remains to be established, it may influence the cyclic nature of spermatogenesis during the epithelial cycle. For instance, the requirements of the seminiferous epithelium to support androgen-dependent cellular events at late stage II during spermiation are quite different from stages VI when meiosis takes place. As such, it is likely that the ITT level required at stage II is different from stage VI and other stages to support spermatogenesis. Nonetheless, the ITT concentration necessary to support spermatogenesis in humans has not been established by quantifying T levels in intratesticular fluid obtained during micro-TESE (microdissection testicular sperm extraction) [160]. Furthermore, studies in rodents have shown that T, besides playing a crucial role in maintaining germ cell adhesion in particular developing spermatids, modulates endocytic vesicle-mediated protein trafficking [161]. Due to the high level of cellular activities in the epithelium to maintain the daily sperm production rate, many cellular proteins, in particular those found at the Sertoli–Sertoli or Sertoli–germ cell interface, are being re-cycled [162]. Studies have shown that the

relative ratio of ITT/cytokines within the micro-environment of the seminiferous epithelium may be crucial to govern these protein recycling events during the epithelial cycle [163]. These studies, while recently performed in rodents, can now be extended to humans by using the human Sertoli cell in vitro system [57].

Androgen Receptor (AR)

T exerts its effects through AR signaling [156, 164–166]. In humans, AR expression is restricted to Sertoli cells [167, 168]. Studies using murine models have shown that specific deletion of AR in Sertoli cells (SC-specific AR KO) leads to meiotic arrest and early spermatogenic maturation arrest [169, 170], and also terminal differentiation of haploid spermatids [171]. Collectively, these findings illustrate the significance of AR-mediated action in spermatogenesis, in particular murine meiosis and spermiogenesis. In men, the AR expression level visualized by immunohistochemistry in Sertoli cells was higher in those with NOA (non-obstructive azoospermia) vs. OA (obstructive azoospermia), and a significant positive correlation was observed between FSH levels and Sertoli cell AR expression in OA patients [167]. However, efforts to relate AR function or distribution to infertility in humans have been unsuccessful. For instance, no correlation was found between AR expression in Sertoli cells with serum T levels, or serum LH, and FSH levels in men with NOA [167]. Also, exogenous FSH was shown to trigger an increase in AR expression in the human testis [167]. However, hCG therapy had no apparent effect, thereby underscoring the significance of FSH-dependent Sertoli cell AR expression [167].

Exon 1 of the AR contains a CAG trinucleotide repeat that encodes a polyglutamine tract in the N-terminus of the AR. This region is required for AR interaction with transcriptional co-regulators, and variation in CAG repeat length, even within normal alleles, influences AR function in that shorter repeats are associated with a more transcriptionally active receptor. Furthermore, an expanded polyglutamine tract confers toxic properties responsible for neuronal and non-neuronal degeneration in the

neurological disorder spinal and bulbar muscular atrophy in which affected men have small testes and gynecomastia (SBMA) [172]. Attempts to correlate the severity of spermatogenic dysfunction with CAG-encoded polyglutamine length polymorphism in the AR gene have, however, yielded inconsistent and conflicting results [173–176]. Interestingly, an insertion mutation near the beginning of the CAG repeat in exon 1 of the AR gene was found in an azoospermic man [177]. Treatment of an infertile man who had a point mutation of p.Val686Ala in the AR ligand-binding domain with prolonged high-dose testosterone therapy was found to produce marked improvement in sperm count and semen quality [178]. Combined with intracytoplasmic microinjection, testosterone treatment resulted in fertility. A point mutation in the transactivation domain (TAD) of the AR gene was found in an infertile man with gynecomastia with a high FSH level, small testes, and Sertoli cell-only syndrome [179]. However, a fertile man with gynecomastia was found to have a p.Pro69Ser mutation within the AR ligand-binding domain but to display no considerable defects in semen quality [180]. Taking these data collectively, it is anticipated that more AR mutation-associated male infertility cases will be identified. As more data are available, a systemic analysis is warranted to relate mutation(s) of the AR gene with idiopathic male infertility. At this point, based on the available data, it is likely that FSH-dependent AR expression is crucial for spermatogenesis. However, more accurate functional assays are necessary to pin-point the importance of AR in male infertility.

Estrogen

Testes are known to produce a considerable amount of estradiol-17 β via aromatase, which is essential to maintain spermatogenesis [10, 12, 181]. In humans, the role of estrogen in spermatogenesis remains a subject of debate. Emerging evidence, however, supports the notion that estrogen is involved in testis development, fluid resorption in the rete testis, maintenance of spermatogenesis, and in the maturation of spermatozoa [10, 181, 182]. Most importantly, aromatization of

T to estradiol-17 β in the hypothalamus provides an important negative feedback signal to gonadotropin secretion [10]. Aromatase is expressed by human Leydig cells, Sertoli cells, spermatocytes, spermatids, and spermatozoa (its presence in spermatogonia remains unknown) [181] while estrogen is produced mostly by Leydig cells in the adult human testis [10].

Estrogen exerts its effects via estrogen receptors ER α (ESR1) and ER β (ESR2) [10, 12]. Studies in rodents have shown that ER α is expressed by Leydig cells and peritubular myoid cells; whereas ER β is found in some Leydig cells, but mostly in Sertoli cells and germ cells [183, 184]. In short, ER α is predominant in the interstitium and ER β in the seminiferous epithelium. Subsequent studies, however, have demonstrated that ER α is also expressed in Sertoli and germ cells in the rat testis [185]. In human testes, the binding of estradiol-17 β to human sperm was first reported in 1981 [186]. In 1998, human sperm were shown to express both the ER α mRNA and protein [187]. Subsequent studies have confirmed the presence of ER β as well as ER α in human sperm [12]. It is now generally accepted that ER α is expressed in spermatogonia, pachytene spermatocytes, and early round spermatids; whereas ER β is expressed in pachytene spermatocytes, early round spermatids, Sertoli cells, and Leydig cells in human testes [188, 189]. A genetic analysis study in 300 infertile Indian men and 255 fertile normal subjects identified single nucleotide polymorphisms (SNPs) (found in 4 subjects) and mutations (found in 8 subjects) in the ER β gene, suggesting ER β gene mutations are a cause of spermatogenesis failure in men. These infertile men displayed normal reproductive tract and serum hormone levels [190]. The few men identified with aromatase deficiency due to autosomal recessive inheritance of mutations in the *CYP19A1* gene tend to have small testes and an abnormal semen analysis. Additionally, hormone levels in men with mutation in ER α and deficient in aromatase have considerable changes in serum T, estradiol, LH, and/or FSH compared to normal subjects (see Chap. 1). While the number of patients is small, these findings

illustrate the significance of estrogen in human spermatogenesis. Furthermore, genetic and pharmacologically induced estrogen deficiency leads to reduced libido in men [191, 192]. In summary, estrogen is known to be involved in the development of the testis, maintenance of male reproductive tract, fluid resorption in the rete testis, and in particular sperm maturation in humans [12, 181, 193, 194].

Small Non-coding RNAs (sncRNAs)

As noted above, spermatogenesis is a highly complicated process that requires the intriguing participation of multiple genes at the transcriptional and post-transcriptional levels to produce spermatozoa. Studies have shown that germ cells, including spermatogonia, spermatocytes, and post-meiotic spermatids all contain abundant levels of non-coding RNAs, such as siRNA (small interfering RNA, 20–25 nucleotides), miRNA (microRNA, 21–24 nucleotides), and piRNAs (Piwi-interacting RNA, 26–31 nucleotides) [195–197]. The most important sncRNAs that are involved in spermatogenesis are miRNAs and piRNAs and the associated pathways based on studies of genetic models in rodents [198–201]. These small RNAs are short single-stranded non-coding nucleotides that are known to directly disrupt target mRNAs through degradation, causing translation repression to block protein synthesis [20, 202]. Since miRNA can bind to more than one mRNA, a specific miRNA can regulate the function of more than a single gene. Small RNAs including miRNAs and piRNA are mostly stored in the chromatoid body which is a dense structure in the germ cell cytosol composed of mainly RNAs and RNA-binding proteins and are involved in the regulation of germ cell apoptosis, proliferation, and differentiation, as well as spermatogonial stem cell self-renewal [200, 203, 204]. Studies have shown an alteration in the expression patterns of small RNAs in infertile men [205–207]. For instance, miR-141, miR-429, and miR-7-1-3p were up-regulated in men with idiopathic non-obstructive azoospermia (NOA) [206] while miR-34c-5p, miR-122, miR-146b-5p,

miR-181a, miR-374b, miR-509-5p, and miR-513a-5p were markedly down-regulated in men with NOA. These miRNAs are possibly involved in regulating germ cell apoptosis [207].

In this context, it is of interest to note that miRNAs and siRNAs are processed by an RNase III endonuclease Dicer, the deletion of which in mice leads to infertility. Dicer is essential for haploid spermatid differentiation [208] and for the assembly and maintenance of cell junctions in the seminiferous epithelium during spermatogenesis [209]. Specific deletion of Dicer in Sertoli cells also leads to infertility with complete absence of spermatozoa in seminiferous tubules and progressive testicular degeneration [210]. While the role of Dicer in human fertility remains to be elucidated, it is obvious that small regulatory RNAs represent a tempting target for non-hormonal male contraception. Also, much work is needed to better understand the role of small RNAs in human spermatogenesis, and their use as diagnostic markers to monitor infertility, for example, men who are at risk because of industrial exposure to toxicant-induced infertility.

Obesity

According to NIH guidelines (see <http://www.nhlbi.nih.gov/health/health-topics/topics/obe/diagnosis>), adults with a body mass index (BMI) >30 (kg/m²) are obese. Based on the latest statistics in 2014, the obese adult population in the U.S. is at 27.7% (<http://www.gallup.com/poll/181271/obesity-rate-inches-2014.aspx>), which is double the world's average of 13% (<http://www.who.int/mediacentre/factsheets/fs311/en/>), illustrating an alarming trend given the health risks associated with obesity. A lower sex hormone binding globulin (SHBG) level is found in men with obesity and/or diabetes, which in turn lowers the total testosterone level (see Chap. 16 and [211]). Emerging evidence suggests a negative correlation between rising BMI and sperm count, sperm concentration, and motile sperm, which impedes male fertility [212–214]. Interestingly, while other studies suggest that obesity has no major impact on fertility, semen quality,

gonadotropin levels, or other sperm parameters despite reduced testosterone levels [215, 216]. The reason(s) behind the different conclusions is not immediately known. Nonetheless, studies have demonstrated possible mechanism(s) by which obesity might lead to reduced spermatogenesis capacity and daily sperm output, as well as reduced sperm count and sperm quality. One proposed mechanism is hyperestrogenism in which serum estrogens are considerably higher in obese men due to an increase in peripheral conversion of testosterone to estrogens by aromatase in adipose tissue [217–219], coupled with a reduced testosterone production [214]. The excessive estrogens in the systemic circulation thus inhibit the release of LH and FSH from the pituitary gland via the negative feedback on the hypothalamus, thereby reducing T production, intratesticular T levels, and the testosterone/estrogen ratio. The reduced T and FSH levels result in suppressed spermatogenesis. However, the correlation between high levels of estradiol and obesity is controversial and is further affected by low SHBG [220], suggesting the need for additional studies. Nonetheless, this mechanism is supported by findings that obese men have considerably lower levels of inhibin B than healthy men [221–223]. Elevated levels of cytokines are another potential cause of hypospermatogenesis in obese men [224]. Other mechanisms that might cause defects in human spermatogenesis in obesity include reduced levels of SHBG, insulin and leptin resistance, sleep apnea, and adiponectin deficiency [225–229]. Additionally, factors involved in the pathogenesis of obesity, such as high calorie diet, genetic, and epigenetic disorders, might also play a role in perturbing sperm production [230, 231].

Besides the disruptive effects of obesity on spermatogenesis, there is emerging evidence that obesity also affects the molecular structure of testicular germ cells and mature spermatozoa, such as an impairment of acrosome reaction [232], leading to altered growth in offspring, increased susceptibility to disease in adults [233], and erectile dysfunction [234]. Studies also suggest that high-fat diets can affect the epigenetic content of sperm or the endocrine content

of seminal fluid, which in turn affects early fetal development [213].

Bariatric surgery [235], such as Roux-en-Y gastric bypass surgery [236], has been reported to increase T levels and improve sexual function in obese men. Much of the increase in T, however, results from an increase in the level of SHBG [236]. Interestingly, there are case reports in which bariatric surgery was followed by impaired semen parameters, possibly by perturbing absorption of vitamins and trace elements [237, 238]. However, one study of six men showed no disruptive changes of bariatric surgery on semen parameters, coupled with an increase in urinary total T levels [239].

Summary

Spermatogenesis is a series of cellular events that take place in the seminiferous tubules of the testis. In this review, we provide a brief overview of human spermatogenesis, from spermatogonial self-renewal via mitosis, meiosis, post-meiotic spermatid development via spermiogenesis, to the release of sperm at spermiation. We discuss the role of Sertoli cell and especially the role of the BTB in spermatogenesis. We also highlight some specific areas of research that deserve future attention. Due to the lack of human testis samples for analysis, in particular those from normal subjects, the study of human spermatogenesis lags far behind studies in rodents. However, human Sertoli cells obtained at biopsy can now be cultured in vitro and maintained up to weeks and months where they remain mitotically active. These cells can be subcultured for creative experiments. We also briefly discuss some emerging fields of research that focus on factors affecting human spermatogenesis. These factors may deserve more attention by investigators in future years.

Acknowledgements The authors wish to thank Drs. Stephen Winters and Ilpo Huhtaniemi for their helpful remarks, comments, insightful thoughts, and suggestions during the preparation of this manuscript for this book. Without this valuable help, this Chapter could not have been written. This work was supported by grants from the National Institutes of Health, R01 HD056034 (to C.Y.C.),

U54 HD029990 Project 5 (to C.Y.C.); National Natural Science Foundation of China (NSFC) 31371176 (to X.X.), China Qianjiang Talents Program QJD1502029 (to X.X.) and Zhejiang Province Department of Science Technology Funding 2016F10010 (to X.X.).

References

1. Ehmcke J, Schlatt S. A revised model for spermatogonial expansion in man: lessons from non-human primates. *Reproduction*. 2006;132:673–80.
2. Schlatt S, Ehmcke J. Regulation of spermatogenesis: an evolutionary biologist's perspective. *Semin Cell Dev Biol*. 2014;29:2–16.
3. Neto FT, Bach PV, Najari BB, Li PS, Goldstein M. Spermatogenesis in humans and its affecting factors. *Semin Cell Dev Biol*. 2016.
4. Amann RP. The cycle of the seminiferous epithelium in humans: a need to revisit? *J Androl*. 2008;29:469–87.
5. O'Donnell L, Nicholls PK, O'Bryan MK, McLachlan RI, Stanton PG. Spermiation: the process of sperm release. *Spermatogenesis*. 2011;1:14–35.
6. Amann RP, Howards SS. Daily spermatozoal production and epididymal spermatozoal reserves of the human male. *J Urol*. 1980;124(2):211–5.
7. Johnson L, Petty CS, Neaves WB. A comparative study of daily sperm production and testicular composition in humans and rats. *Biol Reprod*. 1980;22(5):1233–43.
8. Johnson L, Zane RS, Petty CS, Neaves WB. Quantification of the human Sertoli cell population: its distribution, relation to germ cell numbers, and age-related decline. *Biol Reprod*. 1984;31:785–95.
9. Zitzmann M. Effects of age on male fertility. *Best Pract Res Clin Endocrinol Metab*. 2013;27:617–28.
10. O'Donnell L, Robertson KM, Jones ME, Simpson ER. Estrogen and spermatogenesis. *Endocr Rev*. 2001;22:289–318.
11. McLachlan R, O'Donnell L, Meachem S, Stanton P, de Kretser D, Pratis K, et al. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. *J Androl*. 2002;23:149–62.
12. Carreau S, Hess RA. Oestrogens and spermatogenesis. *Philos Trans R Soc Lond B Biol Sci*. 2010;365:1517–35.
13. Sharpe RM. Regulation of spermatogenesis. In: *The Physiology of Reproduction*. Eds. Knobil, E., Neill, J.D. New York, Raven Press. 1994. pp. 1363–434.
14. O'Donnell L, Meachem SJ, Stanton PG, McLachlan RI. Endocrine regulation of spermatogenesis. In: Neill JD, editor. *Physiology of Reproduction*. 3rd ed. Amsterdam: Elsevier; 2006. p. 1017–69.
15. O'Shaughnessy PJ. Hormonal control of germ cell development and spermatogenesis. *Semin Cell Dev Biol*. 2014;29:55–65.

16. Kilchevsky A, Honig S. Male factor infertility in 2011: semen quality, sperm selection and hematospermia. *Nat Rev Urol.* 2012;9:68–70.
17. Sharpe RM. Environmental/lifestyle effects on spermatogenesis. *Phil Trans R Soc Lond B Biol Sci.* 2010;365:1697–712.
18. Cheng CY, Wong EWP, Lie PPY, Li MWM, Su L, Siu ER, et al. Environmental toxicants and male reproductive function. *Spermatogenesis.* 2011;1:2–13.
19. Wei Y, Schatten H, Sun QY. Environmental epigenetic inheritance through gametes and implications for human reproduction. *Hum Reprod Update.* 2015;21(2):194–208.
20. Campion S, Catlin N, Heger N, McConndell EV, Pacheco SE, Saffarini C, et al. Male reprotoxicity and endocrine disruption. *EXS.* 2012;101:315–60.
21. Wan HT, Mruk DD, Wong CKC, Cheng CY. Targeting testis-specific proteins to inhibit spermatogenesis - lesson from endocrine disrupting chemicals. *Expert Opin Ther Targets.* 2013;17:839–55.
22. Geoffroy-Siraudin C, Loundou Ad, Romain F, Achard V, Courbiere B, Perrard MH, et al. Decline of semen quality among 10932 males consulting for couple infertility over a 20-year period in Marseille. France. *Asian J Androl.* 2012;14:584–90.
23. Jorgensen N, Vierula M, Jacobsen R, Pukkala E, Perheentupa A, Virtanen HE, et al. Recent adverse trends in semen quality and testis cancer incidence among Finnish men. *Int J Androl.* 2011;34:e37–48.
24. Virtanen HE, Sadov S, Vierula M, Toppari J. Finland is following the trend-sperm quality in Finnish men. *Asian J Androl.* 2013;15(2):162–4.
25. Handelsman DJ, Cooper TG. Falling sperm counts and global estrogenic pollution: what have we learned over 20 years? *Asian J Androl.* 2013;15(2):159–61.
26. Foresta C, Moro E, Ferlin A. Y chromosome microdeletions and alterations of spermatogenesis. *Endocr Rev.* 2010;22:226–39.
27. Greenberg SH, Lipshultz LI, Wein AJ. Experience with 425 subfertile male patients. *J Urol.* 1978;119:507–10.
28. Krausz C, Escamilla AR, Chianese C. Genetics of male infertility: from research to clinic. *Reproduction.* 2015;150(5):R159–74.
29. Jamsai D, O'Bryan MK. Mouse models in male fertility research. *Asian J Androl.* 2011;13:139–51.
30. Carrell DT, Aston KI, Oliva R, Emery BR, De Jonge CJ. The “omics” of human male infertility: integrating big data in a systems biology approach. *Cell Tissue Res.* 2016;363(1):295–312.
31. Com E, Melaine N, Chalmel F, Pineau C. Proteomics and integrative genomics for unraveling the mysteries of spermatogenesis: the strategies of a team. *J proteomics.* 2014;107:128–43.
32. Winters SJ, Troen P. Testosterone and estradiol are co-secreted episodically by the human testis. *J Clin Invest.* 1986;78:870–3.
33. Muller J, Skakkebaek NE. Quantification of germ cells and seminiferous tubules by stereological examination of testicles of 50 boys who suffered from sudden death. *Int J Androl.* 1983;6:143–56.
34. Clermont Y. The cycle of the seminiferous epithelium in man. *Am J Anat.* 1963;112:35–51.
35. Dym M. Basement membrane regulation of Sertoli cells. *Endocr Rev.* 1994;15:102–15.
36. Siu MKY, Cheng CY. Dynamic cross-talk between cells and the extracellular matrix in the testis. *BioEssays.* 2004;26:978–92.
37. Mruk DD, Cheng CY. Sertoli-Sertoli and Sertoli-germ cell interactions and their significance in germ cell movement in the seminiferous epithelium during spermatogenesis. *Endocr Rev.* 2004;25:747–806.
38. Cheng CY, Mruk DD. Cell junction dynamics in the testis: Sertoli-germ cell interactions and male contraceptive development. *Physiol Rev.* 2002;82:825–74.
39. Weber JE, Russell LD, Wong V, Peterson RN. Three dimensional reconstruction of a rat stage V Sertoli cell: II. Morphometry of Sertoli-Sertoli and Sertoli-germ cell relationships. *Am J Anat.* 1983;167:163–79.
40. Sharpe RM, McKinnell C, Kivlin C, Fisher JS. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. *Reproduction.* 2003;125:769–84.
41. Auharek SA, Avelar GF, Lara NLM, Sharpe RM, Franca LR. Sertoli cell numbers and spermatogenic efficiency are increased in inducible nitric oxide synthase (iNOS) mutant-mice. *Int J Androl.* 2011;34:e621–9.
42. Berndtson WE, Thompson TL. Changing relationships between testis size, Sertoli cell number and spermatogenesis in Sprague-Dawley rats. *J Androl.* 1990;11:429–35.
43. Wing TY, Christensen AK. Morphometric studies on rat seminiferous tubules. *Am J Anat.* 1982;165:13–25.
44. Wang ZX, Wreford NG, de Kretser DM. Determination of Sertoli cell numbers in the developing rat testis by stereological methods. *Int J Androl.* 1989;12:58–64.
45. Johnson L, Petty CS, Neaves WB. A comparative study of daily sperm production and testicular composition in humans and rats. *Biol Reprod.* 1980;22:1233–43.
46. Amann RP, Howards SS. Daily spermatozoal production and epididymal spermatozoal reserves of the human male. *J Urol.* 1980;124:211–5.
47. Turner TT, Jones CC, Howards SS, Ewing LL, Zegeye B, Gunsalus GL. On the androgen microenvironment of maturing spermatozoa. *Endocrinology.* 1984;115:1925–32.
48. Jarow JP, Chen H, Rosner W, Trentacoste S, Zirkin BR. Assessment of the androgen environment within the human testis: Minimally invasive method to obtain intratesticular fluid. *J Androl.* 2001;22:640–5.
49. Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Synder CN, et al. Dose-dependent

- increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. *J Clin Endocrinol Metab.* 2010;95:3806–13.
50. Takahashi J, Higashi Y, Lanasa JA, Winters SJ, Oshima H, Troen P. Studies of the human testis. XVII. Gonadotropin regulation of intratesticular testosterone and estradiol in infertile men. *J Clin Endocrinol Metab.* 1982;55:1073–80.
 51. Cheng CY, Mruk DD. The blood-testis barrier and its implications for male contraception. *Pharmacol Rev.* 2012;64:16–64.
 52. Pelletier RM. The blood-testis barrier: the junctional permeability, the proteins and the lipids. *Prog Histochem Cytochem.* 2011;46:49–127.
 53. Cheng YH, Wong EWP, Cheng CY. Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. *Spermatogenesis.* 2011;1:209–20.
 54. Yule TD, Montoya GD, Russell LD, Williams TM, Tung KSK. Autoantigenic germ cells exist outside the blood testis barrier. *J Immunol.* 1988;141:1161–7.
 55. Meinhardt A, Hedger MP. Immunological, paracrine and endocrine aspects of testicular immune privilege. *Mol Cell Endocrinol.* 2011;335:60–8.
 56. Chui K, Trivedi A, Cheng CY, Cherbavaz DB, Dazin PF, Huynh ALT, et al. Characterization and functionality of proliferative human Sertoli cells. *Cell Transplant.* 2011;20:619–35.
 57. Xiao X, Mruk DD, Tang EI, Wong CKC, Lee WM, John CM, et al. Environmental toxicants perturb human Sertoli cell adhesive function via changes in F-actin organization mediated by actin regulatory proteins. *Hum Reprod.* 2014;29:1279–91.
 58. O'Donnell L, Stanton P, Bartles J, Robertson D. Sertoli cell ectoplasmic specializations in the seminiferous epithelium of the testosterone-suppressed adult rat. *Biol Reprod.* 2000;63:99–108.
 59. Meng J, Holdcraft RW, Shima JE, Griswold MD, Braun RE. Androgens regulate the permeability of the blood-testis barrier. *Proc Natl Acad Sci USA.* 2005;102:16696–700.
 60. Chung NPY, Cheng CY. Is cadmium chloride-induced inter-Sertoli tight junction permeability barrier disruption a suitable *in vitro* model to study the events of junction disassembly during spermatogenesis in the rat testis? *Endocrinology.* 2001;142:1878–88.
 61. Xiao X, Mruk DD, Lee WM, Cheng CY. c-Yes regulates cell adhesion at the blood-testis barrier and the apical ectoplasmic specialization in the seminiferous epithelium of rat testes. *Int J Biochem Cell Biol.* 2011;43:651–65.
 62. Ilani N, Armanious N, Lue YH, Swerdloff RS, Baravarian S, Adler A, et al. Integrity of the blood-testis barrier in healthy men after suppression of spermatogenesis with testosterone and levonorgestrel. *Hum Reprod.* 2012;27(12):3403–11.
 63. McCabe MJ, Tarulli GA, Laven-Law G, Matthieson KL, Meachem SJ, McLachlan RI, et al. Gonadotropin suppression in men leads to a reduction in claudin-11 at the Sertoli cell tight junction. *Hum Reprod.* 2016;31(4):875–86.
 64. Robillard KR, Hoque MT, Bendayan R. Expression of ATP-binding cassette membrane transporters in rodent and human Sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier. *J Pharmacol Exp Ther.* 2012;340:96–108.
 65. Hoque MT, Kis O, De Rosa MF, Bendayan R. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters. *Antimicrob Agents Chemother.* 2015;59(5):2572–82.
 66. Jesus TT, Oliveira PF, Silva J, Barros A, Ferreira R, Sousa M, et al. Mammalian target of rapamycin controls glucose consumption and redox balance in human Sertoli cells. *Fertil Steril.* 2016;105(3):825–33 e3.
 67. Bardin CW, Gonsalves GL, Cheng CY. The cell biology of the Sertoli cell. In: Desjardins C, Ewing L, editors. *Cell and molecular biology of the testis.* New York: Oxford University Press; 1993. p. 189–219.
 68. Cheng CY, Mruk DD. Biochemistry of Sertoli cell/germ cell junctions, germ cell transport, and spermiation in the seminiferous epithelium. In: Griswold MD, editor. *Sertoli Cell Biology.* 2nd ed. Amsterdam: Elsevier; pp: 2015. p. 333–83.
 69. de Rooij DG. The spermatogonial stem cell niche. *Microsc Res Tech.* 2009;72:580–5.
 70. Phillips BT, Gassei K, Orwig KE. Spermatogonial stem cell regulation and spermatogenesis. *Philos Trans R Soc Lond B Biol Sci.* 2010;365:1663–78.
 71. Zwain I, Morris PL, Cheng CY. Identification of an inhibitory factor from a Sertoli clonal cell line (TM4) that modulates adult rat Leydig cell steroidogenesis. *Mol Cell Endocrinol.* 1991;80:115–26.
 72. Zwain IH, Cheng CY. Rat seminiferous tubular culture medium contains a biological factor that inhibits Leydig cell steroidogenesis: its purification and mechanism of action. *Mol Cell Endocrinol.* 1994;104:213–27.
 73. Saez JM, Avallet O, Naville D, Perrard-Sapori MH, Chatelain PG. Sertoli-Leydig cell communications. *Ann N Y Acad Sci.* 1989;564:210–31.
 74. Tio S, Koppelaar D, Bardin C, Cheng C. Purification of gonadotropin surge inhibiting factor from Sertoli cell-enriched culture medium. *Biochem Biophys Res Commun.* 1994;199:1229–36.
 75. Rebourcet D, O'Shaughnessy PJ, Monteiro A, Milne L, Cruickshanks L, Jeffrey N, et al. Sertoli cells maintain Leydig cell number and peritubular myoid cell activity in the adult mouse testis. *PLoS ONE.* 2014;9(8):e105687.
 76. Rebourcet D, O'Shaughnessy PJ, Pitetti JL, Monteiro A, O'Hara L, Milne L, et al. Sertoli cells control peritubular myoid cell fate and support adult Leydig cell development in the prepubertal testis. *Development.* 2014;141(10):2139–49.
 77. Wen Q, Zheng QS, Li XX, Hu ZY, Gao F, Cheng CY, et al. Wt1 dictates the fate of fetal and

- adult Leydig cells during development in the mouse testis. *Am J Physiol Endocrinol Metab.* 2014;307(12):E1131–43.
78. Jegou B. The Sertoli-germ cell communication network in mammals. *Int Rev Cytol.* 1993;147:25–96.
 79. Griswold M. Interactions between germ cells and Sertoli cells in the testis. *Biol Reprod.* 1995;52:211–6.
 80. Skinner M, Tung P, Fritz I. Cooperativity between Sertoli cells and testicular peritubular cells in the production and deposition of extracellular matrix components. *J Cell Biol.* 1985;100:1941–7.
 81. Skinner MK, Fetterolf PM, Anthony CT. Purification of a paracrine factor, P-Mod-S, produced by testicular peritubular cells that modulates Sertoli cell function. *J Biol Chem.* 1988;263:2884–90.
 82. Cheng CY, Grima J, Stahler MS, Guglielmotti A, Silvestrini B, Bardin CW. Sertoli cell synthesizes and secretes a protease inhibitor, α_2 -macroglobulin. *Biochemistry.* 1990;29:1063–8.
 83. Zwain IH, Grima J, Stahler MS, Saso L, Cailleau J, Verhoeven G, et al. Regulation of Sertoli cell α_2 -macroglobulin and clusterin (SGP-2) secretion by peritubular myoid cells. *Biol Reprod.* 1993;48:180–7.
 84. Mruk DD, Cheng CY. An *in vitro* system to study Sertoli cell blood-testis barrier dynamics. *Methods Mol Biol.* 2011;763:237–52.
 85. Welsh M, Saunders PT, Atanassova N, Sharpe RM, Smith LB. Androgen action via testicular peritubular myoid cells is essential for male fertility. *FASEB J.* 2009;23:4218–30.
 86. Rebourcet D, Wu J, Cruickshanks L, Smith SE, Milne L, Fernando A, et al. Sertoli Cells Modulate Testicular Vascular Network Development, Structure, and Function to Influence Circulating Testosterone Concentrations in Adult Male Mice. *Endocrinology.* 2016;157(6):2479–88.
 87. Allen E. Studies on cell division in the albino rat. *J Morphol.* 1918;31:133–85.
 88. Clermont Y. Kinetics of spermatogenesis in mammals: seminiferous epithelium cycle and spermatogonial renewal. *Physiol Rev.* 1972;52(1):198–236.
 89. Clermont Y. Renewal of spermatogonia in man. *Am J Anat.* 1966;118(2):509–24.
 90. Schulze C. Morphological characteristics of the spermatogonial stem cells in man. *Cell Tissue Res.* 1979;198(2):191–9.
 91. Boitani C, Di Persio S, Esposito V, Vicini E. Spermatogonial cells: mouse, monkey and man comparison. *Semin Cell Dev Biol.* 2016.
 92. Sandlow JI, Feng HL, Cohen MB, Sandra A. Expression of c-KIT and its ligand, stem cell factor, in normal and subfertile human testicular tissue. *J Androl.* 1996;17(4):403–8.
 93. Unni SK, Modi DN, Pathak SG, Dhabalia JV, Bhartiya D. Stage-specific localization and expression of c-kit in the adult human testis. *J Histochem Cytochem.* 2009;57(9):861–9.
 94. Medrano JV, Marques-Mari AI, Aguilar CE, Riboldi M, Garrido N, Martinez-Romero A, et al. Comparative analysis of the germ cell markers c-KIT, SSEA-1 and VASA in testicular biopsies from secretory and obstructive azoospermias. *Mol Hum Reprod.* 2010;16(11):811–7.
 95. Gassei K, Ehmcke J, Dhir R, Schlatt S. Magnetic activated cell sorting allows isolation of spermatogonia from adult primate testes and reveals distinct CFRA1-positive subpopulations in men. *J Med Primatol.* 2010;39:83–91.
 96. Feng HL, Sandlow JI, Sparks AE, Sandra A, Zheng LJ. Decreased expression of the c-kit receptor is associated with increased apoptosis in subfertile human testes. *Fertil Steril.* 1999;71(1):85–9.
 97. Hogarth CA, Griswold MD. The key role of vitamin A in spermatogenesis. *J Clin Invest.* 2010;120:956–62.
 98. Chung SS, Wang X, Roberts SS, Griffey SM, Reczek PR, Wolgemuth DJ. Oral administration of a retinoic acid receptor antagonist reversibly inhibits spermatogenesis in mice. *Endocrinology.* 2011;152:2492–502.
 99. Chung SS, Wang X, Wolgemuth DJ. Prolonged Oral Administration of a Pan-Retinoic Acid Receptor Antagonist Inhibits Spermatogenesis in Mice With a Rapid Recovery and Changes in the Expression of Influx and Efflux Transporters. *Endocrinology.* 2016;157(4):1601–12.
 100. Amory JK, Muller CH, Shimshoni JA, Isoherranen N, Paik J, Moreb J, et al. Suppression of spermatogenesis by bis(dichloroacetyl) diamines is mediated by inhibition of testicular retinoic acid biosynthesis. *J Androl.* 2011;32(1):111–9.
 101. Paik J, Haenisch M, Muller CH, Goldstein AS, Arnold S, Isoherranen N, et al. Inhibition of retinoic acid biosynthesis by the bis(dichloroacetyl) diamine WIN 18,446 markedly suppresses spermatogenesis and alters retinoid metabolism in mice. *J Biol Chem.* 2014;289(21):15104–17.
 102. Heller CG, Moore DJ, Paulsen CA. Suppression of spermatogenesis and chronic toxicity in men by a new series of bis(dichloroacetyl) diamines. *Toxicol Appl Pharmacol.* 1961;3:1–11.
 103. Drobeck HP, Coulston F. Inhibition and recovery of spermatogenesis in rats, monkeys, and dogs medicated with bis(dichloroacetyl) diamines. *Exp Mol Pathol.* 1962;1:251–74.
 104. Plant TM. Undifferentiated primate spermatogonia and their endocrine control. *Trends Endocrinol Metab.* 2010;21:488–95.
 105. van Alphen MM, van de Kant HJ, de Rooij DG. Follicle-stimulating hormone stimulates spermatogenesis in the adult monkey. *Endocrinology.* 1988;123:1449–55.
 106. Simorangkir DR, Ramaswamy S, Marshall GR, Pohl CR, Plant TM. A selective monotropic elevation of FSH but not that of LH, amplifies the proliferation and differentiation of spermatogonia in

- the adult rhesus monkey (*Macaca mulatta*). *Hum Reprod.* 2009;24:1584–95.
107. Selice R, Ferlin A, Garolla A, Caretta N, Foresta C. Effects of endogenous FSH on normal human spermatogenesis in adults. *Int J Androl.* 2011;34:e511–7.
 108. Ruwanpura SM, McLachlan RI, Matthiesson KL, Meachem SJ. Gonadotrophins regulate germ cell survival, not proliferation, in normal adult men. *Hum Reprod.* 2008;23:403–11.
 109. Schulze W, Rehder U. Organization and morphogenesis of the human seminiferous epithelium. *Cell Tissue Res.* 1984;237(3):395–407.
 110. Feng CW, Bowles J, Koopman P. Control of mammalian germ cell entry into meiosis. *Mol Cell Endocrinol.* 2014;382(1):488–97.
 111. Boussouar F, Benahmed M. Lactate and energy metabolism in male germ cells. *Trends Endocrinol Metab.* 2004;15:345–50.
 112. Dias TR, Alves MG, Silva BM, Oliveira BF. Sperm glucose transport and metabolism in diabetic individuals. *Mol Cell Endocrinol.* 2014;396:37–45.
 113. Oliveira PF, Martins AD, Moreira AC, Cheng CY, Alves MG. The Warburg effect revisited - lesson from the Sertoli cell. *Med Res Rev.* 2015;35:126–51.
 114. Oliveira BF, Alves MG, Rato L, Silva J, Sa R, Barros A, et al. Influence of 5 α -dihydrotestosterone and 17 β -estradiol on human Sertoli cells metabolism. *Int J Androl.* 2011;34:e612–20.
 115. McLachlan RI, Rajpert-De Meyts E, Høi-Hansen CE, de Kretser DM, Skakkebaek NE. Histological evaluation of the human testis—Approaches to optimizing the clinical value of the assessment: Mini Review. *Hum Reprod.* 2007;22:2–16.
 116. Clermont Y, Leblond CP. Spermiogenesis of man, monkey, ram and other mammals as shown by the periodic acid-Schiff technique. *Am J Anat.* 1955;96(2):229–53.
 117. de Kretser DM. Ultrastructural features of human spermiogenesis. *Z Zellforsch Mikrosk Anat.* 1969;98(4):477–505.
 118. Clermont Y, Morales C, Hermo L. Endocytic activities of Sertoli cells in the rat. *Ann NY Acad Sci.* 1987;513:1–15.
 119. Cheng CY, Mruk DD. Biochemistry of Sertoli cell/germ cell junctions, germ cell transport, and spermiogenesis in the seminiferous epithelium. In: *Sertoli Cell Biology*, 2nd Edition. Ed. Griswold, M.D., Amsterdam, Elsevier; pp. 333–383. doi: [10.1016/B978-0-12-417047-6.00012.0](https://doi.org/10.1016/B978-0-12-417047-6.00012.0). 2015.
 120. Roosen-Runge EC. Kinetics of spermatogenesis in mammals. *Ann N Y Acad Sci.* 1952;55(4):574–84.
 121. Leblond CP, Clermont Y. Definition of the stages of the cycle of the seminiferous epithelium in the rat. *Ann N Y Acad Sci.* 1952;55(4):548–73.
 122. Hess RA, de Franca LR. Spermatogenesis and cycle of the seminiferous epithelium. *Adv Exp Med Biol.* 2008;636:1–15.
 123. Xiao X, Mruk DD, Wong CK, Cheng CY. Germ cell transport across the seminiferous epithelium during spermatogenesis. *Physiology (Bethesda).* 2014;29(4):286–98.
 124. Heller CG, Clermont Y. Spermatogenesis in man: an estimate of its duration. *Science.* 1963;140(3563):184–6.
 125. Oakberg EF. Duration of spermatogenesis in the mouse and timing of stages of the cycle of the seminiferous epithelium. *Am J Anat.* 1956;99(3):507–16.
 126. Clermont Y, Leblond CP, Messier B. Duration of the cycle of the seminal epithelium of the rat. *Arch Anat Microsc Morphol Exp.* 1959;48(Suppl):37–55.
 127. Ehmcke J, Wistuba J, Schlatt S. Spermatogonial stem cells: questions, models and perspectives. *Human Reprod Update.* 2006;12:275–82.
 128. de Kretser DM, Kerr JB. The cytology of the testis. In: Knobil E, Neill JB, Ewing LL, Greenwald GS, Markert CL, Pfaff DW, editors. *The Physiology of Reproduction*, vol. 1. New York: Raven Press; 1988. p. 837–932.
 129. McLachlan RI, O'Donnell L, Meachem SJ, Stanton PG, De Kretser DM, Pratis K, et al. Identification of specific sites of hormonal regulation in spermatogenesis in rats, monkeys, and man. *Recent Prog Horm Res.* 2002;57:149–79.
 130. Handelsman DJ. Hormonal regulation of spermatogenesis: insights from constructing genetic models. *Reprod Fertil Dev.* 2011;23:507–19.
 131. Itman CM, Mendis SH, Barakat B, Loveland KL. All in the family: TGF- β family action in testis development. *Reproduction.* 2006;132:233–46.
 132. Foresta C, Selice R, Garolla A, Ferlin A. Follicle-stimulating hormone treatment of male infertility. *Curr Opin Urol.* 2008;18:602–7.
 133. De Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. *Hum Reprod Update.* 2002;8:529–41.
 134. Winters SJ, Moore JP. Paracrine control of gonadotrophs. *Semin Reprod Med.* 2007;25:379–87.
 135. Winters SJ, Moore JP. Intra-pituitary regulation of gonadotrophs in male rodents and primates. *Reproduction.* 2004;128:13–23.
 136. McLachlan R, Wreford N, O'Donnell L, de Kretser D, Robertson D. The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. *J Endocr.* 1996;148:1–9.
 137. Huhtaniemi I. A short evolutionary history of FSH- = stimulated spermatogenesis. *Hormones (Athens).* 2015;14:468–78.
 138. Stanton PG. Regulation of the blood-testis barrier. *Semin Cell Dev Biol (in press; PMID:27353840; DOI:10.1016/j.semcd.2016.06.018)*. 2016.
 139. Griswold MD, Heckert L, Linder C. The molecular biology of the FSH receptor. *J Steroid Biochem Mol Biol.* 1995;53:215–8.
 140. Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle stimulating hormone is required for ovarian follicle

- maturation but not male fertility. *Nat Genet.* 1997;15:201–4.
141. Kumar TR. FSHbeta knockout mouse model: a decade ago and into the future. *Endocrine.* 2009;36(1):1–5.
 142. Plant TM, Marshall GR. The functional significance of SH in spermatogenesis and the control of its secretion in male primates. *Endocr Rev.* 2001;22:764–86.
 143. Walker WH, Cheng J. FSH and testosterone signaling in Sertoli cells. *Reproduction.* 2005;130:15–28.
 144. O'Shaughnessy PJ, Johnston H, Willerton L, Baker PJ. Failure of normal adult Leydig cell development in androgen-receptor-deficient mice. *J Cell Sci.* 2002;115:3491–6.
 145. Caroppo E, Niederberger C, Vizziello GM, D'Amato G. Recombinant human follicle-stimulating hormone as a pretreatment for idiopathic oligoasthenoteratozoospermic patients undergoing intracytoplasmic sperm injection. *Fertil Steril.* 2003;80:1398–403.
 146. Santi D, Granata AR, Simoni M. Follicle-stimulating hormone treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis. *Endocr Connect.* 2015;4:46–58.
 147. Saez JM. Leydig cells: endocrine, paracrine, and autocrine regulation. *Endocr Rev.* 1994;15:574–626.
 148. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. *Endocr Rev.* 2002;23:141–74.
 149. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: Elucidating the physiology and pathophysiology of pituitary-gonadal function. *Endocr Rev.* 2000;21:551–83.
 150. Latronico AC, Segaloff DL. Naturally occurring mutations of the luteinizing-hormone receptor: Lessons learned about reproductive physiology and G protein-coupled receptors. *Am J Human Genet.* 1999;65:949–58.
 151. Latronico AC, Arnhold IJ. Inactivating mutations of the human luteinizing hormone receptor in both sexes. *Semin Reprod Med.* 2012;30:382–6.
 152. Winters SJ. Endocrine evaluation of testicular function. *Endocrinol Metab Clin North Am.* 1994;23:709–23.
 153. Scott HM, Mason JI, Sharpe RM. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. *Endocr Rev.* 2009;30(7):883–925.
 154. Jarow JP, Wright WW, Brown TR, Yan X, Zirkin BR. Bioactivity of androgens within the testes and serum of normal men. *J Androl.* 2005;26(3):343–8.
 155. Cheng CY, Gunsalus GL, Morris ID, Turner TT, Bardin CW. The heterogeneity of rat androgen binding protein (rABP) in the vascular compartment differs from that in the testicular tubular lumen: further evidence for bidirectional secretion of rABP. *J Androl.* 1986;7:175–9.
 156. Wang RS, Yeh S, Tzeng CR, Chang C. Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. *Endocr Rev.* 2009;30:119–32.
 157. Nieschlag E, Wickings EJ, Mauss J. Endocrine testicular function in vivo and in vitro in infertile men. *Acta Endocrinol.* 1979;90:544–51.
 158. Roth MY, Lin K, Amory JK, Matsumoto AM, Anawalt BD, Snyder CN, et al. Serum LH correlates highly with intratesticular steroid levels in normal men. *J Androl.* 2009;31:138–45.
 159. Oduwole OO, Vydra N, Wood NE, Samanta L, Owen L, Keevil B, et al. Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception. *FASEB J.* 2014;28:2566–76.
 160. Shinjo E, Shiraiishi K, Matsuyama H. The effect of human chorionic gonadotropin-based hormonal therapy on intratesticular testosterone levels and spermatogonial DNA synthesis in men with non-obstructive azoospermia. *Andrology.* 2013;1(6):929–35.
 161. Yan HHN, Mruk DD, Lee WM, Cheng CY. Blood-testis barrier dynamics are regulated by testosterone and cytokines via their differential effects on the kinetics of protein endocytosis and recycling in Sertoli cells. *FASEB J.* 2008;22:1945–59.
 162. Xiao X, Wong EWP, Lie PPY, Mruk DD, Wong CKC, Cheng CY. Cytokines, polarity proteins and endosomal protein trafficking and signaling—the Sertoli cell blood-testis barrier *in vitro* as a study model. *Methods Enzymol.* 2014;534:181–94.
 163. Li MWM, Mruk DD, Lee WM, Cheng CY. Cytokines and junction restructuring events during spermatogenesis in the testis: An emerging concept of regulation. *Cytokine Growth Factor Rev.* 2009;20:329–38.
 164. Smith LB, Walker WH. The regulation of spermatogenesis by androgens. *Semin Cell Dev Biol.* 2014;30:2–13.
 165. Pihlajamaa P, Sahu B, Janne OA. Determinants of receptor- and tissue-specific actions in androgen signaling. *Endocr Rev.* 2015;36(4):357–84.
 166. Walker WH. Non-classical actions of testosterone and spermatogenesis. *Philos Trans R Soc Lond B Biol Sci.* 2010;365:1557–69.
 167. Kato Y, Shiraiishi K, Matsuyama H. Expression of testicular androgen receptor in non-obstructive azoospermia and its change after hormonal therapy. *Andrology.* 2014;2:734–40.
 168. Griswold M. The central role of Sertoli cells in spermatogenesis. *Semin Cell Dev Biol.* 1998;9:411–6.
 169. De Gendt K, Swinnen J, Saunders P, Schoonjans L, Dewerchin M, Devos A, et al. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. *Proc Natl Acad Sci USA.* 2004;101:1327–32.

170. Chang C, Chen Y, Yeh S, Xu D, Wang R, Guillou F, et al. Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. *Proc Natl Acad Sci USA*. 2004;101:6876–81.
171. Holdcraft RW, Braun RE. Androgen receptor function is required in Sertoli cells for the terminal differentiation of haploid spermatids. *Development*. 2004;131:459–67.
172. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature*. 1991;352:77–9.
173. Delli Muti N, Agarwal A, Buldreghini E, Gioia A, Lenzi A, Boscaro M, et al. Have androgen receptor gene CAG and GGC repeat polymorphisms an effect on sperm motility in infertile men? *Andrologia*. 2014;46(5):564–9.
174. Fietz D, Geyer J, Kliesch S, Gromoll J, Bergmann M. Evaluation of CAG repeat length of androgen receptor expressing cells in human testes showing different pictures of spermatogenic impairment. *Histochem Cell Biol*. 2011;136:689–97.
175. Giaculli VA, Carbone MD, De Pergola G, Guastamacchia E, Resta F, Licchelli B, et al. Could androgen receptor gene CAG tract polymorphism affect spermatogenesis in men with idiopathic infertility? *J Assit Reprod Genet*. 2014;31:689–97.
176. Casella R, Maduro MR, Misfud A, Lipshultz LI, Yong EL, Lamb DJ. Androgen receptor gene polyglutamine length is associated with testicular histology in infertile patients. *J Urol*. 2003;169:224–7.
177. Chen YH, Xu HY, Wang ZY, Zhu ZH, Li CD, Wu ZG, et al. An insertion mutation in the androgen receptor gene in a patient with azoospermia. *Asian J Androl*. 2015;17(5):857–8.
178. Tordjman KM, Yaron M, Berkovitz A, Botchan A, Sultan C, Lumbroso S. Fertility after high-dose testosterone and intracytoplasmic sperm injection in a patient with androgen insensitivity syndrome with a previously unreported androgen receptor mutation. *Andrologia*. 2014;46:703–6.
179. Xu HY, Li CD, Tang LL, Wang LL, Yu X, Gu XM, et al. An infertile man with gynecomastia caused by a novel mutation of the androgen receptor gene. *Asian J Androl*. 2015;17(3):509–10.
180. Petrolis RJ, Hiort O, Struve D, Maciel-Guerra AT, Guerra-Junior G, Palandi de Mello M, et al. Preserved fertility in a patient with gynecomastia associated with the p.Pro695Ser mutation in the androgen receptor. *Sex Dev*. 2014;8:350–5.
181. Carreau S, Wolczynski S, Galeraud-Denis I. Aromatase, estrogens and human male reproduction. *Phil Trans R Soc Lond B Biol Sci*. 2010;365:1571–9.
182. Hess RA. Estrogen in the adult male reproductive tract: A review. *Reprod Biol Endocrinol*. 2003;1(52):1–14.
183. Zhou Q, Nie R, Prins GS, Saunders PTK, Katzenellenbogen BS, Hess RA. Localization of androgen and estrogen receptors in adult male mouse reproductive tract. *J Androl*. 2002;23:870–81.
184. Kotula-Balak M, Gancarczyk M, Sadowska J, Bilinska B. The expression of aromatase, estrogen receptor a and estrogen receptor b in mouse Leydig cells *in vitro* that derived from cryorchid males. *Eur J Histochem*. 2005;49:59–62.
185. Lucas TF, Siu ER, Esteves CA, Monteiro HP, Oliverira CA, Porto CS, et al. 17 β -estradiol induces the translocation of the estrogen receptors ESR1 and ESR2 to the cell membrane, MAPK3/1 phosphorylation and proliferation of cultured immature rat Sertoli cells. *Biol Reprod*. 2008;78:101–14.
186. Cheng CY, Boettcher B, Rose RJ, Kay DJ, Tinneberg HR. The binding of sex steroids to human spermatozoa. An autoradiographic study. *Int J Androl*. 1981;4:1–17.
187. Durkee TJ, Mueller M, Zinaman M. Identification of estrogen receptor protein and messenger ribonucleic acid in human spermatozoa. *Am J Obstet Gynecol*. 1998;178:1288–97.
188. Fietz D, Bergmann M, Hartmann K. In situ hybridization of estrogen receptors a and b and GPER in the human testis. *Methods Mol Biol*. 2016;1366:189–205.
189. Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors a and b in the human reproductive organs. *J Clin Endocrinol Metab*. 2000;85:4835–40.
190. Khattri A, Pandey RK, Gupta NJ, Chakravarty B, Deenadayal M, Singh L, et al. Estrogen receptor beta gene mutations in Indian infertile men. *Mol Hum Reprod*. 2009;15(8):513–20.
191. Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR. Role of oestrogen in male sexual behaviour: Insights from the natural model of aromatase deficiency. *Clin Endocrinol*. 1999;51:517–24.
192. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med*. 2013;369:2457.
193. Sharpe RM. Hormones and testis development and the possible adverse effects of environmental chemicals. *Toxicol Lett*. 2001;120:221–32.
194. Stahl PJ, Stember DS, Goldstein M. Contemporary management of male infertility. *Annu Rev Med*. 2012;63:525–40.
195. Song R, Hennig GW, Wu Q, Jose C, Zheng H, Yan W. Male germ cells express abundant endogenous siRNAs. *Proc Natl Acad Sci USA*. 2011;108:13159–131564.
196. Song R, Ro S, Michaels JD, Park C, McCarrey JR, Yan W. Many X-linked microRNAs escape meiotic sex chromosome inactivation. *Nat Genet*. 2009;41:488–93.
197. Holt JE, Stanger SJ, Nixon B, McLaughlin EA. Non-coding RNA in spermatogenesis and epididymal maturation. *Adv Exp Med Biol*. 2016;886:95–120.

198. de Mateo S, Sassone-Corsi P. Regulation of spermatogenesis by small non-coding RNAs: role of the germ granule. *Semin Cell Dev Biol.* 2014;29:84–92.
199. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. *Nat Rev Mol Cell Biol.* 2010;11:252–63.
200. Eisenberg I, Kotaja N, Goldman-Wohl D, Imbar T. microRNA in Human Reproduction. *Adv Exp Med Biol.* 2015;888:353–87.
201. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004;116:281–97.
202. Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. *Nat Rev Mol Cell Biol.* 2009;10:141–8.
203. Meikar O, Da Ros M, Korhonen H, Kataja N. Chromatoid body and small RNAs in male germ cells. *Reproduction.* 2011;142:195–209.
204. Yadav RP, Kotaja N. Small RNAs in spermatogenesis. *Mol Cell Endocrinol.* 2014;382(1):498–508.
205. Lian J, Zhang X, Tian H, Liang N, Wang Y, Liang C, et al. Altered microRNA expression in patients with non-obstructive azoospermia. *Reprod Biol Endocrinol.* 2009;7:13.
206. Wu W, Qin Y, Li Z, Dong J, Dai J, Lu C, et al. Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p. *Hum Reprod.* 2013;28(7):1827–36.
207. Wang C, Yang C, Chen X, Yao B, Yang C, Zhu C, et al. Altered profile of seminal plasma microRNAs in the molecular diagnosis of male infertility. *Clin Chem.* 2011;57(12):1722–31.
208. Korhonen HM, Meikar O, Yadav RP, Papaioannou MD, Romero Y, Da Ros M, et al. Dicer is required for haploid male germ cell differentiation in mice. *PLoS ONE.* 2011;6(9):e24821.
209. Korhonen HM, Yadav RP, Da Ros M, Chalmel F, Zimmermann C, Toppa J, et al. DICER regulates the formation and maintenance of cell-cell junctions in the mouse seminiferous epithelium. *Biol Reprod.* 2015;93(6):139.
210. Papaioannou MD, Pitetti JL, Ro S, Park C, Aubry F, Schaad O, et al. Sertoli cell Dicer is essential for spermatogenesis in mice. *Dev Biol.* 2009;326(1):250–9.
211. Winters SJ. Monitoring testosterone levels in testosterone-treated men. *Curr Med Res Opin.* 2016;32(2):271–2.
212. Kiess W, Wagner IV, Kratzsch J, Korner A. Male obesity. *Endocrinol Metab Clin North Am.* 2015;44:761–72.
213. Chambers TJG, Anderson RA. The impact of obesity on male fertility. *Hormones.* 2015;14:563–8.
214. Stokes VJ, Anderson RA, George JT. How does obesity affect fertility in men—and what are the treatment options? *Clin Endocrinol.* 2015;82(5):633–8.
215. Teerds KJ, de Rooij DG, Keijer J. Functional relationship between obesity and male reproduction: from humans to animal models. *Hum Reprod Update.* 2011;17(5):667–83.
216. Ramlau-Hansen CH, Hansen M, Jensen CR, Olsen JC, Bonde JP, Thulstrup AM. Semen quality and reproductive hormones according to birth-weight and body mass index in childhood and adult life: two decades of follow-up. *Fertil Steril.* 2010;94:610–8.
217. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. *Diabetes Obesity Metabol.* 2005;7:211–5.
218. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. *J Clin Endocrinol Metab.* 1979;48:633–8.
219. Ghosh S, Ashcraft K, Jahid MJ, April C, Ghajar CM, Ruan J, et al. Regulation of adipose oestrogen output by mechanical stress. *Nat Commun.* 2013;4:1821.
220. Dhindsa S, Batra M, Kuhadiya N, Dandona P. Oestradiol concentrations are not elevated in obesity-associated hypogonadotropic hypogonadism. *Clin Endocrinol.* 2014;80(3):464.
221. Burger HG. Physiological principles of endocrine replacement: estrogen. *Horm Res.* 2001;56(Suppl 1):82–5.
222. Gutorova NV, Kleshchyov MA, Tipisova EV, Osadchuk LV. Effects of overweight and obesity on the spermogram values and levels of reproductive hormones in the male population of the European north of Russia. *Bull Exp Biol Med.* 2014;157:95–8.
223. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. *J Clin Endocrinol Metab.* 1994;79:997–1000.
224. Veldhuis J, Yang R, Roelfsema F, Takahashi P. Proinflammatory Cytokine Infusion Attenuates LH's Feedforward on Testosterone Secretion: Modulation by Age. *J Clin Endocrinol Metab.* 2016;101(2):539–49.
225. Mah PM, Wittert GA. Obesity and testicular function. *Mol Cell Endocrinol.* 2010;316:180–6.
226. Nielsen TL, Hagen C, Wraae K, Brixen K, Petersen PH, Haug E, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. *The Journal of clinical endocrinology and metabolism.* 2007;92(7):2696–705.
227. Landry D, Cloutier F, Martin LJ. Implications of leptin in neuroendocrine regulation of male reproduction. *Reprod Biol Endocrinol.* 2013;13:1–14.
228. Luboshitzky R, Lavie L, Shen-Orr Z, Herer O. Altered luteinizing hormone and testosterone secretion in middle-aged obese men with obstructive sleep apnea. *Obes Res.* 2005;13:780–6.
229. Ec Tsai. Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and

- total testosterone with insulin resistance: Influence of sex hormone-binding globulin and body fat. *Diabetes Care*. 2004;27:861–8.
230. Hammoud AO, Gibson M, Peterson CM, Hamilton BD, Carrell DT. Obesity and male reproductive potential. *J Androl*. 2006;27:619–26.
231. Rato L, Alves MG, Cavaco JE, Oliveira PF. High-energy diets: a threat for male fertility? *Obesity Rev*. 2014;15:996–1007.
232. Samavat J, Natali I, Degl’Innocenti S, Filimberti E, Cantini G, Di Franco A, et al. Acrosome reaction is impaired in spermatozoa of obese men: a preliminary study. *Fertil Steril*. 2014;102:1274–81.
233. Palmer NO, Bakos HW, Fullston T, Lane M. Impact of obesity on male fertility, sperm function and molecular composition. *Spermatogenesis*. 2012;2(4):253–63.
234. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. *Prev Med*. 2000;30:328–38.
235. Lucchese M, Maggi M. Hypogonadism as a new comorbidity in male patient’s selection for bariatric surgery: towards an extended concept of metabolic surgery? *Obes Surg*. 2013;23:2018–9.
236. Hammoud A, Gibson M, Hunt SC, Adams TD, Carrell DT, Kolotkin RL, et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. *J Clin Endocrinol Metab*. 2009;94(4):1329–32.
237. di Frega AS, Dale B, Di Matteo L, Wilding M. Secondary male factor infertility after Roux-en-Y gastric bypass for morbid obesity: case report. *Human Reprod*. 2005;20:997–8.
238. Lazaros L, Hatzi E, Markoula S, Takenaka A, Sofikitis N, Zikopoulos K, et al. Dramatic reduction in sperm parameters following bariatric surgery: report of two cases. *Andrologia*. 2012;44:428–32.
239. Legro RS, Kunselman AR, Meadows JW, Kesner JS, Krieg EFJ, Rogers AM, et al. Time-related increase in urinary testosterone levels and stable semen analysis parameters after bariatric surgery in men. *Reprod Biomed Online*. 2015;30:150–6.
240. Kawakami S, Winters SJ. Regulation of leutinizing hormone secretion and subunit messenger ribonucleic acid expression by gonadal steroids in perfused pituitary cells from male monkeys and rats. *Endocrinology*. 1999;140:3587–93.
241. Nakagawa T, Sharma M, Nabeshima Y, Braun RE, Yoshida S. Functional hierarchy and reversibility within the murine spermatogenic stem cell compartment. *Science*. 2010;328(5974):62–7.
242. Heller CG, Clermont Y. Kinetics of the germinal epithelium in man. *Recent Prog Horm Res*. 1964;20:545–75.
243. Muciaccia B, Boitani C, Berloco BP, Nudo F, Spadetta G, Stefanini M, et al. Novel stage classification of human spermatogenesis based on acrosome development. *Biol Reprod*. 2013;89(3):60.

Sasha Howard MD and Leo Dunkel MD, PhD

Contents

Normal Puberty.....	73
Physiology.....	73
Clinical Markers of Puberty.....	73
Timing of Puberty.....	74
Regulators of the Timing of Puberty.....	75
Endocrine Changes During Puberty.....	77
Sex Steroids and Inhibin-B.....	77
Central Control of Puberty via GnRH Upstream Pathways.....	78
Delayed Puberty.....	82
Presentation.....	82
Self-limited Delayed Puberty.....	82
Hypogonadotropic Hypogonadism.....	83
Hypergonadotropic Hypogonadism.....	84
Delayed Puberty—Diagnosis.....	84
Male Delayed Puberty—Therapeutic Indications.....	85
Management of Delayed Puberty—Therapeutic Principles.....	85
Concluding Remarks.....	87
References.....	87

Normal Puberty

Physiology

Puberty is the maturational process of the reproductive endocrine system that results in final adult

height and body proportion as well as the development of the genital organs and the capacity to reproduce. The onset of puberty is driven by an increase in the frequency and amplitude of pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This activation results in increased luteinizing hormone (LH) and follicular-stimulating hormone (FSH) production by the anterior pituitary which acts on the gonads to stimulate their development, gametogenesis, and sex steroid secretion.

Clinical Markers of Puberty

In boys, the first physical marker of pubertal onset is an increase in testis volume above the prepubertal volume of 3 mL (Tanner stage G2) [1] (Fig. 4.1). There is a classic pattern of pubertal progression with the onset of testicular enlargement followed by pubic hair development and penile growth. The testes increase in size from a prepubertal volume of 1–2 to 4–8 mL even before pubic hair appears and reach 20–30 mL in adulthood [2]. Development of mature spermatogenesis is called spermarche, at which time mature spermatozoa are found in the urine. This hallmark of gonadal maturation occurs at a mean age of 13.5 years, when the mean testis volume reaches 11.5 mL [3]. The tempo and process of puberty are well conserved across ethnicities and populations (Table 4.1).

S. Howard (✉) · L. Dunkel
Barts and the London School of Medicine and Dentistry, Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK
e-mail: s.howard@qmul.ac.uk

Fig. 4.1 Tanner staging of puberty onset in boys from Palmer and Dunkel [4]. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission




Table 4.1 Details of the Tanner stages of puberty

Tanner stage	Males	
	Genitalia	Pubic hair
1	Testis 1–3 ml	None
2	Testis >3 ml Scrotal enlargement	Sparse, lightly pigmented
3	Testis continue to enlarge, penis lengthens	Increases in amounts, darkens, and starts to curl
4	Scrotum darkens, widening of glans penis	Resembles adult type but not spread to medial thighs
5	Adult size and morphology	Spreads to medial thighs, adult distribution

Timing of Puberty

In the general population, there is a near-normal distribution of the timing of puberty, with the mean age of onset of G2 at 11.5 years in boys (Fig. 4.2). In healthy boys, the normal age limits for G2 development are between 9.5 and 14 years [4]. While a large variability in the timing of pubertal onset exists, clear age cutoffs for normal pubertal development have been established. However, the age limits for identifying children who need evaluation for precocious or delayed puberty may vary among different ethnic groups. Within this distribution, there has been in recent years an increasing degree of skew at both ends of the spectrum, as an increasing prevalence of an earlier age of pubertal onset (G2) has been

documented in some populations as well as an increase in the number of children completing puberty at a later age [5].

Peak height velocity (PHV) and peak pubertal growth hormone production coincide approximately with the midpoint of pubertal development (Fig. 4.3). In boys, the PHV coincides with G3-4 at an average age of 13.5 years and achieves an incremental rate of 9.5 cm/yr [6]. Up to 25% of total adult height is achieved from growth during puberty, but the amplitude and peak velocity of the pubertal growth spurt are not fixed and vary with age at onset of puberty [7]. Early puberty is associated with a large pubertal growth spurt, while late maturers, who have a longer prepubertal period of growth, in turn experience a less pronounced pubertal growth




Fig. 4.2 Puberty normogram of the timing of genital Tanner staging in healthy boys. This *staged line* drawing gives age in years on the x-axis and centiles on the y-axis. Each *curved line* represents one genital tanner stage from 1–5 and illustrates the distribution of the timing of each stage in the normal population. These data have been incorporated into UK growth charts and are available at www.growthcharts.rcpch.ac.uk. Original concept and data from van Buuren [167]


Regulators of the Timing of Puberty

Variability in the timing of puberty in healthy adolescents is governed by complex regulatory mechanisms involving genetic, environmental, and other factors [10]. Nutritional status, adoption, geographical migration, and emotional well-being have all been shown to affect pubertal timing [11–13]. While the timing of pubertal onset in girls in most countries in the developed world exhibited a rapid decrease in the first half of the twentieth century [14, 15], in boys, these trends are less clear. A small but significant change in the normal spectrum of timing of G2 development was documented in a European cohort [16] and in the USA [17] but remains controversial [18]. Much has been postulated about this observed secular trend toward an earlier age of pubertal onset in the developed world [19]. It also follows that it is difficult to understand the pathophysiology of delayed puberty before we can interpret this population level advancement in pubertal age.

spurt [8]. Therefore, although extremes of pubertal timing may lead to a small degree of final height reduction due to the reduced overall period of growth in precocious puberty, or poor PHV in delayed puberty [9], in general within wide limits, the timing of puberty does not influence adult height.

Nutritional changes clearly have an important role, as shown by the positive correlation between age at puberty onset and childhood body size [20], most markedly in girls [11]. He and Karlberg demonstrated in a large dataset (n = 3650) that one BMI unit increase between the ages of 2 and 8 years is associated with a 0.11 year advancement in the timing of puberty as

Fig. 4.3 Relationship between peak height velocity and pubertal development (male). *P* pubic hair stage; *PHV* peak height velocity; *T* testicular growth; *G* genital stage. Age ranges presented: in linear format—3rd–97th centiles for each Tanner stage, e.g., G2; in colored boxes—age range in years for each parameter



measured by peak height velocity in both genders [21]. In boys, however, the data are less consistent, with some studies documenting an earlier onset of puberty with greater adiposity, and some a later onset. In particular, more European studies have noted the former trend, while US studies have more often shown the latter [22]. A recent study from the USA reported a far more complex relationship between fat mass and pubertal timing, with overweight status being associated with earlier pubertal onset, while obesity was associated with later onset. These effects also vary between ethnic groups [23]. Thus, one hypothesis in boys is that greater BMI leads to earlier pubertal timing up to the threshold at which obesity occurs. Obesity may delay pubertal timing in boys due to the suppression of the HPG axis with adiposity leading to excess aromatase activity and thus increased estrogen production.

Additional data point to an earlier trend in the age of puberty onset that is independent of BMI [24]. As detailed above, some studies suggest that over the last decade, the age of completion of puberty in males in some populations has become skewed toward later ages [5]. The effect of possible endocrine-disrupting chemicals (EDCs) on the timing of puberty is also an ongoing concern [5, 25]. Polybrominated biphenyls, bisphenol A, atrazine (herbicides), and phthalates, among others, have been suggested as possible EDCs responsible for contributing to this observed trend [26]. For example, children migrating for international adoption, and previously exposed to the estrogenic insecticide DDT in their country of origin, displayed early or precocious pubertal timing [27]. However, a mechanism of action for EDCs through the early initiation of the pulsatility of GnRH has not been conclusively demonstrated. Studies are complicated by the likely differing and possibly divergent influence of variable doses and mixtures of EDCs, and differing effects depending on age and length of exposure [5, 27, 28].

Epigenetic regulators are potential mediators of the effects of the environment on the

hypothalamic control of puberty. However, while experimental data from rats provide evidence for changes in histone acetylation and gene methylation leading to altered gene expression during sexual development, the link between environmental factors and the epigenetic control of puberty has not been established. Although the window of opportunity for the effects of EDC exposure was historically considered to occur in the late prepubertal period, evidence of a fetal and neonatal origin for changes in pubertal timing counters this dogma. A multicenter US study found that prenatal exposure of boys to EDCs such as phthalates, based on the concentrations of four phthalate metabolites in a sample of urine, was associated with a short anogenital index, a marker for reduced masculinization of genital structures [29] (see Chap. 14). Epigenetic changes during fetal life are a potential mechanism for the effects of EDCs in utero [5]. Recent evidence suggests that effects of EDCs may persist in pregnant rats in not only their unborn fetus but into the next generation [30].

Despite the demonstrated importance of environmental factors, the genetic influence on pubertal timing is clearly fundamental. While the timing of pubertal onset varies within and between different populations, it is a highly heritable trait. The timing of sexual maturation is highly correlated within families and in twin studies, suggesting strong genetic determinants [31]. Previous epidemiological studies and genetic approaches estimate that 60–80% of the variation in pubertal onset is under genetic regulation [14, 32, 33]. Despite this strong heritability, however, little is known about the genetic control of human puberty either in the normal population or in cases of disturbed pubertal timing [4]. A lack of clear understanding of the genetic factors that control and trigger the onset of puberty is an important barrier to deciphering the mystery of EDC and other environment/external cues to understand the secular trend toward earlier puberty [34].

Endocrine Changes During Puberty

Gonadotropin-Releasing Hormone and Gonadotropins

The hypothalamus–pituitary–gonadal (HPG) axis is already functional in the late fetal and neonatal period. The development of the HPG axis is exceptional in that GnRH is produced by hypothalamic neurons that develop outside of the central nervous system. The embryonic migration of GnRH neurons from the posterior wall of the nasal cavity to hypothalamus is key for the creation of the neuroendocrine pathways that allow normal pubertal development [35]. The whole process of migration involves no more than a few hundred neurons per hemisphere in the mouse (several thousand in primates or humans) [36]. The absolute number of GnRH neurons required for pubertal development is not known, but there appears to be a degree of redundancy in the system [37]. In addition, adult reeler mice have significantly fewer GnRH neurons in the hypothalamus and display a phenotype of delayed pubertal maturation and low fertility [38].

During gestation, there is an increase in GnRH content, which peaks at 34–38 weeks in the male fetus [39]. At mid-gestation, there is a striking rise in circulating gonadotropin levels in both male and female fetuses which fall to low levels in late gestation. This change in gonadotropin secretion is thought to result from the development of sex steroid negative feedback and from inhibiting influences from the CNS to GnRH neurons.

LH and FSH secretions rise during the first month after birth, probably because the negative feedback effect of placental estrogens is withdrawn. LH is secreted in pulses during this postnatal period indicating control by GnRH [40]. While the HPG axis is active during this ‘mini-puberty,’ it becomes dormant in young children between the age of 2 and 8–9 years [41]. Suppression of the axis is not absolute, however, as LH pulsatility is detectable during this stage using ultrasensitive assays, but pulses are infrequent, of low amplitude and occur mostly at night [42].

The clinical features of puberty are initiated by reactivation of the HPG axis after this relative

quiescence during childhood. During this reactivation, there is a gradual development of a dynamic interplay between the central production of GnRH and gonadotropins, and gonadal sex steroid production, with progressive maturation of negative and positive feedback loops. The central suppressant drive from the CNS gradually abates, and intensifying positive feedback results from the increase in sex steroid production by the gonads. The gonadal inhibition of the hypothalamic–pituitary system occurs later, becoming operative only at mid-puberty, and eventually becomes dominant over the central inhibitory feedback drive (Fig. 4.4). Both mean LH and FSH levels increase through pubertal development, although LH rises to a greater extent, probably due to mechanistic differences in feedback by estradiol and inhibin for these two hormones [43]. These rises are due to both an increase in basal levels of LH and FSH, and to a greater number and amplitude of LH pulses.

Sex Steroids and Inhibin-B

LH controls sex steroid production by upregulating expression of the steroidogenic enzymes and by controlling metabolic activity of the steroid-producing Leydig cells (see Chap. 2). LH may also stimulate Leydig cell proliferation and differentiation [44]. During puberty, plasma testosterone levels increase dramatically. Table 4.2 summarizes the levels of testosterone at various developmental stages with respective testis sizes. The pubertal increase in testis size results primarily from an increased number of proliferating and differentiating germ cells and to an increase in the number of Sertoli cells [45]. In early and mid-puberty, there is a pronounced diurnal rhythm with a morning peak in testosterone levels, but this is less pronounced in later puberty, and declines gradually with age [46], probably due to decreased day–night ratios of gonadotropins [47].

Inhibin-B is a heterodimeric glycoprotein produced by Sertoli cells beginning in the fetus. Several studies show that serum inhibin-B levels in children change in concert with the secretion




Fig. 4.4 A model showing the regulation of the hypothalamic–pituitary–gonadal axis during pubertal development

Table 4.2 Pubertal stages (according to Tanner) with respective testis volumes and plasma testosterone concentrations

Pubertal stage (Tanner)	Testicular volume (mL)	Plasma testosterone (ng/dL)	Plasma testosterone (nmol/L)
1	<4	<10	<0.3
2	4–8	12–69	0.4–2.4
3	8–10	60–275	2.1–9.5
4	10–20	142–515	4.9–17.9
5	20–25	319–775	11.1–26.9

Values adapted from Knorr et al. [2]

of gonadotropins [48–50]. During the ‘mini-puberty,’ serum inhibin-B levels increase to similar [51, 52] or even higher [49] levels than in adolescent boys and adult men. This early inhibin-B secretion is sustained until the age of 18–24 mo; thereafter, serum concentrations decline to lower but readily measurable levels [49]. Early in puberty, between Tanner stages G1

and G2, serum inhibin-B concentrations again increase to reach peak levels at the Tanner stage G2, but then the levels plateau [48, 50].

Central Control of Puberty via GnRH Upstream Pathways

GnRH pulsatility is coordinated by a balancing act between a number of inhibitory and excitatory neuronal and glial inputs (Fig. 4.5) [53]. Inhibitory inputs are primarily from GABAergic and opiateergic neurons, while glutamate and kisspeptin are the central excitatory neuronal signals. Glial cells additionally facilitate GnRH secretion via growth factor-derived signaling [54]. The onset of puberty is triggered by a decline in these inhibitory signals and an amplification of excitatory inputs, leading to increased frequency and amplitude of GnRH pulses [55]. Before the onset of puberty, GABA release in the preoptic area decreases in female rats [56], and in




Fig. 4.5 Genetic regulators in the trans-synaptic and glial control of GnRH neurons during puberty. Adapted from Ojeda et al. [53]

the rhesus monkey, GABA release into the median eminence decreases concomitant with the pubertal increase of GnRH secretion [57]. In female rats, glutamine synthase is downregulated, and glutamate dehydrogenase becomes more abundant in the hypothalamus at puberty, both leading to increased availability of glutamate [58]. Glutamate agonists are potent stimulators of GnRH secretion, and administration in prepubertal primates can stimulate LH and testosterone secretion [59].

Another vital piece in the puzzle of the central control of GnRH release came with the discovery of Kisspeptin. This excitatory neuropeptide was identified as a permissive factor in puberty onset by the discovery of patients with GnRH deficiency who had loss-of-function mutations in the *KISS1* receptor, *KISS1R* (previously known as *GPR54*) [60, 61]. Mice with knockout of *kiss1r*

were simultaneously discovered to be infertile despite anatomically normal GnRH neurons and normal hypothalamic GnRH content [61]. Their phenotype can be rescued by exogenous delivery of GnRH. *Kiss1* knockout mice also have a phenotype consistent with normosmic GnRH deficiency. However, to date, only very rarely have mutations in *KISS1* been found in patients with delayed or absent puberty [62], although two potential activating mutations were identified in patients with central precocious puberty (CPP) [63].

Kisspeptin signals directly to GnRH neurones to control pulsatile GnRH release. Kisspeptin is upregulated in both primates and mice in the peri-pubertal period, and its administration in prepubertal rodents advances the onset of puberty [64]. Kisspeptin also appears to be downregulated in functional hypogonadism,

suggesting its role as a mediator of the action of environmental factors such as nutritional status and emotional well-being on puberty and reproductive capacity. Kisspeptin signaling is an important element of both positive and negative feedback loops in the HPG axis. While kisspeptin has been identified as a pivotal upstream regulator of GnRH neurons, whether kisspeptin is the key factor that triggers the onset of puberty remains unclear.

An additional excitatory neuropeptide, neurokinin B, has been implicated in the upstream control of GnRH secretion. Identification of this pathway was via the discovery of loss-of-function mutations in *TAC3*, encoding neurokinin B, and its receptor *TACR3*, in patients with normosmic GnRH deficiency and pubertal failure [65, 66]. Both *KISS1* and *TAC3* are expressed by neurons in the arcuate nucleus of the hypothalamus that project to GnRH neurons, and their expression is downregulated by estrogen [67]. However, studies of the effects of neurokinin B administration have provided conflicting results. While central administration of neurokinin B agonists failed to stimulate GnRH release in rodents, and *Tacr3* knockout mice have grossly normal fertility [68, 69], primate studies showed that neurokinin B can act to stimulate GnRH release via kisspeptin signaling [70]. Additionally, neurokinin B is expressed more widely in the central nervous system than in kisspeptin, suggesting some differences in the roles of these two neuropeptides in the control of pubertal onset.

Dynorphin, an opioid peptide that is coexpressed with kisspeptin and neurokinin B in so-called KNDy neurons, inhibits the release of GnRH, and together, these peptides are currently believed to play a fundamental role in the GnRH pulse generator. Other neurons regulate GnRH including GABAergic signaling pathways which function in the stress-induced suppression of LH, and *Rfamide-related peptide gene (RFRP)*, the mammalian ortholog of the avian peptide *gonadotrophin-inhibiting hormone (GnIH)* [71].

Glial inputs appear to be predominantly facilitatory during puberty, acting via growth factors and small diffusible molecules, including TGF β 1, IGF-1, and neuregulins that directly or

indirectly stimulate GnRH secretion [72]. Glial cells in the median eminence regulate GnRH secretion through the production of growth factors that activate receptors with tyrosine kinase activity. FGF signaling is required for GnRH neurons to reach their final destination in the hypothalamus [73], as well as for GnRH neuronal differentiation and survival [74]. Additionally, GnRH neuron secretory activity is facilitated by IGF-1 and by members of the epidermal growth factor family such as neuregulin 1 β [54, 75]. Moreover, plastic rearrangements of glia–GnRH neuron adhesiveness, mediated by soluble molecules such as neuronal cell adhesion molecule (NCAM) and synaptic cell adhesion molecule (SynCAM), coordinate the controlled delivery of GnRH to the portal vasculature [72], a process that is subject to sex steroid regulation [76].

The interplay between puberty and metabolism has been the focus of intense study. The role of fat mass in pubertal timing is thought to be mediated, at least in part, through the permissive actions of the metabolic hormone leptin, a key regulator of body mass, secreted from white adipose tissue (WAT) [77]. Absence of leptin signaling results in obesity and infertility, whereas leptin treatment decreases food intake and restores reproductive functions. During fasting, leptin levels decrease and gonadotropin secretion is suppressed. These findings imply that nutritional status, especially fat tissue and leptin, could contribute to pubertal development. Clinical observations have further supported a role for leptin signaling in the onset of puberty, e.g., humans and mice lacking leptin (*Lep ob/ob*) or the leptin receptor (*LepR db/db*) fail to complete puberty and are infertile [78], and in a 12-yr-old girl with congenital leptin deficiency, treatment with recombinant leptin was followed by a pubertal pattern of LH release [79].

GnRH neurons do not express the *LepR*. Instead, leptin appears to indirectly regulate GnRH via actions on cells that are afferent to GnRH neurons such as *LEPR*-expressing GABA neurons from the arcuate nucleus [80], or via cells that interact morphologically with GnRH neurons, partly through nitric oxide signaling,

which is required for leptin action [81], and via kisspeptin/neuropeptide Y neurons [82, 83]. Cross-sectional studies showed that serum leptin levels rise in girls in early puberty [84] but not in boys. In careful longitudinal studies in male rhesus monkeys, leptin levels decreased during the juvenile period and were unchanged during puberty [85, 86], and leptin gene expression in the hypothalamus is unchanged during the development in the rat [87, 88]. Therefore, leptin is probably not the requisite metabolic trigger for the onset of puberty, but rather is a permissive factor signaling healthy energy balance.

Neuropeptide Y (NPY) is involved in many CNS functions, including appetite control and reproduction. Evidence from primate studies suggests that NPY may also have a contributory role in the break restraining the onset of puberty in primates [68, 89]. Ghrelin and other

gut-derived peptides may also form part of the mechanism by which energy homeostasis regulates reproductive development [90]. Both low birthweight and prematurity are associated with earlier onset of puberty [91, 92], particularly in those children with rapid increase in length or weight in the first two years of life [93]. It remains unclear, however, whether childhood obesity, insulin resistance, excess androgens, or other factors may explain this association [94, 95].

While GnRH pulsatility is clearly the central driver of pubertal onset, and aberrant GnRH neuronal development and function lead to hypogonadotropic hypogonadism (HH), our collective understanding of the upstream neuro-circuitry regulating GnRH neurons remains incomplete. Data pointing to hypothalamic regulation via a hierarchical network of genes (Fig. 4.6) have mainly come from a systems




Fig. 4.6 Algorithm for the evaluation of boys with delayed puberty. *CDGP* constitutional delay of growth and puberty, *GI* gastrointestinal, *GH* growth hormone, *GHD* GH deficiency, *PRL* prolactin, and *IGF-1*

insulin-like growth factor 1. Adapted from Palmer and Dunkel [4]. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission

biology approach and from animal models, with little data from human subjects [96]. Candidate transcriptional regulators that have been identified via these approaches include *Oct-2*, *TTF-1*, and *EAPI* [97–99].

Delayed Puberty

Presentation

Disturbances of puberty encompass an important group of pathologies within the field of pediatric endocrinology. First, they are common, affecting over 4% of adolescents. In addition, abnormal timing of pubertal development is associated with adverse health and psychosocial outcomes [100–102]. This has importance for the individual, but also has a potential major impact on public health, especially in view of the secular trend toward an earlier age of puberty onset [25]. Early puberty, in particular, is associated with adverse health outcomes, including breast [103] and endometrial cancer [104], obesity [105], type 2 diabetes [102], cardiovascular disease [106, 107], short stature [108], and even increased mortality [106]. However, persons with delayed puberty are also at risk of short adult height [109–112], decreased bone mineral density [113, 114], and psychological sequelae [115, 116].

Self-limited Delayed Puberty

Self-limited delayed puberty (DP), also known as constitutional delay of growth and puberty (CDGP), represents the most common cause of delayed puberty in both sexes. Up to 63% of boys with delayed puberty have self-limited DP [117]. Self-limited DP segregates within families, with the majority of families displaying an autosomal dominant pattern of inheritance (with or without complete penetrance) [31]. Fifty to 75% of subjects with self-limited DP have a family history of delayed puberty onset [118].

Patients with self-limited DP represent the extreme tail of normal puberty, defined as the markers of the onset of puberty occurring two or

more standard deviation (SD) later than the population mean age for gender. In addition, self-limited DP may encompass older children with delayed pubertal progression, a diagnosis that is aided by the use of puberty nomograms (Fig. 4.2) [119]. The absence of a pathological medical history, signs and symptoms, and a positive family history of delayed puberty in one or both of the parents suggests a diagnosis of self-limited DP; however, before making that diagnosis, pathological conditions must be excluded.

In DP, probably because of a low estrogen concentration for chronological age (but not for bone age), growth hormone (GH) secretion is functionally and temporally reduced for age, and when this functional GH deficiency is prolonged, it may also impact adult height. After the onset of puberty or the initiation of appropriate treatment, growth velocity and GH secretion return to normal. Additionally, in about half of the subjects with constitutional delay, there is delayed maturation during early childhood, and consequently, they are shorter than their peers even before the mean age for the pubertal growth spurt [119].

It has been shown that those self-limited DP subjects who also have reduced growth in childhood may not fully exploit their genetic height potential, resulting in an adult height below their mid-parental target height [112, 120–122], with an average loss of 4.2 cm if untreated [122]. However, the majority of the patients seen at pediatric endocrinology clinics are short because their condition is compounded by two independent factors: short genetic height potential and DP. Other studies showed only a negligible difference in final height, even in DP subjects who have received no intervention [109, 123–128]. This may imply a pathophysiological mechanism in addition to lack of sex steroids contributing to the growth phenotype in some patients with DP, but not in others [128].

In self-limited DP, adrenarche may also occur later than usual [4]. Bone age in self-limited DP is retarded compared to chronological age, but the developmental milestones are achieved at a normal bone age, that is, onset of signs of pubertal development by a bone age of

Table 4.3 Differential diagnoses of male self-limited delayed puberty

	Hypergonadotropic hypogonadism	Hypogonadotropic hypogonadism	Functional hypogonadotropic hypogonadism
Common causes:	Klinefelter syndrome Gonadal dysgenesis Chemotherapy/radiation therapy	CNS tumors/infiltrative diseases Isolated hypogonadotropic hypogonadism Kallmann syndrome Combined pituitary hormone deficiency Chemotherapy/radiation therapy	Inflammatory bowel disease Celiac disease Anorexia nervosa Hypothyroidism Excessive exercise Cystic fibrosis

Table modified from Palmer and Dunkel [4]. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission

13.5 years in boys. Gonadotropin and sex steroid concentrations increase in concert with the progression of the bone age. Thus, all stages of pubertal development occur at an age that is later than average.

There are three main differential diagnoses of self-limited DP [4, 117] (Table 4.3): hypergonadotropic hypogonadism, with primary gonadal failure leading to elevated gonadotropin levels (approximately 7% of males with delayed puberty); functional hypogonadotropic hypogonadism, where late pubertal development is due to maturational delay in the HPG axis secondary to a chronic disease [129] (found in 19–20%), malnourishment [130], excessive exercise [131, 132], or psychological or emotional stress [133]; and permanent hypogonadotropic hypogonadism (HH), characterized by low LH and FSH levels (9% of boys).

Hypogonadotropic Hypogonadism

HH is often diagnosed during the second or third decades of life. Common presenting signs are delayed onset of puberty, poorly developed secondary sexual characteristics, eunuchoid body proportions, or infertility [134]. This condition can be due to a congenital hypothalamic or pituitary disorder or to an acquired central dysfunction secondary to irradiation, surgery, tumor, or a vascular lesion. Tumors causing delayed puberty most commonly interfere with GnRH synthesis or secretion, the most common being craniopharyngioma, germinoma, and Langerhans

cell histiocytosis. A deficiency of other anterior pituitary hormones, diabetes insipidus, and visual disturbance is common. Congenital malformation of the pituitary, hypothalamic, and other midline structures may cause HH, often in conjunction with other pituitary hormone deficiencies.

A picture of ‘idiopathic’ hypogonadotropic hypogonadism (IHH) with no associated anatomical or functional defect in the hypothalamic–pituitary–gonadal axis occurs in 1–10 cases per 100,000 births. Because of different causes and incomplete penetrance, there is a wide spectrum of phenotypes, ranging from complete hypogonadotropic hypogonadism, with lack of pubertal development, to partial hypogonadism with an arrest of pubertal development, and even reversible HH in some patients post treatment [135]. Despite recent advances, with over twenty genes linked with this disorder having been identified, the pathophysiological basis of hypogonadotropic hypogonadism in the majority of individuals remains unclear [136] (see Chap. 5). The condition may be due to the failure of the development of gonadotropin-releasing hormone (GnRH) neurons, lack of activation of GnRH secretion, or disrupted GnRH signaling (including mutations in the *GNRHR* gene). Kallmann syndrome (hypogonadotropic hypogonadism associated with anosmia) is the most common form of isolated HH, accounting for 60% of cases.

Downstream mutations in the GnRH signaling pathway can also present as delayed puberty. LH and FSH are encoded by a common α -subunit

gene and a specific β -subunit gene. Mutations of the β -subunits genes of LH or FSH are extremely rare causes of HH [137, 138] (see Chap. 6).

Functional Hypogonadotropic Hypogonadism

Functional HH is seen in malnutrition and chronic diseases, as exemplified by patients with inflammatory bowel disease, celiac disease, chronic kidney disease, cystic fibrosis, and sickle cell anemia. Undernutrition in states of starvation such as anorexia nervosa, or an imbalance due to excess energy consumption in extreme athletic training, can also cause central GnRH suppression. The factors contributing to these states of functional HH include low fat mass, inflammation, and stress [139, 140].

Hypergonadotropic Hypogonadism

Hypergonadotropic states (chromosomal alterations, syndromes, genetic disorders, and radiotherapy/chemotherapy) are covered elsewhere in this volume (see Chaps. 9 and 10) and may present as pubertal delay. Testicular abnormalities are characterized by elevated gonadotropin and low inhibin-B concentrations, and patients with these abnormalities sometimes have specific physical features.

Delayed Puberty—Diagnosis

The cutoff age for boys who need an evaluation for delayed puberty may vary in different ethnic groups, but in most populations, early signs of secondary sexual development should be present by age 14 years. The evaluation of testicular volume is vital, as an accurate diagnosis of delayed puberty cannot be made without assessment of Tanner genital stage. A thorough medical history should note the symptoms and signs of anorexia nervosa, the intensity of athletic training, and the timing of puberty of both parents, as there is often a family history of DP in cases of self-limited DP (Fig. 4.6). A history of chronic illness, such as celiac disease or

inflammatory bowel disease, suggests a temporary or secondary delay of puberty. Stature and height velocity should be evaluated using appropriate growth charts. Bone age (X-ray film of left hand and wrist read according to standards such as Greulich and Pyle) delay provides useful information in the growth analysis but contributes little to the differential diagnosis. It may be very difficult to distinguish clinically between the diagnosis of self-limited DP and congenital HH in the teenage years [141]. While gonadotropin levels are generally increased in primary testicular failure or in Klinefelter syndrome, single basal serum LH and FSH determinations are not useful in the differential diagnosis of self-limited delay vs hypogonadotropic hypogonadism.

In some cases, the diagnosis of permanent HH can be suspected before the age of pubertal onset, and importantly, if this suspicion arises in the first six months of life, it can be confirmed on the basis of low testosterone and gonadotropin levels, indicating an absence of the normal ‘mini-puberty.’ The presence or absence of ‘red flag’ features remains the strongest discriminator between self-limited DP and IHH. These red flags include cryptorchidism or micropenis, or the presence of the other components of the Kallmann syndrome which include anosmia or hyposmia due to hypoplasia of the olfactory bulbs, as well as cleft lip and palate, unilateral renal agenesis, short metacarpals, sensorineural hearing loss, synkinesia, and color blindness.

Investigation of the differential diagnosis of the two conditions may involve a number of physiological and dynamic tests including assessment of LH pulsatility by frequent blood sampling [42], the prolactin response to provocation [142, 143], the gonadotropin response to GnRH [144, 145] and analogs [146], the testosterone response to hCG [146–148], and first morning-voided urinary FSH and LH levels [149]. Boys with self-limited delay who are destined to undergo spontaneous pubertal development within 6 to 12 months may have a pubertal pattern of response to GnRH (post-GnRH maximum LH levels higher than maximum FSH levels). However, a low

prepubertal LH response to GnRH is usually found in boys with self-limited DP who will develop later than that, as well as in boys with permanent HH. Most recently, a single measurement of inhibin-B <35 pg/mL has been shown to help discriminate prepubertal boys with IHH from DP with high sensitivity [150]; nevertheless, patient follow-up is necessary for a definitive diagnosis in the majority of cases. With the discovery in the last two decades of genes causing HH, genetic testing will no doubt modify the management of many of our male delayed puberty patients [151].

Male Delayed Puberty—Therapeutic Indications

Induction or progression of puberty is indicated for adolescents who have either significantly delayed or arrested puberty, or have been diagnosed with permanent hypogonadism. Appropriate treatment modalities are directed according to the underlying diagnosis.

A management strategy of ‘watchful waiting’ may be appropriate in self-limited DP, where pubertal onset is late but expected to occur spontaneously. However, this decision should be taken in conjunction with the patients, taking into consideration their concerns and expectations. One major concern often raised by patients and their families is the effect of delayed puberty on both current and final height, particularly for patients with concurrent familial short stature. However, patients can be reassured that adult height in DP is usually only slightly below genetic height potential (target height), although there may be large individual variation [121, 152]. If height is not a major concern, reassurance with accurate adult height prediction is frequently sufficient, especially if puberty has already started. DP in adolescents can, however, be associated with significant anxiety about body image in terms of physical size and pubertal immaturity, decreased self-esteem with social isolation, withdrawal from sporting activities, and psychosocial and peer relationship difficulties. In these circumstances, there is evidence that

hormonal therapy can be beneficial [153, 154]. The link between DP and reduced academic performance, substance misuse, and behavioral difficulties is less well established.

In contrast, if ‘red flag’ markers of hypogonadism are present, or if endogenous gonadotropin-dependent puberty has not started after one year of treatment, then permanent HH and other diagnoses should be reconsidered, and a brain MRI should be performed. In such instances, treatment should be initiated promptly in order to optimize skeletal growth and induce secondary sexual characteristics and, therefore, minimize the psychosocial difficulties faced by adolescents with hypogonadism.

Management of Delayed Puberty—Therapeutic Principles

The options for the management of male patients with self-limited DP include monitoring with reassurance, or therapy with low-dose testosterone to augment the growth rate and induce secondary sexual characteristics (Table 4.4). There are numerous published studies of treatment of DP in boys, but most are observational, with a few small randomized controlled trials [154–156]. Most report treatment with short courses of low-dose androgens with outcomes of increased height velocity without advanced bone age, advanced sexual maturation, and often improvement in psychosocial parameters.

The most commonly used treatment regimen for low-dose testosterone for boys with DP is supplementation using intramuscular depot preparations of a testosterone ester [157], at a starting dose of 50 mg each month for 3–6 months; a further 3–6 months of treatment may be given, with dose escalation as required. Oral testosterone undecanoate (where available) at a dose of 40–160 mg daily has recently been shown to be safe and efficacious for pubertal induction in DP, without compromise in final height [119] (Table 4.4). Topical testosterone gels may also be suitable for this indication [158]. Monitoring via serum testosterone increase (to mid-reference range one week post injection), basal LH

Table 4.4 Medications used for the treatment of delayed puberty

Drug and formulation	Induction of puberty in boys		Side effects and cautions
	Self-Limited DP	Hypogonadism	
Testosterone (T) ^a			Erythrocytosis, weight gain, prostatic hyperplasia. High doses can cause premature epiphyseal closure. Not for use in boys with bone age <10 years
T enanthate, cypionate, and propionate. T enanthate has longer duration of effect than T propionate. IM injection	Not recommended before 13.5 years of age. Initial dose 50–100 mg every 4 weeks for 3–6 months. After review of response: repeated treatment with 25–50 mg increment in dose (not exceeding 100 mg)	Can initiate after age 12 years at 50 mg/month. Increase with 50 mg increments every 6–12 months. After reaching 100–150 mg monthly, decrease interval to every 2 weeks. Adult dose 200 mg every 2 weeks	All IM preparations: local side effects (pain, erythema, inflammatory reaction, and sterile abscess). Priapism can occur in patients with sickle cell disease
T undecanoate IM/PO	Starting dose of 40 mg PO OD increasing rapidly to 40 mg BD and subsequently 80 mg BD. Rx paused and then stopped if significant increase in basal LH and/or testicular volume observed (120)	Adult dose is 1000 mg IM every 10–14 weeks	Very rarely, paroxysms of coughing and dyspnoea post-IM injection, ascribed to lipid embolism from the vehicle, hence not licensed in USA
T gel. Transdermal preparations, applied topically at bedtime	No data available	Can be started when approximately 50% adult dose with IM T has been achieved. Adult dose is 50–80 mg daily	Local irritation. After applying, avoid close skin contact with children and women

^aAnabolic steroids are not recommended for the induction of secondary sexual characteristics
Table modified from Palmer and Dunkel [4]. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission

increase, height velocity, testicular volume, and extent of virilization is appropriate. GH deficiency must be excluded if height velocity does not increase with testosterone therapy. Testosterone esters should be avoided in patients with hepatic impairment or hypercalcaemia and used with caution in chronic kidney disease [159]. Preparations are generally well tolerated, but side effects may include headaches, depression, and androgenic effects such as acne. Although anabolic steroids such as oxandrolone have been used historically for short-term increase in height velocity, they are less effective in stimulating pubertal development and therefore are not recommended for the management of boys with delayed puberty.

As discussed above, self-limited DP is commonly seen in combination with idiopathic short stature (ISS). After exclusion of GH deficiency, for example, by the use of a primed GH provocation test, the treatment of GH-replete DP patients with growth hormone remains controversial: It has been approved by the US Food and Drug Administration for the treatment of ISS and height SDS ≤ 2.25 for age, but leads to only a modest increase in adult height, and its use is not recommended by the authors [160, 161].

A further potential pharmacological target in short boys with DP is the inhibition of estrogen biosynthesis from androgens using aromatase inhibitors [162, 163]. Epiphyseal closure is

dependent on estrogens, and thus, aromatase inhibitors (AIs) can potentially act to extend the time period in which long bone growth occurs and therefore increase adult height. Some published data support this use of AIs to delay bone maturation and increase adult height in boys with short stature and/or delayed puberty [162, 163]. However, there remains much uncertainty in terms of efficacy, optimization, and safety profile of AI therapy [164], and the optimal dose, timing, and duration of treatment in ISS and DP remain uncertain. Controlled trials have pointed to potential adverse effects, in particular compromised trabecular bone health in the form of vertebral body deformities in boys with ISS treated with letrozole [165]. Until more information from ongoing studies of these agents is available, active management should not involve aromatase inhibitors unless used within the setting of a clinical trial.

Concluding Remarks

In healthy boys, the normal age limits for the first signs of secondary sexual development are between 9.5 and 14 years. There are multiple genetic and environmental influences on the timing of puberty in the general population, and appropriate age cutoffs for delayed puberty in different ethnic groups may vary.

DP is a frequent problem, and the most common underlying condition is self-limited (or constitutional) DP, which is usually accompanied by delayed growth. However, the differential diagnoses include hypogonadotropic and hypergonadotropic hypogonadism, and these conditions must be considered in boys with pubertal delay. Distinguishing between self-limited DP and permanent hypogonadotropic hypogonadism remains difficult.

Management of male adolescents with DP is dependent on the underlying cause. Treatment of isolated DP involves expectant observation or short courses of testosterone in low doses, while more complex and involved management is required for males with permanent hypogonadism. However, a proportion of young men

with DP will remain adversely affected by their delayed pubertal development and/or short stature in adolescence, which may have long-term consequences. It is not known whether pubertal delay has a negative impact on adult bone mass [166], and whether potentially compromised bone health is a reason to initiate sex steroid replacement. Additionally, the optimal management of males with severe hypogonadotropic hypogonadism (cryptorchidism, micropenis, and lack of spontaneous increase in testicular size in puberty) remains uncertain. Whether such patients would benefit from prepubertal FSH treatment to improve potential for future fertility is another unanswered question (see Chap. 20).

The genetic and environmental basis for both DP and HH is an area of research where there is still much to be discovered, and may bring future benefits for patient management. Our understanding of the key controllers of pubertal onset and its timing is advancing but remains a complex puzzle to be unlocked. Mechanistic discoveries in DP and hypogonadism patients are also likely to shed light on the changes in pubertal timing in the general population.

References

1. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. *Arch Dis Child.* 1970;45(239):13–23.
2. Knorr D, Bidlingmaier F, Butenandt O, Fendel H. Plasma testosterone in male puberty. I. Physiology of plasma testosterone. *Acta Endocrinol.* 1974;75(1):181–94.
3. Nielsen CT, Skakkebaek NE, Richardson DW, Darling JA, Hunter WM, Jorgensen M, et al. Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. *J Clin Endocrinol Metab.* 1986;62(3):532–5.
4. Palmert MR, Dunkel L. Clinical practice. Delayed puberty. *N Engl J Med.* 2012;366(5):443–53.
5. Parent AS, Franssen D, Fudvoye J, Gerard A, Bourguignon JP. Developmental variations in environmental influences including endocrine disruptors on pubertal timing and neuroendocrine control: revision of human observations and mechanistic insight from rodents. *Front Neuroendocrinol.* 2015;38:12–36.
6. Wagner IV, Sabin MA, Pfaffle RW, Hiemisch A, Sergeev E, Korner A, et al. Effects of obesity on

- human sexual development. *Nat Rev Endocrinol*. 2012;8(4):246–54.
7. Bourguignon JP. Growth and timing of puberty: reciprocal effects. *Horm Res*. 1991;36(3–4):131–5.
 8. Gasser T, Sheehy A, Molinari L, Largo RH. Growth of early and late maturers. *Ann Hum Biol*. 2001;28(3):328–36.
 9. Biro FM, McMahon RP, Striegel-Moore R, Crawford PB, Obarzanek E, Morrison JA, et al. Impact of timing of pubertal maturation on growth in black and white female adolescents: the national heart, lung, and blood institute growth and health study. *J Pediatr*. 2001;138(5):636–43.
 10. Gamba M, Pralong FP. Control of GnRH neuronal activity by metabolic factors: the role of leptin and insulin. *Mol Cell Endocrinol*. 2006;254–255:133–9.
 11. Juul A, Teilmann G, Scheike T, Hertel NT, Holm K, Laursen EM, et al. Pubertal development in Danish children: comparison of recent European and US data. *Int J Androl*. 2006;29(1):247–55; discussion 86–90.
 12. Teilmann G, Pedersen CB, Skakkebaek NE, Jensen TK. Increased risk of precocious puberty in internationally adopted children in Denmark. *Pediatrics*. 2006;118(2):e391–9.
 13. Mul D, Fredriks AM, van Buuren S, Oostdijk W, Verloove-Vanhorick SP, Wit JM. Pubertal development in The Netherlands 1965–1997. *Pediatr Res*. 2001;50(4):479–86.
 14. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. *Endocr Rev*. 2003;24(5):668–93.
 15. de Muinich Keizer SM, Mul D. Trends in pubertal development in Europe. *Human Reprod Update*. 2001;7(3):287–91.
 16. Sorensen K, Aksglaede L, Petersen JH, Juul A. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. *J Clin Endocrinol Metab*. 2010;95(1):263–70.
 17. Herman-Giddens ME, Steffes J, Harris D, Slora E, Hussey M, Dowshen SA, et al. Secondary sexual characteristics in boys: data from the pediatric research in office settings network. *Pediatrics*. 2012;130(5):e1058–68.
 18. Euling SY, Herman-Giddens ME, Lee PA, Selvan SG, Juul A, Sorensen TI, et al. Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings. *Pediatrics*. 2008;121(Suppl 3):S172–91.
 19. Ong KK, Ahmed ML, Dunger DB. Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): the European trend. *Mol Cell Endocrinol*. 2006;254–255:8–12.
 20. Biro FM, Khoury P, Morrison JA. Influence of obesity on timing of puberty. *Int J Androl*. 2006;29(1):272–7; discussion 86–90.
 21. He Q, Karlberg J. Bmi in childhood and its association with height gain, timing of puberty, and final height. *Pediatr Res*. 2001;49(2):244–51.
 22. De Leonibus C, Marcovecchio ML, Chiarelli F. Update on statural growth and pubertal development in obese children. *Pediatr Rep*. 2012;4(4):e35.
 23. Lee JM, Wasserman R, Kaciroti N, Gebremariam A, Steffes J, Dowshen S, et al. Timing of puberty in overweight versus obese boys. *Pediatrics*. 2016;137(2):1–10.
 24. Aksglaede L, Juul A, Olsen LW, Sorensen TI. Age at puberty and the emerging obesity epidemic. *PLoS ONE*. 2009;4(12):e8450.
 25. Mouritsen A, Aksglaede L, Sorensen K, Mogensen SS, Leffers H, Main KM, et al. Hypothesis: exposure to endocrine-disrupting chemicals may interfere with timing of puberty. *Int J Androl*. 2010;33(2):346–59.
 26. Caserta D, Maranghi L, Mantovani A, Marci R, Maranghi F, Moscarini M. Impact of endocrine disruptor chemicals in gynaecology. *Human Reprod Update*. 2008;14(1):59–72.
 27. Krstevska-Konstantinova M, Charlier C, Craen M, Du Caju M, Heinrichs C, de Beaufort C, et al. Sexual precocity after immigration from developing countries to Belgium: evidence of previous exposure to organochlorine pesticides. *Hum Reprod*. 2001;16(5):1020–6.
 28. van den Driesche S, Macdonald J, Anderson RA, Johnston ZC, Chetty T, Smith LB, et al. Prolonged exposure to acetaminophen reduces testosterone production by the human fetal testis in a xenograft model. *Sci Transl Med*. 2015;7(288):288ra80.
 29. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect*. 2005;113(8):1056–61.
 30. Dean A, van den Driesche S, Wang Y, McKinnell C, Macpherson S, Eddie SL, et al. Analgesic exposure in pregnant rats affects fetal germ cell development with inter-generational reproductive consequences. *Sci Rep*. 2016;6:19789.
 31. Wehkalampi K, Widen E, Laine T, Palotie A, Dunkel L. Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. *J Clin Endocrinol Metab*. 2008;93(3):723–8.
 32. Gajdos ZK, Hirschhorn JN, Palmert MR. What controls the timing of puberty? An update on progress from genetic investigation. *Curr Opin Endocrinol Diabetes Obes*. 2009;16(1):16–24.
 33. Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at menarche: analyses from the breakthrough generations study. *Paediatr Perinat Epidemiol*. 2011;25(3):306–11.
 34. Tena-Sempere M. Kisspeptin/GPR54 system as potential target for endocrine disruption of reproductive development and function. *Int J Androl*. 2010;33(2):360–8.

35. Wray S. From nose to brain: development of gonadotrophin-releasing hormone-1 neurones. *J Neuroendocrinol*. 2010;22(7):743–53.
36. Cariboni A, Maggi R, Parnavelas JG. From nose to fertility: the long migratory journey of gonadotrophin-releasing hormone neurons. *Trends Neurosci*. 2007;30(12):638–44.
37. Herbison AE, Porteous R, Pape JR, Mora JM, Hurst PR. Gonadotropin-releasing hormone neuron requirements for puberty, ovulation, and fertility. *Endocrinology*. 2008;149(2):597–604.
38. Cariboni A, Rakic S, Liapi A, Maggi R, Goffinet A, Parnavelas JG. Reelin provides an inhibitory signal in the migration of gonadotropin-releasing hormone neurons. *Development*. 2005;132(21):4709–18.
39. Siler-Khodr TM, Khodr GS. Studies in human fetal endocrinology. I. Luteinizing hormone-releasing factor content of the hypothalamus. *Am J Obstet Gynecol*. 1978;130(7):795–800.
40. Waldhauser F, Weissenbacher G, Frisch H, Pollak A. Pulsatile secretion of gonadotropins in early infancy. *Eur J Pediatr*. 1981;137(1):71–4.
41. Beate K, Joseph N, de Nicolas R, Wolfram K. Genetics of isolated hypogonadotropic hypogonadism: role of GnRH receptor and other genes. *Int J Endocrinol*. 2012;2012:147893.
42. Dunkel L, Alfthan H, Stenman UH, Tapanainen P, Perheentupa J. Pulsatile secretion of LH and FSH in prepubertal and early pubertal boys revealed by ultrasensitive time-resolved immunofluorometric assays. *Pediatr Res*. 1990;27(3):215–9.
43. Albertsson-Wikland K, Rosberg S, Lannering B, Dunkel L, Selstam G, Norjavaara E. Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels: a semilongitudinal study throughout puberty in healthy boys. *J Clin Endocrinol Metab*. 1997;82(2):541–9.
44. Chemes HE, Gottlieb SE, Pasqualini T, Domenichini E, Rivarola MA, Bergada C. Response to acute hCG stimulation and steroidogenic potential of Leydig cell fibroblastic precursors in humans. *J Androl*. 1985;6(2):102–12.
45. Rey RA, Campo SM, Bedecarras P, Nagle CA, Chemes HE. Is infancy a quiescent period of testicular development? Histological, morphometric, and functional study of the seminiferous tubules of the cebus monkey from birth to the end of puberty. *J Clin Endocrinol Metab*. 1993;76(5):1325–31.
46. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. *J Clin Endocrinol Metab*. 2009;94(3):907–13.
47. Ankarberg-Lindgren C, Norjavaara E. Changes of diurnal rhythm and levels of total and free testosterone secretion from pre to late puberty in boys: testis size of 3 ml is a transition stage to puberty. *Eur J Endocrinol/Eur Fed Endocr Soc*. 2004;151(6):747–57.
48. Andersson AM, Juul A, Petersen JH, Muller J, Groome NP, Skakkebaek NE. Serum inhibin B in healthy pubertal and adolescent boys: relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone, and estradiol levels. *J Clin Endocrinol Metab*. 1997;82(12):3976–81.
49. Andersson AM, Toppari J, Haavisto AM, Petersen JH, Simell T, Simell O, et al. Longitudinal reproductive hormone profiles in infants: peak of inhibin B levels in infant boys exceeds levels in adult men. *J Clin Endocrinol Metab*. 1998;83(2):675–81.
50. Raivio T, Perheentupa A, McNeilly AS, Groome NP, Anttila R, Siimes MA, et al. Biphasic increase in serum inhibin B during puberty: a longitudinal study of healthy Finnish boys. *Pediatr Res*. 1998;44(4):552–6.
51. Byrd W, Bennett MJ, Carr BR, Dong Y, Wians F, Rainey W. Regulation of biologically active dimeric inhibin A and B from infancy to adulthood in the male. *J Clin Endocrinol Metab*. 1998;83(8):2849–54.
52. Bergada I, Rojas G, Ropelato G, Ayuso S, Bergada C, Campo S. Sexual dimorphism in circulating monomeric and dimeric inhibins in normal boys and girls from birth to puberty. *Clin Endocrinol*. 1999;51(4):455–60.
53. Ojeda SR, Lomniczi A, Mastronardi C, Heger S, Roth C, Parent AS, et al. Minireview: the neuroendocrine regulation of puberty: is the time ripe for a systems biology approach? *Endocrinology*. 2006;147(3):1166–74.
54. Ojeda SR, Prevot V, Heger S, Lomniczi A, Dziedzic B, Mungenast A. Glia-to-neuron signaling and the neuroendocrine control of female puberty. *Ann Med*. 2003;35(4):244–55.
55. Plant TM. Neuroendocrine control of the onset of puberty. *Front Neuroendocrinol*. 2015;38:73–88.
56. Goroll D, Arias P, Wuttke W. Preoptic release of amino acid neurotransmitters evaluated in peripubertal and young adult female rats by push-pull perfusion. *Neuroendocrinology*. 1993;58(1):11–5.
57. Terasawa E, Luchansky LL, Kasuya E, Nyberg CL. An increase in glutamate release follows a decrease in gamma aminobutyric acid and the pubertal increase in luteinizing hormone releasing hormone release in the female rhesus monkeys. *J Neuroendocrinol*. 1999;11(4):275–82.
58. Erecinska M, Silver IA. Metabolism and role of glutamate in mammalian brain. *Prog Neurobiol*. 1990;35(4):245–96.
59. Plant TM, Gay VL, Marshall GR, Arslan M. Puberty in monkeys is triggered by chemical stimulation of the hypothalamus. *Proc Natl Acad Sci USA*. 1989;86(7):2506–10.
60. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. *Proc Natl Acad Sci USA*. 2003;100(19):10972–6.

61. Seminara SB, Messenger S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. *N Engl J Med.* 2003;349(17):1614–27.
62. Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, Erdogan S, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. *N Engl J Med.* 2012;366(7):629–35.
63. Silveira LG, Noel SD, Silveira-Neto AP, Abreu AP, Brito VN, Santos MG, et al. Mutations of the KISS1 gene in disorders of puberty. *J Clin Endocrinol Metab.* 2010;95(5):2276–80.
64. Navarro VM, Fernandez-Fernandez R, Castellano JM, Roa J, Mayen A, Barreiro ML, et al. Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. *J Physiol.* 2004;561(Pt 2):379–86.
65. Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. *Nat Genet.* 2009;41(3):354–8.
66. Guran T, Tolhurst G, Bereket A, Rocha N, Porter K, Turan S, et al. Hypogonadotropic hypogonadism due to a novel missense mutation in the first extracellular loop of the neurokinin B receptor. *J Clin Endocrinol Metab.* 2009;94(10):3633–9.
67. Rance NE. Menopause and the human hypothalamus: evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. *Peptides.* 2009;30(1):111–22.
68. Sandoval-Guzman T, Rance NE. Central injection of senktide, an NK3 receptor agonist, or neuropeptide Y inhibits LH secretion and induces different patterns of Fos expression in the rat hypothalamus. *Brain Res.* 2004;1026(2):307–12.
69. Kung TT, Crawley Y, Jones H, Luo B, Gilchrest H, Greenfeder S, et al. Tachykinin NK3-receptor deficiency does not inhibit pulmonary eosinophilia in allergic mice. *Pharmacol Res Official J Ital Pharmacol Soc.* 2004;50(6):611–5.
70. Ramaswamy S, Seminara SB, Plant TM. Evidence from the agonadal juvenile male rhesus monkey (*Macaca mulatta*) for the view that the action of neurokinin B to trigger gonadotropin-releasing hormone release is upstream from the kisspeptin receptor. *Neuroendocrinology.* 2011;94(3):237–45.
71. Ducret E, Anderson GM, Herbison AE. RFamide-related peptide-3, a mammalian gonadotropin-inhibitory hormone ortholog, regulates gonadotropin-releasing hormone neuron firing in the mouse. *Endocrinology.* 2009;150(6):2799–804.
72. Ojeda SR, Lomniczi A, Sandau US. Glial-gonadotrophin hormone (GnRH) neurone interactions in the median eminence and the control of GnRH secretion. *J Neuroendocrinol.* 2008;20(6):732–42.
73. Gill JC, Tsai PS. Expression of a dominant negative FGF receptor in developing GNRH1 neurons disrupts axon outgrowth and targeting to the median eminence. *Biol Reprod.* 2006;74(3):463–72.
74. Voigt P, Ma YJ, Gonzalez D, Fahrenbach WH, Wetsel WC, Berg-von der Emde K, et al. Neural and glial-mediated effects of growth factors acting via tyrosine kinase receptors on luteinizing hormone-releasing hormone neurons. *Endocrinology.* 1996;137(6):2593–605.
75. Prevot V, Rio C, Cho GJ, Lomniczi A, Heger S, Neville CM, et al. Normal female sexual development requires neuregulin-erbB receptor signaling in hypothalamic astrocytes. *J Neurosci Official J Soc Neurosci.* 2003;23(1):230–9.
76. Garcia-Segura LM, Melcangi RC. Steroids and glial cell function. *Glia.* 2006;54(6):485–98.
77. Elias CF. Leptin action in pubertal development: recent advances and unanswered questions. *Trends Endocrinol Metab TEM.* 2012;23(1):9–15.
78. Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, Kuijper JL, et al. Leptin is a metabolic signal to the reproductive system. *Endocrinology.* 1996;137(7):3144–7.
79. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N Engl J Med.* 1999;341(12):879–84.
80. Zuure WA, Quennell JH, Anderson GM. Leptin responsive and GABAergic projections to the rostral preoptic area in mice. *Journal of Neuroendocrinol.* 2015.
81. Bellefontaine N, Chachlaki K, Parkash J, Vanacker C, Colledge W, d'Anglemon de Tassigny X, et al. Leptin-dependent neuronal NO signaling in the preoptic hypothalamus facilitates reproduction. *J Clin Investig.* 2014;124(6):2550–9.
82. Qiu X, Dao H, Wang M, Heston A, Garcia KM, Sangal A, et al. Insulin and leptin signaling interact in the mouse KISS1 neuron during the peripubertal period. *PLoS ONE.* 2015;10(5):e0121974.
83. Pralong FP. Insulin and NPY pathways and the control of GnRH function and puberty onset. *Mol Cell Endocrinol.* 2010;324(1–2):82–6.
84. Ahmed ML, Ong KK, Morrell DJ, Cox L, Drayer N, Perry L, et al. Longitudinal study of leptin concentrations during puberty: sex differences and relationship to changes in body composition. *J Clin Endocrinol Metab.* 1999;84(3):899–905.
85. Mann DR, Akinbami MA, Gould KG, Castracane VD. A longitudinal study of leptin during development in the male rhesus monkey: the effect of body composition and season on circulating leptin levels. *Biol Reprod.* 2000;62(2):285–91.
86. Plant TM, Durrant AR. Circulating leptin does not appear to provide a signal for triggering the initiation of puberty in the male rhesus monkey

- (Macaca mulatta). *Endocrinology*. 1997;138(10):4505–8.
87. Flier JS. Clinical review 94: What's in a name? In search of leptin's physiologic role. *J Clin Endocrinol Metab*. 1998;83(5):1407–13.
88. Cheung CC, Thornton JE, Nurani SD, Clifton DK, Steiner RA. A reassessment of leptin's role in triggering the onset of puberty in the rat and mouse. *Neuroendocrinology*. 2001;74(1):12–21.
89. El Majdoubi M, Sahu A, Ramaswamy S, Plant TM. Neuropeptide Y: a hypothalamic brake restraining the onset of puberty in primates. *Proc Natl Acad Sci USA*. 2000;97(11):6179–84.
90. Pomerants T, Tillmann V, Jurimae J, Jurimae T. Relationship between ghrelin and anthropometrical, body composition parameters and testosterone levels in boys at different stages of puberty. *J Endocrinol Invest*. 2006;29(11):962–7.
91. Persson I, Ahlsson F, Ewald U, Tuvemo T, Qingyuan M, von Rosen D, et al. Influence of perinatal factors on the onset of puberty in boys and girls: implications for interpretation of link with risk of long term diseases. *Am J Epidemiol*. 1999;150(7):747–55.
92. Adair LS. Size at birth predicts age at menarche. *Pediatrics*. 2001;107(4):E59.
93. Wehkalampi K, Hovi P, Dunkel L, Strang-Karlsson S, Jarvenpaa AL, Eriksson JG, et al. Advanced pubertal growth spurt in subjects born preterm: the Helsinki study of very low birth weight adults. *J Clin Endocrinol Metab*. 2011;96(2):525–33.
94. Dunger DB, Ahmed ML, Ong KK. Early and late weight gain and the timing of puberty. *Mol Cell Endocrinol*. 2006;254–255:140–5.
95. Ibanez L, Valls C, Ong K, Dunger DB, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. *J Clin Endocrinol Metab*. 2006;91(6):2068–73.
96. Ojeda SR, Dubay C, Lomniczi A, Kaidar G, Matagne V, Sandau US, et al. Gene networks and the neuroendocrine regulation of puberty. *Mol Cell Endocrinol*. 2010;324(1–2):3–11.
97. Ojeda SR, Hill J, Hill DF, Costa ME, Tapia V, Cornea A, et al. The Oct-2 POU domain gene in the neuroendocrine brain: a transcriptional regulator of mammalian puberty. *Endocrinology*. 1999;140(8):3774–89.
98. Lee BJ, Cho GJ, Norgren RB Jr, Junier MP, Hill DF, Tapia V, et al. TTF-1, a homeodomain gene required for diencephalic morphogenesis, is postnatally expressed in the neuroendocrine brain in a developmentally regulated and cell-specific fashion. *Mol Cell Neurosci*. 2001;17(1):107–26.
99. Heger S, Mastronardi C, Disen GA, Lomniczi A, Cabrera R, Roth CL, et al. Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis. *J Clin Invest*. 2007;117(8):2145–54.
100. Widen E, Silventoinen K, Sovio U, Ripatti S, Cousminer DL, Hartikainen AL, et al. Pubertal timing and growth influences cardiometabolic risk factors in adult males and females. *Diabetes Care*. 2012;35(4):850–6.
101. Ritte R, Lukanova A, Tjonneland A, Olsen A, Overvad K, Mesrine S, et al. Height, age at menarche and risk of hormone receptor positive and negative breast cancer: a cohort study. *Int J Cancer J Int du Cancer*. 2012.
102. He C, Zhang C, Hunter DJ, Hankinson SE, Buck Louis GM, Hediger ML, et al. Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies. *Am J Epidemiol*. 2010;171(3):334–44.
103. Kvale G, Heuch I, Nilssen S. Re: “Endometrial cancer and age at last delivery: evidence for an association”. *Am J Epidemiol*. 1992;135(4):453–5.
104. Purdie DM, Green AC. Epidemiology of endometrial cancer. *Best Pract Res Clin Obstet Gynaecol*. 2001;15(3):341–54.
105. Elks CE, Loos RJ, Sharp SJ, Langenberg C, Ring SM, Timpson NJ, et al. Genetic markers of adult obesity risk are associated with greater early infancy weight gain and growth. *PLoS Med*. 2010;7(5):e1000284.
106. Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, Khaw KT, et al. Early age at menarche associated with cardiovascular disease and mortality. *J Clin Endocrinol Metab*. 2009;94(12):4953–60.
107. Prentice P, Viner RM. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis. *Int J Obes*. 2013;37(8):1036–43.
108. Ong KK, Northstone K, Wells JC, Rubin C, Ness AR, Golding J, et al. Earlier mother's age at menarche predicts rapid infancy growth and childhood obesity. *PLoS Med*. 2007;4(4):e132.
109. Albanese A, Stanhope R. Does constitutional delayed puberty cause segmental disproportion and short stature? *Eur J Pediatr*. 1993;152(4):293–6.
110. Bierich JR, Nolte K, Drews K, Brugmann G. Constitutional delay of growth and adolescence. Results of short-term and long-term treatment with GH. *Acta Endocrinol*. 1992;127(5):392–6.
111. Crowne EC, Shalet SM, Wallace WH, Eminson DM, Price DA. Final height in girls with untreated constitutional delay in growth and puberty. *Eur J Pediatr*. 1991;150(10):708–12.
112. Crowne EC, Shalet SM, Wallace WH, Eminson DM, Price DA. Final height in boys with untreated constitutional delay in growth and puberty. *Arch Dis Child*. 1990;65(10):1109–12.
113. Moreira-Andres MN, Canizo FJ, de la Cruz FJ, Gomez-de la Camara A, Hawkins FG. Bone mineral status in prepubertal children with constitutional delay of growth and puberty. *Eur J Endocrinol/Eur Fed Endocr Soc*. 1998;139(3):271–5.

114. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. *N Engl J Med.* 1992;326(9):600–4.
115. Crowne EC, Shalet SM. Management of constitutional delay in growth and puberty. *Trends Endocrinol Metab TEM.* 1990;1(5):239–42.
116. Kaltiala-Heino R, Kosunen E, Rimpela M. Pubertal timing, sexual behaviour and self-reported depression in middle adolescence. *J Adolesc.* 2003;26(5):531–45.
117. Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. *J Clin Endocrinol Metab.* 2002;87(4):1613–20.
118. Sedlmeyer IL. pedigree analysis of constitutional delay of growth and maturation: determination of familial aggregation and inheritance patterns. *J Clin Endocrinol Metab.* 2002;87(12):5581–6.
119. Lawaetz JG, Hagen CP, Mieritz MG, Blomberg Jensen M, Petersen JH, Juul A. Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. *J Clin Endocrinol Metab.* 2015;100(4):1376–85.
120. LaFranchi S, Hanna CE, Mandel SH. Constitutional delay of growth: expected versus final adult height. *Pediatrics.* 1991;87(1):82–7.
121. Albanese A, Stanhope R. Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. *J Pediatr.* 1995;126(4):545–50.
122. Wehkalampi K, Vangonen K, Laine T, Dunkel L. Progressive reduction of relative height in childhood predicts adult stature below target height in boys with constitutional delay of growth and puberty. *Horm Res.* 2007;68(2):99–104.
123. Rensonnet C, Kanen F, Coremans C, Ernould C, Albert A, Bourguignon JP. Pubertal growth as a determinant of adult height in boys with constitutional delay of growth and puberty. *Horm Res.* 1999;51(5):223–9.
124. Volta C, Ghizzoni L, Buono T, Ferrari F, Virdis R, Bernasconi S. Final height in a group of untreated children with constitutional growth delay. *Helv Paediatr Acta.* 1988;43(3):171–6.
125. Bramswig JH, Fasse M, Holthoff ML, von Lengerke HJ, von Petrykowski W, Schellong G. Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: accuracy of five different methods of height prediction. *J Pediatr.* 1990;117(6):886–91.
126. Arrigo T, Cisternino M, De Luca F, Saggese G, Messina MF, Pasquino AM, et al. Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. *J Pediatr Endocrinol Metab JPEM.* 1996;9(5):511–7.
127. Sperlich M, Butenandt O, Schwarz HP. Final height and predicted height in boys with untreated constitutional growth delay. *Eur J Pediatr.* 1995;154(8):627–32.
128. Cools BL, Rooman R, Op De Beeck L, Du Caju MV. Boys with a simple delayed puberty reach their target height. *Horm Res.* 2008;70(4):209–14.
129. Pozo J, Argente J. Delayed puberty in chronic illness. *Best Pract Res Clin Endocrinol Metab.* 2002;16(1):73–90.
130. Watson HJ, Bulik CM. Update on the treatment of anorexia nervosa: review of clinical trials, practice guidelines and emerging interventions. *Psychol Med.* 2013;43(12):2477–500.
131. Kujala UM, Alen M, Huhtaniemi IT. Gonadotrophin-releasing hormone and human chorionic gonadotrophin tests reveal that both hypothalamic and testicular endocrine functions are suppressed during acute prolonged physical exercise. *Clin Endocrinol.* 1990;33(2):219–25.
132. Roberts AC, McClure RD, Weiner RI, Brooks GA. Overtraining affects male reproductive status. *Fertil Steril.* 1993;60(4):686–92.
133. Parra Covarrubias A, Ramos Galvan R. The influence of psychosocial deprivation and body composition on plasma gonadotrophins in children and adolescents. *Gac Med Mex.* 1992;128(1):7–13.
134. Silveira LF, Latronico AC. Approach to the patient with hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2013;98(5):1781–8.
135. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, et al. Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med.* 2007;357(9):863–73.
136. Silveira LF, Trarbach EB, Latronico AC. Genetics basis for GnRH-dependent pubertal disorders in humans. *Mol Cell Endocrinol.* 2010;324(1–2):30–8.
137. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. *Endocr Rev.* 2000;21(5):551–83.
138. Layman LC, Lee EJ, Peak DB, Namnoum AB, Vu KV, van Lingen BL, et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. *N Engl J Med.* 1997;337(9):607–11.
139. Savage MO, Beattie RM, Camacho-Hubner C, Walker-Smith JA, Sanderson IR. Growth in Crohn's disease. *Acta Paediatr Suppl.* 1999;88(428):89–92.
140. Opstad PK. Androgenic hormones during prolonged physical stress, sleep, and energy deficiency. *J Clin Endocrinol Metab.* 1992;74(5):1176–83.
141. Dunkel L, Perheentupa J, Virtanen M, Maenpää J. GnRH and HCG tests are both necessary in differential diagnosis of male delayed puberty. *Am J Dis Child.* 1985;139(5):494–8.
142. Dunkel L, Huhtaniemi I. Abnormal prolactin secretion in prepubertal boys with hypogonadotropic hypogonadism—possible involvement in regulation of testicular steroidogenesis. *Int J Androl.* 1985;8(5):385–92.

143. Winters SJ, Johnsonbaugh RE, Sherins RJ. The response of prolactin to chlorpromazine stimulation in men with hypogonadotropic hypogonadism and early pubertal boys: relationship to sex steroid exposure. *Clin Endocrinol.* 1982;16(4):321–30.
144. Zevenhuijzen H, Kelnar CJ, Crofton PM. Diagnostic utility of a low-dose gonadotropin-releasing hormone test in the context of puberty disorders. *Horm Res.* 2004;62(4):168–76.
145. Dunkel L, Perheentupa J, Virtanen M, Maenpaa J. Gonadotropin-releasing hormone test and human chorionic gonadotropin test in the diagnosis of gonadotropin deficiency in prepubertal boys. *J Pediatr.* 1985;107(3):388–92.
146. Segal TY, Mehta A, Anazodo A, Hindmarsh PC, Dattani MT. Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. *J Clin Endocrinol Metab.* 2009;94(3):780–5.
147. Degros V, Cortet-Rudelli C, Soudan B, Dewailly D. The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty. *Eur J Endocrinol/Eur Fed Endocr Soc.* 2003;149(1):23–9.
148. Martin MM, Martin AL. Constitutional delayed puberty in males and hypogonadotropic hypogonadism: a reliable and cost-effective approach to differential diagnosis. *J Pediatr Endocrinol Metab JPEM.* 2005;18(9):909–16.
149. Demir A, Voutilainen R, Juul A, Dunkel L, Alfthan H, Skakkebaek NE, et al. Increase in first morning voided urinary luteinizing hormone levels precedes the physical onset of puberty. *J Clin Endocrinol Metab.* 1996;81(8):2963–7.
150. Coutant R, Biette-Demeneix E, Bouvattier C, Bouhours-Nouet N, Gatelais F, Dufresne S, et al. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. *J Clin Endocrinol Metab.* 2010;95(12):5225–32.
151. Semple RK, Topaloglu AK. The recent genetics of hypogonadotropic hypogonadism - novel insights and new questions. *Clin Endocrinol.* 2010;72(4):427–35.
152. Poyrazoglu S, Gunoz H, Darendeliler F, Saka N, Bundak R, Bas F. Constitutional delay of growth and puberty: from presentation to final height. *J Pediatr Endocrinol Metab JPEM.* 2005;18(2):171–9.
153. Rosenfeld RG, Northcraft GB, Hintz RL. A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. *Pediatrics.* 1982;69(6):681–7.
154. Soliman AT, Khadir MM, Asfour M. Testosterone treatment in adolescent boys with constitutional delay of growth and development. *Metab Clin Exp.* 1995;44(8):1013–5.
155. Kelly BP, Paterson WF, Donaldson MD. Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months. *Clin Endocrinol.* 2003;58(3):267–72.
156. Wilson DM, Kei J, Hintz RL, Rosenfeld RG. Effects of testosterone therapy for pubertal delay. *Am J Dis Child.* 1988;142(1):96–9.
157. De Luca F, Argente J, Cavallo L, Crowne E, Delemarre-Van de Waal HA, De Sanctis C, et al. Management of puberty in constitutional delay of growth and puberty. *J Pediatr Endocrinol Metab JPEM.* 2001;14 Suppl 2:953–7.
158. Rogol AD, Swerdloff RS, Reiter EO, Ross JL, ZumBrunnen TL, Pratt GA, et al. A multicenter, open-label, observational study of testosterone gel (1%) in the treatment of adolescent boys with klinefelter syndrome or anorchia. *J Adolesc Health.* 2014;54(1):20–5.
159. Johansen KL. Treatment of hypogonadism in men with chronic kidney disease. *Adv Chronic Kidney Dis.* 2004;11(4):348–56.
160. Jeong HR, Shim YS, Lee HS, Hwang JS. The effect of growth hormone treatment on height in children with idiopathic short stature. *J Pediatr Endocrinol Metab JPEM.* 2014.
161. Bryant J, Baxter L, Cave CB, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. *Cochrane Database Syst Rev.* 2007(3):CD004440.
162. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. *J Clin Endocrinol Metab.* 2005;90(12):6396–402.
163. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. *Lancet.* 2001;357(9270):1743–8.
164. de Ronde W. Therapeutic uses of aromatase inhibitors in men. *Curr Opin Endocrinol Diabetes Obes.* 2007;14(3):235–40.
165. Hero M, Toivainen-Salo S, Wickman S, Makitie O, Dunkel L. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. *J Bone Miner Res.* 2010;25(7):1536–43.
166. Gilsanz V, Chalfant J, Kalkwarf H, Zemel B, Lappe J, Oberfield S, et al. Age at onset of puberty predicts bone mass in young adulthood. *J Pediatr.* 2011;158(1):100–5, 5 e1–2.
167. van Buuren S. Growth charts of human development. *Stat Methods Med Res.* 2013;23(4):346–68.

Congenital Hypogonadotropic Hypogonadism in Males: Clinical Features and Pathophysiology

5

Ravikumar Balasubramanian MBBS, PhD, MRCP (UK)
and William F. Crowley Jr. MD

Contents

Normal Sexual Development in the Human Male....	95
Ontogeny of GnRH Secretion	95
Normal Gonadal Development in the Male.....	97
Idiopathic or Congenital Hypogonadotropic Hypogonadism	98
Idiopathic Hypogonadotropic Hypogonadism (CHH)	99
Variant Forms of CHH.....	101
Pathophysiology of Congenital CHH.....	102
Genetics of Congenital KS and NCHH.....	104
Complex Syndromic Forms of CHH	114
Functional Cause of HH.....	115
Evaluation of Congenital HH (See also Chap. 4)	116
References.....	117

Normal Sexual Development in the Human Male

Ontogeny of GnRH Secretion

Gonadotropin-releasing hormone (GnRH) is one of the key master regulators of sexual development and reproductive function in humans. This hypothalamic peptide is secreted by a unique network of hypothalamic neurons in a pulsatile pattern

that is critical for its “downstream” biological effects. GnRH-induced pituitary gonadotropin secretion in the human changes dynamically across the development starting in utero, through infancy, puberty, and adulthood (Fig. 5.1). Therefore, understanding the developmental ontogeny of GnRH secretion is essential for assessing normal physiology of sexual maturation as well as pathologic disorders of this process like congenital hypogonadotropic hypogonadism (CHH).

GnRH neurons originate outside the central nervous system (CNS), primarily from the neuro-ectodermally derived embryonic olfactory placode within a smaller subset of these pioneer cells that have recently been shown in murine studies to be of neural crest origin [1]. These developing GnRH neurons then migrate along the olfactory sensory axonal tracts as they enter the forebrain through the cribriform plate and eventually reach their final destination in the medial pre-optic area of the hypothalamus.

GnRH neurons have been observed to be in place within the human hypothalamus by the ninth week of gestation, and secreted gonadotropins can be detected in the fetal circulation by 12–14 weeks of gestation [2]. In the neonatal period, the hypothalamo–pituitary–gonadal (HPG) axis is fully active when its pulsatile pattern of GnRH secretion initiates an initial rise in gonadotropin secretion that in turn initiates the first wave of systemic secretion of hormones from the gonads of fetuses of both sexes [3]. In male infants, this

R. Balasubramanian · W.F. Crowley Jr. (✉)
Medicine, Reproductive Endocrine Unit, Harvard
Medical School, Massachusetts General Hospital,
55 Fruit Street, Boston, MA 02114, USA
e-mail: WCROWLEY@mgh.harvard.edu

R. Balasubramanian
e-mail: RBALASUBRAMANIAN@mgh.harvard.edu




Fig. 5.1 Schematic presentation of the activity of the hypothalamic-pituitary-gonadal axis across the life cycle. During the neonatal window, pulsatile GnRH stimulates LH and FSH secretion which induce adult levels of testosterone and inhibin B. Childhood is marked by a low-amplitude LH secretion and very low T levels. Pubertal reactivation of the HPG axis triggers the onset of sexual maturation, initially in a sleep-entrained pattern

initial wave of HPG axis activity, termed the mini-puberty of infancy, declines by 6 months [3].

This initial neonatal HPG activity in male infants serves two key physiological functions: rapid proliferation of the Sertoli cells [4] and increase in germ cell number [5], both of which ultimately determine future successful spermatogenesis. If in-utero/neonatal activation of the HPG axis is defective, male infants may present with

micropenis and cryptorchidism as seen in patients with CHH (see below). Following this early HPG axis activity in both sexes, the secretory activity of the HPG axis is dampened during most of childhood. However, the HPG axis is not completely quiescent since the pulsatile gonadotropin release, albeit at extremely low-amplitude pulses, has been shown to occur in prepubertal boys using ultrasensitive LH assays [6].

The onset of puberty is subsequently marked by a gradual “reawakening” of the dormant GnRH pulse generator, initially in a sleep-entrained manner, with a striking increase in the amplitude of LH pulses and less change in pulse frequency, resulting in stimulation of the gonads [7, 8]. As puberty progresses, GnRH-induced gonadotropin pulses occur during both the day and night, eventually concatenating in the development of secondary sexual characteristics and the changes in body composition characteristic of puberty. In adult males, GnRH-induced gonadotropin secretion averages one pulse approximately every 2 h (Fig. 5.2), but there is considerable variability among men in both the





Fig. 5.2 Frequent blood sampling (every 10 min for 24 h) for LH in a normal adult male and a man with CHH. **a** Normal adult male pattern of GnRH secretion with high-amplitude LH pulsations (10 pulses in 24 h), normal

serum T level, and normal testicular volume; **b** Apulsatile pattern of GnRH secretion in a CHH male as assessed by a complete absence of endogenous LH pulsations, low serum T levels, and prepubertal-sized testis

Fig. 5.3 Frequent blood sampling (q 10 min for 24 h) of serum T and LH in a normal adult man revealing a nadir T level of 91 ng/dl (to convert to nmol/L, multiply by 0.03467) after a long interpulse interval of LH secretion. Adapted from Spratt et al. [9]



frequency and amplitude of LH pulses as well as in the ensuing T levels. Indeed, 15% of normal men exhibit long interpulse intervals between LH secretory pulses, resulting in a transient decrease in serum testosterone (T) levels to as low as 3.5 nmol/L (Fig. 5.3) [9].

Normal Gonadal Development in the Male

The gonadal sex, i.e., initial development of the fetal testes from undifferentiated gonad, is initiated by the expression of the *SRY* (sex-determining region Y) gene. Fetal testicular Leydig cells, stimulated by placental hCG, produce T that induces the growth, stabilization, and differentiation of the gonadal Wolffian structures (epididymis, vas deferens, and seminal vesicles). The 5α -reductase enzyme converts T to the more potent androgen, 5α -dihydrotestosterone, which induces the formation of the prostate and the external male genitalia. Secretion of anti-Müllerian hormone (AMH) from fetal testicular Sertoli cells causes regression of the Müllerian structures. During the later stages of gestation and in the “neonatal window of mini-puberty,” GnRH-induced LH secretion drives T and insulin-like factor 3 (INSL3) secretion by the Leydig cells

(T levels reaching adult levels in the neonate), directs the completion of the inguino-scrotal phase of testicular descent, and induces further growth of the phallus [10]. This first wave of postnatal Sertoli cell proliferation in response to GnRH-induced FSH secretion results in increases in Sertoli cell number during infancy [11], and this developmental phase is critical for setting the stage for future spermatogenic success in adulthood. Prior to the onset of puberty, there is a gradual threefold increase in testis size as evidenced by postmortem studies in childhood trauma victims [12]. This increase is caused by a lengthening of the seminiferous tubules, due mainly to intense proliferation of Sertoli cells and, to a lesser degree, of immature germ cells [11, 12].

A second phase of Sertoli cell proliferation occurs early in puberty with further increase in number after which gonadal cellular proliferation ceases, Sertoli cells mature and the blood–testis barrier is established, the seminiferous tubular lumen forms, and spermatogenesis is initiated [13, 14]. Both the neonatal and pubertal Sertoli cell maturation phases are marked by discrete developmental windows of neuroendocrine activity [15]. Ultimately, this final complement of mature Sertoli cells is the major determinant of testes size, seminiferous tubular development, and sperm count, as each Sertoli cell can only

support a finite number of germ cells [16–18]. Thereafter, a dramatic increase in meiotic germ cells promotes the most significant increase in testis size that occurs during puberty. Finally, the improvement of spermatogenic efficiency leads to complete maturation of the seminiferous tubules. While intratesticular T plays a central role in stimulating spermatogenesis both directly and in concert with FSH (see Chap. 3), the subsequent increase in systemic T levels induces the secondary sexual characteristics of the adult male. The specific role of FSH in adult males is not yet well established. However, based on the phenotype of the males with mutations in either the FSH β or FSH receptor (see Chap. 6), it appears that FSH is necessary to maintain both qualitative and quantitative normal spermatogenesis.

Idiopathic or Congenital Hypogonadotropic Hypogonadism

HH (i.e., secondary hypogonadotropic hypogonadism) is differentiated from primary testicular disease (i.e., primary hypergonadotropic hypogonadism) by the demonstration of low/inappropriately normal gonadotropin levels in the setting of low sex steroid levels and impaired spermatogenesis. Congenital abnormalities that lead to HH are rare but are well described and result from either hypothalamic GnRH deficiency or pituitary disorders that affect the gonadotropes.

Differential Diagnosis of Congenital Hypogonadotropic Hypogonadism

Hypothalamic Causes

Idiopathic Hypogonadotropic Hypogonadism (IHH)

- Anosmic form: Kallmann syndrome
- Non-anosmic form: Normosmic IHH (nIHH)
- Variant forms of IHH:
 - Fertile eunuch syndrome
 - Reversible form
 - Adult-onset HH

Complex syndromic forms of IHH

Adrenal hypoplasia congenita and IHH
 Morbid obesity syndromes: Prader–Willi syndrome; leptin pathway mutations
 CHARGE syndrome
 TUBB3 E410 K syndrome
 Waardenburg syndrome
 Gordon-Holmes syndrome
 Boucher-Neuhauser syndrome
 Bardet-Biedl syndrome

Pituitary Causes (see also Chap. 8):

HH associated with other pituitary hormone deficiencies
 Genetic defects of the gonadotropin subunits and pituitary transcription factors

Congenital HH (CHH), also referred in the literature as idiopathic hypogonadotropic hypogonadism, results from genetic mutations that lead to abnormalities in GnRH development, secretion, and/or action. CHH presents in two major phenotypic forms: (i) Kallmann syndrome [KS], a syndromic form characterized by GnRH deficiency accompanied by an absence of olfaction (anosmia) with or without other non-reproductive features such as midline defects, skeletal abnormalities, and other somatic features; and (ii) normosmic CHH, characterized by GnRH deficiency with normal sense of smell [19, 20]. Until the discovery of GnRH, CHH was thought to be secondary to pituitary gonadotropin deficiency. However, when GnRH became available, increases in the serum levels of LH and FSH following administration of a single bolus of GnRH in these subjects suggested a hypothalamic defect [21–23] which was subsequently unequivocally confirmed when administration of exogenous GnRH to these patients in a pulsatile fashion completely restored a physiologic pattern and levels of gonadotropins and sex steroids [24, 25].

CHH can also be a component of complex, severe syndromes with multiple somatic abnormalities in which the reproductive phenotype is

but a component of a larger spectrum of phenotypes (see Complex Syndromic Forms of CHH section below). GnRH deficiency may also result from functional causes (e.g., critical illness, excessive exercise, nutritional deprivation, and drugs—especially opiates) (see Functional Cause of HH section below). CHH resulting from impaired production of pituitary gonadotropins with or without other pituitary hormone deficiencies includes genetic mutations in genes encoding LH β (*LHB*) or FSH β (*FSHB*) subunits (see Chap. 6). In addition, mutations in pituitary transcription factors such as *POU1F1*, *GLI2*, *FGF8*, *PROPI*, *LHX3*, *LHX4*, *HESX1*, *SOX3*, *OTX2*, *TBX19*, *TCF7L1* and *SOX2* and structural lesions/tumors involving sellar/pituitary anatomy can also present with hypogonadotropism as part of their complex syndromes. Pituitary disorders causing hypogonadism are discussed in Chap. 8.

Idiopathic Hypogonadotropic Hypogonadism (CHH)

Definition and Incidence

CHH is characterized by an isolated defect in the secretion or function of GnRH. Typically, CHH is diagnosed in adolescence due to a failure of puberty, although rarely it may be possible to diagnose this condition in the male neonates (see below). Diagnostic criteria for CHH in males include (i) absence or failure of completion of puberty by age 18 years, (ii) decreased T levels in the hypogonadal range (e.g., <3.5 nmol/L; 100 ng/dL), (iii) low/normal gonadotropin levels representing absent or reduced GnRH-induced gonadotropin secretion, (iv) otherwise normal hormonal testing of the anterior pituitary, (v) a normal ferritin level to eliminate hemochromatosis, and (vi) normal radiographic imaging of the hypothalamic-pituitary region.

Two distinct clinical forms of CHH have been recognized historically. Franz Kallmann reported a familial form of this condition in 1944, in which CHH was seen in males who also had congenital anosmia, and this simple syndromic form has

since been referred to as Kallmann syndrome (KS) [26]. However, it was subsequently recognized that some patients with CHH presented with a normal sense of smell, and these patients are termed as normosmic CHH (nCHH). The KS form of CHH accounts for nearly 60% of patients while the remaining 40% present with nCHH [27, 28]. Since CHH is a rare clinical condition, definitive data on its prevalence are limited. However, a recent population-based epidemiological study from Finland showed a minimal prevalence estimate of the KS to be 1:48,000 with a clear difference between males (1:30,000) and females (1:125,000) [29]. The prevalence of the normosmic form is likely to be similar with a similar M:F ratio, but epidemiological data will be required to confirm this assertion.

Clinical Features

While the dichotomous classification of CHH into KS and nCHH based upon the presence or absence of sense of smell is frequently used in the literature, a substantial clinical phenotypic overlap is seen between these two forms [30]. Moreover, different family members within a single sibship may manifest either KS, nCHH, or isolated anosmia without reproductive failure [31]. Therefore, stratifying patients according to reproductive phenotypes that relate to the timing of onset of HH and the severity of HH provides greater insight into the clinical spectrum of CHH [30]. Similarly, the presence of specific non-reproductive phenotypes often provides developmental insights into the various organ systems affected by specific genetic forms of CHH [32].

Reproductive Features of CHH Relating to Timing of Onset of GnRH Deficiency and Severity of GnRH Deficiency

- Neonatal Period

As mentioned above, the diagnosis of CHH is typically delayed until adolescence. However, severe GnRH deficiency disrupting the normal neonatal period of HPG activity (i.e.,

mini-puberty) may provide early diagnostic clues for the diagnosis of CHH in newborn male infants. The presence of cryptorchidism and/or micropenis (also referred to as microphallus) in a male infant may indicate CHH, although GnRH deficiency may still be present even if these two phenotypic features are absent. Typically, gonadotropin, sex steroid, and inhibin B levels are inappropriately low in such infants reflecting their inability to normally activate the HPG axis during the neonatal window [33]. Notably, these neonates have otherwise normal sexual differentiation without any urogenital sinus malformations such as hypospadias since early fetal testicular T production from fetal Leydig cells (see Chap. 2) and testicular fetal AMH production are normal [34]. However, cryptorchidism and micropenis in CHH patients indicate that during the late fetal/early neonatal period, endogenous secretion of GnRH is necessary for inguino-scrotal descent of the testes and full growth of the external genitalia [10].

- Adolescence


In the absence of the hallmark neonatal reproductive features of micropenis and/or cryptorchidism, a definitive clinical diagnosis of CHH can only be made when isolated gonadotropin deficiency is manifested at the time of adolescence when boys present with delayed puberty. The clinical hallmark of CHH is the failure of onset of puberty. However, it is important to recall that CHH is rare, and that most adolescents with pubertal delay will represent those with constitutional delay of growth and puberty [CDGP] in whom spontaneous endogenous GnRH activity eventually ensues and puberty is subsequently initiated and completed (see delayed puberty section below and Chap. 4). While distinct from CHH, CDGP is frequently reported among the family members of CHH patients [31]. In our series of 106 patients with CHH, 12% had relatives with a history of delayed puberty [3] versus 1% in the general population [35]. These observations

suggest that delayed puberty may represent the mildest end of the phenotypic spectrum of CHH. In keeping with this notion, recent studies have also reported a shared genetic basis between the two conditions [36].

Considerable clinical heterogeneity is observed in CHH patients at the time of presentation. The vast majority (~75%) of CHH patients are severely testosterone deficient and fail to develop any signs of puberty (Fig. 5.4). Their clinical features include no signs of virilization, (lack of any secondary sex characteristics), absence of an adolescent growth spurt but with delayed epiphyseal fusion resulting in eunuchoidal body proportions (upper/lower body ratio <1; with an arm span exceeding standing height by >6cm) [37], a high-pitched voice, slight anemia, delayed bone age, and prepubertal-sized testes (<4 mL). A large proportion of these severe GnRH-deficient subjects also report a history of cryptorchidism (40%) or microphallus (20%), providing evidence for the lack of activity of the HPG axis during the late fetal/neonatal window [38]. It is, however, important to recognize that the prevalence of microphallus among these severely affected CHH men with no prior puberty might be underestimated given the reported successful induction of phallus growth with androgen therapy during childhood [39].

The remainder of CHH subjects (~25%) present with signs of partial puberty, displaying some degree of spontaneous puberty as assessed by at least two of these criteria: (i) some testicular growth, (ii) a growth spurt, (iii) an increase in the number of erections, and (iv) the initiation of shaving. However, these subjects, in contrast to boys with CDGP, fail to complete sexual maturation and remain hypogonadal. Low libido, lack of erectile function, low energy, and poor muscle bulk are the common somatic symptoms reported by CHH men. Gynecomastia is seen in 20–30% of CHH men and is often related to prior therapy with gonadotropins [30]. The key clinical features are depicted in Fig. 5.4.

Fig. 5.4 Typical presentation of a CHH man with the most severe phenotype, including absence of puberty, eunuchoidal proportions, prepubertal testis, microphallus, and cryptorchidism



Congenital IHH: Typical presentation

History

- Good general health
- Absence of puberty
- Decreased/absent sense of smell

Physical Exam

- Arm span > height
- minimal axillary and pubic hair
- small testis
- Microphallus
- Cryptorchidism

Non-reproductive Features of CHH

Many CHH subjects, especially those with KS, may also exhibit a spectrum of non-reproductive features which may indicate a more complex syndromic genetic etiology (see below). One of the common non-reproductive phenotypes commonly encountered in KS subjects is bimanual synkinesia (also called “mirror movements”) [28, 40]. Bimanual synkinesia is detected when voluntary movements of one hand are associated with similar involuntary movements of the opposite hand. Abnormal fast-conducting ipsilateral corticospinal tract projections are reported in these patients and are hypothesized to underlie the observed mirror movements [41, 42]. Defects in spatial perception have also been found in KS patients with synkinesia [43]. KS patients may also display unilateral renal agenesis [28, 44] and midline craniofacial and palate abnormalities [45]. Other common non-reproductive features include short metacarpals (short fingers, especially the fourth finger) [46], split hand/foot malformation [46], dental agenesis [47], congenital sensorineural hearing loss [32, 48], skin pigmentation anomalies [48], eye movement abnormalities [49], and rarely, cardiovascular defects [50, 51].

Variant Forms of CHH

Fertile Eunuch Syndrome

The first report of a man with the fertile eunuch variant of CHH was in 1950 by McCullagh [52]. These subjects display eunuchoidal proportions and are undervirilized but have normal gonadal size and preserved spermatogenesis. In this disorder, endogenous GnRH secretion, although decreased and insufficient to stimulate full virilization, appears adequate to produce sufficient intra-gonadal T levels to support spermatogenesis and testicular growth. Indeed, these patients can be fertile either spontaneously or with T or hCG therapy without the addition of FSH [53, 54]. The clinical picture of the fertile eunuch thus resembles that of normal mid-pubertal boys; indeed, a nocturnal rise of LH and T secretion synchronous with sleep, as seen normally in mid-puberty, was demonstrated in two men with the fertile eunuch syndrome [54]. These cases may have resulted from defects in GnRH regulation. In contrast, a patient with the fertile eunuch variant has also been described who had detectable, but apulsatile LH secretion associated with a partially inactivating mutation of the GnRH receptor (GnRH-R)

[55]. These data underscore the clinical, genetic, and pathophysiological heterogeneity that exists in this syndrome.

Adult-Onset Hypogonadotropic Hypogonadism

A more delayed adult-onset presentation of nCHH, termed adult-onset hypogonadotropic hypogonadism, has been recognized in men with otherwise completely normal sexual development at puberty but in whom secretion of GnRH subsequently ceased during adulthood [56]. The robust responsiveness of these adult-onset subjects to exogenous GnRH administration demonstrates the hypothalamic nature of their defect. With long-term follow-up, these men fail to recover suggesting that they have a permanent defect in GnRH secretion [57].

Reversal of CHH

Although congenital CHH has been thought to be a lifelong condition, spontaneous recovery of endogenous GnRH secretion, as heralded by spontaneous testicular growth and normalization of sex steroid levels off therapy, has been demonstrated to occur in 10–15% of CHH men [58]. This reversal phenotype was seen following the therapy with a variety of treatments that effectively normalize sex steroid levels, suggesting that this prior exposure to sex steroid hormones is a key element to the milieu in which these “reversals” occur. The precise mechanisms behind this reversal process remain unknown. This phenomenon of “reversal of CHH,” even in those with severe GnRH deficiency such as KS subjects with absent olfactory structures, strongly suggests a hitherto underappreciated plasticity of the GnRH neuronal network that can override developmental and neuroendocrine genetic defects that resulted in the initial hypogonadotropic state at the time of puberty.

In one recent single-center study, nearly 45% of reversal subjects had demonstrable CHH-related gene mutations but a significant enrichment was seen for mutations that disrupt neurokinin B signaling suggesting that the neurokinin

B pathway, although critical for puberty, may be dispensable later in life [59]. Based on other reports from the literature, mutation in the GnRH receptor (*GNRHR*) also seems to be overrepresented in reversal subjects. More recent longitudinal review of these reversal subjects has also revealed a fragility of this reversal phenomenon as some patients slip back into a hypogonadotropic state requiring the resumption of therapy. Hence, it is important for clinicians to periodically reassess CHH subjects for evidence of reversal but also to assess the persistence of this reversal state and reintroduce therapy if required.

Pathophysiology of Congenital CHH

Biochemical Studies

Despite variation in the clinical phenotype of CHH men, their biochemical findings are very similar. By definition, all patients have T levels in the hypogonadal range. Gonadotropins are low/normal in all subjects, which in the setting of low T levels indicates hypogonadotropic hypogonadism (Fig. 5.5). Interestingly, mean LH and FSH levels are significantly higher in those patients with some degree of spontaneous puberty (as reflected by larger testicular sizes, for example) as compared with those men with no prior puberty [30].




Fig. 5.5 Schematic of the hypothalamic–pituitary–gonadal axis in a normal adult male and in congenital hypogonadotropic hypogonadism

Serum levels of the Sertoli cell products, inhibin B and AMH, provide additional gonadal markers of the onset and extent of GnRH deficiency. In the normal ontogeny of inhibin B secretion, levels rise during the neonatal activation of the HPG axis [60] and then decline, but remain readily measurable throughout childhood despite low levels of FSH. During the early stages of puberty, inhibin B levels increase, plateau at stage II of puberty, and remain constant unless spermatogenesis is disrupted [61]. In contrast to normal men, CHH men with absent pubertal development display low/undetectable inhibin B levels [62] which are well below those of normal children [61]. Therefore, prior gonadotropin exposure appears to be required for normal inhibin B production during childhood. Thus, inhibin B levels represent a marker of reproductive axis activity during the fetal/neonatal period among patients with no sexual maturation. In CHH men with partial puberty, baseline inhibin B levels reach the normal range despite low gonadotropins, presumably reflecting adequate Sertoli cell proliferation during the neonatal window and early puberty. AMH, the first detectable secretory product of fetal Sertoli cells [63], is another biochemical marker of pubertal onset [64, 65]. Indeed, AMH levels are high throughout fetal and postnatal life and decline thereafter with the onset of spermatogenesis and the activation of LH-Leydig cell function [65]. Accordingly, AMH levels are high among CHH men with no pubertal development and are lower in those with partial GnRH deficiency [30]. Leydig cells also secrete INSL3 during the fetal and immediate postnatal periods, and INSL3 secretion ceases in childhood until puberty, peaking during adulthood [66]. Similar to inhibin B, baseline INSL3 levels are low in male CHH subjects and increase under gonadotropin stimulation [67]. It remains to be seen whether INSL3 levels and/or other physiological stimulation tests (e.g., kisspeptin stimulation) are able to distinguish adolescent subjects with CDGP from those who may progress to CHH.

Patterns of GnRH Secretion in CHH Subjects

Due to low circulating levels and a short half-life (2–4 min), GnRH in the peripheral circulation cannot be measured, and levels do not accurately reflect GnRH secretion [68]. Consequently, the study of GnRH secretion is limited to inferential approaches. Traditionally, LH is the most commonly used surrogate marker of the GnRH pulse generator [69, 70]. A spectrum of abnormalities in the neuroendocrine pattern of GnRH secretion is observed among CHH men. In the MGH's retrospective study of 78 CHH men, using 10-min blood sampling for LH, 75% of CHH patients failed to exhibit any detectable LH pulses, implying a lack of GnRH pulse generator activity (Figs. 5.2 and 5.6) [30]. The remaining 25% demonstrated abnormal but detectable LH pulses. Among the latter group, the majority of patients displayed a normal LH pulse frequency with a low LH pulse amplitude (Fig. 5.6). Although a higher prevalence (80%) of apulsatile LH secretion is found among those who lack sexual development, detectable LH pulses were identified in up to 20% of subjects in this group




Fig. 5.6 Spectrum of GnRH-induced LH secretion abnormalities in men with CHH based on our retrospective study on 78 CHH men. 75% of CHH men exhibit no detectable LH pulses. 17% had a normal LH frequency but a low LH amplitude. 3% have a low LH amplitude and low frequency, 2% have a normal LH amplitude but low frequency. Finally, 2% have normal LH amplitude and frequency, deemed pathologic in the setting of hypogonadal T levels

[71]. It may be that the initiation of puberty requires higher levels of GnRH stimulation than that are required to maintain a neuroendocrine axis after puberty [72]. Also, 50% of CHH patients with some pubertal development do not exhibit any LH pulses [30]. This finding suggests that transient pubertal activation of the HPG axis may have occurred that was followed by a failure of the GnRH secretory program in these patients. Alternatively, this may reflect a failure to detect a suppressed pulsatile pattern of GnRH because the LH assay was not sufficiently sensitive. From these data, it appears that neither mean gonadotropin levels nor the current pattern of LH secretion is a reliable surrogate marker for complete versus partial CHH.

The responsiveness of LH and FSH to 7 days of GnRH stimulation has been studied in CHH men and has been shown to correlate with the extent of seminiferous tubular development [73]. CHH men with no evidence of prior spontaneous pubertal development (TV \leq 3 ml) showed sharp increases in serum FSH compared to men with some prior evidence of partial puberty (TV $>$ 3 ml), and inhibin B levels remained much lower in the former group. Conversely, the same group exhibited a decreased LH response to GnRH compared to the latter group who displayed robust LH responses to GnRH throughout the 7-day study. These observations underscore the role of negative feedback by inhibin B with increasing seminiferous tubule maturity on FSH responsiveness to GnRH while the LH response to GnRH is governed primarily by the extent of GnRH exposure.

Genetics of Congenital KS and NCHH

Patterns of Inheritance

Mirroring the phenotypic heterogeneity detailed above, the underlying genetic architecture of CHH is equally heterogeneous with mutations in several developmental genes causing KS, and mutations in neuroendocrine genes causing nCHH. Interestingly, some genes participate in the etiology of both KS and nCHH, and some subjects with KS have family members with

nCHH, suggesting that the stratification between KS and nCHH might be oversimplified, and in fact may share common genetic mechanisms. The genetic complexity of CHH is also reflected in its different inheritance patterns. Given the reproductive failure associated with CHH, nearly two-thirds of CHH patients initially present as isolated or sporadic cases [27, 74]. Among familial cases, CHH can be inherited as an X-linked, autosomal dominant, or autosomal recessive trait [27]. Interestingly, in our cohort, the familial cases display a more severe phenotype with 95% of affected subjects presenting with absent pubertal development and a higher prevalence of cryptorchidism (71%) and microphallus (55%) [30]. While the excess of sporadic cases may suggest high rates of spontaneous de novo mutations causing the disease, closer review of their pedigrees, with detailed reproductive and non-reproductive phenotyping, often reveals subtle phenotypes that suggest familial inheritance patterns with variable penetrance [27]. In addition, as more subjects are successfully treated to enhance fertility, the incidence of familial cases may increase. In addition to these Mendelian modes of inheritance, a complex genetic architecture for CHH (occurring in 10–15% of cases) has now been documented wherein mutations in two or more CHH genes can be identified in CHH patients [75]. Almost all of the known CHH genes partake in the oligogenic inheritance mode. These oligogenic mutations presumably act in a synergistic manner, potentially accounting for some of the variable expressivity and incomplete penetrance that is characteristic of CHH.

Over the last three decades, several research groups have used a combination of clinical investigational strategies and contemporary genetic approaches to unravel the growing genetic complexity of CHH and to expand our understanding of the neurobiology of reproduction. To date, nearly 25 causal/contributory genes for the non-syndromic forms of CHH have been identified for this condition with varied modes of inheritance that affect either the development and/or functional integrity of the GnRH neurons (Fig. 5.7).




Fig. 5.7 Genetic causes of CHH showing neurodevelopmental and neuroendocrine regulation of GnRH neurons. Genes to the left are critical to GnRH neuronal migration, whereas those on the right are involved in

proper GnRH function. A number of IGD genes (in the center) are involved in both processes. Adapted from Stamou et al. [213]

Genes Exclusively Causing KS Form of CHH

(i) X-linked recessive inheritance

ANOS1 (previously called *KALI*), encoding anosmin-1 protein

Since the description of affected men by Kallmann et al. [27] in 1944, both X-linked (X-KS) and autosomal KS pedigrees have been recognized. Though the majority of familial cases of KS are inherited autosomally [76], initial attention was focused on several X-KS pedigrees with a complex syndromic presentation that included KS accompanied by ichthyosis, chondroplasia punctata, and choanal atresia. Karyotype analysis revealed a deletion in the tip of the X-chromosome at Xp22.3, suggestive of a

contiguous gene deletion syndrome [77]. Eventually, the first KS gene, *KALI* (now called *ANOS1*), encoding an extracellular matrix protein, anosmin-1, was identified as the cause of KS using positional cloning of Xp22.3 and reported simultaneously by two independent groups [78, 79]. Subsequently, several groups have described many *ANOS1* point mutations and deletions in non-syndromic KS patients [80].

Anosmin-1 is a secreted multi-domain protein consisting of an N-terminal signal peptide followed by a cysteine-rich region (cys-box), a whey acidic protein (WAP)-like four disulfide core motif, four tandem fibronectin type III (FnIII) repeats, and a C-terminal histidine-rich region. *ANOS1* mutations occur across the length of the gene, and most mutations are loss of function

(LOF) in nature (alteration of essential splicing, frameshift, or stop codons) resulting in the lack of synthesis of biologically active anosmin-1 protein. Missense *ANOS1* mutations are rare [80]. The pathophysiology of disruption of anosmin-1 function in humans was studied in a 19-week gestation KS fetus known to harbor a deletion from Xp22.31 to Xpter, i.e., including the entire *ANOS1* gene [81]. Histologic studies revealed arrested migration of GnRH neurons and olfactory neurons at the cribriform plate [81]. This defect of GnRH neuronal migration results in the failure of normal GnRH neuronal axonal communication with the median eminence that is imperative for the activation of the HPG axis. In phenotypic studies of men with *ANOS1* mutations both in our cohort and in others, a severe pubertal phenotype was evident with complete absence of pubertal development, a high frequency of cryptorchidism and micropallus, an apulsatile pattern of LH secretion, low inhibin B levels, and histologically immature testes [30]. Despite the critical developmental role played by anosmin-1 in GnRH neuronal migration, mutations in *ANOS1* account for only 10–14% of familial KS [76] and 8–11% of sporadic KS patients [28]. Human subjects with *ANOS1* mutations, in addition to KS, display several specific non-reproductive features including, unilateral renal agenesis and synkinesia or mirror movements [28, 82]. In keeping with these clinical signatures, anosmin-1 is expressed in non-reproductive tissues such as mesonephric tubules, ureteric bud, digestive tract, large blood vessels, and inner ear [83]. Although several mutations of the *ANOS1* gene cluster in the four fibronectin type III repeat domains [84, 85], no phenotype–genotype correlation has been demonstrated between the non-reproductive phenotypes and location of the mutation.

- (ii) Autosomal dominant KS, with variable penetrance in some pedigrees
 - a. *SOX10*, encoding a transcription factor, SRY (sex-determining region Y) box 10

The candidacy of *SOX10* as a genetic cause of KS came from radiological observations in humans

with *SOX10* mutation-related Waardenburg syndrome (WS), a heterogeneous human “neuro-cristopathy” (i.e., disorders of cells from the neural crest origin) characterized by variable sensorineural deafness, abnormal skin and iris pigmentations, and Hirschsprung’s disease [86]. Imaging of temporal bone abnormalities of WS patients revealed an unexpected frequency of olfactory bulb agenesis, a finding reminiscent of KS [86]. In addition, one male with WS-related olfactory bulb agenesis also exhibited KS (anosmia and CHH). In 2013, Pingault et al. [87] studied 17 KS subjects of both sexes with at least one WS-related feature and 86 random KS cases, and identified eight subjects with a spectrum of *SOX10* mutations (1 initiator codon, 1 frameshift, 1 splice site, and 6 missense mutations), all subsequently shown to be loss-of-function *SOX10* mutations. In addition, study of *Sox10*^{-/-} mutant mice revealed a developmental defect in olfactory ensheathing cells, the specialized glial cell population normally found along the olfactory nerve pathway [87, 88]. In their absence, these mice misrouted their olfactory fibers, with impaired migration of GnRH cells and disorganization of the olfactory nerve layer of the olfactory bulb [55]. A third of the subcohort of KS with hearing loss was enriched for *SOX10* mutations similar to the WS patients who also exhibit hearing loss [56]. This phenotypic overlap between KS and WS is also strongly suggestive of the presumptive role for neural crest cells in GnRH neuronal ontogeny. These observations are in keeping with murine [89] and zebra fish [90] data previously suggesting a critical role for neural crest cells in GnRH neurogenesis. Thus, this important gene provides compelling evidence for a subset of KS to be considered a human neurocristopathy disorder.

b. *SEMA3A*, encoding semaphorin 3A protein

Semaphorin 3A is a secreted guidance cue of the class 3 semaphorin family that had been initially shown to be important for the development of the GnRH neuron system in mice [91]. Loss of *SEMA3A* signaling alters the targeting of vomeronasal nerves and the migration of GnRH neurons into the brain, and hence recapitulates the human KS phenotype [91]. Subsequently,

SEMA3A human mutations have provided validating evidence linking *SEMA3A* signaling and GnRH ontogeny in humans [92, 93]. In a single pedigree, heterozygous deletion of 11–17 *SEMA3A* exons was first identified to cause an autosomal dominant form of KS [92]. Independently, heterozygous *SEMA3A* mutations (1 frameshift mutation and 7 different missense mutations [R66W, N153S, I400V, V435I, T688A, R730Q, and R733H]) were found in a total of 24/386 (6.2%) KS subjects [93]. These mutations either showed impaired secretion of *SEMA3A* protein or reduced signaling of the secreted protein in GN11 cell lines (a neurodevelopmental GnRH cell line) [93]. Taken together, these observations suggest that mutations in *SEMA3A* cause KS via a loss-of-function (LOF) mechanism. In addition, in 5/24 patients with *SEMA3A* missense mutations, additional CHH gene mutations were identified, again confirming an oligogenic pattern of inheritance in CHH [93]. While several non-reproductive features were present, no significant enrichment for any specific non-reproductive feature was apparent in this group of patients.

c. *IL17RD*, encoding interleukin 17 receptor D protein

Once *FGF8/FGFR1* mutations were documented in both KS and nCHH forms of CHH patients (see below), a bioinformatic interactome search-based association study (IBAS) to identify other gene mutations in a “FGF8 synexpression group” revealed 2 genes, *IL7RD*, and *FGF17* as top candidate CHH genes [94]. In 8 KS subjects, seven *IL17RD* missense mutations (2 subjects with homozygous mutations and 6 subjects with heterozygous mutations) were found [94]. The functional effect of the *IL7RD* mutations was tested in a cell-based reporter assay in which cells co-expressing the mutants either displayed loss-of-function activity or decreased cell surface expression. *IL17RD* is a single transmembrane glycoprotein that is one of the major antagonists of FGF downstream signaling in vivo and in vitro [95–97]. High *IL17RD* expression occurs in the

olfactory epithelium at E10.5, i.e., a time frame coinciding with GnRH neuronal fate specification thus suggesting a potential role for this gene in the early development of both GnRH and olfactory neurons [94]. Intriguingly, the *IL17RD* mutations identified were shown to cause loss of function. Given that *IL17RD* is an inhibitor of the FGF8 signaling system, these mutations should putatively increase FGF8 signaling in vitro. While this observation might appear counterintuitive given that *FGF8* and *FGFR1* LOF mutations cause CHH, it has been previously shown that both complete LOF and overexpression of FGF8 increase apoptosis in olfactory progenitor cells whereas a lesser decrease in functional FGF8 expression results in cell survival, suggesting nonlinear dosage effects for FGF8 signaling. Six out of eight (75%) *IL17RD* mutation subjects also displayed hearing loss, an observation consistent with *FGF8*'s role as a morphogen for otic development in both chickens and mice [98]. In 2 heterozygous *IL17RD* mutation subjects, additional missense variants in *FGFR1* and *KISS1R*, two known CHH genes, were identified, thus attesting to an oligogenic mode of inheritance in these pedigrees [94].

(iii) Autosomal recessive KS

FEZF1, encoding FEZ family zinc finger 1
CCDC141, encoding a coiled-coil domain containing protein 141

In a consanguineous family with two affected KS subjects, whole exome sequencing (WES) and autozygosity mapping discovered 2 different homozygous mutations in *FEZF1* (Missense: His278Tyr) and *CCDC141* (Stop-codon: R724X) [99, 100]. In another consanguineous family, an additional homozygous frameshift mutation leading to a premature stop (Ala327fsX13) was identified whose transcript is likely to be sensitive for nonsense-mediated decay [99]. The transcriptional activity of the missense *FEZF1* His278Tyr mutation was studied using a HEK293 cell assay with a Hes5p-DsRed reporter that was previously known to be repressed during cortical neurogenesis. This missense mutation resulted in

intermediate accumulation of the mutated reporter compared to WT FEZF1 suggesting a partial LOF [99].

FEZF1 is a zinc-finger gene encoding a transcriptional repressor selectively present during embryogenesis in the olfactory epithelium [101–103], and *Fezf1*-deficient mice have impaired axonal projection of pioneer olfactory receptor neurons (ORNs) exhibiting a failure of their neurons to penetrate the basal lamina of the CNS [101–103]. These mice have smaller olfactory bulbs and have complete absence of GnRH neurons in the brain [102]. When these experiments were repeated with the basal lamina surgically removed, GnRH neurons were able to reenter the brain suggesting that the WT FEZF1 product may promote a protease expression that will enable the olfactory sensory neurons to make synaptic connections with the olfactory nerve layer of the olfactory bulbs, providing a conduit for the migration of the GnRH neurons into the brain [102]. The presence of two homozygous mutations in each of *FEZF1* and *CCDC141* in the first family suggested an oligogenic inheritance especially since the His278-Tyr mutation was only a partial LOF mutation [99]. In a subsequent study, the same authors showed in murine models that *Ccdc141* is expressed in GnRH neurons and olfactory fibers, and that knockdown of *Ccdc141* reduces GnRH neuronal migration, suggesting that *CCDC141* participates in the embryonic migration of GnRH neurons enabling them to form a hypothalamic neuronal network [95].

(iv) Indeterminate inheritance/oligogenic KS

SEMA3E, encoding semaphorin 3E protein

Similar to *SEMA3A*, semaphorin 3E is another secreted guidance cue of the class 3 semaphorin family [104]. Using a combination of exome sequencing and computational modeling, a recent study implicated a shared point mutation in exon 16 of the *SEMA3E* gene leading to a missense *SEMA3E* R619C Ig-like domain substitution in 2 KS siblings [105]. While recombinant wild-type *SEMA3E* protected maturing GnRH neurons from cell death by triggering a Plexin D1-dependent

(PLXND1-dependent) activation of PI3 K-mediated survival signaling, recombinant mutant *SEMA3E* carrying the KS-associated mutation did not protect GnRH neurons from death [105]. In the same study, *SEMA3E* or *PLXND1* deficiency in mice was shown to increase apoptosis of GnRH neurons in the developing brain, reducing GnRH-positive neurite innervation of the adult median eminence with phenotypic recapitulation of the human hypogonadal state. In addition to the *SEMA3E* mutations, a heterozygous p.F1019C mutation substitution in *CHD7*, a known CHH gene, was also present in the affected siblings, suggesting an oligogenic interaction [105]. The results from this single study strongly suggest a novel neurotrophic function for *SEMA3E*/PLXND1/PI3 K signaling in GnRH neuron development and a role for *SEMA3E* mutations in oligogenic inheritance of KS. Additional *SEMA3E* mutational screening in KS subjects will be required to evaluate the prevalence of *SEMA3E* mutations in CHH.

Genes Exclusively Causing nCHH

(i) Autosomal recessive nCHH

- a. *GNRHR*, encoding the GnRH-receptor protein

A functional GnRH receptor (*GNRHR*) is crucial for both pubertal development and reproductive function. Indeed, hypothalamic GnRH secreted into the hypophyseal portal blood interacts with its high-affinity cognate *GNRHR* expressed in the cell membranes of gonadotrophs. Defects in the *GNRHR* emerged as the first autosomal cause of CHH [106, 107]. *GNRHR* is a G protein-coupled receptor with seven transmembrane segments that activates phospholipase C, leading to the intracellular increase in inositol phosphate [108]. While patients with a *GNRHR* mutation were expected to present with complete HH and unresponsiveness to GnRH stimulation, milder variants have been described. In the first family with a partially inactivating *GNRHR* mutation [106], the affected male had limited testicular growth (8 mL testes), detectable gonadotropins, and a normal

response to a single pharmacologic dose of GnRH. Genetic analysis revealed a compound heterozygous mutation (Gln106Arg and Arg 262Gln substitutions). The parents were phenotypically normal, and each was heterozygous for one of the mutations. In CHO cells, Gln106Arg substitution (localized in the first extracellular loop of the GnRH receptor) markedly reduced the level of GnRH binding and stimulation of IP₃ activity. In contrast, in the Arg262Gln substitution (localized in the third intracellular loop of the GnRH receptor), hormone binding was normal, but IP₃ activation was impaired [106]. Several additional GnRH-R mutations (either homozygous or compound heterozygous) have been found which significantly impair GnRH binding and/or signaling to varying degrees [109]. Interestingly, a spectrum of pubertal development has been observed among CHH males with *GNRHR* mutations depending upon the genotype, ranging from the fertile eunuch syndrome [55] to the most severe form of GnRH deficiency characterized by cryptorchidism, micropallus, undetectable gonadotropins, and absent pubertal development [109]. In addition to autosomal recessive inheritance, the prevalence of heterozygous rare sequence variants in *GNRHR* has been shown to be significantly higher in CHH subjects. However, as expected, biallelic recessive *GNRHR* mutations resulted in more severe phenotypes when compared to the monoallelic heterozygous *GNRHR* mutation individuals who exhibit variable penetrance of phenotypes suggesting as-yet-unidentified genetic and/or environmental factors may combine with heterozygous LOF *GNRHR* alleles to produce reproductive phenotypes [109].

b. *GNRHI*, encoding gonadotropin-releasing hormone

The GnRH gene is located at 8p21–8p11.2 and is the most obvious autosomal candidate gene in CHH. Indeed, the hypogonadal (*hpg*) mouse, in which the GnRH gene has been homozygously deleted, presents with CHH [110]. Surprisingly, after several previous failed attempts to identify *GNRHI* mutations, and 25 years after the discovery of the human sequence, homozygous

frameshift mutations have now been reported in the *GNRHI* gene. Bouligand et al. identified an insertion of a single base pair between the 6th and 7th codons of the *GNRHI* gene that resulted in a frameshift that disrupted the primary sequence of the GnRH preprohormone starting at the 7th amino acid [111]. Indeed, cells transfected with the mutant *GNRH1* allele failed to produce measurable amounts of GnRH [111]. Independently, Chan et al. [112] reported a single base pair deletion in the codon for the 6th amino acid of the GnRH decapeptide, that leads to a frameshift that disrupts the C-terminus of GnRH, a region essential for its function.

In both reports, *GNRHI*-deficient patients were born healthy at term countering the earlier speculation that GnRH may be essential for placental function and fetal survival. However, both patients had severe pubertal delay as well as micropenis and/or cryptorchidism, confirming the severity of these mutations. Moreover, no significant non-reproductive phenotypes were seen arguing against a major function for GnRH in other organ systems.

c. *KISS1R*, encoding the kisspeptin-1 receptor

In 2003, using linkage analysis and homozygosity mapping in inbred families, two groups independently identified inactivating mutations in *KISS1R* (then called GPR54), a G protein-coupled receptor, in nCHH patients [113, 114]. This observation, coupled with complementary mouse genetics, revealed that *Kiss1r*^{-/-} mice were a faithful nCHH mouse model [114], providing compelling evidence that the *KISS1R* receptor and its cognate ligand, kisspeptin, were upstream gatekeepers of GnRH neurons. Since then, a number of mutations in the *KISS1R* have been described in nCHH patients [115]. *KISS1R* is a member of the rhodopsin family of G protein-coupled receptors, and kisspeptin is the endogenous ligand for *KISS1R* and a potent stimulator of gonadotropin release in all mammalian species studied [116, 117]. Several key observations have emerged from the study of human GnRH-deficient subjects with *KISS1R* mutations. Neuroendocrine profiling of probands

with *KISS1R* mutations reveal low-amplitude LH pulses [114, 118], suggesting some degree of persistence of endogenous but dampened GnRH secretion. In addition, in a subject with a *KISS1R* compound heterozygous mutation, exogenous GnRH induced a striking leftward shift in its GnRH-LH dose–response relationship suggesting some degree of endogenous pituitary priming by intact but dampened GnRH pulsatility [114]. Mutations in *KISS1R* account for ~2% of nCHH patients with the presence of cryptorchidism and/or micropenis in the majority of men with biallelic *KISS1R* mutations [119]. These observations strongly suggest that the kisspeptin signaling system is essential for prenatal GnRH secretion and early sexual development [119]. This observation is in keeping with another published report of a male with *KISS1R* mutation who presented with cryptorchidism and micropenis in infancy, in whom neuroendocrine evaluation at 2 months of age revealed undetectable gonadotropins also suggesting a role for *KISS1/KISS1R* system in the “mini-puberty” of infancy [120]. While *KISS1R* inactivating mutations result in CHH, a single heterozygous activating *KISS1R* was shown to potentially contribute to central precocious puberty [121].

d. *KISS1*, encoding kisspeptin 1 peptide

The kisspeptin peptide is coded by the *KISS1* gene, and its proteolytic processing results in different length kisspeptins, all of which retain the amidated carboxy terminal decapeptide and are potent *KISS1R* agonists [122, 123]. Kisspeptin-1 is a 54 amino acid peptide, initially termed metastin due to its ability to inhibit tumor metastasis, represents the longest kisspeptin [124]. While *Kiss1*^{-/-} mice have been known to recapitulate the human nCHH phenotype [125], only recently was a human consanguineous Kurdish pedigree with biallelic p.N115 K inactivating missense mutation in 4 sisters reported [126]. No male biallelic patients with *KISS1* mutations have been so far reported. All four sisters had significant pubertal delay. IP accumulation in COS-7 cells expressing human WT

KISS1R was significantly impaired with the mutant *KISS1*-10 peptide compared to the WT *KISS1*-10 peptide, suggesting a LOF mechanism for the mutation [126]. While no other mutations in the *KISS1* gene have subsequently been reported, this single family and the previously reported *KISS1R* mutations strongly reiterate the critical importance of the *KISS1* signaling pathway in the neuroendocrine control of GnRH release in humans without affecting GnRH migration or GnRH synthesis.

- e. *TAC3*, encoding the neurokinin B peptide and
- f. *TACR3*, encoding the neurokinin B receptor

In 2009, using homozygosity mapping in consanguineous Turkish families, Topaloglu et al. [127] reported missense loss-of-function mutations in both *TACR3*, the gene encoding a G protein-coupled receptor, neurokinin B receptor (NK3R), and *TAC3*, the gene encoding neurokinin B (NKB), the endogenous ligand for *TACR3*, unearthing a previously unrecognized role of the *TAC3/TACR3* pathway in the regulation of the GnRH secretion. Neurokinin B belongs to a phylogenetically conserved family of proteins that also include substance P, neurokinin A, and hemokinin-1 [128]. NK3R has preferential binding to NKB [129] and is predominantly expressed in the brain, specifically the hypothalamus [130, 131] with expression on GnRH neurons as well as co-expression with kisspeptin and dynorphin in a specific subset of neurons termed KNDy (kisspeptin-neurokinin B-dynorphin) neurons found in the arcuate nucleus [132]. Subsequently, homozygous splice site mutations in *TAC3* and *TACR3* were reported and shown to cause alternative splicing and premature truncation of the respective proteins [133, 134]. Gianetti et al. [135] by reviewing the phenotypes of CHH men harboring variants in *TAC3/TACR3* (n = 15) found that >90% of male probands characteristically displayed micropenis, and although they failed to enter puberty as teenagers, longitudinal review showed that 5/15 subjects exhibited ongoing evidence of endogenous HPG axis activity, suggestive of reversal later in life.

These observations strongly suggest that TAC3/TACR3 signaling, while imperative for neonatal mini-puberty and pubertal onset at adolescence, may be relatively less important in adult life. In terms of deciphering the precise mechanism by which NKB signaling regulates GnRH secretion, accumulating evidence suggests a stimulatory role of NKB that is likely mediated by aut synaptic inputs of NKB on KNDy neurons to induce the secretion of gonadotropin-releasing hormone (GnRH) in a kisspeptin- and sex hormone-dependent manner [136].

Genes Causing Both KS and NCHH

- (i) Autosomal dominant with variable penetrance with oligogenic inheritance in some pedigrees
- a. *FGFR1*, encoding the fibroblast growth factor 1 receptor protein
 - b. *FGF8*, encoding fibroblast growth factor 8
 - c. *FGF17*, encoding fibroblast growth factor 17

It has become clear that FGF signaling, known to play multiple roles in central nervous and skeletal system development including brain patterning, branching morphogenesis, and limb development [137], is an important cause of both KS [138] and nCHH forms of CHH [139, 140]. There are 23 mammalian fibroblast growth factors that act by binding and activating one of the four FGFR tyrosine kinase receptors in a heparan sulfate proteoglycan-dependent manner [141]. In two individuals with overlapping interstitial deletions with KS and congenital spherocytosis, Dode et al. [138] first implicated *FGFR1* gene as the underlying cause of KS. Since then, a large number of individual point mutations and deletions of the *FGFR1* gene have been shown to cause both KS and nCHH [139]. These mutations span all the functional domains of the *FGFR1* receptor. Structural and biochemical studies using recombinant FGFR1 proteins show that mutations in the D2 and D3 loops of the receptor cause misfolding and impaired cell surface expression of the *FGFR1* receptor and/or ligand-receptor interactions and binding [139].

Mutations in the cytoplasmic tyrosine kinase domain appear to cause structural perturbations and reduce catalytic activity of this domain [139].

At least 11 different FGFs can activate FGFR1 [137, 141]. However, the specific ligand(s) implicated in GnRH neuron ontogeny were unknown. In a proband with KS and cleft palate with a L342S mutation in the *FGFR1c* gene functional analysis of this mutation showed a selective and dramatic loss of binding affinity of the FGF8b isoform to the *FGFR1* receptor [142]. Integrating this observation with the described overlapping patterns of *FGF8* and *FGFR1* expressions in the brain and defective olfactory bulb neurogenesis seen in *FGF8* hypomorphic mice, a candidate gene approach revealed six *FGF8* gene mutations in GnRH-deficient unrelated probands [142]. Two of the probands also carried additional *FGFR1* mutations confirming oligogenicity in the *FGF8* signaling pathway in human GnRH deficiency [142]. The structural impact of these *FGF8* mutations was confirmed by a crystal structure analysis of the FGF8b/FGFR2c/heparin model, and functional studies revealed reduced FGF8 function in vitro confirming their LOF mechanisms [142]. Both anosmin-1 and FGFR1 bind to heparan sulfate proteoglycans. This association has led to the postulation that CHH in X-linked *ANOS1* mutations may be secondary to a FGF signaling defect on GnRH neuronal development [143]. The importance of the FGF signaling pathway in GnRH neuron ontogeny is further supported by the murine models with targeted ablation of *FGFR1* in the telencephalon [144], and *FGF8* hypomorphic mice both of which lack olfactory bulbs and have reduced GnRH neurons [145]. Phenotypic analysis shows significant variability of the penetrance of reproductive phenotypes in patients with FGF pathway mutations but significant enrichment of digit/limb abnormalities [46], midline facial defects, and dental agenesis in CHH patients with FGF pathway mutations [47].

More recently, as described for IL17RD gene discovery, bioinformatic analysis also revealed *FGF17* as a putative CHH candidate gene [94]. *FGF17* shares 61% overall sequence identity with

FGF8b, signals through FGFR1c, and exhibits the same receptor-binding-specificity profile as FGF8b [146]. Consistent with the homology between FGF17 and FGF8b, the p.Leu342Ser *FGFR1* mutation also abolished FGF17-stimulated signaling through *FGFR1c*, and candidate gene sequencing revealed three unrelated probands which harbored heterozygous missense mutations in *FGF17*, one of whom also had oligogenic mutations in *FGFR1* and *HS6ST1* [94]. Moreover, mouse studies showed that Fgf17 was robustly expressed in the medial olfactory placode where GnRH neurons emerge, and importantly, there was significant reduction in Fgf17 expression in Fgf8 hypomorphic mice [94].

d. *HS6ST1*, encoding heparan sulfate 6-O-sulfotransferase 1 protein

Multiple lines of evidence suggested that *HS6ST1* was a likely candidate gene for CHH: (i) The enzyme encoded by *hst-6* introduces a sulfate specifically in the 6-O-position of the glucosamine sugar moiety within heparan sulfate (HS). Notably, HS with specific 6-O sulfate modifications is required for anosmin-1 and FG8/FGFR1 signaling pathways to exert their function in vivo [147]; (ii) A genetic modifier screen uncovered mutations in the *C. elegans* HS 6-O-sulfotransferase gene (*hst-6*) as suppressors of this *ANOS1* (i.e., *kali*) gain-of-function phenotype [148]. For these reasons, a CHH cohort (n = 338) that was screened for mutations in *HS6ST1* uncovered 7 subjects with KS and nCHH with sequence variants: one homozygous [p.R296W/R296W] and four heterozygous [p.R296Q; p.R313Q; p.R372W (seen in 3 unrelated patients); and p.M394V], indicating that 2% of CHH patients harbor *HS6ST1* mutations and, in some pedigrees, in oligogenic epistasis with other CHH genes [149]. Functional studies revealed that the human mutations have distinct effects in an *ANOS1*-dependent *C. elegans* assay, implying that *HS6ST1* may be required in vivo for *ANOS1*-dependent pathways [149].

e. *CHD7*, encoding chromodomain helicase DNA-binding protein 7 [Note: Mutations in this gene also cause the syndromic form of CHH (see below)]

Inactivating mutations in *CHD7* are known to cause a severe syndromic form of HH referred to as CHARGE syndrome (**C**oloboma, **H**ear/eye defects, **C**hoanal **A**tresia, **R**etardation of growth and development, **G**onadal defects, and **E**ar/hearing abnormalities) [150, 151]. The CHD7 protein belongs to a family of highly conserved proteins and is one of 9 CHD proteins that have in common the ability to hydrolyze ATP to modify chromatin and nucleosome structure [152]. It is known to regulate transcription and has several functional domains including HELICc, SNF2-related helicase/ATPase, BRK, and chromodomains that play significant roles in early embryonic development by controlling target gene expression through its activity in chromatin remodeling [152, 153].

The “gonadal defect” in CHARGE patients is hypogonadotropic hypogonadism and fulfills the clinical definition for CHH, as these patients are typically responsive to exogenous GnRH administration [150]. While truncating LOF mutations in *CHD7* typically cause the full CHARGE phenotype, recent studies show that missense mutations in *CHD7* are enriched in CHH patients (accounting for 5–6% of cases) [154, 155]. In one study, using a surrogate otolith assay in zebrafish, of a representative set of *CHD7* alleles seen in CHH, 11 hypomorphic, null (revealed by rescue experiments), and dominant (revealed by overexpression experiments) alleles were identified [154]. In two families, pathogenic mutations in *CHD7* were seen with mutations in other known IGD genes. Taken together, these data suggest that rare deleterious missense *CHD7* alleles contribute to the mutational burden of patients with both KS and nCHH in the absence of full CHARGE syndrome. These findings strongly implicate a unique sensitivity for *CHD7* in the ontogeny of

GnRH neurons and imply that mutations in *CHD7* contribute to the oligogenic basis of CHH. The question of where *CHD7* fits into the developmental biology of GnRH neurons remains unclear. It is also known that *CHD7* regulates genes involved in neural crest guidance, and there is increasing evidence that the KS form of IGD may also result from impaired neural crest guidance as seen in *SOX10* mutation patients [see above] [156]. In addition, the observation that rare pathogenic *CHD7* variants are associated with nCHH also suggests that, in addition to its neurodevelopmental role, *CHD7* may well also influence subsequent neuroendocrine development pathways of GnRH neurons.

f. *WDR11*, encoding the WD repeat domain 11

The chromosome 10q26 region has been associated previously with abnormal male genital development and function (micropenis, cryptorchidism, and hypogonadism) resulting from interstitial or terminal deletions as well as a balanced translocation [157]. In addition, trisomy involving 10q26 was reported in a KS patient with an unbalanced chromosome translocation, strongly implying the presence of a new KS gene in the 10q26 region [158]. Kim et al. studied a KS patient with a de novo chromosomal translocation, 46,XY, t(10;12)(q26.3;q13.1), and by using a customized oligonucleotide array and cloning the junction fragments, they delineated the precise break points of the de novo translocation to exactly 547 kb away from the 5' end of the *WDR11* gene [159]. In addition, by candidate gene sequencing, five further missense *WDR11* mutations were identified in one KS and in five nCHH patients. *WDR11*'s function is unknown, but it contains twelve WD domains and is highly conserved throughout vertebrate evolution. Kim et al. [159] also identified the transcription factor *EMX1* as a novel interactor with *WDR11*. *EMX1* is a homeobox transcription factor involved in specifying cell fates in the developing central nervous system and has been shown to be involved in the development of olfactory neurons. Analysis of the expression patterns of *WDR11* in

human embryonic olfactory GnRH neuroblasts, as well as in mouse and zebrafish development, revealed overlapping patterns of expression with *EMX1* in regions critical for the formation of the hypothalamus, supporting the opportunity for the two proteins to interact in vivo and to act together during development [159]. Deletion analysis revealed that *WDR11* interacts with *EMX1* via both its N-terminus and its central region, where four of the identified missense mutations (R395W, A435T, R448Q, and H690Q) were located. While R448Q reduced binding to *EMX1*, both A435T and H690Q abolished binding to *EMX1*, physically decreasing the opportunity for productive interaction. Taken together, these genetic and functional data provide strong evidence for *WDR11* as a cause of CHH and KS. Since segregation analysis was not fully possible, the precise mode of inheritance of these mutations remains unclear but the de novo nature of the deletion and heterozygous nature of the mutations indicate an autosomal dominant and an oligogenic inheritance model [160].

- (ii) Autosomal recessive; indeterminate/oligogenic in some pedigrees
- a. *PROK2* gene, encoding prokineticin 2
 - b. *PROKR2* gene, encoding prokineticin receptor 2

The candidacy of the *PROK2/PROKR2* mutations in CHH came initially from unanticipated hypogonadotropism in murine deletions *Prok2*^{-/-} (162) and *Prokr2*^{-/-} [162] that phenocopied human KS with olfactory anomalies, decreased GnRH neuronal migration to the hypothalamus, and produced hypogonadotropic hypogonadism responsive to exogenous gonadotropins. *PROK2* encodes prokineticin 2 (named as prokineticin in view of its stimulation of GI motility [163]), a secreted ligand with highly conserved cysteines and a basic N-terminal amino acid sequence, AVITGA, that is essential for its biological activity [164]. *PROK2* signals through both *PROKR1* and *PROKR2*, two G protein-coupled receptors, but has higher affinity for *PROKR2*. In contrast to the more ubiquitously expressed *PROKR1*, *PROK2* and its cognate receptor,

PROKR2, have a unique expression profile within the CNS including the olfactory system, arcuate nucleus, suprachiasmatic nuclei (SCN) and median eminence [165–167]. *PROK2* is also known to function as a chemoattractant for neural progenitor cells that ultimately populate the olfactory bulb and assist in its dynamic function during life [168]. It has been hypothesized that this olfactory developmental role of *PROK2* is the major determinant of its role in GnRH neuronal ontogeny, and that this effect may be indirect, as both developing and mature GnRH neurons fail to express the ligand *PROK2* or the *PROKR2* receptor.

In keeping with these observations, biallelic LOF mutations in both *PROK2* and *PROKR2* were identified in KS subjects [169] and, surprisingly, in nCHH patients as well [161, 170]. In addition, rather intriguingly, >90% of human mutations in this pathway occur in the heterozygous state [171, 172]. Many *PROKR2* heterozygous pedigrees display variable penetrance suggesting a complex inheritance pattern [170–172]. While oligogenic mutations in other CHH genes account for some of these observations, recent evidence suggests that some of these heterozygous variants may act in a dominant-negative manner [173]. In addition, comparison of biallelic CHH patients to those harboring heterozygous variants, the latter group had a more variable expression of reproductive and non-reproductive features, suggesting that other genetic or non-genetic modifiers may be present in these patients. Although a circadian role for *PROK2* has been identified in rodents, human patients with biallelic mutations in *PROK2* do not exhibit any circadian phenotypes [174]. While the human mutations reveal an imperative role for prokineticin 2 signaling for GnRH neuronal integrity, the precise cellular and molecular mechanisms that link prokineticin 2 to GnRH neurons remain elusive.

- c. *NSMF*, encoding NMDA receptor synaptonuclear signaling and neuronal migration factor

NSMF, previously called NELF (nasal embryonic LHRH factor), emerged as a strong candidate gene

for KS in view of its putative role as an extracellular guidance molecule on growth cones, which is essential for axon growth and routing of GnRH-positive cells along vomeronasal olfactory-derived axons and eventually migration to the hypothalamus [175]. To date, several rare variants in *NSMF* have been identified but several were intronic variants [176, 177] or variants that were seen along with other CHH gene mutations [160, 178], suggesting that *NSMF* variants are unlikely to be causal monogenic variants, but may act as modifiers that synergize with other pathogenic genes to produce the observed human phenotype. In keeping with this notion, mouse knockout studies have revealed variable reproductive phenotypes. While female *Nsmf*^{-/-} mice were reported to have delayed puberty and are subfertile [179], in a recent mouse study, *Nsmf*^{-/-} mice did not display any reproductive phenotype but rather had substantial hippocampal hypoplasia [180].

Complex Syndromic Forms of CHH

While non-reproductive phenotypes are often seen in CHH patients with mutations in several genes described above, there are other genetic forms of CHH that occur in the constellation of specific syndromic somatic phenotypes including (i) morbid childhood obesity syndromes (e.g., Prader–Willi syndrome [181]; syndromic obesity related to leptin pathway mutations [182–184]), (ii) adrenal hypoplasia congenita [185, 186]; (iii) CHARGE syndrome [150, 154]; (iv) cranial nerves palsies and peripheral neuropathy (TUBB3 E410 K syndrome [atypical Moebius]) [187]; (v) sensorineural hearing loss, pigmentation defects, and Hirschsprung disease (Waardenburg syndrome) [87]; (vi) neurodegenerative syndromes: Gordon–Holmes syndrome; Boucher–Neuhauser syndrome [188, 189]; and (vii) ciliopathies (Bartlett–Biedl syndrome) [190, 191]. The reproductive phenotypes in patients with these disorders can be either KS or nCHH or both, depending on the developmental or neuroendocrine defects. While most of these patients have secondary hypogonadism responsive to GnRH,

Table 5.1 Syndromic forms of IHH

Syndrome	Gene/locus name/mode of inheritance	Key phenotypes
Prader–Willi syndrome	Paternal loss of 15q11.2/imprinting disorder	Hypotonia in infancy, developmental delay, cryptorchidism/microphallus in males, abnormal satiety, and intellectual disability
Leptin deficiency	<i>LEP</i> mutation/autosomal recessive	Obesity
Leptin receptor deficiency	<i>LEPR</i> mutation/autosomal recessive	Obesity
PCSK1 deficiency	<i>PCSK1</i> mutation/autosomal recessive	Morbid obesity, hypocortisolism, and hypoinsulinemia
X-linked adrenal hypoplasia congenita	<i>NROB1</i> mutation/X-linked recessive	Adrenal insufficiency
CHARGE syndrome	<i>CHD7</i> mutation/autosomal dominant	<u>C</u> oloboma, <u>H</u> ear defects, choanal <u>A</u> tresia, <u>R</u> etardation of growth and development, <u>G</u> onadal defects, and <u>E</u> ar/hearing abnormalities
TUBB3 E410 K syndrome (atypical moebius)	<i>TUBB3</i> mutation/autosomal dominant	Cranial nerve dysinnervation (III, IV, VI, VII nerves) Peripheral neuropathy
Waardenburg syndrome	<i>SOX10</i> mutation/autosomal dominant	Sensorineural hearing loss, pigmentation defects, and Hirschsprung disease
Gordon-Holmes syndrome Boucher-Neuhauser syndrome	<i>RNF216/OTUD4/PNPLA6</i> mutations/oligogenic inheritance	Ataxia Neurodegeneration
Bardet-Biedl syndrome (BBS)	Multiple BBS genes/varied inheritance including oligogenic (see Ref. [199])	rod-cone dystrophy, truncal obesity, postaxial polydactyly, cognitive impairments, and renal abnormalities

some (e.g., Prader–Willi Syndrome) also display gonadal defects. Table 5.1 lists these commonly recognized syndromic forms of CHH, their recognized/putative genetic etiology, and mode of inheritance.

Functional Cause of HH

Functional forms of HH are characterized by a transient decline in GnRH secretion. Severe weight loss and both acute and chronic illness with calorie deficit result in gonadotropin deficiency. While anorexia nervosa is mostly a disease of women, it also affects males. Hypothalamic amenorrhea (HA) is a well-recognized reversible hypogonadotropic state in females in response to energy deficit, but to date, a clinical syndrome of functional GnRH deficiency in men, that is

analogous to HA, has not been well characterized. However, in healthy men, moderate to severe dietary restriction has been reported to be associated with a mild decrease in T levels because GnRH secretion is impaired [192, 193]. In addition, some [194–196] but not all [197, 198] studies have shown that strenuous physical exercise causes a transient decrease in T levels. Clinically, reversible hypogonadotropism in men is recognized in conjunction with drugs and critical illness and is discussed below.

Drug-induced HH

The use of anabolic steroids may result in reversible HH. This is more commonly seen in men and is manifested by a decrease in gonadotropins, gonadal steroids, and, if sufficiently prolonged, suppressed spermatogenesis [199, 200]. Suppression of the HPG axis following androgen

therapy may last more than 16 weeks following discontinuation of the drug [199, 200]. Chronic treatment with pharmacologic doses of glucocorticoids may also cause hypogonadism [201]. Chronic use of narcotic analgesics may also suppress LH secretion and result in reversible HH [202].

HH Associated with Critical Illness

Any severe chronic illness [203], or acute critical illness [204], surgery [205], myocardial infarction [206], or burn injury [207] may result in decreased T levels. Acute injury also causes immediate suppression of Leydig cell function [208]. Prolonged severe stress may also inhibit pulsatile LH secretion, resulting in HH [208].

Evaluation of Congenital HH (See also Chap. 4)

Clinical criteria for the definition of CHH have been described in the Clinical Features section above. A full clinical examination should be done with special emphasis on linear growth, growth chart review, and measurements for evaluating eunuchoid proportions. Sexual examination for the evaluation of Tanner stages for pubic hair, penis length, and testicular size should be performed. Additional system examination for identifying other non-reproductive features of CHH (see Clinical Features section above) should be performed. The biochemical diagnosis should be made on the basis of basal concentrations of T and pituitary gonadotropins. Although it is clinically important to distinguish secondary hypogonadism from hypothalamic versus pituitary causes, the serum LH response to a single bolus of exogenous GnRH cannot determine whether the defect is localized to the pituitary or hypothalamus, because a subnormal response may occur in both settings. Indeed, patients with complete GnRH deficiency are likely to have had no prior exposure to endogenous GnRH, and in this setting, repeated administration of GnRH is needed to prime the gonadotropes and induce a gonadotropin response. The pretreatment inhibin B level may

be a useful predictor of therapeutic outcome for CHH men who desire to conceive [30, 71]. Finally, while frequent blood sampling to characterize the pulsatile pattern of LH secretion may help refine the diagnosis in a research study, it is not practical in the clinical setting. Sense of smell can be evaluated by history and by formal diagnostic smell tests, such as the University of Pennsylvania smell identification test (UPSIT) [209]. This “scratch and sniff” test evaluates an individual’s ability to identify 40 microencapsulated odorants and can be easily performed in most clinical settings. Identification of anosmia, hyposmia, or normosmia is based on the individual’s score, age at testing, and gender and is interpreted using a standard nomogram in the UPSIT manual.

A semen analysis should be obtained in patients with CHH who are able to produce an ejaculate and should include an assessment of the volume, sperm count, motility, and morphology. Since the seminal vesicles, an exquisitely androgen-dependent organ is the major source of seminal fluid volume, many hypogonadal men may be unable to ejaculate any semen, however. The most recent WHO criteria [210] for normal semen analysis parameters are a volume >1.5 mL, a sperm count ≥ 15 million/mL of ejaculate with progressive motility $\geq 32\%$, and normal morphology in $\geq 4\%$. Because of the variability in sperm counts, it is worthwhile to obtain a second semen specimen if the first sample is abnormal. Finally, in the case of secondary hypogonadism, it is critical to assess other pituitary functions (see Chap. 8), including a prolactin level, to ensure that the defect is isolated to the HPG axis. Serum iron/TIBC or ferritin levels should be measured to exclude hemochromatosis. Patients with HH typically undergo adrenarche at a normal age and should therefore have normal adult male levels of DHEAS. Additional tests include a comprehensive metabolic panel, and inflammatory markers may be needed to rule out severe systemic illness that may cause functional HH. Radiographic evaluation should include a bone age determination, MRI of the pituitary and hypothalamic area, renal ultrasound, and a DEXA scan to

assess bone mineral density. In patients with an adult-onset presentation of hypogonadotropic hypogonadism, other secondary causes such as obesity-related hypogonadism must be considered in the differential diagnosis. Additional investigations should be guided by the presence or absence of other syndromic clinical features.

Genetic testing is useful for diagnosis, prognosis, and genetic counseling of patients with CHH. Genetic inheritance patterns (e.g., X-linked vs. autosomal) and the presence of specific clinical features, specifically non-reproductive features, may allow the prioritization of genetic screening [211]. However, given the variable penetrance and expressivity associated with CHH and demonstration of oligogenic inheritance, multiple gene testing may be required, and several gene testing panels are available for screening for the common genetic causes of CHH [212].

Acknowledgements This work was supported by NICHD/NIH grants (P50 HD028138, K23 HD077043) as part of the National Centers for Translational Research in Reproduction and Infertility.

References

1. Wray S. From nose to brain: development of gonadotrophin-releasing hormone-1 neurones. *J Neuroendocrinol.* 2010;22(7):743–53. PMID: PMC2919238.
2. Kaplan SL, Grumbach MM. The ontogenesis of human foetal hormones. II. Luteinizing hormone (LH) and follicle stimulating hormone (FSH). *Acta Endocrinol (Copenh).* 1976;81(4):808–29.
3. Grumbach MM. A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. *J Clin Endocrinol Metab.* 2005;90(5):3122–7.
4. Sharpe RM, McKinnell C, Kivlin C, Fisher JS. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. *Reproduction.* 2003;125(6):769–84.
5. Muller J, Skakkebaek NE. Abnormal germ cells in maldescended testes: a study of cell density, nuclear size and deoxyribonucleic acid content in testicular biopsies from 50 boys. *J Urol.* 1984;131(4):730–3.
6. Apter D, Cacciatore B, Alfthan H, Stenman UH. Serum luteinizing hormone concentrations increase 100-fold in females from 7 years to adulthood, as measured by time-resolved immunofluorometric assay. *J Clin Endocrinol Metab.* 1989;68(1):53–7.
7. Boyar RM, Rosenfeld RS, Kapen S, Finkelstein JW, Roffwarg HP, Weitzman ED, et al. Human puberty. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. *J Clin Invest.* 1974;54(3):609–18. PMID: PMC301594.
8. Ross JL, Loriaux DL, Cutler GB Jr. Developmental changes in neuroendocrine regulation of gonadotropin secretion in gonadal dysgenesis. *J Clin Endocrinol Metab.* 1983;57(2):288–93.
9. Spratt DL, O’Dea LS, Schoenfeld D, Butler J, Rao PN, Crowley WF Jr. Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. *Am J Physiol.* 1988;254(5 Pt 1):E658–66.
10. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and functional aspects of testicular descent and cryptorchidism. *Endocr Rev.* 1997;18(2):259–80.
11. Cortes D, Muller J, Skakkebaek NE. Proliferation of Sertoli cells during development of the human testis assessed by stereological methods. *Int J Androl.* 1987;10(4):589–96.
12. Muller J, Skakkebaek NE. Quantification of germ cells and seminiferous tubules by stereological examination of testicles from 50 boys who suffered from sudden death. *Int J Androl.* 1983;6(2):143–56.
13. Russell LD, Bartke A, Goh JC. Postnatal development of the Sertoli cell barrier, tubular lumen, and cytoskeleton of Sertoli and myoid cells in the rat, and their relationship to tubular fluid secretion and flow. *Am J Anat.* 1989;184(3):179–89.
14. Dym M, Cavicchia JC. Further observations on the blood-testis barrier in monkeys. *Biol Reprod.* 1977;17(3):390–403.
15. Orth JM. Proliferation of Sertoli cells in fetal and postnatal rats: a quantitative autoradiographic study. *Anat Rec.* 1982;203(4):485–92.
16. Orth JM, Gonsalus GL, Lamperti AA. Evidence from Sertoli cell-depleted rats indicates that spermatid number in adults depends on numbers of Sertoli cells produced during perinatal development. *Endocrinology.* 1988;122(3):787–94.
17. Russell LD, Ren HP, Sinha Hikim I, Schulze W, Sinha Hikim AP. A comparative study in twelve mammalian species of volume densities, volumes, and numerical densities of selected testis components, emphasizing those related to the Sertoli cell. *Am J Anat.* 1990;188(1):21–30.
18. Russell LD, Peterson RN. Determination of the elongate spermatid-Sertoli cell ratio in various mammals. *J Reprod Fertil.* 1984;70(2):635–41.
19. Balasubramanian R, Crowley WF, Jr. Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network. *Mol Cell Endocrinol.* 2011;346(1–2):4–12. PMID: 3226734.
20. Balasubramanian R, Dwyer A, Seminara SB, Pitteloud N, Kaiser UB, Crowley WF, Jr. Human GnRH deficiency: a unique disease model to

- unravel the ontogeny of GnRH neurons. *Neuroendocrinology*. 2010;92(2):81–99. PMID: 3214927.
21. Naftolin F, Harris GW, Bobrow M. Effect of purified luteinizing hormone releasing factor on normal and hypogonadotrophic anosmic men. *Nature*. 1971;232(5311):496–7.
 22. Hashimoto T, Miyai K, Izumi K, Kumahara Y. Isolated gonadotropin deficiency with response to luteinizing-hormone-releasing hormone. *N Engl J Med*. 1972;287(21):1059–62.
 23. Roth JC, Kelch RP, Kaplan SL, Grumbach MM. FSH and LH response to luteinizing hormone-releasing factor in prepubertal and pubertal children, adult males and patients with hypogonadotropic and hypertrophic hypogonadism. *J Clin Endocrinol Metab*. 1972;35(6):926–30.
 24. Crowley WF Jr, McArthur JW. Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH). *J Clin Endocrinol Metab*. 1980;51(1):173–5.
 25. Hoffman AR, Crowley WF Jr. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. *N Engl J Med*. 1982;307(20):1237–41.
 26. Kallmann FJ, Schoenfeld W, Barrera S. The genetic aspects of primary eunuchoidism. *Am J Ment Defic*. 1944;48:203–36.
 27. Seminara SB, Hayes FJ, Crowley WF Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. *Endocr Rev*. 1998;19(5):521–39.
 28. Quinton R, Duke VM, Robertson A, Kirk JM, Matfin G, de Zoysa PA, et al. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. *Clin Endocrinol (Oxf)*. 2001;55(2):163–74.
 29. Laitinen EM, Vaaralahti K, Tommiska J, Eklund E, Tervaniemi M, Valanne L, et al. Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland. *Orphanet J Rare Dis*. 2011;6:41. PMID: 3143089.
 30. Pitteloud N, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2002;87(1):152–60.
 31. Waldstreicher J, Seminara SB, Jameson JL, Geyer A, Nachtigall LB, Boepple PA, et al. The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. *J Clin Endocrinol Metab*. 1996;81(12):4388–95.
 32. Costa-Barbosa FA, Balasubramanian R, Keefe KW, Shaw ND, Al-Tassan N, Plummer L, et al. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. *J Clin Endocrinol Metab*. 2013;98(5):E943–53. PMID: 3644607.
 33. Main KM, Schmidt IM, Skakkebaek NE. A possible role for reproductive hormones in newborn boys: progressive hypogonadism without the postnatal testosterone peak. *J Clin Endocrinol Metab*. 2000;85(12):4905–7.
 34. Huhtaniemi IT, Korenbrot CC, Jaffe RB. HCG binding and stimulation of testosterone biosynthesis in the human fetal testis. *J Clin Endocrinol Metab*. 1977;44(5):963–7.
 35. Styne DM. Puberty and its disorders in boys. *Endocrinol Metab Clin North Am*. 1991;20(1):43–69.
 36. Zhu J, Choa RE, Guo MH, Plummer L, Buck C, Palmert MR, et al. A shared genetic basis for self-limited delayed puberty and idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2015;100(4):E646–54. PMID: PMC4399304.
 37. Castaneyra-Perdomo A, Castaneyra-Ruiz L, Gonzalez-Marrero I, Castaneyra-Ruiz A, Gonzalez-Toledo JM, Castaneyra-Ruiz M, et al. Early treatment of Kallmann syndrome may prevent eunuchoid appearance and behavior. *Med Hypotheses*. 2014;82(1):74–6.
 38. Bardin CW, Ross GT, Rifkind AB, Cargille CM, Lipsett MB. Studies of the pituitary-Leydig cell axis in young men with hypogonadotropic hypogonadism and hyposmia: comparison with normal men, prepubertal boys, and hypopituitary patients. *J Clin Invest*. 1969;48(11):2046–56. PMID: PMC297457.
 39. Bin-Abbas B, Conte FA, Grumbach MM, Kaplan SL. Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. *J Pediatr*. 1999;134(5):579–83.
 40. Conrad B, Kriebel J, Hetzel WD. Hereditary bimanual synkinesis combined with hypogonadotropic hypogonadism and anosmia in four brothers. *J Neurol*. 1978;218(4):263–74.
 41. Krams M, Quinton R, Ashburner J, Friston KJ, Frackowiak RS, Bouloux PM, et al. Kallmann's syndrome: mirror movements associated with bilateral corticospinal tract hypertrophy. *Neurology*. 1999;52(4):816–22.
 42. Krams M, Quinton R, Mayston MJ, Harrison LM, Dolan RJ, Bouloux PM, et al. Mirror movements in X-linked Kallmann's syndrome. II. A PET study. *Brain*. 1997;120(Pt 7):1217–28.
 43. Kertzman C, Robinson DL, Sherins RJ, Schwankhaus JD, McClurkin JW. Abnormalities in visual spatial attention in men with mirror movements associated with isolated hypogonadotropic hypogonadism. *Neurology*. 1990;40(7):1057–63.
 44. Kirk JM, Grant DB, Besser GM, Shalet S, Quinton R, Smith CS, et al. Unilateral renal aplasia in X-linked Kallmann's syndrome. *Clin Genet*. 1994;46(3):260–2.

45. Molsted K, Kjaer I, Giwercman A, Vesterhauge S, Skakkebaek NE. Craniofacial morphology in patients with Kallmann's syndrome with and without cleft lip and palate. *Cleft Palate Craniofac J*. 1997;34(5):417–24.
46. Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, Sykiotis GP, et al. Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. *Genet Med*. 2015;17(8):651–9. PMID: PMC4430466.
47. Baillleul-Forestier I, Gros C, Zenaty D, Bennaceur S, Leger J, de Roux N. Dental agenesis in Kallmann syndrome individuals with FGFR1 mutations. *Int J Paediatr Dent*. 2010;20(4):305–12.
48. Suzuki E, Izumi Y, Chiba Y, Horikawa R, Matsubara Y, Tanaka M, et al. Loss-of-function SOX10 mutation in a patient with Kallmann syndrome, hearing loss, and Iris hypopigmentation. *Horm Res Paediatr*. 2015;84(3):212–6.
49. Chew S, Balasubramanian R, Chan WM, Kang PB, Andrews C, Webb BD, et al. A novel syndrome caused by the E410 K amino acid substitution in the neuronal beta-tubulin isotype 3. *Brain*. 2013;136(Pt 2):522–35. PMID: PMC3572929.
50. Moorman JR, Crain B, Osborne D. Kallman's syndrome with associated cardiovascular and intracranial anomalies. *Am J Med*. 1984;77(2):369–72.
51. Cortez AB, Galindo A, Arensman FW, Van Dop C. Congenital heart disease associated with sporadic Kallmann syndrome. *Am J Med Genet*. 1993;46(5):551–4.
52. McCullagh EP, Beck JC, Schaffenburg CA. A syndrome of eunuchoidism with spermatogenesis, normal urinary FSH and low or normal ICSH: (fertile eunuchs). *J Clin Endocrinol Metab*. 1953;13(5):489–509.
53. Smals AG, Kloppenborg PW, van Haelst UJ, Lequin R, Benraad TJ. Fertile eunuch syndrome versus classic hypogonadotropic hypogonadism. *Acta Endocrinol (Copenh)*. 1978;87(2):389–99.
54. Rogol AD, Mittal KK, White BJ, McGinniss MH, Liebllich JM, Rosen SW. HLA-compatible paternity in two "fertile eunuchs" with congenital hypogonadotropic hypogonadism and anosmia (the Kallmann syndrome). *J Clin Endocrinol Metab*. 1980;51(2):275–9.
55. Pitteloud N, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF Jr, Hayes FJ. The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. *J Clin Endocrinol Metab*. 2001;86(6):2470–5.
56. Nachtigall LB, Boepple PA, Pralong FP, Crowley WF Jr. Adult-onset idiopathic hypogonadotropic hypogonadism—a treatable form of male infertility. *N Engl J Med*. 1997;336(6):410–5.
57. Dwyer AA, Hayes FJ, Plummer L, Pitteloud N, Crowley WF, Jr. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2010;95(9):4235–43. PMID: PMC2936052.
58. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, et al. Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med*. 2007;357(9):863–73.
59. Sidhoum VF, Chan YM, Lippincott MF, Balasubramanian R, Quinton R, Plummer L, et al. Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system. *J Clin Endocrinol Metab*. 2014;99(3):861–70. PMID: PMC3942233.
60. Andersson AM, Muller J, Skakkebaek NE. Different roles of prepubertal and postpubertal germ cells and Sertoli cells in the regulation of serum inhibin B levels. *J Clin Endocrinol Metab*. 1998;83(12):4451–8.
61. Andersson AM, Juul A, Petersen JH, Muller J, Groome NP, Skakkebaek NE. Serum inhibin B in healthy pubertal and adolescent boys: relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone, and estradiol levels. *J Clin Endocrinol Metab*. 1997;82(12):3976–81.
62. Nachtigall LB, Boepple PA, Seminara SB, Khoury RH, Sluss PM, Lecain AE, et al. Inhibin B secretion in males with gonadotropin-releasing hormone (GnRH) deficiency before and during long-term GnRH replacement: relationship to spontaneous puberty, testicular volume, and prior treatment—a clinical research center study. *J Clin Endocrinol Metab*. 1996;81(10):3520–5.
63. Tran D, Muesy-Dessole N, Josso N. Anti-Mullerian hormone is a functional marker of foetal Sertoli cells. *Nature*. 1977;269(5627):411–2.
64. Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G. Antimullerian hormone in patients with hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 1999;84(8):2696–9.
65. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. *J Clin Endocrinol Metab*. 1996;81(2):571–6.
66. Ivell R, Wade JD, Anand-Ivell R. INSL3 as a biomarker of Leydig cell functionality. *Biol Reprod*. 2013;88(6):147.
67. Trabado S, Maione L, Bry-Gaillard H, Affres H, Salenave S, Sarfati J, et al. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of

- different modalities of hormonal treatment: a single-center study of 281 patients. *J Clin Endocrinol Metab.* 2014;99(2):E268–75.
68. Arimura A, Kastin AJ, Gonzalez-Barcena D, Siller J, Weaver RE, Schally AV. Disappearance of LH-releasing hormone in man as determined by radioimmunoassay. *Clin Endocrinol (Oxf).* 1974;3(4):421–5.
 69. Hayes FJ, Crowley WF Jr. Gonadotropin pulsations across development. *Horm Res.* 1998;49(3–4):163–8.
 70. Hayes FJ, McNicholl DJ, Schoenfeld D, Marsh EE, Hall JE. Free alpha-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. *J Clin Endocrinol Metab.* 1999;84(3):1028–36.
 71. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2002;87(9):4128–36.
 72. Spratt DI, Finkelstein JS, O’Dea LS, Badger TM, Rao PN, Campbell JD, et al. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. A model for studies of the hormone’s physiologic effects. *Ann Intern Med.* 1986;105(6):848–55.
 73. Pitteloud N, Thambundit A, Dwyer AA, Falardeau JL, Plummer L, Caronia LM, et al. Role of seminiferous tubular development in determining the FSH versus LH responsiveness to GnRH in early sexual maturation. *Neuroendocrinology.* 2009;90(3):260–8. PMID: PMC2826435.
 74. Georgopoulos NA, Pralong FP, Seidman CE, Seidman JG, Crowley WF Jr, Vallejo M. Genetic heterogeneity evidenced by low incidence of KAL-1 gene mutations in sporadic cases of gonadotropin-releasing hormone deficiency. *J Clin Endocrinol Metab.* 1997;82(1):213–7.
 75. Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. *Proc Natl Acad Sci U S A.* 2010;107(34):15140–4. PMID: 2930591.
 76. Oliveira LM, Seminara SB, Beranova M, Hayes FJ, Valkenburgh SB, Schipani E, et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. *J Clin Endocrinol Metab.* 2001;86(4):1532–8.
 77. Bick D, Curry CJ, McGill JR, Schorderet DF, Bux RC, Moore CM. Male infant with ichthyosis, Kallmann syndrome, chondrodysplasia punctata, and an Xp chromosome deletion. *Am J Med Genet.* 1989;33(1):100–7.
 78. Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, et al. A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. *Nature.* 1991;353(6344):529–36.
 79. Legouis R, Hardelin JP, Levilliers J, Claverie JM, Compain S, Wunderle V, et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. *Cell.* 1991;67(2):423–35.
 80. Hardelin JP, Dode C. The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. *Sex Dev.* 2008;2(4–5):181–93.
 81. Schwanzel-Fukuda M, Bick D, Pfaff DW. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. *Brain Res Mol Brain Res.* 1989;6(4):311–26.
 82. Massin N, Pecheux C, Eloit C, Bensimon JL, Galey J, Kuttent F, et al. X chromosome-linked Kallmann syndrome: clinical heterogeneity in three siblings carrying an intragenic deletion of the KAL-1 gene. *J Clin Endocrinol Metab.* 2003;88(5):2003–8.
 83. Hardelin JP, Julliard AK, Moniot B, Soussi-Yanicostas N, Verney C, Schwanzel-Fukuda M, et al. Anosmin-1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: implications for the developmental anomalies of X chromosome-linked Kallmann syndrome. *Dev Dyn.* 1999;215(1):26–44.
 84. Dode C, Hardelin JP. Kallmann syndrome. *Eur J Hum Genet.* 2009;17(2):139–46. PMID: PMC2986064.
 85. Dode C, Hardelin JP. Clinical genetics of Kallmann syndrome. *Ann Endocrinol (Paris).* 2010;71(3):149–57.
 86. Elmaleh-Berges M, Baumann C, Noel-Petroff N, Sekkal A, Couloigner V, Devriendt K, et al. Spectrum of temporal bone abnormalities in patients with Waardenburg syndrome and SOX10 mutations. *AJNR Am J Neuroradiol.* 2013;34(6):1257–63.
 87. Pingault V, Bodereau V, Baral V, Marcos S, Watanabe Y, Chaoui A, et al. Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. *Am J Hum Genet.* 2013;92(5):707–24. PMID: 3644631.
 88. Barraud P, St John JA, Stolt CC, Wegner M, Baker CV. Olfactory ensheathing glia are required for embryonic olfactory axon targeting and the migration of gonadotropin-releasing hormone neurons. *Biol Open.* 2013;2(7):750–9. PMID: PMC3711043.
 89. Forni PE, Taylor-Burds C, Melvin VS, Williams T, Wray S. Neural crest and ectodermal cells intermix in the nasal placode to give rise to GnRH-1 neurons, sensory neurons, and olfactory ensheathing cells. *J Neurosci.* 2011;31(18):6915–27. PMID: PMC3101109.
 90. Whitlock KE, Wolf CD, Boyce ML. Gonadotropin-releasing hormone (GnRH) cells

- arise from cranial neural crest and adenohipophyseal regions of the neural plate in the zebrafish. *Danio rerio Dev Biol.* 2003;257(1):140–52.
91. Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas JG, Ruhrberg C. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism. *Hum Mol Genet.* 2011;20(2):336–44.
 92. Young J, Metay C, Bouligand J, Tou B, Francou B, Maione L, et al. SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. *Hum Reprod.* 2012;27(5):1460–5.
 93. Hanchate NK, Giacobini P, Lhuillier P, Parkash J, Espy C, Fouveaut C, et al. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. *PLoS Genet.* 2012;8(8):e1002896. PMID: PMC3426548.
 94. Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. *Am J Hum Genet.* 2013;92(5):725–43. PMID: PMC3644636.
 95. Tsang M, Friesel R, Kudoh T, Dawid IB. Identification of Sef, a novel modulator of FGF signalling. *Nat Cell Biol.* 2002;4(2):165–9.
 96. Korsensky L, Ron D. Regulation of FGF signaling: Recent insights from studying positive and negative modulators. *Semin Cell Dev Biol.* 2016;53:101–14.
 97. Furthauer M, Lin W, Ang SL, Thisse B, Thisse C. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. *Nat Cell Biol.* 2002;4(2):170–4.
 98. Ladher RK, Wright TJ, Moon AM, Mansour SL, Schoenwolf GC. FGF8 initiates inner ear induction in chick and mouse. *Genes Dev.* 2005;19(5):603–13. PMID: PMC551580.
 99. Kotan LD, Hutchins BI, Ozkan Y, Demirel F, Stoner H, Cheng PJ, et al. Mutations in FEZF1 cause Kallmann syndrome. *Am J Hum Genet.* 2014;95(3):326–31. PMID: PMC4157145.
 100. Hutchins BI, Kotan LD, Taylor-Burds C, Ozkan Y, Cheng PJ, Gurbuz F, et al. CCDC141 Mutation identified in anosmic hypogonadotropic hypogonadism (Kallmann Syndrome) alters GnRH neuronal migration. *Endocrinology.* 2016;157(5):1956–66. PMID: PMC4870868.
 101. Eckler MJ, McKenna WL, Taghvaei S, McConnell SK, Chen B. Fezf1 and Fezf2 are required for olfactory development and sensory neuron identity. *J Comp Neurol.* 2011;519(10):1829–46. PMID: PMC3268373.
 102. Watanabe Y, Inoue K, Okuyama-Yamamoto A, Nakai N, Nakatani J, Nibu K, et al. Fezf1 is required for penetration of the basal lamina by olfactory axons to promote olfactory development. *J Comp Neurol.* 2009;515(5):565–84.
 103. Shimizu T, Hibi M. Formation and patterning of the forebrain and olfactory system by zinc-finger genes Fezf1 and Fezf2. *Dev Growth Differ.* 2009;51(3):221–31.
 104. Chauvet S, Cohen S, Yoshida Y, Fekrane L, Livet J, Gayet O, et al. Gating of Semaphorin3E/PlexinD1 signaling by neuropilin-1 switches axonal repulsion to attraction during brain development. *Neuron.* 2007;56(5):807–22. PMID: PMC2700040.
 105. Cariboni A, Andre V, Chauvet S, Cassatella D, Davidson K, Caramello A, et al. Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome. *J Clin Invest.* 2015;125(6):2413–28. PMID: PMC4497752.
 106. de Roux N, Young J, Misrahi M, Genet R, Chanson P, Schaison G, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. *N Engl J Med.* 1997;337(22):1597–602.
 107. Layman LC, Cohen DP, Jin M, Xie J, Li Z, Reindollar RH, et al. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. *Nat Genet.* 1998;18(1):14–5.
 108. Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. *Endocr Rev.* 1994;15(4):462–99.
 109. Gianetti E, Hall JE, Au MG, Kaiser UB, Quinton R, Stewart JA, et al. When genetic load does not correlate with phenotypic spectrum: lessons from the GnRH receptor (GNRHR). *J Clin Endocrinol Metab.* 2012;97(9):E1798–807. PMID: 3431570.
 110. Mason AJ, Pitts SL, Nikolics K, Szonyi E, Wilcox JN, Seeburg PH, et al. Gonadal development and gametogenesis in the hypogonadal mouse are restored by gene transfer. *Ann N Y Acad Sci.* 1987;513:16–26.
 111. Bouligand J, Ghervan C, Tello JA, Brailly-Tabard S, Salenave S, Chanson P, et al. Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. *N Engl J Med.* 2009;360(26):2742–8.
 112. Chan YM, de Guillebon A, Lang-Muritano M, Plummer L, Cerrato F, Tsiaras S, et al. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci U S A.* 2009;106(28):11703–8. PMID: 2710623.
 113. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. *Proc Natl Acad Sci U S A.* 2003;100(19):10972–6. PMID: 196911.
 114. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierio JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. *New Engl J Med.* 2003;349(17):1614–27.

115. George JT, Seminara SB. Kisspeptin and the Hypothalamic control of reproduction: lessons from the human. *Endocrinology*. 2012.
116. Steiner RA. Kisspeptin: past, present, and prologue. *Adv Exp Med Biol*. 2013;784:3–7.
117. Seminara SB. Mechanisms of disease: the first kiss—a crucial role for kisspeptin-1 and its receptor, G-protein-coupled receptor 54, in puberty and reproduction. *Nat Clin Pract Endocrinol Metab*. 2006;2(6):328–34.
118. Tenenbaum-Rakover Y, Commenges-Ducos M, Iovane A, Aumas C, Admoni O, de Roux N. Neuroendocrine phenotype analysis in five patients with isolated hypogonadotropic hypogonadism due to a L102P inactivating mutation of GPR54. *J Clin Endocrinol Metab*. 2007;92(3):1137–44.
119. Francou B, Paul C, Amazit L, Cartes A, Bouvattier C, Albarel F, et al. Prevalence of KISS1 Receptor mutations in a series of 603 patients with normosmic congenital hypogonadotropic hypogonadism and characterization of novel mutations: a single-centre study. *Hum Reprod*. 2016;31(6):1363–74.
120. Semple RK, Achermann JC, Ellery J, Farooqi IS, Karet FE, Stanhope RG, et al. Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2005;90(3):1849–55.
121. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, et al. A GPR54-activating mutation in a patient with central precocious puberty. *N Engl J Med*. 2008;358(7):709–15. PMID: 2859966.
122. Lee JY, Moon JS, Eu YJ, Lee CW, Yang ST, Lee SK, et al. Molecular interaction between kisspeptin decapeptide analogs and a lipid membrane. *Arch Biochem Biophys*. 2009;485(2):109–14.
123. Lee YR, Tsunekawa K, Moon MJ, Um HN, Hwang JI, Osugi T, et al. Molecular evolution of multiple forms of kisspeptins and GPR54 receptors in vertebrates. *Endocrinology*. 2009;150(6):2837–46.
124. Thompson EL, Murphy KG. Modulation of the hypothalamic-pituitary-gonadal axis by selective ligands of the KISS1R. *Curr Opin Investig Drugs*. 2010;11(4):432–9.
125. Chan YM, Broder-Fingert S, Seminara SB. Reproductive functions of kisspeptin and Gpr54 across the life cycle of mice and men. *Peptides*. 2009;30(1):42–8. PMID: 2656499.
126. Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, Erdogan S, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. *N Engl J Med*. 2012;366(7):629–35.
127. Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. *Nat Genet*. 2009;41(3):354–8.
128. Semple RK, Topaloglu AK. Neurokinin B and its receptor in hypogonadotropic hypogonadism. *Front Horm Res*. 2010;39:133–41.
129. Misu R, Noguchi T, Ohno H, Oishi S, Fujii N. Structure-activity relationship study of tachykinin peptides for the development of novel neurokinin-3 receptor selective agonists. *Bioorg Med Chem*. 2013;21(8):2413–7.
130. Rance NE, Krajewski SJ, Smith MA, Cholanian M, Dacks PA. Neurokinin B and the hypothalamic regulation of reproduction. *Brain Res*. 2010;1364:116–28. PMID: 2992576.
131. Smith ME, Flynn PM. Distribution of Fos-like immunoreactivity within the rat brain following intraventricular injection of the selective NK(3) receptor agonist senktide. *J Comp Neurol*. 2000;426(3):413–28.
132. Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. *Endocrinology*. 2010;151(8):3479–89. PMID: 2940527.
133. Francou B, Bouligand J, Voican A, Amazit L, Trabado S, Fagart J, et al. Normosmic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations. *PLoS One*. 2011;6(10):e25614. PMID: 3198730.
134. Young J, Bouligand J, Francou B, Raffin-Sanson ML, Gaillez S, Jeanpierre M, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. *J Clin Endocrinol Metab*. 2010;95(5):2287–95.
135. Gianetti E, Tusset C, Noel SD, Au MG, Dwyer AA, Hughes VA, et al. TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. *J Clin Endocrinol Metab*. 2010;95(6):2857–67. PMID: 2902066.
136. Ruiz-Pino F, Navarro VM, Bentsen AH, Garcia-Galiano D, Sanchez-Garrido MA, Ciofi P, et al. Neurokinin B and the control of the gonadotropic axis in the rat: developmental changes, sexual dimorphism, and regulation by gonadal steroids. *Endocrinology*. 2012;153(10):4818–29. PMID: 3512006.
137. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. *Nat Rev Drug Discov*. 2009;8(3):235–53. PMID: 3684054.
138. Dode C, Levilliers J, Dupont JM, De Paepe A, Le Du N, Soussi-Yanicostas N, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. *Nat Genet*. 2003;33(4):463–5.
139. Pitteloud N, Meysing A, Quinton R, Acierno JS Jr, Dwyer AA, Plummer L, et al. Mutations in fibroblast growth factor receptor 1 cause

- Kallmann syndrome with a wide spectrum of reproductive phenotypes. *Mol Cell Endocrinol*. 2006;254–255:60–9.
140. Pitteloud N, Acierno JS, Jr., Meysing A, Eliseenkova AV, Ma J, Ibrahim OA, et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci U S A*. 2006;103(16):6281–6. PMID: 1458869.
 141. Zhang X, Ibrahim OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem*. 2006;281(23):15694–700. PMID: 2080618.
 142. Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. *J Clin Invest*. 2008;118(8):2822–31. PMID: 2441855.
 143. Dode C, Hardelin JP. Kallmann syndrome: fibroblast growth factor signaling insufficiency? *J Mol Med (Berl)*. 2004;82(11):725–34.
 144. Hebert JM, Lin M, Partanen J, Rossant J, McConnell SK. FGF signaling through FGFR1 is required for olfactory bulb morphogenesis. *Development*. 2003;130(6):1101–11.
 145. Chung WC, Moyle SS, Tsai PS. Fibroblast growth factor 8 signaling through fibroblast growth factor receptor 1 is required for the emergence of gonadotropin-releasing hormone neurons. *Endocrinology*. 2008;149(10):4997–5003. PMID: 2582917.
 146. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahim OA, Lao Z, et al. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. *Genes Dev*. 2006;20(2):185–98. PMID: 1356110.
 147. Loo BM, Salmivirta M. Heparin/Heparan sulfate domains in binding and signaling of fibroblast growth factor 8b. *J Biol Chem*. 2002;277(36):32616–23.
 148. Bulow HE, Berry KL, Topper LH, Peles E, Hobert O. Heparan sulfate proteoglycan-dependent induction of axon branching and axon misrouting by the Kallmann syndrome gene *kal-1*. *Proc Natl Acad Sci U S A*. 2002;99(9):6346–51. PMID: 122951.
 149. Tornberg J, Sykiotis GP, Keefe K, Plummer L, Hoang X, Hall JE, et al. Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci U S A*. 2011;108(28):11524–9. PMID: 3136273.
 150. Pinto G, Abadie V, Mesnage R, Blustajn J, Cabrol S, Amiel J, et al. CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. *J Clin Endocrinol Metab*. 2005;90(10):5621–6.
 151. Blake KD, Prasad C. CHARGE syndrome. *Orphanet J Rare Dis*. 2006;1:34. PMID: 1586184.
 152. Colin C, Tobaruella FS, Correa RG, Sogayar MC, Demasi MA. Cloning and characterization of a novel alternatively spliced transcript of the human CHD7 putative helicase. *BMC Res Notes*. 2010;3:252. PMID: 2966464.
 153. Hurd EA, Poucher HK, Cheng K, Raphael Y, Martin DM. The ATP-dependent chromatin remodeling enzyme CHD7 regulates pro-neural gene expression and neurogenesis in the inner ear. *Development*. 2010;137(18):3139–50. PMID: 2926962.
 154. Balasubramanian R, Choi JH, Francescatto L, Willer J, Horton ER, Asimacopoulos EP, et al. Functionally compromised CHD7 alleles in patients with isolated GnRH deficiency. *Proc Natl Acad Sci U S A*. 2014;111(50):17953–8. PMID: 4273325.
 155. Marcos S, Sarfati J, Leroy C, Fouveaut C, Parent P, Metz C, et al. The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients. *J Clin Endocrinol Metab*. 2014;99(10):E2138–43.
 156. Schulz Y, Wehner P, Opitz L, Salinas-Riester G, Bongers EM, van Ravenswaaij-Arts CM, et al. CHD7, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance. *Hum Genet*. 2014;133(8):997–1009.
 157. Choucair N, Abou Ghoch J, Fawaz A, Megarbane A, Chouery E. 10q26.1 Microdeletion: Redefining the critical regions for microcephaly and genital anomalies. *Am J Med Genet A*. 2015; 167A(11):2707–13.
 158. Schinzel A, Lorda-Sanchez I, Binkert F, Carter NP, Bebb CE, Ferguson-Smith MA, et al. Kallmann syndrome in a boy with a t(1;10) translocation detected by reverse chromosome painting. *J Med Genet*. 1995;32(12):957–61. PMID: 1051777.
 159. Kim HG, Ahn JW, Kurth I, Ullmann R, Kim HT, Kulharya A, et al. WDR11, a WD protein that interacts with transcription factor EMX1, is mutated in idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. *Am J Hum Genet*. 2010;87(4):465–79. PMID: 2948809.
 160. Quaynor SD, Kim HG, Cappello EM, Williams T, Chorich LP, Bick DP, et al. The prevalence of digenic mutations in patients with normosmic hypogonadotropic hypogonadism and Kallmann syndrome. *Fertil Steril*. 2011;96(6):1424–30 e6.
 161. Pitteloud N, Zhang C, Pignatelli D, Li JD, Raivio T, Cole LW, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and

- normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci U S A*. 2007;104(44):17447–52. PMID: 2077276.
162. Matsumoto S, Yamazaki C, Masumoto KH, Nagano M, Naito M, Soga T, et al. Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. *Proc Natl Acad Sci U S A*. 2006;103(11):4140–5. PMID: 1449660.
 163. Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY. Identification of two prokineticin cDNAs: recombinant proteins potentially contract gastrointestinal smooth muscle. *Mol Pharmacol*. 2001;59(4):692–8.
 164. Bullock CM, Li JD, Zhou QY. Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. *Mol Pharmacol*. 2004;65(3):582–8.
 165. Burton KJ, Li X, Li B, Cheng MY, Urbanski HF, Zhou QY. Expression of prokineticin 2 and its receptor in the macaque monkey brain. *Chronobiol Int*. 2016;33(2):191–9.
 166. Zhang C, Truong KK, Zhou QY. Efferent projections of prokineticin 2 expressing neurons in the mouse suprachiasmatic nucleus. *PLoS One*. 2009;4(9):e7151. PMID: 2747004.
 167. Masumoto KH, Nagano M, Takashima N, Hayasaka N, Hiyama H, Matsumoto S, et al. Distinct localization of prokineticin 2 and prokineticin receptor 2 mRNAs in the rat suprachiasmatic nucleus. *Eur J Neurosci*. 2006;23(11):2959–70.
 168. Ng KL, Li JD, Cheng MY, Leslie FM, Lee AG, Zhou QY. Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. *Science*. 2005;308(5730):1923–7.
 169. Dode C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler ML, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. *PLoS Genet*. 2006;2(10):e175. PMID: 1617130.
 170. Cole LW, Sidis Y, Zhang C, Quinton R, Plummer L, Pignatelli D, et al. Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. *J Clin Endocrinol Metab*. 2008;93(9):3551–9. PMID: 2567850.
 171. Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Pinero A, Wolczynski S, et al. A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. *J Clin Endocrinol Metab*. 2010;95(2):659–69.
 172. Balasubramanian R, Plummer L, Sidis Y, Pitteloud N, Martin C, Zhou QY, et al. The puzzles of the prokineticin 2 pathway in human reproduction. *Mol Cell Endocrinol*. 2011;346(1–2):44–50. PMID: 3216477.
 173. Abreu AP, Noel SD, Xu S, Carroll RS, Latronico AC, Kaiser UB. Evidence of the importance of the first intracellular loop of prokineticin receptor 2 in receptor function. *Mol Endocrinol*. 2012;26(8):1417–27. PMID: 3404297.
 174. Balasubramanian R, Cohen DA, Klerman EB, Pignatelli D, Hall JE, Dwyer AA, et al. Absence of central circadian pacemaker abnormalities in humans with loss of function mutation in prokineticin 2. *J Clin Endocrinol Metab*. 2014;99(3):E561–6. PMID: 3942237.
 175. Kramer PR, Wray S. Novel gene expressed in nasal region influences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neurons. *Genes Dev*. 2000;14(14):1824–34. PMID: 316793.
 176. Miura K, Acierno JS Jr, Seminara SB. Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). *J Hum Genet*. 2004;49(5):265–8.
 177. Xu N, Kim HG, Bhagavath B, Cho SG, Lee JH, Ha K, et al. Nasal embryonic LHRH factor (NELF) mutations in patients with normosmic hypogonadotropic hypogonadism and Kallmann syndrome. *Fertil Steril*. 2011;95(5):1613–20 e1–7.
 178. Pitteloud N, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. *J Clin Invest*. 2007;117(2):457–63. PMID: 1765517.
 179. Quaynor SD, Ko EK, Chorich LP, Sullivan ME, Demir D, Waller JL, et al. NELF knockout is associated with impaired pubertal development and subfertility. *Mol Cell Endocrinol*. 2015;407:26–36. PMID: 4429764.
 180. Spilker C, Nullmeier S, Grochowska KM, Schumacher A, Butnaru I, Macharadze T, et al. A Jacob/Nsmf gene knockout results in hippocampal dysplasia and impaired BDNF signaling in dendritogenesis. *PLoS Genet*. 2016;12(3):e1005907. PMID: 4792503.
 181. Crino A, Schiaffini R, Ciampalini P, Spera S, Beccaria L, Benzi F, et al. Hypogonadism and pubertal development in Prader-Willi syndrome. *Eur J Pediatr*. 2003;162(5):327–33.
 182. von Schnurbein J, Moss A, Nagel SA, Muehleder H, Debatin KM, Farooqi IS, et al. Leptin substitution results in the induction of menstrual cycles in an adolescent with leptin deficiency and hypogonadotropic hypogonadism. *Horm Res Paediatr*. 2012;77(2):127–33.

183. Farooqi IS, Wangenstein T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. *N Engl J Med*. 2007;356(3):237–47. PMID: 2670197.
184. Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. *Semin Reprod Med*. 2002;20(2):139–44.
185. Seminara SB, Achermann JC, Genel M, Jameson JL, Crowley WF Jr. X-linked adrenal hypoplasia congenita: a mutation in DAX1 expands the phenotypic spectrum in males and females. *J Clin Endocrinol Metab*. 1999;84(12):4501–9.
186. Achermann JC, Gu WX, Kotlar TJ, Meeks JJ, Sabacan LP, Seminara SB, et al. Mutational analysis of DAX1 in patients with hypogonadotropic hypogonadism or pubertal delay. *J Clin Endocrinol Metab*. 1999;84(12):4497–500.
187. Chew S, Balasubramanian R, Chan WM, Kang PB, Andrews C, Webb BD, et al. A novel syndrome caused by the E410 K amino acid substitution in the neuronal beta-tubulin isotype 3. *Brain*. 2013;136(Pt 2):522–35. PMID: 3572929.
188. Quinton R, Barnett P, Coskeran P, Bouloux PM. Gordon Holmes spinocerebellar ataxia: a gonadotrophin deficiency syndrome resistant to treatment with pulsatile gonadotrophin-releasing hormone. *Clin Endocrinol (Oxf)*. 1999;51(4):525–9.
189. Margolin DH, Kousi M, Chan YM, Lim ET, Schmahmann JD, Hadjivassiliou M, et al. Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. *N Engl J Med*. 2013;368(21):1992–2003. PMID: 3738065.
190. Hashimoto T, Kumahara Y. Concerning hypogonadism of Laurence-Moon-Biedl syndrome. *Metabolism*. 1979;28(4):370–2.
191. M’Hamdi O, Ouertani I, Chaabouni-Bouhamed H. Update on the genetics of bardet-biedl syndrome. *Mol Syndromol*. 2013;5(2):51–6. PMID: 3977223.
192. Klibanski A, Beitins IZ, Badger T, Little R, McArthur JW. Reproductive function during fasting in men. *J Clin Endocrinol Metab*. 1981;53(2):258–63.
193. Veldhuis JD, Iranmanesh A, Evans WS, Lizarralde G, Thorner MO, Vance ML. Amplitude suppression of the pulsatile mode of immunoradiometric luteinizing hormone release in fasting-induced hypoandrogenemia in normal men. *J Clin Endocrinol Metab*. 1993;76(3):587–93.
194. Wheeler GD, Wall SR, Belcastro AN, Cumming DC. Reduced serum testosterone and prolactin levels in male distance runners. *JAMA*. 1984;252(4):514–6.
195. McColl EM, Wheeler GD, Gomes P, Bhambhani Y, Cumming DC. The effects of acute exercise on pulsatile LH release in high-mileage male runners. *Clin Endocrinol (Oxf)*. 1989;31(5):617–21.
196. Safarinejad MR, Azma K, Kolahi AA. The effects of intensive, long-term treadmill running on reproductive hormones, hypothalamus-pituitary-testis axis, and semen quality: a randomized controlled study. *J Endocrinol*. 2009;200(3):259–71.
197. Bagatell CJ, Dahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. *J Androl*. 1994;15(1):15–21.
198. Snegovskaya V, Viru A. Steroid and pituitary hormone responses to rowing: relative significance of exercise intensity and duration and performance level. *Eur J Appl Physiol Occup Physiol*. 1993;67(1):59–65.
199. Alen M, Reinila M, Vihko R. Response of serum hormones to androgen administration in power athletes. *Med Sci Sports Exerc*. 1985;17(3):354–9.
200. Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. *Addiction*. 2015;110(5):823–31. PMID: 4398624.
201. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. *Ann Intern Med*. 1986;104(5):648–51.
202. Hallinan R, Byrne A, Agho K, McMahon CG, Tynan P, Attia J. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. *Int J Androl*. 2009;32(2):131–9.
203. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. *Endocrinol Metab Clin North Am*. 2007;36(2):333–48.
204. Van den Berghe G, de Zegher F, Lauwers P, Veldhuis JD. Luteinizing hormone secretion and hypoandrogenaemia in critically ill men: effect of dopamine. *Clin Endocrinol (Oxf)*. 1994;41(5):563–9.
205. Wang C, Chan V, Yeung RT. Effect of surgical stress on pituitary-testicular function. *Clin Endocrinol (Oxf)*. 1978;9(3):255–66.
206. Wang C, Chan V, Tse TF, Yeung RT. Effect of acute myocardial infarction on pituitary-testicular function. *Clin Endocrinol (Oxf)*. 1978;9(3):249–53.
207. Lephart ED, Baxter CR, Parker CR Jr. Effect of burn trauma on adrenal and testicular steroid hormone production. *J Clin Endocrinol Metab*. 1987;64(4):842–8.
208. Spratt DI, Bigos ST, Beitins I, Cox P, Longcope C, Orav J. Both hyper- and hypogonadotropic hypogonadism occur transiently in acute illness: bio- and immunoactive gonadotropins. *J Clin Endocrinol Metab*. 1992;75(6):1562–70.
209. Doty RL. Office procedures for quantitative assessment of olfactory function. *Am J Rhinol*. 2007;21(4):460–73.

210. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World Health Organization reference values for human semen characteristics. *Hum Reprod Update*. 2010;16(3):231–45.
211. Costa-Barbosa FA, Balasubramanian R, Keefe KW, Shaw ND, Al-Tassan N, Plummer L, et al. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. *J Clin Endocrinol Metab*. 2013;98(5):E943–53. PMID: 3644607.
212. GeneTests. [cited June 2016]; Available from: <https://www.genetests.org>.
213. Stamou M, et al. *Endocr Rev*. 2016;2016(1):4–22.

Male Hypogonadism Resulting from Mutations in the Genes for the Gonadotropin Subunits and Their Receptors

Ilpo T. Huhtaniemi MD, PhD

Contents

Introduction	127
Structure of the Gonadotropin Subunit and Gonadotropin Receptor Genes and Proteins	128
Gonadotropin Subunits	128
Gonadotropin Receptors	129
Gonadotropin Secretion and Actions Throughout the Male Life Span	131
Gonadotropin Subunit Mutations	132
Common α -Subunit (CGA) and hCG β -Subunit (CGB)	132
LH β Subunit(LHB) Mutations	134
LHB Polymorphisms	135
FSH β Subunit (FSHB) Mutations	136
FSHB Polymorphisms	137
Gonadotropin Receptor Mutations	138
LHCGR Mutations	138
FSHR Mutations	140
Gonadotropin Receptor Polymorphisms	143
Concluding Remarks	144
References	145

Introduction

The unraveling of the structure of the human genome has allowed for major advances in the diagnostics of inherited diseases. Besides clear

disease-causing mutations, the emerging knowledge about polymorphisms concerning single nucleotides (SNPs), DNA repeats (microsatellites), deletions, and copy number variation in the human genome adds a new level of complexity to genomic function, providing the structural basis for individual variability of the genome and its phenotypic expression. All mutations can, in principle, be classified as inactivating, activating, or neutral, i.e., with no effect on function of the encoded protein. The hormone ligand mutations that are known today are almost invariably inactivating. The polymorphisms, by definition, are neutral, or they have only minor effects at the functional level. In some cases, they may even offer a functional advantage to their carriers. In the case of hormone receptors, the inactivating mutations impair receptor function through a variety of mechanisms, whereas with activating mutations, the receptor becomes constitutively activated in the absence of hormone, or it acquires novel functions not present in the wild-type (WT) receptor.

Reproductive functions, like all functions on the human body that are under genetic control, are affected by specific mutations and polymorphisms of key genes. The focus of this chapter is to review the currently known mutations in the three gonadotropins, pituitary luteinizing hormone (LH), its placental analog, human chorionic gonadotropin (hCG), and pituitary follicle-stimulating hormone (FSH), as well as their cognate receptors (R), the LHCGR and FSHR.

I.T. Huhtaniemi (✉)

Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer, Imperial College, London W12 0NN, UK
e-mail: ilpo.huhtaniemi@imperial.ac.uk

Specific forms of male gonadal dysfunction are caused by these mutations. Common polymorphisms exist in these genes as well, and they may be responsible for borderline alterations of gonadal function. This review concentrates on the role of gonadotropin and gonadotropin receptor mutations and polymorphisms in male gonadal dysfunction. Relevant genetically modified animal models will be described when they enhance our knowledge of the molecular pathogenetic mechanisms underlying the mutations. More information is available on some gonadotropin and gonadotropin receptor mutations found in women, so, for the sake of a more complete presentation, I will also review them briefly.

Structure of the Gonadotropin Subunit and Gonadotropin Receptor Genes and Proteins

Gonadotropin Subunits

FSH, LH, and hCG, together with thyroid-stimulating hormone (TSH), comprise

the family of glycoprotein hormones. Each hormone is composed of two subunits that are coupled by noncovalent interactions: the common α -subunit of 92 amino acids (aa, encoded by the *CGA* gene) and the hormone-specific β -subunit; 111 aa in FSH β (encoded by *FSHB*), 121 aa in LH β (encoded by *LHB*), and 138 aa in hCG β (Encoded by *CGB*) (see Fig. 6.1). hCG is structurally similar to LH, and both hormones have similar actions by activating the common receptor, LHCGR. Gonadotropins are glycosylated through *N*-linked bonds (see Fig. 6.1), and the carbohydrate content of LH is approx. 15%, of FSH 20%, and of hCG 30% [1, 2]. Most conspicuously, the carbohydrate moieties increase the circulating half-lives of the gonadotropins, which are approx. 20 min for LH, approx. 2 h for FSH, and 12–24 h for hCG. The long half-life of hCG is primarily explained by the 24-aa C-terminal extension of its β -subunit, in comparison to LH β , which is heavily glycosylated through four *O*-linked glycosylation sites (see Fig. 6.1). The short half-life of LH is a function of the high proportion of terminal sulfate groups in its carbohydrates; a specific




Fig. 6.1 Schematic presentation of sizes, locations of the carbohydrate side chains, and currently known mutations (red arrows) and functionally significant polymorphisms (green arrows) in the gonadotropin subunits, i.e., *CGA*, *LHB*, *FSHB*, and *CGB*. The numbers below the right ends of the bars indicate the numbers of amino acids in the mature

subunit proteins. Symbols “Y” and “O” indicate the locations of *N*-linked and *O*-linked carbohydrate side chains, respectively. The amino acid numbering includes the signal peptides (24 amino acids for *CGA*, 20 for *LHB*, 18 for *FSHB* and 20 for *CGB*), but the bars only depict the mature peptides. For references, see Table 6.1 and the text

hepatic receptor accelerates the elimination of this type of glycoprotein from the circulation [3].

The *CGA* gene is located on chromosome 6q12.21, *FSHB* is found on chromosome 11p13, and the *CGB/LHB* gene cluster, consisting of one *LHB* and four *CGB* encoding genes and two apparent pseudogenes, is located on chromosome 19q13.32 [4, 5]. *CGA* consists of four exons, and *LHB*, *CGB* and *FSHB* are each composed of three exons. The crystal structures of deglycosylated hCG [6] and FSH [7] are similar and reveal that both subunits contain so-called “cystine knot structures” that are similar to some remotely related growth factor-type signaling molecules. Each subunit has an elongated shape, with two β -hairpin loops on one side of the central cystine knot and a long loop on the other side. The noncovalent interaction between the two subunits

is stabilized by a segment of the β -subunit that extends like a “seatbelt” around the α -subunit and is “locked” by a disulfide bridge.

Gonadotropin Receptors

Like their ligands, the gonadotropin receptors are structurally related glycoproteins, belonging to class A of the large family of G protein-coupled receptors (GPCRs) (see Figs. 6.2 and 6.3) [8–10]. They each have a transmembrane domain that traverses the plasma membrane as seven α -helices connected by three extracellular and three intracellular loops. The glycoprotein hormone receptors form a subgroup within this gene family with a distinct long *N*-terminal extracellular domain, comprising approximately half the size of the





Fig. 6.2 Locations of the currently known mutations of *LHCGR*. Red squares and boxes indicate inactivating mutation and green circles activating mutations. The short lines across the peptide chain depict the exon boundaries.

The original references are found in earlier reviews on the topic [9, 97]. The mutations detected thereafter are described in Refs. [99, 102, 147–149]. *Fs* frame shift, *Ins* insertion, *Del* deletion, *Spl* splice variants, *X* premature stop codon

Fig. 6.3 Locations of the currently known mutations of *FSHR*. Red squares and boxes indicate inactivating mutation and *green circles* activating mutations. The short lines across the peptide chain depict the exon boundaries. The original references are found in earlier reviews on the topic [9, 117]. The mutations detected thereafter are described in Refs. [125, 130–157]. *Del* deletion



receptor. The C-termini of the receptor proteins form short intracellular tails. Whereas the FSHR binds only FSH, LH, and hCG are structurally so similar that they bind to the same LHCGR. Both gonadotropin receptor genes are localized on chromosome 2p21 [8, 10], and they carry considerable structural similarity, especially in their transmembrane domains. The clearest difference is that the first 10 exons encode the extracellular domain of LHCGR, whereas this domain is encoded by 9 exons in the FSHR. The last long eleventh exon in *LHCGR* (tenth in *FSHR*) encodes the transmembrane and intracellular domains.

Gonadotropins bind to the extracellular domain of their cognate receptors. This domain contains several leucine-rich repeats that are found in various proteins responsible for protein–protein interactions. The domain is glycosylated in an *N*-linked fashion, but the role of these structures in receptor function is not clear. The

extracellular and transmembrane domains are connected by a short hinge region that may influence ligand specificity, as shown with a human mutation of *LHCGR* lacking this region [11] and subsequent *in vitro* mutagenesis studies [12]. The transmembrane domain, with its seven membrane-spanning α -helices and intracellular and extracellular loops, resembles other GPCRs and is crucial for signal transduction. In particular, the third intracellular loop, the sixth transmembrane domain, and the cytoplasmic tail are closely involved in G protein coupling and signal transduction. The crystal structure of the gonadotropin receptors (FSHR, and structurally related TSHR) has been partially unraveled [13–15].

The gonadotropin receptors are primarily coupled to a G protein that activates adenylyl cyclase and elevates intracellular cyclic adenosine monophosphate (cAMP) levels [8, 10]. These receptors also activate other signaling




Fig. 6.4 Main signaling cascades employed in LH/hCG and FSH action. *Black arrows* depict pathways common for both hormones, *red arrows* those specific for LH/hCG and *green arrows* those specific for FSH. AA arachidonic acid, AC adenylyl cyclase, ATP adenosine triphosphate, CaM calmodulin, cAMP cyclic adenosine-3':5'-monophosphate, CRE cAMP response element, CREB cAMP response element binding protein, EGFR epidermal growth factor receptor, ERK extracellular signal-regulated kinase, FGF guanine nucleotide exchange factor; G_s stimulatory

guanine nucleotide binding protein; GSK-3 glycogen synthase kinase-3, MEK mitogen/extracellular signal-regulated kinase, PDK1 phosphoinositol-dependent protein kinase, MAPK mitogen-activated protein kinase, MAPKAP, MAPK-activated protein kinase; PGF_2 prostaglandin F_2 , PI3K phosphoinositol 3 kinase, PKA protein kinase A, PKC protein kinase C, PLA₂ phospholipase A₂, RAF rapidly accelerated fibrosarcoma-ser/thr specific protein kinase, Ras small GTPase family, SGK serum glucocorticoid-regulated kinase

pathways, however, including phosphatidylinositol turnover, intracellular Ca^{2+} , mitogen-activated protein kinases, and activation of the G_i protein [8, 10]. The alternate signaling pathways are often activated at higher hormone concentrations and receptor densities in target cells, and their functions may be limited to special circumstances in which gonadotropin levels are elevated, e.g., ovulation, pregnancy, or constitutively activating receptor mutations (see sections on activating mutations). A schematic presentation of the signaling cascades mediating gonadotropin action is shown in Fig. 6.4.

Gonadotropin Secretion and Actions Throughout the Male Life Span

Physiological studies have clarified in great detail the role of gonadotropins in the development and mature functions of male reproduction. In the fetal period, placental hCG, a superagonist of pituitary LH, is responsible for the stimulation of testosterone production by fetal Leydig cells, which is essential for masculinization of the male reproductive organs [16]. This occurs in collaboration with the Sertoli cell product,

anti-Müllerian hormone (or Müllerian-inhibiting substance), and another Leydig cell product, insulin-like factor-3 (INSL3) that regulate, in the male fetus, the involution of the Müllerian ducts and the transabdominal phase of testicular descent, respectively [17, 18]. Although FSH secretion begins in the fetus, and fetal testes express FSHR [19], FSH's role in the fetal period is uncertain. Data from animal models indicate that its first role is the stimulation of Sertoli cell proliferation in the prepubertal testis [20]. Fetal pituitary gonadotropin secretion begins at the end of the first trimester of pregnancy, with high levels in mid-pregnancy, followed by a decline toward the end of gestation, apparently resulting from development of feedback regulation [21]. A secondary increase in gonadotropin levels (often termed “minipuberty”, see Chap. 4) occurs during the first 4–6 mo of postnatal life, which is accompanied by a peak in testosterone production [22] and by Sertoli cell proliferation [23]. Spermatogenesis, however, remains quiescent, apparently because of lack of androgen receptors in Sertoli cells of the postnatal testis [24]. No functional role has been demonstrated for this period of the hypothalamic–pituitary–gonadal activation, and it may represent an adaptation to extrauterine life and the hormonal milieu following elimination of placental hormones.

The prepubertal phase of male development is typified by low circulating gonadotropin levels, but they are not absent, and ultrasensitive assays can detect pulsatile LH secretion especially at night [25]. Prepubertal testes also express both gonadotropin receptors, as shown indirectly by their functional responses to stimulation by hCG or FSH [26].

Puberty is the period of reawakening of gonadotropin secretion (see Chap. 4). At this time, both hormones reach adult levels and the pulsatile secretion pattern. LH activates Leydig cell growth, proliferation, and steroid production. FSH stimulates Sertoli cell proliferation and the metabolic functions (in concert with testosterone) that are needed for the initiation and maintenance of spermatogenesis. Whether FSH is mandatory for the pubertal initiation and adult maintenance of human spermatogenesis is controversial, but it

is clear that qualitatively and quantitatively normal spermatogenesis is possible only in the presence of all endocrine and paracrine factors, including FSH, that are functioning in the pituitary–gonadal axis [27].

Human testicular function is maintained through old age. However, mean testosterone levels and spermatogenesis decline with aging [28–30]. This phenomenon of “andropause” or “late-onset hypogonadism” (LOH) and the controversies of its testosterone replacement therapy has recently received a great deal of attention (see Chap. 17).

When considering the influence of gonadotropin or gonadotropin receptor mutations on male reproductive functions, specific phenotypic effects can be identified during all stages of the male life span.

Gonadotropin Subunit Mutations

Common α -Subunit (CGA) and hCG β -Subunit (CGB)

Mutations in the gonadotropin subunit genes are extremely rare, most likely because of the deleterious effects they would have on reproduction (see Table 6.1). Probably for the same reason, not a single patient with a germ line mutation in the *CGA* has been detected. Such mutations would lead to defective hCG, LH, FSH, and TSH function, a condition that would probably be lethal, particularly because of lack of hCG. Nevertheless, *CGA* knockout mice are viable, though hypogonadal and hypothyroid [31], but because this species does not produce chorionic gonadotropin, the gestation regulation may be under different hormonal control. Only one somatic *CGA* point mutation (E56A) in the ectopically produced hCG of a carcinoma has been described in the literature (see Fig. 6.1) [32]. Rare non-synonymous substitutions have been detected in *CGB5* and *CGB8* at higher frequency in women with recurrent miscarriages [5]. Despite the phenotypic association, only mild functional alterations were detected in the mutant hormones in vitro [33]. One relatively common (4.5% allelic frequency) amino acid-altering point mutation,

Table 6.1 List of currently known mutations and polymorphisms in human LHB and FSHB genes

Gene	Location	Type	Amino acid change	Symptoms in patient (s) ^a	Functional effect	Reference
LHB	Exon 3	Inactivating missense	Q74R	<i>Infertility, delayed puberty</i>	No binding to receptor	[37]
LHB	Exon 2	Inactivating missense	G56D	<i>Infertility, delayed puberty</i>	Disrupted dimerization and secretion	[38]
LHB	Exon2/Intron 2 boundary	Inactivating splice site mutation	Inhibition of intron 2 splicing	<i>Sexual infantilism</i> Secondary amenorrhea, infertility	Disrupted dimerization and secretion	[39]
LHB	Exon 2	Inactivating deletion	Deletion of amino acids 30–32 (HPI)	<i>Testosterone-induced puberty, normal spermatogenesis off-treatment</i>	Reduced stability and secretion, low bioactivity	[40]
LHB	Exon 2 (signal peptide)/ Intron 2	Inactivating compound heterozygous splice site mutation/deletion	Inhibition of intron 2 splicing/Deletion of amino acids 7-10 (LLLL)	<i>Hypogonadism, infertility</i> Secondary amenorrhea, infertility	Disrupted secretion	[41]
LHB	Exon 2	Polymorphism with 2 missense mutations	W28A/I35T	<i>Delayed tempo of puberty</i> Slightly suppressed fertility Association with PCOS?	Increased bioactivity in vitro Short half-life in vivo	[45, 46, 51]
LHB	Exon 3	Polymorphism , missense	G122S	Endometriosis	Not detected	[68]
LHB	Exon 3	Polymorphism , missense	A17T	Not studied	Slight decrease in signaling activity	[69]
LHB	Exon 2	Polymorphism , missense	M14I	Not studied	Unknown	[70]
LHB	Exon 2	Polymorphism , missense	H10R	Not studied	Unknown	[70]
FSHB	Exon 3	Inactivating , 2-bp deletion → frame shift	V79fs105X	Prim. amenorrhea, infertility <i>Azoospermia</i>	Truncated protein, disrupted secretion	[71, 77]
FSHB	Exon 3	Inactivating , missense	C69G	Delayed puberty, hypogonadism	Faulty tertiary structure and disrupted dimerization	[72]
FSHB	Exon 3	Inactivating , missense	C100R	<i>Azoospermia</i>	Faulty tertiary structure and disrupted dimerization	[78]
FSHB	Exon 3	Inactivating , nonsense	Y94X	Prim. amenorrhea, infertility <i>Azoospermia</i>	Disrupted secretion and loss of bioactivity	[73, 74]

(continued)

Table 6.1 (continued)

Gene	Location	Type	Amino acid change	Symptoms in patient (s) ^a	Functional effect	Reference
FSHB	Exon 3	Inactivating, nonsense	Y94X	Prim, amenorrhea, infertility	Disrupted secretion and loss of bioactivity	[75]
FSHB	Exon 3	Inactivating, 1-bp deletion → frame shift	A97fs126X	Prim, amenorrhea, infertility	Disrupted stability and secretion	[76]
FSHB	Exon 3	Polymorphisms, silent	No change (Y94)	High FSH, association with PCOS+obesity	Studied	[158]

The amino acid numbers are counted from the translation start site, i.e., containing the signal peptide

^aFindings on male subjects in *italics*

V79 M, has been detected in heterozygous form in apparently asymptomatic subjects (see Fig. 6.1) [34]. This mutation hampers α/β dimer formation in vitro and, if present in homozygous form, could block sufficient bioactive hCG synthesis and be lethal. Curiously, additional studies have been unable to find this polymorphism in 5 European and Mexican populations [35, 36]. Milder forms of *CGB* mutations could, if they exist, cause intrauterine undermasculinization of male fetuses because of hCG's crucial role in the stimulation of fetal testicular testosterone synthesis. However, because *CGB* is expressed by 4 duplicate genes, mutation in a single *CGB* gene may not be functionally significant.

LH β Subunit(LHB) Mutations

Five reports describing inactivating mutations of the *LHB* gene have so far been published, comprising a total of 6 affected men and 2 women [37–41] (Table 6.1 and Fig. 6.1). The male subjects have similar phenotypes with delayed puberty, sexual infantilism, and infertility. The only exception is the male described by Achard et al. [40], who appeared to have normal spermatogenesis (see below). The men have undetectable LH, elevated FSH and anti-Müllerian hormone, low testosterone, and normal or low-normal inhibin B and estradiol levels. There is an elevated FSH but no LH

response to GnRH stimulation. Testicular size is reduced (5–12 mL) and histological examination revealed [38, 41] tubular hypoplasia and greatly reduced spermatogenesis. Normal pubertal maturation can be induced in these men by testosterone treatment. hCG treatment induces a normal serum testosterone response, and long-term hCG treatment results in testicular enlargement and normal virilization, but spermatogenesis appears to recover only partially, and the men may remain infertile.

The man described by Achard et al. [40] represents a remarkable exception. Despite profound inactivation of LH through a 3-amino acid deletion (Table 6.1), the man had normal spermatogenesis. His other features, such as absent virilization, undetectable serum LH, and low serum testosterone levels, were as in the other men with LH inactivation. It was concluded that in this man, the residual LH activity was able to stimulate intratesticular testosterone levels sufficiently to maintain quantitatively normal spermatogenesis. Upon testicular biopsy, intratesticular testosterone was 20-fold reduced, suggesting that a high intratesticular testosterone concentration may not be necessary for spermatogenesis. The low residual testosterone, in conjunction with elevated FSH, may be sufficient to maintain spermatogenesis. Similar observations have been made on mice with disrupted *LHCGR* function [42, 43]. Perhaps the only reason why the intratesticular testosterone

concentration is so high may be because this organ is the site of testosterone synthesis.

Different types of *LHB* mutations have been detected in affected individuals, including point mutations, deletions in the signal peptide and mature protein encoding regions, and splice site mutations. The severity of the phenotype is in good agreement with the severity of the inactivation of LH function when studied in vitro by expression of the mutated gene product (Table 6.1). Heterozygous family members, both men and women, seem to be asymptomatic, indicating that one functional *LHB* gene can encode sufficient LH synthesis.

These rare cases clarify some points about pituitary LH's developmental role. Because the affected men were apparently normally masculinized at birth and had descended testes, pituitary LH is not needed for the stimulation of testicular testosterone or INSL-3 production in utero. Indeed, fetal testicular testosterone production is initiated seemingly autonomously but becomes subsequently dependent on placental hCG [16, 44], and fetal pituitary LH plays a minimal role in utero. In contrast, the endocrine function of the postnatal testes is critically dependent on pituitary LH, as demonstrated by the total absence of mature Leydig cells in testicular biopsy samples and of spontaneous puberty in its absence.

The two women with homozygous *LHB* inactivation [39, 41] have normal puberty, followed by secondary amenorrhea and infertility. Like men, their LH is undetectable, but FSH is normal to high, estradiol and progesterone are at the follicular level, and testosterone, androstenedione, dehydroepiandrosterone sulfate, and prolactin levels are normal. Apparently theca cell androgen production without LH stimulation is sufficient to provide substrate for FSH-stimulated granulosa cell estrogen production, which explains the normal puberty of the affected females. However, LH stimulation is crucial for ovulation, which explains the infertility of the affected women. In fact, the phenotype of the female *LHB* inactivation is identical with inactivating *LHCGR* mutation (see below).

LHB Polymorphisms

Several polymorphisms have been detected in the *LHB* gene (see Table 6.1 and Fig. 6.1), and their occurrence has been studied in relation to various phenotypic signs of male and female gonadal dysfunction, including hypogonadism and infertility [9, 45]. We concentrate below on findings that concern the effects on male reproductive function.

Of particular interest is the W8R/I15 N polymorphism resulting from two point mutations that are in linkage disequilibrium [46–48]. This variant (V) LH is common worldwide, with considerable ethnic variability in carrier frequency, from 0% in western India to 53.5% in aboriginal Australians [49, 50]. It was originally detected as an immunologically anomalous form of LH in a woman with normal reproductive function but undetectable LH using a specific combination of monoclonal antibodies to detect immunoreactive LH [51]. It has been shown to display increased bioactivity in vitro but to have a shortened circulating half-life [52–54]. However, there is also a report indicating a longer half-life of the variant in the circulation [55]. The discrepancy is likely due to differing experimental conditions used in the studies.

The polymorphism affects variably circulating LH concentrations. No difference was found in LH levels in 73–94-year-old Dutch men who were WT or *V-LHB* carriers [56], but significantly lower serum LH concentrations were detected in *V-LHB* carriers in a large cohort of 40–79-year-old men from 8 European countries [57]. In another study on young Estonian men (mean age 20.1 yrs), *V-LHB* carriers were reported to have higher LH levels than WT controls [58]. Likewise, in women, both higher and lower concentrations of serum LH have been reported in *V-LHB* carriers [48, 59–61]. The best explanation for the discrepant findings is provided by the fact that *V-LHB* has eight additional point mutations in its promoter region [62]. They increase the transcriptional activity of the variant promoter by approximately 50% in vitro. However, the promoter could respond in vivo

differently to various physiological and pathophysiological conditions, resulting in differences in the relative amounts of the two LH forms [63].

The significance of V-LH as a contributing factor to the variability of reproductive functions remains elusive. Most of the existing studies associate the LH variant with various mild reproductive disorders in men and women [reviewed in 9, 45]. In women, it has mild, although statistically significant, associations with fertility problems and ovarian steroidogenesis, including certain types of polycystic ovary syndrome, pregnancy complications, premature ovarian failure, and breast cancer occurrence. Many of these findings have been made in Japan, which, along with its lower frequency in Asian populations [49, 50] may indicate ethnic differences in its phenotypic expression.

In the male, several findings associate V-LH to reproductive function. When pubertal progression was compared in WT boys and heterozygotes for *V-LHB*, there was no difference in the age of onset of puberty, which is mainly determined by the reawakening of hypothalamic gonadotropin-releasing hormone (GnRH) secretion. Instead, the tempo of pubertal progression was significantly slower in boys who were heterozygous for the *V-LHB* allele [64]. When its occurrence was studied in cryptorchidism, the allele frequency in cryptorchid and healthy boys was similar, but when the frequency in cryptorchid boys was correlated with gestation duration, it increased significantly with increasing gestation duration, from 6% in boys born before week 30–45% in boys born beyond week 42 of pregnancy [65]. The final phase of testicular descent, from the inguinal region to the scrotum, depends on testicular testosterone production in late gestation. The tropic stimulus for this activity is provided by the combined action of hCG and pituitary LH, and when the duration of pregnancy is prolonged, the role of pituitary LH becomes more important. If this hormone is less active, as V-LH is, then testosterone production may be compromised, predisposing the post-term boys carrying the *V-LHB* allele to cryptorchidism. There is also a report describing an association of V-LH with familial and sporadic

prostate cancer [66], but no association of V-LH has been found with male infertility [67]. Finally, V-LH is more prevalent in older men who are obese and have low testosterone levels [56].

These findings, together with those in women, indicate that V-LH represents a genetic variant of the hormone with borderline significant effects on a variety of reproductive functions in men and women. Most importantly, the clinician must be aware of its occurrence, because some immunoassay kits for LH are unable to detect V-LH, which may explain unexpectedly low LH levels.

Four other amino acid-altering polymorphisms have been detected in the coding sequence of *LHB*, A17T, M15I, H30R, and G122S [68–70]. Their phenotypic effects are largely unknown, and the functional alterations of some of these mutant hormones have been found marginal.

FSH β Subunit (FSHB) Mutations

Six women [71–76] and three men [73, 74, 77, 78] with a total of five different inactivating mutations of the *FSHB* gene have so far been described in the literature (Fig. 6.1 and Table 6.1). All women had similar phenotypes, with slightly variable severity, including sexual infantilism, lack of follicular development, and infertility, which are readily explained by the lack of FSH action on granulosa cell estrogen production and progression of follicular maturation beyond the early stages.

Of the reports on the 3 men with inactivating *FSHB* mutations, the one from Sweden described a 32-year-old man of Serbian origin who presented with azoospermia, normal puberty and male physical characteristics, and a selective FSH absence [78, 79]. His serum testosterone level was low-normal (11 nmol/L), and LH was slightly elevated (12 IU/L). These findings reflect the small size of his testes (3 mL/6 mL) and the missing FSH effect on their growth at puberty. Genetic analysis demonstrated a homozygous T to C mutation, predicting a C100R substitution in the FSHB protein. It was postulated that the elimination of a cysteine

would impair formation of the proper intramolecular disulfide bond of FSHB. This would result in abnormal tertiary structure during FSHB synthesis, with extensive intracellular degradation, inability to dimerize with the CGA, defective glycosylation, and, finally, inability to form biologically active hormone.

The second male, reported from Israel [77], was an 18-year-old with slight delay of puberty, small testes, azoospermia, and a plasma FSH concentration below 0.5 IU/L. Total testosterone was low (4.5 nmol/L), and LH was increased (24.5 IU/L), indicating a defect in testosterone biosynthesis. DNA sequencing revealed the same homozygous 2-bp deletion in codon 79 that was found previously in female patients [71–73]. The mutation gave rise to a completely altered amino acid sequence between codons 79 and 105 of the FSHB chain, which was followed by a premature stop codon, and lack of translation of amino acids 106–129. Consequently, the translated FSHB protein was truncated and unable to associate with common α -subunit to form bioactive or immunoreactive α/β dimers.

The third man with inactivating *FSHB* mutation, described from Brazil [73, 74], had had normal puberty but presented with infertility resulting from azoospermia. His serum testosterone at the age of 30 yr was normal (26 nmol/L), FSH was low, and LH was elevated. His testes were small (12 mL), and testicular biopsy revealed Leydig cell hyperplasia and sparse, small seminiferous tubules with germinal cell aplasia, peritubular fibrosis, and few Sertoli cells. The C to A mutation in codon 94 of his *FSHB* gene brought about a premature stop codon (TAA). Because the phenotype of the female patient reported with this mutation was less severe than those of women with the other *FSHB* mutations [72–74], it was hypothesized that the missing amino acids 94–129 of FSHB may not bring about complete inactivation of FSH action.

Conspicuously, all 3 men with the *FSHB* mutation were azoospermic. As will be elaborated in the section on *FSHR* mutations, this is not the case with the five men reported to carry

homozygous inactivating *FSHR* mutations [80]. They each displayed variable suppression of spermatogenesis but were not azoospermic. Neither are the knockout mice for *FSHB* [81] or *FSHR* [82, 83] azoospermic, and, moreover, the phenotypes of women with inactivating *FSHB* and *FSHR* mutation were practically identical [71–76, 84]. The more severe phenotype of the ligand mutation in men is curious also for the reason that animal data show the opposite [85], most likely because of the slight constitutive activity of FSHR in the absence of ligand. Why then are the three men with *FSHB* mutation azoospermic? This will be discussed in more detail in connection with *FSHR* mutations.

FSHB Polymorphisms

One functionally significant single nucleotide polymorphism (SNP) of *FSHB*-211G/T [86] has been recently identified and appears to affect both male and female reproductive function. In a study from Estonia, the TT phenotype carrier men had highly significantly lower serum FSH concentrations compared to GG men [87], and in infertile men, FSH was even lower [88]. A similar attenuating effect of the T allele was observed with the high FSH levels in Klinefelter syndrome patients [89]. The apparent mechanism for the reduced *FSHB* expression is attenuated transcriptional activity through an impaired LHX3 binding site [90]. The association of the T allele with lower FSH levels has been confirmed in other populations [91–93] and is associated with lower serum inhibin B and testosterone levels, smaller testes, and a lower sperm concentration. This polymorphism has been suggested as a pharmacogenomics tool to predict the response of men with idiopathic oligozoospermia to FSH therapy [94]. Indeed, significant improvement in sperm parameters following FSH treatment has been demonstrated in the minor allele carriers [91]. In women, curiously, both increased and decreased levels of FSH have been associated with the T allele [95, 96]. The combination of the -211G/T polymorphism with a common *FSHR*

polymorphism in improving the pharmacogenetic prediction will be discussed later.

Gonadotropin Receptor Mutations

Gonadotropin receptor mutations are also quite rare. There are both activating and inactivating mutations in these genes, with widely varying phenotypic effects. Several mechanisms can underlie receptor inactivation: (1) decreased synthesis of receptor protein; (2) aberrant intracellular processing; (3) reduced or absent ligand binding activity; (4) impaired or absent signal transduction; (5) inability to anchor to the plasma membrane; (6) inability to dimerize, if needed, for signal transduction; (7) dominant negative effect, i.e., formation of non-functional dimers, or (8) increased degradation. Unlike the activating mutations, the types of inactivating mutations vary from point nonsense and missense mutations to various size insertions and deletions. In this case, only homozygotes or compound heterozygotes for two different inactivating mutations produce a clear phenotype because the normal function of a single receptor allele supplies a sufficient number of functional receptors to sustain normal gonadotropin action.

Activating receptor mutations can be classified into four categories: (1) receptor activation in the absence of ligand hormone; (2) increased sensitivity of the receptor to its normal ligand; (3) relaxed specificity of the receptor to ligands; and (4) acquired novel functions of the mutated receptor. All activating gonadotropin receptor mutations detected have been missense point mutations that are almost invariably localized to the transmembrane region or its vicinity (see Figs. 6.2 and 6.3). These mutations produce a structural alteration, activating constitutively the signal transduction machinery of the transmembrane region. Most clearly, receptor activation without ligand explains the altered function of these mutations. Abnormal phenotypes occur in heterozygous individuals because activation of the translation product of a single allele is sufficient to initiate the altered functional response.

LHCGR Mutations

Inactivating Mutations

About 30 different LHCGR mutations have been reported (Fig. 6.2). In the human male, LHCGR function is essential at all ages for testicular androgen production. Therefore, these mutations influence male sexual differentiation, development, and mature functions from the fetal period through adulthood. *LHCGR* mutations thus form one etiological subclass of 46, XY disorders of sexual development (DSD). The receptor inactivation varies in completeness, and the phenotype of affected males depends on its extent [9, 10, 97]. In the mildest forms, the phenotype is hypospadias and/or micropenis (Leydig cell hypoplasia, LCH Type 2), and in the completely inactivating form, the male phenotype is complete male to female sex reversal (LCH Type 1) [9, 97]. The latter group presents with near-total to total lack of male type sexual differentiation in utero and during postnatal development. The phenotype resembles the complete form of androgen insensitivity syndrome but notably differs by the lack of pubertal breast development, which, in androgen insensitivity, is explained by the conversion of testosterone to estradiol. On histological examination, the testes of the individuals with complete LHCGR inactivation are totally devoid of mature Leydig cells, which explain the lack of testosterone production and absent masculinization. However, it is apparent that even in complete LHCGR inactivation, some testicular steroidogenesis is possible, because epididymides and vasa deferentia are present [9]. The explanation for these structures may be low, but functionally sufficient, constitutive steroidogenesis in precursor fetal Leydig cells. It could induce in paracrine fashion, partial masculinization of the Wolffian ductal structures. This has also been shown with *LHCGR* knockout mice in which low basal androgen synthesis in their testes can stimulate spermatogenesis, a response which can be eliminated by antiandrogen treatment [42].

In women, LHCGR inactivation causes a milder phenotype with normal intrauterine female

sex differentiation and a seemingly normal FSH-dependent component of ovarian function [9]. Affected women present with primary amenorrhea and normal primary and secondary sex characteristics, increased gonadotropin levels, and a lack of ovarian response to hCG treatment. Histological study of ovarian tissue revealed all stages of follicular development, with the exception of preovulatory follicles and corpora lutea [98]. These observations emphasize the importance of LH for ovulation and formation of corpora lutea. LH may also be needed for the maturation of antral to preovulatory follicles. A very interesting recent study reported on successful pregnancy of a woman with inactivating *LHCGR* mutation following ovum donation [99], indicating that the extragonadal *LHCGR* expression, demonstrated in a variety of male and female organs, is redundant for fertility.

Activating Mutations

The first gonadotropin receptor mutations detected were those activating constitutively the *LHCGR* [100, 101], perhaps because of their striking phenotype. The syndrome caused by this mutation, i.e., familial male-limited precocious puberty (FMPP), is a gonadotropin-independent form of precocious puberty, also called “testotoxicosis”. Boys with FMPP begin to exhibit signs and symptoms of puberty between 0.5 and 3 yr of age. If they remain untreated, puberty progresses rapidly, resulting in premature epiphyseal closure, compromised adult height and associated behavioral problems of premature puberty. For the treatment, various antihormonal therapies have been used (medroxyprogesterone, ketoconazole, cyproterone acetate, anastrozol, bicalutamide) [102] to reduce virilization and advancement of bone age. Men with this syndrome appear to be fertile.

FMPP has been known for a long time and was originally assumed to result from a circulating nongonadotropic factor that induces premature LH-independent activation of Leydig cell function. However, the subsequent detection of point mutations in the *LHCGR* gene, which, in transfection studies, caused constitutive activation of the LH signaling pathway in the absence

of ligand, provided a logical molecular pathogenesis for the syndrome. Today, more than 10 activating mutations of the *LHCGR* gene are known (see Fig. 6.2), and they all (except for one) are localized in or near the transmembrane region of the *LHCGR*, which is pivotal for LH signal transduction. The mutations change the conformation of the transmembrane region of the receptor such that it assumes, at least partially, an activated conformation in the absence of ligand. The consequence is premature activation of Leydig cell testosterone production before the pubertal onset of LH secretion. In cell transfections, the mutated receptor protein usually displays an approx. tenfold increase in basal cAMP production, whereas maximal stimulation is often suppressed. The latter alteration has no physiological importance, because at the circulating levels of LH, receptor occupancy remains relatively low. Whether other signaling pathways that are initiated by *LHCGR* activation (see Fig. 6.4) are also activated has not been systematically studied.

Despite the distinct phenotype in males, no phenotype is known for females with activating *LHCGR* mutation. One explanation is that the LH action initiation in the ovary requires FSH priming, and FSH-dependent paracrine factors may be needed to induce theca cell *LHCGR* responsiveness. Because there is little FSH secretion in these women before the normal age of puberty, the constitutively activated *LHCGR* would not be expected to be prematurely functional. The lack of *LHCGR* in prepubertal granulosa cells is evident, because this receptor is acquired during the later stages of follicular maturation. Therefore, the presence of an activating mutation in the *LHCGR* is functionally unimportant if the gene is not expressed before the age of normal puberty.

A specific Leydig cell tumor phenotype of activating *LHCGR* mutations associated with Leydig cell tumors (LCTs) has been described in six reports on the D578H mutation of *LHCGR* in boys with isosexual precocious puberty without a family history of this condition [103–108]. Besides the symptoms and findings of FMPP, a unilateral testicular mass was found by

ultrasonography in all boys. In each case, well-circumscribed tumors were removed that were composed of nested polygonal cells with abundant eosinophilic cytoplasm and round ovoid nuclei. Mitotic activity was low and Reincke's crystals were absent. When genomic DNA was extracted from the tumor tissues and peripheral blood leukocytes, DNA sequencing revealed that in each reported case the tumor tissues, but not leukocytes, contained a heterozygous somatic mutation encoding a D578H replacement in *LHCGR*. When the mutated receptor was transfected into COS-7 cells, Liu et al. [103] found it to initiate constitutive activation of cAMP and inositol phosphate production, of which the latter response has not been made with other activating *LHCGR* mutations. Besides the tumor phenotype, these subjects differ from FMPP because their *LHCGR* mutation is somatic. This particular mutation has not been detected in the germ line. It remains to be determined whether this mutation is the only one that causes Leydig cell tumorigenesis.

Another report described nodular LCH in a boy with FMPP, which is not a typical finding in this syndrome [109]. The genomic heterozygous D564G mutation detected in this boy caused only partial activation of cAMP production, and similar Leydig cell alterations were not found in other patients affected with the same mutation. Therefore, the mechanism of the nodular hyperplasia appears to differ from that of the D758H mutation.

A third type of testicular tumor reported in a 36-year-old patient with FMPP due to a germ line D578G mutation is testicular seminoma [110]. Although no causative relationship was established for the *LHCGR* mutation and seminoma, the possibility remains that a prolonged high intratesticular testosterone concentration resulting from *LHCGR* stimulation could be oncogenic. However, transgenic mice that overexpress hCG [111] or knockin mice with *LHCGR* activating mutation [112] do not show signs of testicular tumors beyond elevated testosterone production and mild Leydig cell hypertrophy.

The situation with activating *LHCGR* mutations and testicular tumors is somewhat analogous

to familial nonimmunogenic hyperthyroidism and sporadic thyroid adenomas caused by germ line and somatic mutations of the *TSHR* gene, respectively [113, 114]. As in these thyroid disorders, the somatic *LHCGR* mutations brought about greater constitutive activity of the receptor than do germ line mutations. The severe forms would probably be eliminated from the genetic pool because of their strong deleterious effects. The mutation detected occurred in a position where three other amino acid-substituting mutations have been detected in D578 to Y/E/G (see Fig. 6.2). The other forms cause milder receptor activation and, at most, patchy Leydig cell hyperplasia but no tumors. Hence, the high level of basal stimulation of the receptor is important for adenoma formation. Whether high cAMP production alone or additive or synergistic effect of the concomitantly stimulated phospholipase C pathway are involved in tumorigenesis remains to be established. In fact, the analogous mutation in the *TSHR*, D633H, has been found in a patient presenting with insular thyroid carcinoma with metastases [115].

These data emphasize that the same initial phenotype of FMPP may be observed in cases without and with subsequent Leydig cell tumors. Therefore, long-term follow-up with testicular ultrasonography is advised for boys with FMPP to exclude Leydig cell adenoma. Genetic analysis of the *LHCGR* mutation is also advisable if testicular biopsy material is available. Finally, another genetic cause for LCTs is activating mutation in the stimulatory G protein [116].

FSHR Mutations

Inactivating Mutations

Several inactivating mutations have been detected in the *FSHR* gene; most of them in women with hypergonadotropic hypogonadism [9, 117] (see Fig. 6.3). The complete form of *FSHR* mutation in women causes total to near-total arrest of follicular development [84], a process which is dependent on FSH action. The incomplete forms cause a partial phenotype that is responsive to high-dose gonadotropin treatment

Table 6.2 Semen analyses and hormone levels in men homozygous for the inactivating Ala189Val FSHR mutation

Subject	Age (yr)	Fertility	Testis size ml (right/left)	Semen analysis			FSH (IU/L)	LH (IU/L)	Testosterone (nmol/L)	Inhibin B (ng/L)
				Sperm count/mL	Vol. mL	(at age)				
1	47	Two children	16.5/16.5	5×10^6	3.0	(47)	12.5	5.6	8.8	<15
2	55	Two children	13.5/15.8	$<0.1 \times 10^6$	3.3	(55)	15.1	4.2	15.8	33
3	45	infertile	4.0/4.0	$<0.1 \times 10^6$	4.8	(30)	23.5	16.3	14.5	62
4	29	unknown	8.6/6.0	42×10^6	1.5	(29)	39.6	11.1	14.7	54
5	42	unknown	8.0/8.0	$<1.0 \times 10^6$	2.5	(42)	20.6	16.2	26.2	53
Reference range				$>20 \times 10^6$			1–10.5	1–8.4	8.2–34.6	76–447

From Ref. [80]

[118, 119]. In addition to the Finnish-type FSHR inactivation (C → T transition, causing A189 V mutation), which has been found in multiple families [84], all other *FSHR* mutations detected have been sporadic [9, 117].

Five men with totally inactivating mutation of *FSHR* have been described from Finland [80]. These men were identified because they were homozygous brothers of women with hypergonadotropic hypogonadism caused by *FSHR* mutation. The men were normally masculinized, with normal puberty and virilization. Their testes were mildly or severely reduced in size, and all had pathological semen samples, although conspicuously, none was azoospermic (Table 6.2). Moreover, two of the men each had fathered two children. As expected, the men had high FSH levels, low inhibin B, normal or slightly elevated LH, but normal testosterone concentrations [80]. Both testicular sizes and the endocrine parameters of the five men displayed considerable variability. The large age range of the subjects (29–55 yr) may reflect the individual variability in the importance of FSH in maintaining testicular function. More detailed conclusions are limited by the small sample size. These findings were rather surprising because of the concept of a fundamental role for FSH in spermatogenesis, particularly the pubertal initiation of this process. Findings in these men demonstrated that FSH action per se is not necessary for qualitatively

complete spermatogenesis. However, FSH is needed for qualitatively and quantitatively normal spermatogenesis but not necessarily for fertility. Subsequent experiments in mice in which *FSHR* or *FSHB* gene expression was disrupted produced similar results [81–83]; the animals were fertile, but their testes were reduced in size and their spermatogenesis was qualitatively and quantitatively suppressed. The mild phenotype of the men with *FSHR* mutation indicated that they cannot be readily distinguished phenotypically from other men with idiopathic oligozoospermia. In fact, when this was studied in a region with high allelic frequency (1%, northern Finland) for the inactivating *FSHR* mutation, the frequency of the mutation was the same in a cohort of men with idiopathic oligozoospermia and in normal controls [80]. There was no apparent disturbance in pubertal development in these individuals. The sperm quality was highest in the youngest of the five men suggesting that the spermatogenic capacity in the absence of FSH action may be compromised—these men may be fertile only as young adults.

The discrepancy between the azoospermia of the three men with *FSHB* mutation (see above) and the oligoasthenozoospermia, but not azoospermia, in the men with *FSHR* mutation is puzzling. One explanation is that azoospermia is the real phenotype of total elimination of FSH action, and the receptor mutation described is

only partial, with partial inactivation of FSH action that does not totally impede spermatogenesis. All evidence collected thus far about the inactivating A189 V *FSHR* mutation shows, however, that it is near-totally inactivating because of the sequestration of the mutant receptor inside the cell [120]. A minute fraction of the mutated receptor may reach the cell surface but is unable to mediate the signal properly even at high FSH levels. Cells transfected with the mutated *FSHR* gene are devoid of the basal constitutive adenylyl cyclase activity that can be displayed in cells transfected with WT *FSHR* [120]. Likewise, women with this mutation are totally resistant to FSH treatment [121].

A second explanation is that oligozoospermia is the true phenotype of FSH deficiency, and the men with inactivating *FSHB* mutation (see above) have a second disturbance in the regulation of spermatogenesis predisposing to azoospermia. This is quite likely because spermatogenesis is a process that is regulated by a complex network of endocrine, paracrine, and autocrine mechanisms. Two key players in this process with paramount importance are testosterone and FSH. The importance of FSH may be relative; if all other factors function properly, FSH is not vital, and, therefore, men with *FSHR* mutation have qualitatively complete spermatogenesis. If, on the other hand, there is a failure in some other mechanism, then the function of FSH becomes critical. The Israeli patient [77] with *FSHB* mutation had an additional failure in testosterone production that might explain the critical role of loss of FSH function. The Swedish patient was treated for extended periods of time with FSH, but there was no spermatogenic response [78, 79]. It is possible in his case that key paracrine mechanisms had failed, and FSH replacement could not compensate for those deficiencies. Furthermore, these two patients were found because of azoospermia, whereas the *FSHR* mutation patients were detected because they were the brothers of women homozygous for this mutation. Hence, the outcome of genotype/phenotype correlations partly depends on which end of the cascade the search is initiated. The third explanation is that we are dealing

here with a genuine species difference (man versus mouse) of FSH action.

In conclusion, the majority of information available implies that FSH action per se is not mandatory for the pubertal initiation of spermatogenesis or for male fertility. However, FSH improves spermatogenesis both qualitatively and quantitatively. The phenotype of men with defective *FSHR* function varies from severe to mild impairment of spermatogenesis, in the face of apparently normal Leydig cell androgen production. The azoospermia of men with *FSHB* mutation may result from additional contributing factors and not solely from FSH deficiency. However, it is apparent that additional cases of genetically proven FSH deficiency are needed before the existing discrepancy between the phenotypes of the ligand and receptor inactivation can be reconciled.

Activating Mutations

Only two reports of activating *FSHR* mutation in men exist in the scientific literature. The first [122] describes a German man who had undergone hypophysectomy and radiotherapy because of a pituitary tumor and, despite panhypopituitarism and unmeasurable serum gonadotropin levels, displayed persistent spermatogenesis during testosterone treatment. Detailed studies of this patient were undertaken because androgen treatment is not sufficient to maintain spermatogenesis in the absence of gonadotropins. A heterozygous D567G mutation was found in the third intracellular domain of exon 10 of his *FSHR* gene (see Fig. 6.3), and it was shown in vitro to have marginal constitutive activity. Further evidence for the constitutive activation of this mutation has been obtained in transgenic mice expressing the mutant gene [123]. The mutant mice had no phenotype in the wild-type genetic background, but when crossed to the gonadotropin-deficient *hpg* genetic background, a functional Sertoli cell response was observed. These findings indicate that activating *FSHR* mutation may have no phenotype when the LH-testosterone arm of testicular endocrine regulation is normal, but its effect can be seen when LH stimulation of testosterone production is

absent. It also explains why the phenotype of the German patient was observed when his gonadotropin secretion was eliminated by hypophysectomy. In line with the above discussion, male transgenic mice expressing a strongly activating FSHR mutation [124] have no apparent phenotype (Oduwole, Peltoketo and Huh-taniemi, unpublished data).

The second activating *FSHR* mutation in a male was detected in an asymptomatic Argentinian man originally referred for pain during intercourse. He had normal spermatogenesis, profoundly suppressed serum FSH, and normal biochemical markers of FSH action except for twofold elevated AMH [125]. Normal spermatogenesis in the absence of FSH raised the suspicion of *FSHR* mutation, which was detected (N431I) in heterozygous form. This was apparently a neomutation because it was absent in the parents. With different experimental strategies on cells transiently expressing the mutant, it was found that despite decreased cell surface expression, the mutant receptor conferred a low level of constitutive activity associated with markedly altered agonist-stimulated desensitization and internalization. The latter features may explain the persistent activation of the receptor in the absence and presence of FSH.

The search for *FSHR* mutations in candidate diseases, such as premature ovarian failure, ovarian tumors, megalotestes, precocious puberty, and twin pregnancies, has yielded negative results [126–130]. It also remains possible that activating *FSHR* mutation has no abnormal phenotype in otherwise normal individuals. This was the case with the serendipitous discovery of the two males so far described, one with unexpected spermatogenesis following hypophysectomy, the other with unexpected normal spermatogenesis in the face of very low FSH level.

Another surprise concerns the activating FSHR mutations detected in women [117, 131]. The phenotype is pregnancy-associated ovarian hyperstimulation, which is explained by the combination of marginal constitutive activity of the mutant receptor and/or relaxed ligand specificity, where hCG is able to activate FSHR and cause ovarian hyperstimulation during pregnancy.

Gonadotropin Receptor Polymorphisms

Several polymorphisms have been detected in the gonadotropin receptor genes, but relatively little is known thus far about their functional significance. The polymorphisms T307/N680 and A307/S680 in the *FSHR* gene are in linkage disequilibrium in most populations, and with almost equal frequency, at least in individuals of European ethnicity [132]. It was reported from Germany that in women undergoing ovulation induction, the basal FSH concentration of the 680 N/N genotype (6.4 ± 0.4 IU/L) was significantly lower than that of the S/S genotype (8.3 ± 0.6 U/L), and that the latter group required approx. 50% more exogenous FSH to stimulate follicular growth [132]. A subsequent study, quite surprisingly, found that ovarian hyperstimulation syndrome was associated with the poor responder S/S genotype of the previous study [133]. A large body of information on the effect of this polymorphism on ovarian function has appeared thereafter, and a recent review concluded that the 680S allele conveys poorer response to FSH upon ovarian stimulation [134].

Several studies have addressed the associations of the FSHR T307/N680 and A307/S680 polymorphisms on male reproductive function. The initial studies of small size detected no difference in reproductive phenotype for either genotype of men; neither were there functional differences between the two receptor types [135]. When combined with the -29A/G polymorphism, it was found that certain SNP combinations showed significant association with azoospermia in Germany [136], and with testis cancer [137], but there was no association with azoospermia in Italy [138]. When oligozoospermic men were treated with FSH only, those with at least one serine in position 680 showed a statistically significant increase in these sperm parameters, whereas subjects with homozygote T307/N680 showed no difference in any seminal parameters evaluated [139]. Studies from Sweden and Estonia have reported the best sperm parameters in this genotype [140, 141]. Two studies, from Japan and India, have reported that

heterozygosity for the polymorphisms is associated with infertility [142, 143]. An interesting approach was to assess the joint effect of the -211G/T *FSHB* polymorphism and the N680S *FSHR* polymorphism on male reproductive parameters [93]. The TT *FSHB* carriers were more prevalent amongst men with low sperm counts. Although not effective alone, the *FSHR* 680S genotype amplified the effect of the *FSHR* polymorphism. A similar combined effect of the *FSHR*-28A/G, *FSHB*-211G/T, and *FSHR* N680S polymorphism was confirmed by another study [90]. It remains to be seen whether *FSHB* and *FSHR* polymorphism analyses will be a clinically useful pharmacogenomics test to predict which infertile men will benefit from FSH treatment.

Relatively little is known about the possible functional effects of *LHCGR* polymorphisms in men. One early study suggested the relationship of the known *LHCGR* polymorphisms (LQ insert between amino acids 8 and 9) with male undermasculinization [144]. It was found that the polymorphism encoding insertion of leucine and glutamine between codons 8 and 9 of the *LHCGR* protein was significantly associated with those undermasculinized individuals that had a long polymorphic polyglutamine repeat (>26) in their androgen receptor, which is associated with suppressed androgen receptor activity. Also, two single nucleotide polymorphisms of the *LHCGR*, both altering the amino acid sequence (N291S and N312S), were found, both alone and in combination, to be associated with undermasculinization. Another study reported significant association between the N312S polymorphism in exon 10 with spermatogenetic damage [145]. A recent study on *LHCGR* polymorphisms compared the endocrine responses to testis cancer chemotherapy with several endocrine gene polymorphisms and found that the *LHCGR* exon 1 LQ insert protected from cisplatin-induced suppression of testosterone [146].

Inconsistent findings on the phenotypic effects of polymorphisms are not unusual. For example, inconsistencies were observed when the frequency of the common LH polymorphism (see the section on *LHB* Polymorphisms) was studied in women with polycystic ovary syndrome; the

frequency and correlation with the syndrome varied according to ethnicity of the patient cohorts [45]. This is understandable because the phenotypic effects of mild alterations of function of gene products, such as the polymorphisms depend on the genetic background and combined effects of other genes, and, therefore, the phenotypic expression may differ between populations. Overall, the studies on phenotypic effects of the polymorphisms in gonadotropin and gonadotropin receptor genes are still in their infancy and more information about their potential role in the individual variability in pituitary–gonadal function will undoubtedly be obtained in the future. They may provide in the future important targets for pharmacogenomic approaches to treatment.

Concluding Remarks

No germ line mutations of the glycoprotein hormone *CGA* have been reported, apparently because of the dramatic phenotypic effects they would have (possibly embryo lethality). Five inactivating *LHB* mutations have been described in men with normal prenatal masculinization but arrested pubertal development. The common polymorphism in *LHB* affects bioactivity of the hormone and has multiple mild phenotypic effects, including slow tempo of puberty in boys, and is enriched in post-term boys with cryptorchidism. The three men so far described with *FSHB* mutation were azoospermic, but additional patients are needed to confirm the phenotype, particularly because this phenotype conflicts with the findings in *FSHR* inactivation as well as animal models for FSH and *FSHR* inactivation.

Constitutively activating mutations of the *LHCGR* gene give rise to FMPP. Inactivating *LHCGR* mutation results in an array of male phenotypes ranging from micropenis and hypospadias to complete sex reversal (XY, disorder of sexual development), depending on the completeness of inactivation of the receptor. Inactivating *FSHR* mutations in men cause a decrease in testicular size and suppressed quality and quantity of spermatogenesis but not

azoospermia, and some affected men may be fertile. Since the original discovery in 1997, no additional cases have been reported. Only two cases of activating *FSHR* mutations have been detected, and they suggest that the mutation does not have phenotype in men with otherwise normal endocrine function.

The discrepancy between the phenotypes of men with inactivating *FSHB* (azoospermia) and *FSHR* (no azoospermia) mutations must be clarified with additional subjects. Information about the genotypic effects of common polymorphisms in gonadotropin and gonadotropin receptor genes is gradually mounting, and they may form important targets for the pharmacogenetic evaluation of gonadotropin treatment in infertility.

References

- Albrech E, Pepe GJ. Placental endocrine function and hormone action. In: Plant TM, Zeleznik AJ, editors. *Knobil and Neill's Physiology of Reproduction*, Vol. II, 4th ed. Elsevier Inc., Waltham MA, 2015, p. 1783–834.
- Smith LB, Walker WH. Hormone signaling in the testis. In: Plant TM, Zeleznik AJ, editors. *Knobil and Neill's Physiology of Reproduction*, Vol. II, 4th ed, Elsevier Inc., Waltham MA, 2015, p. 637–90.
- Fiete D, Srivastava V, Hindsgaul O, Baenziger JU. A hepatic reticuloendothelial cell receptor specific for SO₄-4GalNAc β 1,4GlcNAc β 1,2Man α that mediates rapid clearance of lutropin. *Cell*. 1991;67:1103–10.
- Bousfield GR, Perry WM, Ward DN. Gonadotropins. Chemistry and biosynthesis. In: Knobil E, Neill JD, editors. *The Physiology of Reproduction*, 2nd ed. New York Raven Press, 1994, p. 1749–92.
- Nagirmaja L, Rull K, Uusküla L, Hallast P, Grigorova M, Laan M. Genomics and genetics of gonadotropin β -subunit genes: unique *FSHB* and duplicated *LHB/CGB* loci. *Mol Cell Endocrinol*. 2010;329:4–16.
- Laphorn AJ, Harris DC, Littlejohn A, et al. Crystal structure of human chorionic gonadotropin. *Nature*. 1994;369:455–61.
- Fox KM, Dias JA, Van Royen P. Three-dimensional structure of human follicle-stimulating hormone. *Mol Endocrinol*. 2001;5:378–89.
- Simoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. *Endocr Rev*. 1997;18:739–73.
- Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. *Endocr Rev*. 2000;21:551–83.
- Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. *Endocr Rev*. 2002;23:141–74.
- Gromoll J, Eiholzer U, Nieschlag E, Simoni M. Male hypogonadism caused by homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: differential action between human chorionic gonadotropin and LH. *J Clin Endocrinol Metab*. 2000;85:2281–6.
- Grzesik P, Kreuchwig A, Rutz C, Furkert J, Wiesner B, Schuelein R, Kleinau G, Gromoll J, Krause G. Differences in signal activation by LH and hCG are mediated by the LH/CG receptor's extracellular hinge region. *Front Endocrinol (Lausanne)*. 2015;6:140.
- Fan QR, Hendrickson WA. Structure of human follicle-stimulating hormone in complex with its receptor. *Nature*. 2005;433:269–77.
- Sanders J, Chirgadze DY, Sanders P, Baker S, Sullivan A, Bhardwaja A, Bolton J, Reeve M, Nakatake N, Evans M, Richards T, Powell M, Miguel RN, Blundell TL, Furmaniak J, Smith BR. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. *Thyroid*. 2007;17:395–410.
- Jiang X, Liu H, Chen X, Chen PH, Fischer D, Sriraman V, Yu HN, Arkinstall S, He X. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. *Proc Natl Acad Sci U S A*. 2012;109:12491–6.
- Teerds KJ, Huhtaniemi I. Morphological and functional maturation of Leydig cells: from rodent models to primates. *Hum Reprod Update*. 2015;21:310–28.
- Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. *Endocr Rev*. 2001;22:657–74.
- Adham IM, Emmen JM, Engel W. The role of the testicular factor INSL3 in establishing the gonadal position. *Mol Cell Endocrinol*. 2000;160:11–6.
- Huhtaniemi IT, Yamamoto M, Ranta T, Jalkanen J, Jaffe RB. Follicle-stimulating hormone receptors appear earlier in the primate fetal testis than in the ovary. *J Clin Endocrinol Metab*. 1987;65:1210–4.
- Orth JM. The role of follicle-stimulating hormone in controlling Sertoli cell proliferation in testes of fetal rats. *Endocrinology*. 1984;115:1248–55.
- Kaplan SL, Grumbach MM, Aubert ML. The ontogenesis of pituitary hormones and hypothalamic factors in the human fetus: maturation of central nervous system regulation of anterior pituitary function. *Recent Prog Horm Res*. 1976;32:161–243.

22. Forest MG, De Peretti E, Bertrand J. Hypothalamic-pituitary-gonadal relationships in man from birth to puberty. *Clin Endocr (Oxf)*. 1976;5:551–69.
23. Simorangkir DR, Marshall GR, Plant TM. Sertoli cell proliferation during prepubertal development in the rhesus monkey (*Macaca mulatta*) is maximal during infancy when gonadotropin secretion is robust. *J Clin Endocrinol Metab*. 2003;88:4984–9.
24. Rey RA, Musse M, Venara M, Chemes HE. Ontogeny of the androgen receptor expression in the fetal and postnatal testis: its relevance on Sertoli cell maturation and the onset of adult spermatogenesis. *Microsc Res Tech*. 2009;72:787–95.
25. Wu FCW, Butler GE, Kelnar CJH, Stirling HF, Huhtaniemi I. Patterns of pulsatile luteinizing hormone and follicle-stimulating hormone secretion in prepubertal (midchildhood) boys and girls and patients with idiopathic hypogonadotropic hypogonadism (Kallmann's syndrome): a study using an ultrasensitive time-resolved immunofluorometric assay. *J Clin Endocrinol Metab*. 1991;72:1229–37.
26. Raivio T, Toppari J, Perheentupa A, McNeilly AS, Dunkel L. Treatment of prepubertal gonadotrophin deficient boys with recombinant human follicle-stimulating hormone. *Lancet*. 1997;350:263–4.
27. Plant TM, Marshall GR. The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. *Endocr Rev*. 2001;22:764–86.
28. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev*. 2005;26:833–76.
29. Perheentupa A, Huhtaniemi I. Aging of the human ovary and testis. *Mol Cell Endocrinol*. 2009;299:2–13.
30. Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. *Asian J Androl*. 2014;16:192–202.
31. Kendall SK, Samuelson LC, Saunders TL, Wood RI, Camper SA. Targeted disruption of the pituitary glycoprotein hormone α -subunit produces hypogonadal and hypothyroid mice. *Genet Dev*. 1995;9:2007–19.
32. Nishimura R, Shin J, Ji I, et al. A single amino acid substitution in an ectopic α subunit of a human carcinoma choriogonadotropin. *J Biol Chem*. 1986;261:10475–7.
33. Nagimaja L, Venclovas Č, Rull K, Jonas KC, Peltoketo H, Christiansen OB, Kairys V, Kivi G, Steffensen R, Huhtaniemi IT, Laan M. Structural and functional analysis of rare missense mutations in human chorionic gonadotrophin β -subunit. *Mol Hum Reprod*. 2012;18:379–90.
34. Miller-Lindholm AK, Bedows E, Bartels CF, Ramey J, Maclin V, Ruddon RW. A naturally occurring genetic variant in the human chorionic gonadotropin- β gene 5 is assembly inefficient. *Endocrinology*. 1999;140:3496–506.
35. Jiang M, Savontaus ML, Simonsen H, Williamson C, Müllenbach R, Gromoll J, Terwort N, Alevizaki M, Huhtaniemi I. Absence of the genetic variant Val79 Met in human chorionic gonadotropin- β gene 5 in five European populations. *Mol Hum Reprod*. 2004;10:763–6.
36. Dominguez-Lopez P, Diaz-Cueto L, Ulloa-Aguirre A, Lopez-Valle MA, Arechavaleta-Velasco F. No evidence of the human chorionic gonadotropin- β gene 5 β V79M polymorphism in Mexican women. *Endocrine*. 2008;34:117–20.
37. Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL. Hypogonadism caused by a single amino acid substitution in the β subunit of luteinizing hormone. *N Engl J Med*. 1992;326:179–83.
38. Valdes-Socin H, Salvi R, Daly AF, Gaillard RC, Quatresooz P, Tebeu PM, Pralong FP, Beckers A. Hypogonadism in a patient with a mutation in the luteinizing hormone β -subunit gene. *N Engl J Med*. 2004;351:2619–25.
39. Lofrano-Porto A, Barra GB, Giacomini LA, Nascimento PP, Latronico AC, Casulari LA, da Rocha Neves Fde A. Luteinizing hormone beta mutation and hypogonadism in men and women. *N Engl J Med* 2007;357:897–904.
40. Achard C, Courtilot C, Lahuna O, Méduri G, Soufir JC, Lière P, Bachelot A, Benyounes H, Schumacher M, Kuttent F, Touraine P, Misrahi M. Normal spermatogenesis in a man with mutant luteinizing hormone. *N Engl J Med*. 2009;361:1856–63.
41. Basciani S, Watanabe M, Mariani S, Passeri M, Persichetti A, Fiore D, Scotto d'Abusco A, Caprio M, Lenzi A, Fabbri A, Gnassi L. Hypogonadism in a patient with two novel mutations of the luteinizing hormone β -subunit gene expressed in a compound heterozygous form. *J Clin Endocrinol Metab* 2012;97:3031–8.
42. Zhang FP, Pakarainen T, Poutanen M, Toppari J, Huhtaniemi I. The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. *Proc Natl Acad Sci U S A*. 2003;100:13692–7.
43. Oduwole OO, Vydra N, Wood NE, Samanta L, Owen L, Keevil B, Donaldson M, Naresh K, Huhtaniemi IT. Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception. *FASEB J*. 2014;28:2566–76.
44. Huhtaniemi IT, Korenbrot CC, Jaffe RB. hCG binding and stimulation of testosterone biosynthesis in the human fetal testis. *J Clin Endocrinol Metab*. 1977;44:963–7.
45. Lamminen T, Huhtaniemi I. A common genetic variant of luteinizing hormone; relation to normal and aberrant pituitary-gonadal function. *Eur J Pharmacol*. 2001;414:1–7.
46. Furui K, Suganuma N, Tsukahara S, et al. Identification of two point mutations in the gene coding

- luteinizing hormone (LH) β -subunit, associated with immunologically anomalous LH variants. *J Clin Endocrinol Metab.* 1994;78:107–13.
47. Pettersson K, Mäkelä MM, Dahlén P, Lamminen T, Huoponen K, Huhtaniemi I. Genetic polymorphism found in the LH β gene of an immunologically anomalous variant of human luteinizing hormone. *Eur J Endocrinol.* 1994;130(Suppl 2):65.
 48. Okuda K, Yamada T, Imoto H, Komatsubara H, Sugimoto O. Antigenic alteration of an anomalous human luteinizing hormone caused by two chorionic gonadotropin-type amino-acid substitutions. *Biochem Biophys Res Comm.* 1994;200:584–90.
 49. Nilsson C, Pettersson K, Millar RP, Coerver KA, Matzuk MM, Huhtaniemi IT. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. International Collaborative Research Group. *Fertil Steril.* 1997;67:998–1004.
 50. Nilsson C, Jiang M, Pettersson K, et al. Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassay. *Clin Endocr (Oxf).* 1998;49:369–76.
 51. Pettersson K, Ding YQ, Huhtaniemi I. An immunologically anomalous luteinizing hormone variant in a healthy woman. *J Clin Endocrinol Metab.* 1992;74:164–71.
 52. Suganuma N, Furui K, Kikkawa F, Tomoda Y, Furuhashi M. Effects of the mutations (Trp8 \rightarrow Arg and Ile15 \rightarrow Thr) in human luteinizing hormone (LH) β -subunit on LH bioactivity in vitro and in vivo. *Endocrinology.* 1996;137:831–8.
 53. Haavisto A-M, Pettersson K, Bergendahl M, Virkamäki A, Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. *J Clin Endocrinol Metab.* 1995;80:1257–63.
 54. Manna PR, Joshi L, Reinhold VN, et al. Synthesis, purification, and structural and functional characterization of recombinant form of a common genetic variant of human luteinizing hormone. *Hum Mol Genet.* 2002;11:301–15.
 55. Wide L, Eriksson K, Sluss PM, Hall JE. The common genetic variant of luteinizing hormone has a longer serum half-life than the wild type in heterozygous women. *J Clin Endocrinol Metab.* 2010;95:383–9.
 56. van den Beld AW, Huhtaniemi IT, Pettersson K, et al. Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men. *J Clin Endocrinol Metab.* 1999;84:1334–9.
 57. Huhtaniemi IT, Pye SR, Holliday KL, Thomson W, O'Neill TW, Platt H, Payne D, John SL, Jiang M, Bartfai G, Boonen S, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Vanderschueren D, Labrie F, Wu FC, European Male Aging Study Group. Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men. *J Clin Endocrinol Metab.* 2010;95:1898–908.
 58. Punab AM, Grigorova M, Punab M, Adler M, Kuura T, Poolamets O, Vihljajev V, Žilaitienė B, Erenpreiss J, Matulevičius V, Laan M. Carriers of V-LH among 1593 Baltic men have significantly higher serum LH. *Andrology.* 2015;3(3):512–9.
 59. Cramer DW, Pettersson KS, Barbieri RL, Huhtaniemi IT. Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone. *Hum Reprod.* 2000;15:2103–7.
 60. Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkova M, White D, Franks S, Anttila L, Pettersson KS, Huhtaniemi IT. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. *J Clin Endocrinol Metab.* 1999;84:1711–5.
 61. Du J-W, Xu K-Y, Qi X-L. Association between mutations of the luteinizing hormone β subunit and female infertility. *Mol Med Reports.* 2012;5:473–6.
 62. Jiang M, Pakarinen P, Zhang FP, El-Hefnawy T, Koskimies P, Pettersson K, Huhtaniemi I. A common polymorphic allele of the human luteinizing hormone β -subunit gene: additional mutations and differential function of the promoter sequence. *Hum Mol Genet.* 1999;8(11):2037–46.
 63. Nilsson CH, Kaleva M, Virtanen H, Haavisto AM, Pettersson K, Huhtaniemi IT. Disparate response of wild-type and variant forms of LH to GnRH stimulation in individuals heterozygous for the LH β variant allele. *Hum Reprod.* 2001;16:230–5.
 64. Raivio T, Huhtaniemi I, Anttila R, et al. The role of luteinizing hormone- β gene polymorphism in the onset and progression of puberty in healthy boys. *J Clin Endocrinol Metab.* 1996;81:3278–82.
 65. Kaleva M, Virtanen H, Haavisto AM, Main K, Skakkebaek NE, Huhtaniemi I, Irjala K, Toppari J. Does variant luteinizing hormone (V-LH) predispose to improper testicular position in late pregnancy? *Pediatr Res.* 2005;58:447–50.
 66. Elkins DA, Yokomizo A, Thibodeau SN, J Schaid D, Cunningham JM, Marks A, Christensen E, McDonnell SK, Slager S, J Peterson B, J Jacobsen S, R Cerhan J, L Blute M, J Tindall D, Liu W. Luteinizing hormone β polymorphism and risk of familial and sporadic prostate cancer. *Prostate* 2003;56:30–6.
 67. Ramanujam LN, Liao W-X, Roy AC, Ng SC. Association of molecular variants of luteinizing hormone with male infertility. *Hum Reprod.* 2000;15:925–8.
 68. Liao WX, Roy AC, Chan C, Arulkumaran S, Ratnam SS. A new molecular variant of luteinizing hormone associated with female infertility. *Fertil Steril.* 1998;69:102–6.
 69. Jiang M, Lamminen T, Pakarinen P, et al. A novel Ala⁻³ Thr mutation in signal peptide of human luteinizing hormone β -subunit: potentiation of the inositol phosphate signalling pathway and

- attenuation of the adenylate cyclase pathway by recombinant variant hormone. *Mol Hum Reprod.* 2002;8:201–12.
70. Hallast P, Nagirnaja L, Margus T, Laan M. Segmental duplications and gene conversion: human luteinizing hormone/chorionic gonadotropin β gene cluster. *Genome Res.* 2005;15:1535–46.
 71. Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhea and infertility due to a mutation in the β -subunit of follicle-stimulating hormone. *Nat Genet.* 1993;5:83–6.
 72. Layman LC, Lee EJ, Peak DB, et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone β -subunit gene. *N Engl J Med.* 1997;337:607–11.
 73. Layman LC, Porto ALA, Xie J, et al. FSH β gene mutations in a female with partial breast development and male sibling with normal puberty and azoospermia. *J Clin Endocrinol Metab.* 2002;87:3702–7.
 74. Lofrano-Porto A, Casulari LA, Nascimento PP, Giacomini L, Naves LA, Casulari da Motta LD, Layman LC. Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone β subunit mutation *Fertil Steril* 2008;90:1169–74.
 75. Berger K, Souza H, Brito VN, d'Alva CB, Mendonca BB, Latronico AC. Clinical and hormonal features of selective follicle stimulating hormone (FSH) deficiency due to FSH β -subunit gene mutations in both sexes. *Fertil Steril* 2005;83:466–70.
 76. Kottler M-L, Chou Y-Y, Chabre O, Richard N, Polge C, Brailly-Tabard S, Chanson P, Guiochon-Mantel A, Huhtaniemi I, Young J. A new FSH β mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. *Eur J Endocrinol.* 2010;162:633–41.
 77. Phillip M, Arbel JE, Segev Y, Parvari R. Male hypogonadism due to a mutation in the gene for the β -subunit of follicle-stimulating hormone. *N Engl J Med.* 1998;338:1729–32.
 78. Lindstedt G, Nyström E, Matthews C, Ernest I, Janson PO, Chatterjee K. Follitropin (FSH) deficiency in an infertile male due to FSH- β gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high luteinizing hormone and normal serum testosterone concentrations. *Clin Chem Lab Med.* 1998;36:663–5.
 79. Lindstedt G, Nyström E, Janson PO. Fall av manlig infertilitet. *Klinisk Kemi i Norden.* 1997;3:81–7.
 80. Tapanainen JS, Jiang M, Vaskivuo T, Huhtaniemi IT. Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. *Nat Genet* 1997;15:205–6.
 81. Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. *Nat Genet.* 1997;15:201–4.
 82. Dierich A, Sairam MR, Monaco L, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. *Proc Natl Acad Sci USA.* 1998;95:13612–7.
 83. Abel MH, Wootton AN, Wilkins V, Huhtaniemi I, Knight P, Charlton HM. The effect of a null mutation in the follicle-stimulating hormone receptor gene on mouse reproduction. *Endocrinology.* 2000;141:1795–803.
 84. Aittomäki K, Dieguez Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. *Cell.* 1995;82:959–68.
 85. Baker PJ, Abel MH, Charlton HM, Huhtaniemi IT, O'Shaughnessy PJ. Failure of normal Leydig cell development in FSH receptor deficient mice but not in FSH β -deficient mice. *Endocrinology.* 2000;144:138–45.
 86. Laan M, Grigorova M, Huhtaniemi IT. Pharmacogenetics of follicle-stimulating hormone action. *Curr Opin Endocrinol Diabetes Obes.* 2012;19:220–7.
 87. Grigorova M, Punab M, Ausmees K, Laan M. FSHB promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men. *Hum Reprod.* 2008;23:2160–6.
 88. Grigorova M, Punab M, Poolamets O, Kelgo P, Ausmees K, Korrovits P, Vihlajev V, Laan M. Increased Prevalance of the 211 T allele of follicle stimulating hormone (FSH) β subunit promoter polymorphism and lower serum FSH in infertile men. *J Clin Endocrinol Metab.* 2010;95:100–8.
 89. Busch AS, Tüttelmann F, Zitzmann M, Kliesch S, Gromoll J. The FSHB–211G>T variant attenuates serum FSH levels in the supraphysiological gonadotropin setting of Klinefelter syndrome. *E J Hum Genet.* 2015;23:700–3.
 90. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, O'Donovan MC. Functional analysis of human promoter polymorphisms. *Hum Mol Genet.* 2003;12:2249–54.
 91. Grigorova M, Punab M, Punab AM, Poolamets O, Vihlajev V, Zilaitienė B, Erenpreiss J, Matulevičius V, Laan M. Reproductive physiology in young men is cumulatively affected by FSH-action modulating genetic variants: FSHR–29G/A and c.2039 A/G, FSHB–211G/T. *PLoS ONE.* 2014;9:e94244.
 92. Ferlin A, Vinanzi C, Selice R, Garolla A, Frigo AC, Foresta C. Toward a pharmacogenetic approach to male infertility: polymorphism of follicle-stimulating hormone β -subunit promoter. *Fertil Steril.* 2011;96:1344–9.

93. Tüttelmann F, Laan M, Grigorova M, Punab M, Söber S, Gromoll J. Combined effects of the variants FSHB-211G>T and FSHR 2039A>G on male reproductive parameters. *J Clin Endocrinol Metab.* 2012;97:3639–47.
94. Busch AS, Kliesch S, Tüttelmann F, Gromoll J. FSHB-211G>T stratification for follicle-stimulating hormone treatment of male infertility patients: making the case for a pharmacogenetic approach in genetic functional secondary hypogonadism. *Andrology.* 2015;3:1050–3.
95. Schüring A, Busch AS, Bogdanova N, Gromoll J, Tüttelmann F. Effects of the FSH- β -subunit promoter polymorphism-211G>T on the hypothalamic-pituitary-ovarian axis in normally cycling women indicate a gender-specific regulation of gonadotropin secretion. *J Clin Endocrinol Metab.* 2013;98:E82–6.
96. Ruth KSD, Beaumont RN, Tyrrell J, Jones SE, Tuke MA, Yaghootkar H, Wood AR, Freathy RM, Weedon MN, Frayling TM, Murray A. Genetic evidence that lower circulating FSH levels lengthen menstrual cycle, increase age at menopause and impact female reproductive health *Hum Reprod.* 2016;31:473–81.
97. Troppmann B, Kleinau G, Krause G, Gromoll J. Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. *Hum Reprod Update.* 2013;19:583–602.
98. Zhang F-P, Poutanen M, Wilbertz J, Huhtaniemi I. Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. *Mol Endocrinol.* 2001;15:182–93.
99. Mitri F, Bentov Y, Behan LA, Esfandiari N, Casper RF. A novel compound heterozygous mutation of the luteinizing hormone receptor-implications for fertility. *J Assist Reprod Genet.* 2014;31:787–94.
100. Kremer H, Mariman E, Otten BJ, Moll GW Jr, Stoelinga GB, Wit JM, Jansen M, Drop SL, Faas B, Ropers HH, et al. cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. *Hum Mol Genet.* 1993;2(11):1779–83.
101. Shenker A, Laue L, Kosugi S, Merendino JJ, Jr., Minegishi T, Cutler GB Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. *Nature* 1993;365:652–4.
102. Özcabi B, Tahmiscioğlu Bucak F, Ceylaner S, Özcan R, Büyükcinal C, Ercan O, Tüysüz B, Evliyaoglu O. Testotoxicosis: report of two cases, one with a novel mutation in LHCGR gene. *J Clin Res Pediatr Endocrinol* 2015;7:242–8.
103. Liu G, Duranteau L, Carel J-C, Monroe J, Doyle DA, Shenker A. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. *N Engl J Med.* 1999;341:1731–6.
104. Sangkhathat S, Kannngum S, Jaruratanasirikul S, Tubtawee T, Chaipayapan W, Patrapinyokul S, Chiengkriwate P. Peripheral precocious puberty in a male caused by Leydig cell adenoma harboring a somatic mutation of the LHR gene: report of a case. *J Med Assoc Thai.* 2010;93:1093–7.
105. Canto P, Söderlund D, Ramón G, Nishimura E, Méndez JP. Mutational analysis of the luteinizing hormone receptor gene in two individuals with Leydig cell tumors. *Am J Med Genet.* 2002;108:148–52.
106. d’Alva CB, Brito VN, Palhares HM, Carvalho FM, Arnhold IJ, Mendonca BB, Latronico AC. A single somatic activating Asp578 His mutation of the luteinizing hormone receptor causes Leydig cell tumour in boys with gonadotropin-independent precocious puberty. *Clin Endocrinol (Oxf).* 2006;65:408–10.
107. Goji K, Teraoka Y, Hosokawa Y, Okuno M, Ozaki K, Yoshida M, Matsuo M. Gonadotropin-independent precocious puberty associated with a somatic activating mutation of the LH receptor gene: detection of a mutation present in only a small fraction of cells from testicular tissue using wild-type blocking polymerase chain reaction and laser-capture microdissection. *Endocrine.* 2009;35:397–401.
108. Kiepe D, Richter-Unruh A, Autschbach F, Kessler M, Schenk JP, Bettendorf M. Sexual pseudo-precocity caused by a somatic activating mutation of the LH receptor preceding true sexual precocity. *Horm Res.* 2008;70:249–53.
109. Leschek EW, Chan WY, Diamond DA, et al. Nodular Leydig cell hyperplasia in a boy with male-limited precocious puberty. *J Pediatr.* 2001;138:949–51.
110. Martin MM, Wu S-M, Martin ALA, Rennert OM, Chan W-Y. Testicular seminoma in a patient with a constitutively activating mutation of the luteinizing hormone/chorionic gonadotropin receptor. *Eur J Endocrinol.* 1998;139:101–6.
111. Rulli SB, Ahtiaainen P, Mäkelä S, Toppari J, Poutanen M, Huhtaniemi Elevated steroidogenesis, defective reproductive organs, and infertility in transgenic male mice overexpressing human chorionic gonadotropin. *Endocrinology.* 2003;144:4980–90.
112. McGee SR, Narayan P. Precocious puberty and Leydig cell hyperplasia in male mice with a gain of function mutation in the LH receptor gene. *Endocrinology.* 2013;154:3900–13.
113. Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. *N Engl J Med.* 1997;337:1675–81.
114. Parma J, Duprez L, Van Sande J, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gsa genes as a cause of toxic

- thyroid adenomas. *J Clin Endocrinol Metab.* 1997;82:2695–701.
115. Russo D, Tumino S, Arturi F, et al. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. *J Clin Endocrinol Metab.* 1997;82:735–8.
 116. Fragoso MC, Latronico AC, Carvalho FM, et al. Activating mutation of the stimulatory G protein (*gsp*) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. *J Clin Endocrinol Metab.* 1998;83:2074–8.
 117. Siegel ET, Kim HG, Nishimoto HK, Layman LC. The molecular basis of impaired follicle-stimulating hormone action: evidence from human mutations and mouse models. *Reprod Sci.* 2013;20:211–33.
 118. Beau I, Touraine P, Meduri G, et al. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. *J Clin Invest.* 1998;102:1352–9.
 119. Touraine P, Beau I, Gougeon A, et al. New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. *Mol Endocrinol.* 1999;13:1844–54.
 120. Rannikko A, Pakarinen P, Manna P, et al. Functional characterization of the human FSH receptor with an inactivating Ala189Val mutation. *Mol Hum Reprod.* 2002;8:311–7.
 121. Vaskivuo TE, Aittomäki K, Anttonen M, et al. Effects of follicle-stimulating hormone (FSH) and human chorionic gonadotropin in individuals with inactivating mutation of the FSH receptor. *Fertil Steril.* 2002;78:108–13.
 122. Gromoll J, Simoni M, Nieschlag E. An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. *J Clin Endocrinol Metab.* 1996;81:1367–70.
 123. Haywood M, Tymchenko N, Spaliviero J, Koch A, Jimenez M, Gromoll J, Simoni M, Nordhoff V, Handelsman DJ, Allan CM. An activated human follicle-stimulating hormone (FSH) receptor stimulates FSH-like activity in gonadotropin-deficient transgenic mice. *Mol Endocrinol.* 2002;16:2582–91.
 124. Peltoketo H, Strauss L, Karjalainen R, Zhang M, Stamp GW, Segaloff DL, Poutanen M, Huhtaniemi IT. Female mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excess. *Endocrinology.* 2010;151:1872–83.
 125. González P, Scaglia HE, Pérez-Solís MA, Durand G, Scaglia J, Zariñán T, Dias JA, Reiter E, Ulloa-Aguirre A. Normal testicular function without detectable follicle-stimulating hormone. A novel mutation in the follicle-stimulating hormone receptor gene leading to apparent constitutive activity and impaired agonist-induced desensitization and internalization. *Mol Cell Endocrinol.* 2012;364:71–82.
 126. Gicaglia LR, da Fonte Kohek MB, Carvalho FM, Villares Fragaso MCB, Mendonca BB, Latronico AC. No evidence of somatic activating mutations on gonadotropin receptor genes in sex cord stromal tumors. *Fertil Steril.* 2000;64:992–5.
 127. Takakura K, Takebayashi K, Wang H-Q, Kimura F, Kasahara K, Noda Y. Follicle-stimulating hormone receptor gene mutations are rare in Japanese women with premature ovarian failure and polycystic ovary syndrome. *Fertil Steril.* 2001;75:207–9.
 128. Tong Y, Liao WX, Roy AC, Ng SC. Absence of mutations in the coding regions of follicle-stimulating hormone receptor gene in Singapore Chinese women with premature ovary failure and polycystic ovary syndrome. *Hormone Metab Res.* 2001;33:221–6.
 129. de la Chesnaye E, Canto P, Ulloa-Aguirre A, Mendez JP. No evidence of mutations in the follicle-stimulating hormone receptor gene in Mexican women with 46, XX pure gonadal dysgenesis. *Am J Med Genet.* 2001;98:129–35.
 130. Montgomery GW, Duffy DL, Hall J, Kudo M, Martin NG, Hsueh AJ. Mutations in the follicle-stimulating hormone receptor and familial dizygotic twinning. *Lancet.* 2001;357:773–4.
 131. Delbaere A, Smits G, De Leener A, Costagliola S, Vassart G. Understanding ovarian hyperstimulation syndrome. *Endocrine.* 2005;26:285–90.
 132. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. *J Clin Endocrinol Metab.* 2000;85:3365–9.
 133. Daelemans C, Smits G, de Maertelaer V, Costagliola S, Englert Y, Vassart G, Delbaere A. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680 Asn polymorphism. *J Clin Endocrinol Metab.* 2004;89:6310–5.
 134. Lledo B, Ortiz JA, Llacer J, Bernabeu R. Pharmacogenetics of ovarian response. *Pharmacogenomics.* 2014;15:885–93.
 135. Simoni M, Gromoll J, Höppner W, Kamischke A, Krafft T, Stähle D, Nieschlag E. Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms. *J Clin Endocrinol Metab.* 1999;84:751–5.
 136. Ahda Y, Gromoll J, Wunsch A, Asatiani K, Zitzmann M, Nieschlag E, Simoni M. Follicle-stimulating hormone receptor gene haplotype

- distribution in normozoospermic and azoospermic men. *J Androl.* 2005;26:494–9.
137. Ferlin A, Pengo M, Selice R, Salmaso L, Garolla A, Foresta C. Analysis of single nucleotide polymorphisms of FSH receptor gene suggests association with testicular cancer susceptibility. *Endocr Relat Cancer.* 2008;15:429–37.
 138. Pengo M, Ferlin A, Arredi B, Ganz F, Selice R, Garolla A, Foresta C. FSH receptor gene polymorphisms in fertile and infertile Italian men. *Reprod Biomed Online.* 2006;13:795–800.
 139. Selice R, Garolla A, Pengo M, Caretta N, Ferlin A, Foresta C. The response to FSH treatment in oligozoospermic men depends on FSH receptor gene polymorphisms. *Int J Androl.* 2011;34:306–12.
 140. Lindgren I, Giwercman A, Axelsson J, Lundberg Giwercman Y. Association between follicle-stimulating hormone receptor polymorphisms and reproductive parameters in young men from the general population. *Pharmacogenet Genomics.* 2012;22:667–72.
 141. Grigorova M, Punab M, Poolamets O, Söber S, Vihljajev V, Žilaitienė B, Erenpreiss J, Matulevičius V, Tsarev I, Laan M. Study in 1790 Baltic men: FSHR Asn680Ser polymorphism affects total testes volume. *Andrology.* 2013;1:293–300.
 142. Shimoda C, Koh E, Yamamoto K, Matsui F, Sugimoto K, Sin HS, Maeda Y, Kanaya J, Yoshida A, Namiki M. Single nucleotide polymorphism analysis of the follicle-stimulating hormone (FSH) receptor in Japanese with male infertility: identification of codon combination with heterozygous variations of the two discrete FSH receptor gene. *Endocr J.* 2009;56:859–65.
 143. Safarinejad MR, Shafiei N, Safarinejad S. Evaluating the role of the FSH receptor gene Thr307-Ala and Asn680-Ser polymorphisms in male infertility and their association with semen quality and reproductive hormones. *BJU Int.* 2011;108:E117–25.
 144. Mongan NP, Hughes IA, Lim HN. Evidence that luteinizing hormone receptor polymorphisms may contribute to male undermasculinisation. *Eur J Endocrinol.* 2002;147:103–7.
 145. Simoni M, Tüttelmann F, Michel C, Böckenfeld Y, Nieschlag E, Gromoll J. Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: association with maldescended testes and male infertility. *Pharmacogenet Genomics.* 2008;18:193–200.
 146. Aschim EL, Oldenburg J, Kristiansen W, Giwercman A, Witczak O, Fosså SD, Haugen TB. Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones. *Hum Reprod.* 2014;29:2844–51.
 147. Bentov Y, Kenigsberg S, Casper RC. A novel luteinizing hormone/chorionic gonadotropin receptor mutation associated with amenorrhea, low oocyte yield, and recurrent pregnancy loss. *Fertil Steril.* 2012;97:1165–8.
 148. Vezzoli V, Duminuco P, Vottero A, Kleinau G, Schülein R, Minari R, Bassi I, Bernasconi S, Persani L, Bonomi M. A new variant in signal peptide of the human luteinizing hormone receptor (LHCGR) affects receptor biogenesis causing Leydig cell hypoplasia. *Hum Mol Genet.* 2015;24:6003–12.
 149. Rivero-Müller A, Potorac I, Pintiaux A, Daly AF, Thiry A, Rydlewski C, Nisolle M, Parent AS, Huhtaniemi I, Beckers A. A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1. *Eur J Endocrinol.* 2015;172:K27–36.
 150. Nakamura Y, Maekawa Y, Yamagata Y, Tamura I, Sugino N. A novel mutation in exon8 of the follicle-stimulating hormone receptor in a woman with primary amenorrhea. *Gyn Endocrinol.* 2008;24:708–12.
 151. Achrekar S, Modi D, Meherji P, Patel ZM, Mahale SD. Follicle stimulating hormone receptor gene variants in women with primary and secondary amenorrhea. *J Assist Reprod Genet.* 2010;27:317–26.
 152. Kuechler A, Hauffa BP, Köninger A, Kleinau G, Albrecht B, Horsthemke B, Gromoll J. An unbalanced translocation unmasks a recessive mutation in the follicle-stimulating hormone receptor (FSHR) gene and causes FSH resistance. *Eur J Hum Genet.* 2010;18:656–61.
 153. Uchida S, Uchida H, Maruyama T, Kajitani T, Oda H, Miyazaki K, Kagami M, Yoshimura Y. Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome. *PLoS ONE.* 2013;8:e75478.
 154. Desai SS, Achrekar SK, Sahasrabudhe KA, Meharji PK, Desai SK, Mangoli VS, Mahale SD. Functional characterization of two naturally occurring mutations (Val514Ala and Ala575Val) in follicle-stimulating hormone receptor. *J Clin Endocrinol Metab.* 2015;100:E638–45.
 155. Chauhan AR, Prasad M, Chamariya S, Achrekar S, Mahale SD, Mittal K. Novel FSH receptor mutation in a case of spontaneous ovarian hyperstimulation syndrome with successful pregnancy outcome. *J Hum. Reprod Sci.* 2015;8:230–3.
 156. Katari S, Wood-Trageser MA, Jiang H, Kalynchuk E, Muzumdar R, Yatsenko SA, Rajkovic A. Novel inactivating mutation of the FSH receptor in two siblings of Indian origin with premature ovarian failure. *J Clin Endocrinol Metab.* 2015;100:2154–7.
 157. Bramble MS, Goldstein EH, Lipson A, Ngun T, Eskin A, Gosschalk JE, Roach L, Vashist N, Barseghyan H, Lee E, Arboleda VA, Vaiman D,

- Yuksel Z, Fellous M, Vilain E. A novel follicle-stimulating hormone receptor mutation causing primary ovarian failure: a fertility application of whole exome sequencing. *Hum Reprod.* 2016;31:905–14.
158. Tong Y, Liao WX, Roy AC, Ng SC. Association of AccI polymorphism in the follicle-stimulating hormone β gene with polycystic ovary syndrome. *Fertil Steril.* 2000;74:1233–6.

Hypogonadism in Males with Congenital Adrenal Hyperplasia

7

Nike M.M.L. Stikkelbroeck MD, PhD
and Hedi L. Claahsen-van der Grinten MD, PhD

Contents

Introduction.....	153	Other Testicular Abnormalities	162
Congenital Adrenal Hyperplasia: Impaired Steroid Synthesis in the Adrenal Gland.....	153	Psychological Factors, Compliance, and Transition ..	163
Prevalence	154	Treatment of Subfertility in CAH Males	163
Presentation and Diagnosis.....	154	Treatment of Hypogonadism and Subfertility.....	163
Genetics.....	154	Genetic Counseling.....	164
Fertility in Males with 21-Hydroxylase Deficiency..	155	Conclusion	164
Reported Fertility in Males with 21-Hydroxylase Deficiency	155	References	164
Causes of Subfertility in CAH Males	155		
Testicular Adrenal Rest Tumors (TART)	156		
Introduction	156		
Prevalence of TART in Adult CAH Patients	156		
Prevalence of TART in Children and Adolescents with CAH.....	156		
Diagnosing TART	156		
Histopathology	157		
Steroid Production	158		
The Origin of TART	159		
Relation Between the Presence of TART and Ther- apeutic Control.....	161		
Influence of TART on Fertility	161		
Other Testicular Tumors in CAH Males.....	161		
Hypogonadotropic Hypogonadism in CAH Males...	161		
Hypergonadotropic Hypogonadism in CAH Males..	162		
Other Causes of Subfertility in CAH Males.....	162		
Testicular Volume in CAH Patients.....	162		

N.M.M.L. Stikkelbroeck (✉)
Division of Endocrinology, Radboud University
Medical Centre, Internal Medicine, Geert
Grooteplein Zuid 8, 6525 GA Nijmegen, The
Netherlands
e-mail: Nike.Stikkelbroeck@radboudumc.nl

H.L. Claahsen-van der Grinten
Pediatrics, Radboud University Nijmegen Medical
Centre, Geert Grooteplein 10, 6525 GA Nijmegen,
The Netherlands
e-mail: Hedi.Claahsen@radboudumc.nl

Introduction

Congenital Adrenal Hyperplasia: Impaired Steroid Synthesis in the Adrenal Gland

Congenital adrenal hyperplasia (CAH) is a group of inherited conditions in which the synthesis of cortisol by the adrenal gland is impaired as a result of an enzyme deficiency. Consequently, the secretion of adrenocorticotropin (ACTH) by the pituitary gland is increased, resulting in hyperplasia of the adrenal cortex and excess production of steroids that do not require the specific deficient enzyme for their synthesis [1]. Figure 7.1 depicts the pathway for normal adrenal steroid synthesis. Mutations in the genes encoding the enzymes 21-hydroxylase, 17-hydroxylase/17,20-lyase, 11-hydroxylase, 3 β -hydroxysteroid dehydrogenase, or the protein StAR (intracellular cholesterol transport protein) lead to CAH. 21-hydroxylase deficiency is by far the most frequent cause of CAH (more than 90% of all cases). This deficiency results in cortisol and aldosterone deficiency and an overproduction of 17-hydroxyprogesterone and androstenedione, leading to androgen excess. Recent




Fig. 7.1 Adrenal steroid synthesis. *StAR* steroidogenic autoregulatory protein; *SCC* (cholesterol) side-chain cleavage enzyme; *3β-HSD* 3β-hydroxysteroid dehydrogenase; *17β-HSD* 17β-hydroxysteroid dehydrogenase

publications describe also transcription factors (PAPPS and cytochrome B5) resulting in insufficient enzymatic activity [2, 3].

Prevalence

Most enzyme deficiencies that cause CAH are extremely rare, except for 21-hydroxylase deficiency and 11-hydroxylase deficiency. The prevalence of classic 21-hydroxylase deficiency worldwide is 1:10.000 to 1:18.000, as derived from results of neonatal screening. Non-classic 21-hydroxylase deficiency is estimated to be more prevalent (1:600), but this diagnosis can easily be missed in males because signs of adrenal androgen excess may go unrecognized. The estimated prevalence of 11-hydroxylase deficiency is 1:100.000 [1].

Presentation and Diagnosis

CAH represents a broad spectrum of phenotypes depending on the severity of the enzymatic defect. In clinical practice, however, CAH is divided into 3 forms. The most severe, classic CAH phenotype is

subdivided into a salt-wasting form (SW-CAH, no residual enzymatic activity) and a simple virilizing form without aldosterone deficiency (SV-CAH, residual enzymatic activity of 1–2%). Non-classic CAH (NC-CAH) has a less severe phenotype with a residual enzymatic activity of 30–50%. Patients with the mildest forms present with symptoms are caused by androgen excess only: premature adrenarche, hirsutism, menstrual irregularities, and infertility, most of which are limited to women (non-classic form) [1].

Genetics

All forms of CAH are characterized by an autosomal recessive inheritance. The genes that encode the various enzymes have all been elucidated [1]. 21-hydroxylase is encoded by the *CYP21* gene. *CYP21* and the homologous pseudogene *CYP21P* are located in the HLA major histocompatibility complex on chromosome 6, a region with a high frequency of genomic recombination. *CYP21* and *CYP21P* are 98% identical, which explains the high mutation rate of the *CYP21* gene. One-third of the described mutations are deletions and large

gene conversions that were caused by recombination between the two homologous loci. The other mutations are small defects that are transferred from the CYP21P pseudogene to the active CYP21 gene, resulting from non-homologous pairing. The genotype–phenotype correlation is reported to be 80–90%, with the best predictions in the most severe and the mildest deficiencies [1, 4].

Of all types of congenital adrenal hyperplasia, 21-hydroxylase deficiency is the most frequent and the most extensively studied. Therefore, this chapter on male hypogonadism in CAH will focus predominantly on 21-hydroxylase deficiency.

Fertility in Males with 21-Hydroxylase Deficiency

Reported Fertility in Males with 21-Hydroxylase Deficiency

Reports on child rate in CAH males show a reduced fertility. Jääskeläinen et al. [5] found a child rate of 0.07 in the complete Finnish male CAH population, compared to 0.34 in age-matched Finnish males. Other authors reported parenthood only as additional information in smaller and selected patient populations. Urban et al. [6] found apparently normal fertility in men with CAH (some even untreated): They described 14 fathers among 20 male patients (aged 18–37 years), and Cabrera et al. [7] reported paternity in 2 of 30 patients (aged 17–43 years). Three more recent reports in large patient cohorts show paternity in 41, 67, and 51%, respectively, in patients who had sought fertility [8–10].

Several recent studies reported results of semen analysis in CAH patients [8, 10–13]. In most of these recent studies, only a subgroup of the study population consented to provide semen for analysis (32–91% of study participants). The combined results of these studies show azoospermia in 5–20% of cases and

oligozoospermia in 20–54% of cases. In the studies in which the upper reference limit of the WHO consensus (>15 million sperm per ml) was used [14], normospermia was found between 34 and 68% [10, 12, 13]. Although reports of semen analysis are hampered by low participation rates and ambiguous use of reference values, we could conclude that spermatogenesis is impaired in a substantial group of CAH males.

In summary, there is substantial evidence that fertility can be impaired in male CAH patients. This finding raises the question to what extent male subfertility in the general population is caused by undiagnosed CAH. Ojeifo et al. [15] investigated basal and ACTH-stimulated serum 17-hydroxyprogesterone levels in a population of 50 males with idiopathic infertility, and compared the results with those of 25 controls. No differences in basal or stimulated levels were found, and they concluded that 21-hydroxylase deficiency is a rare cause of idiopathic male infertility. Pinkas et al. [16] studied a cohort of 484 healthy men attending a fertility clinic and likewise found no patient with CAH (defined as an ACTH-stimulated level of 17-hydroxyprogesterone (17OHP) of ≥ 45 nmol/l, performed in patients whose random mid-morning level of 17OHP was ≥ 6 nmol/l).

Causes of Subfertility in CAH Males

The most frequently reported cause of subfertility in CAH males is the presence of adrenal rest tumors in the testes [7, 17, 18]. These tumors may interfere directly (mechanically or paracrine) or indirectly (endocrine) with testicular function [19, 20]. Subfertility can also be caused by hypogonadotropic or hypergonadotropic hypogonadism. Psychological problems may also be important. The next sections will focus on these topics separately, although, in practice, these factors may not be separated easily.

Testicular Adrenal Rest Tumors (TART)

Introduction

The presence of testicular tumors in male patients with CAH due to 21-hydroxylase deficiency was first described in 1940 by Wilkins et al. [21]. Since then, these tumors have been described in several case reports and patient cohort studies. It is now generally accepted that testicular adrenal rest tumors are the most important cause of infertility leading to gonadal dysfunction and primary gonadal failure [22]. Because of their histological and functional resemblance to adrenocortical tissue, they are generally called *testicular adrenal rest tumors* (TART). These lesions are often found in both testes of adult men with CAH with a typical location within the rete testis. The tumors are benign, although case reports also describe malignant Leydig cell tumors in CAH patients that can be difficult to diagnose.

Due to the central location within the rete testis, the tumors may lead to the obstruction of the seminiferous tubules and consequently infertility. Long-standing chronic obstruction may also lead to the damage of testicular tissue, and thereby impaired Sertoli and Leydig cell function.

Prevalence of TART in Adult CAH Patients

The reported prevalence varies between 0 and 100% [5–7, 12, 17, 18, 23]. It strongly depends on patient selection (prepubertal, adolescent, or adult patients) and on the method of tumor detection (physical examination or imaging techniques). Because of the central location of the tumors, small lesions <2 cm can be easily missed. Therefore, additional techniques such as MRI or ultrasound are necessary to detect smaller lesions.

The first report of a larger patient cohort was by Urban et al. [6] who found no testicular tumors by physical examination in 30 adult patients. Using ultrasonography, however, adrenal rest tumors were described in several studies reporting TART in 2/14 adult patients [5], 9/18

adult patients [7], and 16 of 17 postpubertal patients [17]. In a recent paper with 50 adult patients (18–49 years), Reisch et al. found a prevalence of 61.3% in salt-wasting patients and 47.5% in SV patients [23].

Furthermore, there is a clear association between the prevalence of TART and the genotype of CAH [24]. TART is mostly described in patients with the most severe types of CAH. This may be explained by strongly elevated ACTH levels beginning in utero. The presence of TART in patients with non-classic CAH has only been described anecdotally [12].

Prevalence of TART in Children and Adolescents with CAH

Tumors have also been reported in childhood: Of the 8 patients with testicular tumors described by Avila et al. in a population of 38 patients, 7 were younger than 16 years old [18]. Shanklin et al. reviewed autopsy material of patients with CAH, and noted testicular nodules in 3 of 7 patients less than 8 weeks old, and in all 14 patients older than 14 months [25]. Claahsen et al. found general prevalence of 24% in childhood and adolescence [26]. Other authors found a similar prevalence of 21 and 18.3% [27, 28]. In a recent study, Claahsen-van der Grinten et al. found a high prevalence of TART in CAH children of nearly 100% with a clear increase in prevalence during puberty [29].

Diagnosing TART

The physical examination reveals only a small proportion of all testicular tumors in CAH patients. For the more accurate detection of smaller tumors, imaging techniques such as ultrasound and MR are required [6, 7, 17, 18, 30, 31]. A comparative study in CAH males concluded that ultrasound is the method of choice because it is as sensitive as MR, less costly, and more accessible [32]. Ultrasound features include hypoechoic lesions adjacent to the mediastinum testis, often lobulated and mostly bilateral




Fig. 7.2 **a** Scrotal ultrasound of a 13-year-old male CAH patient showing a mostly hypoechoic rounded lesion in the left testis near the rete testis. **b** T2-weighted MR image of long-standing bilateral testicular adrenal rest

tumor. Note that heterogeneous low-signal-intensity tumors are displaced surrounding high-signal normal testicular tissue. From Claahsen-van der Grinten et al. [22] (Open Access)

(Fig. 7.2) [18, 31–38]. In larger tumors, we have observed hyperechoic reflections probably due to fibrotic strands. Tumor margins may be blurred on ultrasound but are always well defined on MR [32, 39]. On MR imaging, most of the masses are isointense on T1-weighted images and hypointense on T2-weighted images, just as are adrenal glands [32].

Testicular tumors in CAH may resemble malignant testicular tumors by ultrasonography and MR [38, 40]. However, clinical characteristics such as the bilateral presence of lesions and the location of the lesions adjacent to the mediastinum are helpful in differentiating between a benign testicular adrenal rest tumor and a malignant testicular lesion [33, 39, 41]. On the other hand, the ultrasound characteristics of a testicular tumor can suggest the diagnosis of CAH in males with previously undiagnosed CAH who present with a testicular mass [41]. In that case, elevated 17-hydroxyprogesterone levels may indicate 21-hydroxylase deficiency. However, 17-hydroxyprogesterone production

by a Leydig cell tumor in a non-CAH patient has also been reported [42].

Histopathology

Histologically, the testicular tumors in CAH patients resemble Leydig cell tumors, and differentiation can be difficult (Figs. 7.3 and 7.4) [43]. Some differences may exist; however, TART are bilateral in 83% of cases, whereas Leydig cell tumors are bilateral in only 3% of cases. Malignant degeneration has not been reported in TART, but it occurs in 10% of Leydig cell tumors in adults [43]. In addition, TART are located in the mediastinum testis and may decrease in size when ACTH levels are suppressed by increasing the glucocorticoid dose [20, 41, 43–47]. Rich et al. [43] found that both TART and Leydig cell tumors are circumscribed, lobulated, nodular lesions. TART are typically encapsulated nodules that are dark brown (resulting from a greater concentration of





Fig. 7.3 **a** Macroscopic aspect of TART. Note the yellow color and the bands of fibrous tissue. **b** Testicular adrenal rest tumor growing into rete testis (RT) (HE,

original magnification $\times 200$). From Claahsen-van der Grinten et al. [22] (Open Access)

Fig. 7.4 Testicular biopsy of a patient showing seminiferous tubules with hypospermatogenesis and prominent peritubular fibrosis with increased number of peritubular fibroblasts (*arrows*), as well as tubular hyalinisation (*arrowhead*; original magnification $\times 200$). From Claahsen-van der Grinten et al. [22] (Open Access)



lipochrome pigmentation), whereas Leydig cell tumors are usually yellow intratesticular masses. The color distinction is not always reliable, however, because some Leydig cell tumors are occasionally darker. Reinke crystals, which can be found in 25–40% of Leydig cell tumors, have never been observed in TART. In the surrounding parenchyma, seminiferous tubules show atrophic sclerosis in TART, whereas seminiferous tubules are rarely found in Leydig cell

tumors because they are replaced by the tumor [47].

Steroid Production

Steroid production by TART has been investigated both in vitro and in vivo.

Cortisol production by TART has been demonstrated in vivo by testicular venous sampling after

stimulation with ACTH in non-classic CAH patients [48, 49] and, surprisingly, also in a salt-wasting patient [50].

17-hydroxyprogesterone production by a testicular tumor was demonstrated in vivo by testicular vein sampling after ACTH stimulation [51].

Production of 11-hydroxylated steroids, including 21-deoxycortisol (21-DF), 21-deoxycorticosterone (21-DB), and 11beta-hydroxy- Δ^4 -androstenedione (11beta-OHA), has been demonstrated in vitro [51, 52], as well as in vivo [51, 53, 54]. 11-hydroxylase activity is usually restricted to the adrenal cortex. Clark et al. demonstrated 11-hydroxylase activity in vitro in TART from a salt-wasting CAH patient [52]. That study identified abundant angiotensin II receptors, but no LH receptors, in tumor membranes (ACTH receptors were not investigated). In vivo, 11-hydroxylase activity was demonstrated by testicular vein sampling by Blumberg-Tick et al. [53]. Combes-Moukhovskiy et al. showed that stimulation with hCG increased the secretion of 11-hydroxylated steroids [54]. LH/hCG receptors have been found in the normal human adrenal cortex [55]. In a study of 7 male CAH patients with bilateral TART undergoing testis-sparing surgery, Claahsen-van der Grinten et al. measured the concentrations of the adrenal-specific steroid 21DF, and of 17-hydroxyprogesterone (17OHP) and androstenedione (A) in blood taken from the spermatic veins during surgery [56]. In addition, mRNA expression of the adrenal-specific enzymes CYP11B1 and CYP11B2, as well as of ACTH and angiotensin II (AII) receptors, was shown by PCR in 16 testicular tumors from 8 patients [56]. The results show that TART contain adrenal-specific enzymes and produce adrenal-specific steroids suggesting that these tumors arise from adrenal-like cells. The presence at the mRNA level of ACTH and angiotensin II (AII) receptors in the adrenal rest tumors supports this hypothesis.

Testosterone production was shown in vitro by Franco-Saenz et al. [50], but only after stimulation with ACTH or hCG. Interestingly, testosterone production was more responsive to stimulation by ACTH than by hCG. The authors hypothesized the presence of specific receptors for ACTH and hCG in the same cells, a defective

receptor with loss of specificity, or the presence of two different cell lines. In vivo, Kirkland et al. showed increased testosterone production after ACTH infusion into the testicular artery [57].

Benvenega et al. hypothesized from longitudinal observations in a single patient that at least three distinct types of testicular tumors in CAH could be discriminated based on their response to dexamethasone-induced ACTH suppression [58]. The first type is ACTH-dependent, both in terms of growth and steroidogenesis. The second type is only partially responsive to ACTH, since suppression of growth lagged behind the prompt suppression of steroidogenesis. In addition, this type seemed to be responsive to LH/hCG. In the third type, growth is unresponsive to dexamethasone-induced ACTH suppression, unresponsive to gonadotropins, and has lost the ability to synthesize cortisol.

The Origin of TART

Based on histopathology, steroid-producing properties, and ACTH responsiveness, these testicular tumors are considered to consist of steroidogenic cells. It is known that cells of the adrenal cortex and gonads share a common precursor called the adreno-gonadal primordium, and develop in close relationship to each other. It was hypothesized that, due to incorrect splitting of cells, ectopic adrenal cortex cells persist and descend within the testes, and are stimulated by ACTH. Aberrant adrenal tissue has been identified in 7.5% of normal testes by Dahl et al. [59]. The aberrant adrenal cells are thought to retain their potential for glucocorticoid production, and to respond with hyperplasia to increased ACTH stimulation. Val et al. suggest that adrenal cells originate from a different cell population of adrenal-like cells migrating from the mesonephros into the developing gonad. Other studies propose that TART may be derived from pluripotent cells within the testes [60].

A more recent study by Smeets et al. [61] described the molecular characteristics of TART in more detail using qPCR of all relevant genes encoding enzymes important for steroid




Fig. 7.5 Schematic view of the proposed classification of testicular adrenal rests. From Claahsen-van der Grinten et al. [22] (Open Access)

production. Nearly all genes were highly expressed in TART tissue, including all genes that encode the key steroidogenic enzymes. TART expression levels are generally identical to those found in adrenal tissue. The expression of adrenal cortex-specific genes (*CYP21A2*, *CYP11B1*, *CYP11B2*, and *MC2R*) in both TART and adrenal tissue is approximately 1000–10,000 times higher than in testes. In addition, the Leydig cell-specific markers *INSL3* and *HSD17B3* were not only found in testes, but also in TART, both at significantly higher levels than in the adrenal. The authors concluded that TART consist of a more totipotent cell with adrenal and Leydig cell-specific features [61].

Based on clinical, histological, and radiological observations, Claahsen-van der Grinten et al. [22] proposed that the development and growth of TART can be divided into five stages based on histological criteria of TART and the surrounding testicular parenchyma (Fig. 7.5). **Stage 1:** This stage can be defined as the presence of

adrenal-like cells within the rete testis not detectable by scrotal ultrasound. **Stage 2:** In CAH patients, the adrenal rest cells may proliferate in the presence of increased concentrations of growth-promoting factors such as ACTH (and possibly AII). In this stage, the adrenal rest cells may become visible by ultrasound as hypoechogenic lesions. **Stage 3:** Further growth of the adrenal rest cells will compress the rete testis. **Stage 4:** Further hypertrophy and hyperplasia of the adrenal rest cells with progressive obstruction of the rete testis may lead to the induction of fibrosis within the tumor and focal lymphocytic infiltration. Several small tumors within the rete testis become confluent, forming a single lobulated structure separated from testicular tissue by fibrous strands. **Stage 5:** Chronic obstruction subsequently leads to the destruction of the surrounding testicular parenchyma causing irreversible damage [62]. Further studies are necessary to validate the proposed classification of TART.

Relation Between the Presence of TART and Therapeutic Control

Early reports of TART were predominantly in poorly controlled patients [53, 54, 63]. Those observations led to the hypothesis that poor hormonal control and inadequate suppression of ACTH secretion is a dominant etiological factor in the development of TART. This hypothesis is supported by the development of TART in patients without CAH who have elevated ACTH levels, such as Nelson's syndrome [64, 65] or Addison's disease [66]. Furthermore, shrinkage of the tumor after intensifying glucocorticoid therapy has been described in many case reports.

In more recent studies, however, no correlation was found between the presence of TART and the degree of hormonal control [7, 17, 23, 30, 31, 36]. Still, as stated before, there is a clear association between the prevalence of TART and the genotype of CAH [24]. TART is mostly described in patients with the most severe types of CAH, which may be explained by strongly elevated ACTH levels beginning in utero.

Influence of TART on Fertility

TART may interfere directly (mechanically or paracrine) or indirectly (endocrine) with testicular function. The mechanical effect of the tumors can be considerable as a result of their central location adjacent to the mediastinum testis. It can lead to the obstruction of the vascular supply, and compression and atrophy of the seminiferous tubules. Pathological examination revealed that in the cases of large tumors, the residual testicular parenchyma was abnormal and showed atrophy, sclerosis or immaturity, and decreased or absent spermatogenesis [41]. Around small nodules, however, the testicular parenchyma was generally normal [62]. Murphy et al. showed in one patient that, close to the mediastinum and the tumor, germ cells were reduced and spermatogenesis was impaired. Testicular aspiration in other areas, however, showed normal spermatogenesis. In addition to direct mechanical effects

(obstruction or destruction), tumors may have a paracrine effect on the surrounding tissue, i.e., steroids produced by the tumors could be toxic to Sertoli cells or germ cells [67].

Indirect (endocrine) effects of testicular tumors in CAH on fertility could result from steroid secretion by the tumor with suppression of the hypothalamic–pituitary–gonadal axis. The association between infertility, testicular adrenal rest tumors, and depressed serum LH and FSH levels in CAH males has been described [7, 17]. However, the effect of steroid secretion by the tumor cannot be readily separated from the effect of excess steroids secreted by the adrenal glands.

Other Testicular Tumors in CAH Males

There are a few reports of other types of testicular tumors in CAH males. Adesokan et al. presented a case of a testicular adrenal rest tumor in a patient with CAH in combination with a testicular myelolipoma (a tumor of adrenal origin) and a seminoma in a cryptorchid testis [68]. Davis described a Leydig cell tumor with metastases in a CAH patient [69].

Hypogonadotropic Hypogonadism in CAH Males

In male patients with 21-hydroxylase deficiency, as in affected females, adrenal androgens may suppress the hypothalamic–pituitary–gonadal axis both directly and after conversion to estrogens, and thereby lead to hypogonadotropic hypogonadism [70–72].

Augarten et al. described a patient who was referred for secondary infertility and was diagnosed with non-classic 21-hydroxylase deficiency, as was his daughter [73]. Serum FSH and LH levels were decreased and unresponsive to GnRH stimulation. Treatment with prednisone resulted in a decrease in the serum levels of 17-hydroxyprogesterone and androgens, and normalized the response to GnRH. After 4 months of treatment, successful conception took place [73].

Wischusen et al. described a patient with non-classic 21-hydroxylase deficiency, azoospermia, small testes, normal to high serum testosterone levels, and suppressed serum levels of gonadotropins. After treatment with glucocorticoids for several months, the semen quality improved, and he fathered a child [74].

Bonaccorsi et al. presented three cases of male infertility due to 21-hydroxylase deficiency with very low serum gonadotropin levels, two of whom were unresponsive to GnRH stimulation [70]. Unresponsiveness to GnRH was proposed to be caused by increased hypothalamic estrogen production from local aromatization of androstenedione, leading to suppression of GnRH.

Cabrera et al. described 5 patients (out of a group of 30 patients) with poor adrenal control and suppressed gonadotropin levels; azoospermia was documented in 3 [7].

Recent larger series showed hypogonadotropic hypogonadism in 26 of 50 patients (26%) (defined as decreased LH at least once) [8], in approximately 30% of 164 patients [10] (decreased LH, data derived from figure), and in 3 of 22 patients (14%) (defined as decreased FSH, and in all these cases also decreased LH) [13].

The cited cases illustrate that hypogonadotropic hypogonadism is reversible when glucocorticoid therapy is initiated or intensified, or when compliance is improved. More systematically, this was evaluated retrospectively by King et al. who showed the gonadotropin response to intensification of treatment in 9 patients desiring fertility. Recovery of hypogonadotropic hypogonadism was achieved in the majority of cases [8].

It should be emphasized that other causes of hypogonadotropic hypogonadism should be considered in these men, such as hyperprolactinemia, drug abuse (e.g., opioids), and obesity.

Hypergonadotropic Hypogonadism in CAH Males

Hypergonadotropic hypogonadism is mostly seen in patients who have TART. Bouvattier et al. found that FSH levels were significantly

higher in patients who also had TART [10], while King et al. [8] found high FSH levels almost exclusively in those men with CAH due to 21-hydroxylase deficiency who also had TART.

It is possible that primary testicular dysfunction causing high FSH and LH levels will be masked by pituitary suppression, as described in the previous section. Conversely, when elevated adrenal androgens are decreased by raising the glucocorticoid dose, a hypergonadotropic pattern may become clear.

The mechanism by which the testicular damage develops is thought to involve the effects of local steroid production on germ cells and Leydig cells. Also, when TART progresses, local fibrosis may occur, which worsens the testicular damage [62].

Other Causes of Subfertility in CAH Males

Testicular Volume in CAH Patients

Small testes are incidentally reported in males with CAH, especially in poorly controlled patients with low FSH levels [70, 72, 74]. In 101 patients, described in 4 studies, 6 patients had small testes as measured by ultrasonography [5, 7, 17, 18]. More recently, this percentage was confirmed by Bouvattier et al. [10] in a series of 164 men of whom 8% had testicular hypotrophy. Accordingly, small testes have been observed in CAH patients, but not frequently. Testicular volume is relevant with respect to fertility, since it is positively correlated with semen quality [75, 76].

Other Testicular Abnormalities

Varicocele and hydrocele are also known to interfere with testicular function and have been documented by ultrasonography in 4 and 3 cases, respectively, in a group of 18 CAH patients [7]. Semen quality was normal, however, in 3 of the 4 men with varicocele.

Psychological Factors, Compliance, and Transition

Suboptimal psychosocial adaptation to chronic disease has been suggested as a cause for impaired fertility by Jääskeläinen et al. who found a lower child rate in CAH males compared to the healthy male population despite normal gonadal and pituitary function [5].

Arlt et al. showed that subjective health status was significantly impaired, and anxiety and depression scores were increased in both male and female CAH patients [9]. In this multicenter study across the UK, it was explicitly mentioned that the “capture rate” was low, suggesting that a relevant proportion of patients might not be under endocrine control. Male CAH patients may not notice adverse effects from poor adrenal control, and this may contribute to poor attendance and/or poor compliance. To prevent loss to follow-up, the need for dedicated transition from pediatric to adult endocrine care has been emphasized [77].

Treatment of Subfertility in CAH Males

Treatment of Hypogonadism and Subfertility

The optimal treatment is directed by the cause of hypogonadism, but in general, it requires intensification of glucocorticoid treatment. Both with TART or hypogonadotropic hypogonadism, the glucocorticoid dose can be raised or (partially) changed to a more potent glucocorticoid formulation, such as prednisolone or dexamethasone [8, 78–80]. The adverse effects of treatment intensification are weight gain, striae, and other Cushingoid effects. Theoretically, severe overtreatment could (again) lead to the suppression of the gonadal axis. In practice, the necessary dose adjustments and duration of intensified glucocorticoid therapy do not lead to the suppression of the axis. In adolescence, high dosages of glucocorticoids may reduce final height. Patients need to be informed about these adverse

effects. In general, their motivation for fertility leads to tolerance of some adverse effects for a restricted period of time [78].

It needs to be mentioned that, for optimal adrenal control, mineralocorticoid treatment should be considered. Patients with classic 21OHD almost always benefit from fludrocortisone at doses of 0.05–0.2 mg daily, regardless of their tendency for salt wasting. The dose should be adjusted to avoid both hypertension and orthostatic hypotension, to normalize serum potassium, and to suppress plasma renin activity to the low end of the reference range. It is known that optimizing mineralocorticoid treatment (e.g., fludrocortisone) can have a glucocorticoid-sparing effect, since the maintenance of sodium balance reduces vasopressin and ACTH levels [81].

In patients with TART, if tumor size does not decrease after adjusting medical therapy, surgical intervention may be considered. Walker et al. reviewed the surgical management of these tumors and showed that the predominant intervention was orchiectomy in 19 of 28 patients (68%) [39]. In these patients, the tumors were steroid-resistant or were (initially) misdiagnosed as Leydig cell tumors. Walker performed a testis-sparing enucleation in 3 boys with CAH with steroid unresponsive testicular tumors. Postoperative MR and US of the testis in 2 of the 3 patients showed good vascular flow in the remaining tissue and no evidence of recurrent tumor. No semen analysis or gonadal function was reported. Claahsen-van der Grinten et al. studied pituitary-gonadal function before and after testes-sparing surgery in 8 adult CAH patients with long-standing TART and azoospermia [80]; neither gonadal function nor semen quality improved.

Recently, Bry-Gauillard et al. were the first to describe the use of mitotane in a 29-year-old patient with bilateral TART and azoospermia. Mitotane induces a “chemical adrenalectomy” by inhibiting steroid synthesis. Within 2 years of treatment, tumor shrinkage and an increase in sperm count were observed [82].

In the case of long-standing hypogonadotropic hypogonadism that persists in spite of intensification therapy, gonadotropin therapy has

been used [8, 83], but not always successfully. Assisted reproduction techniques, such as intracytoplasmic sperm injection (ICSI) (with preceding testicular sperm extraction (TESE)) and in vitro fertilization (IVF), represent an alternative approach [8, 67].

Prevention of subfertility should ideally begin in (pre)puberty since TART has been described to develop at this age. Screening ultrasonography, adjusting glucocorticoid doses (taking into account the possible adverse effects), and semen analysis (possibly around the age of 20 years) may help predict future fertility problems. Since fertility prognosis is uncertain, we advise cryopreservation of semen at a young adult age.

Genetic Counseling

Genetic counseling of the male CAH patient and his partner is an essential part of preconception care. CAH is autosomal recessive. Since the CAH male patient has two homozygous or compound heterozygous CYP21 mutations, the child will be, by definition, a carrier of one CYP21-mutated allele. When the female partner is a (asymptomatic) carrier (incidence of carriers of about 1:50), there is a 50% risk of having an affected child and a 25% risk of having an affected girl (with possibly some level of congenital virilization, depending on the severity of the combined mutations). Couples planning for children should be informed and counseled about these risks, and genetic testing of the asymptomatic partner is recommended [77].

Conclusion

Fertility in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency can be impaired. Testicular adrenal rest tumors are the most frequent cause of impaired fertility. Their location adjacent to the testicular mediastinum, and their steroid-producing properties, may interfere with spermatogenesis and Leydig cell function. It is sometimes

accompanied by hypergonadotropic hypogonadism. Hypogonadotropic hypogonadotropism is a second major cause of impaired fertility, resulting from suppression of the hypothalamic–pituitary–gonadal axis by adrenal androgen excess. Other testicular abnormalities and psychological factors, such as poor adherence, compliance, and transition problems, may also contribute to impaired fertility. Treatment consists of intensification of glucocorticoid treatment and assisted reproduction techniques. Genetic testing of the asymptomatic female partner is recommended for couples planning to have children.

References

1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocr Rev.* 2000;21(3):245–91.
2. Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. *N Engl J Med.* 2009;360(22):2310–8.
3. Idkowiak J, Randell T, Dhir V, Patel P, Shackleton CH, Taylor NF, et al. A missense mutation in the human cytochrome b5 gene causes 46, XY disorder of sex development due to true isolated 17,20 lyase deficiency. *J Clin Endocrinol Metab.* 2012;97(3):E465–75.
4. New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. *Proc Natl Acad Sci USA.* 2013;110(7):2611–6.
5. Jaaskelainen J, Kiekara O, Hippelainen M, Voutilainen R. Pituitary gonadal axis and child rate in males with classical 21-hydroxylase deficiency. *J Endocrinol Invest.* 2000;23(1):23–7.
6. Urban MD, Lee PA, Migeon CJ. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. *N Engl J Med.* 1978;299(25):1392–6.
7. Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 2001;86(7):3070–8.
8. King TF, Lee MC, Williamson E, Conway GS. Experience in Optimising Fertility Outcomes in Men with Congenital Adrenal Hyperplasia due to 21 Hydroxylase Deficiency. *Clin Endocrinol.* 2015.
9. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. *J Clin Endocrinol Metab.* 2010;95(11):5110–21.

10. Bouvattier C, Esterle L, Renoult-Pierre P, de la Perriere AB, Illouz F, Kerlan V, et al. Clinical outcome, hormonal status, gonadotrope axis, and testicular function in 219 adult men born with classic 21-hydroxylase deficiency. A French national survey. *J Clin Endocrinol Metab.* 2015;100(6):2303–13.
11. Mnif MF, Kamoun M, Mnif F, Charfi N, Kallel N, Ben Naceur B, et al. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Am J Med Sci.* 2012;344(5):363–73.
12. Falhammar H, Nystrom HF, Ekstrom U, Granberg S, Wedell A, Thoren M. Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. *Eur J Endocrinol/Eur Fed Endocr Soc.* 2012;166(3):441–9.
13. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 2009;94(5):1665–70.
14. World Health Organisation. WHO laboratory manual for the examination and processing of human semen 2010.
15. Ojefo JO, Winters SJ, Troen P. Basal and adrenocorticotrophic hormone-stimulated serum 17 alpha-hydroxyprogesterone in men with idiopathic infertility. *Fertil Steril.* 1984;42(1):97–101.
16. Pinkas H, Fuchs S, Klipper-Aurbach Y, Zvulunov A, Raanani H, Mimouni G, et al. Non-classical 21-hydroxylase deficiency: prevalence in males with unexplained abnormal sperm analysis. *Fertil Steril.* 2010;93(6):1887–91.
17. Stikkelbroeck NM, Otten BJ, Pasic A, Jager GJ, Sweep CG, Noordam K, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 2001;86(12):5721–8.
18. Avila NA, Premkumar A, Shawker TH, Jones JV, Laue L, Cutler GB Jr. Testicular adrenal rest tissue in congenital adrenal hyperplasia: Findings at gray-scale and color Doppler US. *Radiology.* 1996;198(1):99–104.
19. Cutfield RG, Bateman JM, Odell WD. Infertility caused by bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency). *Fertil Steril.* 1983;40(6):809–14.
20. Cunnah D, Perry L, Dacie JA, Grant DB, Lowe DG, Savage MO, et al. Bilateral testicular tumours in congenital adrenal hyperplasia: A continuing diagnostic and therapeutic dilemma. *Clin Endocrinol.* 1989;30(2):141–7.
21. Wilkins L, Fleishmann W, Howard JE. Macrogenitosomia precox associated with hyperplasia of the androgenic tissue of the adrenal and death from corticoadrenal insufficiency. *Endocrinology.* 1940;26:385–95.
22. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM, Sweep FC, Hermus AR. Testicular adrenal rest tumours in congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab.* 2009;23(2):209–20.
23. Reisch N, Rottenkolber M, Greifenstein A, Krone N, Schmidt H, Reincke M, et al. Testicular adrenal rest tumors develop independently of long-term disease control: a longitudinal analysis of 50 adult men with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency. *J Clin Endocrinol Metab.* 2013;98(11):E1820–6.
24. Mouritsen A, Jorgensen N, Main KM, Schwartz M, Juul A. Testicular adrenal rest tumours in boys, adolescents and adult men with congenital adrenal hyperplasia may be associated with the CYP21A2 mutation. *Int J Androl.* 2010;33(3):521–7.
25. Shanklin DR, Richardson AP Jr, Rothstein G. Testicular hilar nodules in adrenogenital syndrome. The nature of the nodules. *Am J Dis Child.* 1960;1963(106):243–50.
26. Claahsen-van der Grinten HL, Sweep FC, Blickman JG, Hermus AR, Otten BJ, HL. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Eur J Endocrinol/Eur Fed Endocr Soc.* 2007;157(3):339–44.
27. Aycan Z, Bas VN, Cetinkaya S, Yilmaz Agladioglu S, Tiryaki T. Prevalence and long-term follow-up outcomes of testicular adrenal rest tumours in children and adolescent males with congenital adrenal hyperplasia. *Clin Endocrinol.* 2013;78(5):667–72.
28. Martinez-Aguayo A, Rocha A, Rojas N, Garcia C, Parra R, Lagos M, et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 2007;92(12):4583–9.
29. Claahsen-van der Grinten HL, Dehzad F, Kamphuis-van Ulzen K, de Korte CL. Increased prevalence of testicular adrenal rest tumours during adolescence in congenital adrenal hyperplasia. *Hormone research in paediatrics.* 2014;82(4):238–44.
30. Willi U, Atares M, Prader A, Zachmann M. Testicular adrenal-like tissue (TALT) in congenital adrenal hyperplasia: detection by ultrasonography. *Pediatr Radiol.* 1991;21(4):284–7.
31. Vanzulli A, DelMaschio A, Paesano P, Braggion F, Livieri C, Angeli E, et al. Testicular masses in association with adrenogenital syndrome: US findings. *Radiology.* 1992;183(2):425–9.
32. Avila NA, Premkumar A, Merke DP. Testicular adrenal rest tissue in congenital adrenal hyperplasia: comparison of MR imaging and sonographic findings. *AJR Am J Roentgenol.* 1999;172(4):1003–6.
33. Shawker TH, Doppman JL, Choyke PL, Feuerstein IM, Nieman LK. Intratesticular masses

- associated with abnormally functioning adrenal glands. *J Clin Ultrasound: JCU*. 1992;20(1):51–8.
34. Keely EJ, Matwijiw I, Thliveris JA, Faiman C. Congenital adrenal hyperplasia with testicular tumors, aggression, and gonadal failure. *Urology*. 1993;41(4):346–9.
 35. Dieckmann K, Lecomte P, Despert F, Maurage C, Sirinelli D, Rolland JC. Congenital adrenal hyperplasia and testicular hypertrophy. *Archives de pediatrie: organe officiel de la Societe francaise de pediatrie*. 1995;2(12):1167–72.
 36. Avila NA, Shawker TS, Jones JV, Cutler GB Jr, Merke DP. Testicular adrenal rest tissue in congenital adrenal hyperplasia: serial sonographic and clinical findings. *AJR Am J Roentgenol*. 1999;172(5):1235–8.
 37. Proto G, Di Donna A, Grimaldi F, Mazzolini A, Purinan A, Bertolissi F. Bilateral testicular adrenal rest tissue in congenital adrenal hyperplasia: US and MR features. *J Endocrinol Invest*. 2001;24(7):529–31.
 38. Coakley FV, Hricak H, Presti JC Jr. Imaging and management of atypical testicular masses. *Urol Clin North Am*. 1998;25(3):375–88.
 39. Walker BR, Skoog SJ, Winslow BH, Canning DA, Tank ES. Testis sparing surgery for steroid unresponsive testicular tumors of the adrenogenital syndrome. *J Urol*. 1997;157(4):1460–3.
 40. Strauss S, Gottlieb P, Kessler A, Graif M, Heyman Z, Manor H. Non-neoplastic intratesticular lesions mimicking tumour on ultrasound. *Eur Radiol*. 2000;10(10):1628–35.
 41. Rutgers JL, Young RH, Scully RE. The testicular “tumor” of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. *Am J Surg Pathol*. 1988;12(7):503–13.
 42. Solish SB, Goldsmith MA, Voutilainen R, Miller WL. Molecular characterization of a Leydig cell tumor presenting as congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1989;69(6):1148–52.
 43. Rich MA, Keating MA. Leydig cell tumors and tumors associated with congenital adrenal hyperplasia. *Urol Clin North Am*. 2000;27(3):519–28.
 44. Burke EF, Gilbert E, Uehling DT. Adrenal rest tumors of the testes. *J Urol*. 1973;109(4):649–52.
 45. Newell ME, Lippe BM, Ehrlich RM. Testis tumors associated with congenital adrenal hyperplasia: A continuing diagnostic and therapeutic dilemma. *J Urol*. 1977;117(2):256–8.
 46. Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. *Am J Surg Pathol*. 1985;9(3):177–92.
 47. Knudsen JL, Savage A, Mobb GE. The testicular ‘tumour’ of adrenogenital syndrome—a persistent diagnostic pitfall. *Histopathology*. 1991;19(5):468–70.
 48. Fore WW, Bledsoe T, Weber DM, Akers R, Brooks RT Jr. Cortisol production by testicular tumors in adrenogenital syndrome. *Arch Intern Med*. 1972;130(1):59–63.
 49. Radfar N, Bartter FC, Easley R, Kolins J, Javadpour N, Sherins RJ. Evidence for endogenous LH suppression in a man with bilateral testicular tumors and congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1977;45(6):1194–204.
 50. Franco-Saenz R, Antonipillai I, Tan SY, McCorquodale M, Kropp K, Mulrow PJ. Cortisol production by testicular tumors in a patient with congenital adrenal hyperplasia (21-hydroxylase deficiency). *J Clin Endocrinol Metab*. 1981;53(1):85–90.
 51. Dominguez OV. Biosynthesis of steroids by testicular tumors complicating congenital adrenocortical hyperplasia. *J Clin Endocrinol Metab*. 1961;21:663–74.
 52. Clark RV, Albertson BD, Munabi A, Cassorla F, Aguilera G, Warren DW, et al. Steroidogenic enzyme activities, morphology, and receptor studies of a testicular adrenal rest in a patient with congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1990;70(5):1408–13.
 53. Blumberg-Tick J, Boudou P, Nahoul K, Schaison G. Testicular tumors in congenital adrenal hyperplasia: Steroid measurements from adrenal and spermatic veins. *J Clin Endocrinol Metab*. 1991;73(5):1129–33.
 54. Combes-Moukhovskoy ME, Kottler ML, Valensi P, Boudou P, Sibony M, Attali JR. Gonadal and adrenal catheterization during adrenal suppression and gonadal stimulation in a patient with bilateral testicular tumors and congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1994;79(5):1390–4.
 55. Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV. Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. *J Clin Endocrinol Metab*. 1996;81(6):2397–400.
 56. Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Span PN, Ross HA, Meuleman EJ, et al. Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. *J Clin Endocrinol Metab*. 2007;92(9):3674–80.
 57. Kirkland RT, Kirkland JL, Keenan BS, Bongiovanni AM, Rosenberg HS, Clayton GW. Bilateral testicular tumors in congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 1977;44(2):369–78.
 58. Benvenega S, Smedile G, Lo Giudice F, Trimarchi F. Testicular adrenal rests: evidence for luteinizing hormone receptors and for distinct types of testicular nodules differing for their autonomization. *Eur J Endocrinol/Eur Fed Endocr Soc*. 1999;141(3):231–7.

59. Dahl EV, Bahn RC. Aberrant adrenal cortical tissue near the testis in human infants. *Am J Pathol.* 1962;40:587–98.
60. Val P, Jeays-Ward K, Swain A. Identification of a novel population of adrenal-like cells in the mammalian testis. *Dev Biol.* 2006;299(1):250–6.
61. Smeets EE, Span PN, van Herwaarden AE, Wevers RA, Hermus AR, Sweep FC, et al. Molecular characterization of testicular adrenal rest tumors in congenital adrenal hyperplasia: lesions with both adrenocortical and Leydig cell features. *J Clin Endocrinol Metab.* 2015;100(3):E524–30.
62. Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa CA. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. *Fertil Steril.* 2008;89(3):597–601.
63. Srikanth MS, West BR, Ishitani M, Isaacs H Jr, Applebaum H, Costin G. Benign testicular tumors in children with congenital adrenal hyperplasia. *J Pediatr Surg.* 1992;27(5):639–41.
64. Hamwi GJ, Gwinup G, Mostow JH, Besch PK. Activation of testicular adrenal rest tissue by prolonged excessive acth production. *J Clin Endocrinol Metab.* 1963;23:861–9.
65. Johnson RE, Scheithauer B. Massive hyperplasia of testicular adrenal rests in a patient with Nelson's syndrome. *Am J Clin Pathol.* 1982;77(4):501–7.
66. Seidenwurm D, Smathers RL, Kan P, Hoffman A. Intratesticular adrenal rests diagnosed by ultrasound. *Radiology.* 1985;155(2):479–81.
67. Murphy H, George C, de Kretser D, Judd S. Successful treatment with ICSI of infertility caused by azoospermia associated with adrenal rests in the testes: case report. *Hum Reprod (Oxford, England).* 2001;16(2):263–7.
68. Adesokan A, Adegboyega PA, Cowan DF, Kocurek J, Neal DE Jr. Testicular “tumor” of the adrenogenital syndrome: A case report of an unusual association with myelolipoma and seminoma in cryptorchidism. *Cancer.* 1997;80(11):2120–7.
69. Davis JM, Woodroof J, Sadasivan R, Stephens R. Case report: congenital adrenal hyperplasia and malignant Leydig cell tumor. *Am J Med Sci.* 1995;309(1):63–5.
70. Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. *Fertil Steril.* 1987;47(4):664–70.
71. Molitor JT, Chertow BS, Fariss BL. Long-term follow-up of a patient with congenital adrenal hyperplasia and failure of testicular development. *Fertil Steril.* 1973;24(4):319–23.
72. Moore GW, Lacroix A, Rabin D, McKenna TJ. Gonadal dysfunction in adult men with congenital adrenal hyperplasia. *Acta Endocrinol.* 1980;95(2):185–93.
73. Augarten A, Weissenberg R, Pariente C, Sack J. Reversible male infertility in late onset congenital adrenal hyperplasia. *J Endocrinol Invest.* 1991;14(3):237–40.
74. Wischusen J, Baker HW, Hudson B. Reversible male infertility due to congenital adrenal hyperplasia. *Clin Endocrinol.* 1981;14(6):571–7.
75. Lenz S, Giwercman A, Elsborg A, Cohr KH, Jelnes JE, Carlsen E, et al. Ultrasonic testicular texture and size in 444 men from the general population: Correlation to semen quality. *Eur Urol.* 1993;24(2):231–8.
76. Arai T, Kitahara S, Horiuchi S, Sumi S, Yoshida K. Relationship of testicular volume to semen profiles and serum hormone concentrations in infertile Japanese males. *Int J Fertil Women's Med.* 1998;43(1):40–7.
77. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2010;95(9):4133–60.
78. Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Hermus AR. Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. *Fertil Steril.* 2007;88(3):705.e5–8.
79. Mouritsen A, Juul A, Jorgensen N. Improvement of semen quality in an infertile man with 21-hydroxylase deficiency, suppressed serum gonadotropins and testicular adrenal rest tumours. *Int J Androl.* 2010;33(3):518–20.
80. Claahsen-van der Grinten HL, Otten BJ, Takahashi S, Meuleman EJ, Hulsbergen-van de Kaa C, Sweep FC, et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. *J Clin Endocrinol Metab.* 2007;92(2):612–5.
81. Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR, HL. Congenital adrenal hyperplasia–pharmacologic interventions from the prenatal phase to adulthood. *Pharmacol Ther.* 2011;132(1):1–14.
82. Bry-Gauillard H, Cartes A, Young J. Mitotane for 21-hydroxylase deficiency in an infertile man. *N Engl J Med.* 2014;371(21):2042–4.
83. Rohayem J, Tuttmann F, Mallidis C, Nieschlag E, Kliesch S, Zitzmann M. Restoration of fertility by gonadotropin replacement in a man with hypogonadotropic azoospermia and testicular adrenal rest tumors due to untreated simple virilizing congenital adrenal hyperplasia. *Eur J Endocrinol/Eur Fed Endocr Soc.* 2014;170(4):K11–7.

Male Hypogonadism Due to Disorders of the Pituitary and Suprasellar Region

8

Rosario Pivonello MD, PhD, Ciro Salzano MD,
Mariano Galdiero MD and Annamaria Colao MD, PhD

Contents

Introduction	169	Physiopathology of Hypogonadism	180
Prolactinomas	169	Diagnosis.....	182
Physiopathology of Hypogonadism	169	Therapy	182
Diagnosis.....	171	References	182
Therapy	171		
Acromegaly	173		
Physiopathology of Hypogonadism	173		
Diagnosis.....	174		
Therapy	174		
Cushing's Disease.....	176		
Physiopathology of Hypogonadism	176		
Diagnosis.....	176		
Therapy	177		
Non-functioning/Gonadotroph Adenomas.....	178		
Physiopathology of Hypogonadism	178		
Diagnosis.....	178		
Therapy	179		
Non-pituitary Sellar and Parasellar Tumors.....	179		
Physiopathology of Hypogonadism	179		
Diagnosis.....	180		
Therapy	180		
Non-tumorous Causes of Acquired Hypogonadotropic Hypogonadism.....	180		

R. Pivonello · C. Salzano · A. Colao (✉)
Dipartimento di Medicina Clinica e Chirurgia,
Sezione di Endocrinologia, Federico II University
of Naples, via S. Pansini 5, 80131 Naples, Italy
e-mail: colao@unina.it

R. Pivonello
e-mail: rosario.pivonello@unina.it

C. Salzano
e-mail: cirosalzano89@gmail.com

M. Galdiero
I.O.S. & Coleman Srl, via Alcide de Gasperi, 107,
80011 Acerra, Naples, Italy
e-mail: mariano.galdiero@gmail.com

Introduction

The primary regulator of testicular function is gonadotropin-releasing hormone (GnRH) that is secreted episodically by hypothalamic neurons into the portal vascular system. GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which are produced by gonadotrophs of the anterior pituitary. LH stimulates the synthesis of testosterone after binding to specific receptors on Leydig cells, whereas Sertoli cells within the seminiferous tubules are the target of FSH ([1, 2], and Chaps. 2 and 3). Accordingly, mass lesions and other disorders of the suprasellar region or pituitary that disrupt GnRH or LH/FSH production result in impaired testicular function that is designated “hypogonadotropic hypogonadism” because LH and FSH production are deficient. These disorders are the subject of this chapter.

Prolactinomas

Physiopathology of Hypogonadism

Prolactinoma is the most common pituitary tumor, with an estimated prevalence in the adult

population of 100 cases per million [3]. The frequency varies with age and sex, occurring most often in females between ages 20 and 50 years at which time the ratio between the sexes is estimated to be 4–10:1. After the fifth decade of life, by contrast, the frequency of prolactinomas is similar in both sexes [4, 5]. Men with prolactinomas usually present with macroadenomas (tumors ≥ 10 mm in diameter), and with very high prolactin levels, erectile dysfunction, loss of libido and/or infertility. These symptoms are related to the hypogonadism that occurs secondary to hyperprolactinemia [6]. They may also have headache and a visual disturbance.

Hyperprolactinemia disrupts male gonadal function at several levels (Fig. 8.1). High levels of prolactin suppress GnRH secretion and consequently, decrease gonadotropin and testosterone production [7, 8]. Experiments in rats revealed that prolactin suppresses GnRH secretion by a direct action on the arcuate nucleus to inhibit kisspeptin expression [9]. In some cases, hyperprolactinemia induces clinical hypogonadism notwithstanding normal serum

FSH, LH and testosterone levels [10]. There appears to be an exaggerated diurnal variation in testosterone secretion in men with prolactin-producing tumors, so that normal morning values do not guarantee normal values throughout the day [11]; however, the mechanism for this effect is not known. Others have suggested that hyperprolactinemia reduces the conversion of testosterone to dihydrotestosterone [12, 13]. If so, the symptoms of hypogonadism associated with hyperprolactinemia may not be solely due to the decrease in serum testosterone levels [14]. In fact, testosterone replacement therapy may not reverse the loss of libido typical of men with prolactinoma until the prolactin level is normalized by the administration of a dopamine agonist [15], suggesting the existence of a CNS libido center that is prolactin-regulated. Experiments in rats suggest that hyperprolactinemia impairs sexual function by modulating dopaminergic signaling and by directly arresting penile erection by affecting the penile corpus cavernosum [16].

Another mechanism to explain the suppression of gonadal function in men with prolactinoma is a direct tumor mass effect on gonadotrophs. Large adenomas often cause deficiency of multiple anterior pituitary hormones, including the gonadotropins. However, a tumor mass effect appears to be less important than is hyperprolactinemia in the development of hypogonadism in most men with prolactinomas. In fact, there is no significant difference in the prevalence of testosterone deficiency between men with micro- or macroprolactinomas, either before or after medical treatment. Among patients with macroadenomas, however, testosterone levels are inversely correlated with tumor size, perhaps reflecting the increasing likelihood of panhypopituitarism as well as effects of high prolactin levels with larger tumors [17, 18].

Studies in male rats provide evidence that prolactin also affects the testes directly. Prolactin receptors are present in all stages of the cycle of the seminiferous epithelium, on spermatogonia and spermatocytes, and on rodent Sertoli and Leydig cells [19]. PRL modulates testosterone production by regulating the bioconversion of




Fig. 8.1 Effects of hyperprolactinemia on the hypothalamic–pituitary–testicular axis

precursor steroids to testosterone under the influence of LH, and by upregulating LH receptor expression. However, there is no evidence so far for direct prolactin effects on the human testis.

The semen analysis in hyperprolactinemic men is characterized by fewer sperm implying spermiogenic arrest, and by reduced sperm motility and/or quality. In addition to the gonadotropin disturbance, hyperprolactinemia may produce structural changes in testicular cells expressing the androgen receptor [20]. On the other hand, male reproductive functions are normal in prolactin-KO and prolactin receptor-KO mice [21–23]. Thus, the functions of PRL in the testis remain uncertain.

Diagnosis

Young adult women with prolactinomas came to medical attention because of galactorrhea and irregular menses, but in men this tumor can be difficult to recognize. The symptoms and signs of hypogonadism (Table 8.1) may not become obvious until the tumor becomes large, or hyperprolactinemia and gonadotropin deficiency become severe. Therefore, the diagnosis of prolactinoma in men is often delayed until a visual field defect or other symptoms secondary to tumor pressure on surrounding structures occur (e.g., headaches, seizures, altered personality, cranial nerve palsies, symptoms related to the deficiencies of other pituitary hormones, hydrocephalus). With long-standing hypogonadism, the testes are usually soft but of normal size, and the semen analysis frequently reveals low semen volume, oligozoospermia or azoospermia [24]. Most men with hyperprolactinemia have low-normal serum levels of LH, testosterone and

dihydrotestosterone, and low frequency and amplitude spontaneous LH secretory episodes [25] together with a normal increase in serum LH levels following GnRH administration [8]. The identification of a high prolactin level is the beginning of the diagnostic process; however, other causes of hyperprolactinemia should be excluded. Prolactin levels in patients with prolactin-secreting adenomas are usually higher than 100 ng/ml and tend to be proportional to the size of the tumor. Adenoma size is also correlated with hormonal dysfunction prevalence at presentation and following treatment [17].

Lower PRL values are generally found with medication use, pituitary stalk compression, renal failure, cirrhosis, hypothyroidism and polycystic ovary disease [26]. Macroprolactin is a large molecular weight variant in which serum prolactin levels are increased because of binding to an IgG producing a large macromolecule with reduced hormone clearance; it is usually associated with clinical problems [27]. Computerized tomography (CT) and magnetic resonance (MR) allow for detailed noninvasive imaging of the pituitary gland. Both methods are effective in identifying large pituitary tumors; CT is better for defining bone erosions and calcified structures, but MR with gadolinium enhancement provides superior anatomical detail to detect prolactinomas and their relationship to neighboring structures. MR is more sensitive than CT in the identification of microadenomas [28].

Therapy

Current therapeutic options for patients with prolactinomas include observation, medical therapy with dopamine agonists (e.g., bromocriptine, cabergoline), transsphenoidal or transcranial surgery, and conventional or stereotactic radiotherapy.

The first-line treatment of prolactinoma is generally pharmacotherapy with a dopamine agonist [29–32]. These drugs were developed based on the finding that prolactin synthesis and secretion are regulated by the tonic inhibitory effects of hypothalamic dopamine via dopamine

Table 8.1 Clinical manifestations secondary to hypogonadism in men with prolactinoma

Infertility	Loss of pubic hair
Decreased libido	Osteoporosis
Impotence	Apathy
Gynecomastia	Loss of muscle mass
Galactorrhea	Decreased sense of well-being

D2 receptors on lactotrophs. Bromocriptine mesylate is a semisynthetic ergot alkaloid and long-acting dopamine receptor agonist. It normalizes prolactin levels in 80–90% and 60–75% of patients with micro- and macroprolactinomas, respectively [31]. Generally, the therapeutic doses are in the range of 2.5–15 mg/day, and most patients are successfully treated with 7.5 mg or less. However, doses as high as 20–30 mg/day may be necessary for patients who demonstrate resistance. Headache, nasal congestion, nausea, vomiting and dizziness are common side effects. Quinagolide is a more selective D2 agonist with only mild antagonistic effects at α_1 -adrenoceptors. It is better tolerated, and 100 times more potent than bromocriptine and readily crosses the blood–brain barrier. This drug induces an excellent response both in normalizing prolactin levels and in restoring gonadal function, with normalization of libido and improvement in the ejaculation and in nocturnal penile tumescence and rigidity parameters. Usual doses are 0.15–0.6 mg/day. However, at least 6–12 months of treatment is needed to obtain a significant improvement in seminal fluid parameters and circulating testosterone levels. Quinagolide is not available in the USA.

The most commonly used dopamine agonist is cabergoline because of its prolonged duration of action and lower incidence of side effects. Tumor shrinkage and/or disappearance were observed in 60–88% of cases [33]. Cabergoline appears to be more efficacious than bromocriptine in normalizing prolactin levels and in restoring gonadal function. Normalization of serum prolactin levels was followed by restoration of gonadal function in all patients with microprolactinomas, and in most patients with macroadenomas [34]. Moreover, the beneficial effects occurred more rapidly than with bromocriptine or quinagolide [35]. In cabergoline-treated patients, the percentage of immature germ cells was lowered and sperm viability, swollen tails and penetration into bovine cervical mucus were increased significantly during the first 3 months of treatment [36]. Generally, the median starting dose of cabergoline was 1 mg/week in patients with macroprolactinomas and 0.5 mg/week in those with idiopathic

hyperprolactinemia or microprolactinomas. The dosage may be increased up to 1–3 mg twice weekly with a goal of PRL <50 ng/ml. Dosage increases should occur every 4 weeks. In addition, cabergoline may be effective in patients resistant to bromocriptine or quinagolide [31]. Furthermore, treatment with cabergoline and androgen replacement therapy may improve the metabolic profile and reduce the prevalence of metabolic syndrome in male hyperprolactinemic patients with concomitant testosterone deficiency [37].

Approximately 24 and 11% of patients demonstrate resistance to bromocriptine and cabergoline, respectively [31]. So far, there is no evidence that somatostatin receptor agonists are effective in patients with prolactinomas resistant to dopamine agonists.

Surgery may be necessary in men who have not tolerated or have not responded to medical therapy, with invasive macroadenomas and visual field impairment with no immediate response to dopamine agonists, or in patients with complications, such as intra-tumoral hemorrhage or cerebrospinal fluid fistula [38, 39]. A transsphenoidal or endoscopic transnasal approach is the preferred technique for microadenomas and most macroadenomas, while craniotomy is rarely necessary. Surgical success rates are highly dependent on the size of the tumor and the experience and skill of the surgeon. Pituitary tumors are almost always benign adenomas, and the preservation or restoration of anterior pituitary function, including gonadal function, is an important goal of surgery.

Because of the excellent therapeutic responses to medical therapy and surgery, radiotherapy is generally not considered a primary treatment for prolactinomas, but is reserved for patients who are refractory to medical and surgical therapy. Hypopituitarism, including hypogonadism, is a frequent side effect following radiotherapy.

In the uncommon case of hyperprolactinemia and hypogonadism induced by prolactinoma that is resistant or intolerant to medical therapy, and with contraindications to surgery, gonadotropin therapy can be used to induce virilization and advance spermatogenesis sufficiently to achieve fertility [40, 41].

It is noteworthy that, in patients treated with dopamine agonists for hyperprolactinemia, especially those with large tumors and panhypopituitarism, hypogonadism can persist despite normalization of prolactin levels, so that testosterone replacement therapy becomes necessary in addition to dopamine agonist therapy [15].

Acromegaly

Physiopathology of Hypogonadism

Acromegaly is characterized by the excessive production of growth hormone (GH). More than 99% of cases of acromegaly result from a tumor of the pituitary gland secreting either GH alone, or both GH and prolactin. Gangliocytomas of the hypothalamus or pituitary, and ectopic neuroendocrine tumors secreting GH-releasing hormone (GH-RH), account for less than 1% of cases. Patients with acromegaly have a considerable burden of complications and coexisting morbidities. In particular, acromegaly is associated with cardiovascular and metabolic diseases such as hypertension, glucose intolerance or diabetes, cardiomyopathy and sleep apnea which all increase the risk of morbidities and mortality [42].

Hypogonadism has been reported in 49–70% of acromegalic patients [43]. Secretion of prolactin by the tumor together with GH, stalk disruption by suprasellar growth, and destruction of gonadotrophs by tumor have been implicated in the development of hypogonadism. However, Katznelson et al. [44] described low testosterone levels in 39% of men with somatotroph microadenomas, most of whom had normal prolactin levels. Therefore, other factors may contribute to the pathogenesis of hypogonadism in acromegaly. GH excess is often associated with a low level of sex hormone-binding globulin (SHBG), so that free testosterone levels should be measured to accurately diagnose testosterone deficiency in men with

acromegaly. Hypogonadism occurs more often in patients with macroadenomas than in those with microadenomas because of the tumor mass effect on surrounding normal tissue.

GH appears to regulate testicular function by stimulating the local production of IGF-1 which modulates steroidogenesis and spermatogenesis. GH receptors are located in both the male and female gonads and genitalia [45]. Furthermore, GH is important in the development of the male and female reproductive systems, as demonstrated by the expression of GH receptors not only on the testis and ovary but also on Wolffian and Müllerian duct-derived structures [46]. GH administration to rats increases Leydig and Sertoli cell responses to FSH and LH [47]. However, high levels of GH and IGF-1 induce severe testicular alterations and disrupt the hypothalamic–pituitary–testicular axis. Repeated administration of very high doses of GH in dogs reduced LH and testosterone levels as well as testicular weight with germ cell degeneration and epithelial atrophy [48]. In a human study, administration of GH (0.01–0.03 mg/day/kg) for 3 weeks to eight healthy male volunteers increased estradiol levels and decreased anti-Müllerian hormone, inhibin B and LH levels, whereas the GH antagonist pegvisomant reduced only estradiol [49]. The extent of testicular damage appears to be related to the severity of acromegaly. In fact, serum GH and IGF-1 levels correlated negatively with serum dihydrotestosterone levels (Fig. 8.2). Several mechanisms have been proposed to explain these findings, including a change in androgen metabolism [50], FSH and LH suppression by increased somatostatin tone, a decrease in the serum concentration of SHBG, and lactogenic effects of GH separate from those of prolactin [51]. In addition, prostatic dysfunction, leading to alterations of the seminal fluid, may occur in men with acromegaly. In fact, GH/IGF-1 excess causes prostate enlargement with a high prevalence of prostatic abnormalities [52].




Fig. 8.2 Relationship between serum GH and IGF-1 levels to serum dihydrotestosterone (DHT). Reprinted from Colao et al. [57]

Diagnosis

The symptoms of hypogonadism in men with acromegaly are similar to those of men with prolactinoma and include oligozoospermia and reduced sperm motility. These manifestations, like acromegalic-specific clinical features (Table 8.2), progress slowly. Therefore, the diagnosis of acromegaly is often delayed for as many as 5–15 years.

The specific clinical manifestations of acromegaly are caused by excessive GH/IGF-1 secretion. In addition, pituitary tumor mass effects (headaches, hypopituitarism and visual disturbances) are common, because of the high

Table 8.2 Specific clinical features of acromegaly

Recent acral growth	Osteoarthritis
Prognathism and malocclusion	Kyphosis
Frontal bossing	Carpal tunnel syndrome
Widened spaces between the teeth	Proximal muscle weakness
Increased breadth of the nose	Fatigue
Generalized visceromegaly	Deep and resonant voice
Cardiomyopathy	Hyperhidrosis
Hypertension	Psychological disorders

prevalence of macroadenomas (about 75% of somatotroph adenomas).

It is now known that an elevated random serum GH level is not absolutely necessary for the diagnosis of acromegaly. By contrast, serum IGF-1 levels are invariably high in acromegaly. If the IGF-1 level is increased, and a random GH level is normal, an oral glucose tolerance test (75 g) is used to establish the diagnosis. A normal response is a decrease in the serum GH level to <1 µg/l, but acromegalic patients do not suppress normally, and 20% of patients have a paradoxical GH rise [53].

After the clinical and endocrine diagnosis of acromegaly is made, radiological evaluation of the pituitary gland should be performed, preferably by MR with gadolinium enhancement to localize and delineate the tumor from the surrounding tissues. GH-secreting tumors tend to be larger than prolactinomas at the time of the radiographic evaluation, perhaps due to a later clinical presentation.

Therapy

The treatment goals for men with hypogonadism secondary to acromegaly are the normalization of serum GH and IGF-1, and prolactin levels when hyperprolactinemia is present, and the preservation and restoration of gonadotropin secretion and testicular function.

Trans-sphenoidal adenectomy is the preferred treatment for GH-secreting tumors, inducing an endocrine remission in 80% of patients with microadenomas, and 50% of those with macroadenomas in experienced centers [54]. It is likely that many centers do not achieve these success rates, however, which is a matter of concern. Surgery relieves the compression of adjacent structures, including the pituitary stalk and surrounding pituitary cells. If gonadotropin secretion is normal prior to surgery, gonadal function can be restored if GH secretion normalizes. Tominaga et al. [55] reported serum testosterone concentrations of less than 300 ng/dl (10.5 nmol/L) in 14/20 men (70%) with active acromegaly. Postoperatively, the serum GH level normalized in 14 patients, while the testosterone concentration returned to normal in 11 patients (79%), restoring gonadal function. This increase in testosterone levels may result from an increase of SHBG production [56], or an increase in LH secretion [57].

The three classes of medical therapy for acromegaly are based on receptor targets of the GH/IGF-1 axis: pituitary somatostatin receptor subtypes, pituitary dopamine D₂ receptors and peripheral GH receptors [58].

Somatostatin analogues normalize IGF-1 levels in 60–70% of patients and achieve tumor shrinkage in about 40% of patients. Long-acting analogues of somatostatin are available and improve compliance. Octreotide-LAR consists of octreotide incorporated into microspheres of a biodegradable polymer. It is injected intramuscularly at a dose of 10, 20 or 30 mg (every 4 weeks). Slow-release lanreotide is a similar preparation and is administered intramuscularly at a dose of 30 mg (every 1–2 weeks) or 60 mg (every 4 weeks). Lanreotide Autogel achieves the same effect as slow-release lanreotide, but is longer acting. It is administered by deep subcutaneous injection at a dose of 120 mg (every 6–8 weeks). Pasireotide is being evaluated in patients with acromegaly. Based on differences in binding affinity and functional activity, pasireotide may have a stronger inhibitory effect on GH secretion with tumors that express somatostatin (sst) receptors other than sst₂ [59]. Important side effects of somatostatin analogues are gallstone formation,

which is generally silent, abdominal cramps, and decreased glucose tolerance, especially with pasireotide [60–66]. Suppression of GH and IGF-1 levels by somatostatin analogue therapy for 6 months was associated with a significant increase in LH and total testosterone and dihydrotestosterone levels; in most hypogonadal men, there was also improvement in sperm number and motility [61].

Dopamine agonists are less effective than are somatostatin analogues in normalizing IGF-1 levels (10–30% of patients) and reducing the tumor mass (<20% of cases). However, dopamine agonists are effective in those GH-secreting tumors that also secrete prolactin, or immunostain positively for prolactin. In addition, combined treatment with somatostatin analogues and dopamine agonists induces a greater suppression of IGF-1 levels compared with drug alone and improves testicular function [62].

Pegvisomant is the only GH receptor antagonist available for clinical use [63]. It has been shown in clinical trials to normalize IGF-1 levels in up to 97% of patients and can improve comorbidities such as insulin resistance. Furthermore, because the efficacy of pegvisomant is not dependent on tumor somatostatin receptor expression, pegvisomant effectively inhibits IGF-1 secretion in patients who are non-responders or partial responders to somatostatin analogues. GH secretion is not inhibited during pegvisomant therapy, and pegvisomant does not treat the tumor, necessitating regular monitoring for pituitary tumor growth.

Radiation therapy should be considered for patients with contraindications to pituitary surgery, or those whose operation and/or medical treatment has failed. Radiotherapy induces a slow response and may damage normal pituitary tissues, leading to hypopituitarism, and worsening hypogonadism in 50% of patients 10 years after irradiation. Stereotactic radiation surgery (SRS), either in single or hypofractionated protocols, has undergone rapid technical improvement. With this approach, the temporal lobe, the optical system and the normal pituitary are exposed to less radiation. SRS may be associated with better biochemical remission, and estimates of hypopituitarism range from 6 to 30% [64].

Cushing's Disease

Physiopathology of Hypogonadism

Cushing's disease is characterized by chronic glucocorticoid excess secondary to hypersecretion of ACTH and other proopiomelanocortin peptides. It is commonly caused by a pituitary corticotroph adenoma.

Gonadal and sexual dysfunctions are common in men with Cushing's syndrome [65–69]. High levels of glucocorticoids decrease serum testosterone levels through several mechanisms (Fig. 8.3). Excessive production of glucocorticoids may produce gonadotropin deficiency by acting at the pituitary and hypothalamic levels. Two regions of the mouse GnRH promoter (distal and proximal negative glucocorticoid response elements) regulate transcriptional repression by glucocorticoids. Glucocorticoid receptors appear to induce glucocorticoid repression of GnRH gene transcription by virtue of their association within a multiprotein complex at the negative glucocorticoid response element [70]. In addition, elevated levels of glucocorticoids directly suppress testicular function, inducing apoptosis in Leydig cells [71], inhibiting LH receptor signal

transduction, decreasing the oxidative activity of 11 β -hydroxysteroid dehydrogenase and impairing Leydig cell steroidogenesis [72].

Diagnosis

Since the description by Dr. Harvey Cushing at the beginning of the twentieth century, it is well known that hypogonadism is common in active Cushing's disease [73] (Table 8.3).

Males have loss of libido, impotence, oligozoospermia and histological damage to the testes. Basal LH and FSH levels are commonly decreased, the response to GnRH is impaired, and testosterone levels are low. The hypogonadotropic hypogonadism in male patients is reversible and improves after hypercortisolism is suppressed or blocked [65, 68].

When Cushing's syndrome is suspected, initial laboratory testing to detect hypercortisolism includes measurement of 24-hour urinary free cortisol excretion, and/or the 1 mg overnight dexamethasone suppression test [74]. The sensitivity and specificity of the first test in detecting cortisol excess are 95 and 98%, respectively. Because of the difficulty in obtaining 24-hour




Fig. 8.3 Mechanisms involved in the induction of hypogonadism in men with Cushing's disease

Table 8.3 Clinical features of Cushing's syndrome

Centripetal obesity	Proximal myopathy
Buffalo hump	Abdominal pain
Moon face	Psychiatric disturbances
Facial plethora	Hypertension
Purple striae	Backache, vertebral collapse, fracture
Skin thinning	Polydipsia, polyuria
Easy bruising	Renal calculi
Acne, oily skin	Hyperpigmentation
Skin infections	Male hypogonadism
Lethargy	Hirsutism, oligomenorrhea

urine collections in many outpatients, some physicians use the 1 mg overnight dexamethasone suppression test with a diagnostic cutoff of 1.8 µg/dL in the morning cortisol level (sensitivity 98% and specificity 80%). Another diagnostic approach is the late-night (11 PM) salivary cortisol determination [75]. Cortisol is highly stable in saliva, and the level is positively correlated with free serum or plasma cortisol levels and is independent of the rate of salivary flow.

Once the diagnosis of Cushing's syndrome is established, the source of the excess cortisol production needs to be determined. The plasma level of ACTH in the late afternoon is useful in identifying the ACTH-dependent pathologic state. At this time of day, plasma ACTH levels exceed 10 ng/L in Cushing's disease, while plasma ACTH levels are generally suppressed in Cushing's syndrome secondary to adrenal disease. The high-dose dexamethasone test (8 mg) and the CRH test can be performed to obtain a clearer differential diagnosis. In Cushing's disease, serum cortisol levels and 24-hour urinary free cortisol excretion are generally suppressed after the 8-mg dexamethasone test, and ACTH levels rise following CRH stimulation.

Pituitary ACTH-secreting adenomas are most often microadenomas with a diameter <5 mm in 45% of cases, and only 10–20% of patients with Cushing's disease have a macroadenoma [76]. While MR imaging is required in all patients

with ACTH-dependent Cushing's syndrome, pituitary MR imaging is often normal in patients with corticotropinomas. MR should be performed with thin overlapping sections and high field strength (1.5 T) magnets. In the absence of a detectable pituitary tumor, bilateral inferior petrosal venous sinus and peripheral vein catheterization with simultaneous collection of samples for measurement of ACTH should be performed to localize ACTH production to the pituitary and exclude the ectopic production of ACTH [77]. Stimulation with CRH, together with bilateral and simultaneous sampling, increases the sensitivity of this procedure.

Therapy

The hypogonadotropic hypogonadism characteristic of male Cushing's disease is a reversible phenomenon [65, 68]. In fact, cure of hypercortisolism restores the decreased plasma testosterone, FSH and LH levels to normal and improves sexual and gonadal dysfunctions.

Trans-sphenoidal adenomectomy, after accurate preoperative localization of the corticotroph adenoma, represents the treatment of choice for Cushing's disease patients, but can be technically challenging [78]. The remission rate for microadenomas has ranged from 48.7 to 100%, whereas for those with macroadenomas, it has ranged from 30.8 to 100%. A trans-sphenoidal approach was also successfully used in ACTH-producing adenomas located in the pituitary stalk. A recent meta-analysis reported that 11.5–47.4% of patient will experience recurrence of their disease as long as 10 years after surgery, so that follow-up must be life-long [79].

Transcranial surgery (TCS) has been used in the past and is occasionally used today.

Patients unresponsive to surgical treatment, or those in whom surgery is deemed inappropriate (large invasive tumors, or high surgical risk), are referred for pituitary irradiation with adjunctive medical therapy [80]. There is some evidence that stereotactic radiation may lead to biochemical remission faster than with conventional radiation

therapy, while estimates of new hypopituitarism at 4–5 years range from 5 to 35%.

The development of novel medical therapies may limit the use of radiotherapy to patients who are unresponsive to or intolerant of medical treatment, or it may result in the deferral of radiotherapy until after a period of control of cortisol secretion by medical therapy.

Current medical therapies include drugs to decrease ACTH secretion, inhibit corticosteroid synthesis or block their peripheral actions [78]. The first class of drugs (serotonin antagonists, dopamine agonists, GABA agonists and somatostatin analogues) inhibit ACTH release. However, few cases so treated have achieved permanent remission. The second group of drugs includes inhibitors of steroidogenesis (ketoconazole, metyrapone, aminoglutethimide and mitotane). These drugs have the advantage of being rapidly effective in most cases. However, the mechanism(s) of action has little selectivity, and extra-adrenal effects are likely to occur. Ketoconazole inhibits various cytochrome P450 enzymes, including C17-20 lyase involved in the synthesis of sex steroids. Thus, the drug not only lowers cortisol levels, but also decreases testosterone levels such that gynecomastia, impotence, loss of libido and oligozoospermia could occur [81]. The third class of drugs is represented by the glucocorticoid antagonist (mifepristone). Although a potentially important therapy that has been approved by the FDA to control hyperglycemia in adults with Cushing's syndrome, few patients have been treated with mifepristone, and further clinical studies are needed to assess long-term effectiveness and safety, and the impact on gonadal function. Few studies have reported the efficacy of cabergoline treatment in patients with Cushing's disease and Nelson's syndrome [82]. With each of these drugs, improvement in hypercortisolemia and insulin sensitivity may result in a rise in SHBG, LH and testosterone levels.

Finally, bilateral adrenalectomy is reserved for cases in which other treatment modalities have failed. However, the risk of Nelson's syndrome is high with this approach. Adrenal

surgery is followed by a rapid and definitive control of cortisol excess in nearly all patients, but it induces adrenal insufficiency.

Non-functioning/Gonadotroph Adenomas

Physiopathology of Hypogonadism

Clinically non-functioning pituitary adenomas (NFPA) represent about 30% of pituitary tumors and are the most commonly encountered macroadenomas [83]. The prevalence of NFPA is 1.5 per 100.000 people, and among them, gonadotroph adenomas account for 43–64% of silent adenomas. Hypogonadism is present in about half of the patients with NFPA, of whom about 50% have mild hyperprolactinemia [83], reflecting stalk compression that might contribute to impaired gonadal function.

The majority of “non-functional” tumors are inefficiently secreting rather than non-secreting. They usually synthesize and immunostain for FSH and/or LH, and/or free α - and β -subunits [84]. Gonadal dysfunction in men with NFPA is primarily related to intra-sellar expansion of the tumor with compression of residual glandular tissue and may cause hypopituitarism both by direct compression of the portal vessels that limits delivery of hypothalamic releasing factors and by focal ischemic necrosis of the normal pituitary tissue [85]. LH secretion is impaired in about 53% of NFPA [103–105]. However, disruption of ACTH, TSH and GH secretion may further inhibit gonadal function.

Diagnosis

The majority of NFPA are diagnosed incidentally or as a result of headache, visual disturbances or neurological symptoms. Less often, deficient pituitary hormone secretion, including gonadotropin deficiency with hypogonadism, brings the patient to medical attention. These tumors can attain considerable size before manifesting

clinically. A mild or moderate increase in the prolactin level is common. A complete endocrine evaluation, including measurement of FSH, LH, α -subunit, testosterone, TSH, FT4, ACTH, cortisol, GH and IGF-1, as well as prolactin should be performed in order to recognize functional lesions and diagnose hypopituitarism. Magnetic resonance imaging with gadolinium enhancement represents the best way to detect a pituitary tumor.

Therapy

Trans-sphenoidal resection of the adenoma is the preferred and most effective treatment for symptomatic NFPA since it may improve visual field defects and permit recovery of pituitary function [86]. In NFPA microadenoma <5 mm, neither radiological nor hormonal surveillance is recommended, while in NFPA microadenoma >5 mm, most authors propose close clinical and MRI surveillance. Some patients with NFPA less than 40 mm in diameter may experience a restoration of gonadal function if the normal pituitary is not destroyed and its ability to secrete gonadotropins is regained after decompression. In NFPA larger than 40 mm, on the other hand, recovery is much less likely, and surgery may in fact worsen testosterone deficiency [87]. This fact reflects the difficulty in preserving or restoring anterior pituitary function in patients with very large tumors. In a recent study that analyzed patients undergoing trans-sphenoidal surgery using intra-operative high-field magnetic resonance imaging, the recovery rate for the gonadotroph axis within 2–3 months after surgery was 32% [88].

Because of their large size, however, surgery alone is often not curative, and radiotherapy is often performed as adjuvant therapy after surgery [89] especially in those with subtotal removal [90] although the risk of hypopituitarism is increased. In one study, the risk of new or worsening hypopituitarism was 21% with hypogonadism in at least 10 of patients [91].

Somatostatin and dopamine receptors have been identified in NFPA. This suggests that somatostatin analogues or dopamine agonists could be useful in the treatment of refractory NFPA. In a recent study, 36 NFPA macroadenomas patients were found to be positive to DR2. Among them, 9 patients were treated with cabergoline, followed by tumor volume reduction $\geq 25\%$ in 67%; hypogonadotropic hypogonadism was observed in 2 patients [92]. Furthermore, Greenman et al. found a reduction in tumor volume in 38% of 69 NFPA macroadenomas treated with cabergoline [93]. However, available drugs benefit only a minority of patients, and additional studies are needed to investigate whether subgroups of patients with NFPA will respond to medical therapy.

Gonadotropin therapy is indicated if the patient desires spermatogenesis and fertility (Chap. 20). If fertility is not the requested outcome, testosterone is administered to stimulate virilization, improve sexual function and maintain bone and muscle mass (Chap. 18). In patients with multiple pituitary hormone deficiencies, replacement therapy of all deficient hormones is required for complete improvement of gonadal function.

Non-pituitary Sellar and Parasellar Tumors

Physiopathology of Hypogonadism

Non-pituitary intra-sellar and parasellar tumors include craniopharyngioma, Rathke's cleft cyst, epidermoid, infundibuloma, chordoma, lipoma, colloid cyst, germinoma, dermoid, teratoma, dysgerminoma, ectopic pinealoma, glioma, oligodendroglioma, ependymoma, astrocytoma, meningioma, enchondroma, metastatic tumors and lymphoma. In a recent study of over 2500 patients having a pituitary MRI, non-adenomatous sellar masses accounted for 18% of lesions most notably Rathke's cleft cysts (19%), craniopharyngiomas (15%) and meningiomas (15%)

[94, 95]. These masses may interfere with GnRH synthesis and secretion, or directly impair FSH and LH production, inducing hypogonadotropic hypogonadism. In addition, the modest hyperprolactinemia that occurs secondary to hypothalamic stalk compression could impair gonadal function.

Diagnosis

Non-pituitary sellar and suprasellar tumors may present with symptoms of anterior pituitary hormone failure, including gonadotropin deficiency [96]. In one study of patients with craniopharyngioma, 60–70% was diagnosed with hypogonadotropic hypogonadism preoperatively and the risk increased further after surgery [97]. On the other hand, most patients with Rathke's cleft cysts are asymptomatic, and <10% exhibit hypogonadotropic hypogonadism [98]. Mild hyperprolactinemia is common in patients with craniopharyngiomas, meningiomas or cystic lesions [96].

Impairment of visual fields and decreased visual acuity occur because of the proximity of the lesion to the optic nerves, chiasm and optic tracts. The tendency of these tumors to infiltrate parasellar structures causes cranial neuropathy. Tumors obstructing cerebrospinal fluid flow (craniopharyngioma, meningioma, germinoma) increase intracranial pressure. This event is characterized by visual impairment and headaches. Masses compressing the deep subfrontal region of the brain may induce personality changes and dementia. In addition, these lesions may impair hypothalamic function and disrupt appetite control, causing polyphagia and massive obesity, or starvation.

Although it is difficult to reach a specific preoperative diagnosis on MR imaging, many lesions have characteristic findings that are useful in differential diagnosis [94, 95]. For example, calcifications are suggestive of craniopharyngiomas, meningiomas, chordomas, teratomas and gliomas. Erosion of the floor of the sella is frequently observed in meningiomas of the middle fossa and in Rathke's cleft cysts.

Therapy

Gonadal impairment secondary to non-pituitary intra-sellar and parasellar masses may recover following treatment of the lesion. The choice of treatment depends on the nature of the disease. However, surgery represents the first option in most cases. Surgical treatment generally involves trans-sphenoidal decompression of the mass, when possible, attempting to limit damage and restore normal function of the pituitary gland.

Radiotherapy is recommended for residual tumor after surgery, and for brain metastases. Medical therapy is not generally performed with dysgerminomas or metastatic lesions that require radiotherapy and chemotherapy. Children with precocious puberty due to hamartomas that produce GnRH can be treated with GnRH analogues to suppress gonadotropin secretion since surgery may not be curative or may result in extensive complications, including fatality [99]. These agents do not affect the tumor itself.

When hypogonadism persists after surgical treatment, or remains after conventional treatment, androgen replacement therapy is used to restore physiologic serum concentrations of testosterone (Chap. 18). If fertility is desired, Leydig cell function is stimulated by the administration of human chorionic gonadotropin (Chap. 20). Spermatogenesis may be restored by hCG alone; however, hFSH is sometimes necessary as well. In patients with hypopituitarism, adequate replacement therapy further improves gonadal function.

Non-tumorous Causes of Acquired Hypogonadotropic Hypogonadism

Physiopathology of Hypogonadism

Non-neoplastic diseases of the hypothalamus and pituitary (Table 8.4) may also induce hypogonadotropic hypogonadism [100]. Among them, the most frequent are cystic lesions (53%) and inflammatory lesions (9%). In these disorders, hypogonadism is primarily due to gonadotropin deficiency secondary to hypothalamic–pituitary

Table 8.4 Non-tumorous causes of acquired hypogonadotropic hypogonadism

Pituitary apoplexy
Empty sella syndrome
Aneurysm
Pituitary abscess
Tuberculosis
Sarcoidosis
Giant cell granuloma
Lymphocytic hypophysitis
Histiocytosis X
Hemochromatosis
Arachnoid cyst
Mucocele
Post-surgery/irradiation
Head trauma

damage, and it is present in about 23–29% of patients. In addition, GH/IGF-1, thyroid hormone and CRH/ACTH/cortisol play a permissive role in the regulation of spermatogenesis and testosterone production. In this way, deficiency of all or some anterior pituitary hormones, together with the increase in prolactin, may induce hypogonadism.

Hypogonadotropic hypogonadism is also common in patients with lesions of the pituitary stalk [101]. These lesions may be neoplastic or inflammatory, or are sometimes congenital. The abnormality may be limited to the stalk or may extend into the pituitary.

Pituitary apoplexy results in anterior pituitary failure secondary to hemorrhagic or ischemic infarction [102]. Hemorrhage usually occurs into a pituitary tumor, whereas ischemia may involve a normal pituitary gland in the setting of increased intracranial pressure, during anticoagulation therapy, and in women in the postpartum period. Hormone deficiencies following apoplexy include GH (88%), gonadotropins (58–76%), ACTH (66%), TSH (42–53%) and prolactin (67–100%).

Empty sella is defined as a sella that is completely or partially filled by cerebrospinal fluid, owing to arachnoid herniation into the pituitary

fossa. This herniation remodels and enlarges the bony sella, and flattens the pituitary gland against the sella floor. Empty sella, especially a partially empty sella, is usually an incidental anatomical finding, and functional pituitary damage is infrequent. The fact that patients are usually asymptomatic derives from the large functional reserve of the adenohypophysis. However, hypogonadism is not rare and occurs in approximately 15% of cases [103, 104]. Empty sella can also occur following pituitary surgery, radiotherapy, infection, or trauma, and during the evolution of autoimmune hypophysitis, Sheehan's syndrome and neurosarcoidosis. With "secondary" empty sella, flattening of the pituitary is more pronounced, and hypogonadism is more common.

Aneurysms of the cavernous sinus, as well as infectious (bacterial or fungal abscesses, tuberculosis, toxoplasmosis) and inflammatory processes (sarcoidosis, giant cell granuloma, lymphocytic hypophysitis, histiocytosis X) can mimic a pituitary adenoma, causing mass effect and hypothalamic-hypophyseal endocrine dysfunction secondary to infiltration and replacement of normal tissue [94, 95].

An arachnoid cyst is a diverticulum of the arachnoidal membrane of Liliequist. Fifteen percent of these cysts occur in the sellar and parasellar region. This mass may compress the hypothalamic–pituitary unit inducing endocrine disorders, including hypogonadism, producing impotence or low libido.

Mucoceles are slowly expanding, mucous-filled cystic lesions that arise in the paranasal sinuses. These cysts result from the accumulation and retention of mucous secretions in a sinus secondary to the occlusion of the ostium draining the sinus. Sphenoid mucocele with suprasellar extension can also increase prolactin levels by compressing the pituitary stalk.

Radiation of the head for treatment of primary central nervous system tumors, nasopharyngeal tumors or brain metastases may cause the gradual onset of hypothalamic–pituitary failure [106]. The most frequent endocrine abnormalities following cranial radiotherapy are growth hormone deficiency (up to 90%), hypothyroidism (65%),

hypogonadism (61%) and mild hyperprolactinemia. Although the mechanism of radiation damage to the hypothalamus and pituitary gland is not known, it presumably involves direct injury to the secreting cells, to the stroma or its microvasculature, or damage to the vascular channels that transfer the hypothalamic hormones to the pituitary.

Head trauma may cause hypogonadism [106–108]. Hypotestosteronemia is found in 60–70% of patients within 1 week following severe traumatic brain injury. GnRH–LH secretion most often recovers, however, with hypotestosteronemia in only 10% of patients 6–9 months after injury [108]. Stalk trauma may increase prolactin levels further worsening gonadal function. Sexual dysfunction, depression and lack of motivation with a history of head trauma may indicate post-traumatic stress disorder [109].

Diagnosis

These diseases are characterized by extensive damage to pituitary function. Therefore, hypogonadism is rarely reported as an isolated manifestation, but instead is frequently associated with hypopituitarism and diabetes insipidus. In addition, headache, vomiting, ophthalmoplegia and visual loss occur with acute onset in pituitary apoplexy or head trauma and may occur progressively in the empty sella syndrome, infectious and inflammatory processes, mucocoele, arachnoid cyst, giant cell granuloma and echinococcal cysts.

Considering the importance of hypopituitarism in the induction of hypogonadism, anterior pituitary function testing (in some cases including GnRH stimulation to assess gonadotroph function by measuring FSH and LH; insulin tolerance testing to assess corticotroph and somatotroph secretion by measuring serum cortisol and GH levels; and TRH stimulation to assess TSH levels), prolactin and testosterone levels, and a semen analysis are mandatory in this group of patients.

Nowadays, MR is an essential tool in the differential diagnosis of sellar masses and in the evaluation of patients with head trauma.

However, biopsy and histology are often necessary to confirm the diagnosis.

Therapy

The treatment goals in this group of patients are: (1) to reduce or eliminate the mass effects of the lesion, (2) to correct hormonal deficiencies including those that impair gonadal function, and (3) to preserve residual pituitary function. The specific treatments for the various diseases discussed are beyond the scope of this chapter. However, most lesions are initially treated surgically to eliminate the mass effects. Androgen replacement therapy is used to correct hypogonadism (Chap. 18). When fertility is desired, treatment with exogenous gonadotropins (hCG ± hFSH) is generally successful (Chap. 20). Finally, when panhypopituitarism is present, hormonal replacement therapy is mandatory.

References

1. Matsumoto A, Bremner WJ. Testicular disorders, In: Melmed S, Polonsky KS, Larsen PR, and Kronenberg HM, ed. *Williams Textbook of Endocrinology*, 13th ed. Elsevier 2016, 695–784.
2. de Kretser DM, Loveland K, O'Bryan M. Spermatogenesis, in, Jameson JL and DeGroot LJ, *Endocrinology: Adult and Pediatric*, 7th Edition, Elsevier, 2015; 36:2325–53.
3. Colao A, Lombardi G Growth hormone and prolactin excess. *Lancet*. 1998;352:1455–61.
4. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. *Eur J Endocrinol* 2003;148: 325–331.
5. Mindermann T, Wilson CB age-related and gender-related occurrence of pituitary adenomas. *Clin Endocrinol (Oxf)*. 1994;41:359–64.
6. Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. *Pituitary*. 2015;18: 108–15.
7. Sarkar DK, Yen SS. Hyperprolactinemia decreases the luteinizing hormone-releasing hormone concentration in pituitary portal plasma: a possible role for β -endorphin as a mediator. *Endocrinology*. 1985;116:2080–4.

8. Bouchard P, Lagoguey M, Brailly S, Schaison G. Gonadotropin-releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperprolactinemia. *J Clin Endocrinol Metab.* 1985;60:258–62.
9. Araujo-Lopes R, Crampton JR, Aquino NS, Miranda RM, Kokay IC, Reis AM, Franci CR, Grattan DR. Szawka RE Prolactin regulates kisspeptin neurons in the arcuate nucleus to suppress LH secretion in female rats. *Endocrinology.* 2014;155(3):1010–20.
10. Shimon I, Benbassat C. Male prolactinomas presenting with normal testosterone levels. *Pituitary.* 2014; 17(3):246–50.
11. Winters SJ. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. *J Androl.* 1991;12:185–90.
12. Manandhar MS, Thomas JA. Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro. *Invest Urol.* 1976;14:20–2.
13. Magrini B, Ebner JR, Burckhardt P, Felber JP. Study on the relationship between plasma prolactin and androgen metabolism in man. *J Clin Endocrinol Metab.* 1976;43:944–7.
14. Galdiero M, Pivonello R, Grasso LFS, Cozzolino A, Colao A. Growth hormone, prolactin and sexuality. *J Endocrinol Invest.* 2012;35(782):794.
15. Franks S, Jacobs HS, Martin N, Nabarro JD. Hyperprolactinemia and impotence. *Clin Endocrinol.* 1978;8:277–87.
16. Rehman J, Christ G, Alyskewycz M, Kerr E. Melman a experimental hyperprolactinemia in a rat model: Alteration in centrally mediated neuroerectile mechanisms. *Int J Impot Res.* 2000;12:23–32.
17. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy on micro- and macroprolactinomas in men. *J Clin Endocrinol Metab.* 2000;85:3053–7.
18. Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. *Pituitary.* 2015;18:108–15.
19. Waeber C, Reymond O, Reymond M, Lemarchand-Beraud T. Effects of hyper- and hypo-prolactinemia on gonadotropin secretion, rat testicular luteinizing hormone/human chorionic gonadotropin receptors and testosterone production by isolated Leydig cells. *Biol Reprod.* 1983;28(1):167–77.
20. Sluczanoska-Glabowska S. The effect of hyperprolactinemia on morphology and function of androgen receptor expressing cells in rat testis, epididymis and prostate. *Ann Acad Med Stetin.* 2004;50:123–34.
21. Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. *Endocrinology.* 1998;139:3691–5.
22. Binart N, Melaine N, Pineau C, Kercret H, Touzalin AM, Imbert-Bolloré P, Kelly PA, Jégou B. Male reproductive function is not affected in prolactin receptor-deficient mice. *Endocrinology.* 2003;144:3779–82.
23. Kelly PA, Binart N, Lucas B, Bouchard B, Goffin V. Implications of multiple phenotypes observed in prolactin receptor knockout mice. *Front Neuroendocrinol.* 2001;22:140–5.
24. De Rosa M1, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. *Clin Endocrinol (Oxf).* 2006;64:307–13.
25. Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hyponadal men with hyperprolactinaemia. *Clin Endocrinol.* 1984;21:257–63.
26. Conner P, Fried G. Hyperprolactinemia; etiology, diagnosis and treatment alternatives. *Acta Ostet Gynecol Scand.* 1998;77:249–62.
27. Wallace IR, Satti N, Courtney CH, Leslie H, Bell PM, Hunter SJ, McCance DR, Sheridan R, Atkinson AB. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. *J Clin Endocrinol Metab.* 2010;95:3268–71.
28. FitzPatrick M, Tarataglinio L, Hollander MD, Zimmerman RA, Flanders AE. Imaging of sellar and parasellar pathology. *Radiol Clin North Am.* 1999;37:101–21.
29. Biller BM et al. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. *BMC Endocr Disord.* 2010;10:10.
30. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. *Expert Opin Investig Drugs.* 2002;11:787–800.
31. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. *Endocr Rev.* 2006;27:485–534.
32. Faje A, Nachtigall L. Current treatment options for hyperprolactinemia. *Expert Opin Pharmacother.* 2013;14:1611–25.
33. De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. *J Clin Endocrinol Metab.* 2004;89:621–5.
34. Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, Zarrilli S, Merola B, Lombardi G. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. *Eur J Endocrinol.* 1996;135:548–52.
35. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti M, Musatti L, Verbessem G, Scanlon MF. Treatment of macroprolactinomas with cabergoline:

- A study of 85 patients. *Clin Endocrinol.* 1997;46:409–12.
36. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. *Eur J Endocrinol.* 1998;138:286–93.
 37. Auriemma RS, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. *Neuroendocrinology.* 2015;101:66–81.
 38. Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M. Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. *Acta Neurochir (Wien).* 2016;158:933–42.
 39. Lamberts SW, Hofland LJ. Future treatment strategies of aggressive pituitary tumors. *Pituitary.* 2009;12:261–4.
 40. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. *Ann Med.* 1998;30:452–9.
 41. Isurugi K, Kajiwara T, Hosaka Y, Minowada S. Successful gonadotrophin treatment of hypogonadism in postoperative patients with macroprolactinoma and persistent hyperprolactinaemia. *Int J Androl.* 1993;16:306–10.
 42. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LØ, Laurberg P, Pedersen L, Dekkers OM, Sørensen HT, Jørgensen JO. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. *Eur J Endocrinol.* 2016;175:181–90.
 43. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. *Endocr Rev.* 2004;25:102–52.
 44. Katznelson L, Kleinberg D, Vance ML, Stravou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. *Clin Endocrinol.* 2001;54:183–8.
 45. Lobie PE, Breipohl W, Aragón JG, Waters MJ. Cellular localization of the growth hormone receptor/binding protein in the male and female reproductive systems. *Endocrinology.* 1990;126:2214–21.
 46. Hull KL, Harvey S. Growth hormone: A reproductive endocrine paracrine regulator? *Rev Reprod.* 2000;5:175–82.
 47. Spiteri-Grech J, Barlett JMS, Nieschlag E. Regulation of testicular insulin-like growth factor-I in pubertal growth hormone-deficient male rats. *J Endocrinol.* 1991;131:279–85.
 48. Sjogren I, Jonsson M, Madej A, Johansson HE, Ploen L. Effects of very high doses of human growth hormone (hGH) on the male reproductive system in the dog. *Andrologia.* 1998;30:37–42.
 49. Andraessen M, Frystyk J, Faber J, Kristensen L, Juul A. Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist. *Andrology.* 2013;1:595–601.
 50. Roellsema F, Moblenaar AJ, Frolich M. The influence of bromocriptine and transsphenoidal surgery on urinary androgen metabolic excretion in acromegaly. *Acta Endocrinol.* 1984;107:302–11.
 51. Zweirska-Korcza K, Ostrowska Z, Zych F, Buntner B. The levels of pituitary-testicular axis hormones and SHBG in active acromegaly following bromocriptine treatment. *Endocr Regul.* 1991;25:211–6.
 52. Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marìno V, Di Sarno A, Merola B, Lombardi G. Prostate hyperplasia: An unknown feature of acromegaly. *J Clin Endocrinol Metab.* 1998;83:775–9.
 53. Duncan E, Wass AH. Investigation protocol: Acromegaly and its investigation. *Clin Endocrinol.* 1999;50:285–93.
 54. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. *Eur J Endocrinol.* 2005;152:378–9.
 55. Tominaga A, Uozumi T, Arita K, Kurisu K, Yano T, Hirohata T, Eguchi K, Iida K, Kawamoto H. Effects of surgery on testosterone secretion in male patients with pituitary adenomas. *Endocr J.* 1996;43:307–12.
 56. Hammond GL, Wu TS, Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. *Curr Opin Endocrinol Diabetes Obes.* 2012;19:183–9.
 57. Colao A, De Rosa M, Pivonello R, Balestrieri A, Cappabianca P, Di Sarno A, Rochira V, Carani C, Lombardi G. Short-term suppression of GH and IGF-1 levels improves gonadal function and sperm parameters in men with acromegaly. *J Clin Endocrinol Metab.* 2002;87:4193–7.
 58. Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A. Current and future medical treatments for patients with acromegaly. *Expert Opin Pharmacother.* 2016;17:1631–42.
 59. Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. *Pituitary.* 2016;19:235–47.
 60. McKeage K. Pasireotide in acromegaly: A review. *Drugs.* 2015;75(9):1039–48.
 61. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients—A clinical research center study. *J Clin Endocrinol Metab.* 1995;80:2768–75.
 62. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B,

- Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. *J Clin Endocrinol Metab.* 1997;82:518–23.
63. Freda PU. Pegvisomant therapy for acromegaly. *Exp Rev Endocrinol Metab.* 2006;1:489–98.
 64. Iwata H, Sato K, Nomura R, Tabei Y, Suzuki I, Yokota N, Inoue M, Ohta S, Yamada S, Shibamoto Y. Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus. *J Neurooncol.* 2016;128:267–75.
 65. Lutton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. Reversible gonadotropin deficiency in male Cushing's disease. *J Clin Endocrinol Metab.* 1977;45:488–95.
 66. Smals AG, Kloppenborg PW, Benraad TJ. Plasma testosterone profiles in Cushing's syndrome. *J Clin Endocrinol Metab.* 1977;45:240–5.
 67. McKenna TJ, Lorber D, Lacroix A, Rabin D. Testicular activity in Cushing's disease. *Acta Endocrinol (Copenh).* 1979;91:501–10.
 68. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. *J Clin Endocrinol Metab.* 1985;61:536–40.
 69. Marazuela M1, Cuerda C, Lucas T, Vicente A, Blanco C, Estrada J. Anterior pituitary function after adrenalectomy in patients with Cushing's syndrome. *Postgrad Med J.* 1993; 69:547–51.
 70. Chandran UR, Attardi B, Friedman R, Zheng ZW, Roberts JL, Defranco DB. Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor. *J Biol Chem.* 1996;271:20412–20.
 71. Gao HB, Tong MH, Hu YQ, Guo QS, Ge R, Hardy MP. Glucocorticoid induces apoptosis in rat Leydig cells. *Endocrinology.* 2002;143:130–8.
 72. Sankar BR, Maran RR, Sudha S, Govindarajulu P, Balasubramanian K. Chronic corticosterone treatment impairs Leydig cell 11 β -hydroxysteroid dehydrogenase activity and LH-stimulated testosterone production. *Horm Metab Res.* 2000;32:142–6.
 73. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations. *Bull Johns Hopkins Hosp.* 1932;137:50–4.
 74. Carroll TB, Findling JW. The diagnosis of Cushing's syndrome. *Rev Endocr Metab Disord.* 2010;11:147–53.
 75. Carroll T, Raff H, Findling JW. Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. *Endocr Pract.* 2009;15:335–42.
 76. Hwang YC, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. Comparisons between macroadenomas and microadenomas in Cushing's disease: Characteristics of hormone secretion and clinical outcomes. *J Korean Med Sci.* 2009;24:46–51.
 77. Colao A, Faggiano A, Pivonello R, Giralaldi FP, Cavagnini F, Lombardi G. Study group of the Italian Endocrinology Society on the pathophysiology of the hypothalamic-pituitary-adrenal axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. *Eur J Endocrinol.* 2001;144:499–507.
 78. Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, Brue T, Bruzzi P, Casanueva FF, Chanson P, Colao A, Reincke M, Stalla G, Tsagarakis S. Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: Systematic review assessing criteria used to define remission and recurrence. *Eur J Endocrinol.* 2015;172:R227–39.
 79. Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. *Endocr Rev.* 2015;36:385–486.
 80. Tritos NA1, Biller BM. Update on radiation therapy in patients with Cushing's disease. *Pituitary.* 2015;18:263–8.
 81. Sonino N, Boscaro. Medical therapy for Cushing's disease. *Endocrinol Metab Clin N Am* 1999;28: 211–22.
 82. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1 year treatment with cabergoline. *J Endocrinol Invest.* 1999;22:860–5.
 83. Cury ML, et al. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. *Arg Bras Endocrinol Metabol.* 2009;53:31–9.
 84. Mayson SE, Snyder PJ. Silent pituitary adenomas. *Endocrinol Metab Clin North Am.* 2015;44:79–87.
 85. Ferrante E, et al. Non-functioning pituitary adenoma database: A useful resource to improve the clinical management of pituitary tumors. *Eur J Endocrinol.* 2006;155:823–9.
 86. Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. *J Clin Endocrinol Metab.* 1986;62:1173–9.
 87. Galland F, Vantghem MC, Cazabat L, Boulin A, Cotton F, Bonneville JF, Jouanneau E, Vidal-Trécan G, Chanson P. Management of non-functioning pituitary incidentaloma. *Ann Endocrinol (Paris).* 2015;76:191–200.
 88. Berkman S, Schlaffer S, Nimsky C, Fahlbusch R, Buchfelder M. Follow-up and long-term outcome of nonfunctioning pituitary adenoma operated by transsphenoidal surgery with intraoperative high-field magnetic resonance imaging. *Acta Neurochir (Wien).* 2014;156:2233–43.
 89. Park KJ, Kano H, Parry PV, Niranjana A, Flickinger JC, Lunsford LD, Kondziolka D.

- Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. *Neurosurgery*. 2011;69:1188–99.
90. Lee MH, Lee JH, Seol HJ, Lee JI, Kim JH, Kong DS, Nam DH. Clinical concerns about recurrence of non-functioning pituitary adenoma. *Brain Tumor Res Treat*. 2016;4:1–7.
 91. Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, Lee JY, Kano H, Park KJ, Niranjana A, Kondziolka D, Barnett GH, Rush S, Golfinos JG, Lunsford LD. Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: A multicenter study. *J Neurosurg*. 2013;119:446–56.
 92. Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, Gadelha MR. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. *Clin Endocrinol (Oxf)*. 2015;82:739–46.
 93. Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N. Treatment of clinically non-functioning pituitary adenomas with dopamine agonists. *Eur J Endocrinol*. 2016;175:63–72.
 94. Freda PU, Post KD. Differential diagnosis of sellar masses. *Endocrinol Metab Clin N Am*. 1999;28:81–117.
 95. Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: Ten-year experience in 2598 patients. *J Clin Endocrinol Metab*. 2011;96:1633–41.
 96. Shin JL, Asa SL, Woodhouse LJ, Smyth HS, Ezzat S. Cystic lesions of the pituitary: Clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. *J Clin Endocrinol Metab*. 1999;84:3972–82.
 97. Chakrabarti II, Amar AP, Couldwell W, Weiss MH. Long-term neurological, visual, and endocrine outcomes following transnasal resection of craniopharyngioma. *J Neurosurg*. 2005;102:650–7.
 98. Culver SA, Grober Y, Ornan DA, Patrie JT, Oldfield EH, Jane JA Jr, Thorner MO. A case for conservative management: Characterizing the natural history of radiographically diagnosed Rathke cleft cysts. *J Clin Endocrinol Metab*. 2015;100:3943–8.
 99. Debeneix C1, Bourgeois M, Trivin C, Sainte-Rose C, Brauner R. Hypothalamic hamartoma: comparison of clinical presentation and magnetic resonance images. *Horm Res*. 2001;56:12–8.
 100. Valassi E, Biller BM, Klibanski A, Swearingen B. Clinical features of nonpituitary sellar lesions in a large surgical series. *Clin Endocrinol (Oxf)*. 2010;73:798–807.
 101. Turcu AF, Erickson BJ, Lin E, Guadalix S, Schwartz K, Scheithauer BW, Atkinson JL, Young WF Jr. Pituitary stalk lesions: the Mayo Clinic experience. *J Clin Endocrinol Metab*. 2013;98:1812–8.
 102. Sibal L, et al. Pituitary apoplexy: A review of clinical presentation, management and outcome in 45 cases. *Pituitary*. 2004;7:157–63.
 103. Guitelman M, Garcia Basavilbaso N, Vitale M, Chervin A, Katz D, Miragaya K, Herrera J, Cornalo D, Servidio M, Boero L, Manavela M, Danilowicz K, Alfieri A, Staldecke G, Glerean M, Fairstein Day P, Ballarino C, Mallea Gil MS, Rogozinski A. Primary empty sella (PES): a review of 175 cases. *Pituitary*. 2013;16:270–4.
 104. Zuhur SS, Kuzu I, Ozturk FY, Uysal E, Altuntas Y. Anterior pituitary hormone deficiency in subjects with total and partial primary empty sella: do all cases need endocrinological evaluation? *Turk Neurosurg*. 2014;24:374–9.
 105. Kyriakais N, Lynch J, Orme SM, Gerrard G, Hatfield P, Loughrey C, Short SC, Murray RD. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. *Clin Endocrinol (Oxf)*. 2016;84:372–9.
 106. Lee SC, Zasler ND, Kreutzer JS. Male pituitary-gonadal dysfunction following severe traumatic brain injury. *Brain Inj*. 1994;8:571–7.
 107. Lecoq AL, Chanson P. Hypopituitarism following traumatic brain injury: diagnostic and therapeutic issues. *Ann Endocrinol (Paris)*. 2015; 76(6 Suppl 1):S10–8. (Fr).
 108. Bavisetty S, Bavisetty S, McArthur DL, Dusick JR, Wang C, Cohan P, Boscardin WJ, Swerdloff R, Levin H, Chang DJ, Muizelaar JP, Kelly DF. Chronic hypopituitarism after traumatic brain injury: Risk assessment and relationship to outcome. *Neurosurgery*. 2008;62:1080–93.
 109. Silva PP, Bhatnagar S, Herman SD, Zafonte R, Klibanski A, Miller KK, Tritos NA. Predictors of hypopituitarism in patients with traumatic brain injury. *J Neurotrauma*. 2015;15(32):1789–95.

Klinefelter Syndrome and Other Forms of Primary Testicular Failure

John K. Amory MD, MPH
and William J. Bremner MD, PhD

Contents

Overview	187
Historical Description of Klinefelter Syndrome.....	188
Pathophysiology of Klinefelter Syndrome	188
Clinical Features of Klinefelter Syndrome.....	190
Morbidity Associated with Klinefelter Syndrome	191
Diagnosis of Klinefelter Syndrome	192
Treatment of Klinefelter Syndrome.....	192
Klinefelter Syndrome and Infertility	193
Other Forms of Primary Hypogonadism.....	193
References	194

Overview

Klinefelter syndrome (KS) is the most common sex chromosome disorder in men affecting roughly 1 in 400–600 males across all ethnic groups [1, 2]. It is also the most common cause of primary testicular failure, resulting in impairments in both spermatogenesis and testosterone production. The hypogonadism associated with KS can range from mild to severe, leading to a marked variation in clinical presentation. Men with KS possess at least one additional or “supernumerary” X chromosome resulting in a 47, XXY genotype. The clinical phenotype in the adult is that of absent spermatogenesis and

varying degrees of hypogonadism, manifested by a tall body habitus with sparse body and facial hair, gynecomastia, diminished libido and very small (<6 cc) testes. In childhood, common presenting features can include delayed speech development, learning difficulties at school, unusually rapid growth in mid-childhood and truncal obesity. Laboratory analysis reveals low or low-normal serum testosterone and elevated serum gonadotropin levels, with FSH elevated to a greater degree than LH. The clinical diagnosis is confirmed using chromosomal analysis (karyotyping) of either peripheral blood leukocytes or tissue, which usually reveals a 47, XXY genotype, although infrequently additional X chromosomes may be present, or an individual may be mosaic (47, XXY/46, XY). Treatment consists of testosterone therapy for improved virilization, sexual function, bone density and quality of life. Gynecomastia is treated with cosmetic surgery after androgen replacement has begun. Infertility can be addressed by testicular sperm extraction “TESE” coupled with intracytoplasmic sperm injection “ICSI” if sperm are recovered during TESE, although these procedures are expensive and effective in only some men. Alternative options, including artificial insemination with donor sperm or adoption are reasonable alternatives. This chapter will summarize the initial historical description of KS as well as our current understanding of the epidemiology, pathophysiology, clinical manifestations and treatment of individuals with KS. In addition, we will discuss

J.K. Amory (✉) · W.J. Bremner
Department of Medicine, University of Washington,
1959 NE Pacific St., Box 356429, Seattle,
WA 98195, USA
e-mail: jamory@uw.edu

W.J. Bremner
e-mail: wbremner@uw.edu

the outcomes of assistive reproductive techniques in couples in which than man has KS.

Historical Description of Klinefelter Syndrome

In 1940, Harry F. Klinefelter Jr., a native of Baltimore and a graduate of the Johns Hopkins medical school, spent a year working as a “traveling fellow” with Dr. Fuller Albright in the Metabolic Ward of the Massachusetts General Hospital in Boston [3]. At that time, Dr. Albright was at the height of his formidable academic career and among many other subjects was interested in the endocrinology of sexual development and the therapeutic applications of the recently available steroid hormones. Dr. Albright had identified a group of adult men with a previously uncharacterized syndrome typified by gynecomastia, small testes and varying degrees of eunuchoidism. Dr. Albright assigned Dr. Klinefelter the task of further describing this syndrome for publication.

Klinefelter, Albright and their colleague Dr. Edward Reifenstein Jr. published their description of the syndrome in a classic paper in *The Journal of Clinical Endocrinology* in 1942 [4]. In this paper, they described a cohort of 9 men “characterized by gynecomastia, aspermatogenesis without a-Leydigism and increased excretion of follicle-stimulating hormone.” The authors noted the presence of testosterone-producing Leydig cells in testicular biopsy specimens, as well as a marked increase in FSH production, comparable to that seen in castrated men. The authors suggested that the markedly elevated FSH levels were secondary to the absence of a testicular hormone other than testosterone. This postulated hormone, called inhibin by prior researchers, is in fact lacking in individuals with KS, but its identity and role in endocrine feedback in the male would not be fully elucidated for over 50 years [5].

As to the cause of the syndrome, Klinefelter and his colleagues were uncertain. They ruled out testicular inflammation, infection or obstruction of the vas deferens, and noted on testicular

biopsy specimens that the lesion involved the seminiferous tubules without dramatically affecting the histology of the Leydig cells, testicular interstitium or epididymis. They recommended testosterone therapy (available since the late 1930s) for those with signs or symptoms of hypogonadism, but noted that this therapy did not improve the gynecomastia or infertility.

Although Drs. Klinefelter, Reifenstein and Albright first described the clinical and endocrine manifestation of KS in 1942, it was not until 1956 following the ascertainment of DNA as the main instrument of heredity that the additional X chromosomes or “Barr bodies” were identified in tissue from patients with KS [6, 7]. Three years later Jacobs and Strong confirmed the association between the extra X chromosome and KS by cytogenetic analysis of metaphase chromosomes, establishing KS as a sex chromosome disorder with a 47, XXY karyotype [8]. Further work has demonstrated that some individuals may be mosaic (47, XXY/46, XY) with the extra X chromosome detectable only in peripheral blood or the testes; rare individuals with 48, XXXY and 49, XXXXY karyotypes have also been described [9].

Pathophysiology of Klinefelter Syndrome

Most cases of KS appear to occur through sporadic chromosomal non-disjunction during parental gametogenesis in either the sperm or the egg. A seminal study using DNA probes to X chromosome restriction site polymorphisms demonstrated that in one series of 32 individuals with KS the additional X chromosome was of paternal origin in 17 (53%) of cases, of maternal origin in 14 (44%) of cases and due to a post-zygotic mitotic error in one (3%) case (Table 9.1) [10]. Since these are sporadic errors in gametogenesis, there is no evidence that KS is familial, or is likely to recur within a given family after one child with KS is born. Chromosomal analysis of sperm has demonstrated that normal older men produce higher

Table 9.1 Mechanism of origin of additional X chromosome in 47, XXY males

Sex chromosomes	Responsible cell division	X-linked loci	Frequency (%)
$X^M X^P Y$	Paternal meiosis	Identical to father	53
$X^{M1} X^{M2} Y$	Maternal meiosis I	Identical to mother	34
$X^{M1} X^{M1} Y$	Maternal meiosis II	Single maternal chromosome with heterozygosity in distal loci	9
$X^{M1} X^{M1} Y$	Mitotic (post-zygotic)	Single homozygous maternal chromosome	3


frequencies of XY sperm which could increase their chances of fathering a child with KS [11].

In an individual with KS, the extra X chromosome forms a dense chromatin mass, or “Barr body” within the nuclei of somatic cells, but exactly how the presence of this extra chromosome leads to testicular failure remains a mystery. Microarray analysis reveals over- and underexpression of various genes on the X chromosome and autosomes that presumably contribute to the features of KS [12]. Testicular biopsy specimens from infants with KS may reveal only a reduced number of germ cells [13]. After puberty, fibrosis of the seminiferous tubules begins, eventually leading to small, firm testes and azoospermia [4]. Testicular biopsy specimens from adults with KS reveal marked seminiferous tubule hyalinization with focal areas of immature seminiferous tubule formation

and fibrosis with a resulting increase in the amount of interstitium (Fig. 9.1). An absence of functional Sertoli cells in the seminiferous tubules is accompanied by low-level inhibin B in serum [5], the hormone whose existence Klinefelter and colleagues had hypothesized in their original paper.

The hormonal axis in boys with KS can appear normal until puberty, with no apparent differences in levels of testosterone (T), luteinizing hormone (LH) or follicle-stimulating hormone (FSH) compared to controls [14–16]. In addition, gonadotropin production in response to GnRH stimulation is normal. However, at the time of puberty, elevated basal FSH and LH levels and an exaggerated FSH and LH response to GnRH stimulation, and low or low-normal testosterone levels are seen, presaging the hormonal abnormalities seen in adults with KS.

Fig. 9.1 Testicular biopsy specimens an individual with KS. Note focal areas of immature seminiferous tubules interspersed with completely hyalinized tubules and an increase in interstitial tissues (photograph courtesy of Dr. C. Alvin Paulsen)



Testosterone production in a man with KS declines with aging in a fashion similar to controls [17, 18].

The cause of the language difficulties often encountered by individuals with KS is not well understood; however, high-resolution MRI scans of the brains of a small number of men with KS have demonstrated a relative reduction in left temporal lobe gray matter compared with control subjects [19]. Interestingly, individuals with KS who had been treated with testosterone had larger left temporal lobe volumes than individuals with KS who had not received testosterone therapy. Moreover, verbal fluency scores were significantly improved in the KS-testosterone groups as compared with the KS-no testosterone group, demonstrating that relatively low levels of testosterone during development may play a major role in the verbal and language problems related to KS.

The pathophysiology of KS-related gynecomastia is also unclear. Individuals with KS do exhibit mildly elevated levels of estradiol, probably from increases in peripheral aromatization and decreased clearance. However, histologic analysis of breast tissue from individuals with KS demonstrates *intraductal* hyperplasia rather than the ductal hyperplasia seen in high estrogen states in the male such as cirrhosis [20].

Clinical Features of Klinefelter Syndrome

The major clinical manifestations of KS are those of pre-pubertal androgen deficiency and infertility. Because testicular failure occurs before puberty, some of the normal developmental changes in puberty do not occur. This leads to the classic phenotype of KS: long legs, with an arm span frequently greater than height, gynecomastia, decreased muscle mass and increased abdominal adiposity, decreased facial and body hair, and small testes—which often measure less than 5 cc in volume. Long legs may be partly due to overexpression of the short stature homeobox (SHOX) gene on the X chromosome

Table 9.2 Clinical and physical characteristics of men with Klinefelter syndrome

Feature	Percent
Infertility	99–100
Small testes	99–100
Gynecomastia	50–75
Decreased facial and pubic hair	50–80
Decreased penis size	10–25

[21]. The penis may be decreased in size but is often of normal length. Gynecomastia is variable, but is often prominent and may require surgical correction. Mosaicism may present more subtly, as affected individuals can appear anywhere along a phenotypic spectrum between classical KS and “normal.” Infertility is almost universal; however, children have been fathered by men mosaic for KS [22] and via assisted reproductive techniques (see below). The frequency of various symptoms and signs of KS is summarized in Table 9.2.

Hormonally, roughly one-half of affected men have decreased total testosterone levels, almost all have elevated gonadotropins, particularly FSH, but estradiol levels are usually fairly normal (Table 9.3) [18]. More than 90% of men have increased levels of serum gonadotropins, particularly FSH, as inhibin B levels are very low [5]. Because of low levels of androgens, individuals with KS can have low bone mineral density and are at increased risk of osteoporosis, even despite seemingly adequate androgen therapy [23]. This is likely due to failure to achieve peak bone mass early in life, as testosterone replacement before the age of 20 can improve bone mass to normal levels, whereas testosterone therapy started later in life is less effective [24]. As a result, calcium and vitamin D supplementation as well as baseline densitometry are probably prudent in individuals with KS, especially those who began androgen therapy later in life.

At one time, individuals with KS were thought to be frequently retarded and/or at increased risk of criminal behavior [25, 26]. These studies were based on pre-selected (usually committed or incarcerated) populations, however, and were not

Table 9.3 Serum hormones in men with Klinefelter Syndrome

Hormone	Mean \pm SD	Reference range	% Abnormal
Testosterone (ng/mL)	2.7 \pm 1.6	2.8–8.8	45
FSH (IU/L)	35.4 \pm 16.2	1–8	100
LH (IU/L)	22.3 \pm 11.6	2–12	83
Estradiol (pg/mL)	26.5 \pm 13.2	18–44	6
Prolactin (ng/mL)	16.5 \pm 11.3	5–20	33

representative of the syndrome as a whole. Subsequent population-based studies have demonstrated a non-significant, but slightly increased rate of incarceration among individuals with KS. This increased rate of imprisonment is most likely accounted for by lower average scores on IQ tests compared with controls [27].

Individuals with KS can exhibit significant deficits in language processing skills including: reading and spelling, verbal processing speed, verbal and non-verbal executive abilities and motor dexterity [28, 29]. In general, this leads to lower average school performance and an increased frequency of psychological consultation. In addition, adolescent males with KS exhibit lowered sexual activity compared with their peers [30]. Expression of genes on the supernumerary X chromosome in the central nervous system may contribute to these behaviors [31]. It is important to remember that individual variation in mental function is marked, and some individuals with KS perform well above average on intelligence tests. Moreover, it seems likely that early developmental interventions and language tutoring in boys can assist in preventing disabling difficulties with language skills later in adult life [25, 32].

Morbidity Associated with Klinefelter Syndrome

Data from large population-based studies of chromosome abnormalities at birth have demonstrated that the KS occurs in about 1 in

400–600 male births [33–35]. However, only 25% of men with KS appear to receive a diagnosis [32], suggesting that many men with KS do not receive appropriate medical care. The failure to diagnose most men with KS, could likely be addressed by routine testicular examination in clinical settings, as the testes of most men with KS are much smaller than normal (usually less than 5 cc in KS vs. greater than 15 cc in normal men). However, testicular examinations are frequently not performed by clinicians seeing young men for reasons other than infertility or testicular discomfort. Alternatively, greater awareness of KS in the general population could improve rates of diagnosis.

In adults, overall age-matched mortality appears to be roughly doubled [36, 37]. Most of this increase is from non-neoplastic diseases of the cardiovascular, respiratory and digestive systems, and diabetes; however, the incidence of breast cancer and autoimmune disease is somewhat increased [38, 39].

In particular, the risk of breast cancer is 20-fold higher in men with KS, who account for 4% of all breast cancer cases in men. Fortunately, breast cancer in men is rare, so the absolute risk of breast cancer in a given man with KS is well under 1%. As a result, screening mammography is not generally recommended [40]. Men with KS also have an increased risk of extra-gonadal germ cell tumors [41]. Such patients are young and frequently present with advanced disease, often of the mediastinum. It is thought that these neoplasms arise from primordial germ cells that failed to complete migration to the fetal testes during embryogenesis. These germ cell precursors may then undergo malignant transformation partly in response to the elevated gonadotropin levels seen in individuals with KS. Fortunately, these tumors are rare even in individuals with KS, and most of these tumors respond well to chemotherapy.

There may be an increased risk of autoimmune disease in individuals with KS. Systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis and even rare forms of vasculitis such as Takayasu's arteritis have been reported in KS patients, although the true relative increase in risk

is difficult to calculate due to the small number of individuals affected [42–44]. It has been speculated that this possible increased risk of autoimmune disease is due to an increase in the estrogen to testosterone ratio, as it is believed that elevated levels of circulating estrogen may place premenopausal women at increased risk of autoimmune disease [45]. Alternative explanations for this increased risk of autoimmune disease in individuals with KS include abnormalities in “regulatory” T-lymphocyte subsets, as is observed in women with autoimmune disease. It is interesting to note that androgen therapy has been observed to improve clinical symptoms of autoimmune disease as well as correcting some of the laboratory features of autoimmunity [46].

Diabetes mellitus, usually type 2, is more common in individuals with KS than in the general population [47, 48] and may be present even before puberty [49]. The mechanism of diabetes in men with KS is probably due to a post-receptor defect in insulin action [50].

In addition to diabetes, men with KS may be at increased risk of other elements of the metabolic syndrome [51], especially when KS occurs in combination with obesity [52, 53]. As a result, screening for hypertension and hyperlipidemia should occur early in men with KS for the purposes of preventing premature atherosclerosis [51].

Taurodontism (an enlargement of the pulp in molar teeth) is seen in almost half of men with KS [54]. Taurodontism is diagnosed by dental X-rays and predisposes to premature dental caries and tooth loss. Good dental hygiene and frequent cleaning may be protective.

Early varicose veins are a feature of KS with 20% of men having severe varicosities at a relatively early age [55]. In addition to lower-extremity venous ulcers and an increased risk of deep-vein thrombosis have been noted [56, 57]. There is speculation that a defect in venous basement membrane connective tissue is present in some individuals with KS.

Diagnosis of Klinefelter Syndrome

KS is unique in that it can be diagnosed at almost any age: in utero, in a pre-pubertal boy, in an adolescent or even an adult male presenting to either a general practice or to an infertility clinic. Chromosomal karyotyping on amniotic fluid obtained from amniocentesis for an abnormal triple-screen or for advanced maternal age will reveal KS with great accuracy. KS can be suggested in pre-pubertal children by a testicular size of less than 2 cm after the age of six years [58]. Additional clues to the diagnosis of KS in a pre-pubertal male are verbal learning disabilities or taurodontism. After puberty, men with KS will often exhibit tall stature (usually greater than 184 cm.) with disproportionately long legs and frequently manifest an arm span that is greater than their height [59]. In adults, the diagnosis of KS should be considered in men with gynecomastia, primary hypogonadism, infertility or osteoporosis. Since serum testosterone levels may be normal, serum gonadotropins should also be measured. Peripheral blood karyotyping can be used to confirm the diagnosis, although this test can be negative in mosaic individuals, and tissue karyotype may be necessary [9].

Treatment of Klinefelter Syndrome

Testosterone therapy results in a more “male” phenotype, with increases in facial and pubic hair, muscle size and strength, increased libido and bone mineral density and improved mood [24, 49, 60, 61]. Optimally, testosterone therapy is begun at puberty allowing boys with KS to experience pubertal changes in tandem with their peers. In addition, this allows for optimal enhancement of bone mineral density. Even if testosterone therapy is not initiated until adulthood, it is still associated with beneficial improvements in mood, behavior and sense of well-being [61]. Testosterone therapy has no beneficial impact on infertility or on

gynecomastia, which requires surgical resection if bothersome.

Testosterone therapy is safely and easily accomplished by either periodic intramuscular injection of testosterone esters, or transdermal gels described in detail elsewhere in this volume. The replacement dose for intramuscular esters of testosterone is 200 mg IM every other week in adults. Adolescents are usually started at lower doses (e.g., 50–100 mg every 2–4 weeks) and are gradually increased to adult doses over 2–3 months [14]. Side effects of testosterone therapy include weight gain, mostly due to increases in lean body mass, and acne. In older men, erythrocytosis is seen with some frequency. Induction or a worsening of sleep apnea may occur [60]. In general, testosterone therapy is both beneficial and well tolerated by individuals with KS, most of whom continue therapy long term [62]. Twenty-year follow-up of cohorts of men with KS treated with testosterone have demonstrated marked improvements in mental health, working capacity social adjustment and inter-personal relationships that are similar to improvements seen in hypogonadal control cohorts [63]. As a result, most physicians feel that early recognition and treatment with testosterone therapy is of great benefit to the long-term health and welfare of men with KS.

Klinefelter Syndrome and Infertility

Why men with KS are infertile is unknown. Mouse models of KS suggest that common genes that escape X inactivation may be responsible for the infertility and other manifestations of KS [64]. Before 1992, donated sperm or adoptions were the only options for fertility for individuals with KS. Since then, however, dramatic advances in the treatment of infertility in individuals with KS have occurred. Numerous births resulting from intracytoplasmic sperm injection (ICSI) of sperm obtained from surgical testicular extractions “TESE” in patients with KS have been published [65–67]. While some patients with non-mosaic KS do not have sperm on testicular biopsy [68], this technique offers a chance at fertility for those

who do, roughly 50% of men [69]. Early analysis of spermatozoa obtained by testicular biopsy in individuals with KS has revealed an increased prevalence of sperm with additional X chromosomes [70], higher rates of aneuploidy [71] and trisomy 21 [72]. Roughly 5% of testicular spermatozoa from men with KS are aneuploid, compared with less than 1% from men with normal karyotypes, likely due to meiotic errors in euploid spermatocytes [73]. The good news, however, is that follow-up of babies born from men with KS by TESE/ICSI has not demonstrated an increased risk of genetic abnormalities [74, 75]. As a result, pre-implantation genetic diagnosis of embryos from couples with KS is not currently recommended to prevent the transmission of genetic abnormalities.

Recently, two groups have explored whether performing “early” TESE in adolescents or young adults will result in a finding sperm in a greater proportion of procedures. These studies enrolled young men between 12 and 25 of age [76, 77]. Unfortunately, the sperm retrieval rate in the young men in these studies was still only 50%. As a result, it is probably reasonable to wait until a man with KS desires fertility to perform TESE, as early TESE does not appear to increase the chance of finding sperm, allowing for fertility treatments.

Other Forms of Primary Hypogonadism

KS is the most common form of primary hypogonadism. Other causes of primary hypogonadism (i.e., low serum testosterone and elevated gonadotropins) include: toxic exposures (especially radiation and/or chemotherapy as part of treatment for cancer), history of testicular torsion, trauma or congenital cryptorchidism, history of post-pubertal mumps orchitis, autoimmune orchitis, HIV and rare congenital deficiencies in testosterone biosynthetic enzymes, gonadotropin receptors or other uncommon conditions such as myotonic dystrophy. Frequently, the diagnosis is clear by history and physical examination and routine laboratory testing. Referral to an

endocrinologist skilled in distinguishing among these uncommon forms of primary hypogonadism is appropriate if the diagnosis remains unclear.

References

- Smyth CM, Bremner WJ. Klinefelter syndrome. *Arch Intern Med.* 1998;158:1309–14.
- Amory JK, Anawalt BD, Paulsen CA, Bremner WJ. Klinefelter's syndrome. *Lancet.* 2000;356:333–5.
- Beighton P, Beighton G, Klinefelter HF Jr. In: *The man behind the syndrome.* Berlin: Springer; 1986. p. 214.
- Klinefelter HF Jr, Reifenstein EC Jr, Albright F. Syndrome characterized by gynecomastia, aspermatogenesis without a-Leydigism and increased excretion of follicle-stimulating hormone. *J Clin Endocrinol.* 1942;2:615–27.
- Anawalt BD, Bebb RA, Matsumoto AM, et al. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. *J Clin Endocrinol Metab.* 1996;81:3341–5.
- Bradbury IT, Bunge RG, Boccabella RA. Chromatin test in Klinefelter's syndrome. *J Clin Endocrinol Metab.* 1956;16:689–90.
- Plunkett ER, Barr ML. Testicular dysgenesis affecting the seminiferous tubules principally, with chromatin-positive nuclei. *Lancet.* 1956;183:302–3.
- Jacobs PA, Strong JA. A case of human intersexuality having a possible XXY sex-determining mechanism. *Nature.* 1959;183:302–3.
- Paulsen CA, Gordon DL, Carpenter RW, Gandy HM, Drucker WD. Klinefelter's syndrome and its variants: A hormonal and chromosomal study. *Recent Prog Horm Res.* 1968;22:245–70.
- Jacobs PA, Hassold TJ, Whittington E, et al. Klinefelter's syndrome: An analysis of the origin of the additional sex chromosome using molecular probes. *Ann Hum Genet.* 1988;52:93–109.
- Lowe X, Eskenazi B, Nelson DO, Kidd S, Alme A, Wyrobek AJ. Frequency of XY sperm increases with age in fathers of boys with Klinefelter syndrome. *Am J Hum Genet.* 2001;69:1046–54.
- Huang J, Zhang L, Deng H, Chang L, Liu Q, Liu P. Global transcriptome analysis of peripheral blood identifies the most significantly down-regulated genes associated with metabolism regulation in Klinefelter syndrome. *Mol Reproduc Dev.* 2015;82:17–25.
- Mikamo K, Aguerif M, Hazeglin P, Martin-DU PR. Chromatin-positive Klinefelter's syndrome: A quantitative analysis of spermatogonadal deficiency at 3, 4 and 12 months of age. *Fertil Steril.* 1968;19:731–9.
- Winter JS. Androgen therapy in Klinefelter syndrome during adolescence. *Birth Defects.* 1991;26:234–5.
- Sorensen K, Nielson J, Wohlert M, Bennett P, Johnsen SH. Serum testosterone of boys with karyotype 47, XXY (Klinefelter's syndrome) at birth. *Lancet.* 1981;2:1112–3.
- Salbenblatt JA, Bender BG, Puck MH, Robinson A, Faiman C, Winter JS. Pituitary-gonadal function in Klinefelter's syndrome before and during puberty. *Periatr Res.* 1985;19:82–6.
- Gabrilove JL, Freiberg EK, Thornton JC, Nicolis GL. Effect of age on testicular function in patients with Klinefelter's syndrome. *Clin Endocrinol (Oxf).* 1979;11:343–7.
- Pacenza N, Pasqualini T, Gottlieb S, Knoblovits P, Costanzo PR, Stewart Usher J, Rey RA, Martínez MP, Aszpis S. Clinical presentation of Klinefelter's syndrome: Differences according to age. *Int J Endocrinol.* 2012;324835.
- Patwardhan AJ, Eliez S, Bender B, Linden MG, Reiss AL. Brain morphology in Klinefelter syndrome: Extra X chromosome and testosterone supplementation. *Neurology.* 2000;54:2218–23.
- Wang C, Baker HWG, Burger HG, DeKretser DM, Hudson B. Hormonal studies in Klinefelter's syndrome. *Clin Endocrinol (Oxf).* 1975;4:399–411.
- Ottesen AM1, Aksglaede L, Garn I, Tartaglia N, Tassone F, Gravholt CH, Bojesen A, Sørensen K, Jørgensen N, Rajpert-De Meyts E, Gerdes T, Lind AM, Kjaergaard S, Juul A. Increased number of sex chromosomes affects height in a nonlinear fashion: A study of 305 patients with sex chromosome aneuploidy. *Am J Med Genet A.* 2010;152:1206–12.
- Warbury E. A fertile patient with Klinefelter's syndrome. *Acta Endocrinol.* 1963;43:12–26.
- Van den Bergh JP, Hermus AR, Spruyt AI, Sweep CG, Corstens FH, Smals AG. Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. *Osteoporos Int.* 2001;12:55–62.
- Kubler A, Schulz G, Cordes U, Beyer J, Krause U. The influence of testosterone substitution on bone mineral density in patients with Klinefelter's syndrome. *Exp Clin Endocrinol.* 1992;100:129–32.
- Barr ML, Shaver EL, Carr DH, Plunkett ER. The chromatin-positive Klinefelter syndrome among patients in mental deficiency hospitals. *Resident J Ment Defic.* 1960;4:89–107.
- Schroder J, de la Chapelle A, Hakola P, Virkkunen M. The frequency of XYY and XXY men among criminal offenders. *Acta Psychiatr Scand.* 1981;63:272–6.
- Witkin HS, Mednick SA, Schulsinger F, et al. Criminality in XYY and XXY men. *Science.* 1976;193:547–54.

28. Boone KB, Swerdloff RS, Miller BL, Geschwind DH, et al. Neuropsychological profiles of adults with Klinefelter's syndrome. *J Int Neuropsychol Soc.* 2001;7:446–56.
29. Sorenen K. Physical and mental development of adolescent males with Klinefelter syndrome. *Horm Res.* 1992;37(Suppl 3):55–61.
30. Samango-Sprouse C. Mental development in polyploidy X Klinefelter syndrome: Effects of incomplete X inactivation. *Semin Reprod Med.* 2001;19:193–202.
31. Zitzmann M1, Bongers R, Werler S, Bogdanova N, Wistuba J, Kliesch S, Gromoll J, Tüttelmann F. Gene expression patterns in relation to the clinical phenotype in Klinefelter syndrome. *J Clin Endocrinol Metab.* 2015;100:E518–23.
32. Bojesen A1, Juul S, Birkebaek N, Gravholt CH. Increased mortality in Klinefelter syndrome. *J Clin Endocrinol Metab.* 2004;89:3830–4.
33. Maclean H, Harnden DH, Court-Brown WM. Abnormalities of sex chromosome constitution in newborn babies. *Lancet.* 1961;2:406–8.
34. Hamerton JL, Canning N, Ray M, Smith S. A cytogenetic survey of 14,069 newborn infants. *Clin Genet.* 1975;8:223–43.
35. Neilsen J, Wohlert M. Sex chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. *Hum Genetics.* 1991;87:81–3.
36. Price WH, Clayton JK, Wilson J, Collyer S, DeMey R. Causes of death in X-chromatin positive males (Klinefelter's syndrome). *J Epidemiol Community Health.* 1985;39:330–6.
37. Swerdloff AJ, Hermon C, Jacobs PA, Alberman E, Beral V, Daker M, Fordyce A, Youmings S. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: A cohort study. *Ann Hum Genet.* 2001;65:177–88.
38. Sasco AJ, Lowefels AB, Pasker-de Jong P. Epidemiology of male breast cancer: A meta-analysis of published case-controlled studies and discussion of epidemiologic factors. *Int J Cancer.* 1993;53:538–49.
39. Swerdloff AJ1, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA, United Kingdom Clinical Cytogenetics Group. Mortality in patients with Klinefelter syndrome in Britain: A cohort study. *J Clin Endocrinol Metab.* 2005;90:6516–22.
40. Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. *Br J Cancer.* 1995;71:416–20.
41. Lee MW, Stephens RL. Klinefelter's syndrome and extragonadal germ cell tumors. *Cancer.* 1987;60:1053–5.
42. French MA, Hughes P. Systemic lupus erythematosus and Klinefelter's syndrome. *Ann Rheum Dis.* 1983;42:471–3.
43. Berginer VM, Paran E, Hirsh M, Abelliovich D. Klinefelter's and Takayasu's syndromes in one patient—a pure coincidence? *Angiology.* 1983;34:170–2.
44. Armstrong RD, Macfarlane DG, Panayi GS. Ankylosing spondylitis and Klinefelter's syndrome: does the X chromosome modify disease expression? *Br J Rheumatol.* 1985;24:277–81.
45. Grossman CJ. Regulation of the immune system by sex steroids. *Endocr Rev.* 1984;5:435–53.
46. Bizzaro A, Valentini G, DiMartino G, et al. Influences of testosterone therapy on clinical and immunological features of autoimmune disease associated with Klinefelter's syndrome. *J Clin Endocrinol Metab.* 1987;63:32–41.
47. Hsueh WA, Hsu TH, Federman DD. Endocrine features of Klinefelter's syndrome. *Medicine (Baltimore).* 1978;57:447–61.
48. Neilsen J. Diabetes Mellitus in patients with aneuploid chromosome aberrations and the parents. *Humagenetik.* 1972;16:165–70.
49. Bardsley MZ, Falkner B, Kowal K, Ross JL. Insulin resistance and metabolic syndrome in prepubertal boys with Klinefelter syndrome. *Acta Paediatr.* 2011;100:866–70.
50. Geffner ME, Kaplan SA, Bersh N, et al. Insulin resistance in Klinefelter's syndrome. *Clin Res.* 1985;33:128A.
51. Aksgladade L, Link K, Giwercman A, Jorgensen N, Skakkebaek NE, Juul A. 47, XXY Klinefelter syndrome: Clinical characteristics and age-specific recommendations for medical management. *Am J Med Genet C Semin Med Genet.* 2013;163C:55–63.
52. Gravholt CH, Jensen AS, Host C, Bojesen A. Body composition, metabolic syndrome and type 2 diabetes in Klinefelter syndrome. *Acta Paediatr.* 2011;100:871–7.
53. Bojesen A, Host C. Gravholt CH Klinefelter syndrome, type 2 diabetes and the metabolic syndrome: The impact of body composition. *Mol Hum Reprod.* 2010;16:396–401.
54. Jorgenson RJ. The conditions manifesting taurodontism. *Am J Med Genet.* 1982;11:435–42.
55. Becker KL. Clinical and therapeutic experiences with Klinefelter's syndrome. *Fertil Steril.* 1972;23:568–78.
56. Campbell WA, Newton MS, Price WH. Hypostatic leg ulceration and Klinefelter's syndrome. *J Ment Defic Res.* 1980;24:115–7.
57. Campell WA, Price WH. Venous thromboembolic disease in Klinefelter's syndrome. *J Med Genet.* 1979;16:439–42.
58. Laron Z, Hochman H. Small testes in prepubertal boys with Klinefelter's syndrome. *J Clin Endocrinol Metab.* 1971;32:671–4.
59. Leonard JM, Bremner WJ, Capell PT, Paulsen CA. Male hypogonadism: Klinefelter and Reifensien syndrome. *Birth Defects.* 1975;11:17–22.
60. Matsumoto AM. Hormonal therapy of male hypogonadism. *Endocrinol Metab Clin North Am.* 1994;23:857–75.
61. Nielsen J, Pelson B, Sorensen K. Follow-up of 30 Klinefelter males treated with testosterone. *Clin Genet.* 1988;33:262–9.

62. Mackey MA, Conway AJ, Handelsmen DJ. Tolerability of intramuscular injections of testosterone ester in an oil vehicle. *Hum Repro.* 1995;10:862–5.
63. Nielsen J, Pelsen B. Follow-up 20 years later of 34 Klinefelter males with karyotype 47, XXY and 16 hypogonadal males with karyotype 46, XY. *Hum Genet.* 1987;77:188–92.
64. Lue YH, Wang C, Liu PY, Erkilli K, Swerdloff RS. Insights into the pathogenesis of XXY phenotype from comparison of the clinical syndrome with an experimental XXY mouse model. *Pediatr Endocrinol Rev.* 2010;1:140–4.
65. Palermo GP, Schlegel PN, Sills ES, et al. Births after intracytoplasmic injection of sperm obtained by testicular extraction from men with non-mosaic Klinefelter syndrome. *N Eng J Med.* 1998;338:588–90.
66. Ron-El, Friedler S, Strassburger D, Komarovskiy D, Schachter M, Raziel A. Birth of a healthy neonate following the intracytoplasmic injection of testicular spermatozoa from a patient with Klinefelter's syndrome. *Hum Repro.* 1999;14:368–70.
67. Nodar F, De Vincentiis S, Olmedo S, Papier S, Urrutia F, Acosta A. Birth of twin males with normal karyotype after intracytoplasmic sperm injection with use of testicular spermatozoa from a nonmosaic patient with Klinefelter's syndrome. *Fert Steril.* 1999;71:1149–52.
68. Gordon DL, Krmpotic E, Thomas W, Gandy HM, Paulsen CA. Pathologic testicular findings in Klinefelter syndrome. *Arch Intern Med.* 1972;130:726–9.
69. Okada H, Fujioka H, Tatsumi N, et al. Klinefelter's syndrome in the male infertility clinic. *Hum Repro.* 1999;14:946–52.
70. Foresta C, Galeazzi C, Bettella A, Marin P, Rossato M, Garolla A, Ferlin A. Analysis of meiosis in intratesticular germ cells from subjects affected by classic Klinefelter syndrome. *J Clin Endocrinol Metab.* 1999;84:3807–10.
71. Bergere M, Wainer R, Nataf V, Bailly M, Gombault M, Ville Y, Selva J. Biopsied testis cells of four 47, XXY patients: fluorescence in-situ hybridization and ICSI results. *Hum Reprod.* 2002;17:32–7.
72. Hennbicq S, Pelletier R, Bergues U, Rousseaux S. Risk of trisomy 21 in offspring of patients with Klinefelter's syndrome. *Lancet.* 2001;30:2104–5.
73. Vialard F, Bailly M, Bouazzi H, Albert M, Pont JC, Mendes V, Bergere M, Gomes DM, de Mazancourt P, Selva J. The high frequency of sperm aneuploidy in Klinefelter patients and in non-obstructive azoospermia is due to meiotic errors in euploid spermatocytes. *J Androl.* 2012;33:1352–9.
74. Greco E, Scarselli F, Minasi MG, Casciani V, Zavaglia D, Dente D, Tesarik J, Franco G. Birth of 16 healthy children after ICSI in cases of non-mosaic Klinefelter syndrome. *Hum Repro.* 2013;28:1155–60.
75. Modureira C, Cunha M, Sousa M, Neto AP, Pinho MJ, Viana P, Concalves A, Silva J, Teixeira da Silva J, Oliveira C, Ferraz L, Doria S, Carvalho F, Barros A. Treatment by testicular sperm extraction and Intracytoplasmic sperm injection of 65 azoospermic patients with non-mosaic Klinefelter syndrome with birth of 17 healthy children. *Andrology.* 2014;2:623–31.
76. Ploton L, Giscard d'Estaing S, Cuzin B, Brosse A, Benchaib M, Lornage J, Ecochard R, Dijoud F, Lejeune H. Preliminary results of a prospective study of testicular sperm extraction in young versus adult patients with non-mosaic 47, XXY Klinefelter syndrome. *J Clin Endocrinol Metab.* 2015;100:961–7.
77. Nahata L, Yu RN, Paltiel HJ, Chow JS, Logvinenko T, Rosoklija I, Cohen LE. Sperm retrieval in adolescents and young adults with Klinefelter syndrome: A prospective, pilot study. *J Pediatr.* 2016;170:260–5.

Peter A. Lee MD, PhD, Christopher P. Houk MD
and Jorma Toppari MD, PhD

Contents

Introduction	197	Infertility	206
Definitions	197	Germ Cell Counts (Unilateral and Bilateral)	208
Epidemiology	199	Age of Treatment and Fertility	208
Normal Development and Descent of the Testis	199	Spermatogenesis	208
Germ Cell Development and the Congenitally		Paternity and Related Factors	209
Cryptorchid Testis	202	Testicular Cancer	210
Ascended Testis	203	Tumors and Age at Orchidopexy	211
The Clinical Evaluation	204	Summary	212
Physical Examination	204	References	212
Laboratory Testing	204		
Treatment	205		
Surgical Treatment	205		
Hormonal Treatment	205		
Consequences of Cryptorchidism	206		
Hormone Production and Sexual Development	206		

Introduction

An undescended testis, the most appropriate term, is one that is not fully descended into the scrotum by 3 months of age. Undescended testes may be palpable or truly cryptorchid (hidden or non-palpable). It is usually unclear whether an innate defect of the testis caused non-descent or a normal testis has not descended because of a defect or obstruction. Regardless, of course, appropriate therapy involves surgical repositioning the cryptorchid testis into the scrotum because a non-scrotal position is associated with impaired spermatogenesis and malignant predisposition. When congenital, surgical correction is optimally done as soon as possible after 6 months of age. When a previously normally positioned testis is found to be non-descended (hence, an ascended testis), corrective surgery can be performed as soon as the diagnosis is verified. The major concerns relate to degeneration of germ cells, resulting in diminished spermatogenesis, and malignant transformation.

P.A. Lee (✉)
The Milton S. Hershey Medical Center
500 University Drive, P.O. Box 850,
Hershey, PA 17033-0850, USA
e-mail: plee@psu.edu

C.P. Houk
Department of Pediatrics Medical College
of Georgia, Georgia Rege University,
Augusta, GA, USA
e-mail: chouk@augusta.edu

J. Toppari
Department of Physiology Institute
of Biomedicine, University of Turku,
Department of Pediatrics, Turku University Hospital,
Turku, Finland
e-mail: jortop@utu.fi




Fig. 10.1 Undescended testes along the pathway of normal testicular descent into the scrotum, and ectopic locations. Illustration by Dr. James Grubola, Professor of Fine Arts, University of Louisville

Definitions

Cryptorchidism

The undescended testis, a physical finding, may or may not be visible or palpable. The testis may be palpated at various locations along the usual path of descent, or at ectopic locations that deviate from that path (Fig. 10.1). Etiologies are genetic, hormonal, anatomic, or metabolic, as occurring with galactosemia [1]. Unilateral non-descent accounts for more than 75% of cases, the remainder are bilateral [2–4]. It is important to

verify lack of descent, determine whether the maldescended testis was congenital, ascended, or acquired to exclude a retractile testis, particularly during the mid-childhood years when the cremasteric reflex is most pronounced [5].

Congenital cryptorchidism is present since birth. An **ascended testis**, documented to be descended at birth and during infancy, has subsequently ascended above the scrotal position during childhood. Commonly occurring from about 5 years of age until pubertal onset, ascent may be a consequence of atypically low activity of the hypothalamus–pituitary–testicular axis during childhood. A **retractile testis** that readily

retracts into a supra-scrotal position by the cremasteric reflex is considered a normal testis and usually resides in the scrotum. A continuum may exist so that retractile testis is the less-affected end of the spectrum of the ascended testis. In this review, cryptorchidism that occurs as a complication of inguinal area surgery or trauma is referred to as **acquired cryptorchidism** [6], although many reports have used the term “acquired” to refer to ascended testes in general, occurring without a previous insult.

A non-palpable testis may also indicate an **absent testis**, which is felt to be a consequence of agenesis, dysgenesis or an intrauterine accident such as occluded blood supply or testicular torsion (vanishing testis syndrome). Bilateral absence of the testes is referred to **anorchia**.

An **ectopic testis** is undescended and located elsewhere than along the normal pathway of descent (Fig. 10.1). The mechanism may be an abnormal primary attachment of the gubernaculum to structures other than the base of the scrotum, such as laterally or medially in the femoral, penile, or perineal areas.

Orchidopexy is the surgical relocation of the testis into the scrotum. It is the most successful therapy for cryptorchidism, while hormonal therapy is not recommended.

Epidemiology

The prevalence of cryptorchidism is 2–9% in full-term infants [7–14]. Among premature infants, the prevalence is as high as 21%, but diminishes with advancing gestational age and increasing birthweight. It is also noteworthy that there is an increased prevalence of both cryptorchidism and hypospadias among those born early and with low birthweights, although these findings may be more likely to be associated with a more pervasive development defect [15]. As a consequence of spontaneous descent after birth in both the term and premature infant, the prevalence of cryptorchidism

Table 10.1 Prevalence of cryptorchidism in relation to age and gestational age [7, 8, 10, 12]

<i>At birth</i>	
Overall	2.7–6.7%
Bilateral	3.0%
Unilateral	1.9%
<i>Related to birth and gestational age</i>	
>2500 grams	2.7–5.5%
<2499 grams	21.0–28.9%
>37 weeks	2.1%
<i>At 3 months of age</i>	
Overall	0.9–1.6%
3 months from EDC	1.3%
<i>Based upon birthweight</i>	
<2000 gm	7.7%
2000–2500 gm	1.7–4.6%
>2500 gm	0.9–1.4%

decreases to approximately 1–2% by 3 months of age (Table 10.1) [14, 16]. Spontaneous descent is more likely among boys who weigh <2500 g at birth or are gestational age <37 weeks [8]. The likelihood of descent in the 3 months after birth is greater for bilateral maldescent and if the scrotum is large and well developed at birth [7, 9].

After the age of one year, the prevalence of non-descent ranges from 0.7 to 2.0% of males with unilateral and bilateral cryptorchid testes [3, 7, 9, 14, 17, 18], similar to the 0.82% found among untreated Nigerian schoolboys aged 5–13 years [19].

The incidence of cryptorchidism and other urogenital malformations has been reported to have increased in recent decades. The estimated prevalence varies considerably in different regions [20, 21], however, perhaps from different levels of exposure to anti-androgenic chemicals, with hormone-disrupting actions, such as pesticides and phthalates [22]. Increasing incidence trends have been reported from Denmark and the United Kingdom [9, 10, 14, 23, 24]. These studies used rather similar diagnostic criteria for the ascertainment of cryptorchidism, the children

having been prospectively examined by trained researchers.

Normal Development and Descent of the Testis

Testicular development involves a cascade of sequential steps under the control of numerous genes [25]. Several transcription factors are known to contribute to the initial development of the adrenogenital primordium [26, 27] including *EMX2* (*Empty Spiracles 2*), *LHX1* (*Lim Homeobox Gene 1*), *WT1* (*Wilms Tumor 1*), and *WNT4* (*Wingless-type MMTV Integration Family Member 4*). Mutations in these genes cause agenesis or dysgenesis of the gonads, adrenal glands, and the urogenital system. Further development to the bipotential gonad requires *LHX9* (*Lim Homeobox Gene 9*), *NR5A* (*Nuclear Receptor Subfamily 5 Group A Member*; previously called *SF1*, *Steroidogenic Factor 1*), *GATA4* (*GATA Binding Protein 4*), *DMRT1/2* (*Doublesex- and Mab3-related transcription factor*), and *CBX2* (*Chromobox Homolog 2*).

The primordial germ cells (PGCS) migrate from the epiblast to the developing gonadal ridge under the guidance of Kit ligand and c-Kit receptor interaction [28]. Soon thereafter, testicular differentiation of the gonad is initiated by the *SRY* gene product (*Sex determining region of the Y-chromosome*) [29]. Expression starts in the somatic cells that differentiate into Sertoli cells forming the seminiferous cords [30]. Peritubular myoid cells surround the cords, and Leydig cells develop in the interstitial space. The Sertoli cells regulate testicular development. *SRY* regulates *SOX9* (*SRY-box Containing Gene 9*) in the Sertoli cells which determines the gonadal structure [31]. If *SRY* is missing (as in 46, XX), *WNT4* and *RSPO1* (*R-spondin 1*) lead the gonadal development toward the ovary [32]. *FOXL2* (*Forkhead box L2*) is necessary for the maintenance of the ovary. *SOX9* regulates the production of fibroblast growth factor 9 (*FGF9*) and prostaglandin D2 (*PGD2*) in Sertoli cells, and these reciprocally stimulate *SOX9* expression. *SOX9* and *FGF9* together inhibit the ovarian

genes *WNT4*, *RSPO1* and *FOXL2* that, in turn, suppress *SOX9*. Thus, there is a complex gene interaction network in the gonads securing normal development, and if this fails, gonads may become dysgenetic [32].

Sertoli cells secrete growth factors that influence Leydig and peritubular myoid cell differentiation, such as Desert hedgehog (*DHH*) and platelet-derived growth factors (*PDGF*). After differentiation, Leydig cells start to secrete testosterone and insulin-like peptide 3 (*INSL3*) which masculinize the genital structures and regulate testicular descent into the scrotum. Placental human chorionic gonadotropin and pituitary luteinizing hormone stimulate Leydig cell differentiation, proliferation, and hormone production.

Sertoli cells also secrete anti-Müllerian hormone (AMH) from the 7th week of gestation [33], which leads to the involution of Müllerian ducts. AMH is an excellent marker of the presence of testicular tissue in an infant.

Other developmental events that relate to testicular descent involve the formation of associated ducts, the gubernaculum, and the tunica vaginalis (the serous membrane covering a portion of the testes and epididymis). The gubernaculum develops from mesenchyme, becoming a ligamentous band of tissue that connects the lower end of the epididymis and the base of the scrotum. The processus vaginalis, a peritoneal out-pocketing next to the internal inguinal ring adjacent to the gubernaculum, elongates progressively through the inguinal canal. The testicular ductal system develops from the paired Wolffian ducts under testosterone stimulation, with the portion adjacent to the testes becoming rete testes with ejaculatory ducts at the distal end. Concomitantly, dihydrotestosterone produced in target tissues, such as fetal genital skin, by 5-alpha reductase type 2, *SRD5A2*, stimulates male external genital differentiation.

Testicular descent [34, 35] occurs after a morphologic reorientation repositions the testis caudally at the level of the lower pole of the metanephric kidney. Then, trans-abdominal migration relocates the testis from the posterior abdominal wall to the inguinal region, accomplished by 15 weeks of fetal life, followed by

trans-scrotal migration. Cranial suspensory ligament regression allows both relative intra-abdominal testicular repositioning and trans-inguinal migration. Androgen control of this process is implied by the persistence of intra-abdominal testes in patients with androgen insensitivity syndrome [36], failure of regression in animals treated with an anti-androgen [37], and cranial ligament regression in female animals treated in utero with androgens [38].

Trans-inguinal migration through the inguinal canal to the base of the scrotum occurs after 26 weeks of fetal life [39]. Descent is usually accomplished by the 32nd week but may not be fully complete until post-natal life. Concomitantly, the testis carries the processus vaginalis into the scrotum. Leydig cell-derived insulin-like peptide 3 (*INSL3*) regulates gubernacular development and regression together with androgens [40]. This androgen-dependent phase involves the gubernaculum, cremaster muscles, the genitofemoral nerve, neurotransmitters, cytokines, intra-abdominal pressure, and epididymal maturation. Some patients with maldescent fail to have attachment of the epididymis to the testes [41]. The gubernaculum, which is intertwined with cremaster muscle, plays a role [42, 43], regressing, perhaps creating a relative negative pressure toward the inguinal canal, concomitant with trans-inguinal migration [42].

It is recognized that the factors causing testicular descent are complex and incompletely understood. Androgen stimulation involves paracrine factors and catabolic enzymes such as acid phosphatase that stimulate gubernacular regression [44]. Animal studies suggest a role for the genitofemoral nerve [45]. In spite of these potential genetic regulators, identifiable genetic causes of cryptorchidism are rare. While *INSL3* plays a role in establishing gonadal position in animals [46], mutations in the coding region of the *INSL3* gene do not appear to commonly cause human cryptorchidism [47]. It has been shown that RXFP2 (relaxin family peptide receptor 2), a receptor of *INSL3*, is required for gubernacular development and is necessary for testicular descent [48]. Polymorphisms in the

RXFP2 gene may play a role in undescend [49]. Systemic factors may be more frequent with bilateral cryptorchidism while paracrine regulators may be disrupted when only one testis is undescended. Anatomic problems precluding descent could include a detached epididymis [40], testicular-splenic, or testicular hepatic fusion [50]. Inguinal hernia is a common finding with cryptorchidism and is more likely a result than a cause of maldescent.

A **hormonal role** (gonadotropin-stimulated testosterone production) in testicular descent has been postulated for many years, [51] although factors controlling testicular descent are clearly more complicated. Animal data are consistent with time-specific androgen stimulation of both the abdominal and inguinal phases of descent [52, 53]. Orchidectomy will halt gubernacular regression, and estrogen treatment prevents testicular descent in animals, perhaps via down-regulation of *INSL3* expression [54–57].

The testis secretes AMH by the 8–9th fetal week, followed within a week by Leydig cell testosterone production, and by week 12, the hypothalamic-pituitary-testicular (HPT) axis is functional to play a crucial role in final testicular descent [58]. After a decline from about week 17 to term, the HPT axis is reactivated in the first few months after birth, with near adult circulating levels of testosterone at one to three months of age although much of the circulating testosterone is bound to sex hormone binding globulin, with values approaching those seen in men, at this stage of development [59]. This may stimulate spontaneous descent of undescended testes occurring at this age. Failure of spontaneous descent after 6 months of age may be related to diminished hormone levels.

There are contradictory reports of hormonal levels in boys with cryptorchid testes. Early studies reported decreased testosterone levels in cryptorchid infants [60] or preterm cryptorchid infants [61] compared with babies without cryptorchidism, possibly a result of diminished LH secretion [62, 63]. However, more recent research using more sensitive assays has not confirmed that result [64]. A prospective study

that compared hormone levels at 3 months of age during “minipuberty” in cryptorchid and control boys reported different results between Danish and Finnish boys. The Finnish group of cryptorchid boys had slightly elevated LH and FSH levels but lower inhibin B levels as compared with non-cryptorchid boys, while among the Danish neonates with cryptorchidism, only FSH levels were significantly higher than in non-cryptorchid boys. Inhibin B levels were lower in both Danish cryptorchid and control newborns than in boys in Finland [65] while testosterone levels did not differ between the groups. When androgen bioactivity was measured in a recombinant cell bioassay, however, all 3-month-old boys with measurable bioactivity had fully descended testes, while all 16 boys with testicular position in the inguinal canal or higher had unmeasurable androgen bioactivity [66]. The explanation for these provocative findings is unclear but may relate to the sensitivity of the testosterone radioimmunoassay or differences between populations, and deserves further study. AMH levels have also been reported to be diminished among boys with cryptorchidism [67], suggesting a role for AMH in testicular descent or a consequence of dysfunctional testis. During childhood after the completion of minipuberty, physiologically low LH, FSH, and testosterone levels among cryptorchid boys are not different from values in boys without cryptorchidism [64].

An older report of diminished LH responses to GnRH stimulation among prepubertal boys with undescended testes [68] has led to the unsubstantiated suggestion of mild hypogonadotropic hypogonadism (HH) among cryptorchid boys during childhood. Although patients with congenital HH often do have cryptorchidism, HH is rare among adults with a history of cryptorchidism [69]. Elevated FSH levels during the peripubertal period in some cryptorchid boys suggest instead partial gonadal failure [70], perhaps a consequence of maldescent during childhood. Inhibin B levels vary considerably among boys, and those with cryptorchidism generally have levels within the reference range [71].

Germ Cell Development and the Congenitally Cryptorchid Testis

At birth, the numbers of germ cells in cryptorchid testes has been reported to be similar to those in descended testes [72, 73]. However, after the transformation of gonocytes into adult dark (AD) spermatogonia which begins between 3 and 9 months of age, the undescended testis has fewer AD spermatogonia. **This apparent diminished transformation resulting in diminished germ cells provides the primary rationale for early surgical intervention [74].** Further, regarding the risk of tumor development, intra-tubular germ cell neoplasia in situ (GNIS) in the second and third decades contain enzymatic markers similar to neonatal gonocytes, suggesting that failure of transformation into AD spermatogonia may result in testicular tumors. Testes that remain cryptorchid beyond infancy acquire a progressively more abnormal microscopic appearance [75–79] with progression with increasing age [80]. Comparison of findings at 9 months and 3 years (see below) confirm these differences and document that orchidopexy at the earlier date reverses the process [81]. The poorer growth of the cryptorchid testis that results in diminished volume compared with descended testes is also reversed by spontaneous or surgical descent [82].

The study comparing germ cells in testes with orchidopexy at 9 versus 36 months [81, 82] is the most compelling evidence for the age of recommended surgery for the congenital cryptorchid testis, even though this study could not be fully controlled since cryptorchidism is an outcome of a set of heterogeneous disorders [83]. The recommendation for orchidopexy is between 6 and 12 months of age because spontaneous descent is unlikely to occur after 6 months of age while there is progressive loss of germ cells after 12 months of age. The dramatic reduction in germ cell number between 9 and 36 months of age (Fig. 10.2) provides a clear indication for earlier surgery that is beneficial for testicular growth and germ cell development [84, 85]. Other studies have




Fig. 10.2 Mean germ cell numbers in testicular biopsy specimens among boys having unilateral, bilateral, and intra-abdominal testes at surgery at 9 months and 3 years. Data (mean + SD at 9 months respectively) 96.1 + 68.7, 69.7 + 49.2, 106.6 + 79.0 and at 3 years 9.8 + 21.3, 10.2 + 13.1, 2.2 + 3.4

verified these results [86–88]. An assessment of hormones and semen in adult men born with cryptorchidism who had bilateral biopsies at orchidopexy found that more severe histopathology tended to be associated with lower sperm density and higher FSH levels [89], although the association was not statistically significant perhaps because of the small sample size and wide age range at surgery. In clinical practice, biopsy at orchidopexy has not been shown to have value in predicting future fertility.

It has been theorized for some time that diminished germ cells of the undescended testis might be a consequence of relative gonadotropin deficiency, and hence, GnRH might be a beneficial adjunct therapy after orchidopexy. Pooled effect estimates in a meta-analysis of comparative clinical trials indicated that cryptorchid children treated with GnRH had a higher number of germ cells per seminiferous tubule at various prepubertal ages after biopsy when compared with controls [90]. This suggests that some boys with cryptorchidism may benefit from GnRH treatment as adjunctive to orchidopexy in improving the fertility index. However, longer outcome follow-up is necessary to determine if fertility is increased.

Ascended Testis

Ascent during childhood of a previously normally descended testis (acquired undescended testis) occurs when the testis becomes tethered above the scrotum in an unacceptable position. Acquired UDT is seen in 1–3% of boys during childhood. This may occur among some boys with a retractile testis due to spasticity of the cremaster muscle, or as a consequence of improper elongation of the spermatic cord due to fibrous remnant of the processus vaginalis [23, 91–96]. It is now widely accepted that testes may ascend from the full scrotal position during early- or mid-childhood years inasmuch as boys with undescended testes have been reported whose medical records clearly documented descended or retractile testes that become persistently above the scrotal location [97–100]. The age distribution at orchidopexy is bimodal, with an initial and larger peak within the first five years of life, and a second peak between 8 and 11 years of age. This distribution could be a consequence of acquired cryptorchidism or ascending testes [101]. The pathogenesis of the acquired undescended testis is unclear. It has been suggested that ascending testis may occur more frequently among boys born with undescended testes that undergo spontaneous descent in early infancy by 3 months of age [102]. There is also a suggestion that altered feeding patterns (decreased breast feeding and use of soy formulas) may increase the incidence of ascending cryptorchidism [103], although this has not been confirmed.

Previously, it was felt that ascending testes had the potential for normal function. Since most boys with ascending cryptorchidism have spontaneous testicular descent during puberty [104, 105], surgery was traditionally deferred and performed only in those boys in whom spontaneous descent failed to occur at puberty [106]. One retrospective study involved 2 groups of adult men with a history of ascending testes: group 1 had orchidopexy for lack of spontaneous descent at ages 4.75–17.8 years ($n = 26$) while group 2 represented men with spontaneous testicular descent during puberty ($n = 32$) [107]. Overall, men who had unilateral ascent had

smaller testes, lower sperm concentration and progressive sperm motility, and softer testicular consistency than control men. No significant differences in fertility parameters were found between men with spontaneous descent versus those with orchidopexy. Those who had bilateral ascent also had smaller mean testicular volume and softer testicular consistency, but also a lower paternity rates, higher LH and FSH and lower inhibin B levels, and reduced sperm concentrations and progressive motility than control men. This latter group was not different from men who had bilateral congenital cryptorchidism. Testicular volume, reproductive hormones, semen quality (better for unilateral than bilateral), and successful paternity rates did not differ between the groups. Small testicular size for age of ascending testes was noted at surgery [108]. Testicular volumes smaller than normal for age by ultrasonography were observed at follow-up after operation in boys and men who had previously been treated with orchidopexy at diagnosis of uni- or bilateral ascended cryptorchidism ($n = 155$) [109]. Testicular size of ascended undescended testes estimated by orchidometer after spontaneous descent at puberty ($n = 494$) or after pubertal orchidopexy ($n = 85$) found that >90% had volumes within normal limits, while in over 50% of unilateral cases the affected testis was smaller at follow-up than the other testis that had always been descended [110]. An evaluation of men with unilateral cryptorchidism who delayed surgery until age 20–30 years found severe maturation arrest (22%), germinal cell aplasia (70%), or tubular atrophy (8%) in the orchidectomy specimens, and no differences in semen parameters or testosterone levels before or after surgery suggesting that testicular function by this age was essentially from the descended testis [111].

A reduced number of germ cells per tubule have been reported in unilaterally ascended testis and also in the normally descended contralateral testis [112], which is interpreted as an innate defect in testicular development in both testes in unilateral as well as bilateral cryptorchidism. By contrast, when a testis is found to be absent, the contralateral descended testis often has an

increased volume, increased germ cell proliferation, and dissimilar maturation patterns compared with the contralateral descended testis of patients with unilateral cryptorchidism. These findings do not suggest an underlying endocrinopathy or other testicular defect, or risk of infertility for patients with a solitary testes [113]. In a systematic follow-up of testicular growth in puberty, testes that had been cryptorchid (either unilateral or bilateral) grew slower and remained smaller than descended testes, and there was no compensatory growth in the contralateral testis as compared with control [114]. In contrast, testes of monorchid boys were larger than control.

The Clinical Evaluation

Physical Examination

If the scrotum is empty, it is fundamental to decide whether the testis is present or not. Repeated physical examinations may be necessary if it is unclear whether a testis is present, or to determine the location of a palpable testis. Incompletely descended testes are not usually fixed in position. A testis may at one examination be just palpable at the internal inguinal ring, and on another occasion be impalpable, or the location may be high scrotal on one occasion and within the inguinal canal on another. Also, the location upon physical examination may differ from that when the patient is under general anesthesia in preparation for surgery. If a testis is not palpable, laparoscopy may be used to determine not only its presence, but also its location [115, 116].

In a prepubertal male, confirmation of an undescended testis often requires two physical examinations because of intra- and inter-observer bias in diagnosing undescended testes [115]. After 6 months of age, the cremasteric reflex is active, and the testes readily retract into the upper scrotum, or even to the external inguinal ring if a boy is anxious, nervous, or cold, all of which are common occurrences during a medical examination. A careful physical examination is essential to determine whether a testis is cryptorchid or

retractile [117]. A retractile testis is diagnosed when a testis can be pulled into the scrotum and held there for a brief period, after which it does not immediately retract.

Laboratory Testing

LH, FSH, and T levels are measured in the newborn, during infancy from 6 weeks to 4 months, and at puberty to exclude hypogonadotropic hypogonadism. Inhibin B levels may also be useful [118]. When neither testis is palpable, hormone stimulation, usually with hCG, is also useful since a rise in the serum testosterone level indicates the presence of functional Leydig cells. AMH levels can also be used as an index of Sertoli cell mass [119].

Treatment

An evaluation and treatment guideline for cryptorchidism was recently published by the American Urological Association [120]. Imaging for cryptorchidism is not recommended prior to referral, which should occur by 6 months of age. Orchidopexy is the most successful therapy to relocate the testis into the scrotum, while hormonal therapy is not recommended. Successful scrotal repositioning of the testis may reduce but does not prevent the potential long-term issues of infertility and testis malignancy. Appropriate counseling and follow-up of the patient is essential.

A Nordic consensus on treatment of undescended testes was published in 2007 summarizing current information and making treatment recommendations [119]. These include a recommendation against hormonal treatment based upon poor results and the possibility of long-term adverse effects upon spermatogenesis, and recommend orchidopexy between 6 and 12 months of age, or at diagnosis, if later, to be performed by pediatric urologist/surgeons with pediatric anesthesiologists.

The rationale for treatment of cryptorchidism includes the increased risk of infertility and testicular cancer and the need to correct hernias and decrease the risk of torsion. While bilateral cryptorchidism is associated with infertility if the testes remain undescended beyond puberty, the beneficial effect on fertility of orchidopexy during childhood has not been definitively shown [121]. However, the benefit of reducing the risk of malignancy is assumed. For boys with unilateral cryptorchidism, it has been questioned whether treatment to bring the testis into a scrotal location influences fertility since the percentages of men with azoospermia or oligospermia have been reported to be similar for men with surgical treatments or no treatment [121]. However, the question of whether early surgery is beneficial has not been verified since outcome data are for those whose surgery was generally at ages considerably older than is recommended currently. While semen analysis may be abnormal, evidence (see below) suggests that paternity rates have not been shown to differ from control men [122].

Surgical Treatment

Diagnostic laparoscopy can be used to determine the location of a non-palpable testis and, if needed, to complete orchidopexy [116]. The diagnostic laparoscopy is used to plan the surgical approach, and when no evidence for a testis or associated vasculature is found, it will prevent unnecessary open surgical exploration [116]. Surgical therapy for the palpable undescended testis is commonly orchidopexy using a transverse groin incision over the internal ring, incising the external oblique aponeurosis lateral to the external ring. The testis is located and together with the spermatic cord is freed and placed into the scrotum. Success rates are related to whether the testis was palpable or not, the age at surgery, and the choice of surgical procedure. Success rates are generally greater than 90%, being somewhat lower for abdominal testes [119].

Hormonal Treatment

While human chorionic gonadotropin (hCG) testing is used in bilateral cryptorchid patients with non-palpable testes for diagnostic purposes [123], it is not currently recommended as a treatment modality. When descent occurred with such hormonal therapy, it was seldom permanent [124, 125]. Furthermore, hCG treatment has been associated with inflammatory changes in the testes and long-term adverse effects on germ cell development [126–129]. Hormonal treatment can be considered for patients in whom the testis is in the upper scrotum, or with a high likelihood of retractile testes that cannot be confirmed by routine physical examination or those with a high anesthesia risk. Infants with hypogonadotropic hypogonadism can also be treated with gonadotropins during minipuberty, which may induce testicular descent.

Consequences of Cryptorchidism

Hormone Production and Sexual Development

Testosterone levels are generally normal in adult men who were cryptorchid [130, 131, 133]. A minority of formerly unilateral cryptorchid men has elevated FSH and inhibin B levels, however, while inhibin B levels are lower among formerly bilaterally cryptorchid men than controls, and correlate inversely with other markers of fertility, including FSH, LH, total and free testosterone, sperm density, and sperm motility/morphology. FSH levels for men with bilateral and unilateral cryptorchidism are compared with results in control men in Fig. 10.3. Few formerly unilateral cryptorchid men had elevated FSH and low inhibin B levels, while the majority of men who had orchiopexy for bilateral cryptorchidism had elevated FSH and low inhibin B levels. Figure 10.4 shows that FSH levels are inversely related to sperm density, a relationship that has also been reported elsewhere [132]. There is also a positive relationship




Fig. 10.3 Circulating FSH levels among formerly cryptorchid men compared with control men. The majority of men in the unilateral group have FSH levels within the normal range while almost half of men who had bilateral cryptorchidism had elevated FSH levels

between inhibin B levels and sperm density for formerly unilaterally cryptorchid men (Fig. 10.5).

Testosterone production in cryptorchid patients results in full stimulation of growth and pubertal maturation of androgen-responsive tissues [133]. Compensatory hypertrophy of the non-affected testis in unilateral cryptorchidism, or in the less-affected testis in bilateral cryptorchidism, may or may not occur, either before or after correction of the cryptorchidism [115, 134]. Catch-up testicular growth may occur after orchidopexy, and mean testicular volume for men with corrected unilateral maldescent is usually within the normal adult range [135] although the undescended testis in unilateral cryptorchid boys remains smaller than their descended testis [115].

Among men with idiopathic infertility, there is a significant positive correlation between testicular volume and indices of spermatogenesis (sperm density and motility), and an inverse relationship with serum FSH levels [137]. On the other hand, no correlation has been found between testicular volume at orchidopexy and paternity, hormone levels, sperm counts, and testicular volume in adulthood in either unilaterally or bilaterally cryptorchid men [89].

Fig. 10.4 Inverse relationship between FSH levels and sperm density among formerly cryptorchid men





Fig. 10.5 A direct relationship is present between Inhibin B levels and sperm density among formerly unilateral cryptorchid men



Infertility

While the mechanisms remain incompletely understood, the abnormalities in germ cell development in cryptorchidism lead to diminished sperm count and poor sperm motility that increase the risk for infertility.

Germ Cell Counts (Unilateral and Bilateral)

In men with bilateral orchidopexy between 10 and 16 years of age [136, 137], germ cell counts at biopsy at the time of orchidopexy were positively correlated with adult sperm density and combined testicular volume although the percentage of tubular sections containing spermatogonia did not predict sperm density in adulthood [138]. Assessment after orchidopexy when unilateral or bilateral cryptorchidism was performed before 2 years of age [139, 140] found that two-thirds of men, the portion having biopsy evidence for the second stage of maturation to adult dark (Ad) spermatogonia, had normal sperm density. An age relationship was found: all with orchidopexy and biopsy before age 2 years had germ cells, while there was an increased risk for germ cell absence with orchidopexy at older ages [141]. Among boys with good fertility potential (normal numbers of tubular germ cells and normal gonadotropin and inhibin B levels), the mean number of adult dark spermatogonia was significantly greater than in those with low fertility potential [142]. The relationship between sperm density (million/ml) after bilateral cryptorchidism for men who had testicular biopsy at orchidopexy during the first 2 decades of life [83] demonstrating germ cell loss and normal or abnormal adult dark spermatogonia is shown in Table 10.2.

Age of Treatment and Fertility

Because of progressive damage to germ cells over time, earlier treatment is believed to improve fertility [143]. Age at orchidopexy and sperm concentration is inversely related; however,

Table 10.2 Median and range of sperm density (million/ml) after bilateral cryptorchidism for men who had testicular biopsy at orchidopexy during the first 2 decades of life [83]

Category	Median	Range
Mild	37	0–83
Severe	1	0–58
Normal adult dark	58	0–127
Abnormal adult dark	1	0–58

Germ cell loss was categorized as mild, moderate, severe, and normal or abnormal adult dark spermatogonia. No significant differences were noted for any group

published data do not consistently suggest a better prognosis for fertility with earlier surgery although few subjects have had surgery at a very young age [144]. Surgery before age 8 years in one series showed a better prognosis [145], while a second study found no difference among men with unilateral or bilateral cryptorchidism treated before 7 years [146]. A comparison of cases in which surgery was performed between 2 and 7 years of age versus 10 and 12 years of age also found no difference in fertility potential [147]. However, in one report [148] of formerly cryptorchid men who had surgery in the first 2 years of life, the percentage with normal sperm counts and motility exceeded 95%, with an even better fertility prognosis if orchidopexy was performed in the first year of life, with no significant difference between the patients with bilateral or unilateral cryptorchidism.

Spermatogenesis

Using semen analyses as an index of fertility, variable results among men who had cryptorchidism suggest considerable differences in fertility potential. Sperm density was found to be normal in only 4% of men with bilateral maldescent, and in 23% with unilateral cryptorchidism [131], consistent with other reports [130, 149]. Sperm density for formerly bilateral or unilateral cryptorchid men compared with control men is shown in Fig. 10.6. After unilateral cryptorchidism, it appears that the formerly undescended testis may have little sperm production




Fig. 10.6 Sperm density among formerly cryptorchid men shows diminished levels among formerly bilaterally cryptorchid men while the majority from the unilateral group is normal. Note that control men are men who did not have cryptorchidism but may have reproductive abnormalities

however, since a novel study of men after unilateral vasectomy of the unaffected normally descended testis revealed that most had azoospermia or very low sperm density [149, 150].

Paternity and Related Factors

Paternity rates (attempted at least 12 months, with and without success) among men with orchidopexy for uni- or bilateral cryptorchidism

were compared with a control group of men matched for age at operation for non-reproductive system [2, 3, 151]. Differences of sperm density related to successful paternity are shown for these groups (Fig. 10.7), together with percentages of men from the Pittsburgh cohort together with composite literature reports (Fig. 10.8).

Rates were significantly reduced among formerly bilaterally cryptorchid men (success rate 65% of 49 men). However, no significant difference was found between formerly unilaterally cryptorchid men and controls (success rates 90% of 359 men and 93% of 443 men, respectively). The men in these studies were operated on between 1955 and 1975, and their age ranged from one month to adolescence at the time of operation. Hence, cases with both congenital and ascended cryptorchidism were likely included. Among the formerly unilaterally cryptorchid men, no significant association was observed between the age at orchidopexy, successful paternity or sperm concentration [2, 152]. Inhibin B levels correlated negatively and FSH levels correlated positively with age at operation ($n = 84$), with men operated by the age of two years ($n = 10$) having higher inhibin B levels, which suggests a beneficial effect of earlier orchidopexy. Inhibin B levels correlated positively with sperm concentration ($n = 117$, with no association among control men ($n = 58$)).






Fig. 10.7 Sperm density compared with success at attempted paternity for formerly unilateral cryptorchid men and control men

Fig. 10.8 Paternity data from a meta-analysis of reported cases and patients from the Pittsburgh cohort. The first 2 columns are from formerly unilaterally cryptorchid men, the next two from formerly bilateral cryptorchid men, and the final column the control group from the Pittsburgh study



[153]. Furthermore, early orchidopexy may benefit adult-age Leydig cell function insofar as a weak negative association between age at orchidopexy and testosterone levels among adult men with a history of operated unilateral cryptorchidism was found ($n = 105$) [154]. Men with a single testis (due to absence or orchiectomy) have similar success rates in attempted paternity as men who have been treated surgically for unilateral cryptorchidism during childhood or control men [155].

Another survey of attempted paternity among 94 men with unilateral or bilateral cryptorchidism who had surgery during childhood [156] found 34 of 53 men (64%) had succeeded within 12 months of attempted pregnancy, with subsequent success after longer attempts in 19%, and no success for 17%. Because uni- and bilateral groups were assessed together, these data do not allow a comparison between these groups.

Testicular Cancer

An increased risk for testicular cancer is a second major potential consequence of cryptorchidism. The origin of malignant cells appears to be germ cells that remain in the early stages of differentiation. This may be a consequence of excessive proliferation of precursor germ cells with associated loss of intercellular communications [157] or a failure of maturation of these precursors. Testicular germ cell neoplasia in situ (GNIS; previously called carcinoma-in situ, CIS) precedes germ cell tumor [158], although it is not clear that all instances of GNIS ultimately develop into tumors. Placenta-like alkaline phosphatase antibody-positive cells (a marker of both undifferentiated germ cells and unclassified germ cell neoplasia) have been identified at biopsy during orchidopexy at young ages [159].

A recent meta-analysis found an overall cancer risk of 2.90-fold (95% CI-2.21-3.82), with heterogeneity related to laterality, surgery, age of surgery, and unilateral or bilateral [160]. Reports of the increased risk of tumors in males with cryptorchidism vary from 4-fold to tenfold [161] and suggest a lifetime risk that is 4–5 times greater than in the general population [162, 163], with odds ratios of 9.3 with bilateral cryptorchidism, and 2.4 for unilateral. A much greater cancer risk is present among men with uncorrected cryptorchidism (RR 15.9 or 11/69) [164].

The rate of development of testicular cancer has typically been assessed as the proportion of testicular cancer patients with a history of cryptorchidism, rather than the percentage of formerly cryptorchid men who develop testicular tumors. In either situation, the risk may differ depending upon the inclusion of patients with unilateral or bilateral cryptorchidism, age and mode of therapy, occurrence of spontaneous descent or ascent, location of the undescended testis, and the presence of other developmental anomalies.

A case-control study of men with testicular germ cell tumors found a significant association with cryptorchidism, with an odds ratio of 3.82 [165]. The odds ratio was 5.86 for bilateral, and 2.71 for unilateral cryptorchidism. When the men in the unilateral group who developed a tumor in the contralateral testis were assessed separately, the odds ratio for the affected previously undescended testis was 4.02, and for the unaffected testis was 1.42. Positive associations with testicular cancer for the entire population, not just those who had cryptorchidism, were also noted for early onset of puberty (voice change, shaving), infertility, and a sedentary lifestyle. A protective effect of exercise was found, but no association with vasectomy was identified.

An increased cancer risk is likely among boys with intra-abdominal testes, an abnormal karyotype, abnormal external genitalia, and the presence of malignant precursor cells [166].

Tumors and Age at Orchidopexy

Testicular cancer may have its origin in the fetus when germ cell development is abnormal and GNIS—cells form inside seminiferous cords and begin to proliferate during puberty to appear as cancer in young men [167]. If so, surgical correction of cryptorchidism may not influence the risk of testicular cancer dramatically. While there are reports suggesting that treatment of cryptorchidism before puberty is beneficial compared with post-pubertal surgery [168, 169], even the small benefit was challenged in another large registry study [170]. Thus, it is not clear whether bringing the testis into a scrotal location reduces the risk of testicular cancer. When age at correction was considered for patients with previous unilateral cryptorchidism, no increased risk of cancer was found for those who had successful surgery before the age of 10 years (odds ratio 0.60), whereas the risk was increased with surgery at age 10 years or older (odds ratio 6.75). It is noteworthy that the risk associated with undescended testes was eliminated in that study by orchidopexy before the age of 10 years. In addition, there was a significant association between age at orchidopexy (age 3 to >14 years) and risk of cancer. Data are not sufficient to assess whether there is a risk for the contralateral testis in unilateral cryptorchidism.

Although the benefits of orchidopexy in reducing the risk of neoplasia may be uncertain, the general view is that bringing the testis into a scrotal or near scrotal position is indicated. A scrotal position would allow for earlier detection of physical changes that might indicate malignancy. For this reason, orchidopexy has been recommended even for post-pubertal males who are healthy except for cryptorchidism since the risk of malignancy is considered to exceed the perioperative morbidity and mortality [171]. Most recommend biopsy of the testis at the time of orchidopexy in pubertal and post-pubertal boys.

Summary

Cryptorchidism, the condition in which one or both testes have not descended fully into the scrotum, is one of the most frequent developmental anomalies of the human male. Although there is spontaneous descent in the first few months of life in many males born with this condition, the prevalence thereafter is about 1%. Genetic direction of testicular descent remains poorly understood. There are multiple etiologies of cryptorchidism, both anatomic and hormonal, with some testes having the potential for normal function.

The life-long consequences of cryptorchidism are poor semen quality and increased risk for testicular cancer. Germ cells in the undescended testis fail to undergo normal differentiation from early infancy, hence the recommendation for surgical treatment between 6 and 12 months of age. Men born with bilaterally undescended testes frequently have decreased inhibin B and elevated FSH levels and have a substantially reduced paternity rate. By contrast, only a small portion of men who had unilateral cryptorchidism remain infertile. The risk of developing a testicular tumor, primarily of germ cell origin, is increased substantially particularly among the bilateral group and those not corrected before puberty.

References

- Gubbels CS, Welt CK, Dumoulin JC, Robben SG, Gordon CM, Dunselman GA, Rubio-Gozalbo ME, Berry GT. The male reproductive system in classic galactosemia: cryptorchidism and low semen volume. *J Inherit Metab Dis*. 2013;36(5):779–86. doi:10.1007/s10545-012-9539-1 Epub 2012 Oct 11.
- Lee PA, O'Leary LA, Songer NJ, Coughlin MT, Bellinger MF, LaPorte R. Paternity after unilateral cryptorchidism. *Pediatrics*. 1996;98:676–9.
- Lee PA, O'Leary LA, Songer NJ, Coughlin MT, Bellinger MF, LaPorte RE. Paternity after bilateral cryptorchidism: a controlled study. *Arch Pediatr Adolesc Med*. 1997;151:260–3.
- Thorup J, Cortes D. The incidence of maldescended testes in Denmark. *Pediatr Surg Int*. 1990;5:2–5.
- Caesar RE, Kaplan GW. The incidence of the cremasteric reflex in normal boys. *J Urol*. 1994;152:779–80.
- Abes M, Bakal U, Petik. Ascending testis following inguinal hernia repair in children. *Eur Rev Med Pharmacol Sci*. 2015;19:2949–51.
- John Radcliffe Hospital Cryptorchid Study Group. Cryptorchidism—An apparent substantial increase since 1960. *Brit Med J*. 1986;293:401–1404.
- John Radcliffe Hospital Cryptorchidism Study Group. Clinical diagnosis of cryptorchidism. *Arch Dis Child*. 1988;63:587–91.
- John Radcliffe Hospital Cryptorchidism Study Group. Cryptorchidism: a prospective study of 7500 consecutive male births, 1984–8 *Arch Disease in Childhood* 1992;67:892–899.
- Scorer CG. The descent of the testes. *Arch Dis Child*. 1964;39:605–9.
- Jackson MB, Chilvers C, Pike M, Ansell P, Bull D. Cryptorchidism: an apparent substantial increase since 1960. *Brit Med J*. 1986;293:1401–4.
- Berkowitz GS, Lapinski RH, Dolgin SE, Gazella JG, Bodian CA, Holzman IR. Prevalence and natural history of cryptorchidism. *Pediatrics*. 1993;92:44–49.
- Villumsen A, Zachau-Christiansen B. Spontaneous alteration in position of the testes. *Arch Dis Child*. 1966;41:198–200.
- Boisen KA, Kaleva M, Main KM, Virtanen HE, Haavisto AM, Schmidt IM, et al. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. *Lancet*. 2004;363:1264–9.
- Jensen MS, Wilcox AJ, Olsen J, Bonde JP, Thulstrup AM, Ramlau-Hansen CH, et al. Cryptorchidism and hypospadias in a cohort of 934,538 Danish boys: the role of birth weight, gestational age, body dimensions, and fetal growth. *Am J Epidemiol*. 2012;1(175):917–25.
- Berkowitz GS, Lapinski RH, Dolgin SE, Gazella JG, Bodian CA, Holzman IR. Prevalence and natural history of cryptorchidism. *Pediatrics*. 1993;92:44–49.
- Colodny AH. Undescended testes—Is surgery necessary? *N Engl J Med*. 1986;314:510–1.
- Koyle MA, Rajfer J, Ehrlich RM. The undescended testis. *Pediatr Ann*. 1988;17(39):42–6.
- Okeke AA, Osegbe DN. Prevalence and characteristics of cryptorchidism in a Nigerian district. *BJU Int*. 2001;88:941–5.
- Toppiari J, Kaleva M, Virtanen HE. Trends in the incidence of cryptorchidism and hypospadias, and methodological limitations of registry-based data. *Hum Reprod Update*. 2001;7:282–6.
- Kaleva M, Virtanen H, Haavisto AM, Main K, Skakkebaek NE, Toppari J. Incidence of cryptorchidism in Finnish boys. *Horm Res*. 2001;55:54.

22. Lee PA, Houk CP. Cryptorchidism. *Curr Opin Endocrinol Diab Obes.* 2013;20(3):210–6.
23. Acerini CL, Miles HL, Dunger DB, Ong KK, Hughes IA. The descriptive epidemiology of congenital and acquired cryptorchidism in a UK infant cohort. *Arch Dis Child.* 2009;94:868–72.
24. Buemann B, Henriksen H, Villumsen AL, Westh A, Zachau-Christiansen B. Incidence of undescended testis in the newborn. *Acta Chir Scand Suppl.* 1961;283(Suppl):289–93.
25. Witchel SF, Lee PA. Ambiguous Genitalia. In: Sperling MA, editor. *Pediatric endocrinology*, Saunders, Phila.; 2002. Chapter 6, p 111–133.
26. Sekido R, Lovell-Badge R. Genetic control of testis development. *Sex Dev.* 2013;7:21–32.
27. Biason-Lauber A. Control of sex development. *Best Pract Res Clin Endocrinol Metab.* 2010;24:163–86.
28. Wylie C. Germ cells. *Curr Opin Genet Dev.* 2000;10:410–3.
29. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. *Nature.* 1990;346:240–4.
30. Hiramatsu R, Harikae K, Tsunekawa N, Kurohmaru M, Matsuo I, Kanai Y. FGF signaling directs a center-to-pole expansion of tubulogenesis in mouse testis differentiation. *Development.* 2010;137:303–12.
31. Sekido R, Lovell-Badge R. Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer. *Nature.* 2008;453:930–4.
32. Munger SC, Capel B. Sex and the circuitry: progress toward a systems-level understanding of vertebrate sex determination. *Wiley Interdiscip Rev Syst Biol Med.* 2012;4:401–12.
33. Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. *Mol Cell Endocrinol.* 2003;211:21–31.
34. Hutson JM, Donahoe PK. The hormonal control of testicular descent. *Endocr Rev.* 1986;7:270–83.
35. Hutson JM, Baker M, Terada M, Zhou B, Paxton G. Hormonal control of testicular descent and the cause of cryptorchidism. *Reprod Fertil Dev.* 1994;6:151–6.
36. Barthold JS, Kumasi-Rivers K, Upadhyay J, Shekarriz B, Imperato-Meginley J. Testicular position in the androgen insensitivity syndrome: implications for the role of androgens in testicular descent. *J Urol.* 2000;164:497–501.
37. van der Schoot P, Elger W. Androgen-induced prevention of the outgrowth of cranial gonadal suspensory ligaments in fetal rats. *J Androl.* 1992;13:534–42.
38. Lee SM, Hutson JM. Effect of androgens on the cranial suspensory ligament and ovarian position. *Anat Rec.* 1999;255:306–15.
39. Heyns CF. The gubernaculum during testicular descent in the human fetus. *J Anat.* 1987;153:93–112.
40. Zimmermann S, Steding G, Emmen JM, Brinkmann AO, Nayernia K, Holstein AF, Engel W, Adham IM. Targeted disruption of the *Ins13* gene causes bilateral cryptorchidism. *Mol Endocrinol.* 1999;13:681–91.
41. Schindler AM, Diaz P, Cuendet A, Sizonenko PC. Cryptorchidism: a morphological study of 670 biopsies. *Helv Paediatr Acta.* 1987;42:145–58.
42. Heyns CF, Human HJ, DeKlerk DP. Hyperplasia and hypertrophy of the gubernaculum during testicular descent in the fetus. *J Urol.* 1986;135:1043–7.
43. Heyns CF, Human HJ, Werely CJ, DeKlerk DP. The glycosaminoglycans of the gubernaculum during testicular descent in the fetus. *J Urol.* 1990;143:612–7.
44. Levy JB, Husmann DA. The hormonal control of testicular descent. *J Androl.* 1995;16:459.
45. Beasley SW, Hutson JM. Effect of division of genitofemoral nerve on testicular descent in the rat. *Aust N Z J Surg.* 1987;57:49–51.
46. Adham IM, Emmen JM, Engel W. The role of the testicular factor *INSL3* in establishing the gonadal position. *Mol Cell Endocrinol.* 2000;160:11–6.
47. Baker LA, Nef S, Nguyen MT, Stapleton R, Pohl H, Parada LF. The insulin-3 gene: lack of a genetic basis for human cryptorchidism. *J Urol.* 2002;167:2534–7.
48. Huang Z, Rivas B, Agoulnik AI. Insulin-like 3 signaling is important for testicular descent but dispensable for spermatogenesis and germ cell survival in adult mice. *Biol Reprod.* 2012;87:143.
49. Foresta C, Zuccarello D, Garolla A, Ferlin A. Role of hormones, genes, and environment in human cryptorchidism. *Endocr Rev.* 2008;29:560–80.
50. Lund JM, Bouhadiba N, Sams V, Tsang T. Hepato-testicular fusion: an unusual case of undescended testes. *BJU Int.* 2001;88:439–40.
51. Engle ET. Experimentally induced descent of the testis in the Macacus monkey by hormones from the anterior pituitary and pregnancy urine. *Endocrinology.* 1932;16:513.
52. Husmann DA, McPhaul MJ. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat. *Endocrinology.* 1991;129:1409–16.
53. Husmann DA, McPhaul MJ. Reversal of flutamide-induced cryptorchidism by prenatal time-specific androgens. *Endocrinology.* 1992;131:1711–5.
54. Baumans V, Dijkstra G, Wensing CJ. The effect of orchidectomy on gubernacular outgrowth and regression in the dog. *Int J Androl.* 1982;5:387–400.
55. Baumans V, Dijkstra G, Wensing CJ. The role of a non-androgenic testicular factor in the process of testicular descent in the dog. *Int J Androl.* 1983;6:541–52.
56. Kogan SJ. Fertility in cryptorchidism. *Eur J Pediatr.* 1987;146(Suppl2):S21–4.
57. Emmen JM, McLuskey A, Adham IM, Engel W, Verhoef-Post M, Themmen AP, et al. Involvement

- of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. *Endocrinology*. 2000;141:846–9.
58. Grinspon RP, Loreti N, Braslavsky D, Valeri C, Schteingart H, Ballerini MG, Bedecarrás P, Ambao V, Gottlieb S, Ropelato MG, Bergadá I, Campo SM, Rey RA. *Front Endocrinol (Lausanne)*. 2014;7, 5:51.
 59. Aydın B, Winters SJ. Sex hormone-binding globulin in children and adolescents. *J Clin Res Pediatr Endocrinol*. 2016;8:1–12.
 60. Gendrel D, Job JC, Roger M. Reduced post-natal rise of testosterone in plasma of cryptorchid infants. *Acta Endocrinol*. 1978;89:372–8.
 61. Baker BA, Morley R, Lucas A. Plasma testosterone in preterm infants with cryptorchidism. *Arch Dis Child*. 1988;63:1198–200.
 62. Gendrel D, Roger M, Job JC. Plasma gonadotropin and testosterone values in infants with cryptorchidism. *J Pediatr*. 1980;97:217–20.
 63. Pouplard A, Job JC, Luxembourg I, Chaussain JL. Antigonadotropic cell antibodies in the serum of cryptorchid children and infants and of their mothers. *J Pediatr*. 1985;107:26–30.
 64. Cortes D, Clasen-Linde E, Hutson JM, Li R, Thorup J. The Sertoli cell hormones inhibin-B and anti Müllerian hormone have different patterns of secretion in prepubertal cryptorchid boys. *J Pediatr Surg*. 2016;51(3):475–80.
 65. Suomi AM, Main KM, Kaleva M, Schmidt IM, Chellakooty M, Virtanen HE, et al. Hormonal changes in 3-month-old cryptorchid boys. *J Clin Endocrinol Metab*. 2006;91:953–8.
 66. Raivio T, Toppari J, Kaleva M, Virtanen H, Haavisto AM, Dunkel L, et al. Serum androgen bioactivity in cryptorchid and noncryptorchid boys during the postnatal reproductive hormone surge. *J Clin Endocrinol Metab*. 2003;88:2597–9.
 67. Donahoe PK, Ito Y, Morikawa Y, Hendren WH. Mullerian inhibiting substance in human testes after birth. *J Pediatr Surg*. 1977;12:323–30.
 68. Job J-C, Garnier PE, Chaussain J-L, Toublanc JE, Canlorbe P. Effect of synthetic luteinizing hormone-releasing hormone on the release of gonadotropins in hypophysogonadal disorders of children and adolescents. *J Pediatr*. 1974;84:371–4.
 69. Lipschulz LI, Caminos-Torees R, Greenspan CS, Snyder PJ. Testicular function after orchiopexy for unilateral undescended testis. *New Eng J Med*. 1976;295:15–8.
 70. Lee PA, Hoffman WH, White JJ, Engel RME, Blizzard RM. Serum gonadotropins in cryptorchidism: an indicator of functional testes. *Am J Dis Child*. 1974;127:530–2.
 71. Christiansen P, Andersson A-M, Skakkebaek NE, Juul A. Serum inhibin B, FSH, LH, and testosterone levels before and after human chorionic gonadotropin stimulation in prepubertal boys with cryptorchidism. *Euro J Endocrinol*. 2002;147:95–101.
 72. Cortes D, Thorup JM, Beck BL. Quantitative histology of germ cells in the undescended testes of human fetuses, neonates and infants. *J Urol*. 1995;154:1188–92.
 73. Hadziselimovic F, Herzog B, Buser M. Development of cryptorchid testes. *Eur J Pediatr*. 1987;146 (Suppl 2):S8–12.
 74. Cobellis G, Noviello C, Nino F, Romano M, Mariscoli F, Martino A, Parmeggiani P, Papparella A. Spermatogenesis and cryptorchidism. *Front Endocrinol (Lausanne)*. 2014;5:63. doi:10.3389/fendo.2014.00063. eCollection 2014.
 75. Mengel W, Heinz HA, Sippe WG, Hecker WC. Studies on cryptorchidism: a comparison of histological findings in the germinative epithelium before and after the second year of life. *J Pediatr Surg*. 1974;9:445–50.
 76. Hedinger C. The histopathology of the cryptorchid testis. In: Bierich JR, Rager K, Ranke MB, editors. *Maldescensus thesis*. Munchen: Urban and Schwarzenberg; 1977. p. 29–37.
 77. Hedinger C. Histological data in cryptorchidism. In: Job J-C, editor. *Cryptorchidism, diagnosis and treatment*, vol. 6., *Pediatric and Adolescent Endocrinology* Karger: New York; 1979. p. 3–13.
 78. Hedinger CE. Histopathology of undescended testes. *Eur J Pediatr*. 1982;139:266–70.
 79. Hadziselimovic F. Histology and ultrastructure of normal and cryptorchid testes. In: Hadziselimovic F, editor. *Cryptorchidism, management and implications*. Berlin: Springer; 1983. p. 35–58.
 80. Mancini RE, Rosenberg E, Cullen M, Lavieri CJ, Vilar O, Bergada C, Andrada AJ. Cryptorchid and scrotal human testes. I. Cytological, cytochemical and quantitative studies. *J Clin Endocr Metab*. 1965;25:927–42.
 81. Kollin C, Karpe B, Hesser U, Granholm T, Ritzén EM. Surgical treatment of unilaterally undescended testes: testicular growth after randomization to orchiopexy at age 9 months or 3 years. *J Urol*. 2007;178(4 Pt 2):1589–93; discussion 1593.
 82. Kollin C, Granholm T, Nordenskjöld A, Ritzén EM. Growth of spontaneously descended and surgically treated testes during early childhood. *Pediatrics*. 2013;131(4):e1174–80.
 83. Rey RA. Early orchiopexy to prevent germ cell loss during infancy in congenital cryptorchidism. *J Clin Endocrinol Metab*. 2012;97:4358–61.
 84. Kollin C, Hesser U, Ritzén EM, et al. Testicular growth from birth to two years of age, and the effect of orchidopexy at age nine months: a randomized, controlled study. *Acta Paediatr*. 2006;95:318–24.
 85. Kollin C, Stukenborg JB, Nurmio M, Sundqvist E, Gustafsson T, Söder O, et al. Boys with undescended testes: endocrine, volumetric and morphometric studies on testicular function before and after orchidopexy at nine months or three years of age. *J Clin Endocrinol Metab*. 2012;97:4588–95.

86. Cortes D, Thorup J, Petersen BL. Testicular histology in cryptorchid boys—Aspects of fertility. *J Ped Surg Spec.* 2006;1:34–7.
87. Kim SO, Hwang EC, Hwang IS, et al. Testicular catch up growth: the impact of orchiopexy age. *Urology.* 2011;78:886–9.
88. Park KH, Lee JH, Han JJ, Lee SD, Song SY. Histological evidences suggest recommending orchiopexy within the first year of life for children with unilateral inguinal cryptorchid testis. *Int J Urol.* 2007;14:616–21.
89. Kraft KH, Canning DA, Snyder HM 3rd, Kolon TF. Undescended testis histology correlation with adult hormone levels and semen analysis. *J Urol.* 2012;188(4 Suppl):1429–35.
90. Chua ME, Mendoza JS, Gaston MJ, Luna SL Jr, Morales ML. Jr. Hormonal therapy using gonadotropin releasing hormone for improvement of fertility index among children with cryptorchidism: a meta-analysis and systematic review. *J Pediatr Surg.* 2014;49:1659–67.
91. Wyllie GG. The retractile testis. *Med J Aust.* 1984;140:403–5.
92. Hutson JM, Goh DW. Can undescended testes be acquired? *Lancet.* 1993;341:504.
93. Lamah M, McCaughey ES, Finlay FO, Burge DM. The ascending testis: is late orchidopexy due to failure of screening or late ascent? *Pediatr Surg Int.* 2001;17:421–3.
94. Eardley I, Saw KC, Whitaker RH. Surgical outcome of orchidopexy. II. Trapped and ascending testes. *Br J Urol.* 1994;73:204–6.
95. Clarnette TD, Rowe D, Hasthorpe S, Hutson JM. Incomplete disappearance of the processus vaginalis as a cause of ascending testis. *J Urol.* 1997;157:1889–91.
96. Smith JA, Hutson JM, Beasley SW, Reddihough DS. The relationship between cerebral palsy and cryptorchidism. *J Pediatr Surg.* 1989;24:1303–5.
97. Hack WW, Goede J, van der Voort-Doedens LM, et al. Acquired undescended testis: putting the pieces together. *Int J Androl.* 2012;35:41–5.
98. Mayr J, Rune GM, Holas A, Schimpl G, Schmidt B, Haberlik A. Ascent of the testis in children. *Eur J Pediatr.* 1995;154:893–5.
99. Garcia J, Navarro E, Guirado F, Pueyo C, Fernandez A. Spontaneous ascent of the testis. *Br J Urol.* 1997;79:113–5.
100. Wohlfahrt-Veje C, Boisen KA, Boas M, et al. Acquired cryptorchidism is frequent in infancy and childhood. *Int J Androl.* 2009;32:423–8.
101. Hack WW, Meijer RW, Van Der Voort-Doedens LM, et al. Previous testicular position in boys referred for an undescended testis: further explanation of the late orchidopexy enigma? *BJU Int.* 2003;92:293–6.
102. John Radcliffe Hospital Cryptorchidism Study Group. Boys with late descending testes: the source of patients with “retractile” testes undergoing orchidopexy? *Br Med J.* 1986;293:789–90.
103. Barthold JS1, Hossain J, Olivant-Fisher A, Reilly A, Figueroa TE, Banihani A, et al. Altered infant feeding patterns in boys with acquired nonsyndromic cryptorchidism. *Birth Defects Res A Clin Mol Teratol.* 2012;94:900–7.
104. Hack WW, Meijer RW, van der Voort-Doedens LM, Bos S, Haasnoot K. Natural course of acquired undescended testis in boys. *Br J Surg.* 2003;90:728–31.
105. Sijstermans K, Hack WW, van der Voort-Doedens LM, Meijer RW, Haasnoot K. Puberty stage and spontaneous descent of acquired undescended testis: implications for therapy? *Int J Androl.* 2006;29:597–602.
106. Hack WW, van der Voort-Doedens LM, Sijstermans K, Meijer RW, Pierik FH. Reduction in the number of orchidopexies for cryptorchidism after recognition of acquired undescended testis and implementation of expectative policy. *Acta Paediatr.* 2007;96:915–8.
107. van Brakel J, Kranse R, de Muinck Keizer-Schrama SM, Hendriks AE, de Jong FH, Hack WW, et al. Fertility potential in a cohort of 65 men with previously acquired undescended testes. *J Pediatr Surg.* 2014;49:599–605.
108. Meij-de Vries A, Hack WW, Heij HA, Meijer RW. Perioperative surgical findings in congenital and acquired undescended testis. *J Pediatr Surg.* 2010;45:1874–81.
109. van der Plas EM, Zijp GW, Froeling FM, van der Voort-Doedens LM, Meij-de Vries A, Goede J, Hack WW. Long-term testicular volume after orchidopexy at diagnosis of acquired undescended testis. *J Urol.* 2013;190:257–62.
110. Hack WW, van der Voort-Doedens LM, Goede J, van Dijk JM, Meijer RW, Sijstermans K. Natural history and long-term testicular growth of acquired undescended testis after spontaneous descent or pubertal orchidopexy. *BJU Int.* 2010;106:1052–9.
111. Irkilata HC, Kibar Y, Basal S, Kurt B, Gunal A, Alp BF, et al. The impact of simple orchiectomy on semen quality and endocrine parameters in postpubertal cryptorchid men. *Int Urol Nephrol.* 2012;44:1617–22.
112. Rusnack SL, Wu HY, Huff DS, Snyder HM 3rd, Zderic SA, Carr MC, et al. The ascending testis and the testis undescended since birth share the same histopathology. *J Urol.* 2002;168:2590–1.
113. Kraft KH, Bhargava N, Schast AW, Canning DA, Kolon TF. Histological examination of solitary contralateral descended testis in congenital absence of testis. *J Urol.* 2012;187:676–80.
114. Sadov S, Koskenniemi JJ, Virtanen HE, Perheentupa A, Petersen JH, Skakkebaek NE, et al. Testicular growth during puberty in boys with and without a history of congenital cryptorchidism. *J Clin Endocrinol Metab.* 2016;101:2570–7.

115. Tsujihata M, Miyake O, Yoshimura K, Kakimoto K, Matsumiya K, Takahara S, et al. Laparoscopic diagnosis and treatment of nonpalpable testis. *Int J Urol.* 2001;8:692–6.
116. Froeling FMJA, Sorber MJG, De La Rosette JJMCH, De Vries JDM. The nonpalpable testis and the changing role of laparoscopy. *Urology.* 1994;43:222–7.
117. Giannopoulos MF, Vlachakis IG, Charissis GC. 13 years' experience with the combined hormonal therapy of cryptorchidism. *Horm Res.* 2001;55:33–7.
118. Ritzén EM, Bergh A, Bjerknes R, Christiansen P, Cortes D, Haugen SE, et al. Nordic consensus on treatment of undescended testes. *Acta Paediatr.* 2007;96:638–43.
119. Lee MM, Misra M, Donahoe PK, MacLaughlin DT. MIS/AMH in the assessment of cryptorchidism and intersex conditions. *Mol Cell Endocrinol.* 2003;211:91–8.
120. Kolon TF, Herndon CD, Baker LA, Baskin LS, Baxter CG, Cheng EY, et al. American Urological Association. Evaluation and treatment of cryptorchidism: AUA guideline. *J Urol.* 2014;192:337–45.
121. Chilvers C, Dudley NE, Gough MH, Jackson MB, Pike MC. Undescended testis: the effect of treatment on subsequent risk of subfertility and malignancy. *J Pediatr Surg.* 1986;21:691–6.
122. Miller KD, Coughlin MT, Lee PA. Fertility after unilateral cryptorchidism: paternity, time to conception, pretreatment testicular location and size, hormone and sperm parameters. *Horm Res.* 2001;55:249–53.
123. Tzvetkova P, Tzvetkov D. Diagnosis of abdominal bilateral cryptorchidism: HCG stimulation test. *Urol Int.* 2001;67:46–8.
124. Bertelloni S, Baroncelli GI, Ghirri P, Spinelli C, Saggese G. Hormonal treatment for unilateral inguinal testis: comparison of four different treatments. *Horm Res.* 2001;55:236–9.
125. Saggese G, Ghirri P, Gabrielli S, Cosenza GCM. Hormonal therapy for cryptorchidism with a combination of human chorionic gonadotropin and follicle-stimulating hormone. *AJDC.* 1989;143:980–2.
126. Hjertkvist M, Lackgren G, Ploen L, Bergh A. Does HCG treatment induce inflammation-like changes in undescended testes in boys? *J Pediatr Surg.* 1993;28:254–8.
127. Kaleva M, Arsalo A, Louhimo I, Rapola J, Perheentupa J, Henriksén K, et al. Treatment with human chorionic gonadotropin for cryptorchidism: clinical and histological effects. *Int J Androl.* 1996;19:293–8.
128. Heiskanen P, Billig H, Toppari J, Kaleva M, Arsalo A, Rapola J, et al. Apoptotic cell death in the normal and cryptorchid human testis: the effect of human chorionic gonadotropin on testicular cell survival. *Pediatr Res.* 1996;40:351–6.
129. Dunkel L, Taskinen S, Hovatta O, Tilly JL, Wikström S. Germ cell apoptosis after treatment of cryptorchidism with human chorionic gonadotropin is associated with impaired reproductive function in the adult. *J Clin Invest.* 1997;100:2341–6.
130. Werder EA, Illig R, Torresani T, Zachmann M, Baumann, Ott F, Prader A. Gonadal function in young adults after surgical treatment of cryptorchidism. *Brit J Med.* 1976;2:1357–9.
131. Lee PA, Coughlin MT. Fertility after bilateral cryptorchidism: evaluation by paternity, hormone and semen data. *Horm Res.* 2001;55:28–32.
132. Gracia J, Sanchez Zalabardo J, Sanchez Garcia C, Ferrandez A. Clinical, physical, sperm and hormonal data in 251 adults operated on for cryptorchidism is childhood. *BJU Int.* 2000;85:1100–13.
133. Taskinen S, Wikstrom S. Effect of age at operation, location of testis and preoperative hormonal treatment on testicular growth after cryptorchidism. *J Urol.* 1997;158:471–3.
134. Takihara H, Baba Y, Ishizu K, Ueno T. Sakatokud. Testicular development following unilateral orchiopexy measured by a new orchimeter. *Urology.* 1990;36:370–2.
135. Bujan L, Mieusset R, Mansat A, Moatti JP, Mondinat C, Pontonnier F. Testicular size in infertile men: relationship to semen characteristics and hormonal blood levels. *Brit J Urol.* 1989;64:632–7.
136. Cortes D, Thorup J. Histology of testicular biopsies taken at operation for bilateral maldescended testes in relation to fertility in adulthood. *Br J Urol.* 1991;68:285–91.
137. Engeler DS, Hosli PO, Hubert J, Bannwart F, Sulser T, Amin MB, et al. Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. *Urol.* 2000;56:144–8.
138. Gracia J, Sanchez J, Garcia C, Pueyo C, Ferrandez A. What is the relationship between spermatozoa per milliliter at adulthood and the tubular fertility index at surgical age for patients with cryptorchidism? *J Pediatr Surg.* 1998;33:594–6.
139. Canavese F, Mussa A, Manenti M, Cortese MG, Ferrero L, Tuli G, et al. Sperm count of young men surgically treated for cryptorchidism in the first and second year of life: fertility is better in children treated at a younger age. *Eur J Pediatr Surg.* 2009;19:388–91.
140. Feyles F, Peiretti V, Mussa A, Manenti M, Canavese F, Cortese MG, et al. Improved sperm count and motility in young men surgically treated for cryptorchidism in the first year of life. *Eur J Pediatr Surg.* 2014;24:376–80.
141. Cortes D, Thorup JM, Visfeldt J. Cryptorchidism: aspects of fertility and neoplasms. A study including data of 1,335 consecutive boys who underwent testicular biopsy simultaneously with surgery for cryptorchidism. *Horm Res.* 2001;55:21–7.
142. Thorup J, Kvist K, Clasen-Linde E, Petersen BL, Cortes D. The relation between adult dark spermatogonia and other parameters of fertility potential

- in cryptorchid testes. *J Urol.* 2013;190(4 Suppl):1566–71.
143. Ludwig G, Potempa J. Optimal time for treating cryptorchidism. *Dtsch Med Wochenschr.* 1975;100:680–3.
 144. Hadziselimovic F. Early successful orchidopexy does not prevent from developing azoospermia. *Int Braz J Urol.* 2006;32:570–3.
 145. Trsinar B, Muravec UR. Fertility potential after unilateral and bilateral orchidopexy for cryptorchidism. *World J Urol.* 2009;27:513–9.
 146. Puri P, O'Donnell B. Semen analysis of patients who had orchidopexy at or after seven years of age. *Lancet ii.* 1988;1051–2.
 147. Cortes D, Thorup JM, Lindenberg S. Fertility potential after unilateral orchiopexy: simultaneous testicular biopsy and orchiopexy in a cohort of 87 patients. *J Urol.* 1996;155:1061–5.
 148. Yavetz H, Harash B, Paz G, Yogey L, Jaffa AJ, Lessing JB, et al. Cryptorchidism: incidence and sperm quality in infertile men. *Andrologia.* 1992;24:293–7.
 149. Eldrup J, Steven K. Influence of orchidopexy for cryptorchidism on subsequent fertility. *Br J Surg.* 1980;67:269–70.
 150. Alpert PF, Klein RS. Spermatogenesis in the unilateral cryptorchid testis after orchiopexy. *J Urol.* 1983;129:301–2.
 151. Lee PA, Coughlin MT. Fertility after bilateral cryptorchidism. Evaluation by paternity, hormone, and semen data. *Horm Res.* 2001;55:28–32.
 152. Coughlin MT, Bellinger MF, Lee PA. Age at unilateral orchiopexy: effect on hormone levels and sperm count in adulthood. *J Urol.* 1999;162:986–8; discussion 989.
 153. Lee PA, Coughlin MT, Bellinger MF. Inhibin B: comparison with indexes of fertility among formerly cryptorchid and control men. *J Clin Endocrinol Metab.* 2001;86:2576–84.
 154. Lee PA, Coughlin MT. Leydig cell function after cryptorchidism: evidence of the beneficial result of early surgery. *J Urol.* 2002;167:1824–7.
 155. Lee PA, Coughlin MT. The single testis: paternity after presentation as unilateral cryptorchidism. *J Urol.* 2002;168:1680–2; discussion 1682–3.
 156. Calleja Aguayo E, Delgado Alvira R, Estors Sastre B, González Esgueda A, Gracia Romero J. Fertility survey of patients operated on of cryptorchidism in the pediatric age. *Cir Pediatr.* 2012;25:78–81.
 157. Gondos B. Ultrastructure of developing and malignant germ cells. *Eur Urol.* 1993;23:68–75.
 158. Cortes D, Thorup J, Frisch M, Moller H, Jacobsen GK, Beck BL. Examination for intratubular germ cell neoplasia (ITGCN) at operation for undescended testis in boys. A follow-up study. *J Urol.* 1994;151:722–5.
 159. Jørgensen N, Rajpert-De Meyts E, Graem N, Müller J, Giwercman A, Skakkebaek NE. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. *Lab Invest.* 1995;72:223–31.
 160. Lip SZ, Murchison LE, Cullis PS, Govan L, Carachi R.A. Meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. *Arch Dis Child.* 2013;98:20–6.
 161. Giwercman A, Muller J, Skakkebaek NE. Cryptorchidism and testicular neoplasia. *Horm Res.* 1988;30:157–63.
 162. Cortes D. Cryptorchidism-aspects of pathogenesis, histology and treatment. *Scand J Urol Nephrol.* 1998;32:1–54.
 163. Moller H, Cortes D, Engholm G, Thorup J. Risk of testicular cancer with cryptorchidism and with testicular biopsy: cohort study. *BMJ.* 1998;317:729.
 164. Pike MC, Chilvers C, Peckham MJ. Effect of age at orchidopexy on risk of testicular cancer. *Lancet.* 1986;1:1246–8.
 165. United Kingdom Testicular Cancer Study Group. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. *BMJ.* 1994;308:1393–9.
 166. Cortes D, Visfeldt J, Moller H, Thorup J. Testicular neoplasia in cryptorchid boys at primary surgery: case series. *BMJ.* 1999;319:888–9.
 167. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. *Hum Reprod Update.* 2006;12:303–23.
 168. Pettersson A, Richiardi L, Nordenskjold A, Kaisjer M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. *N Engl J Med.* 2007;356:1835–41.
 169. Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. *J Urol.* 2007;178:1440–6; discussion 6.
 170. Myrup C, Schnack TH, Wohlfahrt J. Correction of cryptorchidism and testicular cancer. *N Engl J Med.* 2007;357:825–6.
 171. Oh J, Landman J, Evers A, Yan Y, Kibel AS. Management of the postpubertal patient with cryptorchidism: an updated analysis. *J Urol.* 2002;167:1329–33.

Samuel M. Kim MD, Swaytha Yalamanchi MD
and Adrian S. Dobs MD

Contents

Introduction.....	219
Pathophysiology.....	220
Hemochromatosis.....	221
Alcohol-Induced Liver Injury.....	222
Hepatitis B/C.....	224
Nonalcoholic Fatty Liver Disease.....	225
Implications of Hypogonadism in End-Stage Liver Disease.....	227
Diagnosis.....	228
Testosterone Treatment.....	229
Conclusions.....	230
References.....	231

Introduction

Chronic liver disease (CLD) and cirrhosis are common chronic medical illnesses, often from preventable causes, and remain the 12th leading

cause of mortality in the United States [1]. New cases of CLD are diagnosed by persistently elevated liver enzymes, radiological evidence of cirrhosis, histopathology, or a clinical consequence of CLD such as variceal bleeding or ascites [1]. The progression of CLD from hepatocyte injury to cirrhosis is characterized by a diffuse, fibrosing, and generally irreversible condition that disrupts the normal architecture of the liver, particularly in the sinusoids [1]. The major etiologies of CLD include alcohol, hepatitis B or C infection, hemochromatosis, and nonalcoholic fatty liver disease (NAFLD) (Table 11.1). Data from National Health and Nutrition Examination Survey (NHANES) demonstrate that the prevalence of chronic liver disease ranged from 12 to 15% from 1988 to 2008 in the United States [2]. The overall prevalence rate of hepatitis B infection was approximately 0.3%, hepatitis C virus 1.6%, and alcoholic liver disease 2%. These prevalence rates have stayed relatively stable in the past two decades while that of NAFLD has increased from 5.5 to 11% in the last 20 years. NAFLD represented more than 75% of liver disease cases from 2005 to 2008. Hepatitis C virus (26%) remained the most common cause of cirrhosis with the highest number of liver transplants, while alcohol (20–25%) was a close second [2].

CLD or cirrhosis is associated with multiple systemic processes, and one of the underappreciated comorbidities is testosterone deficiency [3, 4]. Men with advanced liver disease present with phenotypic manifestations typical of hypogonadism. The exact prevalence of low testosterone in liver disease patients has not been

S.M. Kim · S. Yalamanchi
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, School of Medicine, Johns Hopkins University, 1830 E. Monument Street, Suite 333, Baltimore, MD 21231, USA
e-mail: skim337@jhmi.edu

S. Yalamanchi
e-mail: syalama3@jhmi.edu

A.S. Dobs (✉)
Division of Endocrinology, Department of Medicine and Oncology, Diabetes, and Metabolism, School of Medicine, Johns Hopkins University, 1830 E. Monument St., Suite 328, Baltimore, MD 21287, USA
e-mail: adobs@jhmi.edu

Table 11.1 Causes of chronic liver disease in the United States with reported prevalence and associated level of hypogonadism

Causes of chronic liver disease	Prevalence in United States	Associated type of hypogonadism
Nonalcoholic fatty liver disease (NAFLD)	11%	Unclear, but likely more secondary
Alcoholic liver disease (ALD)	2%	Both primary and secondary
Hepatitis B/C	0.3% Hep B, 1.6% Hep C	Unclear, potentially more primary
Hereditary hemochromatosis	0.4%	Predominantly secondary, but likely a component of primary as well

Table 11.2 Total testosterone, free testosterone, and SHBG in various chronic liver diseases

	Total T	Free T	SHBG
Nonalcoholic fatty liver disease (NAFLD) ^a	Decreased	Decreased	Decreased
Alcoholic liver disease (ALD) ^a	Decreased	Decreased	Increased
Hepatitis B/C ^a	Decreased	Decreased	Increased
Hereditary hemochromatosis ^a	Decreased	Decreased	Increased
End-stage liver disease (decompensated cirrhosis)	Decreased	Decreased	Decreased
Post liver transplantation	Increased	Increased	Decreased

^aPatient with stable chronic liver disease without evidence of decompensate cirrhosis including signs of hepatic encephalopathy, ascites, or variceal bleeding

carefully studied, but limited literature suggests that hypogonadism, defined by low free testosterone, occurs in 70–80% of patients with CLD, with evidence of both primary testicular failure and disruption of the hypothalamic-pituitary-gonadal (HPG) regulation (Table 11.2) [4–6]. Among men with cirrhosis, low serum testosterone has been reported in up to 90% [7–10] with worsening hypogonadism corresponding to worsening liver failure [11].

Pathophysiology

The pathogenesis of hypogonadism in liver disease is complex, differs by diagnosis, and is hypothesized to be mediated in part by toxic metabolites affecting the hypothalamic-pituitary-gonadal (HPG) axis, hyperestrogenemia, and altered protein synthesis [12].

Cirrhosis, particularly end-stage cirrhosis, is most commonly associated with central hypogonadism [11]. Individuals with cirrhosis may lose luteinizing hormone (LH) pulsatility, suggestive of hypothalamic dysfunction [12]. The response to human chorionic gonadotropin (hCG) is

blunted, consistent with an impaired gonadotropic response [12–14]. Systemic disease, in general, is associated with central hypogonadism, and is hypothesized to be due to downregulation of GnRH production by elevated inflammatory cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)- α resulting in functional suppression of the HPG axis [7, 15]. Hyperprolactinemia may also be seen in liver disease, particularly in alcohol-related liver disease, likely due to alterations in the dopaminergic system that contribute to GnRH suppression with suppression of the HPG axis [16–22].

However, hypogonadism in the setting of liver disease may also be due to testicular damage. In particular, ethanol and its metabolites have been shown to exert a toxic effect on Leydig cells and are involved in onset of the fibrogenic processes [12, 23]. In vitro studies of isolated Leydig cells, isolated perfused rat testes, and testicular homogenates have consistently shown reduced testosterone synthesis [13, 24]. Despite damage to Leydig cells, testosterone levels in patients may be normal early in the disease process due to a compensatory increase in LH.

Estrogen levels can be elevated in men with cirrhosis, which is hypothesized to be due, at least in part, to reduced metabolism and clearance of estrogen, as well as portosystemic shunting further resulting in impaired/bypassed estradiol metabolism, and increased peripheral aromatization of testosterone [7, 11, 25–27]. Estrone and estradiol production may also be increased secondary to increased production of androstenedione from the adrenal glands. Increased androstenedione may be due to a combination of a shift in androgenic steroidogenesis from cortisol to androstenedione with worsening liver disease and to inflammation-mediated inhibition of conversion of DHEA to DHEA-S [12, 28]. Ethanol may also exacerbate hyperestrogenemia by increasing aromatase activity and interfering with sex hormone endocrine homeostasis before the onset of severe liver dysfunction [29, 30].

Elevation in estrogen in conjunction with decreased testosterone levels results in an increased estrogen/androgen ratio, felt to contribute to feminizing features of liver disease, including altered fat distribution, gynecomastia, spider angiomas, palmar erythema and reduced prostate volume [13].

The liver regulates testosterone bioavailability via production of SHBG and albumin and is also responsible for the production of enzymes important in the aromatization, conversion to dihydrotestosterone (DHT) and breakdown of androgens. Plasma testosterone binds with high affinity predominantly to SHBG (~60%) and albumin (~38%) [31]. SHBG levels are frequently elevated in certain forms liver disease, resulting in increased total testosterone, but lower free or bioavailable testosterone levels. SHBG levels are low in NAFLD and NASH and are often normal in hemochromatosis. Regulation of SHBG is multifactorial with hepatic signaling molecules and increasing levels of estrogen and decreasing levels of testosterone hypothesized to be important driving factors in SHBG elevation. Thus, early in liver disease, total testosterone levels may be elevated, when free testosterone levels are actually low. SHBG levels normalize after clinical decompensation, likely due to severity of impaired synthetic capacity despite hormonal stimuli. Testosterone, in turn, is

important in protein synthesis (including albumin), modulation of liver regeneration, inhibition of cytokine release, and anabolic effects related to liver metabolism [12].

Hemochromatosis

Hemochromatosis is characterized by iron overloading leading to systemic illnesses such as diabetes mellitus, hyperpigmentation, arthralgias, cardiomyopathy, cirrhosis and hepatocellular carcinoma, and hypogonadism [32]. The most notable iron overloading syndrome, hereditary hemochromatosis (HH), is one of the more common autosomal genetic disorders in Caucasians with an estimated prevalence of 1 per 220–250 individuals. HH can be divided into the primary HFE gene defect and non-HFE-related disease. The most common HFE gene defect is a missense mutation in which tyrosine is substituted for cysteine at amino acid position 282 of the protein product C282Y. The defective HFE protein signals that the body is incorrectly deficient in iron because it fails to stimulate normally the production of hepcidin, leading to increased iron absorption from the upper intestine. In addition to HH, there are multiple secondary iron overload syndromes such as thalassemia major and parental iron overload from frequent blood transfusions [32].

Liver injury and hypogonadism are two of the more common abnormalities in HH [33]. Reported prevalence rates of hypogonadism have ranged from 10 to 100% [33–35]. While liver disease is seen earlier in the disease course, hypogonadism is generally seen in its later stages. The exact timeframe for the manifestation of these symptoms is not clear. However, McDermott et al. in 2005 reported the 20 year follow-up of 141 men age 24–77 years who were diagnosed with HH with evidence of iron deposition on liver biopsy at a single center in Ireland. At the time of diagnosis of HH, those with hypogonadism were on average 56 years of age while nonhypogonadal males averaged 52 years of age [33]. They found that only 9 men (6.4%) had abnormally low testosterone levels with low

gonadotropin concentrations. This is in contrast to patients with juvenile (non-HFE) HH who have more severe iron overload, and generally present with delayed pubertal development rather than cardiac or liver disease [35].

Liver injury is hypothesized to occur as a consequence of cellular degradation products from hepatocyte injury from iron deposition, activating Kupffer cells which stimulate hepatic stellate cells to synthesize collagen leading to fibrosis and cirrhosis. In HH, C282Y homozygotes with serum ferritin levels >1000 micrograms/L have a higher risk of cirrhosis with prevalence of 20–45% while fewer than 2% of patients with ferritin <1000 micrograms/L have cirrhosis [32].

In HH, testosterone and LH levels are often low [33]. Iron deposition is found in the pituitary with high predilection for gonadotrophic cells. On the other hand, the secretion of ACTH and TSH is usually normal. There is decreased expression of transferrin and transferrin receptor in iron loaded gonadotrophs secondary to iron deposition [36, 37]. The depressed LH and testosterone with pituitary iron deposition is most consistent with secondary hypogonadism, but there may also be a component of primary hypogonadism since iron deposition is also found in testicular cells. Given that many of these studies did not involve a concomitant liver biopsy, it is not clear to what degree liver disease may contribute to hypogonadism in this setting.

SHBG levels are sometimes increased in HH [38]. Yeap et al. [36] showed that heterozygotes with the C282Y polymorphism without evidence of iron overload tend to have higher SHBG levels than do men who do not carry this mutation, but have normal total and free testosterone levels. These data suggest that the C282Y polymorphism may somehow influence SHBG levels, while the hypothalamic-pituitary-gonadal axis remains intact in the absence of significant iron overload [34]. It is nevertheless important to note that patients with HH may have other causes of hypogonadism such as obesity or Klinefelter syndrome [39].

Phlebotomy, with the goal of normalization of ferritin levels, remains a key treatment for hemochromatosis. Limited data suggest that

phlebotomy can partially reverse hepatic fibrosis in approximately 30% of cases, and significantly lower the rate of HH-related HCC if iron removal is achieved before cirrhosis develops [40]. However, it is unclear if testicular atrophy or biochemical hypogonadism can be reversed with phlebotomy since it is hypothesized that hypogonadism may be a manifestation of irreversible iron deposition and damage to the pituitary gland [41].

In conclusion, HH is a genetic iron overloading syndrome with liver disease usually presenting before hypogonadism. Although advanced liver disease may contribute to hypogonadism, HH seems to occur predominantly due to iron deposition and damage to the pituitary gland. Primary hypogonadism due to iron deposition in the testes is less commonly seen [42]. Phlebotomy has been shown to reverse some degree of CLD before progression to cirrhosis, but further studies are needed to understand its potential impact on hypogonadism.

Alcohol-Induced Liver Injury

Alcoholic liver disease (ALD) is classified into three histologic stages: alcoholic fatty liver, alcoholic hepatitis, and cirrhosis. Fatty liver is a result of steatosis in the setting of heavy drinking, occurring in about 90% of individuals who drink more than 60 mLs per day [43]. In general, fatty liver can be arrested or significantly reversed with alcohol cessation [44]. Alcoholic hepatitis is characterized by inflammatory changes and degeneration of hepatocytes. Patients may have clinical signs of nausea, abdominal pain, hepatomegaly, fever, jaundice, and bleeding. Alcoholic hepatitis is associated with a very high short-term mortality rate and chronically, approximately 40–50% of patients are at risk for progression to cirrhosis [45]. Cirrhosis remains the final stage of ALD with about 10–15% of patients with alcoholism generally at risk [46].

While dose relationship is the most important risk factor for ALD, other important risk factors need to be considered. In general, men who ingest more than 2–3 oz (60–90 mL) of alcohol per day, or woman who ingest more than 1 oz




Fig. 11.1 Proposed mechanisms for hypogonadism in the setting of alcoholic liver disease. Alcohol is postulated to affect the *hypothalamus/pituitary* via attenuation of LH pulsatility, though the role of GnRH pulsatility remains unclear at this time. Alcohol also affects the *testes* with inhibition of conversion of retinol to retinal (important in spermatogenesis), inhibition of multiple enzymes

necessary for testosterone biosynthesis, and downregulation of LH and GABA receptors. Alcohol additionally acts *peripherally* via increased aromatization of testosterone to estrogen in the setting of portosystemic shunting of androgens and increased conversion to active estrogen forms, overall resulting in higher relative estrogen levels

(30 mL) per day for 10 or more years, are at higher risk of cirrhosis [43]. Two important categories include individuals with (1) *alcohol dependence* which includes those who drink excessively and develop physical tolerance; and (2) *alcohol abuse* which includes those engaged in negative social and health consequences of drinking [46]. A large study from Denmark also suggested that the type of alcohol was important, with beer or spirits more likely to be associated with liver disease compared to other drinks such as wine [47]. Binge drinking, female gender, obesity, malnutrition, and family history of alcohol dependence were also associated with a higher risk of ALD [48].

The bidirectional nature of ALD and hypogonadism remains an active area of research. ALD is known to contribute to both biochemical and clinical hypogonadism (Fig. 11.1). In fact, alcoholic patients seem to have more profound phenotypic and biochemical evidence of hypogonadism than other forms of liver disease potentially since alcohol

has a direct toxic effect at each level of the hypothalamic-pituitary-gonadal axis.

Most studies suggest that the hypogonadism in alcoholism far precedes, sometimes by years, the development of liver disease. In men with significant history of alcohol abuse, but without histological or biochemical evidence of liver disease, more than 50% showed primary gonadal damage with testicular atrophy and infertility, and notably seminiferous tubular atrophy, marked peritubular fibrosis, and loss of germ cells [28]. Additionally, impairment of conversion of testosterone to its active metabolite dihydrotestosterone (DHT), in the setting of reduced levels of 5-alpha reductase, has been reported [49]. Ylikahri et al. reported in 1974 that short-term alcohol administration (<4 h) to young healthy male volunteers did not alter testosterone levels, but longer administration (weeks) resulted in a reduction in testosterone concentrations [50]. Badr et al. demonstrated that mice treated with high volumes of alcohol

(one-third of caloric intake) showed much higher reductions in testosterone and marked testicular changes compared to iso-calorically pair-fed controls without alcohol intake [51].

Ethanol has several direct adverse effects on the testes. Alcohol inhibits the conversion of retinol to its active metabolite retinal, which is essential for normal spermatogenesis [52]. High doses of ethanol impair testosterone synthesis from the precursor cholesterol by inhibiting multiple enzymes including 3-beta-hydroxysteroid dehydrogenase, 17-oxoreductase and 17–20 desmolase [53]. While short-term alcohol exposure leads to increased expression of LH receptors in Leydig cells, long term exposure downregulates LH receptors as well as gamma amino butyric acid (GABA) receptors, suggesting alcohol may affect LH receptor through cell membrane potential [54].

If alcohol produced solely direct testicular atrophy, a much higher level of gonadotropins, especially LH would be expected, but that is often not the case, suggesting that ethanol also affects hypothalamic-pituitary function. While some older data suggest that ethanol may reduce the pulsatility of LH secretion independent of the liver disease [52], the effect of ethanol on GnRH pulsatility has not been thoroughly studied. Bannister et al. [55] measured LH levels in blood samples drawn every 15 min for 6 or 8 hours in men with chronic alcohol liver disease without clinical signs of gonadal failure compared to those with phenotypic signs of hypogonadism such as testicular atrophy and hair loss. In men without clinical signs of hypogonadism, the pulsatility of LH was preserved, but those with overt signs of gonadal failure showed severely decreased LH hormone levels and an attenuation of pulsatility [52].

In the periphery, alcohol may increase aromatase activity, converting androgens to estrogens even beyond what can be explained by obesity. In alcoholic liver disease, estrogen sulfate may be converted to active estrogens in the liver through NF-kb [55]. Relative estrogen levels may further be increased as a result of portosystemic shunting leading to increased androgen substrate for bioconversion by extrahepatic peripheral aromatase. It is unclear to what

degree the relative excess estrogen may contribute to the inhibition of LH secretion [49]. Estrone and estradiol levels may also be increased secondary to increased production of androstenedione from the adrenal cortex [16].

Many of the studies that examined alcoholism and hypogonadism were performed in the 1970s and 1980s, highlighting the need for new research. In summary, existing data suggest that acute alcohol consumption results in transient primary hypogonadism while longer term alcohol use, even in the absence of liver damage, is associated with both primary and secondary hypogonadism. In those who develop cirrhosis, hypogonadism seems to be more profound than in other causes of liver disease. The reversibility of hypogonadism in those with chronic liver disease who abstain from alcoholism has not been well studied.

Hepatitis B/C

Hepatitis B (HBV) and Hepatitis C (HCV) are the leading cause of hepatocellular carcinoma, cirrhosis, and transplantation. Within the United States, HBV and HCV are responsible for 15 and 26% of cirrhosis cases, respectively. This section will focus on predominantly HCV given HBV rates have been declining with increasing vaccination use [2].

It is estimated that between 2.5 and 4.7 million people in the United States had chronic HCV between 2003 and 2010, with major risk factors including current or prior intravenous drug use, and treatment with blood products before 1987 [56]. About Approximately 20% of patients clear HCV without additional treatment. Of the 75–80% who develop chronic infection, up to 25% will develop cirrhosis over a period of 20–30 years. It also important to note that more than 50% of HIV-infected intravenous drug users have HCV [56].

While HCV is associated with multiple immune-mediated conditions such as mixed cryoglobulinemia, glomerulonephritis, thyroiditis, arthritis, and peripheral neuropathy [57], it remains to be seen if there is a direct relationship

between HCV with hypogonadism, especially in the setting of compensated liver disease. Multiple studies have suggested that hypogonadism is not seen with hepatitis C infection until liver architectural damage is present, as evidenced by elevated SHBG and total testosterone levels [58].

Ferri et al. (2002) compared 207 men with HCV (all with compensated liver disease) to age-matched men without liver disease, and demonstrated that plasma levels of total and free testosterone were generally lower in the former group [59]. However, testosterone levels were not significantly correlated with the severity of the liver disease based on ultrasound and laboratory testing.

It is postulated that one mechanism by which HCV induces hepatocyte injury is through the production of reactive oxygen species (ROS) via expression of core protein with direct mitochondrial injury [60]. HCV may also induce ROS-mediated damage to sperm given that somewhere between 30–80% of those with hypospermatogenesis have evidence of ROS damage, including damage to sperm membranes and DNA [61]. Lorusso et al. showed that patients with chronic HCV have impaired sperm quality, particularly the percentage of spermatozoa with normal progressive motility and morphology [62].

The exact prevalence of low testosterone in HCV has not been thoroughly studied, likely due to multiple co-morbidities in HCV patient such as alcohol use, HIV, and HBV infection. Also, many studies looking at the relationship between hypogonadism and HCV were conducted in the setting of interferon treatment. More recently, antiviral drugs such as ledipasvir (inhibitor of viral phosphoprotein) and sofosbuvir (RNA chain terminator) have shown sustained virologic response up to 94–99% in those with genotype 1 HCV infections [63]. Additional studies are needed to examine the impact of these new treatments on testosterone levels.

There have been ongoing concerns that elevated testosterone levels may be a risk factor for the development of HCV-related HCC given that males have a higher risk of HCC than females. One prospective Japanese study of 46 males with

HCV-related cirrhosis found that increased total testosterone was associated with HCV–HCC risk, but a case-control study in Australia with 35 HCV patients did not find any significant association [64]. White et al. (2012) performed one of the largest cross-sectional studies in the U. S. of 308 HCV compensated liver patients with mild to advanced fibrosis. They reported a significant 27% increase in advanced fibrosis risk and 16% inflammatory activity risk for each 1 ng/ml increase in total testosterone [65]. The study examined risk of fibrosis and inflammatory activity based on three groups of total testosterone: low (≤ 4.11 ng/mL), middle (4.12–5.91 ng/mL), and highest (≥ 5.91 ng/ml). HBV was reported to augment androgen receptor (AR) signaling using HepG2 carcinoma cells, which may lead to elevated testosterone and subsequent proliferation, apoptosis, and inflammatory response of the hepatocyte, increasing risk of HCC [66]. Increases in total testosterone may be explained by high SHBG levels, and SHBG has been proposed as a marker for HCC [67]. Given somewhat similar mechanism of invasion between HCV and HBV, it may be that HCV could have a similar response.

In summary, whether HCV causes hypogonadism independent of liver disease remains unclear, and should be a focus of further studies. There are data to suggest that HCV may induce ROS-mediated damage in the testes. Additionally, limited data suggest that patients with higher levels of endogenous testosterone and SHBG may be at increased risk for HCC, fibrosis, and inflammatory activity, but the mechanism is not well understood at this time.

Nonalcoholic Fatty Liver Disease

According to the American Association for the Study of Liver Diseases (AASLD), the diagnosis of nonalcoholic fatty liver disease (NAFLD) requires (1) evidence of hepatic steatosis by imaging or histology, and (2) no other causes for secondary hepatic fat accumulation such as alcohol consumption or steatogenic medications. In general, NAFLD is associated with metabolic




Fig. 11.2 Schematic of progression from fatty liver to cirrhosis. Nonalcoholic fatty liver disease (NAFLD) is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). The former has a prevalence of 6.3–33% and is characterized by hepatic

steatosis without hepatocellular injury. The latter has a prevalence of 3–5% and is characterized by hepatocellular injury. Importantly, NASH can progress to cirrhosis, which could potentially lead to decompensated liver disease and/or hepatocellular carcinoma

syndrome including obesity, diabetes mellitus, and dyslipidemia. NAFLD should be differentiated into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). While NAFL is defined by the presence of hepatic steatosis without hepatocellular injury, NASH includes hepatocyte injury. NAFLD is a spectrum of liver injury progressing from lipid accumulation within hepatocytes, to inflammation and ballooning of hepatocytes, and to eventual scarring and cirrhosis (Fig. 11.2). Estimates of the worldwide prevalence of NAFL range from 6.3 to 33%, with a median of 20%, while the prevalence of NASH is estimated to be 3–5% [68].

It is well documented that men with metabolic syndrome have an increased prevalence of hypogonadism [68, 69]. However, the bidirectional nature of the relationship is complex and multifactorial (Fig. 11.3; see Chaps. 15 and 17). It is important to understand these associations in order to determine if these risk factors are independently associated with the development of hepatic steatosis to inform the development of relevant treatment strategies [70]. The actual prevalence of hypogonadism in NAFLD is not established at this time.

One leading hypothesis is that obesity is the predominant driver of hypogonadism in patients with NAFLD/metabolic syndrome. Excess of leptin, an adipokine, in obese men directly inhibits Leydig cell androgenesis. Both subcutaneous and visceral adipose tissue may directly affect gonadotropin release by the pituitary by either increased secretion of cytokines such as TNF- α or

IL-2, or by increased conversion of circulating androgens into estrogens, which further contribute to negative feedback. Aromatase is expressed in adipose tissues, and obese patients may have increased expression of the enzyme. Additionally, SHBG, a major testosterone transport protein, is decreased in obese patients, contributing to low total testosterone levels [71] (see Chap. 15).

Another idea is that increased visceral adipose tissue which is partly due to testosterone deficiency increases hepatic exposure to free fatty acids, which can lead to worsening hepatic insulin resistance and systemic insulin resistance [71]. Leydig cell function may also be directly impaired in men with insulin resistance [72]. There is some evidence that testosterone treatment can decrease visceral adiposity and improve insulin sensitivity [73].

There have been a number of studies that suggest that androgen deficiency and low SHBG levels in metabolic syndrome patients may be independently associated with hepatic steatosis. In a large retrospective cohort study of 1912 Korean men, hepatic steatosis was associated with lower serum testosterone levels (14.2 vs. 17.2 nmol/l). When these results were adjusted for confounders such as age, BMI, lipid panel, diabetes, exercise, and high-sensitivity reactive protein (hs-CRP), low serum testosterone still remained associated with hepatic steatosis [70]. Additionally, there have been other studies showing that testosterone replacement in hypogonadal men is followed by reduction in visceral adiposity and circulating TNF α levels [74], and in




Fig. 11.3 Proposed mechanism of the bidirectional relationship between hypogonadism and nonalcoholic fatty liver disease. Adipose tissue may play a central role in the bidirectional relationship between hypogonadism and nonalcoholic fatty liver disease. Increased free fatty acid secretion results in insulin resistance and subsequently decreased testosterone production. Leptin may also be directly be toxic to the testes. Downregulation of

testosterone production may lead to reduced activation of androgen receptors on hepatocytes, further increasing hepatic steatosis. Free fatty acid production from adipocytes can also have a direct steatogenic effect on the liver. Adipose tissues can also increase cytokine production, leading to central downregulation of the HPG axis and promoting peripheral conversion of testosterone to estrogen [69–72]

obese men with obstructive sleep apnea, by reduced liver fat measured by CT scan [75]. Furthermore, low SHBG has been associated with NAFLD, which is likely one of the major reasons for low testosterone. SHBG levels are lower with increasing obesity [76], type 2 diabetes [77], and metabolic syndrome. The $\text{TNF}\alpha$ and $\text{IL1}\beta$ increase seen in metabolic syndrome has been shown to reduce SHBG expression in HepG2 cells by decreasing $\text{HNF4}\alpha$ (hepatocyte nuclear factor 4- α), which is responsible for activating promoters of multiple genes expressed in liver that function in lipid metabolism [78].

Finally, there is growing research in the relationship between testosterone and microRNAs (miRNAs) in the liver. Some studies suggest that downregulation of miRNAs in liver may ultimately lead to liver diseases, and that testosterone is linked to miRNA regulation in the mouse liver [79]. Specifically, testosterone seems to affect miRNA upregulation of 6 miRNAs: miR-22, miR-690, miR-122, let-7A, miR-30D, and let-7D.

Currently, the treatment for NAFLD is limited with most of the focus on dietary and lifestyle modification, vitamin E, metformin, and pioglitazone, while testosterone treatment is not routinely used [68]. It is likely that obesity and androgen deficiency are interdependent, and further studies need to address whether treatment of androgen deficiency is helpful in men with hepato-steatosis.

Implications of Hypogonadism in End-Stage Liver Disease

Cirrhosis is defined histologically as a diffuse hepatic process described by fibrosis and conversion of normal liver tissue into abnormal nodules after progression from chronic liver injury. In general, cirrhosis is not a reversible process. Cirrhosis is generally classified into two main stages of compensated and decompensated. Decompensated cirrhosis is characterized by ascites, variceal bleeding, encephalopathy, and

hepatorenal syndrome with an estimate of 5–7% yearly progression from the compensated to decompensated stage. Child-Pugh's score and MELD-Na which includes INR, bilirubin, creatinine, sodium, and recent dialysis, are the predominant scores used to evaluate for the prognosis of end-stage liver disease in cirrhosis patients [1, 80].

Testosterone levels are generally low in men with advanced liver disease and continue to decline with hepatic decompensation [7]. SHBG levels also decline despite an initial increase in the early course of liver disease [81]. The previous sections focused on the implications of hypogonadism in stable, chronic liver disease, and this section will discuss the relationship between hypogonadism and decompensated liver disease with focus on the implications of hypogonadism in end-stage liver disease. There are data to suggest that low testosterone levels predict mortality in cirrhosis, independent of MELD-Na score, predict prognosis and can be used to prioritize for liver transplantation [82, 83].

In cirrhosis, the phenotypic presentation includes gynecomastia, palmar erythema, hair loss, and poor libido, which is likely due to increase in the estrogen to androgen ratio. Also, the chronic use of spironolactone as a diuretic also functions as an antiandrogen and can increase the level of estradiol [84], further potentiating gynecomastia and impotence. Muscle wasting is common in cirrhosis, which may be partly due to decreased nutrition with decreased appetite in the setting of chronic inflammation. Although muscle wasting is associated with mortality in patients with cirrhosis, it was unrelated to the extent of liver dysfunction by conventional scoring systems, and its relationship with hypogonadism remains unclear. However, low testosterone contributes to muscle wasting through its effects on cell differentiation and myocyte proliferation [85].

Low bone mineral bone density (BMD) is seen in upward of 60% of patients undergoing liver transplant evaluation, with micro-architectural deterioration of bone tissue leading to increased risk of bone fragility and twofold increase in the risk of fracture [86]. There are

multiple hypotheses concerning low BMD including the effect of impaired osteoblast activity from alcohol or iron overload, impaired calcium absorption from hyperbilirubinemia, and low vitamin D levels [87, 88]. The level of liver failure based on Child-Pugh system seems to correlate with the increase in bone loss, while the role of testosterone deficiency needs further investigation.

Up to 80% of patients with cirrhosis have insulin resistance [89]. Since there is a strong relationship between low testosterone levels and insulin resistance in men with diabetes, androgen deficiency may play a role in the development of insulin resistance in cirrhosis.

Testosterone is known to suppress the immune system, reducing macrophage activation and the generation of cytokines such as IL-2 [90], but the data remain controversial in terms of how hypogonadism, liver disease, and the immune system are linked. There has been some interest in the use of testosterone pre-transplant for its immune suppressive effects. Finally, cirrhotic patients report higher levels of psychological distress and general fatigue, which in part may be from androgen deficiency [83].

Thus, low testosterone levels may partly contribute to many of the complications seen in patients with cirrhosis, such as muscle wasting, low BMD, insulin resistance, alterations in immune system, and psychologic changes.

Diagnosis

The diagnosis of hypogonadism in the setting of liver disease can be challenging. Due to elevation in SHBG levels, total testosterone levels may be high despite low free and bioavailable testosterone levels. Alternatively low SHBG levels may result in low total with normal free testosterone levels. Signs and symptoms of hypogonadism, as outlined above, may overlap with those of liver disease and associated comorbidities, further underscoring the need for an accurate biochemical assessment of testosterone.

The 2010 guidelines from the Endocrine Society recommend utilizing total testosterone

(TT), sex hormone binding globulin (SHBG), and luteinizing hormone (LH) levels to diagnose hypogonadism. The guidelines further recommend considering free and/or bioavailable testosterone levels in the setting of conditions, associated with elevated SHBG levels, including hepatic cirrhosis and hepatitis [91].

Testosterone Treatment in Liver Disease Patients

The impact of treatment of hypogonadism in liver disease is controversial. The 2010 Endocrine Society guidelines recommend testosterone treatment for symptomatic men with classical androgen deficiency syndromes that is aimed at inducing and maintaining secondary sex characteristics and at improving sexual function, sense of well-being and bone density [91]. The guidelines do not specifically comment on androgen treatment in the setting of liver disease.

Few trials have examined the effects of testosterone therapy in men with liver disease and are limited by small sample size, study design, and heterogeneous patient groups. In an early study, Wells et al. (1960) randomized men ($n = 97$) with biopsy-proven cirrhosis on hospital admission, regardless of baseline testosterone levels, to receive prednisolone/corticotropin ($n = 27$) (20 mg daily of prednisolone for the first 4 weeks followed by 140 mg every 4 weeks beginning week 7, along with long-acting corticotropin every 2 weeks), intramuscular testosterone ($n = 26$) (100 mg of testosterone propionate on alternate days for the first 4 weeks followed by 300 mg every 2 weeks), or a control group ($n = 27$) for a total of 14–86 weeks. Both the prednisolone and testosterone groups had an increase in serum albumin levels. Furthermore, mortality occurred in 55% of controls compared to 26% in the prednisone group and 31% in the testosterone group. Overall, these findings were felt at the time to suggest a possible mortality benefit with testosterone therapy. However, interpretation of these results is difficult as treatment duration and patient follow-up were variable and the study was not blinded.

Fenster et al. (1966) randomized 32 men with alcoholic cirrhosis to receive intramuscular testosterone versus methenolone versus placebo for 1 month, and found no benefit with treatment [92]. Puliyl et al. in 1978 randomized participants ($n = 14$ men, $n = 17$ women) with biopsy-proven cirrhosis of any etiology to receive intramuscular testosterone ($n = 12$) or standard of care ($n = 9$) for 4 weeks. At the end of the trial, the testosterone group had a subjective feeling of improvement and an increase in albumin with a decrease in ascites and pedal edema [93]. The size and duration of the study are notable limitations.

A Cochrane review (2006) ($n = 499$) demonstrated that anabolic steroids (testosterone, oxandrolone, methenolone) got men with alcoholic liver disease (hepatitis and cirrhosis) reduced gynecomastia, but had no effect on sexual function, liver biochemistry, liver histology, complications of liver disease (RR 1.25, 95% CI 0.74–2.10), liver-related mortality (RR 0.83, 95% CI 0.60–1.15), or overall mortality (RR 1.01, 95% CI 0.79–1.29). Testosterone was not associated with an increase in nonserious adverse events (RR 1.14, 95% CI 0.50–2.59) or serious adverse events (RR 4.54, 95% CI 0.57–36.30). There was, however, a trend toward statistical significance with the treatment group reporting three patients with portal or hepatic thrombosis, one with myocardial infarction, and three with polycythemia versus only one with polycythemia in the control group [94]. Overall, however, this study has been criticized in that a high proportion of noncirrhotic subjects with alcoholic hepatitis ceased alcohol consumption during the study, potentially impacting the ability to detect benefits of testosterone treatment.

The Copenhagen Study Group for Liver Disease (1986) performed a double-blind placebo-controlled multicenter trial in which they randomized men to either oral testosterone 200 mg three times/day ($n = 134$) or placebo ($n = 87$) for a median of 28 months. Despite improvement in gynecomastia, no differences were seen in liver biochemistry, histology, or mortality (25%; 95% CI 18–33%) versus placebo (21%; 95% CI, 13–31%). A difference in adverse events could

not be excluded. This study has been criticized, as a low testosterone level was not an inclusion criterion, thus potentially impacting the ability to detect benefits of testosterone treatment [95].

Most recently, Yurci et al. (2011) enrolled men ($n = 12$) with low free testosterone levels with various etiologies of cirrhosis, and treated all participants with 50 mg of testosterone gel for 6 months. Gynecomastia was reduced (subareolar breast tissue 28.83 ± 17.18 mm; 15.00 ± 6.74 mm, $P = 0.007$), while muscle strength, as assessed by hydraulic hand dynamometer, improved (34.03 ± 7.24 kg; 39.18 ± 5.99 kg, $P < 0.001$). Further, although BMD was not significantly improved, the study was not powered for this outcome. No adverse events were seen in this study [96].

Thus, reduction in gynecomastia appears to be the only consistent benefit across existing studies of testosterone therapy in men with liver disease. Although adverse events have not been increased, larger trials are needed to adequately evaluate safety. Concerns regarding testosterone utilization specific to a population with liver disease have focused on the risk of hepatocellular carcinoma. Small cohort and retrospective studies have shown an association between higher endogenous testosterone levels and HCC [64, 97]. In a Taiwanese study of men without cirrhosis, free testosterone was associated with HCC, but in multivariable analysis, independent associations with estradiol and SHBG were not seen [64]. A study in a Japanese population suggested that an elevated estradiol/testosterone ratio was associated with increased risk of HCC [97]. Low endogenous testosterone levels have also been associated with higher rates of hepatocellular carcinoma in a largely Caucasian cohort of men [97], with low testosterone hypothesized to reflect increased severity of liver disease, rather than an involvement in tumorigenesis [7]. Other studies have not demonstrated a link between testosterone levels and hepatocellular carcinoma [67]. In terms of men being treated with testosterone, reports of hepatocellular effects are limited to oral oxymetholone, which is no longer approved for use due to its established hepatotoxicity [98].

Liver transplantation results in changes to the HPG axis (affected by pre-transplant metabolic insults, immunosuppression and graft function) and protein synthesis, which can in turn affect recovery from hypogonadism. Total and free testosterone levels may be reduced beyond pre-transplant levels for up to one month after surgery, felt to be due at least in part to high-dose immunosuppressive therapy [12, 99, 100]. More than one-third of men after liver transplant do not normalize testosterone levels, many with persistent evidence of hypergonadotropic hypogonadism [12, 101]. Increase in gonadotropin output, notably LH, has further been described as a key factor in normalization of free testosterone levels in the first year after surgery. Hyperprolactinemia also resolves in the majority of patients, which is felt to be due to a combination of changes in endocrine-metabolic function and the suppressive effect of calcineurin inhibitors on prolactin gene expression [12, 102, 103]. Tacrolimus, like cyclosporine, may have a direct toxic effect on Leydig cells [104, 105]. Furthermore, glucocorticoids are known suppress GnRH and inhibit the synthesis of adrenal androgens.

Conclusions

In conclusion, hypogonadism in the setting of liver disease is common, and its etiology is multifactorial. In general, chronic liver disease is associated with central hypogonadism, though exceptions exist, most commonly in alcoholic liver disease because ethanol has a direct toxic effect on the testes. In NAFLD and NASH, low testosterone may be explained by low SHBG. The role of testosterone treatment in hypogonadal men with chronic liver disease remains controversial in the absence of reliable safety data, although adverse events have not been increased in smaller studies. Despite early and limited data on the possible beneficial effect of testosterone in improvement of morbidity and mortality in liver disease, taken in sum, testosterone treatment is associated only with a possible improvement in gynecomastia. Hypogonadism may be reversible

after liver transplantation. Well-designed and adequately powered studies are needed to understand the consequences of hypogonadism in liver disease, as well as efficacy and safety of treatment strategies.

References

1. Starr SP, Raines D. Cirrhosis: diagnosis, management, and prevention. *Am Fam Physician*. 2011;84(12):1353–9.
2. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol* 2011;9(6):524–530.e1; quiz e60.
3. Eshraghian A, Taghavi SA. Systematic review: endocrine abnormalities in patients with liver cirrhosis. *Arch Iran Med*. 2014;17(10):713–21.
4. Wass J OK. Oxford handbook of diabetes and endocrinology. 2014;3:657–659.
5. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Immunosuppressive and post-operative effects of orthotopic liver transplantation on bone metabolism. *Liver Transpl*. 2004;10(5):638–47.
6. Kaymakoglu S, Okten A, Cakaloglu Y, Boztas G, Besisik F, Tascioglu C, et al. Hypogonadism is not related to the etiology of liver cirrhosis. *J Gastroenterol*. 1995;30(6):745–50.
7. Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. *J Gastroenterol Hepatol*. 2015;30(2):244–51.
8. Grossmann M, Hoermann R, Gani L, Chan I, Cheung A, Gow PJ, et al. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. *Clin Endocrinol (Oxf)*. 2012;77(2):323–8.
9. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. *Osteoporos Int*. 2001;12(6):484–92.
10. Kharb S, Garg MK, Puri P, Brar KS, Pandit A, Srivastava S. Assessment of thyroid and gonadal function in liver diseases. *Indian J Endocrinol Metab* 2015;19(1):89–94.
11. Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Scholmerich J, et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. *Eur J Gastroenterol Hepatol*. 2003;15(5):495–501.
12. Foresta C, Schipilliti M, Ciarleglio FA, Lenzi A, D'Amico D. Male hypogonadism in cirrhosis and after liver transplantation. *J Endocrinol Invest*. 2008;31(5):470–8.
13. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. *Eur J Endocrinol*. 2005;152(4):501–13.
14. Leung PC, Steele GL. Intracellular signaling in the gonads. *Endocr Rev*. 1992;13(3):476–98.
15. Jones TH, Kennedy RL. Cytokines and hypothalamic-pituitary function. *Cytokine*. 1993;5(6):531–8.
16. Van Thiel DH, McClain CJ, Elson MK, McMillan MJ, Lester R. Evidence for autonomous secretion of prolactin in some alcoholic men with cirrhosis and gynecomastia. *Metabolism*. 1978;27(12):1778–84.
17. De Besi L, Zucchetta P, Zotti S, Mastrogioacomo I. Sex hormones and sex hormone binding globulin in males with compensated and decompensated cirrhosis of the liver. *Acta Endocrinol (Copenh)*. 1989;120(3):271–6.
18. De Palo EF, Bassanello M, Lancerin F, Spinella P, Gatti R, D'Amico D, et al. GH/IGF system, cirrhosis and liver transplantation. *Clin Chim Acta*. 2001;310(1):31–7.
19. McClain CJ, Kromhout JP, Elson MK, Van Thiel DH. Hyperprolactinemia in portal systemic encephalopathy. *Dig Dis Sci*. 1981;26(4):353–7.
20. Mukherjee S, Kar M, Dutta S. Observation on serum prolactin in hepatic cirrhosis. *J Indian Med Assoc*. 1991;89(11):307–8.
21. Corenblum B, Shaffer EA. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission. *Horm Metab Res*. 1989;21(12):675–7.
22. Simon-Holtorf J, Monig H, Klomp HJ, Reinecke-Luthge A, Folsch UR, Kloehn S. Expression and distribution of prolactin receptor in normal, fibrotic, and cirrhotic human liver. *Exp Clin Endocrinol Diabetes*. 2006;114(10):584–9.
23. Madersbacher S, Grunberger T, Maier U. Andrological status before and after liver transplantation. *J Urol*. 1994;151(5):1251–4.
24. Maria N, Colantoni A, van Thiel D. The liver and endocrine function. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. 3rd ed, ch. 205, pp 1870–1885. Philadelphia: Lippincott Williams & Wilkins, 2000.
25. Bandyopadhyay SK, Moulick A, Saha M, Dutta A, Bandyopadhyay R, Basu AK. A study on endocrine dysfunction in adult males with liver cirrhosis. *J Indian Med Assoc* 2009;107(12):866, 868–9.
26. Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. *J Clin Endocrinol Metab*. 1975;40(6):1018–26.
27. Green JR, Mowat NA, Fisher RA, Anderson DC. Plasma oestrogens in men with chronic liver disease. *Gut*. 1976;17(6):426–30.

28. Kley HK, Niederau C, Stremmel W, Lax R, Strohmeyer G, Kruskemper HL. Conversion of androgens to estrogens in idiopathic hemochromatosis: comparison with alcoholic liver cirrhosis. *J Clin Endocrinol Metab.* 1985;61(1):1–6.
29. Tadic SD, Elm MS, Subbotin VM, Eagon PK. Hypogonadism precedes liver feminization in chronic alcohol-fed male rats. *Hepatology.* 2000;31(5):1135–40.
30. Rubin E, Lieber CS, Altman K, Gordon GG, Southren AL. Prolonged ethanol consumption increases testosterone metabolism in the liver. *Science.* 1976;191(4227):563–4.
31. Braunstein G. Chapter 12. Testes. In: Gardner DG, Shoback D. eds. *Greenspan's Basic & Clinical Endocrinology*, 9e. New York, NY: McGraw-Hill; 2011. <http://accessmedicine.mhmedical.com/Content.aspx?bookid=380&Sectionid=39744052>. Accessed March 11, 2016.
32. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology.* 2011;54(1):328–43.
33. McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. *J Clin Endocrinol Metab.* 2005;90(4):2451–5.
34. Yeap BB, Beilin J, Shi Z, Knuiman MW, Olynyk JK, Chubb SA, et al. The C282Y polymorphism of the hereditary hemochromatosis gene is associated with increased sex hormone-binding globulin and normal testosterone levels in men. *J Endocrinol Invest.* 2010;33(8):544–8.
35. Pelusi C, Gasparini DI, Bianchi N, Pasquali R. Endocrine dysfunction in hereditary hemochromatosis. *J Endocrinol Invest.* 2016;39(8):837–47.
36. Tampanaru-Sarmesiu A, Stefaneanu L, Thapar K, Kontogeorgos G, Sumi T, Kovacs K. Transferrin and transferrin receptor in human hypophysis and pituitary adenomas. *Am J Pathol.* 1998;152(2):413–22.
37. Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. *N Engl J Med.* 2004;350(23):2383–97.
38. Walton C, Kelly WF, Laing I, Bu'lock DE. Endocrine abnormalities in idiopathic haemochromatosis. *Q J Med* 1983 Winter;52(205):99–110.
39. O'Sullivan EP, McDermott JH, Howel Walsh C. All that is hypogonadal in haemochromatosis is not due to iron deposition. *Ir J Med Sci.* 2007;176(1):45–7.
40. Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. *Hepatology.* 2006;44(2):472–7.
41. Gautier A, Laine F, Massart C, Sandret L, Piguel X, Brissot P, et al. Liver iron overload is associated with elevated SHBG concentration and moderate hypogonadotropic hypogonadism in dysmetabolic men without genetic haemochromatosis. *Eur J Endocrinol.* 2011;165(2):339–43.
42. Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. *Ann Intern Med.* 1984;101(5):629–32.
43. O'Shea RS, Dasarthy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. *Hepatology.* 2010;51(1):307–28.
44. Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. *Keio J Med.* 1999;48(4):184–8.
45. Bird GL, Williams R. Factors determining cirrhosis in alcoholic liver disease. *Mol Aspects Med.* 1988;10(2):97–105.
46. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. *Alcohol Res Health.* 2003;27(3):209–19.
47. Becker U, Gronbaek M, Johansen D, Sorensen TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. *Hepatology.* 2002;35(4):868–75.
48. Sato N, Lindros KO, Baraona E, Ikejima K, Mezey E, Jarvelainen HA, et al. Sex difference in alcohol-related organ injury. *Alcohol Clin Exp Res* 2001;25(5 Suppl ISBRA):40S–45S.
49. Chiao YB, Van Thiel DH. Biochemical mechanisms that contribute to alcohol-induced hypogonadism in the male. *Alcohol Clin Exp Res* 1983 Spring;7(2):131–134.
50. Ylikahri R, Huttunen M, Harkonen M, Adlercreutz H. Letter: Hangover and testosterone. *Br Med J.* 1974;2(5916):445.
51. Badr FM, Bartke A, Dalterio S, Bulger W. Suppression of testosterone production by ethyl alcohol. Possible mode of action. *Steroids.* 1977;30(5):647–55.
52. Bannister P, Handley T, Chapman C, Losowsky MS. Hypogonadism in chronic liver disease: impaired release of luteinising hormone. *Br Med J (Clin Res Ed).* 1986;293(6556):1191–3.
53. Cicero TJ, Badger TM. Effects of alcohol on the hypothalamic-pituitary-gonadal axis in the male rat. *J Pharmacol Exp Ther.* 1977;201(2):427–33.
54. Ciofalo FR. Chronic alcohol ingestion and alpha-adrenergic receptor characteristics. *Proc West Pharmacol Soc.* 1979;22:367–9.
55. Jiang M, Klein M, Zanger UM, Mohammad MK, Cave MC, Gaikwad NW, et al. Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. *J Hepatol.* 2016;64(1):44–52.
56. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. *Ann Intern Med.* 2014;160(5):293–300.

57. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. *Dig Liver Dis.* 2014;15(46 Suppl 5):S165–73.
58. Nguyen HV, Mollison LC, Taylor TW, Chubb SA, Yeap BB. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. *Intern Med J.* 2006;36(6):362–6.
59. Ferri C, Bertozzi MA, Zignego AL. Erectile dysfunction and hepatitis C virus infection. *JAMA.* 2002;288(6):698–9.
60. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. *J Virol.* 2006;80(14):7199–207.
61. Zini A, Garrels K, Phang D. Antioxidant activity in the semen of fertile and infertile men. *Urology.* 2000;55(6):922–6.
62. Lorusso F, Palmisano M, Chironna M, Vacca M, Masciandaro P, Bassi E, et al. Impact of chronic viral diseases on semen parameters. *Andrologia.* 2010;42(2):121–6.
63. Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. *Drugs.* 2015;75(6):675–85.
64. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. *Cancer Res.* 2000;60(18):5106–10.
65. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. *Hepatology.* 2012;55(3):759–68.
66. Chiu CM, Yeh SH, Chen PJ, Kuo TJ, Chang CJ, Chen PJ, et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. *Proc Natl Acad Sci U S A.* 2007;104(8):2571–8.
67. Lukanova A, Becker S, Husing A, Schock H, Fedirko V, Trepo E, et al. Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers? *Int J Cancer.* 2014;134(1):164–73.
68. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology.* 2012;55(6):2005–23.
69. Hazlehurst JM, Tomlinson JW. Non-alcoholic fatty liver disease in common endocrine disorders. *Eur J Endocrinol.* 2013;169(2):R27–37.
70. Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. *BMC Gastroenterol* 2012;12:69-230X-12-69.
71. Mantzoros CS. Role of leptin in reproduction. *Ann N Y Acad Sci.* 2000;900:174–83.
72. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. *J Clin Endocrinol Metab.* 2005;90(5):2636–41.
73. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. *Clin Endocrinol (Oxf).* 2005;63(3):239–50.
74. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. *Clin Endocrinol (Oxf).* 2010;73(5):602–12.
75. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial. *Eur J Endocrinol* 2015;173(5):X3-12-0525e.
76. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. *J Clin Endocrinol Metab.* 1977;45(6):1211–9.
77. Birkeland KI, Hanssen KF, Torjesen PA, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. *J Clin Endocrinol Metab.* 1993;76(2):275–8.
78. Rhee J, Ge H, Yang W, Fan M, Handschin C, Cooper M, et al. Partnership of PGC-1alpha and HNF4alpha in the regulation of lipoprotein metabolism. *J Biol Chem.* 2006;281(21):14683–90.
79. Delic D, Grosser C, Dkhil M, Al-Quraishy S, Wunderlich F. Testosterone-induced upregulation of miRNAs in the female mouse liver. *Steroids.* 2010;75(12):998–1004.
80. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *International Ascites Club. Hepatology.* 1996;23(1):164–76.
81. Maruyama Y, Adachi Y, Aoki N, Suzuki Y, Shinohara H, Yamamoto T. Mechanism of feminization in male patients with non-alcoholic liver cirrhosis: role of sex hormone-binding globulin. *Gastroenterol Jpn.* 1991;26(4):435–9.
82. Agboghroma CO. Gynaecological and reproductive health issues in HIV-positive women. *West Afr J Med* 2010;29(3):135–142.
83. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. *AIDS.* 2009;23(Suppl 1):S55–67.

84. Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL. Interaction of digitalis and spironolactone with human sex steroid receptors. *J Clin Endocrinol Metab.* 1978;46(2):338–44.
85. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. *Am J Physiol Endocrinol Metab.* 2003;285(1):E197–205.
86. Collier J. Bone disorders in chronic liver disease. *Hepatology.* 2007;46(4):1271–8.
87. George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. *World J Gastroenterol.* 2009;15(28):3516–22.
88. Alcalde Vargas A, Pascasio Acevedo JM, Gutierrez Domingo I, Garcia Jimenez R, Sousa Martin JM, Ferrer Rios MT, et al. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation. *Transplant Proc* 2012;44(6):1496–1498.
89. Carter MW, Kraft JM, Hatfield-Timajchy K, Snead MC, Ozeryansky L, Fasula AM, et al. The reproductive health behaviors of HIV-infected young women in the United States: A literature review. *AIDS Patient Care STDS.* 2013;27(12):669–80.
90. Muehlenbein MP, Bribiescas RG. Testosterone-mediated immune functions and male life histories. *Am J Hum Biol* 2005;17(5):527–558.
91. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95(6):2536–59.
92. Wells R. Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. *Lancet.* 1960;2(7166):1416–9.
93. Puliyl MM, Vyas GP, Mehta GS. Testosterone in the management of cirrhosis of the liver—a controlled study. *Aust N Z J Med.* 1977;7(6):17–30.
94. Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. *Cochrane Database Syst Rev* 2006;(4):CD003045.
95. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. *Hepatology* 1986;6(5):807–813.
96. Yurci A, Yucesoy M, Unluhizarci K, Torun E, Gursoy S, Baskol M, et al. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. *Clin Res Hepatol Gastroenterol.* 2011;35(12):845–54.
97. Montalto G, Miceli M, Soresi M, Amodio R, Carroccio A, Cartabellotta A, et al. Sex hormones in patients with liver cirrhosis and hepatocellular carcinoma. *Oncol Rep* 1997;4(1):173–176.
98. Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, Kronenberg H. Androgen-induced hepatoma. *Lancet.* 1975;1(7904):430–2.
99. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. *Calcif Tissue Int.* 1997;60(2):148–54.
100. Reinhardt W, Patschan D, Pietruck F, Philipp T, Janssen OE, Mann K, et al. Free androgen index is superior to total testosterone for short-term assessment of the gonadal axis after renal transplantation. *Horm Res.* 2005;64(5):248–52.
101. Jin B, McCaughan GW, Handelsman DJ. Effects of liver disease and transplantation on the human prostate. *J Androl* 1999;20(4):559–565.
102. Nagai Y, Ohsawa K, Ohta M, Hisada A, Yamashita H, Yoshizawa M, et al. Inhibitory effect of cyclosporin A on prolactin synthesis in GH3 cells. *Tohoku J Exp Med.* 1996;180(4):337–46.
103. Wera S, Belayew A, Martial JA. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. *FEBS Lett.* 1995;358(2):158–60.
104. Seethalakshmi L, Flores C, Malhotra RK, Pallias JD, Tharakan D, Khauli RB, et al. The mechanism of cyclosporine's action in the inhibition of testosterone biosynthesis by rat Leydig cells in vitro. *Transplantation.* 1992;53(1):190–5.
105. Kantarci G, Sahin S, Uras AR, Ergin H. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. *Transplant Proc* 2004;36(1):178–179.

Male Hypogonadism Due to Cancer and Cancer Treatments

12

Rod T. Mitchell BSc, MBChB, PhD,
Jan-Bernd Stukenborg MSc, PhD
and Kirsi Jahnukainen MD, PhD

Contents

Introduction	235	Chemotherapy and Leydig Cell Function	241
Pre-treatment Testicular Dysfunction	236	Radiotherapy and Leydig Cell Function	242
Hodgkin's Disease	236	Clinical Impact of Impaired Leydig Cell Function...	243
Testicular Cancer	236	Genetic Damage Following Cytotoxic Therapy	244
Pediatric Malignancies	236	Fertility Preservation for Males Undergoing Cancer Treatment	244
Cancer Treatment and Gonadal Function	237	Semen Cryopreservation and Assisted Reproduction	244
Cancer Treatment and Hypothalamic-Pituitary Function	237	Hormonal Therapy for Fertility Preservation	245
Cancer Treatment and Spermatogenesis	238	Ex Vivo Techniques for Fertility Preservation	246
Chemotherapy-Induced Damage to the Germinal Epithelium	238	100 Years in Search of the Conditions Required for Male Germ Cell Differentiation in Vitro	248
Spermatogenetic Failure After Treatment of Haematological Malignancy	239	Summary	249
Spermatogenetic Failure After Testicular Cancer	240	References	250
Irradiation-Induced Damage to Germinal Epithelium	240		
Cancer Treatment and Leydig Cell Function	241		

Introduction

Survival rates after cancer treatment have increased dramatically in recent decades, resulting in an increasing focus on the harmful effects of cancer treatment for these patients [1]. One of the major long-term effects of cancer and its treatment is compromised reproductive function in both males and females [2]. These effects may occur as a result of direct effects on the gonads or indirect effects via damage to the hypothalamus or pituitary. In males, there may be impairment of testicular function prior to the commencement of treatment while exposure to cytotoxic therapies may result in damage to the seminiferous epithelium leading to oligo- or azoospermia [3]. In addition to effects on the germinal epithelium there may also be damage to the Leydig cells, resulting in impaired testosterone production [4].

R.T. Mitchell
MRC Centre for Reproductive Health, Queens
Medical Research Institute, University of Edinburgh,
47 Little France Crescent, Edinburgh, Lothian
EH164TJ, Scotland, UK
e-mail: rod.mitchell@ed.ac.uk

J.-B. Stukenborg
Department of Women's and Children's Health,
Karolinska Institutet and University Hospital,
Nordfertil Research Lab Stockholm, Pediatric
Endocrinology Unit, Q2:08, Stockholm 17176,
Sweden
e-mail: jan-bernd.stukenborg@ki.se

K. Jahnukainen (✉)
Division of Haematology-Oncology and Stem Cell
Transplantation, Children's Hospital, Helsinki
University Central Hospital, University of Helsinki,
PL281, Helsinki 00029, Finland
e-mail: Kirsi.Jahnukainen@hus.fi

The precise nature of the damage, and the potential for recovery, is determined by a number of factors which include intrinsic factors, such as the genetic factors that modulate the sensitivity of an individual's germinal epithelium, and the cancer diagnosis, and extrinsic factors such as the specific treatment regimen in terms of the agent, dosage and frequency [2, 5–11]. The state of testicular development, between prepubertal and adult, may also influence the effects of cancer treatment on subsequent development and function [11]. Age and developmental stage also determine the options available to preserve reproductive potential in these patients [2].

This chapter will describe the effects of cancer and its treatments on male reproductive function in terms of damage to the seminiferous epithelium and testosterone production. We will also discuss the options, both established and experimental, for fertility preservation in these patients.

Pre-treatment Testicular Dysfunction

Alterations in germinal epithelial function have been demonstrated in patients with cancer before any treatment is commenced. This is particularly apparent in men with testicular cancer and Hodgkin's Disease (HD). Because of severe debilitation or impotence, not all men are able to provide semen for cryopreservation prior to treatment. As a result many of the studies relating to germinal epithelial function prior to treatment examined only men who were able to produce a semen sample, and therefore may have selected a slightly healthier cohort leading to an underestimation of the extent of gonadal dysfunction pre-treatment.

Hodgkin's Disease

The literature describes varying degrees of semen quality impairment in HD patients prior to treatment. Some studies found a high degree of impaired spermatogenesis based on semen analysis [12–15] while others found normozoospermia in more than 50% of HD patients [16–21]. Pubertal

patients with HD have significantly lower mean inhibin B levels and higher mean FSH and LH levels than controls, which is indicative of spermatogenetic dysfunction among the paediatric HD population [22]. The pathogenesis of HD-associated dyspermia is not clearly understood. Studies incorporating testicular biopsies have failed to find any evidence for direct tumour involvement in the testis [12, 23]. Poor semen quality has been attributed to hypothalamic dysfunction, increased catabolism, malnutrition and immunological imbalances, affecting the lymphocytic cell and cytokine profiles (interleukin and tumour necrosis factor) [24].

Testicular Cancer

Testicular cancer is also associated with oligozoospermia in over 50% of men before treatment [25, 26]. In patients with unilateral testicular cancer, irreversibly impaired spermatogenesis in the contralateral testis has been demonstrated in up to 24% of patients [27]. This observation supports the concept of a "testicular dysgenesis syndrome" (TDS) comprising low sperm counts, hypospadias, cryptorchidism and testicular cancer, and is thought to be related to foetal development complications [28] (see Chap. 14). Accordingly, the prevalence of testicular cancer among men with an abnormal semen analysis has been calculated to be 20 times higher than in the normal population [29]. Other possible causes of dyspermia include local tumour effects, to which elevation of scrotal temperature, alterations in testicular blood flow, and disruption of the blood–testis barrier may contribute. Furthermore, sperm antibodies have been found in a high proportion of patients with testicular cancer [30]. Finally, testicular cancer may be hormonally active, and local hormone production may impair spermatogenesis.

Pediatric Malignancies

The preliminary histological findings of testicular biopsies obtained from prepubertal males before initiation of gonadotoxic therapy suggest possible

abnormal germ cell maturation [31]. Testicular biopsies were cryopreserved for experimental fertility preservation for 29 patients with solid tumours and for 5 patients who underwent hematopoietic stem cell transplantation (HSCT) for benign disease. A total of 27 patients had adequate tissue for histological analysis. In total, 22 children (81% of patients) had normal and 5 (19%) had increased numbers of germ cells per tubule for their age. However, 19% (5/26) of boys older than 6 months had no evidence of adult dark spermatogonia and 56% (9/16) of those older than 6 years had no evidence of primary spermatocytes on biopsy, which would be expected based on age norms [32–34]. These observational studies suggest maturation delay of spermatogenesis. If boys

with serious childhood diseases truly have delayed maturation in spermatogenesis, this may affect the fertility potential of testicular tissue cryopreserved for fertility preservation. Further investigation regarding the impact of these preliminary histological findings is warranted.

Cancer Treatment and Gonadal Function

Cancer treatment may result in damage to the gonad either as a result of direct effects on the gonad, or indirectly from damage to the hypothalamic-pituitary unit with resulting downstream effects on gonadal function and fertility (Fig. 12.1).




Fig. 12.1 Effect of cytotoxic therapies on the hypothalamic–pituitary–testicular axis in children and adults. Differences in hormonal profile, cellular composition and cellular maturity can result in differential effects of cancer

treatment in children compared with adults. SSC—spermatogonial stem cell. * Insufficient evidence to determine effects of cancer treatment

Cancer Treatment and Hypothalamic-Pituitary Function

Following cranial irradiation, gonadotropin deficiency is the second most common pituitary hormone abnormality after growth hormone deficiency. Although in the short term, doses of 30–50 Gy may result in precocious puberty (more frequently in young girls than boys), and doses of at least 30 Gy may result in true gonadotropin deficiency in the longer term [35]. In a study of 45 children treated with cranial radiation, severe gonadotropin deficiency was observed in 11% of cases, resulting in lack of, or slow progression of puberty, with a reduced gonadotropin response to GnRH [36]. Studies in post-pubertal patients have demonstrated that in some the serum levels of testosterone are reduced, and LH and FSH levels may be low. However, demonstration of a preserved pituitary response to GnRH [37] and growth hormone-releasing hormone [38] following cranial

irradiation suggests initial hypothalamic hypogonadism, with pituitary insufficiency occurring later.

Cancer Treatment and Spermatogenesis

Chemotherapy-Induced Damage to the Germinal Epithelium

Testicular cells, especially rapidly dividing germ cells, are highly sensitive to cytotoxic treatment (Fig. 12.2). Low doses of these treatments deplete the pool of differentiating spermatogonia, while reserve spermatogonial stem cells (SSCs) survive, and spermatocytes and spermatids continue their maturation into sperm [39] (Fig. 12.2). Testicular involution after such gonadotoxic damage is a slow process that among sexually mature men occurs over several weeks until temporary or permanent azoospermia ensues.

Risk of Infertility	Chemotherapy Agent (cumulative dose for prolonged azoospermia)	Mechanism of action
High or Moderate	<p>Alkylating agents</p> <p>Cyclophosphamide (19g/m²) Busulphan (600g/m²) Melphalan (140g/m²) Ifosfamide (60g/m²) Procarbazine (4g/m²) BCNU (carmustine) CCNU (lomustine)</p> <p>Platinum agents</p> <p>Cis-platinum (600g/m²) Carboplatin (2g/m²)</p>	<p>Direct DNA or RNA damage</p> <p>Induction of Apoptosis</p>
Low	<p>Antimetabolites</p> <p>Methotrexate Mercaptopurine Cytarabine</p> <p>Vinca Alkaloids</p> <p>Vincristine Vinblastine</p> <p>Antitumour Antibiotics</p> <p>Bleomycin Dactinomycin Doxorubicin</p> <p>Podophyllotoxins</p> <p>Etoposide</p> <p>Other</p> <p>Asparaginase</p>	<p>Inhibition of DNA or RNA Synthesis</p> <p>Inhibition of Mitosis</p> <p>Deamination of Proteins</p> <p>Introduction of DNA Strand breaks (antimetabolites)</p>

Fig. 12.2 Risk of infertility based on the prospect of prolonged azoospermia according to cumulative dose of chemotherapeutic agent exposure [40, 41], Busulfan: [42], Ifosfamide: [43], Carbo: [44], Procarbazine: [45], Cis-platinum: [46, 47]

Recovery of sperm production after a cytotoxic insult in puberty or adulthood depends on the ability of mitotically quiescent SSCs to survive and resume mitotic activity and to produce differentiating spermatogonia. If the damage is severe (e.g. as a result of a high cumulative dose of alkylating agents), all SSCs may commit to apoptosis and the patient becomes permanently infertile. Spermatogonia have been shown to be similarly susceptible to such depletion at all stages of life.

Alkylating agents, including cyclophosphamide and the combination of mechlorethamine and procarbazine, have been associated with increased risk of impaired spermatogenesis [48, 49]. Agents with the potential to cause impaired spermatogenesis include also ifosfamide at doses $>60 \text{ g/m}^2$ [43, 50–52]. Higher doses have greater risks compared to lower doses [48, 49, 53]. The threshold dose of cyclophosphamide, in relation to infertility, has been shown to be between 7.5 and 10 g/m^2 [10, 54, 55]. Recent observations suggest that slow recovery of spermatogenesis may occur even after these high doses, and permanent sterility may appear after 19 – 20 g/m^2 of cyclophosphamide [40, 41]. Similar threshold doses for incipient testicular failure have also been reported for other alkylating agents [41, 45, 55, 56], carboplatin and cisplatin [5, 44]. However, a recent large study of non-irradiated childhood cancer survivors failed to identify any threshold dose for alkylating agent exposure that predicted impaired spermatogenesis or azoospermia after a median follow-up of 21 years [53]. There may be other factors, in addition to absolute doses and regimen, such as genetic variation in drug metabolising pathways, which modulate the impact of alkylating agent exposure on spermatogenesis or its recovery [53].

Spermatogenetic Failure After Treatment of Haematological Malignancy

At diagnosis, between 40 and 70% of children with acute lymphoblastic leukaemia (ALL) and 50% of those with acute myeloid leukaemia (AML) are

considered to be standard risk, and as a result will receive treatment that combines chemotherapy agents from a number of different classes [57]. These regimens typically involve the use of antimetabolite or vinca alkaloid chemotherapy which inhibits DNA and RNA synthesis and mitosis. Evaluation of testicular biopsies of ALL patients immediately following termination of therapy has revealed that 40% exhibit severe impairment of the tubular fertility index (with less than 40% of their seminiferous tubules containing spermatogonia; [58]). This index tends to improve for most patients as more time elapses after treatment [58, 59]. Long-term follow-up of childhood leukaemia survivors revealed that treatment with these cell cycle-specific cytotoxic drugs, without a high dose of alkylating agent cyclophosphamide, does not totally deplete SSCs, and that spermatogenesis is reinitiated from the surviving reserve stem cell population [40, 60].

Gonadotoxicity following exposure to the ABVD (doxorubicin, vinblastine, dacarbazine and bleomycin) protocol, without a high dose of alkylating agent for HD, is relatively mild with 90% of adult patients having normal gonadotropin levels and sperm counts 12 months after therapy [19, 61]. However, more than 3 courses of alkylating agent (cyclophosphamide, nitrogen mustard, or procarbazine)-based chemotherapy for HD is known to cause azoospermia or result in inhibin B and FSH levels consistent with oligozoospermia in 70–90% of patients [21, 49, 61–63]. Standard-risk non-Hodgkin lymphoma (NHL) patients who are treated with chemotherapy including antimetabolites, vinca alkaloids and low-dose alkylating agents have a low risk of developing testicular insufficiency similar to that of ALL patients.

Patients initially classified as standard-risk leukaemia or NHL may be re-assigned to a more gonadotoxic treatment regimen in the case of treatment failure/relapse. 30–40% of patients with acute leukaemia carry high-risk features. To be cured, these patients require treatment with allogeneic HSCT. Conditioning for HSCT is associated with a significant risk of germ cell failure with azoospermia in 85% of men and oligozoospermia in the remainder [64–66]. Germ

cell failure with raised serum levels of FSH and decreased testicular growth in puberty is observed among most of the male patients irrespective of the type of conditioning therapy [65, 67]. The probability for recovery of spermatogenesis after HSCT is associated with the type of conditioning therapy, age of the patient, time interval since transplantation and absence of chronic graft versus host disease [65, 66]. One-third of adult HSCT patients receiving high-dose cyclophosphamide treatment had sperm in the ejaculate after a recovery period of 1 year, while those patients receiving cyclophosphamide combined with busulfan or thiotepa showed first recovery after 3 years. Following total body irradiation (TBI), recovery of spermatogenesis never occurred before the 4th year after transplantation [65]. Similar findings have recently been reported in the paediatric population. HSCT conditioning with busulfan or cyclophosphamide was associated with a larger adult testicular volume, lower serum levels of FSH and the more frequent presence of spermatozoa compared to those conditioned with TBI [68].

Spermatogenetic Failure After Testicular Cancer

The other group of patients in whom the effects of chemotherapy on testicular function have been widely investigated is those with testicular cancer [44, 69–71]. To attempt to delineate which abnormalities are a result of cytotoxic chemotherapy, several of these studies also examined pre-treatment testicular function, or compared chemotherapy-treated patients with those who underwent orchidectomy alone [69–71]. All have demonstrated greater testicular dysfunction in the cytotoxic-treated groups, with evidence of germinal epithelial damage indicated by raised FSH levels and/or reduced sperm counts. Lampe and colleagues [44] analysed data from 170 patients with testicular germ cell cancers who underwent treatment with either cisplatin- or carboplatin-based chemotherapy. 40 (24%) were azoospermic pre-treatment, and a further 41 (24%) were oligozoospermic. For a median of 30 months after the


completion of chemotherapy, only 64% of those who were normospermic before therapy remained normospermic, whilst 54 (32%) of the total cohort were azoospermic and 43 (25%) were oligozoospermic. The probability of recovery to a normal sperm count was found to be higher for men with a normal pre-treatment sperm count, those who received carboplatin- rather than cisplatin-based therapy, and those treated with less than five cycles of chemotherapy. Brydøy and colleagues [72] reported that the paternity rate, by natural conception or using assisted reproductive techniques (ART), when sperm reappeared in their semen, was approximately 10% at 5 years in the patient group having received high-dose cisplatin (total cisplatin dose >850 mg), and about 35% in the group with low-dose cisplatin (total cisplatin dose ≤ 850 mg). However, even in the high-dose cisplatin group, the paternity rate increased to 85% after 15 years post-treatment. These data showed that the time necessary for the restoration of spermatogenesis in order to father children was as long as 5–10 years or more.

Irradiation-Induced Damage to Germinal Epithelium

The germinal epithelium is very susceptible to irradiation-induced damage (Fig. 12.3). This depends on the field of treatment, total dose and fractionation [73, 74]. The progenitor and differentiating spermatogonia are radiosensitive to scattered doses as low as 0.1 Gy leading to short-term cessation of spermatogenesis [9]. Doses of 2–3 Gy also affect SSCs and cause long-term azoospermia [9, 75–77]. Doses in excess of 6 Gy deplete the SSC pool and lead to permanent infertility [9, 78].

TBI, as conditioning for haematological stem cell transplantation, is associated with significant germ cell failure [64]. Following treatment with TBI (10 or 13 Gy), azoospermia was found in 85% of men, and oligozoospermia occurred in the remainder [65]. Following TBI, recovery of spermatogenesis never occurred before the 4th year after transplantation; therefore, azoospermia after hematopoietic stem cell transplantation may

Fig. 12.3 Dose-dependent effects on spermatogenesis following single-dose irradiation in adults



be overestimated if semen samples are evaluated too soon after transplantation [65]. Fractionation of radiotherapy has been shown to increase germ cell toxicity possibly because of repeated hits to activated reserve stem cells [78–80]. However, a long-term follow-up study of 106 male survivors after paediatric allogeneic HSCT does not support this notion [68]. The mean adult testicular volume of 6 mL after single-fraction TBI was significantly smaller than the 11 mL after fractionated TBI. Lower serum levels of FSH after fractionated TBI further suggest that fractionation may slightly decrease the detrimental effect of irradiation on the testis [68].

Whilst most of the literature concerning radiotherapy effects on testicular function concerns the use of traditional radiotherapy techniques, recent technological advances have provided new methods for delivering radiotherapy which result in more localised treatment with less scatter dose [81]. These improvements will likely reduce damage to the testis for many treatments targeting radiation to the pelvic region without delivering radiotherapy to the gonad.

Cancer Treatment and Leydig Cell Function

While effects on the seminiferous epithelium are manifest by impacts on spermatogenesis and fertility, Leydig cell dysfunction may manifest as

raised LH levels with normal or low-normal testosterone levels. Such Leydig cell effects are usually associated with much higher doses of radiotherapy/chemotherapy than those which damage seminiferous epithelium.

Chemotherapy and Leydig Cell Function

Evidence for Leydig cell dysfunction following chemotherapy has been described in several studies [4, 42, 44, 82, 83]. In a study of 209 men with a variety of haematological malignancies (including 160 with HD) treated with either MVPP or ChlVPP/EVA hybrid, LH levels were higher in patients compared with a cohort of age-matched controls (mean LH 7.9 versus 4.1 IU/l) [4]. Increased LH levels suggest pituitary compensation to a reduction in testosterone production causing reduced hypothalamic-pituitary negative feedback. Testosterone may still remain within the reference range as mild Leydig cell dysfunction may be reflected by raised LH together with low-normal to normal testosterone levels. This combination was found in 67 (32%) following chemotherapy, compared with 2 (4%) of healthy controls. A further 12 (6%) of the chemotherapy-treated patients had a raised LH level alone [4]. These results suggest that a significant proportion of men treated with cytotoxic chemotherapy have biochemical abnormalities indicative of

compensated Leydig cell dysfunction, although recent evidence suggests that there is probably no increased risk for frankly subnormal levels of testosterone after treatment with alkylating agents, [40, 43, 50, 52, 67] or cisplatin [47].

Testicular function following high-dose chemotherapy used as preparation for bone marrow transplantation has also been studied. In a study of 155 men treated with cyclophosphamide (200 mg/kg) or busulphan and cyclophosphamide (busulphan 16 mg/kg, cyclophosphamide 200 mg/kg) [42], 67 of 109 who received cyclophosphamide (61%), but only 8 of 46 (17%) patients treated with busulphan and cyclophosphamide, had recovery of testicular function defined by normal LH, FSH and testosterone levels with evidence of sperm production, after an average of 2–3 years post-transplantation. The only prospective study to examine testicular function following high-dose treatment reported data in 13 men who received either BEAM (BCNU, etoposide, Ara-C and melphalan) ($n = 11$) or melphalan and single-fraction TBI ($n = 2$) [82]. All had previously received multi-agent chemotherapy and four had abnormal semen parameters before transplantation. All patients were azoospermic 2–3 months post-transplantation with raised FSH levels. LH levels increased and testosterone levels decreased after transplantation indicating Leydig cell dysfunction in addition to germ cell failure. The association between Leydig cell dysfunction and germinal epithelial function was clearly illustrated in a study of 68 patients treated with high-dose chemotherapy (either cyclophosphamide, BCNU and etoposide, busulphan and cyclophosphamide or BCNU, etoposide, doxorubicin and melphalan) as conditioning for bone marrow transplantation. They demonstrated that the majority of those with raised FSH (88% of the patients) also had raised LH level (69% of the patients). In addition, none of the 13 patients with a normal FSH level had an increased LH level. Although this is not surprising given the relative susceptibilities of the Leydig cells and the germinal epithelium to damage, it leaves open the possibility that germinal cell dysfunction plays a role in Leydig cell insufficiency [4].

There was also evidence of recovery of Leydig cell function with a gradual recovery of germinal cell function during the first 10 years after chemotherapy which further indicates that germinal epithelial dysfunction may be etiologically important in the occurrence of Leydig cell insufficiency [4].

In men with testicular cancer, there are several important considerations regarding the effect of treatment on gonadal function. These men are generally young adults in the age range where preservations of reproductive function and fertility are particularly important. In addition to the potential effects of cytotoxic treatment, these men are likely to have significant pre-existing testicular abnormalities (e.g. cryptorchidism, germinal aplasia, contralateral malignant/pre-malignant cells) that may be compounded by treatment. Separating the testicular effects of cancer treatment from pre-existing testicular dysfunction is challenging [44, 69–71, 83]. In an attempt to determine which abnormalities result from cytotoxic chemotherapy, several of these studies also examined pre-treatment testicular function, or compared chemotherapy-treated patients with those who underwent orchidectomy alone. In a study of 170 patients with testicular germ cell cancers treated with cisplatin- or carboplatin-based chemotherapy, compensated Leydig cell dysfunction, as indicated by a raised LH level in the presence of a normal testosterone level, was found in 59–75% of men following chemotherapy, compared with 6–45% in those following unilateral orchidectomy alone [44]. An age-adjusted increase in hypogonadism, defined as LH >12 IU/L or testosterone <8 nmol/L, has also been described in a cohort of 1183 patients with testicular cancer with odds ratios ranging from 3.5 to 7.9 depending on treatment regimen [83].

Radiotherapy and Leydig Cell Function

The testis is one of the most radiosensitive tissues, with very low doses of radiation causing significant impairment of function. Damage may be caused during direct irradiation of the testis or, more commonly, from scattered radiation during treatment directed at adjacent tissues. As previously

described, radiotherapy effects on gonadal function depend on the dose, treatment field and fractionation schedule [84]. While relatively low doses may result in damage to the seminiferous epithelium and oligozoospermia [85], much higher doses (>20 Gy) appear to be required to cause Leydig cell dysfunction. However, significant rises in LH have been demonstrated following single-radiation doses above 0.75 Gy [9] and fractionated doses above 2 Gy [77]. No change in testosterone levels was seen at these doses, indicating compensated Leydig cell damage and LH values gradually return to normal levels over 30 months.

Radiotherapy doses delivered directly to the gonad are often in the range of 20–24 Gy which result in eradication of germ cells [86] causing permanent azoospermia [87]. Such radiation doses delivered to the testis have also been shown to result in Leydig cell insufficiency [88], whilst studies involving lower radiation doses have not resulted in testosterone deficiency [9, 75]. In a study of 20 men, previously treated with unilateral orchidectomy for testicular cancer, who received direct testicular irradiation at a dose of 20 Gy in 10 fractions for pre-malignant changes in the remaining testis, there was a significant increase in mean LH levels within the first three months (10.4–15.6 IU/L), with a decrease in mean serum testosterone levels (13.3–10.8 nmol/L) [89]. Similar results were observed in adults treated with high-dose (30 Gy) testicular irradiation following unilateral orchidectomy. Serum testosterone levels were significantly reduced (12.5 versus 16.0 nmol/L), and LH levels were significantly increased (6 versus 16 IU/L) compared with a control group who had undergone unilateral orchidectomy without subsequent radiotherapy [11]. This study also highlighted the potential importance of age in determining the extent of Leydig cell dysfunction. In the five adult men treated with the same testicular dose of irradiation during childhood, the effect on Leydig cell function was more dramatic. The median LH levels was >32 IU/L and the median testosterone level was <2.5 nmol/L, and there was no response to hCG stimulation, suggesting that the prepubertal testis is much more vulnerable to radiation-induced Leydig cell damage [11]. Several other studies have

demonstrated Leydig cell dysfunction for male survivors of childhood cancer receiving radiotherapy, including direct radiotherapy to the testis and total body irradiation [40, 67, 68, 90, 91]. Differences in Leydig cell sensitivity between those treated in childhood or in adulthood may be due to important differences in the Leydig cell populations between children and adults. The adult Leydig cell population is not present in prepuberty; however, studies in rats indicate that the stem cell progenitors that give rise to the adult Leydig cell population are present in the prepubertal testis [92]. Sensitivity of these two populations to cytotoxic therapy may decrease from prepuberty to adulthood.

A study using radiotherapy to impair Leydig cell function in 7 men with prostate cancer demonstrated that even with relatively high doses of radiotherapy (17–24 Gy in 2–3 fractions), Leydig cell function is maintained over 3 years of follow-up [93]. However, the results of these studies should be considered in the context of the patient population, namely aged men, with pre-existing pathology/treatment and relatively low pre-radiotherapy testosterone levels.

Clinical Impact of Impaired Leydig Cell Function

While a substantial proportion of men treated for cancer have evidence of mildly impaired Leydig cell function, as indicated by raised LH and low/subnormal testosterone levels, the clinical impact of this effect is not entirely clear. For men with true hypogonadism, there is a clear benefit of androgen replacement on sexual function, bone density, body composition and quality of life [94, 95]; however, there are limited data in patients with cancer. In a cohort of 203 men treated with either MVPP, ChlVPP/EVA hybrid or high-dose chemotherapy for a variety of malignancies, 32% were identified with biochemical evidence of mild Leydig cell insufficiency as defined by a raised LH and a testosterone level in the lower half of the normal range, or frankly subnormal [4]. They had a significantly reduced bone mineral density at the hip compared with a similarly treated cohort with normal hormone levels, with some evidence of altered

body composition, reduced sexual activity and alterations in mood [96, 97]. The men were then enrolled into a 12-month randomised, single-blind placebo-controlled trial of testosterone replacement [98]. During the 12-month study period, however, there was no significant improvement in bone density, body composition, sexual function, energy levels or mood in the testosterone-treated group compared with the controls.

Thus, based on the evidence available, the mild biochemical abnormalities (raised LH, low/normal testosterone) observed in many men following cytotoxic chemotherapy are of limited clinical importance in the vast majority of patients, and androgen replacement cannot be routinely recommended for such patients. However, it remains possible that a minority of men with more marked biochemical abnormalities may benefit from androgen therapy. More studies are needed.

Genetic Damage Following Cytotoxic Therapy

In addition to impairment of steroidogenesis and sperm production, there has been concern that cytotoxic chemotherapy may also result in transmissible genetic damage. Animal studies have demonstrated untoward effects in the offspring of animals treated with cytotoxic agents, but no clear evidence for this has been reported in humans. Increased aneuploidy frequency has been observed in human sperm following chemotherapy for HD [99, 100] and an increase in chromosomal abnormalities has been demonstrated several years after treatment for testicular cancer [101], while a study of men who had been treated for cancer in childhood showed that their sperm carried as much healthy DNA as controls [102]. A study of 25 childhood cancer survivors, their healthy partners and 43 offspring also revealed no increased genomic instability in the latter [103]. The majority of epidemiological studies concerning the outcome of pregnancies have not shown any increase in genetically mediated birth defects, altered sex ratios or birthweight effects in the offspring of cancer

survivors [104–106]; however, one study involving 8162 children with a paternal history of cancer from a cohort of almost 2 million children, demonstrated a modest increase (Relative Risk = 1.17) in the risk of congenital abnormalities [107]. Given the evidence thus far, it is reasonable to conclude that patients treated with cytotoxic therapy who remain fertile are at no/low increased risk of fathering children with genetic abnormalities.

Fertility Preservation for Males Undergoing Cancer Treatment

Semen Cryopreservation and Assisted Reproduction

At present the only established method for preserving reproductive potential in patients undergoing potentially sterilising therapy is cryopreservation of semen for use in ART such as intracytoplasmic sperm injection (ICSI). This should be offered to all men in whom their treatment has a risk of subsequent infertility, and the British Fertility Society recommends that all post-pubertal patients requiring treatment for cancer should be offered sperm banking. A semen sample is most frequently obtained by masturbation, although penile vibratory stimulation or electrostimulation can also be performed under anaesthetic; however, the motility and sperm count may be lower when the latter method is used [108]. Epididymal aspiration and testicular biopsy have also been used to obtain gametes for cryostorage; however, the risk of compromising testicular function questions the suitability of the latter technique. In the UK, semen cryopreservation is governed by the Human Fertilisation and Embryology Act. This legislation stipulates that the individual must understand the implications of what is proposed and that written, informed consent must be obtained prior to semen cryopreservation [109].

Despite recommendations, the option of sperm banking is not always offered. This may be due to issues such as cost, lack of facilities and a poor prognosis from the underlying condition [110].

Typical rates for storage range between 40 and 70% [111], with lack of information often cited as the most common reason for failing to bank [112]. In a study of 902 men with HD, 40% cryopreserved semen before the start of treatment at the median age of 31 years. Three hundred thirty four men wanted to have a child during the median follow-up of 13 years (range 5–36). Ninety nine of 128 (77%) men with no spontaneous success had cryopreserved semen. Altogether, 48 of 78 (62%) men who used the cryopreserved sperm had success with ART and had at least one child. Patients treated with alkylating- or second-line chemotherapy were more likely to subsequently use cryopreserved sperm. The availability of cryopreserved semen doubled the odds of post-treatment fatherhood [113].

Despite the success of semen cryopreservation as an option to males undergoing potentially gonadotoxic therapy, there are important limitations to its utility for certain patient groups. Men with malignancies may have impaired testicular function prior to treatment [114]. There may be difficulty producing a semen sample, and even when a sample can be produced, there may be oligozoospermia and/or reduced sperm motility. Oligozoospermia is found in a third to a half of patients with HD, non-Hodgkin's lymphoma and testicular cancer pre-treatment, and also in men with leukaemia or soft tissue cancers [17, 115]. Whilst successful fertilisation may be achieved with only a few viable sperm using ICSI, pregnancy rates using this method are lower with abnormal than with normal semen [116]. Another important patient group is children, who despite the relative quiescence of the hypothalamic–pituitary–gonadal axis, are still at significant risk of infertility as a result of cytotoxic therapies [3]. Therefore, alternative strategies to preserve or restore fertility in young patients are currently under investigation, although they remain experimental.

Hormonal Therapy for Fertility Preservation

Hormonal suppression of testicular activity has been postulated as a potential strategy for the

preservation of fertility in patients treated for cancer (for detailed review see [3]). This is based on the hypothesis that suppression of the HPG axis prior to cytotoxic therapy would protect the gonad from cytotoxic damage, a concept based largely on a belief that the prepubertal testis is somewhat protected from permanent chemotherapy-induced gonadal damage [10]. In fact, the prepubertal testis is susceptible to damage from cytotoxic therapy and germ cell proliferation has been shown to occur in the prepubertal human and non-human primate testis [117, 118]. On the other hand, numerous studies in rodents (reviewed in [119]) have demonstrated protection of spermatogenesis when hormonal suppression is commenced using agents such as sex steroids, GnRH antagonists or analogues before or during treatment. It has even been shown that recovery of spermatogenesis can be enhanced when hormonal suppression is induced after treatment. However, differences in hormonal and spermatogenic regulation in rodents and primates may account for the failure to translate this strategy successfully into primates, including humans (see below).

Treatment of adult rats for 6 weeks with testosterone and estradiol, prior to irradiation or procarbazine treatment, resulted in a higher germ cell repopulation index and sperm head count compared to rats receiving irradiation alone [120–122]. Short-term (2 weeks) treatment of rats with a GnRH analogue prior to procarbazine treatment also resulted in a strain-dependant increase in stem cell index and subsequent recovery of sperm counts close to normal values and significantly higher than procarbazine-only treated rats at 90 days [123, 124].

GnRH analogues have also been shown to stimulate recovery of spermatogenesis following irradiation or procarbazine treatment in adult rats [125–128]. The use of a depot formulation of the GnRH analogue, goserelin, in irradiated rats receiving 3.5 Gy, resulted in a 91% repopulation index compared to 31% in the controls at 10-week post-irradiation [126]. Similar results were obtained for treatment with GnRH analogues following procarbazine treatment [127]. GnRH analogues administered to rats up to 15–20 weeks after irradiation can also result in

increased numbers of tubules containing differentiating germ cells derived from surviving stem cells 6 weeks later [127, 128]. These results, along with studies demonstrating no cytoprotective effect from chemotherapy or irradiation in a mouse strain with congenital complete gonadotropin deficiency [129], suggest that the mechanism for restoring spermatogenesis is not due to suppressing germ cell activity during cytotoxic treatment. Instead, studies have suggested that the mechanism may involve a reduction in the high levels of intra-testicular testosterone caused by cytotoxic treatment [130] or release of germ cells from the block on differentiation [131]. Transplantation studies have indicated that the block in spermatogonia differentiation following irradiation may be due to damage to somatic cells rather than germ cells [132].

Attempts to reproduce the beneficial effects of GnRH analogues/antagonists in rodents on radiation-induced cytotoxicity in non-human primates have been unsuccessful. For example, the GnRH antagonist cetrorelix failed to increase the proportion of seminiferous tubule cross sections containing germ cells in rhesus monkeys subjected to testicular irradiation [133, 134].

Studies using hormonal manipulations in humans have also failed to demonstrate preservation or restoration of fertility in patients treated for cancer [119]. These studies included the use of GnRH analogues [135, 136], GnRH analogue plus testosterone [137], GnRH analogue plus an antiandrogen [138], testosterone [139] or medroxyprogesterone acetate given before or after treatment [140] in men receiving chemotherapy and/or radiotherapy for HD and testicular cancer. One further study in adult patients treated with cyclophosphamide for nephritis demonstrated that testosterone therapy was associated with recovery by six months in 5/5 patients compared with 1/5 who did not receive testosterone [141]. Overall, no consistent effect of treatment was demonstrated in these studies. However, it must be recognised that in one study there was no control group, and the majority of studies involved 20 patients or less, and are likely to be underpowered to demonstrate any significant effect. Several studies demonstrated

that the majority of patients in the control group recovered spermatogenesis, which also reduces the chances of demonstrating a protective effect of hormonal manipulation, whilst the study in which no recovery was seen in either group may indicate that the cytotoxic treatment may result in a complete loss of spermatogonia.

Many of the human studies were carried out before it became clear that hormonal treatments in the rodent studies were demonstrating restoration rather than protection of spermatogenesis, and none of the studies involved the continuation of gonadal-suppressive therapy for a significant period of time after the completion of chemotherapy or radiotherapy. Thus, carefully designed, adequately powered studies are warranted to determine whether suppression of gonadal function with a GnRH agonist or testosterone for a fixed time during and after the completion of irradiation or chemotherapy may prove successful in reducing the impact of these treatments on fertility.

Ex Vivo Techniques for Fertility Preservation

As discussed above, cryopreservation of semen is considered routine clinical practice in many countries. Pubertal boys and men who are able to produce a semen sample should always be offered the possibility to cryopreserve their sperm if they are at risk of infertility due to a gonadotoxic treatment. Unfortunately, prepubertal boys, who are not able to produce sperm at the time their gonadotoxic treatments start, do not have this possibility [142]. In some adults, there may also be other factors, such as ethical or religious beliefs, that exclude cryopreservation of semen as an option for fertility preservation. For these boys and men, testicular biopsy, cryopreservation of the testicular tissue and ex vivo differentiation of male germ cells might be an option, although this approach remains experimental, and currently there are no functional techniques available to generate mature human gametes ex vivo (Fig. 12.4).




Fig. 12.4 Experimental approaches for fertility preservation in young men prior to cytotoxic therapy. Testicular tissue is removed from the testis prior to cancer treatment. Tissue or isolated cells may be cryopreserved, cultured or xenografted. The material may be replaced in the host

testis following the completion of treatment or alternatively differentiated germ cells may be recovered and used for assisted reproduction, e.g. intracytoplasmic sperm injection (ICSI)

Although our understanding of human spermatogenesis has increased dramatically in recent decades, details of the highly complex process of controlling human spermatogenesis are still inadequately understood (see Chap. 3). The limited access to normal human testicular tissue, accounting also for the lack of functional in vitro models, might be one of the main reasons behind this. The use of animal models to elucidate the process of human spermatogenesis is limited as a result of species differences [143, 144]. However, in recent decades, different strategies, including animal studies with a focus on male germ cell or tissue transplantation [145–149], or the use of different types of in vitro cultures [150–156], including various pluripotent stem

cells types [157, 158] and the recently described very small embryonic-like stem cells (VSELs) [159, 160], have explored the spermatogenic progress in detail. Prominent experimental conditions for ex vivo differentiation of mammalian male germ cells include (i) in vitro culture systems; (ii) testicular tissue (xeno) grafting; and (iii) SSC transplantation into the seminiferous tubules of the testis [155, 161, 162]. Among these experimental strategies, germ cell or testicular tissue transplantation have demonstrated possibilities to mature SSCs and more advanced germ cells in testicular microenvironments similar to those present in vivo.

Among the three ex vivo differentiation strategies, auto-transplantation of cryopreserved

SSCs or testicular tissue into the patient's testis represents a potential clinical tool for preservation of fertility following gonadotoxic treatment. However, the risk of reintroducing the disease due to re-transplantation of malignant cells back into the patient, particularly in patients with ALL, is one of the major limiting factors for future clinical application of this technique. The establishment of "decontamination" strategies to eliminate malignant cells from testicular tissue fragments is extremely challenging. So far, a specific marker for SSCs has not been identified [163]. Decontamination protocols involving enrichment and isolation of SSCs or the depletion of malignant cells have become a focus for research during recent years [164–166]. However, transplantation of cryopreserved testicular tissue or germ cells back into the patient after treatment is currently unsafe for patients with haematological cancer [142].

100 Years in Search of the Conditions Required for Male Germ Cell Differentiation in Vitro

At the beginning of the last century, organ culture conditions focusing on the differentiation of male germ cells from a variety of different species revealed several important factors necessary for male germ cell differentiation, including in vitro maintenance of the microenvironment provided by the seminiferous epithelium and thereby the intact cell-to-cell communication pathways of somatic and germ cells [155]. These early experiments, followed by many others in the following decades, also demonstrated the importance of maintaining temperature below that of the body [167–169], the need for cell–cell contacts [170–172], the supportive effect on viability of media components including pyruvate, glutamine, vitamins A, C and E, the non-supportive effect of gonadotropins for the success of germ cell cultures [167], as well as the negative influence of high oxygen levels on the viability of cells in vitro [162]. Studies focusing on in vitro differentiation of male germ cells

combined with somatic cells, and studies involving enriched germ cell types such as spermatogonia and spermatocytes, clearly demonstrated that a microenvironment resembling the three-dimensional organisation of the seminiferous epithelium in situ (thereby providing cell–cell contact) should be provided [150, 155, 173–175].

The first successful differentiation of human male germ cells with completion of meiosis and the spermiogenic process in vitro was reported in the late 1990s. Tesarik and colleagues obtained human sperm in vitro via the use of seminiferous tubule cultures at 30 °C [153, 176]. The same group also reported the birth of healthy infants as a result of ICSI using in vitro-differentiated sperm from azoospermic patients [153]. In these reports, the differentiation of primary spermatocytes into haploid spermatids, which in vivo takes up to 32 days [176, 177], was reported to occur within 48 h [176] in vitro. Although earlier investigators reported a similar speed for germ cell differentiation in vivo and in vitro, another group reported four years later a similar feature of in vitro maturation. Primary spermatocytes obtained from azoospermic patients with meiotic arrest exhibited features of haploid round spermatids, when cultured for 2–5 days on Vero cells [178].

So far, differentiation of undifferentiated spermatogonia to elongated spermatids has been reported in connection with organ culture and three-dimensional cell culture methodologies [150, 151, 155, 179–182]. In 2011, Sato et al. reported the first successful differentiation of murine SSCs into functional sperm in vitro using organ culture [150, 179, 183] in combination with 10% Knockout Serum Replacement or AlbuMAX (40 mg/ml) instead of conventional foetal bovine serum. Recently, a study using testicular material from 16 patients with cryptorchidism (mean age \pm SEM 29 \pm 2 years) demonstrated the differentiation of human SSCs up to functional haploid spermatids [184]. Germ cell differentiation in that study was achieved using DMEM/F12 cell culture medium, 10% foetal bovine serum, retinoic acid and stem cell

factor in a conventional single cell culture for 7–10 days [184].

In parallel with the successful establishment of organ cultures for murine spermatogenesis, the establishment of three-dimensional culture systems has recently provided novel insights into the process of male germ cell differentiation/proliferation and the formation of testicular somatic microenvironments *in vitro* [154, 155, 174, 175, 185]. Three-dimensional culture systems, using agar, methylcellulose or extracellular matrixes, were first established as clonogenic assays for multipotent hematopoietic cells [186], and were subsequently developed and adapted to the requirements needed for clonal expansion of male germ cells [154, 155, 174, 181, 182]. Regardless of the matrix used to generate the three-dimensional environment, differentiation of male germ cells through meiosis could be demonstrated, pointing out the important effect of physical contact between the cells, in accordance with results from previous organ culture experiments [155].

Methods for establishing a decellularized testicular matrix (DTM) from cadaveric human testicular tissue in order to support spermatogenesis *in vitro* for fertility preservation have recently been reviewed [156]. In a recent study, Baert and colleagues reported important insights into the components of the basal membrane. Interestingly, proteomic analysis of the DTM used revealed, in addition to well-known components such as laminin, collagens I and IV, glycosaminoglycans and fibronectin, more than 100 unique proteins belonging to, or associated with testicular extracellular matrix. These new findings indicate a need for further experiments to elucidate the role and potential use of scaffolds made from human DTM for fertility preservation.

In addition to experimental definitions of appropriate culture conditions, current studies are also focusing on optimal cryopreservation techniques for immature testicular tissue and their effects on SSCs in murine and human cells/tissue. These studies suggest that the cryopreservation process itself does not impact on survival or differentiation capacity of the germ cells [152, 187–190]. Consideration must be given to potential abnormalities such as

genetic/epigenetic instabilities of *in vitro*-generated gametes, which have been described, for example, in connection with bone marrow or human embryonic and foetal mesenchymal stem cells [191, 192]. However, initial experiments focusing on the effects of long-term culture of SSCs are promising and suggest genomic stability of these cells [193]. However, additional studies are mandatory to address efficiency and safety concerns in order for these techniques to be used clinically.

Summary

Testicular dysfunction may be present in males with cancer prior to commencing treatment often in relation to the underlying malignancy. Treatment with chemotherapy and radiotherapy may also result in significant testicular damage, primarily as a result of damage to the seminiferous epithelium resulting in infertility, whilst Leydig cell impairment may also occur, albeit generally at higher exposures.

For chemotherapy, alkylating agents, such as cyclophosphamide and procarbazine, are most commonly implicated in damage to the seminiferous epithelium. A large proportion of men receiving procarbazine-containing regimens for the treatment of lymphomas are rendered permanently infertile, whilst alternative regimens such as ABVD appear to have a significant advantage in terms of testicular function, with a return to normal fertility in the vast majority of patients. Leydig cell dysfunction can occur in men receiving chemotherapy, although this may be of little/no clinical significance in the majority of patients. Radiotherapy-induced damage to the germinal epithelium is common with changes to spermatogonia following as little as 0.1 Gy, and permanent infertility after fractionated doses of 6 Gy and above, whereas clinically significant Leydig cell impairment occurs rarely with doses of less than 20 Gy.

The management of males about to commence treatment for cancer should always include counselling regarding the possible effects of treatment on testicular function, and sperm

banking should be offered to all post-pubertal patients undergoing potentially sterilising therapy. Regular semen analyses should be offered to men following cytotoxic treatment to allow appropriate family planning. Measurement of testosterone and LH are appropriate for men with symptoms consistent with testosterone deficiency who have received significant doses of irradiation to the testes, procarbazine-containing chemotherapy or high-dose chemotherapy. Mild elevations of LH accompanied by testosterone levels within the normal range (the most common abnormality) do not generally require treatment, but patients with subnormal testosterone levels and markedly elevated LH levels may benefit from androgen replacement. For prepubertal patients, there are currently no established options to preserve fertility; however, experimental strategies to cryopreserve testicular tissue biopsies and generate mature gametes *ex vivo* are currently being developed, and may be an option for these patients in the future.

References

1. Ward E, et al. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin.* 2014;64(2):83–103.
2. Anderson RA, et al. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. *Lancet Diabetes Endocrinol.* 2015;3(7):556–67.
3. Mitchell RT, et al. Male fertility and strategies for fertility preservation following childhood cancer treatment. *Endocr Dev.* 2009;15:101–34.
4. Howell SJ, et al. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. *J Clin Oncol.* 1999;17(5):1493–8.
5. Meistrich ML, et al. Recovery of sperm production after chemotherapy for osteosarcoma. *Cancer.* 1989;63(11):2115–23.
6. Pryzant RM, et al. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. *J Clin Oncol.* 1993;11(2):239–47.
7. da Cunha MF, et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. *J Clin Oncol.* 1984;2(6):571–7.
8. Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. *Br Med J (Clin Res Ed).* 1985;291(6507):1457–60.
9. Rowley MJ, et al. Effect of graded doses of ionizing radiation on the human testis. *Radiat Res.* 1974;59(3):665–78.
10. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. *JAMA.* 1988;259(14):2123–5.
11. Shalet SM, et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. *J Endocrinol.* 1989;120(1):161–5.
12. Viviani S, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. *Eur J Cancer.* 1991;27(11):1389–92.
13. Rueffer U, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. *Ann Oncol.* 2001;12(9):1307–11.
14. Sieniawski M, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. *Ann Oncol.* 2008;19(10):1795–801.
15. van der Kaaij MA, et al. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. *Haematologica.* 2009;94(12):1691–7.
16. Marmor D, et al. Semen analysis in Hodgkin's disease before the onset of treatment. *Cancer.* 1986;57(10):1986–7.
17. Padron OF, et al. Effects of cancer on spermatozoa quality after cryopreservation: a 12-year experience. *Fertil Steril.* 1997;67(2):326–31.
18. Fitoussi, et al., Semen analysis and cryoconservation before treatment in Hodgkin's disease. *Ann Oncol.* 2000;11(6): 679–84.
19. Tal R, et al. Follow-up of sperm concentration and motility in patients with lymphoma. *Hum Reprod.* 2000;15(9):1985–8.
20. Gandini L, et al. Testicular cancer and Hodgkin's disease: evaluation of semen quality. *Hum Reprod.* 2003;18(4):796–801.
21. Paoli D, et al. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. *Hum Reprod.* 2016;31(2):263–72.
22. Krawczuk-Rybak M, et al. Assessment of gonadal function in boys and adolescents at the diagnosis of neoplastic disease. *J Pediatr Endocrinol Metab.* 2012;25(5–6):453–8.
23. Shekarriz M, et al. Cryopreservation and semen quality in patients with Hodgkin's disease. *Cancer.* 1995;75(11):2732–6.
24. Barr RD, Clark DA, Booth JD. Dyspermia in men with localized Hodgkin's disease. A potentially reversible, immune-mediated disorder. *Med Hypotheses.* 1993;40(3):165–8.
25. Hendry WF, et al. Semen analysis in testicular cancer and Hodgkin's disease: pre- and post-treatment findings and implications for cryopreservation. *Br J Urol.* 1983;55(6):769–73.
26. Meirov D, Schenker JG. Cancer and male infertility. *Hum Reprod.* 1995;10(8):2017–22.

27. Berthelsen JG. Testicular cancer and fertility. *Int J Androl.* 1987;10(1):371–80.
28. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Hum Reprod.* 2001;16(5):972–8.
29. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. *J Urol.* 2005;174(5): 1819–22; discussion 1822.
30. Guazzieri S, et al. Sperm antibodies and infertility in patients with testicular cancer. *Urology.* 1985;26(2):139–42.
31. Pietzak EJ 3rd, et al. Histology of testicular biopsies obtained for experimental fertility preservation protocol in boys with cancer. *J Urol.* 2015;194(5):1420–4.
32. Hadziselimovic F, Herzog B, Buser M. Development of cryptorchid testes. *Eur J Pediatr.* 1987;146(Suppl 2):S8–12.
33. Huff DS, et al. Abnormal germ cell development in cryptorchidism. *Horm Res.* 2001;55(1):11–7.
34. Nistal M, Paniagua R. Occurrence of primary spermatocytes in the infant and child testis. *Andrologia.* 1984;16(6):532–6.
35. Darzy KH, Shalet SM. Hypopituitarism after cranial irradiation. *J Endocrinol Invest.* 2005;28(5 Suppl):78–87.
36. Rappaport R, et al. Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. *J Clin Endocrinol Metab.* 1982;54(6):1164–8.
37. Constine LS, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. *N Engl J Med.* 1993;328(2):87–94.
38. Ogilvy-Stuart AL, et al. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone. *Clin Endocrinol (Oxf).* 1997;46(5):571–8.
39. van Alphen MM, van de Kant HJ, de Rooij DG. Depletion of the spermatogonia from the seminiferous epithelium of the rhesus monkey after X irradiation. *Radiat Res.* 1988;113(3):473–86.
40. Jahnukainen K, et al. Semen quality and fertility in adult long-term survivors of childhood acute lymphoblastic leukemia. *Fertil Steril.* 2011;96(4):837–42.
41. Gurgan T, Salman C, Demiroglu A. Pregnancy and assisted reproduction techniques in men and women after cancer treatment. *Placenta.* 2008;29 Suppl B: 152–9.
42. Sanders JE, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. *Blood.* 1996;87(7):3045–52.
43. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? *Pediatr Blood Cancer.* 2008;50(2):347–51.
44. Lampe H, et al. Fertility after chemotherapy for testicular germ cell cancers. *J Clin Oncol.* 1997;15(1):239–45.
45. Bokemeyer C, et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. *Ann Hematol.* 1994;68(3):105–10.
46. Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. *Fertil Steril.* 1997;68(1):1–5.
47. Petersen PM, et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. *Ann Oncol.* 1994;5(4):355–8.
48. Lopez Andreu JA, et al. Persistent altered spermatogenesis in long-term childhood cancer survivors. *Pediatr Hematol Oncol.* 2000;17(1):21–30.
49. van Beek RD, et al. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood. *Hum Reprod.* 2007;22(12):3215–22.
50. Ghavamzadeh A, et al. Thyroid, parathyroid, gonadal, and pancreatic beta-cell function after bone marrow transplantation with chemotherapy-only conditioning. *Transplant Proc.* 2003;35(8): 3101–4.
51. Gundgurthi A, et al. Endocrine complications after busulfan and cyclophosphamide based hematopoietic stem cell transplant: A single tertiary care centre experience. *Indian J Endocrinol Metab.* 2013;17(5):855–63.
52. Panasiuk A, et al. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan. *Br J Haematol.* 2015;170(5):719–26.
53. Green DM, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. *Lancet Oncol.* 2014;15(11):1215–23.
54. Aubier F, et al. Male gonadal function after chemotherapy for solid tumors in childhood. *J Clin Oncol.* 1989;7(3):304–9.
55. Meistrich ML, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. *Cancer.* 1992;70(11):2703–12.
56. Wyns C, et al. Options for fertility preservation in prepubertal boys. *Hum Reprod Update.* 2010;16(3):312–28.
57. Essig S, et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol.* 2014;15(8):841–51.
58. Lendon M, et al. Testicular histology after combination chemotherapy in childhood for acute

- lymphoblastic leukaemia. *Lancet*. 1978;2(8087):439–41.
59. Wallace WH, et al. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. *Int J Androl*. 1991;14(5):312–9.
 60. Nurmio M, et al. Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility. *J Clin Endocrinol Metab*. 2009;94(6):2119–22.
 61. Behringer K, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. *J Clin Oncol*. 2013;31(2):231–9.
 62. Dohle GR. Male infertility in cancer patients: Review of the literature. *Int J Urol*. 2010;17(4):327–31.
 63. Lee SJ, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol*. 2006;24(18):2917–31.
 64. Sarafoglou K, et al. Gonadal function after bone marrow transplantation for acute leukemia during childhood. *J Pediatr*. 1997;130(2):210–6.
 65. Anserini P, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. *Bone Marrow Transplant*. 2002;30(7):447–51.
 66. Rovo A, et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. *Blood*. 2006;108(3):1100–5.
 67. van Casteren NJ, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. *Pediatr Blood Cancer*. 2009;52(1):108–12.
 68. Wilhelmsson M, et al. Adult testicular volume predicts spermatogenetic recovery after allogeneic HSCT in childhood and adolescence. *Pediatr Blood Cancer*. 2014;61(6):1094–100.
 69. Hansen SW, Berthelsen JG, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. *J Clin Oncol*. 1990;8(10):1695–8.
 70. Stuart NS, et al. Long-term toxicity of chemotherapy for testicular cancer—the cost of cure. *Br J Cancer*. 1990;61(3):479–84.
 71. Palmieri G, et al. Gonadal function after multimodality treatment in men with testicular germ cell cancer. *Eur J Endocrinol*. 1996;134(4):431–6.
 72. Brydoy M, et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. *Eur Urol*. 2010;58(1):134–40.
 73. Brauner R, et al. Leydig-cell function in children after direct testicular irradiation for acute lymphoblastic leukemia. *N Engl J Med*. 1983;309(1):25–8.
 74. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. *Med Pediatr Oncol*. 1999;33(1):2–8.
 75. Kinsella TJ, et al. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin's disease. *J Clin Oncol*. 1989;7(6):718–24.
 76. Pedrick TJ, Hoppe RT. Recovery of spermatogenesis following pelvic irradiation for Hodgkin's disease. *Int J Radiat Oncol Biol Phys*. 1986;12(1):117–21.
 77. Shapiro E, et al. Effects of fractionated irradiation of endocrine aspects of testicular function. *J Clin Oncol*. 1985;3(9):1232–9.
 78. Centola GM, et al. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. *J Androl*. 1994;15(6):608–13.
 79. Ash P. The influence of radiation on fertility in man. *Br J Radiol*. 1980;53(628):271–8.
 80. Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. *Pediatr Clin North Am*. 1997;44(2):489–503.
 81. Yau I, et al. Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer. *Int J Radiat Oncol Biol Phys*. 2009;74(5):1481–6.
 82. Chatterjee R, et al. Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma. *Bone Marrow Transplant*. 1994;13(5):519–22.
 83. Nord C, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. *Eur Urol*. 2003;44(3):322–8.
 84. Thomson AB, et al. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. *Best Pract Res Clin Endocrinol Metab*. 2002;16(2):311–34.
 85. Wallace WH, Thomson AB. Preservation of fertility in children treated for cancer. *Arch Dis Child*. 2003;88(6):493–6.
 86. Petersen PM, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. *J Clin Oncol*. 2002;20(6):1537–43.
 87. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. *J Natl Cancer Inst Monogr*. 2005;34:12–7.
 88. Bang AK, et al. Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. *Int J Radiat Oncol Biol Phys*. 2009;75(3):672–6.
 89. Giwercman A, et al. Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in

- 20 patients. *J Clin Endocrinol Metab.* 1991;73(3):596–603.
90. Romerius P, et al. Hypogonadism risk in men treated for childhood cancer. *J Clin Endocrinol Metab.* 2009;94(11):4180–6.
91. Leung W, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. *J Clin Oncol.* 2000;18(18):3273–9.
92. Kilcoyne KR, et al. Fetal programming of adult Leydig cell function by androgenic effects on stem/progenitor cells. *Proc Natl Acad Sci U S A.* 2014;111(18):E1924–32.
93. Faria S, Cury F, Souhami L. Prospective phase I study on testicular castration induced by radiation treatment. *Can J Urol.* 2015;22(1):7635–9.
94. Bhasin S, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95(6):2536–59.
95. Smith LB, Mitchell RT, McEwan IJ. Testosterone: from basic research to clinical applications. Springer briefs—reproductive biology series, 2013.
96. Howell SJ, et al. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. *Clin Endocrinol (Oxf).* 2000;52(5):609–16.
97. Howell SJ, et al. Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. *Br J Cancer.* 2000;82(4):789–93.
98. Howell SJ, et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. *Clin Endocrinol (Oxf).* 2001;55(3):315–24.
99. Monteil M, et al. Increased aneuploid frequency in spermatozoa from a Hodgkin's disease patient after chemotherapy and radiotherapy. *Cytogenet Cell Genet.* 1997;76(3–4):134–8.
100. Robbins WA, et al. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. *Nat Genet.* 1997;16(1):74–8.
101. Genesca A, et al. Significance of structural chromosome aberrations in human sperm: analysis of induced aberrations. *Hum Genet.* 1990;85(5):495–9.
102. Thomson AB, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. *Lancet.* 2002;360(9330):361–7.
103. Winther JF, et al. Radiotherapy for childhood cancer and risk for congenital malformations in offspring: a population-based cohort study. *Clin Genet.* 2009;75(1):50–6.
104. Robbins WA. Cytogenetic damage measured in human sperm following cancer chemotherapy. *Mutat Res.* 1996;355(1–2):235–52.
105. Signorello LB, et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. *J Clin Oncol.* 2012;30(3):239–45.
106. Winther JF, et al. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. *J Clin Oncol.* 2012;30(1):27–33.
107. Stahl O, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. *J Natl Cancer Inst.* 2011;103(5):398–406.
108. Hovav Y, et al. Electroejaculation before chemotherapy in adolescents and young men with cancer. *Fertil Steril.* 2001;75(4):811–3.
109. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? *Lancet Oncol.* 2005;6(4):209–18.
110. Schover LR, et al. Oncologists' attitudes and practices regarding banking sperm before cancer treatment. *J Clin Oncol.* 2002;20(7):1890–7.
111. Edge B, Holmes D, Makin G. Sperm banking in adolescent cancer patients. *Arch Dis Child.* 2006;91(2):149–52.
112. Schover LR, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. *J Clin Oncol.* 2002;20(7):1880–9.
113. van der Kaaij MA, et al. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. *Hum Reprod.* 2014;29(3):525–33.
114. Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease. A prospective study. *JAMA.* 1981;245(13):1323–8.
115. Chung K, et al. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. *Eur J Obstet Gynecol Reprod Biol.* 2004;113(Suppl 1):S7–11.
116. Aboulghar MA, et al. Fertilization and pregnancy rates after intracytoplasmic sperm injection using ejaculate semen and surgically retrieved sperm. *Fertil Steril.* 1997;68(1):108–11.
117. Berensztein EB, et al. Apoptosis and proliferation of human testicular somatic and germ cells during prepuberty: high rate of testicular growth in newborns mediated by decreased apoptosis. *J Clin Endocrinol Metab.* 2002;87(11):5113–8.
118. Kelnar CJ, et al. Testicular changes during infantile 'quiescence' in the marmoset and their gonadotrophin dependence: a model for investigating susceptibility of the prepubertal human testis to cancer therapy? *Hum Reprod.* 2002;17(5):1367–78.
119. Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. *J Natl Cancer Inst Monogr.* 2005;34:36–9.

120. Kurdoglu B, et al. Protection from radiation-induced damage to spermatogenesis by hormone treatment. *Radiat Res.* 1994;139(1):97–102.
121. Parchuri N, Wilson G, Meistrich ML. Protection by gonadal steroid hormones against procarbazine-induced damage to spermatogenic function in LBNF1 hybrid rats. *J Androl.* 1993;14(4):257–66.
122. Delic JI, Bush C, Peckham MJ. Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen. *Cancer Res.* 1986;46(4 Pt 2):1909–14.
123. Ward JA, et al. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. *Cancer Res.* 1990;50(3):568–74.
124. Kangasniemi M, et al. Rapid protection of rat spermatogenic stem cells against procarbazine by treatment with a gonadotropin-releasing hormone antagonist (Nal-Glu) and an antiandrogen (flutamide). *Endocrinology.* 1995;136(7):2881–8.
125. Pogach LM, et al. Partial prevention of procarbazine induced germinal cell aplasia in rats by sequential GnRH antagonist and testosterone administration. *Cancer Res.* 1988;48(15):4354–60.
126. Meistrich ML, Kangasniemi M. Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia. *J Androl.* 1997;18(1):80–7.
127. Meistrich ML, Wilson G, Huhtaniemi I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. *Cancer Res.* 1999;59(15):3557–60.
128. Shuttlesworth GA, et al. Enhancement of a spermatogonial proliferation and differentiation in irradiated rats by gonadotropin-releasing hormone antagonist administration. *Endocrinology.* 2000;141(1):37–49.
129. Crawford BA, et al. Testing the gonadal regression-cytoprotection hypothesis. *Cancer Res.* 1998;58(22):5105–9.
130. Porter KL, Shetty G, Meistrich ML. Testicular edema is associated with spermatogonial arrest in irradiated rats. *Endocrinology.* 2006;147(3):1297–305.
131. Meistrich ML, et al. Mechanism of protection of rat spermatogenesis by hormonal pretreatment: stimulation of spermatogonial differentiation after irradiation. *J Androl.* 2000;21(3):464–9.
132. Zhang Z, Shao S, Meistrich ML. The radiation-induced block in spermatogonial differentiation is due to damage to the somatic environment, not the germ cells. *J Cell Physiol.* 2007;211(1):149–58.
133. Boekelheide K, et al. Gonadotropin-releasing hormone antagonist (Cetrorelix) therapy fails to protect nonhuman primates (*Macaca arctoides*) from radiation-induced spermatogenic failure. *J Androl.* 2005;26(2):222–34.
134. Kamischke A, et al. Gonadal protection from radiation by GnRH antagonist or recombinant human FSH: a controlled trial in a male nonhuman primate (*Macaca fascicularis*). *J Endocrinol.* 2003;179(2):183–94.
135. Johnson DH, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. *Blood.* 1985;65(4):832–6.
136. Kreuser ED, et al. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. *Horm Metab Res.* 1990;22(9):494–8.
137. Waxman JH, et al. Failure to preserve fertility in patients with Hodgkin's disease. *Cancer Chemother Pharmacol.* 1987;19(2):159–62.
138. Brennemann W, et al. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-Tryptophan-6 luteinizing hormone releasing hormone. *Clin Investig.* 1994;72(11):838–42.
139. Redman JR, et al. Semen cryopreservation and artificial insemination for Hodgkin's disease. *J Clin Oncol.* 1987;5(2):233–8.
140. Fossa SD, Klepp O, Norman N. Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. *Br J Urol.* 1988;62(5):449–53.
141. Masala A, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. *Ann Intern Med.* 1997;126(4):292–5.
142. Jahnukainen K, Mitchell RT, Stukenborg JB. Testicular function and fertility preservation after treatment for haematological cancer. *Curr Opin Endocrinol Diabetes Obes.* 2015;22(3):217–23.
143. Ehmcke J, Wistuba J, Schlatt S. Spermatogonial stem cells: questions, models and perspectives. *Human reproduction update.* 2006;12(3):275–82.
144. Jahnukainen K, Stukenborg JB. Clinical review: Present and future prospects of male fertility preservation for children and adolescents. *J Clin Endocrinol Metab.* 2012;97(12):4341–51.
145. Jahnukainen K, et al. Fertility preservation after sterilizing therapy through autologous ectopic grafting of cryopreserved testicular tissue in prepubertal monkeys. *Cancer Research.* 2012. In press.
146. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. *Proc Nat Acad Sci U S A.* 1994;91(24):11298–302.
147. Honaramooz A, et al. Sperm from neonatal mammalian testes grafted in mice. *Nature.* 2002;418(6899):778–81.
148. Schlatt S, et al. Limited survival of adult human testicular tissue as ectopic xenograft. *Hum Reprod.* 2006;21(2):384–9.

149. Galuppo AG. Spermatogonial stem cells as a therapeutic alternative for fertility preservation of prepubertal boys. *Einstein (Sao Paulo)*. 2015;13(4):637–9.
150. Sato T, et al. In vitro production of functional sperm in cultured neonatal mouse testes. *Nature*. 2011;471(7339):504–7.
151. Sato T, et al. Testis tissue explantation cures spermatogenic failure in c-Kit ligand mutant mice. *Proc Natl Acad Sci U S A*. 2012;109(42):16934–8.
152. Yokonishi T, et al. Offspring production with sperm grown in vitro from cryopreserved testis tissues. *Nat Commun*. 2014;5:4320.
153. Tesarik J, et al. Restoration of fertility by in-vitro spermatogenesis. *Lancet*. 1999;353(9152):555–6.
154. Reda A, et al. In vitro Spermatogenesis - Optimal Culture Conditions for Testicular Cell Survival, Germ Cell Differentiation, and Steroidogenesis in Rats. *Front Endocrinol (Lausanne)*. 2014;5:21.
155. Stukenborg JB, et al. New horizons for in vitro spermatogenesis? An update on novel three-dimensional culture systems as tools for meiotic and post-meiotic differentiation of testicular germ cells. *Mol Hum Reprod*. 2009;15(9):521–9.
156. Baert Y, et al. Derivation and characterization of a cytocompatible scaffold from human testis. *Hum Reprod*. 2015;30(2):256–67.
157. Kurimoto K, Saitou M. Mechanism and reconstitution in vitro of germ cell development in mammals. *Cold Spring Harb Symp Quant Biol*. 2015.
158. Kjartansdottir KR, et al. A combination of culture conditions and gene expression analysis can be used to investigate and predict hesc cell differentiation potential towards male gonadal cells. *PLoS One*. 2015;10(12):e0144029.
159. Kurkure P, et al. Very small embryonic-like stem cells (VSELs) detected in azoospermic testicular biopsies of adult survivors of childhood cancer. *Reprod Biol Endocrinol*. 2015;13:122.
160. Anand S, Patel H, Bhartiya D. Chemoablated mouse seminiferous tubular cells enriched for very small embryonic-like stem cells undergo spontaneous spermatogenesis in vitro. *Reprod Biol Endocrinol*. 2015;13:33.
161. Hou J, et al. Generation of male differentiated germ cells from various types of stem cells. *Reproduction*. 2014;147(6):R179–88.
162. Stukenborg JB, et al. Male germ cell development in humans. *Horm Res Paediatr*. 2014;81(1):2–12.
163. Song HW, Wilkinson MF. Transcriptional control of spermatogonial maintenance and differentiation. *Semin Cell Dev Biol*. 2014;30:14–26.
164. Valli H, et al. Fluorescence- and magnetic-activated cell sorting strategies to isolate and enrich human spermatogonial stem cells. *Fertil Steril*. 2014;102(2):566–580 e7.
165. Nickkholgh B, et al. Enrichment of spermatogonial stem cells from long-term cultured human testicular cells. *Fertil Steril*. 2014;102(2): 558–565 e5.
166. Sadri-Ardekani H, et al. Eliminating acute lymphoblastic leukemia cells from human testicular cell cultures: a pilot study. *Fertil Steril*. 2014;101(4): 1072–1078 e1.
167. Steinberger A. In vitro techniques for the study of spermatogenesis. *Methods in enzymology*, 1975;39 (Journal Article): 283–296.
168. Mieuisset R, Bujan L. Testicular heating and its possible contributions to male infertility: a review. *Int J Androl*. 1995;18(4):169–84.
169. Nakamura M, Romrell LJ, Hall PF. The effects of temperature and glucose on protein biosynthesis by immature (round) spermatids from rat testes. *J cell biology*. 1978;79(1):1–9.
170. Steinberger A, Steinberger E. In vitro culture of rat testicular cells. *Exp Cell Res*. 1966;44(2): 443–52.
171. Steinberger A, Steinberger E. Tissue culture of male mammalian gonads. *In Vitro*, 1970;5(Journal Article): 17–27.
172. Steinberger A, Steinberger E, Perloff WH. Mammalian testes in organ culture. *Exp Cell Res*, 1964;36(Journal Article): 19–27.
173. Hofmann MC, et al. Immortalization of germ cells and somatic testicular cells using the SV40 large T antigen. *Experimental Cell Research*, 1992;201 (Journal Article): 417–435.
174. Lee JH, et al. In vitro spermatogenesis by three-dimensional culture of rat testicular cells in collagen gel matrix. *Biomaterials*. 2006;27(14):2845–53.
175. Lee JH, et al. In vitro differentiation of germ cells from nonobstructive azoospermic patients using three-dimensional culture in a collagen gel matrix. *Fertility and Sterility*, 2007;10(Journal Article): 1016/j fertnstert.
176. Tesarik J. Overcoming maturation arrest by in vitro spermatogenesis: search for the optimal culture system. *Fertil Steril*. 2004;81(5):1417–9.
177. Amann RP. The cycle of the seminiferous epithelium in humans: a need to revisit? *J Androl*. 2008;29(5):469–87.
178. Tanaka A, et al. Completion of meiosis in human primary spermatocytes through in vitro coculture with Vero cells. *Fertil Steril*. 2003;79 Suppl 1 (Journal Article):795–801.
179. Sato T, et al. In vitro production of fertile sperm from murine spermatogonial stem cell lines. *Nat Commun*. 2011;2:472.
180. Yokonishi T, et al. In vitro spermatogenesis using an organ culture technique. *Methods Mol Biol*. 2013;927:479–88.
181. Abu Elhija M, et al. Differentiation of murine male germ cells to spermatozoa in a soft agar culture system. *Asian J Androl*. 2012;14(2):285–93.
182. Stukenborg JB, et al. Coculture of spermatogonia with somatic cells in a novel three-dimensional soft-agar-culture-system. *J Androl*. 2008;29(3): 312–29.

183. Sato T, et al. In Vitro Spermatogenesis in Explanted Adult Mouse Testis Tissues. *PLoS One*. 2015;10(6):e0130171.
184. Yang S, et al. Generation of haploid spermatids with fertilization and development capacity from human spermatogonial stem cells of cryptorchid patients. *Stem Cell Reports*. 2014;3(4):663–75.
185. Dores C, Alpaugh W, Dobrinski I. From in vitro culture to in vivo models to study testis development and spermatogenesis. *Cell Tissue Res*, 2012.
186. Parent-Massin D. Relevance of clonogenic assays in hematotoxicology. *Cell Biol Toxicol*. 2001;17(2):87–94.
187. Arkoun B, et al. Does soaking temperature during controlled slow freezing of pre-pubertal mouse testes influence course of in vitro spermatogenesis?. *Cell Tissue Res*, 2015.
188. Yokonishi T, Ogawa T. Cryopreservation of testis tissues and in vitro spermatogenesis. *Reprod Med Biol*. 2016;15:21–8.
189. Baert, Y., et al., Cryopreservation of testicular tissue before long-term testicular cell culture does not alter in vitro cell dynamics. *Fertil Steril*. 2015;104(5): 1244–1252 e4.
190. Yango P, et al. Optimizing cryopreservation of human spermatogonial stem cells: comparing the effectiveness of testicular tissue and single cell suspension cryopreservation. *Fertil Steril*. 2014;102(5):1491–1498 e1.
191. Redaelli S, et al. From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. *Stem Cell Res Ther*. 2012;3(6):47.
192. Frost J, et al. The effects of culture on genomic imprinting profiles in human embryonic and fetal mesenchymal stem cells. *Epigenetics*. 2011;6(1):52–62.
193. Nickkholgh, B., et al., Genetic and epigenetic stability of human spermatogonial stem cells during long-term culture. *Fertil Steril*. 2014;102(6): 1700–1707 e1.

Exercise and Male Hypogonadism: Testosterone, the Hypothalamic-Pituitary-Testicular Axis, and Exercise Training

13

Anthony C. Hackney PhD, DSc, Travis Anderson MA
and Jennifer Dobridge MA

Contents

Introduction	257
Physiological Actions of Testosterone	259
Androgenic Effects.....	259
Anabolic Effects.....	259
Factors Affecting Circulating Testosterone.....	259
Exercise and Pituitary—Testicular Function.....	260
Normal Men—Exercise Responses	260
Exercise-Hypogonadal Males	262
The Overtraining Syndrome	268
Athletes and Anabolic-Androgenic Steroids	269
Physiologic Adaptation and Exercise Performance ..	269
Mechanisms of Action.....	270
Prevalence of AAS Usage.....	272
Other Anabolic Substances.....	272
Anabolic Steroids—A Banned Substance.....	273

Conclusions.....	274
References	275

Introduction

Athletes who compete in endurance-based sports events are swimming, running, cycling, and skating faster than ever before, and world records in many events are being broken on a nearly annual basis [1]. There are several factors contributing to this improvement in human exercise performance. First, coaches working with athletes have improved scientific knowledge because of advances in the fields of Sports Medicine—Exercise Physiology. Second, sporting equipment changes have allowed some improvements in events [1, 2]. Third and perhaps most important, is the greater level of exercise training that athletes are performing in our modern era [1–4]. For example, it is not uncommon for marathon runners to complete 150–250 km of intensive running per week, or for tri-athletes to spend 3–4 h per day in swim, run and cycle training. This large volume of exercise training results in physiological changes and adaptations that are highly beneficial to the human organism, such as enhanced cardiac output, an enhanced arterial-venous oxygen difference, increased erythrocyte number, decreased body adiposity, and increased mitochondrial density [3]. However, this great volume of exercise training can also place a tremendous amount

A.C. Hackney (✉)
Department of Exercise and Sport Science;
Department of Nutrition, Schools of Public Health &
Medicine, University of North Carolina, Fetzer Hall,
Chapel Hill, NC 27599, USA
e-mail: ach@email.unc.edu

T. Anderson
Department of Kinesiology, University of North
Carolina at Greensboro, 1408 Walker Ave., 238C
HHP Building, Greensboro, NC 27402, USA
e-mail: t_ander2@uncg.edu

J. Dobridge
Department of Exercise and Sport Science,
University of North Carolina, Fetzer Hall, Chapel
Hill, NC 27599, USA

of stress on the human organism, and can result in unwanted physiological responses and medical problems which can compromise to some extent the ability of an athlete to perform.

A physiological system that is extremely sensitive to the stress of exercise training is the endocrine reproductive system. A growing body of research over the last 35 years reveals how chronic exposure to endurance exercise training results in the development of endocrine reproductive dysfunction [5–9]. The vast majority of the research on exercise and endocrine reproductive dysfunction has focused upon sporting women [10–12]. A growing number of studies, however, have begun to address the question of how exercise training affects the endocrine reproductive system in men. Comparatively, however, published research reports in this area remain relatively few in number. Nevertheless, many researchers hypothesize that the effect of endurance exercise training on the male endocrine reproductive system may be comparable to that found in sporting women; i.e., endurance-exercise-trained athletes of both sexes can develop hypogonadism-like characteristics. Specifically, some men chronically exposed to endurance exercise training develop low basal, resting levels of total and free testosterone. Most of these men display clinically “normal” levels of the hormone testosterone, but the levels are at the extreme low end of normal (<15 nmol/L) [13].

A general label applied to these men has been “endurance trained men with low resting testosterone.” While this is an accurate descriptive phrase for their condition, it is cumbersome to use. According to Taber’s Medical Dictionary, “hypogonadism” can be defined as “defective internal secretion of the gonads” [14]. This is a simplistic definition not giving an indication of the level of “defect” [clinical versus subclinical] or the root of the “defect” [e.g., hypergonadotropic versus hypogonadotropic]. Nonetheless, we chose to use this definition, and will refer to “endurance trained men with low resting testosterone” as having the “exercise-hypogonadal male condition” (EHMC) [15, 16]. This term serves as an operational definition for this special case of exercise men discussed in this

chapter. These men have several common characteristics;

- Their low testosterone levels do not appear to be a transient phenomenon related to the stress–strain of an acute exercise bout, or prior drug (“doping”) usage.
- In many cases, it appears that an adjustment in the regulatory axis [to allow a new lower set point for circulating testosterone] has occurred.
- They typically have a history of early involvement in organized sport and exercise training resulting in many years of almost daily exposure to varying intensities of physical activity.
- The type of exercise training history most prevalent in these men is prolonged, endurance-based activities such as: distance running [10 km or marathons], cycling, race walking, cross-country skiing, or triathlons.

A second endocrine reproductive disturbance also occurs in male athletic populations. This problem is a pseudo-hypergonadism brought about by the use of anabolic-androgenic steroid pharmaceutical agents. The term “pseudo-hypergonadism” is used because in reality, the usage of exogenous anabolic-androgenic steroids results in an atrophy of the gonads and reduced endogenous sex-steroid hormone production because of hypothalamic-pituitary suppression. The extremely high circulating levels of anabolic-androgenic pharmaceutical agents actually mask the endogenous hypogonadism which is occurring.

Evidence points to large numbers of athletes taking anabolic-androgenic steroid agents in an attempt to stimulate muscular growth, development, and strength. The usage of these agents has been a persistent occurrence in sports for approximately 70 years. Unfortunately, athletes and coaches continue to ignore the reports of serious medical side effects associated with such usage [17].

The intent of this review is to present an overview of select endocrine reproductive problems that occur in men involved in exercise training. Specifically discussed are: (a) how

endurance exercise training affects the male reproductive endocrine system to induce hypogonadal-like conditions resulting in suppressed circulating testosterone levels [denoted here as the EHMC], and (b) anabolic-androgenic steroid abuse and the reproductive dysfunction that is associated with the use of these pharmaceutical agents.

The following discussion is delimited to the relationship between exercise endocrinology and reproduction in men. Research in this area in women is the subject of several authoritative reviews [12, 18].

Physiological Actions of Testosterone

Testosterone is the most important sex hormone in males, and has multiple physiological functions. These roles can be dichotomized into two major categories:

- Androgenic effects, which are related to reproductive function and to the development of male secondary sex characteristics.
- Anabolic effects, which are related more generally to the stimulation of tissue growth and development.

A complete discussion of these categories is beyond the scope of this chapter. What follows, instead, is a brief overview of the major androgenic and anabolic effects of testosterone.

Androgenic Effects

The foremost reproductive role of testosterone is to stimulate the production of sperm. Activation of androgen receptors in Sertoli cells, peritubular myoid cells and Leydig cells by testosterone stimulates and catalyzes the maturation and development of sperm through down-stream target mechanisms that are incompletely understood [19–22].

Testosterone also stimulates the differentiation, development, and function of the male accessory sex glands (prostate, seminal vesicles, and epididymis) that aid in sperm development and function as well as in copulation. Finally, testosterone stimulates the development of male secondary sex characteristics, such as the deeper male voice, increased body hair, penile growth, sex drive (libido), and male behavior patterns [20–23].

Anabolic Effects

Testosterone and 5- α dihydrotestosterone (DHT) are powerful anabolic hormones that stimulate nitrogen retention and protein synthesis [19]. During puberty, testosterone acts in concert with other hormones to increase bone mass, and to initiate the adolescent growth spurt. In the adult, testosterone is needed to maintain protein anabolism and thereby structural proteins. Athletes who use anabolic steroids (i.e., pharmacologically derived testosterone-like compounds) take advantage of this effect to increase skeletal muscle mass [3, 6, 19, 20, 22]. This latter action by testosterone is due to androgen receptor activation of muscle gene transcription including that of insulin-like growth factor (IGF)-1 [24]. In a related fashion, testosterone also decreases myostatin expression (TGF- β family member and inhibitor of muscle development) [24]. Testosterone also stimulates hematopoiesis and increases sodium reabsorption in the kidney. Finally, studies in animals reveal that testosterone also plays a role in increasing skeletal muscle glycogen synthesis and storage [20].

Factors Affecting Circulating Testosterone

Hypothalamic-Pituitary-Testicular Axis

Testosterone production by the testis is under control of the hypothalamic-pituitary unit [25]. The operation and components of this axis are discussed in detail elsewhere in this volume (see Chap. 1) and will not be repeated here. The

hypothalamic-pituitary-testicular axis hormones addressed within this discussion are testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), inhibin, and prolactin (PRL).

Cardiovascular Factors

Testosterone is freely diffusible through tissues, and thus its secretion from the testis is directly affected by testicular blood flow. Testicular blood flow is a function of cardiac output, vascular vasoconstriction and vasodilatation. Therefore, factors that influence vascular tone can also affect testosterone secretion (e.g., increased sympathetic nervous system activity) [26].

The metabolic clearance rate (MCR) of testosterone varies among normal men, but is approximately 100 L per day [19, 20]. MCR involves target tissue uptake as well as degradation by the liver, and is influenced by the portion of the hormone bound to carrier proteins (principally sex hormone-binding globulin [SHBG]). The degradation process involves the conversion of testosterone into functional metabolites, such as estradiol and dihydrotestosterone, and degradation products, such as 17-ketosteroids, sulfates, and glucuronides, which are excreted into the urine [19, 20, 27]. Hepatic clearance is primarily a function of hepatic blood flow, such that changes in the hepatic blood flow influence the removal rate of testosterone [19]. This latter phenomenon is influenced by exercise, as hepatic blood flow is reduced during exercise as blood is shunted toward the active muscles [3, 28–30].

During exercise, there is movement of plasma from the vascular space. Since testosterone is bound to carrier proteins, an increase or decrease in the plasma volume leads to dilution or concentration of the circulating testosterone level. These changes, however, are not indicative of changes in the normal hormonal turnover rate [28]. For example, it is not uncommon during prolonged exercise (≥ 1 h) for transient plasma volume decreases of 10–20% to occur [28] leading to

a compensatory increase in testosterone (total) concentration of a similar magnitude. Whether these highly transient changes in the concentration of testosterone due to changes in plasma volume have a persistent physiological impact is a point of debate, and remains to be determined.

Other Factors

In addressing factors affecting changes in blood levels of testosterone, it is important to consider the other physiological and non-physiological factors that could account for variations in testosterone response among studies. Examples include the blood-sampling method, diurnal variations in hormone concentrations, hormone detection methodology, experimental research protocol or design, or age, emotional stress, diet, and sleep patterns of the subject-patient. These factors are discussed in detail elsewhere [6, 27, 28]. Collectively, all of the aforementioned considerations must be carefully examined when comparing the hormonal results of research studies if a valid interpretation of the endocrine system's responses to exercise is to be made. Figure 13.1 is a summary that illustrates some of these physiological and non-physiological factors that impact upon circulating testosterone levels in men [31].

Exercise and Pituitary—Testicular Function

Normal Men—Exercise Responses

Testosterone

It is generally accepted that short-term, maximal, and anaerobic-type exercise results in an elevation of the circulating testosterone level (see Table 13.1 for definitions of exercise-types terminology) [28, 32–34]. It is still an issue of some debate whether this effect is due solely to hemoconcentration and reduced metabolic clearance, or whether there is also an increase in testosterone production [6, 27, 35].

Fig. 13.1 Illustrated are the factors that influence circulating testosterone levels in normal men at rest and in response to a physical exercise bout. This figure is based upon the information from references [22, 25, 27, 28]




Table 13.1 Categorization and definition of exercise intensive and exercise-type relative to exercise studies of physically fit men

Category term	Relative intensity (%VO _{2max})	Energy pathway predominating	Typical duration	Other terminology
Light or easy exercise	<35	Aerobic	>30 min	Submaximal
Moderate exercise	>35 < 70	Aerobic	>30 min < 180 min	Submaximal
Heavy exercise	>70	Aerobic—anaerobic	<120 min	Submaximal
Maximal exercise	100	Aerobic—anaerobic	<15 min	Maximal or max
Supra-maximal exercise	>100	Anaerobic	<1 min	Sprints, power

In quantifying exercise intensity it is typical to express it as a relative percentage of an individual’s maximal oxygen uptake (VO_{2max}; i.e., = maximal aerobic capacity)

Based upon; Bouchard et al. [169]

Unlike changes during maximal exercise, testosterone responses to submaximal exercise are more variable, and seem dependent on the duration and intensity of exercise. Progressive increases in testosterone levels during moderate intensity exercise lasting 45–90 min have been found [28, 36, 37]. However, 90 min of submaximal moderate intensity exercise has also been reported to produce no change or a slight decrease in testosterone concentrations [28, 36]. Exercise of a moderate or hard intensity until exhaustion of

greater than ~2 h duration typically lowers testosterone concentrations [28, 36, 37].

Several explanations for these dissimilar changes during submaximal exercise have been proposed. Initially, hemoconcentration may increase the testosterone concentration; but as exercise continues, testicular testosterone production declines. The latter change may be due partly to reduced testicular blood flow [29, 30]. Hepatic blood flow may also decline reducing hepatic clearance [29, 30]. This latter change

may be offset by an increased uptake of testosterone by peripheral target tissue (i.e., skeletal muscle) as exercise duration continues, gradually reducing circulating testosterone levels.

Interestingly, these acute effects of a bout of maximal and submaximal exercise on testosterone levels are transient. That is, the changes are typically short-lived and normalize during the recovery period (1–24 h) [28, 35, 38–40].

Gonadotropins

Research results examining the gonadotropin response to maximal and anaerobic-type exercise are somewhat contradictory [35, 41, 42]; however, the majority of the evidence indicates there are small transient increases in the circulating gonadotropins [40, 43–49]. In addition, the outcomes of these studies, and their interpretations, are subject to methodological limitations. In many cases, researchers did not obtain blood samples frequently enough to assess the highly pulsatile gonadotropin secretory profile [12, 19, 27]. Resistance-type exercise induces small increases in serum gonadotropin levels in both men and women [46, 49–51].

Likewise, the prolonged (~1–2 h) submaximal exercise responses of the gonadotropins vary considerably for both men and women [28, 46, 47]. Evidence of significant increase, decrease, and no change has been reported [36, 40, 43, 44, 46, 47]. If submaximal exercise is extended for extremely long periods, or until exhaustion occurs, gonadotropin levels are suppressed [46, 51–54].

These acute exercise-induced gonadotropin disturbances are transient and last for relatively short periods into the recovery from exercise [35]. The exception to this point is that submaximal exercise of many hours duration can produce disturbances that last several days [53, 54]. Interestingly, scant research exist on the influence of exercise on the pulsatile release of the gonadotropins in men, and these findings are inconclusive [36, 37, 41, 43, 44].

Other Pituitary Hormones—Prolactin

PRL presents an interesting paradox in the reproductive physiology of exercise. At physiological

concentrations, PRL may be necessary for normal testicular function, while high PRL levels disrupt both central and peripheral aspects of the hypothalamic-pituitary-testicular axis [19, 55]. Circulating PRL concentrations increase during most exercise. The magnitude of the increase appears approximately proportional to the intensity of the activity [28, 46, 56]. Short-term, maximal, and anaerobic-type exercise increases PRL levels [28, 46, 56–60]. Submaximal exercise of 30 to 60 min duration, provided it is intense enough, increases circulating PRL levels as well [28, 47, 57–60]. Extending the duration of a submaximal exercise bout augments the magnitude of the PRL response [27, 47, 56, 57].

There are several factors that further increase the PRL response to prolonged exercise: (a) consumption of a diet rich in fat, (b) fasting for an extended period of time prior to exercise, (c) performing exercise in conditions promoting an increase in body temperature, and (d) administration of β -adrenergic blocking agents prior to exercise [28, 47, 57, 60]. On the other hand, PRL release is inhibited by α -adrenergic blockade [28, 47]. Exercise training history (i.e., training type or mode) also seems to have a positive or negative influence on this response to submaximal exercise [28].

PRL changes following maximal exercise or submaximal exercise of 1–2 h duration appear transient in nature [57–59]. Interestingly, Hackney and associates have reported nocturnal PRL levels are 2–3 times greater following 1.5 h of intensive endurance exercise than when no daytime exercise was performed [43, 61].

Exercise-Hypogonadal Males

Basal Hormonal Responses

Retrospective comparative studies examining isolated, single blood samples have found lower testosterone levels in chronically endurance-trained males. The subjects in those studies were typically endurance athletes (e.g., distance runners) who had been involved with the physical training aspects of their sport for 1–15 years. In those studies, total and free testosterone levels

were only 60–85% of the levels of matched sedentary controls [7, 40, 59, 62–64]. Many of the early studies reporting this finding suffered from small sample sizes. However, recent work with larger numbers of subjects has substantiated those findings [65, 66]. These low resting testosterone levels seem highly reproducible, and are not just an aberration of the athletes' seasonal training regime [66]. Furthermore, SHBG levels have not been reported to differ from sedentary, age-matched control men [65].

Prospective studies have also been conducted in which blood samples have been collected over weeks or months of endurance training regimens. Thus far, findings from such studies have been inconsistent. Some reports reveal significant reductions (decreases of 20–40%) in resting testosterone levels following 1–6 months of intensive training [66–70], whereas other studies have found no significant change in resting testosterone after 2–9 months of training [71–74]. Differences in the initial training status of the subjects, or the training dosage administered within these studies, may explain the discrepant findings. It is also possible that some of these prospective studies were too brief compared to the retrospective studies in which the men with low testosterone levels had been training for many years. To this point, landmark work by Safarinejad and colleagues [75] showed that prolonged training exposure (60 weeks) resulted in significant reductions in free and total testosterone, gonadotropins, and stimulated gonadotropin production.

Exercise-hypogonadal men also display other reproductive hormonal abnormalities in addition to low basal testosterone levels. The most frequently reported finding involves no significant elevation in resting LH to correspond with the decrease in testosterone (i.e., hypogonadotropic-hypogonadism) [40, 64, 76]. Additionally, resting levels of PRL may be decreased [40, 64]. Altered LH and PRL levels at rest in EHMC men have been interpreted by some researchers to indicate dysfunction of the hypothalamic-pituitary-testicular axis. These findings for LH and PRL have been reported in several

retrospective and prospective studies [7, 40, 62, 64, 76, 77]. Interestingly, the long-term prospective study of Safarinejad and colleagues [75], noted earlier, reported a significant decline in basal LH and FSH with training exposure by 12 weeks.

There are a number of retrospective investigations in which basal, resting blood samples were collected (i.e., serially every 20 or 30 min for 4–8 h periods) in EHMC men and in sedentary control men. Results are similar to those of the isolated-sampling studies: resting total and free testosterone concentrations of the trained subjects were typically only 60–80% of those found in control men [62, 78]. As in isolated single blood-sampling studies, resting LH levels were not significantly elevated. Again, these findings have been interpreted to represent dysfunction in the hypothalamic-pituitary function.

As noted, the hormonal findings described above have primarily been found in endurance athletes (i.e., distance runners and tri-athletes). It is highly unlikely, however, that these hormonal alterations are limited to this athletic—exercise group. The prevalence of these phenomena in endurance athletes most likely represents the tendency of researchers to focus upon this group, following the initial lead of early studies conducted in the 1980s. As scientists studying exercise expand their endocrinological studies to include other athletic groups involved with some components of endurance training, it is highly likely that comparable data will come forward as is beginning to be seen in preliminary findings [79].

Exercise Responses—Testosterone, Gonadotropins, and Other Hormones

Few studies have compared whether EHMC men and normal men respond differently to exercise. Evidence suggests that in response to a single exercise bout (maximal or submaximal in nature) the direction of the hormonal changes is similar. Testosterone and PRL are increased while the gonadotropin responses are variable in both groups of men [40, 77]. In the recovery from exercise, however, the two groups differ. In normal men, the reproductive hormones display




Fig. 13.2 Comparison of the percent change in hormone levels of exercise-hypogonadal (EHM) condition men versus normal, untrained men. Comparison is between a 4 h (overall mean response) period following a maximal exercise bout and that of a four period of rest in both groups of men. The plotted mean (\pm SE) responses of each group represent a delta value (i.e., exercise session

4 h overall response –control session 4 h overall response). Abbreviations *T* testosterone*, *LH* luteinizing hormone*, *PRL* prolactin*, *C* cortisol, *E2* estradiol. The * denotes significance differences between the groups ($P < 0.05$). The data are based upon the findings in reference [40]

some degree of negative feedback “rebound” inhibition during the hours of recovery following exercise [40, 58]. In EHMC men, this rebound effect is diminished or eliminated. Currently, it is unclear whether this represents an adjustment in regulatory aspects of the controlling axis, or whether a temporal displacement shift has occurred in the axis of the EHMC men. Obviously, the resting, basal levels of the hormones in each of these groups are vastly different; therefore, relative changes in response to exercise must be compared. Figure 13.2 displays recovery hormonal responses of exercise-hypogonadal men and normal men as relative change following an identical exercise bout [40].

Mechanistic Studies

Some studies have attempted to elucidate the mechanism for the proposed hypothalamic-pituitary-testicular axis dysfunction in exercise-hypogonadal men. These studies have focused on examining whether the dysfunction is central

(hypothalamic or pituitary) or peripheral (testicular) in nature.

Several investigators have reported that EHMC men have altered PRL and LH release when either an exogenous stimulus and, or an exercise bout are used to provoke hormone secretion [40, 52, 75, 76, 80]. Figures 13.3 and 13.4 illustrate an augmented PRL response and a reduced LH response to metoclopramide and GnRH stimulation, respectively, in EHMC men when compared to the matched sedentary controls [80]. Hyperprolactinemia is associated with decreased circulating testosterone levels [19, 81]. However, while the PRL response to metoclopramide was augmented, there is no evidence that EHMC men are chronically hyperprolactinemic. The converse has been actually been demonstrated (see earlier discussion). The reduction in LH release could also reduce testosterone levels. Reports indicate that testicular sensitivity and response to exogenous stimuli are comparable in exercise-hypogonadal men and




Fig. 13.3 Mean (\pm SE) integrated area under the PRL response curve over 3 h following the injection of the dopamine antagonist metoclopramide (see reference [80] for dosage). This challenge to the pituitary was performed

in endurance exercise-trained male runners and in age-matched sedentary controls. Significant between group differences ($P < 0.05$) are denoted with an asterisk




Fig. 13.4 Mean (\pm SE) integrated area under the LH response curve over 3h following the injection of GnRH (gonadorelin hydrochloride) (see reference [80] for dosage). This challenge to the pituitary was performed

in endurance exercise-trained male runners and in age-matched sedentary controls. Significant between group differences ($P < 0.05$) are denoted with an asterisk

sedentary males [40, 80, 82]. In contrast, Kujala et al. reported that the testicular response to a stimulus (human chorionic gonadotropin [hCG]) is attenuated following 4 h of exhaustive exercise [52].

Collectively, these findings suggest the development of both a central and a peripheral problem in the hypothalamic-pituitary-testicular axis; however, data in this area are limited and not yet definitive.

Cortisol

Researchers have demonstrated that acute pharmacological or pathological increases in cortisol secretion are associated with a decrease in circulating testosterone levels [38, 83]. Several investigators have alluded to these hormonal changes as a potential mechanism for the low testosterone levels in EHMC men [6, 27, 38, 83]. A single, acute exercise bout at high intensity (>60% of maximal aerobic capacity) could transiently increase circulating cortisol, which could bring about the observed reductions in testosterone via inhibitory effects on GnRH, LH or Leydig cell function [19]. Current evidence suggests, however, that hypercortisolemia is an unlikely mechanism for exercise-hypogonadism, since there are relatively small, transient changes in cortisol levels in response to exercise [43, 49, 50, 55, 58, 84–87], and exercise-induced changes in cortisol are well within the physiological range, regardless of whether the exercise is of moderate or high intensity. This point is illustrated in Fig. 13.5 [88]. Nevertheless, systematic research examining the role of exercise-induced cortisol changes upon testosterone production remains inadequate.

Physiological Consequences of Low Testosterone Levels in Athletes

There is evidence that the low resting testosterone level in men doing endurance training has detrimental effects on testosterone-dependent physiological processes. However, the extent of the evidence is somewhat limited. Several reports of decreased spermatogenesis or oligospermia in EHMC men have been published [21, 75, 89–93]. One of the most well-controlled studies was by Arce et al. [90]. Some key findings from that study are displayed in Table 13.2. Other investigators have reported that endurance-trained men may have a lowered sex drive—libido, but a direct cause-and-effect linkage between a lower sex drive and circulating testosterone levels was not proven in those reports [82, 91, 94–97]. Accordingly, other factors may have affected the libido of those athletes (e.g., overall fatigue and psychological stress), but this area has not been well studied in exercising men [22, 94]. Additionally, there is some evidence that endurance training has no effect upon sperm characteristics and the spermatogenesis process [74].

Relative to the androgenic-anabolic actions of testosterone, there are no documented detrimental




Fig. 13.5 Mean cortisol levels over 24 h in endurance athletes on three separate occasions; *Filled circle* control—baseline day with no exercise, *Filled triangle* exercise day involving two moderate intensity exercise sessions morning and afternoon, and *Filled square* exercise day

involving two high intensity exercise sessions morning and afternoon. Significant increases ($P < 0.05$) in cortisol occurred on the exercise days; however, the changes were transient in nature. The data are based upon the results in reference [88]

Table 13.2 Semen characteristics of endurance-trained runners, resistance trained weight lifters, and sedentary controls (values are means \pm SE)

	Runners (<i>N</i> = 10)	Weight lifters (<i>N</i> = 8)	Controls (<i>N</i> = 10)	P value
<i>Totals</i>				
Volume (ml)	4.2 \pm 0.5	3.0 \pm 0.5	2.5 \pm 0.5	0.9
Sperm density ($\times 10^6 \cdot \text{ml}^{-1}$)	78 \pm 12*	122 \pm 15	176 \pm 25	<0.01
Total sperm count ($\times 10^6$)	332 \pm 74	342 \pm 36	376 \pm 59	1.86
Normal motile count ($\times 10^6$)	55 \pm 11	104 \pm 20	107 \pm 22	0.09
<i>Motility</i>				
Forward progressive (%)	40.8 \pm 4.7**	58.0 \pm 4.6	58.7 \pm 2.4	<0.01
Nonprogressive (%)	5.0 \pm 1.0	2.8 \pm 1.5	2.0 \pm 1.0	0.17
Nonmotile (%)	54.2 \pm 4.9	39.2 \pm 3.9	39.3 \pm 1.9	1.01
<i>Morphology</i>				
Normal (%)	40.2 \pm 2.1†	54.8 \pm 2.9	47.0 \pm 3.3	<0.01
Large (%)	2.7 \pm 0.8	1.7 \pm 0.9	2.3 \pm 1.0	0.76
Small (%)	4.3 \pm 0.8	2.6 \pm 0.7	2.4 \pm 0.5	0.10
Amorphous (%)	34.1 \pm 2.5	30.1 \pm 2.6	37.4 \pm 2.8	0.19
Immature (%)	17.2 \pm 2.4**	10.5 \pm 2.1	10.9 \pm 1.2	0.03
Round cells ($\times 10^6$)	8.3 \pm 1.7**	0.6 \pm 0.4	2.5 \pm 0.9	<0.01
In vitro sperm penetration of CM—Penetrak (mm)	22 \pm 5*	—	43 \pm 7	0.04

These data are reproduced from: Arce et al. [90]

* $P < 0.05$ for runners versus controls. ** $P < 0.05$ for runners versus weight lifters and controls

† $P < 0.05$ for runners versus weight lifters

effects of the lower testosterone levels (i.e., decreased protein synthesis and muscle mass development). However, this area needs more thorough examination. An additional area in need of research concerns the impact of the exercise-associated decline in testosterone levels on bone demineralization in trained men. Currently, there are no conclusive findings that endurance training results in male osteoporosis [98]. In fact, the bone mineral density of the lower extremities was increased in high mileage runners [99–101]. On the other hand, several compelling case reports have described male athletes with extremely low testosterone levels and reduced bone mineral density [102, 103].

Thus the question arises, is it necessary for endurance-trained males to supplement with testosterone-like substances in order to safeguard against loss of androgenic-anabolic processes? This question has not been addressed thoroughly

in the literature. In one case study, Burge et al. [82] described a male runner with hypogonadotropic hypogonadism who responded favorably to clomiphene citrate treatment over a 5-month period. Testosterone and gonadotrophin concentrations increased into the normal range, and the subject's sexual function improved. Whether treatment was necessary is an issue of debate. There is little evidence that disruptions in testosterone-dependent processes are sufficient to warrant action, but physicians must use their own medical judgment on a case-by-case basis. In extreme cases, especially among men with a very low body mass index, such steps may be necessary, and a well-developed pharmacological course of therapy could be highly advantageous and efficacious (see section “[Anabolic Steroid—A Banned Substance](#)”).

Conversely, there may be beneficial physiological adaptations from lowered testosterone

levels. Some research indicates that lowering testosterone levels (i.e., but, not to hypogonadal levels) may have cardiovascular protective effects and decrease the risk of coronary heart disease [104]. A study from Germany demonstrated that a pharmacologically induced reduction in endogenous testosterone levels resulted in significant increases in high-density lipoprotein in men [105]. Whether the lowering of testosterone directly contributed to the exercise-related increase in HDL remains to be determined [106]. Nonetheless, it is important to recognize that increased physical activity promotes a healthy cardiovascular risk profile, including increased circulating HDL [107].

The Overtraining Syndrome

Several researchers have suggested that reproductive hormones in exercise-hypogonadal men are suppressed because they are “overtraining” and/or are developing the “Overtraining Syndrome.” This terminology can be confusing to non-Exercise Physiology researchers; hence some explanation is warranted. The terms “Overtraining Syndrome” and “overtraining” are frequently used interchangeably. The term “overtraining” actually refers to the *process* of heavier than usual exercise training, while the term “Overtraining Syndrome” refers to the *product* of too much of the overtraining process [2, 4, 7–9, 108–112]. The Overtraining Syndrome is a pathological condition in which an athlete experiences consistent and persistent exercise performance incompetence that does not reverse itself after a few days of rest and recovery. Furthermore, there is no underlying medical reason or explanation for the declining performance. This exercise performance impairment can manifest itself within athletic competition as well as during exercise training. Concurrent with the declining physical performance is a host of other psycho-physiological consequences that are adverse and negative in nature. Some of the most general and commonly reported consequences and symptoms are listed in Table 13.3.

Table 13.3 Consequences and symptoms of the overtraining syndrome

↓ Physical performance
↑ Severe constant fatigue
↑ Persistent muscle soreness
↑ Overuse muscular-skeletal injuries
↓ Appetite
↑ Lethargy
↑ Depression
↑ Disturbed sleep patterns
↑ Overall mood disturbances—shifts
↑ Immune system deficits
↑ Mental concentration difficulties
Δ Submaximal—maximal heart rate responses to exercise (↑, ↓)
↓ Maximal oxygen uptake
Δ Submaximal—maximal lactate response to exercise (↑, ↓)
See references: [2, 4, 113]
↑ Increase
↓ Decrease
Δ Change; decrease and, or increase

One commonly reported endocrine change among overtrained athletes is suppressed circulating levels of testosterone [2, 4, 7, 9, 110–112]. Furthermore, in some cases, suppressed levels of LH, FSH, and inhibin have been reported as well as a reduced testosterone to cortisol ratio [27, 108–113]. While these changes appear nearly identical to those reported for EHMC men, it does not seem to represent the same phenomena. The hormone changes that are found in overtraining athletes appear to be only temporary. When the exercise training load of these overtraining athletes is reduced, their diets are adjusted to allow macro-nutrient—caloric balance, and increased periods of rest are incorporated into the training program, their hormonal profiles return to normal [113, 114]. Incorporation of more rest into the training of EHMC men seems to have no substantial impact upon their resting hormone levels. Neither do EHMC men display Overtraining Syndrome symptoms (see Table 13.3). Furthermore, most researchers studying the exercise-hypogonadal issue have

been careful to insure that their subjects under investigation are not going through periods of intensive training; and that when they are evaluated they are well rested.

Thus, the hormonal changes found in EHMC men appear to be a more stable accommodation within the hypothalamic-pituitary-testicular axis while those in overtraining athletes are transient (i.e., returning to normal after adequate rest-recovery) and are associated with a declining physical performance.

Athletes and Anabolic-Androgenic Steroids

Anabolic-androgenic steroids are pharmacological agents that are similar to testosterone in structure [115, 116]. They have anabolic-androgenic actions like testosterone; however, these agents have been chemically modified in an effort to enhance their anabolic actions. Athletes use anabolic-androgenic steroids in an attempt to facilitate physiological development beyond that achieved with exercise training alone (e.g., increased body weight, muscular strength-power-speed or endurance) [115, 116]. These agents are used by athletes involved in many sports. However, sports such as track and field (mostly in the throwing events), weight-lifting, bodybuilding, and football report the highest prevalence of usage [103]. Regrettably, evidence points to nonathlete use being on the rise with the intent being for altering the body image [117, 118]. For the remainder of the discussion, anabolic-androgenic steroids will be referred to as AAS.

Physiologic Adaptation and Exercise Performance

It is now clearly established that testosterone and AAS supplementation increase muscle mass and maximal voluntary muscle strength [119–122]. Early studies suggested equivocal effects of AAS usage on athletic or exercise performance [119]. It is important to recognize, however, that because of ethical reasons most of those

sanctioned studies did not administer AASs at the high dosages used by athletes. This prompted researchers to report no effects whereas anecdotal reports by individual users touted large, substantial effects. Those anecdotal reports were tainted by their lack of scientific control for confounding factors such as extent of training and “the placebo effect.” Nonetheless, the findings in those “non-experimental” studies suggested body mass gains of 10 or 20 kg, as well as up to 30% increases in muscle strength [120]. Several well-controlled short-term studies have found smaller, but significant, increases in body mass, lean body mass, muscular strength, and concurrent reductions in fat mass [119, 120].

AAS usage is not limited to “weight-lifting–power” athletes. Endurance athletes (e.g., distance runners and tri-athletes) have also been found to use AAS. Interestingly, relative to endurance athletes, most studies have failed to demonstrate a substantial, beneficial effect of AAS on maximal oxygen consumption (i.e., key determinate to aerobic—endurance capacity) [115–119]. It has been proposed that endurance athletes who use AAS choose to do so because they recover from exercise training bouts more rapidly. This idea seems logical since performing more exercise training is a major stimulus to improve the cardiovascular-respiratory system, and thereby aerobic performance, and androgen treatment should negate the decline in testosterone that normally follows heavy exercise.

In addition to the myogenic effects of exogenous testosterone use, androgens have also promote erythropoiesis (i.e., hence potentially increasing oxygen carrying capacity of the blood and cardiovascular function; see later section, Erythropoietic Effects) [123]. The impetus for this line of research stemmed from early studies that found following puberty (and subsequent increases in testosterone), men developed a higher red blood cell and hemoglobin mass [124]. Since then, the use of exogenous synthetic androgens has been shown to affect hematocrit by stimulating erythropoietin production, altering iron metabolism by suppressing hepcidin, and by direct effect on bone marrow cells [123, 125]. Hypogonadal men have a lowered hematocrit

and hemoglobin [126], and androgen treatment can return those parameters to normal levels [127], although it is unclear whether the same effect would occur in exercise-induced hypogonadism.

Mechanisms of Action

AAS are thought to affect athletes through mechanisms that are both physiological and psychological in nature [120]. These proposed mechanisms include: (a) activating steroid hormone receptors and androgen-responsive genes in skeletal muscle cells, (b) producing an anti-catabolic effect within the skeletal muscle, and (c) inducing motivational psychological effects. It is presently unclear to what extent each of these mechanisms contributes to the overall physiological adaptation and performance changes found in AAS users. Most likely, these elements combine synergistically to bring about the changes noted.

Steroid Hormone Receptors

AAS activate androgen receptors in skeletal muscle cells, which stimulate the promoters of specific genes and induce protein synthesis [119, 120]. Of these proteins, one that appears to be important in increased muscle mass and strength is insulin-like growth factor-1 (IGF-1) [128]. IGF-1 mRNA in skeletal muscle is increased by testosterone treatment of older men [129], and is reduced in testosterone deficiency [130]. In certain cells, most notably prostate epithelium, the action of testosterone is amplified by its irreversible bioconversion to 5- α dihydrotestosterone by the enzyme 5- α reductase. In skeletal muscle cells, however, the activity of this enzyme is weak [131]. The number of muscle androgen receptors is increased by androgens in certain experimental models [132, 133]. A number of transcription factors have been shown to interact with androgen receptors and to up-regulate androgen receptor function [134]. Of these factors, supervillin, a 205-kDa actin-binding protein, has been shown to be androgen regulated [135].

Importantly, exercise training seems to be necessary for AAS to exert any beneficial effect on performance. As an illustration, research has shown a greater exercise performance improvement with AAS usage by experienced weight lifters than by novice subjects [115, 119, 120]. The experienced weight lifters were capable of training with heavier weights, and of producing relatively greater muscle tension during exercise. AAS effectiveness also appears dependent upon the number of unbound steroid hormone receptor sites in skeletal muscle, which may be increased by resistance exercise training (i.e., intensive, powerful exercise activities [anaerobic]) [48, 51, 119, 120].

Anti-catabolic Actions

There is evidence that a portion of the anabolic effect of testosterone and AAS is via an antiglucocorticoid action. Cortisol is catabolic because one of its actions is to induce protein degradation [28, 36, 55]. Cortisol is secreted in large amounts in response to exercise, which may provide proteins for energy metabolism, and deplete the free amino acid pool of proteogenesis precursors [28, 36, 55]. Glucocorticoid receptors are found in skeletal muscle cells, and AAS can bind these receptors [136, 137] to block the binding of cortisol. This prevents cortisol from inducing muscle protein breakdown and depleting the free amino acid pool [34, 115, 120]. For example, in men with severe burn injury, testosterone treatment markedly reduced protein breakdown [129]. A similar effect could enhance recovery from exercise training by allowing amino acid precursors to be available for tissue repair and regeneration. Interestingly, athletes have indicated that AAS help them train more intensely and recover faster [115, 120].

Erythropoietic Effects

In healthy individuals, Medlinsky et al. [138] demonstrated in 1969 that testosterone administration increased erythropoietin production, the major regulatory hormonal mechanism for red blood cell production leading to increased hemoglobin and hematocrit. Furthermore, androgens directly affect bone marrow, iron

uptake into erythrocytes, and enhance hemoglobin synthesis partly by suppressing hepcidin production [139, 140]. Moreover, androgens can increase the concentration of 2,3-DPG, facilitating a rightward shift in the oxyhemoglobin dissociation curve and hence promote oxygen delivery at the tissues; however, this effect was shown only in anemic patients or older adults and may not occur to a great extent in healthy younger athletic populations [139, 141, 142].

Psychological Effects

An important aspect of the AAS effect may be enhancement of the “motivational psychological state” of the athlete [120, 143]. This thought is supported by the notion that athletes indicate their emotional sense of well-being; euphoria, aggressiveness, and tolerance to stress, are all enhanced when they are using these agents. These emotions are positive motivators, and allow the athlete to train harder and to perform more intensive exercise training. This in turn would allow a greater exercise stimulus to be presented to muscle cells, and thus result in improved adaptation.

Side Effects of Usage

There are a large number of side effects associated with AAS usage [144]. Some of these effects are transient in nature; however, other effects seem more permanent and persist long after usage has stopped. Table 13.4 lists those side effects that have been reported in the literature. Brooks and associates [120] have categorized and subdivided the principal side effects into those attributable to:

- normal physiological actions of male sex-steroid hormones that are inappropriate in the recipient, and
- toxic effects caused by the chemical structure of the drug (principally “C-17 α alkylated” oral AAS).

One extremely important area concerning side effects involves the greater risk of cardiovascular disease associated with AAS use. For example,

Table 13.4 Major side effects associated with anabolic steroid usage in athletes

Acne
Aggressiveness
Altered electrolyte balance
Alterations in clotting factors
Altered thyroid function tests
Alterations in libido
Clitoral enlargement (women)
Depressed spermatogenesis
Decreased endogenous testosterone production
Decreased gonadotropin production
Dizziness
Depressed immune function
Decreased high-density lipoprotein
Edema
Elevated creatine kinase and lactate dehydrogenase
Elevated total cholesterol
Elevated triglycerides
Elevated blood glucose
Elevated blood pressure
Gastrointestinal distress
Gynecomastia and breast tenderness
Increase apocrine sweat gland activity
Increased nervous tension
Liver toxicity
Lower voice (women)
Masculinization (women)
Muscle cramps—spasms
Nosebleeds
Polyuria
Prostatic hypertrophy (and perhaps cancer)
Premature closure of epiphyses (children)
Psychosis
Wilm’s tumor

See references: [120, 145]

during AAS use, especially when taken orally, total cholesterol tends to increase, while HDL-cholesterol demonstrates a marked decline [145]. It appears that AAS influence hepatic triglyceride lipase (HTL) and lipoprotein lipase

(LPL). HTL is primarily responsible for the clearance of HDL-cholesterol, while LPL facilitates the cellular uptake of free fatty acids and glycerol. Androgens and AASs stimulate HTL, presumably resulting in decreased serum levels of HDL-cholesterol [145, 146]. AAS use may also provoke a transient hypertensive state. Data suggest that high dose usage significantly increases diastolic blood pressure. The increases in diastolic blood pressure typically subside after abstinence from AAS [145–148].

There is evidence that AAS use elicits structural changes in cardiomyocytes, and that myocardial ischemic tolerance is decreased after usage [145, 149, 150]. Echocardiographic studies in bodybuilders using AAS reported mild hypertrophy of the left ventricle with decreased diastolic relaxation, resulting in decreased diastolic filling [145, 148]. Some investigators have associated cardiomyopathy, myocardial infarction, and cerebrovascular accidents with abuse of AASs [130, 131]. However, a possible causal relationship has not been directly proved [151, 152]. Such physiological effects have negative influence on cardiovascular health risk factors; unfortunately, no rigorous scientific study-based data appear ethically available due to the risks associated with the long-term use, but case studies with self-administered AAS users have pointed to such associations [144, 151–153].

Many additional serious side-effects of AAS use exist which can compromise the overall health, and impact upon the morbidity and mortality of a user [153]. It is especially noteworthy to mention the serious liver disorders that can occur; such as hepatotoxicity, fatty liver and liver neoplasm, as well as anecdotal reports of permanent hypothalamic-pituitary-testicular suppression (see Table 13.4 for complete listing) [153].

Prevalence of AAS Usage

Usage of AAS by athletes is illegal, and often has negative ramifications on athletic eligibility (see Discussion below). As a consequence, the number of athletes using these agents is difficult to determine (i.e., most individuals are unwilling to

admit use). Mistakenly, body builders are often cited for prevalent use of AASs. In self-report studies, estimate usage rates range from 5 to 30% of the professional and amateur athletic populations [143, 154, 155]. This even includes high school athletes and expectant athletes. For example, Buckley and associates [155] studied a North American sample of 3400 high school seniors, and found that over 6% used AAS periodically. In that study, the majority of the users were sports athletes. Interestingly, 35% were nonathletes who cited improved appearance as their main reason for taking the drugs. Regrettably, 20% of AAS users in that study had obtained their drugs from a health care, medical professional. Research by Yesalis et al. [156] in the 1990s put the total number of users within the United States at over 1 million. There is no evidence that number has declined in spite of the warnings issued by healthcare providers of the dangers of usage [143, 154–157]. In fact, recent work by Albertson et al. [158] suggests that usage, especially recreational, may be increasing.

Other Anabolic Substances

There are many other “anabolic agents” an athlete can use for supplementation. One that has received a large amount of press coverage is androstenedione, a precursor for both androgens and estrogens (testosterone and estradiol). Androstenedione is a weak androgen, and is poorly converted to more potent androgen forms. Instead, most orally administered androstenedione is metabolized to testosterone glucuronide and other metabolites before release into the general circulation [159]. Several well-controlled studies have been conducted to examine the effects of androstenedione usage [119, 160, 161]. Collectively, based upon evaluations of circulating androgen levels, muscle strength or morphology, these studies suggest that no credible evidence exists for an enhanced anabolic effect.

Dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) are the most abundant circulating steroid hormones in humans. DHEA, as with androstenedione, may serve as a precursor for

androgens and estrogens; although, direct actions through nuclear and G-protein receptors have also been reported [162]. Theoretically, use of DHEA or DHEA-S as a supplement could have beneficial anabolic effects. In older adults, its use increased circulating androgen levels and subjective ratings of physical and psychological well-being [163]. It is perhaps most beneficial to those with adrenal insufficiency and those on high dosage glucocorticoid therapy [119]. Its effects on muscle strength and performance in athletes remain questionable [117, 119].

Recombinant growth hormone is used by some athletes (e.g., weight lifters) to increase muscle mass and strength. Growth hormone is a powerful endogenous anabolic hormone. It facilitates amino acid uptake and protein synthesis within many body tissues of which skeletal muscle is strongly influenced. Growth hormone also stimulates production of IGF-1, which is also anabolic. In addition, growth hormone has metabolic effects such as stimulating glucose uptake, free fatty acid mobilization, and lipolysis [28, 36, 55]. Human studies examining the efficacy of growth hormone usage in exercising men are limited [164, 165]. Muscle hypertrophy has been demonstrated, but the effects upon muscular strength are equivocal. Conversely, there are negative consequences to supplementation with growth hormone. Large dosages can result in edema, cardiomegaly, arthralgias, elevated blood glucose, peripheral neuropathy, atherosclerosis, and heart disease [120]. The risk for developing some of these side effects is enhanced when growth hormone is used in conjunction with AAS.

Anabolic Steroids—A Banned Substance

The International Olympic Committee (IOC) and all major sports governing organizations throughout the world have banned the use of substances taken for the purpose of unfairly and artificially improving performance in competition. Included on the banned substance list are varieties of AAS and similar agents.

In an attempt to deter usage by athletes, it is typical for major sporting events (Olympics, International—National Championship competitions) to have drug-testing programs (“doping control”) to determine if any banned substance has been used to enhance performance. Furthermore, sport governing organizations perform random testing of national level athletes annually. Unfortunately, the logistical and financial considerations of such banned substance-testing make frequent, large-scale examination of all athletic competitions impossible. Therefore, many violators go undetected. Furthermore, the allure of sport fame and fortune are so strong in many societies that athletes are willing to risk being detected in order to gain a competitive edge. For example, AAS have been on the IOC list of banned substances since 1975 [143]. Since that time, 15 total winter and summer Olympic Games have taken place. Every one of these Olympic Games has involved a “doping scandal” of some type in which athletes were caught using banned substances. Many of these cases involved AAS usage.

It is important to note, however, that although many athletes abuse AAS as performance-enhancing drugs, there are legitimate uses of these substances. In cases of medical need, the World Anti-Doping Association (WADA) permits athletes to apply for a therapeutic use exemption (TUE) for a banned substance. In 2014, 897 TUE were granted, representing a 41% increase from 2013 (2014, WADA Annual Report). Of the TUE in 2013, only a small number were for anabolic agents (~3%) as noted at the WADA Paris Symposium that year [166].

WADA has strict guidelines for the control of therapeutic use exemptions (TUE), particularly with those substances otherwise considered to be performance enhancing. Specifically, WADA requires that the use of testosterone replacement therapy (TRT) be granted to only those male athletes who have what are considered to be an “organic androgen deficiency” [166]. This deficiency category is divided into primary (e.g., Klinefelter Syndrome, cryptorchidism, direct testicular trauma and torsion, and radiation or chemotherapy treatments) and secondary (e.g.,

pituitary disorders, sickle-cell disease, and anatomical issues) androgen deficiencies [166]. These are separate and distinct from disorders considered to be “functional androgen deficiencies” most commonly associated with athletes, resulting from severe stress, overtraining, or chronic systemic illnesses. According to the TUE Physician Guidelines on androgen deficiency:

TUE should only be approved for androgen deficiency that has an organic etiology. TUE should not be approved for androgen deficiency due to functional disorder.

TUE for androgen deficiency should not be approved for females.

WADA—TUE Physician Guidelines [166]

In order for athletes to be granted a TUE, an application to WADA must be submitted, with information regarding the history, physical examination and testing/laboratory evaluation by the primary physician, most commonly an endocrinologist. Even then, there are strict requirements for the application and dosage for TRT, since testosterone has a dose-proportional response [122], thereby opening the possibility for unfair advantages in athletes with TUE [167]. Of course, there will always be athletes and coaches who may try to take advantage of this system, but it is important to understand that physicians still have a legitimate recourse for TRT use when practicing medicine with elite athletes. Please note that many sports also impose their regulations, dictated by individual governing bodies, which may not align with WADA guidelines.

Conclusions

Endurance exercise training does have significant effects upon the major male reproductive hormone, testosterone, and the hypothalamic-pituitary axis that regulates testicular function. A growing body of evidence suggests that testosterone is chronically lowered in endurance exercise-trained men, and we have referred to this condition as “exercise-hypogonadism.” While the

mechanism of this lowering of testosterone is currently unclear, it may be related to a dysfunction or a readjustment within the hypothalamic-pituitary-testicular regulatory axis brought about by years of endurance training. Currently, the time course of these changes, including their reversibility, remains unresolved, and is in need of further scientific investigation [168]. The lowered testosterone levels of the men with EHMC could potentially disrupt anabolic or androgenic testosterone-dependent processes. Conversely, the alterations in testosterone levels brought about by endurance training could have cardiovascular protective effects, and may thus be beneficial to these men.

Similar reproductive hormonal profiles exist in EHMC men and in men undergoing overtraining who develop the Overtraining Syndrome. However, the hormonal changes with the Overtraining Syndrome are transient, and appear to reflect the stress of excessive physical training. An increase in the rest and recovery portions of training regimens seems to eliminate any hormonal abnormalities in overtraining men, but not so in EHMC men.

Some athletes are using anabolic-androgenic steroid agents in an attempt to induce muscular growth, development, and strength gains. Current evidence suggests that they are effective in producing the outcomes that athlete’s desire. Unfortunately, athletes seem to be ignorant of, or are willing to ignore, the serious medical side effects and health consequences associated with usage of these agents. Unfortunately, their usage has been a persistent occurrence and problem in sports for the last 60 + years, even though there are legitimate medical usages that are permitted.

While there is a large volume of literature concerning reproductive endocrine dysfunction in exercising women, the number of studies in men is relatively small. Thus, many questions regarding the male reproductive adaptive process to exercise training remain unanswered. Consequently, this area of exercise endocrinology is in need of continued study and investigation.

Acknowledgements This work is dedicated to those colleagues who have inspired us with their work and have shown themselves to be the utmost of professionals—Dr. Stanley Hauerwas, Dr. Robert G. McMurray, and the late Dr. Wayne E. Sinning, Dr. Atko Viru, and Dr. Manfred Lehmann.

References

- Raglin J, Barzdukas A. Overtraining in athletes: the challenge of prevention—a consensus statement. *Health & Fitness J.* 1999;3:27.
- Lehmann M, Foster C, Keul J. Overtraining in endurance athletes: a brief review. *Med Sci Sports Exerc.* 1993;25:854–62.
- Brooks GA, Fahey TD, White TP. Neural-endocrine control of metabolism. *Exercise physiology: human bioenergetics and its application*, 2nd ed. Toronto: Mayfield, 1996:144–72.
- Hackney AC, Pearman SN, Nowacki JM. Physiological profiles of overtrained athletes: a review. *J Appl Sport Psych.* 1990;2:21–9.
- Fry RW, Morton AR, Keast D. Overtraining in athletes: an update. *Sports Med.* 1991;12:32–65.
- Hackney AC. Endurance training and testosterone levels. *Sports Med.* 1989;8:117–27.
- Hackney AC, Dolny DG, Ness RJ. Comparison of resting reproductive hormonal profiles in select athletic groups. *Biology of Sport.* 1988;4:200–8.
- Kenttä G, Hassmén P. Overtraining and recovery—a conceptual model. *Sports Med.* 1998;26:1–16.
- Kuipers H, Keizer HA. Overtraining in elite athletes—review and directions for the future. *Sports Med.* 1988;6:79–92.
- Boyd TW, Paramenter R, Stanforth P, Rotkis TC, Wilmore J. Impaired gonadotropin responses to gonadotropin-releasing hormone stimulation in endurance-trained women. *Fertil Steril.* 1984;41:359–63.
- Dale E, Gerlach D, Whilwhite AL. Menstrual dysfunction in distance runners. *Obstet Gynecol.* 1974;54:47.
- Loucks AB. Exercise training in the normal female: effects of exercise stress and energy availability on metabolic hormones and LH pulsatility. In: Warren MP, Constantini NW, editors. *Sports Endocrinology*. Totowa: Humana Press; 2000. p. 165–80.
- Tietz NW. *Clinical guide to laboratory tests*. Philadelphia: Saunders, 1990: 284, 314–45.
- Taber's Medical Dictionary, 14th ed. Philadelphia: F A Davis Co., 1983.
- Hackney AC, Moore AW, Brownlee KK. Testosterone and endurance exercise: development of the “exercise-hypogonadal male condition”. *Acta Physiol Hung.* 2005;92(2):121–237.
- Hackney AC. Effects of endurance exercise on the reproductive system of men: the “exercise-hypogonadal male condition”. *J Endocrinol Invest.* 2008;31(10):932–8.
- Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. *Sports Med.* 2004;34(8):513–54.
- Petit MA, Prior JC. Exercise and the hypothalamus: ovulatory adaptations. In: Warren MP, Constantini NW, editors. *Sports Endocrinology*. Totowa: Humana Press; 2000. p. 133–63.
- Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tracts. In: Wilson JD, editor. *Williams textbook of endocrinology*. Philadelphia: Saunders; 1992. p. 799–852.
- Newshole EA. *Biochemistry for the medical sciences*. London: Wiley & Son; 1983. p. 711–33.
- Arce JC, DeSouza M.J. Exercise and male factor infertility. *Sports Med* 1993;15:146–69.
- Zitzmann M, Nieschlag E. Testosterone levels in healthy men in relation to behavioural and physical characteristics: facts and constructs. *Eur J Endocrinol.* 2001;144:183–97.
- Christiansen K. Behavioral effects of androgen in men and women. *J Endocrinol.* 2001;170:39–48.
- Marcell TJ, Harman SM, Urban RJ, Metz DD, Rodgers BD, Blackman MR. Comparison of GH, IGF-1, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. *Am J Physiol Endocrinol Metab.* 2001;281:E1159–64.
- Widmaier EP. Metabolic feedback in mammalian endocrine systems. *Horm Metab Res.* 1992;24:147–53.
- Eik-Nes KB. On the relationship between testicular blood flow and the secretion of testosterone. *Can J Physiol Pharmacol.* 1964;42:671–2.
- Hackney AC. The male reproductive system and endurance exercise. *Med Sci Sports Exerc.* 1996;28:180–9.
- Viru A. *Hormonal ensemble in exercise—hormones in muscular activity*, vol. 1. Boca Raton: CRC; 1985. p. 7–88.
- Cadoux-Hudson TA, Few JD, Imms FJ. The effect of exercise on the production and clearance of testosterone in well trained young men. *Eur J Appl Physiol* 1995; 54:321–5.
- Keizer HA, Poortman J, Bunnik GS. Influence of physical exercise on sex-hormone metabolism. *J Appl Physiol.* 1980;48:765–9.
- Southren AL, Gordon GG, Tochimoto S. Further study of factors affecting the metabolic clearance rate of testosterone in man. *J Clin Endocrinol Metab.* 1968;28(8):1105–12.
- Kuoppasalmi K, Mavri H, Rehunen S, Harkonen M, Adlercreutz H. Effect of strenuous anaerobic running on plasma growth hormone, cortisol, luteinizing hormone, testosterone, androstenedione and estrone and estradiol. *J Steroid Biochem.* 1976;7:823–9.

33. Schmid P, Pusch PP, Wolf WW, Pilger E, Pessenhofer H, Schwabegger G, Pristautz H, Pürstner P. Serum FSH, LH and testosterone in humans after physical exercise. *Int J Sports Med* 1982;384–89.
34. Metivier G, Gauthier R, de la Chevotriere J, Grymala D. The effect of acute exercise on the serum levels of testosterone and luteinizing (LH) hormone in human male athletes. *J Sports Med Phys Fit.* 1980;20:235–7.
35. Zmuda JM, Thompson PD, Winters SJ. Exercise increases serum testosterone and sex hormone-binding globulin levels in older men. *Metabolism.* 1996;45(8):935–9.
36. McMurray RG, AC Hackney. Endocrine responses to exercise and training. In: Garrett W, DT Kirkendall editors. *Exercise and Sport Science.* Philadelphia: Lippincott, Williams & Wilkins, 2000: 135–62.
37. Hackney AC. Testosterone, the hypothalamo-pituitary-testicular axis and endurance exercise training: a review. *Biol Sport.* 1996;13:85–98.
38. Cumming DC. The male reproductive system, exercise and training. In: Warren MP, Constantini NW, editors. *Sports Endocrinology.* Totowa: Humana Press; 2000. p. 119–32.
39. Aakvaag A, Sand T, Opstad PK, Fonnum F. Hormonal changes in serum in young men during prolonged physical strain. *Eur J Appl Physiol Occup Physiol.* 1978;39:283–91.
40. Hackney AC, Fahrner CL, Stupnicki R. Reproductive hormonal responses to maximal exercise in endurance-trained men with low resting testosterone levels. *Exp Clin Endocrinol Diabetes.* 1997;105: 291–5.
41. Kuopposalmi K, Naveri H, Harkonen N, Adlerkreutz H. Plasma cortisol, androstenedione, testosterone and luteinizing hormone in running exercise of various intensities. *Scand J Clin Lab Invest.* 1980;40:403–9.
42. DiLuigi L, Guidetti L, Baldari C, Fabbri A, Moretti C, Romanelli F. Physical stress and qualitative gonadotropin secretion: LH biological activity at rest and after exercise in trained and untrained men. *Int J Sports Med.* 2002;23:307–12.
43. Hackney AC, Ness RJ, Schrieber A. Effects of endurance exercise on nocturnal hormone concentrations in males. *Chronobiol Int.* 1989;6:341–6.
44. Viru A. Plasma hormones and physical exercise. *Int J Sports Med.* 1992;13:201–9.
45. Kindermann W, Schnabel A, Schmitt WM, Biro G, Cassens J, Weber F. Catecholamines, growth hormone, cortisol, insulin and sex hormones in aerobic and anaerobic exercise. *Eur J Appl Physiol.* 1982;49:389–99.
46. Galbo H, Hummer L, Peterson IB, Christensen NJ, Bie N. Thyroid and testicular hormonal responses to graded and prolonged exercise in men. *Eur J Appl Physiol.* 1977;36:101–6.
47. Galbo H, Kjaer M, Mikines KJ. Neurohormonal system. In: Skinner J, Corbin CB, Landers DM et al. editors. *Future directions in exercise and sport science research.* Champaign: Human Kinetics, 1989:339–45.
48. Kraemer WJ, Patton JF, Knuttgen HG, et al. Hypothalamic-pituitary-adrenal responses to short-duration high-intensity cycle exercise. *J Appl Physiol.* 1989;66:161–6.
49. Cumming DC, Wall SR, Galbraith MA, Belcastro A. Reproductive hormone responses to resistance exercise. *Med Sci Sports Exerc.* 1987;19:234–8.
50. Guezennec Y, Leger F, Hostr FL, Aymonud M, Pesquies PC. Hormone and metabolite response to weight-lifting training sessions. *Int J Sports Med.* 1986;7:100–5.
51. Kraemer WJ. Endocrine response to resistance exercise. *Med Sci Sports Exerc.* 1988;20:S152–7.
52. Kujala UM, Alen M, Huhtaniemi IT. Gonadotrophin-releasing hormone and human chronic gonadotrophin tests reveal that both hypothalamic and testicular endocrine functions are suppressed during acute prolonged physical exercise. *Clin Endocrinol.* 1990;33:219–25.
53. Opstad PK. Androgenic hormones during prolonged physical stress, sleep and energy deficiency. *J Clin Endocrinol Metab.* 1992;74:1176–83.
54. Opstad PK. The hypothalamic-pituitary regulation of androgen secretion in young men after prolonged physical stress combined with energy and sleep deprivation. *Acta Endocrinol.* 1992;127: 231–6.
55. Galbo H. Hormonal and metabolic adaptation to exercise. Georg Thieme Stuttgart: Verlag; 1983. p. 2–117.
56. Gawel MJ, Alaghband-Zadeh J, Park DM, Rose FC. Exercise and hormonal secretion. *Postgrad Med J.* 1979;55:373–6.
57. Brisson G, Volle MA, DeCarufel D, Desharnais D, Tanaka M. Exercise-induced dissociation of the blood prolactin response in young women according to sports habits. *Horm Metab Res.* 1980;12 (5):201–5.
58. Hackney AC, Premo MC, McMurray RG. Influence of aerobic versus anaerobic exercise on the relationship between reproductive hormones in men. *J Sports Sci.* 1995;13:305–11.
59. Hackney AC, Sharp RL, Runyon W, Ness R. Effects of intensive training on the prolactin response to submaximal exercise in males. *J Iowa Acad Sci.* 1989;96:52–3.
60. Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. *J Clin Endocrinol Metab.* 1972;35:840–51.
61. Hackney AC, Davis HC, Lane AR. Exercise augments the nocturnal prolactin rise in exercise-trained men. *Ther Adv Endocrinol Metab.* 2015;6 (5):217–22.

62. Hackney AC, Sinning WE, Bruot BC. Reproductive hormonal profiles of endurance-trained and untrained males. *Med Sci Sports Exerc.* 1988;20:60–5.
63. Hackney AC. 2002; Personal communication.
64. Wheeler GD, Wall SR, Belcastro AN, Cumming DC. Reduced serum testosterone and prolactin levels in male distance runners. *JAMA.* 1984;252:514–6.
65. Hackney AC, Fahrner CL, Gullege TP. Basal reproductive hormonal profiles are altered in endurance trained men. *J Sports Med Phys Fitness.* 1998;38:138–41.
66. Gullege TP, Hackney AC. Reproducibility of low resting testosterone concentrations in endurance trained men. *Eur J Appl Physiol.* 1996;73:582–3.
67. Hackney AC, Sharp RL, Runyan WS, Ness RJ. Relationship of resting prolactin and testosterone in males during intensive training. *Br J Sport Med.* 1989;23:194.
68. Wheeler GD, Singh M, Pierce WD, Epling WF, Cumming DC. Endurance training decreases serum testosterone levels in men without change in luteinizing hormone pulsatile release. *J Clin Endocrinol Metab.* 1991;72:422–5.
69. Obminski Z, Szczypaczewska M, Tomaszewski W. Resting concentrations of cortisol and testosterone in blood of cyclists in the training and competitive periods. *Medycyna Sportowa.* 2001;114:23–6.
70. Urhausen A, Kullmer T, Kindermann W. A 7-week follow-up study of the behaviour of testosterone and cortisol during the competition period in rowers. *Eur J Appl Physiol.* 1987;56:528–33.
71. Alen A, Parkarinen A, Hakkinen K, Komi P. Responses of serum androgenic-anabolic and catabolic hormones to prolonged strength training. *Int J Sports Med.* 1988;9:229–33.
72. Bonifazi M, Bela E, Carl G, Lodi L, Martelli G, Zhu B, Lupo C. Influence of training on the response of androgen plasma concentrations to exercise in swimmers. *Eur J Appl Physiol.* 1995;70:109–14.
73. Fellmann N, Coudert J, Jarrige J, Bedu M, Denis C, Boucher D, Lacour JR. Effects of endurance training on the androgenic response to exercise in man. *Int J Sports Med.* 1985;6:215–9.
74. Lucia A, Chicharro JL, Perez M, Serratoso L, Bandres F, Legido JC. Reproductive function in male endurance athletes: sperm analysis and hormonal profile. *J Appl Physiol.* 1996;81:2627–36.
75. Safarinejad MR, Azma K, Kolahi AA. The effects of intensive, long-term treadmill running on reproductive hormones, hypothalamus-pituitary-testis axis, and semen quality: a randomized controlled study. *J Endocrinol.* 2009;200(3):259–71.
76. MacConnie S, Barkan A, Lampman RM, Schork M, Beitins IZ. Decreased hypothalamic gonadotropin-releasing hormone secretion in male marathon runners. *N Engl J Med.* 1986;315:411–7.
77. Duclos M, Corcuff JB, Rashedi M, Fougere B. Does functional alteration of the gonadotropic axis occur in endurance trained athletes during and after exercise? A preliminary study. *Eur J Appl Physiol.* 1996;73:427–33.
78. McColl EM, Wheeler GD, Bhambhani Y, Cumming DC. The effects of acute exercise on pulsatile LH release in high-mileage male runners. *Clin Endocrinol (Oxf).* 1989;31:617–21.
79. Ozen SV. Reproductive hormones and cortisol responses to plyometric training in males. *Biol Sport.* 2012;29(3):193–7.
80. Hackney AC, Sinning WE, Bruot BC. Hypothalamic-pituitary-testicular axis function in endurance-trained males. *Int J Sports Med.* 1990;11:298–303.
81. Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. *Clin Endocrinol* 1984; 21 (3):257-63.
82. Burge MR, Lanzi RA, Skarda ST, Eaton RP. Idiopathic hypogonadotropic hypogonadism in a male runner is reversed by clomiphene citrate. *Fertil Steril.* 1997;68:745.
83. Cumming DC, Quigley ME, Yen SS. Acute suppression of circulating testosterone levels by cortisol in men. *J Clin Endocrinol Metab.* 1983;57:671–3.
84. Dessypris A, Kuoppasalmi H, Adlercreutz HJ. Plasma cortisol, testosterone, androstenedione and luteinizing hormone (LH) in a non-competitive marathon run. *J Steroid Biochem.* 1976;7:33–7.
85. Urhausen A, Gabriel H, Kindermann W. Blood hormones as markers of training stress and overtraining. *Sports Med.* 1995;20:251–76.
86. Urhausen A, Kindermann W. Biochemical monitoring of training. *Clin. J. Sports Med.* 1992;2:52–61.
87. Wittert GA, Livesey J, Espiner E, Donald R. Adaptation of the hypothalamo-pituitary adrenal axis to chronic exercise stress in humans. *Med Sci Sports Exerc.* 1996;28:1015–9.
88. Hackney AC, Viru A. Twenty-four-hour cortisol response to multiple daily exercise sessions of moderate and high intensity. *Clin Physiol.* 1999;19:178–82.
89. Ayers JWT, Komesu V, Romani T, Ansbacher R. Anthropomorphic, hormonal, and psychologic correlates of semen quality in endurance-trained male athletes. *Fertil Steril.* 1985;43:917–21.
90. Arce JC, DeSouza J, Pescatello LS, Luciano AA. Subclinical alterations in hormone and semen profile in athletes. *Fertil Steril.* 1993;59:398–404.
91. Skarda S, Burge MR. Prospective evaluation of risk factors for exercise-induced hypogonadism in male runners. *West J Med.* 1998;169:9–12.
92. Roberts AC, McClure RD, Weiner RL, Brooks GA. Overtraining affects male reproductive status. *Fertil Steril.* 1993;60:686–92.
93. Wise LA, Cramer DW, Hornstein MD, Ashby RK, Missmer SA. Physical activity and semen quality

- among men attending an infertility clinic. *Fertil Steril*. 2011;95(3):1025–30.
94. McGrady AV. Effects of psychological stress on male reproduction: a review. *Arch Androl*. 1984;13:1–7.
 95. Baker ER, Leuker R, Stumpf PG. Relationship of exercise to semen parameters and fertility success of artificial insemination donors. *Fertil Steril* 1984;41:107S (abstract).
 96. Baker ER, Stevens C, Leuker R. Relationship of exercise to semen parameters and fertility success of artificial insemination donors. *JSC Med Assoc*. 1988;84:580–2.
 97. Editorial—special survey: running and sex. *The Runner* 1982;May:26–35.
 98. MacDougall JD, Webber CE, Martin J, Ormerod S, Chesley A, Younglai EV, Gordon CL, Blinkie CJ. Relationship among running mileage, bone density, and serum testosterone in male runners. *J Appl Physiol*. 1992;73:1165–70.
 99. MacKelvie KJ, Taunton JE, McKay HA, Khan KM. Bone mineral density and serum testosterone in chronically trained, high mileage 40–55 year old male runners. *Br J Sports Med*. 2000;34(4):273–8.
 100. Behre H, Kliesch S, Leifke E, Link T, Nieschlag NJ. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. *J Clin Endocrinol Metab* 1997;82:2386–390.
 101. Ackerman KE, Skrinar GS, Medvedova E, Misra M, Miller KK. Estradiol levels predict bone mineral density in male collegiate athletes: a pilot study. *Clin Endocrinol (Oxf)*. 2012;76(3):339–45.
 102. Riggs BL, Eastell R. Exercise, hypogonadism, and osteopenia. *JAMA*. 1986;256:392–3.
 103. Rigotti NA, Roberts N, Jameson L. Osteopenia and bone fractures in a man with anorexia nervosa and hypogonadism. *JAMA*. 1986;256:385–8.
 104. Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA*. 1996;276:205–10.
 105. von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre H. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). *J Clin Endocrinol Metab*. 1997;82:3367–72.
 106. Wood PD, Haskell WL, Stern MP, Lewis S, Perry C. Plasma lipoprotein distributions in male and female runners. *Ann N Y Acad Sci*. 1977;301:748–63.
 107. Taylor AJ, Watkins T, Bell D, Carrow J, Bindeman J, Scherr D, Feuerstein I, Wong H, Bhattarai S, Vaitkus M, O'Malley PG. Physical activity and the presence and extent of calcified coronary atherosclerosis. *Med Sci Sports Exerc*. 2002;34:228–33.
 108. Lehmann M, Lormes W, Opitz-Gress A, Steinacker J, Netzer N, Foster C, Gastmann U. Training and overtraining: an overview and experimental results in endurance sports. *J Sports Med Phys Fitness*. 1997;37:7–17.
 109. Fry AC, Kraemer W. Resistance exercise overtraining and overreaching: neuroendocrine responses. *Sports Med*. 1997;23:106–29.
 110. Fry RW, Morton AR, Garcia-Webb P, Keast D. Monitoring exercise stress by changes in metabolic and hormonal responses over a 24-h period. *Eur J Appl Physiol*. 1991;63:228–34.
 111. Fry RW, Morton AR, Garcia-Webb P, Crawford GPM, Keast D. Biological responses to overload training in endurance sports. *Eur J Appl Physiol*. 1992;64:335–44.
 112. Hackney AC. Neuroendocrine system, exercise overload and regeneration. In: Lehmann M, et al., editors. *Overload, performance incompetence, and regeneration in sport*. Stuttgart: Kluwer Academic-Plenum; 1999. p. 173–87.
 113. Barron JL, Noakes TD, Levy W, Smith C, Millar RP. Hypothalamic dysfunction in overtrained athletes. *J Clin Endocrinol Metab*. 1985;60:803–6.
 114. Lane AR, Duke JW, Hackney AC. Influence of dietary carbohydrate intake on the free testosterone: cortisol ratio responses to short-term intensive exercise training. *Eur J Appl Physiol*. 2010;108(6):1125–31.
 115. American College of Sports Medicine. *Position statement on the use of anabolic steroids*. Indianapolis: ACSM Publishing; 1990.
 116. Rogol AD, Yesalis CE. Clinical Review—*anabolic-androgenic steroids and athletes: what are the issues?* *J Clin Endocrinol Metab*. 1992;74:465–9.
 117. Wichstrøm L. Predictors of future anabolic androgenic steroid use. *Med Sci Sports Exerc*. 2006;38(9):1578–83.
 118. Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. *Ann Epidemiol*. 2014;24(5):383–98.
 119. Rogol A. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. *Curr Opin Pediatr*. 2000;12:382–7.
 120. Brooks GA, TD Fahey, TP White. *Ergogenic aids. Exercise physiology: human bioenergetics and its application*, 2nd ed. Mountain View: Mayfield Publishing 1996:617–30.
 121. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. *J Clin Endocrinol Metab*. 1997;82:407–13.
 122. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim L, Shen R, Storer TW.

- Testosterone dose-response relationship in healthy young men. *Am J Physiol Endocrinol Metab.* 2001;281:E1172–81.
123. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. *J Endocrinol Invest.* 2009;32(8):704–16.
 124. Vahlquist B. The cause of the sexual differences in erythrocyte hemoglobin and serum iron levels in human adults. *Blood.* 1950;5(9):874–5.
 125. Shahidi NT. Androgens and erythropoiesis. *N Engl J Med.* 1973;289(2):72–80.
 126. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. *Eur J Med Res.* 1997;2(7):293–8.
 127. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85(8):2670–7.
 128. Arnold AM, Peralta JM, Thonney ML. Ontogeny of growth hormone, insulin-like growth factor-I, estradiol and cortisol in the growing lamb: effect of testosterone. *J Endocrinol.* 1996;150:391–9.
 129. Urban RJ, Bodenbunrg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. *Am J Physiol.* 1995;269:E820–6.
 130. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. *J Clin Endocrinol Metab.* 1998;83:1886–92.
 131. Wilson JD. The role of 5 alpha-reduction in steroid hormone physiology. *Reprod Fertil.* 2001;13:673–8.
 132. Inoue K, Yamasaki S, Fushiki T, Okada Y, Sugimoto E. Androgen receptor antagonist suppresses exercise-induced hypertrophy of skeletal muscle. *Eur J Appl Physiol.* 1994;69:88–91.
 133. Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, Ferrando AA. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. *J Clin Endocrinol Metab.* 1999;84:2705–11.
 134. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. *Endocr Rev.* 2002;23:175–200.
 135. Ting HJ, Yeh S, Nishimura K, Chang C. Supervillin associates with androgen receptor and modulates its transcriptional activity. *Proc Natl Acad Sci.* 2002;99:661–6.
 136. Danhaive PA, Rousseau CG. Evidence for sex-dependent anabolic response to androgenic steroids mediated by muscle glucocorticoid receptors in the rat. *J Steroid Biochem.* 1988;29:575–81.
 137. Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. *J Clin Endocrinol Metab.* 1999;84:3515–21.
 138. Medlinsky J, Napier C, Gurney C. The use of an antiandrogen to further investigate the erythropoietic effects of androgens. *J Lab Clin Med.* 1969;74(1):85–92.
 139. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, Connor Westfall J, Bae H, Gordeuk V, Bhasin S. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. *J Gerontol A Biol Sci Med Sci* 2014; 69(6):725–35.
 140. Moriyama Y, Fisher JW. Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. *Blood.* 1975;45(5):665–70.
 141. Parker JP, Beirne GJ, Desai JN, Raich PC, Shahidi NT. Androgen-induced increase in red-cell 2,3-diphosphoglycerate. *N Engl J Med.* 1972;287(8):381–3.
 142. Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolfe RR. Testosterone administration in severe burns ameliorates muscle catabolism. *Crit Care Med.* 2001;29:1936–42.
 143. Mottram DR, George AJ. Anabolic steroids. *Baillieres Best Pract Res Clin Endocrinol Metab.* 2000;14:55–69.
 144. Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions. *Rev Endocr Metab Disord.* 2015;16(3):199–211.
 145. Kuipers H. Anabolic steroids: side effects. In: Fahey TD, editors. *Encyclopedia of sports medicine and science.* Internet Society for Sport Science: <http://sports.org>, 1998.
 146. Alen M, Rahkila P. Anabolic-androgenic steroids effects on endocrinology and lipid metabolism in athletes. *Sports Med.* 1988;6:327–32.
 147. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in power lifters ingesting anabolic steroids. *J Clin Endocrinol Metab.* 1987;64:960–3.
 148. DePiccoli B, Giada F, Benetton A, Sartori E, Piccolo E. Anabolic steroid use in body builders: an echocardiographic study of left ventricular morphology and function. *Int J Sports Med* 1991; 12:408–12.
 149. Haupt HA. Anabolic steroids and growth hormone. *Am J Sports Med.* 1993;21:468–74.
 150. Wilson JD. Androgen abuse in athletes. *Endocr Rev.* 1988;9:181–91.
 151. Tirabassi G, Gioia A, Giovannini L, Boscaro M, Corona G, Carpi A, Maggi M, Balercia G. Testosterone and cardiovascular risk. *Intern Emerg Med* 2013; Suppl 1:S65-9.
 152. Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. *Eur J Endocrinol.* 2015;173(2):R47–58.

153. El Osta R, Almont T, Diligent C, Hubert N, Eschwège P, Hubert J. Anabolic steroids abuse and male infertility. *Basic Clin Androl.* 2016;26:2.
154. Laure P. Epidemiological approach of doping in sport. *J Sports Med Phys Fitness.* 1997;37:218–24.
155. Buckley WE, Yasalis CE, Friedl KE, Anderson WA, Streit A, Wright JE. Estimated prevalence of anabolic steroid use among male high school seniors. *JAMA.* 1988;260:3441–5.
156. Yesalis CE III, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. *JAMA.* 1993;270:1217–21.
157. Bamberger M., Yaeger D. Over the edge. *Sports Illustrated* 1997;86:60–70.
158. Albertson TE, Chenoweth JA, Colby DK, Sutter ME. The changing drug culture: use and misuse of appearance-and performance-enhancing drugs. *FP Essent.* 2016;41:30–43.
159. Leder BZ, Catlin DH, Longcope C, Ahrens B, Schoenfeld DA, Finkelstein JS. Metabolism of orally administered androstenedione in young men. *J Clin Endocrinol Metab.* 2001;86:3654–8.
160. King D, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, Parsons KA. Effects of oral androstenedione on serum testosterone and adaptations to resistance training in young men. *JAMA*1999; 281:2020–2028.
161. Leder BZ, Longcope, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration and serum testosterone concentrations in young men. *JAMA* 2000;283:779–82.
162. Prough R, Clark BJ, Klinge CM. Novel mechanisms for DHEA action. *J Mol Endocrinol.* 2016; JME-16-0013.
163. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. *Ann NY Acad Sci.* 1995;774:128–42.
164. Deyssig R, Frisch H, Blum WF, Waldhor T. Effect of growth hormone treatment on hormonal parameters, body composition, and strength in athletes. *Acta Endocrinol.* 1993;128:313–8.
165. Yarasheski KE, Cambell JA, Smith K, Rennie MJ, Holloszy OJ, Bier DM. Effect of growth hormone and resistance exercise on muscle growth in young men. *Am J Physiol Endocrinol Metab.* 1992;25: E261–7.
166. World Anti-doping Association (WADA). Androgen deficiency/male hypogonadism: TUE Physician Guidelines 2015. WADA Headquarters, Montreal (Quebec) H4Z 1B7, Canada.
167. Handelsman DJ, Heather A. Androgen abuse in sports. *Asian J Androl.* 2008;10(3):403–15.
168. Viru A, Viru M. Biochemical monitoring of sport training. Champaign: Human Kinetics Publishing; 2001. p. 5–192.
169. Bouchard C, Shephard RJ, Stephens T, Sutton JR, McPherson BD. Exercise, fitness, and health: a consensus of current knowledge. Champaign, IL: Human Kinetics; 1990.
170. Lehmann M, Knizia K, Gastmann U, Petersen G, Khalaf A, Bauer S, Kerp L, Keul J. Influence of 6-week, 6 days per week, training on pituitary function in recreational athletes. *Br J Sports Med.* 1993;27:186–92.
171. Winder WW, Hagberg JM, Hickson RR, Ehsani AA, McLane JA. Time course of sympathoadrenal adaptation to endurance exercise training in man. *J Appl Physiol.* 1978;45:370–4.

Richard M. Sharpe BSc, MSc, PhD

Contents

Introduction	281
Environmental/Lifestyle Effects on the Adult Male	283
Seasonal Effects on Testicular Function	283
Occupational Effects on Testicular Function: General Aspects	284
Occupational/Environmental Exposure to Pesticides/Fungicides/PCBs.....	285
Occupational/Lifestyle Effects on Scrotal Temperature	287
Other Lifestyle/Dietary Factors Affecting the Adult Male	289
Environmental/Lifestyle Effects on the Adult Testis that Arise During Fetal Development	291
Testicular Dysgenesis Syndrome (TDS) and the Masculinization Programming Window.....	291
What Maternal Lifestyle Factors or Exposures Might Impact Reproductive Development/Androgen Exposure of the Male Fetus?.....	294
Future Prospects.....	296
References	297

Introduction

The notion that our environment can adversely impact male reproductive development and/or function is not an idea at the top of the list for most clinicians. There are probably very good practical reasons for this stance—for example, few will have encountered patients in whom reproductive dysfunction was diagnosed as being

altered by some environmental factor. Does this mean that such causes are rare or does it mean that they go unrecognized? Unfortunately, we probably still lack sufficient understanding to definitively answer this question, but hopefully this chapter will go some way toward addressing it.

When viewed from an evolutionary perspective, it is clear that the environment and reproductive function are inextricably linked, as evidenced by the fact that the majority of mammals (‘seasonal breeders’) exhibit seasonal hypogonadism and infertility under the influence of daylight length and other environmental cues [1]. Humans are not seasonal breeders, but as we undoubtedly have seasonally breeding ancestors in our evolutionary past, residues of such effects are likely, as discussed later in this chapter. But perhaps the most important lesson to be learned is that seasonal breeding evolved so as to ensure that offspring are born at the optimum time of year for survival, which usually equates to the availability of a good food supply. Thus, environmental factors, of which daylight is the most invariable, were adopted as cues via which to regulate function of the reproductive system—this seems to work primarily via central regulation of the hypothalamic–pituitary axis [2]. However, effects of the environment on reproduction are far more pervasive than this. The well-established relationship between food intake/energy balance and onset of puberty/maintenance of menstrual cycling in females is another example, and the mechanisms via which these effects occur are now being established (e.g., leptin) [3]. These examples remind us that we have evolved so as to

R.M. Sharpe (✉)
MRC Centre for Reproductive Health, the Queen’s
Medical Research Institute, University of Edinburgh,
47 Little France Crescent, EH164TJ Edinburgh, UK
e-mail: r.sharpe@ed.ac.uk

be 'in tune' with our environment and, if we accept this premise, we must also recognize that when our environment or lifestyle changes dramatically, then there may be health consequences. The major changes in Western diet (increased intake of refined carbohydrates, dairy products/fats) and lifestyle (e.g., widespread artificial light, increased sedentary habits, increased recreational and pharmaceutical drug use) over the last century are therefore certain to have had some impact, but the extent to which these changes may have affected our general or reproductive health is unclear, with the notable exception of obesity and obesity-related disorders.

In the past 20 years the specter of more widespread environmental adverse effects on male reproductive function has arisen, fuelled by the possibility of 'falling sperm counts' and increase in other male reproductive disorders [4, 5]. Though this remains a somewhat controversial topic, some aspects, such as the increased incidence of testicular germ cell cancer over the past 50+ years, and the high prevalence of young men with low sperm counts (<20 million/ml) are beyond dispute [4]. Such changes must have a lifestyle/environmental cause, and the various possibilities are outlined below. There are strong beliefs that testis germ cell cancer may be the tip of an iceberg, signaling to us about a more fundamental underlying syndrome of disorders ('testicular dysgenesis syndrome') that may have a common origin in fetal life during the masculinization process [4–6]. Much of this is still hypothesis, but the evidence in its favor has grown substantially, based on clinical and experimental animal studies [4, 7, 8]. True or not, this hypothesized syndrome has played an important part in opening our eyes to the fundamental importance of fetal and neonatal life in 'setting up the male reproductive system for adulthood.' This reality is very much in step with thinking in other areas of medicine in which the fetal origins of adult disease are recognized increasingly as being of fundamental importance. Such developments have turned the spotlight on the pregnant woman and, with the dramatic changes that have been occurring in women's lifestyles in the past two decades or so, and the

later age for first pregnancies, it seems inevitable that this must have lifelong consequences for the fetus. These may be good or bad, but if they adversely affect the reproductive health of the offspring [4–6], such effects can remain 'hidden' for 30 or more years, with the result that recognition of the effect and its 'cause' is extremely difficult to investigate in a definitive manner.

In parallel with the developments outlined above, there has been a veritable explosion of studies aimed at establishing that the reproductive health of humans and wildlife is being adversely impacted by so-called endocrine disruptors. This is a broad and complex area with much controversy and uncertainty, and whether or not endocrine disruptors really do exert significant effects on human male reproductive health still remains an open question [4, 5, 9]. However, we must recognize that man-made products such as DDT and PCBs, which undoubtedly exert a range of biological effects in wildlife, persist in us all and are to some extent passed from one generation to the next via breast milk and the food chain. Although these products have been banned/restricted in use for decades, their persistence makes them a continuing issue, and indeed, they have been added to by more recent brominated and fluorinated compounds which also bioaccumulate to a significant degree, and evidence for their potential adverse adult-onset reproductive effects following maternal exposure during pregnancy has begun to emerge [4, 10, 11]. These and numerous other man-made chemicals are part of our everyday environment, and it is more likely than not that some of these compounds will have a biological effect upon some of us. Such effects may be benign, beneficial or perhaps most likely adverse, but proving cause and effect in human studies is fraught with problems; hence, evidence for this is sought from animal experimental studies. However, as detailed later in this chapter, emerging evidence for animal-human differences in susceptibility to the adverse effects of certain key contaminants questions how reliable it is to use animal models to estimate human risk.

Environmental/Lifestyle Effects on the Adult Male

These fall into four different categories, namely the effects of season, occupation, lifestyle/diet and chemical exposures (Fig. 14.1). These are dealt with separately, but it is emphasized that they are not independent factors, and that combinations of circumstances, rather than individual factors, may be more important in causing reproductive health changes. In a similar vein, some individuals may be predisposed to an adverse effect of a chemical or lifestyle factor, for example, because of their genetic background.


Seasonal Effects on Testicular Function

Though humans are considered to be non-seasonal mammals, we are undoubtedly sensitive to photoperiod [12], as exemplified by ‘seasonal affective disorder’ and by seasonal trends in the frequency of births and in the incidence of twins. Such effects are most obvious in Northern Europe where photoperiodic changes are most extreme [13]. Furthermore, both longitudinal and cross-sectional studies have

demonstrated that sperm counts in men are consistently ~30% lower in summer than in spring and/or winter [14–16], though not all studies have reported such effects, and they may be less apparent or absent in tropical countries [17]. An alternative explanation is that exposure to the higher summer temperature is responsible for lowering sperm production (see below), though temperature changes do not account for all of the seasonal trends in births, especially in Northern Europe [12]. If the reported ‘seasonal’ changes in sperm counts/seminal quality are an echo from our seasonally breeding ancestors, then this may be rather variable in its effect and, in most men, is unlikely to exert a major effect on their fertility. It is likely that any effects of season in humans/individuals will be driven by seasonal changes in the duration of melatonin secretion, as in seasonally breeding animals (below).

Studies in seasonally breeding animals have established the key pathways via which daylight length is able to regulate the reproductive axis, and melatonin secreted by the pineal gland plays a pivotal role [1, 2]. It is therefore curious that young men with hypogonadotropic hypogonadism (HH) show abnormal blood levels of melatonin, being increased in males with

Fig. 14.1 Main environmental and lifestyle factors affecting testicular development and/or function in adulthood



idiopathic HH and decreased in males with Kallmann syndrome, when compared with controls [18, 19]. However, as melatonin levels may be normalized by testosterone replacement therapy in HH men, it implies that the abnormal melatonin level may be a consequence rather than a cause of the HH [18], although this reasoning may not extend to men with hypergonadotropic hypogonadism [19]. More generally, the evidence for seasonal fluctuations in testosterone levels in men is equivocal [20] and is likely to be highly confounded by the influence of other factors such as obesity, activity levels and age.

Occupational Effects on Testicular Function: General Aspects

Numerous published studies have retrospectively surveyed the occupations of men attending infertility clinics and/or compared occupations of fertile and infertile groups. There is some consensus in showing, for example, that farmers/agricultural workers or lorry drivers, painters or welders may be over-represented among infertile men, but overall the findings of such studies are inconsistent and have failed to identify common occupational causes of male infertility [21–24]. Occupation is only one of a range of factors that may cause male infertility, and therefore searching for such factors among patients at the infertility clinic may not be the most sensitive approach. Unfortunately, alternative approaches such as the direct investigation of particular working groups also have various problems [25]. Low participation rates are common and may be biased toward those who have experienced, or suspect, a fertility problem [26]. This makes interpretation of any findings difficult. Another common problem is the low numbers of workers who may eventually compose the ‘exposed’ or control groups, as many published studies involve 30–50 men or less per group [23, 25, 27]. As sperm counts and other semen parameters show great variation between subjects, detection of a workplace/occupational effect against such a background requires considerable numbers of

subjects; otherwise, the study will lack sufficient power to detect anything other than a major change in semen parameters [25]. For example, ~80 control and ‘exposed’ men would be required to detect a 20% fall in sperm count. Moreover, because within-subject variation in semen parameters can also be substantial, a rigorous study should involve two or more semen samples per subject, adding considerably to study complexity and cost.

Finally, there are likely to be many confounding factors in any occupational study. These may include age, ejaculatory frequency/abstinence, smoking and alcohol consumption, recreational drug use, time spent seated (see below), recent infection or febrile period, past history of cryptorchidism and sexually transmitted disease [28]. Attempts can be made to control for some of these factors, but with the generally small numbers of subjects involved, this is inevitably less than satisfactory. Against this background, it is therefore unsurprising that relatively few occupations or workplace exposures have been shown **consistently** to impact significantly on male reproductive health (usually on sperm counts/fertility). However, there is reasonable evidence to suggest that exposure to some solvents [29], older glycol ethers [23, 30] and inorganic lead [31, 32] can impact one or more aspects of semen quality in exposed workers and in some instances affect fertility or miscarriage rates (though effects on the latter two parameters are small). Nevertheless, other studies that showed no significant effect of similar exposures can also be found in the literature [e.g., 33, 34]. This would support the view that such workplace exposures have relatively minor effects on semen quality and male fertility, though in some individuals, such as those with a low sperm count for other reasons, such effects might significantly impact fertility.

Information on occupational impacts on testosterone levels in men is even more equivocal, in part for reasons of study group sizes as just outlined for semen quality aspects. Moreover, any adverse effect on testosterone levels should automatically trigger a compensatory increase in LH secretion that will return testosterone levels

toward normal, unless the factor(s) in question exerts its adverse effect via altering secretion of LH. While any such compensatory change should theoretically be detectable via LH measurement and calculation of the LH/testosterone ratio, the inter-individual variation in LH and its pulsatile secretion pattern as well as the circadian rhythm in testosterone levels can make differences difficult to detect unless changes are extreme, which would be unusual. Reasons such as these probably explain why the literature on this topic is small with highly equivocal, and usually very minor, findings. These will not be reviewed in any detail here, but an example is a Chinese study of 154 electrical power-plant workers, half of whom were exposed to electromagnetic fields, which was associated with a 3% average drop ($p = 0.015$) in total testosterone levels [35]; such a change is likely to be incidental. Where occupation has been associated with altered testosterone levels, it has been mainly in connection with pesticide/fungicide exposure, which is outlined below. A more convincing study involved Italian policemen exposed to traffic fumes [36], compared with police office workers. Those exposed to traffic fumes exhibited $\sim 20\%$ reduction in free testosterone levels, a difference that was even more marked ($\sim 29\%$) when those in the age range 30–40 years were compared [36]. Unfortunately, LH levels and the LH/testosterone ratio were not reported in that particular study, although a similar earlier study by the same authors ($N = 166$ traffic-exposed vs. 166 non-exposed) reported a mean 50% increase in LH levels (from 1.8 to 2.7 mIU/ml; $p < 0.001$), although no testosterone levels were reported in that study! [37] Thus, it *appears* that high exposure to traffic pollutants may induce compensated Leydig cell failure (i.e., decreased or normal testosterone in the face of elevated LH), but this requires direct confirmation in a properly designed study in which both LH and testosterone are measured in the same men. As to mechanism, there is some evidence that diesel exhaust might suppress expression of steroidogenic factor-1 in developmental animal studies [38].

Occupational/Environmental Exposure to Pesticides/Fungicides/PCBs

The occupational exposure associated with the greatest change in sperm count and fertility was workplace exposure to the nematicide, dibromochloropropane (DBCP; Table 14.1). This toxin induced azoospermia or oligospermia in a high percentage of exposed workers, both those involved in its manufacture and those involved in its application on crops [39–41]. In a substantial proportion of DBCP-exposed workers who became azoospermic, no recovery of sperm counts occurred following removal from exposure [39, 40]. This *lone* example is frequently cited as reassuring evidence of the rarity of such workplace effects on sperm counts and male fertility. In reality this reassurance is a veil. The effects of DBCP were revealed, even though the affected workforces comprised fairly low numbers, because it had **catastrophic** effects on sperm counts/fertility. We can be reassured that similar catastrophes will also reveal themselves, but more modest effects of occupation on sperm counts/fertility will remain difficult or impossible to identify in all but very large, well-controlled studies. The latter are hugely expensive and laborious, both of which act as strong deterrents to their application.

The DBCP experience has had several important repercussions, the most scientifically important being the impetus that it gave to studies of wider pesticide exposure and male reproductive function, especially changes in semen quality and male fertility. Conversely, it has also helped trigger the default view that pesticide exposure results in lowered sperm counts/infertility, which has become more or less accepted as dogma in some circles. There have also been numerous studies of pesticide exposure and hormone levels in men, which is the primary focus of this chapter. However, as there is clear evidence that men with low sperm counts are at increased risk of having compensated Leydig cell failure [42, 43], it makes sense to consider the evidence for pesticide effects on both aspects of male reproductive function together.

Table 14.1 Main examples of environmental chemicals that have been studied in relation to potential impacts on spermatogenesis or steroidogenesis in adult men

Chemical type	Uses	Nature of exposure	Possible effects
Dibromochloropropane (DBCP)	Nematicide	Occupational	Irreversible azoospermia
DDT/DDE and related pesticides	Pesticides	Food chain and environmental	?Changes in semen quality and/or LH and testosterone
Polychlorinated Biphenyls (PCBs)	Electrical equipment + others	Food chain and environmental	?Changes in semen quality and/or LH and testosterone
Organophosphates	Pesticide	Occupational	?Changes in semen quality and/or LH and testosterone
Pyrethroids	Pesticide	Environmental	?Changes in semen quality and/or LH and testosterone

There are numerous studies that show significant associations between exposure to various pesticides/fungicides and reduced semen quality (Table 14.1), but there are nearly as many studies showing no significant association. As this is not the primary focus of this chapter, only a brief overview is given here, and readers are referred to a 2008 review [44]. This paper reviewed all studies spanning a 15-year period and reported that only 13 of 20 studies showed a significant negative association between environmental or occupational pesticide exposure and semen quality with similar disparity for other parameters (e.g., sperm DNA damage). When considering individual pesticides or classes of pesticides, the results are in general equally inconsistent, for example, for persistent organochlorine pesticides such as DDT/DDE [45–48]. Recent studies that have focused on other pesticides such as organophosphates [47, 49, 50] or pyrethroids [51] have perhaps shown a more consistent association between exposure and reduced semen quality.

In terms of pesticide exposure and sex hormone levels in men, the perspective is quite similar to that for semen quality, although not as many studies have investigated hormone levels. Thus,

reduced blood testosterone levels with or without altered (up/down) LH levels have been reported in men exposed to persistent organochlorine pesticides such as DDT/DDE [52], to organophosphates [53] or pyrethroids [51, 54]. However, for each of these classes of compounds there are comparable studies (mostly larger in size) showing no significant alteration of testosterone and/or LH levels in association with exposure to DDT/DDE or other persistent organochlorine pesticides [55–59], to organophosphates [60] or pyrethroids [61].

The inconsistencies in studies that have assessed the association between pesticide exposure and male reproductive function may be partly attributed to inter-study variation in a range of factors, such as methods, country of study, exposure assessments and outcomes [44]. Perhaps more important may be that many of the studies are based on either male partners of infertile couples or farmers/occupationally exposed men, neither of which is representative of the general male population. It is perhaps noteworthy that the majority of studies unaffected by such limitations have mostly found no association between pesticide exposure and male

reproductive dysfunction [46, 48, 58, 61], although there are exceptions [53, 62], bearing in mind also that there will be significant under-reporting of negative data in the published literature. Arguably, the most informative study was the US LIFE study which was prospective and involved 501 male partners of couples who were just stopping contraceptive use, and in whom exposure to 36 PCBs, 9 organochlorine pesticides and 10 polybrominated diethyl ethers was measured [48]. Although a range of statistically significant associations was found between exposure to individual chemicals or classes of chemicals and semen quality, most of the associations were positive not negative. In this study, as well as in all of the others cited, it should be emphasized that where significant associations have been found between exposure(s) and semen quality or testosterone levels, the 'effect' sizes, whether negative or positive, have been generally small and could be incidental. The tentative conclusion, based on present data, is that for the general population at current levels of pesticide exposure, there is unlikely to be any biologically meaningful effect on adult male reproductive function although there may be some risk for those who are more highly exposed via their occupations, such as farmers.

Occupational/Lifestyle Effects on Scrotal Temperature

Another situation in which occupational effects on male reproductive function might become apparent is if the 'occupational effect' applies to a large proportion of men; 'scrotal heating' may be one such example. Scrotal, and therefore testicular, temperature has to be maintained some 3–4 C lower than core body temperature if normal spermatogenesis is to occur, and this is achieved via a vascular heat exchanger system, the pampiniform plexus (Fig. 14.2). Interference with the normal scrotal cooling process can profoundly affect sperm production, quality and fertility [63–65], although there is no clear evidence for effects on testosterone levels. A straightforward example of this is the effects of




Fig. 14.2 Schematic diagram to illustrate the central mechanisms involved in cooling of the testis, and the various occupational or lifestyle factors that can interfere with their function. The primary mechanism of cooling the testis is by heat loss from the scrotum, and this necessitates air flow around it. The resulting cooling of the testis means that testicular venous blood is also cool when it leaves the testis and this blood is used to cool incoming warm arterial blood within the pampiniform plexus via heat exchange and via the diversion of ~40% of incoming arterial blood into the testicular vein via numerous arterio-venous anastomoses; the presence of a varicocele may interfere with heat exchange within the pampiniform plexus

repeated Finnish sauna exposure over 3 months, which lowered sperm counts and motility and induced adverse effects to sperm chromatin packaging but did not measurably alter testosterone levels; all of the adverse effects of the sauna were reversible within 6 months [66]. In theory, occupational or lifestyle factors that interfere with scrotal cooling/thermoregulation could be significant factors in lowering sperm counts [66, 67]. Examples of such potential factors are exposure to radiant heat, the wearing of tight trousers/underwear, time spent having hot baths and time spent seated (Fig. 14.2). Most of the older studies that sought to investigate

such factors could rely only on establishing an association between such factors and poor semen quality, and perhaps not surprisingly the evidence proved equivocal or only marginally convincing in most cases [reviewed in ref. 25]. However, several epidemiological studies have shown that occupations involving prolonged sitting, and thus reduction in airflow around the scrotum [63, 66], are associated with significant reductions in sperm counts. An example is car or taxi driving [68, 69]. Away from occupational situations, the worst case might be paraplegic men who are confined to wheelchairs [70], although the poor semen quality in such men may have other contributory causes such as impaired accessory sex gland function, infection and increased proinflammatory cytokines [71].

More objective studies became possible once the technical problems relating to measurement of changes in scrotal temperature had been overcome, as this enabled *quantification* of scrotal heating. Scrotal temperature was measured continuously in normal young men or in men from couples planning their first pregnancy, and a significant relationship between average daily scrotal temperature and sperm counts was established [72]. Moreover, the same studies linked scrotal temperature to the amount of time spent seated, i.e., the more sedentary the lifestyle/occupation, the higher the average scrotal temperature, and this has been confirmed in more extensive recent studies [73]. Application of continuous scrotal temperature monitoring in reasonably large numbers of healthy men has demonstrated unequivocally that increase in average scrotal temperature is clearly linked to lower sperm counts as well as to associated changes in blood levels of FSH and inhibin-B [72–74]. Such findings raised the expectation that our increasingly sedentary lifestyles in the West might induce negative effects on semen quality in a high proportion of men [25], but this expectation is proving to be overly simplistic. For example, although time spent seated is an important determinant of scrotal temperature, the

former has only a weak relationship with semen quality [74] and fertility [75], and other factors such as obesity [76], night-time scrotal temperature [73] and genetic determinants of scrotal temperature [77] may prove to be more important. There is reasonably strong evidence that physical activity is associated with better semen quality [75, 78] and marginally higher testosterone levels [78], when compared to men who have sedentary lifestyles. While this may be related to lower scrotal temperature, as physical activity is likely to improve scrotal cooling, there may be other effects of physical activity that also impact testis function.

From a clinical perspective, the number of men in whom infertility is induced partly or totally by elevated scrotal temperature is likely to be low. However, there are three other points to be kept in mind. First, even quite mild elevations in scrotal temperature in animal studies can increase DNA damage and miscarriage rates [64, 79], so its effects on sperm can be qualitative as well as quantitative. Second, ‘treatment’ to lower overall scrotal temperature in patients who have poor semen quality, though being a ‘shot in the dark,’ is relatively noninvasive and can be quite effective in some cases [80]—and there are no side effects! The discovery that there are genetic determinants of scrotal temperature [77] also reinforces the possibility that some individuals may be predisposed to adverse effects of prolonged seating or radiant heat on semen quality. While such individuals cannot yet be recognized, careful attention to lifestyle factors to minimize scrotal heating in all men with fertility problems is therapeutically benign and can have only beneficial effects. Third, the well-established, if inconsistent, effect of a varicocele on semen quality in men, may itself induce such effects by interfering with normal cooling of incoming arterial blood in the pampiniform plexus [76] (Fig. 14.2), and it is possible that such an effect might be exacerbated by the time spent seated or make such individuals more susceptible to effects of radiant heat than men without a varicocele.


Other Lifestyle/Dietary Factors Affecting the Adult Male

The preceding section dealing with scrotal temperature obviously applies as much to sedentary lifestyles outside, as well as inside, of the workplace. Probably, the most important other factors are dietary habits, in particular obesity and alcohol intake, smoking, stress and recreational/sporting drug use.

Unlike the well-established relationship between caloric intake and maintenance of menstrual cycles in women, there is no such straightforward relationship in men regarding sperm counts. Underweight and overweight men both have a slightly increased risk of having low sperm counts, though there is considerable variation between studies, especially with regard to obesity [81, 82]. Moreover, there is only limited

evidence that it is obesity per se that causes any semen quality changes (Fig. 14.3). Thus, although a 14-week residential weight loss program in 43 severely obese men was shown to increase semen volume and total sperm count [83], similar studies with small numbers of obese men undergoing bariatric surgery-induced weight loss have so far failed to find consistent benefits, and some studies even point to deleterious effects [84]. Nevertheless, the evidence that male obesity can negatively impact fertility is convincing. For example, obesity is over-represented among infertile men [80, 81], and in the setting of assisted reproduction, male obesity is associated with reduced embryo quality and pregnancy rate in the absence of any significant changes in semen quality [85]. Indeed, a recent meta-analysis of 30 studies ($n = 115, 158$ men) reported that male obesity was associated with a 66% increase

Fig. 14.3 Schematic representation of the major reproductive changes in men that are associated with obesity and current thinking as to what may be the key causal factors and pathways



in risk of infertility and a 35% reduction in live birth rate per cycle of assisted reproduction in the absence of significant differences in conventional semen parameters [86]. The underlying cause of obesity-related male infertility remains unclear and is likely to be multi-factorial [87]. However, there is compelling evidence emerging that points to changes in fatty acid composition of semen and sperm as being important [88, 89], and both human [90] and animal [91] studies provide evidence that the fat composition of our diets may be important in determining this and affecting semen quality (Fig. 14.3). Thus, it may be specific dietary factors in obese men that is important in relation to changes in semen quality and/or fertility, and that therefore not all obese men will be affected.

In contrast to the equivocal data on semen quality, the evidence that visceral obesity in men is associated with a fall in total testosterone levels in both young [92] and older [93] men is much more compelling (Fig. 14.3), and it is now widely accepted that visceral obesity and its associated metabolic changes invariably impact testosterone levels, encapsulated in the metabolic syndrome [94]; however, metabolic syndrome-associated changes in testosterone levels are dissociated from any change in semen parameters [95]. The primary mechanism via which obesity/the metabolic syndrome reduces testosterone levels is via suppression of pituitary LH secretion, but the mechanisms that underpin this are complex and incompletely known, but certainly involve changes in estradiol and sex hormone-binding globulin levels [96, 97] (Fig. 14.3). These interplay with the effects of adipokines, such as leptin and adiponectin, which may act both centrally [97, 98] or directly on the testis [99], although a recent systematic review suggests that direct testicular effects are probably of minor importance in comparison with central effects [99]. As other chapters in this book deal with these aspects, in particular the relationship of hypogonadism to the metabolic syndrome, they will not be discussed further here. However, there is one emerging aspect that has been hitherto overlooked, and which may turn out in the

long term to be an important player, the gut microbiome.

There are various lines of evidence that the gut microbiome can affect male reproductive function, although the number of studies is presently too few to enable assessment of how important this might be [100]. However, its potential importance is highlighted by a series of intervention studies in mice, which have shown that feeding them from 8 weeks of age (young adulthood) with the probiotic species *Lactobacillus reuteri* was able to protect the mice against diet-induced, age-related obesity [101]. However, far more interesting was that this intervention completely prevented the age-related development of impaired spermatogenesis, reduced testis weight and hypogonadism [102], although until such studies are repeated, it is too early to conclude that similar effects could apply to man. The protective effects of the probiotic treatment were equally apparent in mice maintained on either a standard (control) diet or maintained on a 'Western style diet.' A series of studies by these authors have shown that the beneficial effects of the probiotic feeding regime appear to result from modulation of specific proinflammatory cytokines, such as interleukin-10 and interleukin-17A [102, 103]. As obesity/metabolic syndrome and hypogonadism are linked intrinsically to a more proinflammatory cytokine profile in blood in men [94, 104], it raises the interesting possibility that such health-relevant changes could be ameliorated either via probiotic supplementation or by dietary changes that alter the gut microbiome, an area richly deserving of further study.

Smoking by men sometimes emerges from epidemiology studies as a risk factor for low sperm counts or altered sperm morphology, but this is an inconsistent finding and 'effect' sizes are small [105]. Conversely, smoking is consistently associated with increased rather than decreased total and free testosterone levels, the mechanism for which is uncertain [106, 107]. As outlined below, smoking by mothers during pregnancy is associated with a consistent and substantial (20–40%) reduction in sperm counts

in resulting male offspring in adulthood [25], whereas testosterone levels are unaffected [108]. In a large population-based cross-sectional study of >8000 young men, moderate alcohol intake was not associated with any change in semen quality, but was positively associated with free testosterone levels [109], whereas heavy alcohol intake is associated with lowered total testosterone levels [110].

Psychological stress arising for various reasons is usually associated with reduced semen quality with effects both on sperm count and motility, and testosterone levels are also usually lowered [111, 112]. The mechanisms behind such changes involve a complex interplay at various levels between the hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes; among these, direct inhibitory effects of adrenal cortisol on testicular testosterone production and indirect effects via cortisol-induced decrease in SHBG levels are probably important [111]. It should be noted, however, that much of the available data stem from experimental animal studies, as studies in men are much more difficult to control for confounding factors [111].

Though Western males are generally less physically active today than 30 or so years ago, for those who do participate in sports, it is far more competitive and this has led to usage of performance-enhancing drugs, the most common being anabolic androgenic steroids [113]. Outside of sports, there has been an explosion in use of the same drugs in pursuit of improving physique and body image [113]. Such use is now considered to be perhaps the single most important determinant of hypogonadism in young men [114], although this will be dependent on factors such as type of steroid, dose administered and perhaps duration of administration [115]. Although much of the anabolic steroid use is clandestine, clinicians faced with athletic young men with hypogonadism should always bear this possibility in mind [113, 115]. Similar awareness should be practiced for other non-steroidal drugs, as we live in an age when use of a range of ‘recreational’ drugs is widespread. For example, 25% of young American

men report using marijuana within the last month [116], and 45% of Danish young men within the past 3 months [117]. In the latter study, which was a population-based study ($N = 1215$), regular weekly use of marijuana was associated with ~30% decrease in sperm count, and if marijuana use was combined with other recreational drugs, the decrease was >50% [117]. Considering the scale of marijuana/other recreational drug use, these statistics suggest that this may be a very important determinant of low sperm counts in young men. As has been found with tobacco smoking, marijuana use is associated with a significant increase in total (but not free) testosterone levels [117]. In contrast, use of opiate-based drugs by young men is associated with a uniform and quite substantial decrease in testosterone levels, based on a meta-analysis of 17 studies [118].

Finally, vigorous exercise such as long-distance running may result in temporary suppression of testosterone levels in men and minor decrements in semen quality, though the changes are by no means as pronounced as the anti-reproductive effects that can occur in female athletes [119, 120]. In contrast, less severe exercise generally has no effect on testosterone levels [120] (see Chap. 13).

Environmental/Lifestyle Effects on the Adult Testis that Arise During Fetal Development

Testicular Dysgenesis Syndrome (TDS) and the Masculinization Programming Window

There is growing evidence that a syndrome of inter-connected disorders affecting the human male, so-called TDS, may have a common origin in fetal life during the period of masculinization [4, 6–8]. Manifestations of this syndrome in adulthood can include low sperm counts/reduced fertility and/or testicular germ cell cancer as well as a history of cryptorchidism and/or hypospadias (Fig. 14.4)—recent evidence suggests that lowered testosterone levels or compensated Leydig




Fig. 14.4 Schematic diagram to illustrate the cellular basis and general pathways via which the disorders that comprise ‘testicular dysgenesis syndrome’ (TDS) are thought to arise in the human. Abnormal testicular cell differentiation/function (=dysgenesis) appears to be an integral part of this syndrome of disorders, but several causal pathways might lead to this occurrence, including genetic, environmental and/or lifestyle factors. Note also that the resulting disorders that arise because of TDS occur with differing frequency, varying from quite common (poor semen quality, cryptorchidism) to rare (testicular germ cell cancer). Note also that some of the

disorders may occur for reasons other than TDS (e.g., cryptorchidism, hypospadias) or because of effects after birth/in adulthood (e.g., poor semen quality). TDS disorders are thought to arise primarily as a consequence of, or associated with, subnormal testosterone production and/or action within a discrete fetal time window, termed the ‘masculinization programming window (MPW),’ which is reckoned to occur somewhere within the time period of 8- to 12-weeks gestation. In theory, androgen exposure within the MPW can be determined retrospectively by measurement of anogenital distance (AGD), though in practice such use may have limitations (see text)

cell failure could also be a part of TDS [43, 121]. Some of these disorders appear to be increasing in incidence, with environmental/lifestyle causes implicated in this increase [4, 6]. An integral part of this syndrome of disorders is evidence for impaired testosterone production/action [7, 8], during a specific fetal period termed the ‘masculinization programming window’ (MPW; Fig. 14.4) [7]. This period has been shown in animal studies to be the critical period when sufficient fetal androgen action is required to program later development of all male reproductive organs, including their ultimate size [7, 8, 122, 123]. The available evidence suggests that an MPW also exists in humans and probably lies within the period 8- to 12-weeks gestation [7, 8],

and based on the animal studies and emerging human data, the level of androgen exposure during the MPW could be deduced at any age by measurement of the anogenital distance (AGD) [7, 8].

As a result of the discovery of the MPW and the emerging credibility of the TDS hypothesis, the focus has shifted toward trying to identify what factors, acting via the pregnant mother, might adversely impact fetal testis testosterone production, a task that is severely constrained because of the inaccessibility of the human fetus (it is only a few cm in length during the MPW) and because fetal androgen production cannot be monitored directly [8]. Therefore, most of the available evidence derives from epidemiological

studies that have looked for associations between occurrence of ‘TDS disorders’ (e.g., cryptorchidism, hypospadias) and specific maternal exposures or lifestyle factors. This literature is too extensive to discuss in detail here, so just the aspects that are most directly relevant to this chapter are presented. Further details and reference trails can be found elsewhere [4–8].

It is first worth making some general points, in particular to remind readers of just how common are the disorders that may comprise the TDS. For example, the two most common congenital malformations in children of either sex are both TDS disorders, namely cryptorchidism and hypospadias, which affect 2–9 and 0.3–1.0% of boys at birth, respectively [4, 6, 8]. This is not to imply that all cases of cryptorchidism and hypospadias are part of TDS, because they may arise as a consequence of other deficiencies/syndromes which might not be directly connected to TDS. One way in which some potential discrimination might be applied is via measurement of AGD, because if AGD is abnormally small, it would imply that there had been androgen deficiency/resistance during the period of the MPW, so that the case in question could be classified as likely to be TDS. Where this has been done for cases of cryptorchidism and hypospadias and reference made to population-based normal data for AGD in one particular center, it is clear that the majority (but not all) of cases of cryptorchidism and hypospadias have AGD measurements below the normal 50th centile [124]. Therefore, based on AGD it may be possible to at least putatively identify possible TDS and non-TDS cases, at least for cryptorchidism and hypospadias. Reduced AGD has also been associated with androgen receptor polymorphisms such as longer CAG repeat length, which impairs androgen signaling [125].

Extending the same line of thinking to adult-onset cases of suspected TDS, namely those with low sperm counts, low testosterone/compensated Leydig cell failure or testicular germ cell cancer, has only so far been done in a superficial way, and only in relation to sperm count [8]. The available studies support the view that men with lower sperm counts and/or

infertility have an associated shorter AGD [126–129], although a recent Chinese study did not find this [130]. It seems unlikely, however, that AGD could be used clinically in any diagnostic or predictive way, because of considerable inter-individual variation and confounding by body size and adiposity [8, 131, 132].

Of more direct relevance to the present chapter is the potential association of AGD with blood testosterone levels and Leydig cell function. There is a single human [127] and a single experimental rat [122] study showing a similar magnitude, positive association between AGD and adult blood testosterone levels. However, several other pieces of data support a role for prenatal events, including fetal androgen exposure, as a determining factor for adult Leydig cell function. First, birth weight has been shown to be positively associated with blood testosterone levels in adult men across the full birth weight spectrum [133], and this is independent of adult obesity/BMI, which can itself be a determinant as discussed earlier. Second, a population-based study of >8000 European young men showed that low sperm counts, a TDS disorder that occurs in ~20% of young men [134], are not associated with any change in blood testosterone levels but are associated with compensated Leydig cell failure [43]. Evidence that such a change could emanate from fetal life as a consequence of subnormal fetal androgen action on adult Leydig stem cells, comes from an experimental animal study showing that compensated adult Leydig cell failure is induced in rats and mice when fetal androgen production/action is reduced [121]. The human health significance of compensated Leydig cell failure is not clear at present, although one line of thinking is that it might identify a subset of men whose Leydig cells may ‘wear out’ during aging due to their compensated ‘over-functioning,’ which might then lead to frank hypogonadism and its attendant morbidities. However, frank hypogonadism is not a very prevalent feature among aging men, whereas ~10% exhibit compensated Leydig cell failure [135].

An indirect but powerful argument in favor of environmental factors impacting testosterone

levels in men is the evidence from three independent studies showing that the more recently a man has been born, the lower will be his testosterone level at any age [136–138]. This implies that something new in our lifestyle or exposures is exerting an adverse effect on testosterone levels in men, the most likely explanation being the increase in adiposity and its associated lowering of testosterone levels [92–94]. However, specific dietary factors and/or chemical exposures could be contributory factors, including those occurring in fetal life (via the mother). Unfortunately, it seems unlikely that it is feasible to design studies that could address the latter possibility in a meaningful way.

What Maternal Lifestyle Factors or Exposures Might Impact Reproductive Development/Androgen Exposure of the Male Fetus?

Of necessity, all studies that have addressed this question in human pregnancy are association studies. By far the largest and most consistent finding is that smoking by mothers during pregnancy is associated with reduced testis size and sperm counts in resulting male offspring [reviewed in ref 25]; the reductions reported are substantial, ranging from 20 to 40%. The mechanism underlying the presumed effect is unknown but is presumed to reflect a smoking-induced reduction in Sertoli cell number [25]. Maternal smoking has not been associated with any obvious change in adult male testosterone levels [108], although this has not been studied in as much depth as sperm counts. More recently, experimental evidence has emerged to suggest that protracted use of acetaminophen and/or other painkillers in early pregnancy might reduce testosterone production by the fetal human testis [139, 140]. This finding is supported by the fact that 4 independent epidemiological studies have shown a significantly increased risk (~twofold) of cryptorchidism in sons of mothers who reported protracted use of acetaminophen during pregnancy [139, 141–143]. Whether acetaminophen use in pregnancy

is associated with adult-onset TDS disorders, and whether it might predispose to development of compensated Leydig cell failure have not been studied yet and will prove challenging to investigate given the time gap between exposure and sought for ‘effects.’ Nevertheless, this possibility is in urgent need of investigation as the majority of women report use of acetaminophen and/or other painkillers in pregnancy [144].

The issue of environmental ‘endocrine-active’ chemicals has received enormous attention over the past few decades, and there is widespread belief that such compounds do impact human health, and in particular male reproductive health; such effects are presumed to be mainly during fetal or early postnatal life and thus to affect the developing testis. The initial focus was on ‘environmental estrogens,’ because if pregnant rats or mice are exposed in utero to high levels of potent exogenous estrogens, such as diethylstilbestrol (DES) or ethinyl estradiol, testosterone production by the fetal testis is reduced by 80–90%, a change that will lead to irreversible impairment of masculinization and development of the male reproductive system [145–147]. However, there have been two important research developments which strongly suggest that, at least as far as the developing fetal human testis is concerned, environmental estrogenic chemicals are unlikely to pose any significant risk, irrespective of their estrogenic potency or the level of exposure. First, evidence from both in vitro cultures [148] and ex vivo xenografts [149] of human fetal testes into nude mice demonstrates that even after exposure to very high doses of DES, no inhibition of testosterone secretion is evident, whereas exposure of rat and mouse fetal testes to the same estrogen doses profoundly suppresses testosterone production [146, 147]. This dramatic difference in effect is presumably explained by the absence of ESR1 (estrogen receptor- α) from human fetal Leydig cells, whereas it is present in fetal rodent Leydig cells [146, 149]. Second, detailed studies by Fowler and colleagues of the human fetal testis have shown that it has enormously high levels of bioactive estrogens, far higher than in the fetal human ovary and ~1000 times higher than the

already extremely high levels in maternal blood [150]. Why there should be such high bioactive estrogen levels in the fetal human testis is not known, but in their presence it makes sense to not have any endogenous system that would allow estrogens to suppress fetal Leydig cell steroidogenesis. Thus, rodents are not a good model for the human when considering whether or not estrogenic chemicals pose any threat to the steroidogenic function of the human fetal testis.

Partly because of the findings above, the focus of concern regarding environmental chemicals and their potential contribution to TDS disorders, has switched to those that can potentially alter production of endogenous testosterone by the fetal testis or interfere with the downstream actions of androgens via androgen receptor (AR) antagonism and thus interfere with masculinization. An important driver of such studies has been the finding that exposure of pregnant rats to high doses of certain phthalate esters, which are widely used plasticizers to which we are all exposed, can induce a spectrum of reproductive disorders in the male offspring that is remarkably similar to human TDS [147, 151–154]. However, in a rather remarkable replay of the estrogen story described above, *in vitro* and xenograft studies involving human fetal testes have shown categorically that exposure to the same phthalates at comparable doses that cause TDS disorders in exposed male rats has no effect on testosterone production by the fetal human testis [155–157]. These negative findings are supported by similar negative findings after exposure of pregnant marmosets to high doses of phthalates during the presumptive MPW [158]. However, the latter study also assessed the effects of the same dose of phthalates on the newborn marmoset testis and found that it acutely caused ~50% suppression of blood testosterone levels [158, 159], indicating a fundamental difference between the fetal and newborn primate testis in its susceptibility to the adverse effects of certain phthalates. However, it needs to be kept in mind that the doses of phthalates that are needed to induce suppression of fetal testosterone in rats or in newborn marmosets are far in excess of human exposure

levels. Having said this, epidemiological studies have provided evidence for a negative association between exposure to certain phthalates and blood testosterone levels in men [160, 161] although the ‘effects’ are small and are not found consistently in every study [162].

Other than exposure to phthalates, most human studies have focused on whether exposure to pesticides, most of which have varying degrees of weak endocrine-disrupting activity, might be associated with TDS disorders or altered AGD. Of necessity, most of the studies have focused on the association with cryptorchidism, because of its high prevalence, and/or hypospadias, and have investigated boys born to mothers who were either occupationally exposed (e.g., greenhouse workers) or who lived in an area where relatively high pesticide exposure is likely to have occurred (e.g., farmer’s wives, or recent use of DDT for malaria control). Some of the studies determined pesticide exposure indirectly, for example via a detailed questionnaire [163], or based on the nature of their job (e.g., greenhouse workers) [164, 165], or where they lived (e.g., farming area) [166], while other studies have measured pesticide exposure directly in breast milk [167] or in maternal blood [168, 169]. The results have proved to be very mixed, and overall fewer studies have found a significant association between cryptorchidism and maternal pesticide exposure than studies that have found no significant association [166]. Moreover, even in the positive studies, the ‘effect’ sizes have been small. It is not possible to discuss all of the findings and inconsistencies here, so readers are referred to a recent review [166]. It is worth emphasizing that the inconsistency of findings may simply be a reflection of the inherent difficulties in doing such studies in populations in which other confounding factors may be present (e.g., maternal age or parity, maternal diet/obesity, ethnic or geographic differences), although similar arguments could be voiced to dismiss studies in which positive associations have been found. On the other hand, it does seem reasonable to conclude that, when viewed together, the various studies support the view that maternal pesticide exposure is unlikely

to be a major cause of cryptorchidism in boys from the general population. Nevertheless, it would seem prudent for pregnant women to minimize exposure to pesticides, especially if their exposure is likely to be high in comparison with the general population (e.g., greenhouse workers), as these tend to show a little stronger evidence for an association between exposure and occurrence of cryptorchidism [166].

Whether exposure to pesticides during pregnancy might increase risk of adult-onset TDS disorders or hypogonadism is unknown as such studies are extremely difficult to undertake.

Future Prospects

Arguably, the most important development with regard to male reproductive dysfunction in recent years has been the recognition that disorders presenting in adulthood might have their origin in fetal or neonatal life, in particular during the presumptive MPW. Such thinking is very much in line with the evolution in thinking about the origins of other common medical disorders such as cardiovascular disease and type 2 diabetes. However, even on the assumption that the fetal period is the most important in terms of shaping lifelong reproductive health, we do not appear to have made great progress in identifying what factors acting via the mother might be responsible for predisposing toward the development of a reproductive disorder.

This is not to imply that **ALL** male reproductive dysfunction has its origins in fetal life but rather to indicate that susceptibilities are put in place that may then predispose to effects by other genetic, environmental or lifestyle factors—these may exert their effects at various stages in life or throughout long periods of life. There is nothing remotely controversial in such thinking as all human health disorders ultimately result from an interaction between genetic and environmental/lifestyle factors.

An important (and overlooked) aspect of the environmental/lifestyle components is that they are intrinsically preventable. Before this possibility can be realized, however, the causative

factor(s) have to be identified and their mechanisms of effect established. As this chapter will have demonstrated, we are a long way from achieving this for most environmental and lifestyle factors that are recognized as potentially impacting on male reproductive health, whether during development or in adulthood. The exception is time spent seated and scrotal heating, as methods and studies are now in place that are able to more precisely assess their risk to sperm counts and whether this impacts on fertility, sperm DNA damage and so on.

Perhaps the other important development has been the recognition that diet and obesity can profoundly affect both the spermatogenic and steroidogenic functions of the adult testis, even if the pathways of effect are still to be fully resolved. It seems remarkable that we have previously overlooked or underestimated the importance and degree of potential impact of such dietary factors, especially when considering the extent of the evidence that links such factors to the most prevalent (and increasing) obesity-related disorders in modern societies. A reasonable extrapolation of this thinking is that we may also have overlooked the effects of the changing nature of dietary factors during pregnancy and their potential impact on the developing fetal testis. Indeed, there is now a substantial body of evidence which indicates that, for pregnancies, the diet of either mother or father may exert lifelong health-changing effects both on the developing fetus and on the children which that fetus then fathers or mothers, so-called intergenerational effects [170, 171]; the fact that this includes reproductive effects and Leydig cell steroidogenic effects in grandsons as the result of grand-paternal exposure to a high fat diet is a sobering thought [170, 172].

Such intergenerational effects result from epigenetic changes (?to the germ cells) in the parents that are then transmitted to the offspring, though the precise mechanisms underlying this are only just beginning to emerge. Remarkably, it appears that paternally mediated effects (of diet) seem to involve changes (e.g., in non-coding small RNAs) to seminal plasma and epididymal sperm rather than to testicular germ cells

[172–175], but we can expect rapid expansion of understanding in this area in the coming years. Although the importance of these primarily experimental findings to human health remains to be determined, such findings bring me back neatly to where I started this chapter. Because, from an evolutionary perspective, intergenerational effects of parental diet are likely to represent yet another mechanism via which we are attuned to our environment, but in this case the effect is to attune the future offspring to their anticipated (dietary) environment.

References

- Lincoln GA, Short RV. Seasonal breeding: Nature's contraceptive. *Rec Progr Horm Res.* 1980;36:1–52.
- Lincoln GA, Rhind SM, Pompolo S, Clarke JJ. Hypothalamic control of photoperiod-induced cycles in food intake, body weight and metabolic hormones in rams. *Am J Physiol Regul Integr Comp Physiol.* 2001;281:R76–90.
- Sanchez-Garrido A, Tena-Sempere M. Metabolic control of puberty: roles of leptin and kisspeptins. *Horm Behav.* 2013;64:187–94.
- Skakkebaek NE, Rajpert-De Meyts E, Buck-Louis GM, Toppari J, Andersson A-M, Eisenberg ML, Jensen TK, Jorgensen N, Swan SH, Sapra KJ, Ziebe S, Priskhorn L, Juul A. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. *Physiol Rev.* 2016;96:55–97.
- Sharpe RM. Sperm counts and fertility in men: a rocky road ahead. *EMBO Rep.* 2012;13:398–403.
- Skakkebaek NE, Rajpert-de Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Hum Reprod.* 2001;16:972–8.
- Welsh M, Saunders PTK, Finken M, Scott HM, Hutchison GR, Smith LB, Sharpe RM. Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. *J Clin Invest.* 2008;118:1479–90.
- Dean A, Sharpe RM. Anogenital distance or digit length ratio as measures of fetal androgen exposure: relationship to male reproductive development and its disorders. *J Clin Endocrinol Metab.* 2013;98:2230–8.
- Hauser R, Skakkebaek NE, Hass U, Toppari J, Juul A, Andersson A-M, Kortenkamp A, Heindel JJ, Trasande L. Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union. *J Clin Endocrinol Metab.* 2015;100:1267–77.
- Woodruff TJ, Zota AR, Schwartz JM. Environmental chemicals in pregnant women in the United States: NHANES 2003–2004. *Environ Health Perspect.* 2011;119:878–85.
- Vested A, Ramlau-Hansen CH, Olsen SF, Bonde JP, Kristensen SL, Halldorsson TI, Becher G, Haug LS, Ernst EH, Toft G. Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. *Environ Health Perspect.* 2013;121:453–8.
- Rojansky N, Brzezinski A, Schenker JG. Seasonality in human reproduction: an update. *Hum Reprod.* 1992;7:735–45.
- Rojansky N, Benshushan A, Meisdorf S, Lewin A, Laufer N, Safran A. Seasonal variability in fertilization and embryo quality rates in women undergoing IVF. *Fertil Steril.* 2000;74:476–81.
- Jorgensen N, Andersen A-G, Eustache F, Irvine DS, Suominen J, Petersen JH, Andersen AN, Auger J, Cawood EH, Horte A, Jensen TK, Jouannet P, Keiding N, Vierula M, Toppari J, Skakkebaek NE. Regional differences in semen quality in Europe. *Hum Reprod.* 2001;16:1012–9.
- Chen Z, Godfrey-Bailey L, Schiff I, Hauser R. Impact of seasonal variation, age and smoking status on human semen parameters: the Massachusetts general hospital experience. *J Exp Clin Assist Reprod.* 2004;1:2. doi:10.1186/1743-1050-1-2.
- Zhang X-Z, Liu J-H, Sheng H-Q, Wu H-J, Wu Y, Yao K-S, Lu J-C, Zhang F-B. Seasonal variation in semen quality in China. *Andrology.* 2013;1:639–43.
- Chia SE, Lim ST, Ho LM, Tay SK. Monthly variation in human semen quality in male partners of infertile women in the tropics. *Hum Reprod.* 2001;16:277–81.
- Luboshitzky R, Wagner O, Lavi S, Here P, Lavie P. Abnormal melatonin secretion in hypogonadal men: the effect of testosterone treatment. *Clin Endocrinol.* 1997;47:463–9.
- Kumanov P, Tomova A, Isidori A, Nordio M. Altered melatonin in hypogonadal men: clinical evidence. *Int J Androl.* 2005;28:234–40.
- Smith RP, Coward RM, Kovac JR, Lipshultz LI. The evidence for seasonal variations of testosterone in men. *Maturitas.* 2013;74:208–12.
- Henderson J, Rennie GC, Baker HWG. Association between occupational group and sperm concentration in infertile men. *Clin Reprod Fertil.* 1986;4:275–81.
- Kenkel S, Rolf C, Nieschlag E. Occupational risks for male fertility: an analysis of patients attending a tertiary referral centre. *Int J Androl.* 2001;24:318–26.
- Cherry N, Moore H, McNamee R, Pacey A, Burgess G, Clyma J-A, Dippnall M, Baillie H, Povey A. Participating centres of Chaps-UK.

- Occupation and male infertility: glycol ethers and other exposures. *Occup Environ Med.* 2008;65:708–14.
24. Vaziri MH, Gilani MAS, Kavoursi A, Firoozeh M, Jazanai RK, Dizaj AVT, Mohseni H, Lankarani NB, Azizi M, Yazdi RS. The relationship between occupation and semen quality. *Int J Fertil Steril.* 2011;5:66–71.
 25. Sharpe RM. Environment, lifestyle and male infertility. *Baillieres Clin Endocrinol Metab.* 2000;14:489–503.
 26. Larsen SB, Abell A, Bonde JP. Selection bias in occupational sperm studies. *Am J Epidemiol.* 1998;147:681–5.
 27. Grajewski B, Cox C, Scradler SM, Murray WE, Edwards RM, Turner TW, Smith JM, Shekar SS, Evenson DP, Simon SD, Conover DL. Semen quality and hormone levels among radiofrequency heater operators. *J Occup Environ Med.* 2000;42:993–1005.
 28. Tas S, Lauwerys R, Lison D. Occupational hazards for the male reproductive system. *Crit Rev Toxicol.* 1996;26:261–307.
 29. Cherry N, Labreche F, Collins J, Tulandi T. Occupational exposure to solvents and male infertility. *Occup Environ Med.* 2001;58:635–40.
 30. Welch LS, Schrader SM, Turner TW, Cullen MR. Effects of exposure to ethylene glycol ethers on shipyard painters: II. Male reproduction. *Am J Ind Med.* 1988;14:509–26.
 31. Apostoli P, Kiss P, Porru S, Bonde JP, Vanhoorne M. Male reproductive toxicity of lead in animals and humans. ASCLEPIOS study group. *Occup Environ Med.* 1998;55:364–74.
 32. Sallmen M, Lindbohm ML, Anttila A, Taskinen H, Hemminki K. Time to pregnancy among the wives of men occupationally exposed to lead. *Epidemiology.* 2000;11:141–7.
 33. Kolstad HA, Bonde JP, Spano M, Giwercman A, Zschiesche W, Kaae D, Larsen SB, Roeleveld N. Change in semen quality and sperm chromatin structure following occupational styrene exposure. ASCLEPIOS. *Int Arch Occup Environ Health.* 1999;72:135–41.
 34. Lemasters GK, Olsen DM, Yiin JH, Lockey JE, Shukla R, Selevan SG, Schrader SM, Toth GP, Evenson DP, Huszar GR. Male reproductive effects of solvent and fuel exposure during aircraft maintenance. *Reprod Toxicol.* 1999;13:155–66.
 35. Wang Z, Fei Y, Liu H, Zheng S, Ding Z, Jin W, Pan Y, Chen Z, Wang L, Chen G, Xu Z, Zhu Y, Yu Y. Effects of electromagnetic fields exposure on plasma hormonal and inflammatory pathway biomarkers in male workers of a power plant. *Int Arch Occup Environ Health.* 2016;89:33–42.
 36. Sancini A, Tomei F, Tomei G, Ciarrocca M, Palermo P, Gioffre PA, Tasciotti Z, Fiaschetti M, Cetica C, Caciari T. Exposure to urban stressors and free testosterone plasma values. *Int Arch Occup Environ Health.* 2011;84:609–16.
 37. Tomao E, Tomei G, Rosati MV, Caciari T, Danese D, Gamberale D, Vacca D, Palermo P, Anzelmo V, Tomei F. Luteinizing hormone (LH) levels in male workers exposed to urban stressors. *Sci Total Environ.* 2009;407:4591–5.
 38. Takeda K, Tsukue N, Yoshida S. Endocrine-disrupting activity of chemicals in diesel exhaust and diesel exhaust particles. *Environ Sci.* 2004;11:33–45.
 39. Eaton M, Schenker M, Whorton MD, Samuels S, Perkins C, Overstreet J. Seven-year follow-up of workers exposed to 1,2-dibromo-3-chloropropane. *J Occup Med.* 1986;28:1145–50.
 40. Potashnik G, Portah A. Dibromochloropropane (DBCP): a 17-year reassessment of testicular function and reproductive performance. *J Occup Environ Med.* 1995;37:1287–92.
 41. Goldsmith JR. Dibromochloropropane: epidemiological findings and current questions. *Ann NY Acad Sci.* 1997;837:300–6.
 42. Andersson AM, Jorgensen N, Frydelund-Larsen L, Rajpert-de Meys E, Skakkebaek NE. Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls. *J Clin Endocrinol Metab.* 2004;89:3161–7.
 43. Jorgensen N, Joensen UN, Toppari J, Punab M, Erenpreiss J, Zilaitiene B, Paasch U, Salzbrunn A, Fernandez MF, Virtanene HE, Matulevicius V, Olea N, Jensen TK, Petersen JH, Skakkebaek NE, Andersson AM. Compensated reduction in Leydig cell function is associated with lower semen quality variables: a study of 8182 European young men. *Hum Reprod.* 2016;31:947–57.
 44. Perry MJ. Effects of environmental and occupational pesticide exposure on human sperm: a systematic review. *Hum Reprod Update.* 2008;14:233–42.
 45. Magnusdottir EV, Thorsteinsson T, Thorsteindottir S, Hemisdottir M, Olafsdottir K. Persistent organochlorines, sedentary occupation, obesity and human male subfertility. *Hum Reprod.* 2005;20:208–15.
 46. Toft G, Rignell-Hydbom A, Tyrkile E, Shvets M, Giwercman A, Lindh CH, Pedersen HS, Ludwicki JK, Lesovoy V, Hagmar L, Spano M, Manicardi GC, Bonefeld-Jorgensen EC, Thulstrup AM, Bonde JP. Semen quality and exposure to persistent organochlorine pollutants. *Epidemiology.* 2006;17:450–8.
 47. Martenies SE, Perry MJ. Environmental and occupational pesticide exposure and human sperm parameters: a systematic review. *Toxicology.* 2013;307:66–73.
 48. Mumford SL, Kim S, Chen Z, Gore-Langton RE, Barr DB, Buck Louis GM. Persistent organic pollutants and semen quality: the LIFE study. *Chemosphere.* 2015;135:427–35.
 49. Perry MJ, Venners SA, Chen X, Liu X, Tang G, Xing H, Barr DB, Xu X. Organophosphorous

- pesticide exposures and sperm quality. *Reprod Toxicol.* 2011;31:75–9.
50. Melgarejo M, Mendiola J, Koch HM, Monino-Garcia M, Noguera-Velasco JA, Torres-Cantero AM. Associations between urinary organophosphate pesticide metabolite levels and reproductive parameters in men from an infertility clinic. *Environ Res.* 2015;137:292–8.
 51. Radwan M, Jurewicz J, Wielgomas B, Sobala W, Piskunowicz M, Radwan P, Hanke W. Semen quality and the level of reproductive hormones after environmental exposure to pyrethroids. *J Occup Environ Med.* 2014;56:1113–9.
 52. Emeville E, Giton F, Giusti A, Olive A, Fiet J, Thome J-P, Blanchet P, Multigner L. Persistent organochlorine pollutants with endocrine activity and blood steroid hormone levels in middle-aged men. *PLoS ONE.* 2013;8:e66460.
 53. Omoike OE, Lewis RC, Meeker JD. Association between urinary biomarkers of exposure to organophosphate insecticides and serum reproductive hormones in men from NHANES 1999–2002. *Reprod Toxicol.* 2015;53:99–104.
 54. Meeker JD, Barr DB, Hauser R. Pyrethroid insecticide metabolites are associated with serum hormone levels in adult men. *Reprod Toxicol.* 2009;27:155–60.
 55. Hagmar L, Bjork J, Sjodin A, Bergman A, Erfurth EM. Plasma levels of persistent organohalogen and hormone levels in adult male humans. *Arch Environ Health.* 2001;56:138–43.
 56. Martin SA Jr, Harlow SD, Sowers MF, Longnecker MP, Garabrant D, Shore DL, Sandler DP. DDT metabolite and androgens in African-American farmers. *Epidemiology.* 2002;13:454–8.
 57. Cocco P, Loviselli A, Fadda D, Ibba A, Melis M, Oppo A, Serra S, Taberlet A, Tocco MG, Flore C. Serum sex hormones in men occupationally exposed to dichloro-diphenyl-trichloro ethane (DDT) as young adults. *J Endocr.* 2004;182:391–7.
 58. Giwercman A, Rignell-Hydrom A, Toft G, Rylander L, Hagmar L, Lindh C, Pedersen HS, Ludwicki JK, Lesovoy V, Shvets M, Spano M, Manicardi GC, Bizzaro D, Bonfeld-Jorgensen EC, Bonde JP, INUENDO. Reproductive hormone levels in men exposed to persistent organohalogen pollutants: a study of Inuit and there European cohorts. *Environ Health Perspect.* 2006;114:1348–53.
 59. Ferguson KK, Hauser R, Altshul L, Meeker JD. Serum concentrations of *p*, *p'*-DDE, HCB, PCBs and reproductive hormones amongst men of reproductive age. *Reprod Toxicol.* 2012;34:429–35.
 60. Blanco-Munoz J, Morales MM, Lacasana M, Aguilar-Garduno C, Bassol S, Cebrian ME. Exposure to organophosphate pesticides and male hormone profile in floriculturists of the state of Morelos, Mexico. *Hum Reprod.* 2010;25:1787–95.
 61. Yoshinaga J, Imai K, Shiraiishi H, Nozawa S, Yoshiike M, Mieno MN, Andersson A-M, Iwamoto T. Pyrethroid insecticide exposure and reproductive hormone levels in healthy Japanese male subjects. *Andrology.* 2014;2:416–20.
 62. Goncharov A, Rej R, Negoita S, Schymura M, Santiago-Rivera A, Morse G, The Akwesasne Task Force on the Environment, Carpenter DO. Lower serum testosterone associated with elevated polychlorinated biphenyl concentrations in native American men. *Environ Health Perspect.* 2009;117:1454–1460.
 63. Mieusset R, Bujan L. Testicular heating and its possible contributions to male infertility: a review. *Int J Androl.* 1995;18:169–84.
 64. Setchell BP. Heat and the testis. *J Reprod Fertil.* 1998;114:179–84.
 65. Mieusset R, Bujan L. The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men. *Int J Androl.* 1995;17:186–91.
 66. Garolla A, Torino M, Sartini B, Cosci I, Patassini C, Carraro U, Foresta C. Seminal and molecular evidence that sauna exposure affects human spermatogenesis. *Hum Reprod.* 2013;28:877–85.
 67. Thonneau P, Bujan L, Multigner L, Mieusset R. Occupational heat exposure and male fertility: a review. *Hum Reprod.* 1998;13:2122–5.
 68. Figa-Talamanca I, Cini C, Varricchio GC, et al. Effects of prolonged automobile driving on male reproductive function: a study among taxi drivers. *Am J Ind Med.* 1996;30:750–8.
 69. Bujan L, Daudin M, Charlet J-P, Thonneau P, Mieusset R. Increase in scrotal temperature in car drivers. *Hum Reprod.* 2000;15:1355–7.
 70. Brindley GS. Deep scrotal temperature and the effect on it of clothing, air temperature, activity, posture and paraplegia. *Br J Urol.* 1982;54:49–55.
 71. Ibrahim E, Lynne CM, Brackett NL. Male fertility following spinal cord injury: an update. *Andrology.* 2016;4:13–26.
 72. Hjollund NH, Bonde JP, Jensen TK, Olsen J. Diurnal scrotal skin temperature and semen quality. The Danish first pregnancy planner study team. *Int J Androl.* 2000;23:309–18.
 73. Hjollund NH, Storgaard L, Ernst E, Bonde JP, Olsen J. The relation between daily activities and scrotal temperature. *Reprod Toxicol.* 2002;16:209–14.
 74. Hjollund NH, Storgaard L, Ernst E, Bonde JP, Olsen J. Impact of diurnal scrotal temperature on semen quality. *Reprod Toxicol.* 2002;16:215–21.
 75. Gaskins AJ, Afeiche MC, Hauser R, Williams PL, Gillman MW, Tanrikut C, Petrozza JC, Chavarro JE. Paternal physical and sedentary activities in relation to semen quality and reproductive outcomes among couples from a fertility center. *Hum Reprod.* 2014;29:2575–82.
 76. Garolla A, Torino M, Miola P, Caretta N, Pizzol D, Menegazzo M, Bertoldo A, Foresta C. Twenty-four-hour monitoring of scrotal temperature in obese men and men with varicocele as a mirror of

- spermatogenic function. *Hum Reprod.* 2015;30:1006–13.
77. Hjøllund NH, Storgaard L, Ernst E, Bonde JP, Christensen K, Olsen J. Correlation of scrotal temperature in twins. *Hum Reprod.* 2002;17:1837–8.
 78. Vaamonde D, Da Silva-Grigoletto ME, Garcia-Manso JM, Barrera N, Vaamonde-Lemos R. Physically active men show better semen parameters and hormone values than sedentary men. *Eur J Appl Physiol.* 2012;112:3267–73.
 79. Paul C, Melton DW, Saunders PTK. A single, mild transient scrotal heat stress causes DNA damage, subfertility and impairs formation of blastocysts in mice. *Reproduction.* 2008;136:73–84.
 80. Jung A, Eberl M, Schill WB. Improvement of semen quality by nocturnal scrotal cooling and moderate behavioural change to reduce genital heat stress in men with oligoasthenoteratozoospermia. *Reproduction.* 2001;121:595–603.
 81. Sermondade N, Faure C, Fezeu L, Shayeb AG, Bonde JP, Jensen TK, et al. BMI in relation to sperm count: an updated systematic review and collaborative meta-analysis. *Hum Reprod Update.* 2012;19:221–31.
 82. Du Plessis SS, Cabler S, McAlister DA, Sabanegh E, Agarwal A. The effect of obesity on sperm disorders and male infertility. *Nat Rev Urol.* 2016;7:153–61.
 83. Hakonsen LB, Thulstrup AM, Aggerholm AS, Olsen J, Bonde JP, Andersen CY, Bungum M, Ernst EH, Hansen ML, Ernst EH, Ramlau-Hansen CH. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men. *Reprod Health.* 2011;8:24.
 84. Rosenblatt A, Faintuch J, Cecconello I. Abnormalities of reproductive function in male obesity before and after bariatric surgery—a comprehensive review. *Obes Surg.* 2015;25:1281–92.
 85. Anifandis G, Dafopoulos K, Messini CI, Polzos N, Messinis IE. The BMI of men and not sperm parameters impact on embryo quality and the IVF outcome. *Andrology.* 2013;1:85–9.
 86. Campbell JM, Lane M, Owens JA, Bakos HW. Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. *Reprod Biomed Online.* 2015;31:593–604.
 87. McPherson NO, Lane M. Male obesity and subfertility, is it really about increased adiposity? *Asian J Androl.* 2015;17:450–8.
 88. Andersen JM, Ronning PO, Heming H, Bekken SD, Haugen TB, Witczak O. Fatty acid composition of spermatozoa is associated with BMI and with semen quality. *Andrology.* 2016;. doi:[10.1111/andr.12227](https://doi.org/10.1111/andr.12227).
 89. Lu JC, Jing J, Yao Q, Fan K, Wang GH, Feng RX, Liang YJ, Chen L, Ge YF, Yao B. Relationship between lipids levels of serum and seminal plasma and semen parameters in 631 Chinese subfertile men. *PLoS ONE.* 2016;11:e0146304.
 90. Jensen TK, Heitmann BL, Jensen MB, Hall-dorsson TI, Andersson A-M, Skakkebaek NE, Joensen UN, Lauritsen MP, Christiansen P, Dalgard C, Lassen TH, Jorgensen N. High dietary intake of saturated fat is associated with reduced semen quality among 701 young Danish men from the general population. *Am J Clin Nutr.* 2013;97:411–8.
 91. Saez-Lancellotti TE, Boarelli PV, Romero AA, Funes AK, Cid-Barria M, Cabrillana ME, Monclus MA, Simon L, Vicenti AE, Fornes MW. Semen quality and sperm function loss by hypercholesterolemic diet was recovered by addition of olive oil to diet in rabbit. *PLoS ONE.* 2013;8:e52386.
 92. Nielsen TL, Hagen C, Wraae K, Brixen K, Petersen PH, Haug E, Larsen R, Andersen M. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. *J Clin Endocrinol Metab.* 2007;92:2696–705.
 93. Tajar A, Huhtaniemi IT, O'Neill TW, Lee DM, Finn JD, Pye SR, Lee DM, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FCW, EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European male aging study (EMAS). *J Clin Endocrinol Metab.* 2012;97:1508–16.
 94. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. *Amer J Med.* 2011;124:578–87.
 95. Ventimiglia E, Capogrosso P, Colichia M, Boeni L, Serino A, Castagna G, Clementi MC, La Croce G, Regina C, Bianchi M, Mirone V, Damiano R, Montorsi F, Salonia A. Metabolic syndrome in white European men presenting for primary couple's infertility: investigation of the clinical and reproductive burden. *Andrology.* 2016;. doi:[10.1111/andr.12232](https://doi.org/10.1111/andr.12232).
 96. Antonio L, Wu FCW, O'Neill TW, Pye SR, Carter EL, Finn JD, Rutter MK, Laurent MR, Huhtaniemi IP, Han TS, Lean MEJ, Keevil BG, Pendleton N, Rastrelli G, Forti G, Bartfai G, Casanueva FF, Kula K, Punab M, Giwercman A, Claessens F, Decallonne B, Vanderschueren D, The EMAS Study Group. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. *J Clin Endocrinol Metab.* 2015;100:1396–1404.
 97. Lopez M, Tena-Sempere M. Estrogens and the control of energy homeostasis. *Trends Endocrinol Metab.* 2015;26:411–21.
 98. Roa J, Tena-Sempere M. Connecting metabolism and reproduction: roles of central energy sensors and key molecular mediators. *Mol Cell Endocrinol.* 2015;397:4–14.
 99. Kawwass JF, Summer R, Kallen CB. Direct effects of leptin and adiponectin on peripheral reproductive

- tissues: a critical review. *Mol Hum Reprod.* 2015;21:617–32.
100. Dai Z, Wu Z, Hang S, Zhu W, Wu G. Amino acid metabolism in intestinal bacteria and its potential implications for mammalian reproduction. *Mol Hum Reprod.* 2015;21:389–409.
 101. Poutahidis T, Kleinewietfeld M, Smillie C, Levkovich T, Perotta A, Bhela S, Varian BJ, Ibrahim YM, Lakritz JR, Keraney SM, Chatzigeorgidis A, Hafler DA, Alm EJ, Erdman SE. Microbial reprogramming inhibits Western diet-associated obesity. *PLoS ONE.* 2013;8:e68596.
 102. Poutahidis T, Springer A, Levkovich T, Qi P, Varian BJ, Lakritz JR, et al. Probiotic microbes sustain youthful serum testosterone levels and testicular size in aging mice. *PLoS ONE.* 2014;9:e84877.
 103. Erdman SE, Poutahidis T. Probiotic ‘glow of health’: it’s more than skin deep. *Benef Microbes.* 2014;5:109–19.
 104. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Chaner KS, Hugh Jones T. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *J Clin Endocrinol Metab.* 2004;89:3313–8.
 105. Vine MF. Smoking and male reproduction: a review. *Int J Androl.* 1996;19:323–37.
 106. English KM, Pugh PJ, Parry H, Scutt NE, Chaner KS, Jones TH. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. *Clin Sci.* 2001;100:661–5.
 107. Wang W, Yang X, Liang J, Liao M, Zhang H, Qin X, Mo L, Lv W, Mo Z. Cigarette smoking has a positive and independent effect on testosterone levels. *Hormones.* 2013;12:567–77.
 108. Ramlau-Hansen CH, Thulstrup AM, Olsen J, Ernst E, Andersen CY, Bonde JP. Maternal smoking in pregnancy and reproductive hormones in adult sons. *Int J Androl.* 2007;31:565–72.
 109. Jensen TK, Swan SH, Jorgensen N, Toppari J, Redmon B, Punab M, Drobnis EZ, Haugen TB, Zilaitiene B, Sparks AE, Irvine DS, Wang C, Jouannet P, Brazil C, Paasch U, Salzbrunn A, Skakkebaek NE, Andersson A-M. Alcohol and male reproductive health: a cross-sectional study of 8344 healthy men from Europe and the USA. *Hum Reprod.* 2014;29:1801–9.
 110. Emanuele MA, Emanuele N. Alcohol and the male reproductive system. *Alcohol Res Health.* 2001;25:282–7.
 111. Nargund VH. Effects of psychological stress on male fertility. *Nat Rev Urol.* 2015;12:373–82.
 112. Viau V. Functional cross-talk between the hypothalamic-pituitary-gonadal and—adrenal axes. *J Neuroendocrinol.* 2002;14:506–13.
 113. Rahnema CD, Crosnoe LE, Kim ED. Designer steroids—over-the-counter supplements and their androgenic component: review of an increasing problem. *Andrology.* 2015;3:150–5.
 114. Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, Lipshultz LI. Anabolic steroid induced hypogonadism in young men. *J Urol.* 2013;190:2200–5.
 115. Wu FCW. Endocrine aspects of anabolic steroids. *Clin Chem.* 1997;43:1289–92.
 116. Eisenberg ML. The association between marijuana use and male reproductive health. *Amer J Epidemiol.* 2015;182:482–4.
 117. Gundersen TD, Jorgensen N, Andersson A-M, Bang AK, Nordkap L, Skakkebaek NE, Priskorn L, Juul A, Jensen TK. Association between use of marijuana and male reproductive hormones and semen quality: a study among 1,215 healthy young men. *Amer J Epidemiol.* 2015;182:473–81.
 118. Bawor M, Bami H, Dennis BD, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Steiner M, Anglin R, Coote M, Pare G, Thabane L, Samaan Z. Testosterone suppression in opioid users: a systematic review and meta-analysis. *Drug Alcohol Depend.* 2015;149:1–9.
 119. Elias AN, Wilson AF. Exercise and gonadal function. *Hum Reprod.* 1993;8:1747–61.
 120. De Souza MJ, Arce JC, Pescatello LS, Scherzer HS, Luciano AA. Gonadal hormones and semen quality in male runners. A volume threshold effect of endurance training. *Int J Sports Med.* 1994;15:383–91.
 121. Kilcoyne KR, Smith LB, Atanassova N, Macpherson S, McKinnell C, van den Driesche S, Jobling M, Chambers TJG, de Gendt K, Verhoeven G, O’Hara L, Platts S, de Franca L, Lara NLM, Anderson RA, Sharpe RM. Fetal programming of adult Leydig cell function via androgenic effects on stem/progenitor cells. *Proc Natl Acad Sci USA.* 2014;111:E1924–32.
 122. Drake AJ, van den Driesche S, Scott HM, Hutchison GR, Seckl JR, Sharpe RM. Glucocorticoids amplify dibutyl phthalate-induced disruption of testosterone production and male reproductive development. *Endocrinology.* 2009;150:5055–64.
 123. Macleod DJ, Sharpe RM, Welsh M, Fiskem M, Scott HM, Hutchison GR, Drake AJ, van den Driesche S. Androgen action in the masculinization programming window and development of male reproductive organs. *Int J Androl.* 2011;33:279–87.
 124. Thankamony A, Lek N, Carroll D, Williams M, Dunger DB, Acerini CL, Ong KK, Hughes IA. Anogenital distance and penile length in infants with hypospadias or cryptorchidism: comparison with normative data. *Environ Health Perspect.* 2014;122:207–11.
 125. Eisenberg ML, Hsieh TC, Pasluszak AW, McIntyre MG, Walters RC, Lamb DJ, Lishultz LI. The relationship between anogenital distance and the androgen receptor CAG repeat length. *Asian J Androl.* 2013;15:286–9.
 126. Eisenberg ML, Hsieh MH, Walters RC, Krasnow R, Lipshultz LI. The relationship between anogenital

- distance, fatherhood, and fertility in adult men. *PLoS ONE*. 2011;6:e18973.
127. Eisenberg ML, Jensen TK, Walters RC, Skakkebaek NE, Lipshultz LI. The relationship between anogenital distance and reproductive hormone levels in adult men. *J Urol*. 2012;187:594–8.
 128. Mendiola J, Stahlhut RW, Jorgensen N, Liu F, Swan SH. Shorter anogenital distance predicts poorer semen quality in young men in Rochester, New York. *Environ Health Perspect*. 2011;119:958–63.
 129. Mendiola J, Melgarejo M, Monino-Garcia M, Cutillas-Tolin A, Noguero-Velasco JA, Torres-Cantero AM. Is anogenital distance associated with semen quality in male partners of subfertile couples. *Andrology*. 2015;3:672–6.
 130. Zhou N, Sun L, Yang H, Chen Q, Wang X, Yang H, Tan L, Chen H, Zhang G, Ling X, Huang L, Zou P, Peng K, Liu T, Liu J, Ao L, Zhou Z, Cui Z, Cao J. Anogenital distance is associated with serum reproductive hormones, but not with semen quality in young men. *Hum Reprod*. 2016;31:958–67.
 131. Eisenberg ML, Lipshultz LI. Anogenital distance as a measure of human male fertility. *J Assist Reprod Genet*. 2015;32:479–84.
 132. Thankamony A, Pasterski V, Ong KK, Acerini CL, Hughes IA. Anogenital distance as a marker of androgen exposure in humans. *Andrology*. 2016; doi:10.1111/andr.12156.
 133. Vanbillemont G, Lapauw B, Bogaert V, De Naeyer H, De Bacquer D, Ruige J, Kaufman JM, Taes YE. Birth weight in relation to sex steroid status and body composition in young healthy male siblings. *J Clin Endocrinol Metab*. 2010;95:1587–94.
 134. Jorgensen N, Asklund C, Carlsen E, Skakkebaek NE. Coordinated European investigations of semen quality: results from studies of Scandinavian young men is a matter of concern. *Int J Androl*. 2006;29:54–61.
 135. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, The EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. *J Clin Endocrinol Metab*. 2010;95:1810–1818.
 136. Travison T, Araujo A, O'Donnell A, Kupelian V, McKinlay J. A Population-level decline in serum testosterone levels in American men. *J Clin Endocrinol Metab*. 2007;92:196–202.
 137. Andersson A, Jensen T, Juul A, Petersen J, Jørgensen T, Skakkebaek N. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. *J Clin Endocrinol Metab*. 2007;92:4696–705.
 138. Perheentupa A, Makinen J, Laatikainen T, Vierula M, Skakkebaek NE, Andersson A-M, Toppari J. A cohort effect on serum testosterone levels in Finnish men. *Eur J Endocrinol*. 2013;168:227–33.
 139. Kristensen DM, Hass U, Lesne L, Lottrup G, Jacobsen PR, Desdoits-Lethimonier C, Boberg J, Petersen JH, Toppari J, Jensen TK, Brunak S, Skakkebaek NE, Nellemann C, Main KM, Jegou B, Leffers H. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Hum Reprod*. 2011;26:235–44.
 140. Van den Driesche S, MacDonald J, Anderson RA, Johnston ZC, Chetty T, Smith LB, McKinnell C, Dean A, Homer NZ, Jorgensen A, Camacho-Moll M-E, Sharpe RM, Mitchell RT. Prolonged exposure to acetaminophen reduces testosterone production by the human fetal testis in a xenograft model. *Sci Transl Med*. 2015;7:288ra80.
 141. Jensen MS, Henriksen TB, Rebordosa C, Thulstrup AM, Toft G, Sorensen HT, Bonde JP, Olsen J. Analgesics during pregnancy and cryptorchidism: additional analyses. *Epidemiology*. 2011;22:610–2.
 142. Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sorensen HT, Bonde JP, Henriksen TB, Olsen J. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology*. 2010;21:779–85.
 143. Snijder CA, Kortenkamp A, Steegers EA, Jad-doe VW, Hofman A, Hass U, Burdorf A. Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadias in the offspring: the Generation R Study. *Hum Reprod*. 2012;27:1191–201.
 144. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol*. 2005;193:771–7.
 145. Haavisto TE, Adamsson NA, Myllymaki SA, Toppari J, Paranko J. Effects of 4-tert-octylphenol, 4-tert-butylphenol and diethylstilbestrol on prenatal testosterone surge in the rat. *Reprod Toxicol*. 2003;17:593–605.
 146. Delbes G, Levacher C, Habert R. Estrogen effects on fetal and neonatal testicular development. *Reproduction*. 2006;132:527–38.
 147. van den Driesche S, Walker M, McKinnell C, Scott HM, Eddie SL, Seckl JR, Drake AJ, Smith LB, Anderson RA, Sharpe RM. Proposed role for COUP-TFII in regulating fetal Leydig cell steroidogenesis, perturbation of which results in masculinization disorders in rodents. *PLoS ONE*. 2012;7:e37064.
 148. N'Tumba-Byn T, Moison D, Lacroix M, Lecureuil C, Lesage L, Prud'homme SM, Pozzi-Gaudin S, Frydman R, Benachi A, Livera G, Rouiller-Fabre V, Habert R. Differential effects of bisphenol A and diethylstilbestrol on human, rat and mouse fetal Leydig cell function. *PLoS ONE*. 2012;7:e51579.

149. Mitchell RT, Sharpe RM, Anderson RA, McKinnell C, Macpherson S, Smith LB, Wallace WHB, Kelnar CJH, van den Driesche S. Diethylstilboestrol exposure does not reduce testosterone production in human fetal testis xenografts. *PLoS ONE*. 2013;8:e61726.
150. Fowler PA, Drake AJ, Antignac JP, Le Bizec B, Connolly L, Panagiotis F, Soffientini U, O'Shaughnessy PJ. New insights into human fetal development: endogenous oestrogens, maternal smoking and gene methylation. In: Program & Abstracts of 8th Copenhagen Workshop on Endocrine Disruptors, April 2015.
151. Mylchreest E, Wallace DG, Cattley RC, Foster PMD. Dose-dependent alterations in androgen-regulated male reproductive development in rats exposed to Di(*n*-butyl) phthalate during late gestation. *Toxicol Sci*. 2000;55:143–51.
152. Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, Gray LE Jr. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. *Toxicol Sci*. 2000;58:339–49.
153. Fisher JS, Macpherson S, Marchetti N, Sharpe RM. Human 'testicular dysgenesis syndrome': a possible model using in-utero exposure of the rat to dibutyl phthalate. *Hum Reprod*. 2003;18:1383–94.
154. van den Driesche S, Kolovos P, Platts S, Drake AJ, Sharpe RM. Inter-relationship between testicular dysgenesis and Leydig cell function in the masculinization programming window in the rat. *PLoS ONE*. 2012;7:e30111.
155. Lambrot R, Muczynski V, Lecureuil C, Angenard G, Coffigny H, Pairault C, Moison D, Frydman R, Habert R, Rouiller-Fabre V. Phthalates impair germ cell development in the human fetal testis in vitro without change in testosterone production. *Environ Health Perspect*. 2009;117:32–7.
156. Mitchell RT, Childs AC, Anderson RA, van den Driesche S, Saunders PTK, McKinnell C, Wallace WHB, Kelnar CJH, Sharpe RM. Do phthalates affect steroidogenesis by the human fetal testis? Exposure of human fetal testis xenografts to di (*n*-butyl) phthalate. *J Clin Endocrinol Metab*. 2012;97:E341–8.
157. Heger NE, Hall SJ, Sandrof MA, McDonnell EV, Hensley JB, McDowell EN, Martin KA, Gaido KW, Johnson KJ, Boekelheide K. Human fetal testis xenografts are resistant to phthalate-induced endocrine disruption. *Environ Health Perspect*. 2012;120:1137–43.
158. McKinnell C, Mitchell RT, Walker M, Morris K, Kelnar CJ, Wallace WH, Sharpe RM. Effect of fetal or neonatal exposure to monobutyl phthalate (MBP) on testicular development and function in the marmoset. *Hum Reprod*. 2009;24:2244–54.
159. Hallmark N, Walker M, McKinnell C, Mahood IK, Scott H, Bayne R, Coutts S, Anderson RA, Greig I, Morris K, Sharpe RM. Effects of monobutyl and di (*n*-butyl) phthalate in vitro on steroidogenesis and Leydig cell aggregation in fetal testis explants from the rat: comparison with effects in vivo in the fetal rat and neonatal marmoset and in vitro in the human. *Environ Health Perspect*. 2007;115:390–6.
160. Meeker JD, Calafat AM, Hauser R. Urinary metabolites of di(2-ethylhexyl) phthalate are associated with decreased steroid hormones levels in adult men. *J Androl*. 2009;30:287–97.
161. Mendiola J, Meeker JD, Jorgensen N, Andersson A-M, Liu F, Calafat AM, Redmon JB, Drobnis EZ, Sparks AE, Wang C, Hauser R, Swan SH. Urinary concentrations of di(2-ethylhexyl) phthalate metabolites and serum reproductive hormones: pooled analysis of fertile and infertile men. *J Androl*. 2012;33:488–98.
162. Joensen UN, Frederiksen H, Jensen MB, Lauritsen MP, Olesen IA, Lassen TH, Andersson A-M, Jorgensen N. Phthalate excretion pattern and testicular function: a study of 881 healthy Danish men. *Environ Health Perspect*. 2012;120:1397–403.
163. Gaspari L, Paris F, Jandel C, Kalfa N, Orsini M, Daures JP, Sultan C. Prenatal environmental risk factors for genital malformations in a population of 1442 French male newborns: a nested case-control study. *Hum Reprod*. 2011;26:3155–62.
164. Andersen HR, Schmidt IM, Grandjean P, Jensen TK, Budt-Jorgensen E, Kjaerstad MB, Baelum J, Nielsen JB, Skakkebaek NE, Main KM. Impaired reproductive development in sons of women occupationally exposed to pesticides during pregnancy. *Environ Health Perspect*. 2008;116:566–72.
165. Wohlfahrt-Veje C, Andersen HR, Jensen TK, Grandjean P, Skakkebaek NE, Main KM. Smaller genitals at school age in boys whose mothers were exposed to non-persistent pesticides in early pregnancy. *Int J Androl*. 2012;35:265–72.
166. Virtanen HE, Adamsson A. Cryptorchidism and endocrine disrupting chemicals. *Mol Cell Endocrinol*. 2012;355:208–20.
167. Damgaard IN, Skakkebaek NE, Toppari J, Virtanen HE, Shen H, Schramm KW, Petersen JH, Jensen TK, Main KM and the Nordic Cryptorchidism Study Group. Persistent pesticides in human breast milk and cryptorchidism. *Environ Health Perspect*. 2006;114:1133–1138.
168. Longnecker MP, Gladen BC, Cupul-Uicab LA, Romano-Riquer SP, Weber JP, Chapin RE, Hernandez-Avila M. In utero exposure to the antiandrogen 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene (DDE) in relation to anogenital distance in male newborns from Chiapas, Mexico. *Amer J Epidemiol*. 2007;165:1015–22.
169. Trabert B, Longnecker MP, Brock JW, Klebanoff MA, McGlynn KA. Maternal pregnancy levels of *trans*-nonachlor and oxychlorodane and prevalence of cryptorchidism and hypospadias in boys. *Environ Health Perspect*. 2012;120:478–82.

170. Fullston T, Palmer NO, Owens JA, Mitchell M, Bakos HW, Lane M. Diet-induced paternal obesity in the absence of diabetes diminishes the reproductive health of two subsequent generations of mice. *Hum Reprod.* 2012;27:1391–400.
171. Fullston T, Ohlsson Teague EMC, Palmer NO, DeBlasio MJ, Mitchell M, Corbett M, Print CG, Owens JA, Lane M. Paternal obesity initiates metabolic disturbances in two generations of mice with incomplete penetrance to the F2 generation and alters the transcriptional profile of testis and sperm microRNA content. *FASEB J.* 2013;27:4226–4243.
172. Chambers TJG, Morgan MD, Heger AH, Sharpe RM, Drake AJ. High-fat diet disrupts metabolism in two generations of rats in a parent-of-origin specific manner without affecting the intra-testicular germ-cell transcriptome. *Sci Rep.* 2016;6:31857.
173. Ouvrier A, Alves G, Damon-Soubetrand C, Marceau G, Cadet R, Janny L, Brugnon F, Kocer A, Pommier A, Lobaccaro JMA, Drevet JR, Saez F. Dietary cholesterol-induced post-testicular infertility. *PLoS ONE.* 2011;6:e26966.
174. Terashima M, Barbour S, Ren J, Yu W, Han Y, Muegge K. Effect of high fat diet on paternal sperm histone distribution and male offspring liver gene expression. *Epigenetics.* 2015;10:861–71.
175. Cropley JE, Eaton SA, Aiken A, Young PE, Giannoulatou E, Ho JWK, Bucklind ME, Keam SP, Hutvagner G, Humphreys DT, Langley KG, Henstridge DC, Martin DIK, Febbraio MA, Suter CM. Male-lineage transmission of an acquired metabolic phenotype induced by grand-paternal obesity. *Mol Metab.* 2016;. doi:[10.1016/j.molmet.2016.06.08](https://doi.org/10.1016/j.molmet.2016.06.08).

Geoffrey L. Hammond PhD

Contents

Introduction.....	305
Sex Steroids, SHBG and Diseases Associated with the Metabolic Syndrome.....	306
SHBG: Regulator of Androgen and Estrogen Action.....	307
Structure and Function of Human SHBG.....	308
Tissue Specific Expression of Human SHBG.....	310
Regulation of Plasma SHBG Production by the Liver.....	311
Lessons from Naturally Occurring <i>SHBG</i> Polymorphism.....	314
SHBG: Biomarker or Agent in Disease Etiology.....	316
SHBG and Free Testosterone Measurements.....	317
Conclusions.....	318
References.....	318

Introduction

The metabolic syndrome (MetS) incorporates a cluster of clinical signs and symptoms including elevated blood glucose, central obesity, increased blood pressure, and abnormal HDL cholesterol or triglyceride levels that are collectively associated with increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease. The MetS was originally considered to be an age-related condition but is now known to be associated with

insulin resistance. Remarkable worldwide increases in the incidence of T2DM have been attributed to changes in lifestyles and nutrition choices that promote the MetS in young adults and children. The prevalence of the MetS is similar in men and women, but sex differences in the risk for cardiovascular disease and T2DM have been linked to differences in androgen exposures. Interest in the relationship between androgens and the MetS has been stimulated further by the emerging use of testosterone treatment for middle-aged and older men because of concerns that it may increase risk for cardiovascular disease. However, recent studies suggest that these risks are either uncertain [1] or unfounded [2], and may be outweighed by the beneficial effects of testosterone replacement in terms of obesity, T2DM, sexual function and osteoporosis [3], especially when testosterone replacement is managed conservatively [1]. It is now well accepted that the plasma concentrations of testosterone, and its access to target tissues and cells, are regulated primarily by sex hormone-binding globulin (SHBG). There is also a substantial body of information that plasma SHBG levels represent a biomarker of the MetS and the risk associated with developing cardiovascular disease or T2DM, and emerging evidence suggests that SHBG may even participate in the predisposition to these diseases. This chapter provides a contemporary overview of how SHBG is produced and functions in the context of the MetS, and how it may be utilized as a biomarker of its associated diseases.

G.L. Hammond (✉)
Cellular & Physiological Sciences, Life Sciences
Center, The University of British Columbia, 2350
Health Sciences Mall, Vancouver, BC V6T 1Z3,
Canada
e-mail: geoffrey.hammond@ubc.ca

Sex Steroids, SHBG and Diseases Associated with the Metabolic Syndrome

Clinical and epidemiological studies over several decades have implicated circulating testosterone, as a major risk factor for the MetS and its associated diseases in men [4, 5] and women [6]. It is now generally acknowledged that there is an inverse relationship between total testosterone levels and the number of MetS risk factors [5] and men with low circulating testosterone levels are at increased risk for developing the MetS [4, 7], while the opposite is true in men with high testosterone levels [8], irrespective of their body mass index. By contrast, as summarized recently [6], elevated circulating testosterone levels in women are associated with increased risk for the MetS and T2DM. Estrogens have also been implicated in the genesis of the MetS [9], and it has recently been reported that a low estradiol: testosterone ratio is protective against the MetS, at least in men [7].

It is also now well accepted that SHBG is the major determinant of plasma testosterone levels in healthy men [10], and that SHBG regulates the access of both testosterone and estradiol to target tissues [11, 12]. In recognition of this, most studies of sex steroids and the MetS have examined how SHBG might be co-implicated as a risk factor, and there is substantial evidence that SHBG levels are low in MetS patients [5], and that low plasma SHBG levels predict the development of the MetS in both men [13, 14] and women [15, 16]. Several studies also indicate that low plasma SHBG levels are an independent risk factor beyond traditional risk factors such as BMI, blood pressure, glucose and triglycerides in men [13, 14], but evidence for this in women is less compelling.

While reduced insulin sensitivity is a consistent finding in T2DM, diabetes is uncommon in insulin resistant (IR) patients unless there is also β cell dysfunction [17]. As such, the relationship between SHBG, sex steroids and T2DM differs from that found in patients with MetS. In the Tromso study [18], men with higher estradiol levels had an increased risk of incipient diabetes

independent of obesity while men with lower total testosterone and SHBG levels had an increased risk of diabetes that was no longer significant after adjusting for waist circumference. Moreover, a meta-analysis of 23 cross-sectional and 10 prospective studies found that a low concentration of SHBG was associated with a higher risk of developing T2DM, but this relationship was much stronger for postmenopausal women than for men [19], and a study of adults at high risk for developing T2DM found that obesity and glycemia were far more important determinants of incident diabetes than was SHBG for either sex [20]. Other disorders associated with the MetS in which SHBG levels may be low include nonalcoholic fatty liver disease (NAFLD), obstructive sleep apnea (OSA), psoriasis, and gout.

SHBG is found in the fetal circulation and in umbilical cord blood. Although the significance of SHBG, and the factors which regulate its expression at this stage of development are unknown, cord blood SHBG levels were lower among babies born to overweight mothers, most of whom had gestational diabetes [21]. SHBG levels are low in children and adolescents diagnosed with MetS [22], and in the children of parents with MetS [23]. Detailed metabolic profiling of young adults revealed a strong association between SHBG and circulating lipids and metabolites reflecting the degree of adiposity and IR, and low SHBG levels in early adulthood predicted the development of IR even after adjustment for adiposity, insulin and testosterone levels [24].

Many studies have shown that weight loss through caloric restriction, metformin treatment in combination with lifestyle changes, or following bariatric surgery increases serum SHBG levels, and a few studies have also shown the associated improvement in IR (Table 15.1). Improvement in IR with resistance training is also associated with a rise in SHBG even though BMI was unchanged [25]. In adult men, the rise in SHBG following bariatric surgery is associated with a rise in testosterone that is greater in younger men [26], whereas there is a decline in testosterone levels when women with PCOS lose weight [27].

Table 15.1 Hormone changes following bariatric surgery in men

Ref.	n	BMI (kg/m ²)		Testosterone ng/dL (nmol/L)		SHBG nmo/L		MetS		HOMA-IR	
		Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post
[148]	22	46.2 ± 0.9	-16.6%	340 ± 21	636 ± 186		+21.6				
[149]	33	50.3 ± 6.1	31.5 ± 4.7	248 ± 91	546 ± 165	18.3 ± 11.8	42.7 ± 18.1				
[26]	20	43.6	34.8	8.1	13.2	19	39				
[150]		46.9 ± 7.8	30.9 ± 5.0	256 ± 121	508 ± 161	25.0 ± 12.3	48.5 ± 16.1			11.8 ± 7.8	3.5 ± 4.7
[151]	20	50.4 ± 8.7		302 ± 102							
[152]	28	50.1 ± 11.2	35.9 ± 7.02	(8.31 ± 3.24)	(12.7 ± 3.8)	23.4 ± 17.4	37.8 ± 18.5	75%	25%		

Post measurements were made 6–12 months after surgery

Overall, why SHBG is associated with the MetS and to a lesser extent with T2DM, and the role SHBG plays in determining how androgens or estrogens influence MetS and T2DM risk are only partly understood, and may differ by sex, as discussed below.

SHBG: Regulator of Androgen and Estrogen Action

Plasma SHBG is produced as a glycoprotein by hepatocytes, and is released into the blood circulation as a homodimer of identical subunits, each of which contains a single steroid-binding site for active androgens and estrogens [12]. Human SHBG binds 5 α -dihydrotestosterone (DHT) with about 5 times greater affinity than testosterone and about 20 times higher affinity than estradiol [28]. There are sex differences in human SHBG production by the liver at different stages of the life cycle, and the occupancy of SHBG steroid-binding sites in men and women differs greatly [11]. Plasma levels of SHBG are usually about twofold higher in women than in men but far fewer SHBG steroid-binding sites are occupied in women than in men, in whom SHBG is largely occupied by testosterone [11, 28]. The obvious corollary of this sex difference is that

SHBG functions differently in women than in men.

In women, SHBG appears to play a primary role in limiting the access of both testosterone and estradiol to their target cells. This has been evident ever since the early findings that low plasma SHBG levels are directly associated with increased bioavailable testosterone and symptoms of hyperandrogenism [29]. To illustrate this further, marked 5–10 fold increases in plasma SHBG levels after administration of some oral contraceptives accentuate reductions in free testosterone levels, and are often used to reduce hyperandrogenic symptoms, including hirsutism [30]. In addition, low plasma SHBG levels in obese postmenopausal women are linked to increase risk for endometrial cancer because they increase free estradiol levels [31]. Plasma levels of SHBG also increase by 5–10 fold in women during pregnancy, and it is assumed that this is caused by estrogen-dependent increases in liver SHBG production [29]. The functional importance of elevated plasma SHBG levels during pregnancy is unclear but it may limit the exposure of pregnant women to fetal adrenal androgens that escape metabolism by the placenta, as illustrated by the transient manifestations of severe androgen excess in a pregnant woman with a rare case of SHBG deficiency due to

mutations with both *SHBG* alleles [32]. Women with gestational diabetes have lower plasma SHBG levels [33], and recent reports indicate that low pre-pregnancy levels of SHBG are associated with increased risk for gestational diabetes even in women who were of normal weight with no previous history of this condition [34].

Measurements of plasma SHBG and total testosterone levels are used together to calculate the plasma concentrations of free testosterone, which are generally considered to be the most reliable measure of androgenic activity in both sexes [35]. However, the mathematical algorithms used for this purpose are less than optimal, and the recent identification of human SHBG variants with abnormal steroid-binding activities or immunological properties highlights the pressing need for more direct methods to measure free testosterone levels based on sensitive and specific mass spectrometric methods [36]. The following sections summarize recent advances in our understanding of the functional properties of SHBG, as well as its production by the liver in health and disease, and highlight gaps in our knowledge that remain to be filled.

Structure and Function of Human SHBG

The evolutionary origins of SHBG remain obscure, but its monomeric form comprises two laminin G-like (LG) domains found in the C-terminal regions of several extracellular proteins (Fig. 15.1 a), including protein S and gas6 [37–39]. Protein S and gas6 are potential ligands for the Axl/Sky subfamily of receptor tyrosine kinases and they interact with these receptors through their “SHBG-like domains” [40]. Protein S and gas6 do not bind steroids, and SHBG appears to have acquired its function as a steroid-binding protein early in the evolution of vertebrates because it is present in the fishes [41, 42].

The quaternary structure of the SHBG homodimer has never been resolved but there is evidence that it adopts a torpedo-like head to head conformation [43]. The N-terminal LG

domain contains the steroid-binding site and the dimerization domain (Fig. 15.1b), and its crystal structure has been determined with several different androgens or estrogens in the steroid-binding site [44–46]. These structures show how different steroids are positioned within a hydrophobic binding pocket, and how critical amino acid residues participate in the steroid-binding interactions. In particular, they indicate that androgens and estrogens are accommodated very differently within the hydrophobic core of each SHBG monomer, and that the binding of androgens and estrogens exert differences in the positioning of specific residues on their surface [46], including those within a flexible loop region [47] that covers an entrance to the steroid-binding pocket (Fig. 15.1b). The positioning of this flexible loop has been proposed to influence the flux of androgens and estrogens into and out of the binding site differently, but an additional entrance or exit to the steroid-binding site for estrogens may also exist that is not accessible to androgens [36].

High-resolution crystal structures have also revealed the mechanism of how the SHBG monomers associate as a homodimer, and show that both monomers of the homodimer can bind a steroid ligand [48]. What remains to be determined is whether occupancy of the steroid-binding site of one monomer exerts allosteric effects that influence the steroid-binding affinity of the partner monomer, and whether androgens and estrogens exert different effects in this regard. If this is the case, it may have a different impact of the function SHBG in women in whom steroid occupancy of the binding sites is less than 20%, while in men ~50% of the sites are normally occupied by androgens [11, 28].

It has also been known for many years that calcium maintains the integrity of the SHBG homodimer and its ability to bind steroids with high affinity [49]. This explains why the steroid-binding activity of SHBG in EDTA plasma is disrupted by freeze thaw cycles. Structural resolution of the N-terminal LG domain of SHBG identified the calcium-binding site responsible for this (Fig. 15.1b), and provided evidence that calcium binding exerts




Fig. 15.1 Human SHBG and its structural and functional properties. **a** Domain structures of human SHBG and other proteins with tandem Laminin G-like (LG) domains. Human SHBG resembles the LG4 and LG5 domain structure found in the C-terminus of the laminin A chain. Protein S and Gas6 are large extracellular proteins that comprise a GLA (multiple γ -carboxyglutamic acid) domain followed by several EGF-like domains and similar tandem LG4 and LG5 “SHBG-like domain” that interacts with the Axl/Sky subfamily of receptor tyrosine kinases. **b** The crystal structure of the SHBG LG4 domain in complex with 5α -dihydrotestosterone (DHT) together with the predicted structure of the LG4 domain (gray).

The unstructured flexible loop region that covers an entrance to the steroid-binding pocket is shown as a *dashed green line*, and the dimer interface that holds two monomers together in a head to head manner to form the SHBG homodimer is also indicated. The position of the calcium atom (*yellow center*), the binding of which is essential for maintaining dimerization and the integrity of the steroid-binding is shown, as are the positions of the two zinc atoms (*blue center*); including the zinc atom that is held in position by a histidine in the flexible loop region of human SHBG and influences the specificity of steroid binding. The DHT is positioned in the steroid-binding site

long-range allosteric effects that integrate both dimerization and steroid-binding activities [44–46]. The crystal structures also revealed the

presence of two zinc-binding sites in the N-terminal LG domain (Fig. 15.1b); one of which is highly conserved across species and is

probably structurally important, although this has not been formally proven [50]. The other zinc-binding site is located within the loop region that covers the steroid-binding site, and a zinc atom is held in place by a histidine residue in this location (Fig. 15.1b). Importantly, occupancy of this zinc-binding site specifically reduces the binding affinity of human SHBG for estrogens but not androgens [50]. While this may not be relevant to the activities of SHBG in blood where free zinc concentrations are very low, it may be relevant in other extravascular tissue compartments where they are particularly high, such as in the prostate and male reproductive tract.

Although the SHBG C-terminal LG domain structure has not been resolved, it can be modeled (Fig. 15.1b) on that of the N-terminal LG domain [12]. The C-terminal LG domain does not participate in steroid binding or dimerization, but it normally contains two sites for *N*-linked glycosylation. One of these *N*-glycosylation sites is invariably conserved across vertebrate species and is predicted to be functionally important [51]. There is also a relatively common human SHBG variant (SHBG D327 N) that contains an additional *N*-glycosylation site within the C-terminal LG domain [52].

Well before the structure of SHBG was resolved, reports appeared describing interactions between SHBG and other proteins, especially those within the plasma membranes of cells [53, 54], leading to proposals that the function of SHBG extends beyond those of a plasma transport protein [55]. These functions included cell-signaling activities that may explain in part the non-genomic actions of steroids [56] or the endocytotic delivery of steroids to their target cells [57]. The realization that SHBG was structurally related to the proposed receptor-binding domains of protein S and Gas6 [40] fueled interest in these ideas, as did the demonstration that the nonspecific endocytotic receptor megalin is capable of recognizing SHBG and internalizing it together with its ligand [58]. However, functional receptors for SHBG that exert activities in physiological contexts remain

to be identified. The most likely reason for this is that early observations of interactions between SHBG and cell membrane proteins were made using purified preparations of SHBG and their potential targets, or tissue culture systems where purified SHBG was added in the absence of other plasma proteins. These experimental designs neglected the fact that SHBG is a trace protein in biological fluids, and there are many other proteins including those that have structurally related domains that could compete with its binding to membrane proteins *in vivo*.

However, an interaction between SHBG and the extracellular matrix-associated proteins, fibulin-1D and fibulin-2 has been identified under conditions that satisfy these experimental caveats [59]. These members of the fibulin family not only recognize and sequester SHBG from dilutions of plasma samples that mimic those in extravascular tissue compartment, but do so in a ligand-dependent and ligand-specific manner [59]. Moreover, the interaction was favored when the SHBG steroid-binding site was occupied by estradiol *in vitro* as well as *in vivo* in the endometrial stroma [59]. In mice expressing a human *SHBG* transgene, SHBG also leaves the blood vasculature in the endometrial stroma and accumulates in the stromal matrix when estrogens levels are elevated during the estrus cycle [59]. These observations at least provide direct evidence that SHBG is capable of acting in extravascular compartments of some tissues to modulate the accessibility of sex steroids to their target cells.

Tissue Specific Expression of Human SHBG

The *SHBG* locus is located within the short arm of human chromosome 17 [60], and comprises multiple transcription units defined by the utilization of different promoter regions that flank alternative exon 1 sequences [61–63]. These studies indicated that *SHBG* encodes a large number of transcripts, which all contain alternative exon 1 sequences spliced to a common exon

2 sequence followed by up to six other exon sequences, but only two of them have been shown to encode a functional SHBG protein (Fig. 15.2). The biologically most important of these is the mRNA in the liver that encodes the SHBG precursor polypeptide that includes the secretion signal polypeptide sequence encoded by exon 1 within an ~ 4.5 kb *SHBG* transcription unit [12]. By contrast, the major *SHBG* transcript in the testis [61] contains a noncoding alternative exon 1 sequence (Fig. 15.2), and there is evidence that an AUG translation initiation codon within exon 2 produces an N-terminally truncated SHBG isoform starting with Met30 in the mature SHBG sequence [64]. This SHBG isoform is produced in male germ cells and is not secreted, but it appears to bind steroids in same way as plasma SHBG and accumulates in the acrosome of sperm [64]. Although the function of this human sperm SHBG isoform is unknown, its concentration in the acrosome declines with age and correlates with sperm motility [65].

Cell-specific expression of *SHBG* in the human testis differs from that observed in subprimate species in which the gene is expressed in Sertoli cells resulting in the production of the SHBG homologue, known as the androgen-binding protein, which is secreted into the seminiferous tubules where it is thought to act to promote sperm maturation within the male reproductive tract [66]. Although SHBG is present in human seminal plasma [67], it does not originate from Sertoli cells because the human *SHBG* promoter contains a binding site for USF transcription factors that repress transcription in Sertoli cells, and these sequences are absent the *SHBG* genes of subprimate species [64]. This species difference in the cell type expression of SHBG in the testis is enigmatic but may be related to differences in the spatial organization of spermatogenic cells within the seminiferous tubules.

None of the other alternative exon 1 containing *SHBG* transcripts encodes a secretion signal

polypeptide in frame with coding sequences for an SHBG-like polypeptide. However, “humanized mice” expressing an *SHBG* transgene have demonstrated that extrahepatic expression of *SHBG* occurs in some cell types, such as the androgen sensitive epithelial cells of the proximal convoluted tubules of the kidney, and much of the human SHBG produced by these cells remains within them [68]. Furthermore, the SHBG that accumulates within these cells is N-terminally truncated and incompletely glycosylated, much like the SHBG isoform in the acrosome [65], and it appears to act to sequester DHT from the extracellular environment and modify its access to the androgen receptor [69]. This raises the possibility that the alternative *SHBG* transcripts identified in human prostate cancer cells [62, 63] encode SHBG isoforms that function within the cells rather than having to be secreted to act, but this will only be resolved when these intracellular SHBG isoforms are actually isolated and characterized from human tissues.

Regulation of Plasma SHBG Production by the Liver

Early studies indicated that SHBG production by the liver is under hormonal, nutritional and metabolic control [29]. Reductions in plasma SHBG in boys during puberty were initially thought to reflect a negative effect of androgen on SHBG production, but this was difficult to reconcile with a lack of any increase in plasma SHBG levels in men after orchiectomy [70]. A normal pubertal decline in SHBG was also been reported in siblings with complete androgen insensitivity, implying that the substantial reductions in SHBG levels in boys during puberty are not androgen-dependent [71]. Importantly, these changes in SHBG levels during puberty in boys occur with advancing age irrespective of any changes in total testosterone [72], and cause increases in albumin-bound and free




Fig. 15.2 Structural organization of the human *SHBG* locus, showing the two main transcription units expressed in the liver and male germ cells, together with the positions of common polymorphism associated with individual differences in the production or function of plasma SHBG. The ~4.5 kb transcription unit for the *SHBG* mRNA in the liver that encodes the SHBG precursor polypeptide (encoded by exons 1–8) includes ~800 bp of promoter sequence upstream of exon 1 that encode the secretion polypeptide (SP) that is remove co-translationally to yield the mature SHBG

monomer of LG4 and LG5 domains. The ~7 kb transcription unit encodes the most abundant alternative *SHBG* transcript found in testicular germ cells, and it comprises an alternative exon 1a sequence spliced into exons 2–8. Exon 1a is noncoding but translation can initiate from the AUG codon (in exon 2) for Met30 in the mature SHBG polypeptide to yield an N-terminally truncated SHBG isoform that accumulates in the acrosome. Those SNPs in linkage disequilibrium with each other are indicated with symbols (* or §), respectively

testosterone that likely contributes to male sexual development [73]. Clearly other factors account for reductions in plasma SHBG levels in girls during puberty, and there is evidence that increases in body weight and composition are the main operative agents of these changes [74]. Reductions in plasma SHBG are more pronounced in girls with premature puberty, many of whom are overweight, and SHBG measurements have been useful as a prognostic indicator of risk for T2MD in these individuals [75], as highlighted in a recent review [76].

In healthy adults, SHBG levels remain relatively constant, and in elderly men and women changes in plasma SHBG are modest, with modest age-related increases in men during old age that has been attributed to GH deficiency [77]. Small reductions in SHBG levels in postmenopausal women are unlikely to be related to a loss of ovarian estrogen because transdermal hormone replacement therapy does not influence plasma SHBG levels [78], and are more likely to be associated with changes in body composition [79], hormones like leptin and adiponectin [80],

thyroid hormone status [81], or the metabolic state of the liver [82].

Early reports that plasma SHBG levels are very low in obese men [83], but very high in patients with anorexia nervosa [84], provided the first indication that nutritional status or metabolic factors influence the production or plasma clearance of SHBG. It was also recognized early on that plasma SHBG levels are elevated in hyperthyroid individuals and in patients after treatment with thyroid hormone [29], which itself exerts profound effects on metabolic state.

The very low levels of SHBG in obese men and women remained unexplained until it was reported that treatment of human HepG2 hepatoblastoma cells with insulin decreased SHBG production in vitro [85]. This provided credence to the idea that elevated insulin levels were responsible for the low plasma SHBG levels in insulin-resistant obese individuals, but the cellular mechanisms responsible for this have never been identified. Although, SHBG levels are normal in children with type 1 diabetes [86], they are in the upper normal ranges in men and

women with type 1 diabetes, and display an inverse correlation with fasting insulin levels [87]. While the latter observations were interpreted as confirmation of a negative effect of insulin on hepatic SHBG production, a strong association between SHBG and glucose levels was also observed in subjects with T2DM in the same study.

Hyperglycemia is the primary consequence of deficiencies in insulin production or action in patients with type 1 diabetes or T2DM, and the question of how nutrition and metabolic state might influence plasma SHBG production by the liver was therefore re-examined in HepG2 cells, as well as in humanized mice that express human *SHBG* transgenes in the liver under the control of the *SHBG* promoter [88]. These studies failed to confirm a direct effect of insulin on *SHBG* expression in the liver in vitro or in vivo. Instead they demonstrated that *SHBG* is regulated in the liver by the monosaccharides, glucose and fructose, rather than insulin. Moreover, they presented a detailed mechanism for how these effects are mediated at the level of *SHBG* transcription [88], thereby providing the first molecular explanation for why plasma SHBG levels are so low in patients with the MetS [4, 89]. The finding that monosaccharides, and fructose in particular, potentially downregulated *SHBG* expression in hepatocytes also provided an explanation for why the wide-spread use of high fructose corn starch as a food and beverage supplement has been associated with the remarkable increases in the prevalence of the MetS and T2DM worldwide.

The transcription unit responsible for SHBG production by the liver was originally identified through experiments using different human *SHBG* transgenes in mice [68], as well as with *SHBG* promoter-driven reporter constructs in HepG2 cells [90]. Together these studies demonstrated that the ~4.5 kb transcription unit, which includes an ~800 bp promoter flanking exon 1 (Fig. 15.2), is sufficient to drive *SHBG* transcription in the liver. The use of DNase I footprinting assays and reporter gene assays also allowed the mapping of *cis*-elements within the promoter that interact with hepatic

nuclear protein extracts [90]. The latter studies revealed that the binding of HNF4 α to a nuclear hormone receptor (NHR) response element close to the *SHBG* transcription start site compensates for lack of a TATA box, and substitutes for the TATA-binding protein in recruiting the transcriptional machinery to the proximal promoter of *SHBG*. At that time, the realization that HNF4 α plays a key role in the regulation of *SHBG* expression was particularly enlightening because *HNF4 α* had just been identified as the first gene to be implicated in Maturity Onset Diabetes of the Young [91].

As a member of the NHR family of transcription factors, HNF4 α , binds to palindromic DNA response elements that also bind other members of the NHR family, including the COUP-TFs [92]. Importantly, HNF4 α and COUP-TF1 compete for the same response element in the *SHBG* promoter and to exert opposing actions on *SHBG* transcription, with HNF4 α increasing transcription while COUP-TF1 represses it [90]. This explained for the first time how HNF4 α and COUP-TF1 might serve as the on-off switches of *SHBG* transcription in hepatocytes under a wide range of pathophysiological conditions related to the MetS.

The underlying mechanism of how oral glucose and fructose downregulate hepatic SHBG production involves their rapid hepatic metabolism into acetyl-CoA, the immediate precursor of palmitic acid: the first of the long chain fatty acids produced in the liver [88]. A buildup of palmitate in HepG2 cells after treatment with monosaccharides is indicative of increased lipogenesis, and occurs in concert with reductions in HNF4 α and SHBG mRNA levels, and concurrent reductions in SHBG secretion [88]. A strong positive correlation between hepatic HNF4 α and SHBG mRNA levels has been also observed in a study of male and female cancer patients [93]. Furthermore, in the later study, hepatic HNF4 α and SHBG mRNA levels were also inversely related to hepatic triglyceride levels and decreased in relation to body mass index. Why HNF4 α levels decrease in hepatocytes under conditions where lipogenesis is enhanced may be

related to the fact that fatty acyl Coenzyme A thioesters and palmitoleic (C16:1) and oleic acid (C18:1) were originally identified as potential ligands of HNF4 α [94–96], which may induce conformational changes in HNF4 α [97] and somehow destabilize it. It is also possible that other dietary fatty acids, such as linoleic acid, and long-chain fatty acid metabolites bind HNF4 α and alter its levels or activity as a transcription factor [98]. This of interest because recent studies have indicated that diets rich in linoleic acid may increase plasma SHBG levels [99].

This interplay between HNF4 α and COUP-TF as key regulators of *SHBG* expression in hepatocytes is emerging as a common mechanism that accounts for other links between abnormal plasma SHBG levels and clinical conditions related to an abnormal metabolic state. In patients with the MetS, an increase in free fatty acid flux due to a failure to suppress lipolysis in adipocytes will increase hepatic free fatty acids [100], and thereby contribute to reductions in hepatic HNF4 α levels and *SHBG* expression. By contrast, high plasma levels of SHBG are usually found in individuals with hyperthyroidism, while low levels are associated with thyroid hormone deficiencies [29] and the reason for this is that thyroid hormone influences hepatic SHBG production indirectly by altering hepatic HNF4 α levels [101]. Low plasma SHBG levels are also frequently observed in patients with hepatic steatosis that predisposes to T2DM [102], and have been independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with T2DM [103]. The low plasma SHBG levels in NAFLD patients likely reflects the substantial accumulation of fatty acids in their livers [104], including palmitic acid that is linked to reduced hepatic HNF4 α levels [88].

Increases in the plasma levels of pro-inflammatory cytokines (TNF α and IL-1 β) and reduced levels of adiponectin, which are typically seen in overweight individuals at risk for the MetS [105], have been recently shown to downregulate [106, 107] and upregulate [108] *SHBG* production by the liver, respectively, and they also do this by changing hepatic HNF4 α

levels. By contrast, the transcription factor PPAR γ interacts with a different NHR response element in the *SHBG* proximal promoter to repress transcription [109], and this probably accounts for the lower plasma SHBG levels in subjects with the hyperactive 12 Ala PPAR γ variant [110] that has been linked to low risk for T2DM and myocardial infarction [111]. However, the use of insulin sensitizers, like pioglitazone, that act by stimulating PPAR γ , increase plasma SHBG levels in individuals with the MetS [112]. This may be explained by the fact that the NHR response element in the *SHBG* proximal promoter that binds PPAR γ can also bind HNF4 α [90], as well as several other orphan members of the NHR family, including CAR and LXR, which can all potentially compete for binding at this site. Improvements in hepatic metabolic state induced by pioglitazone and other insulin sensitizers, likely change the hepatic complement of these orphan NHRs, which may account for changes in *SHBG* expression after their use.

Lessons from Naturally Occurring *SHBG* Polymorphism

Individual differences in plasma sex steroid and SHBG levels were recognized as an inherited trait in early studies [113], but the genetic basis for this was not appreciated until human *SHBG* was cloned and sequenced [61, 114]. The first SHBG variant to be characterized at the genetic level explained why SHBG monomers in the serum of some individuals migrate with an unusually large molecular size in denaturing polyacrylamide gels [38, 115], and was shown to be caused by an Asp327 to Asn substitution that introduces an additional consensus site for N-glycosylation and an extra N-linked oligosaccharide per monomer [52]. The nonsynonymous SNP (rs6259) responsible for the SHBG D327 N variant (Fig. 15.2) is common in most ethnic groups globally. While the steroid-binding activity of SHBG D327 N is normal [52], a reduction in its plasma clearance rate may account for why carriers of SHBG D327 N have slightly higher plasma SHBG levels [116], and in part explain

reports that SHBG D327 N has a protective effect on T2DM risk [117, 118].

Several *SHBG* polymorphisms linked to differences in plasma SHBG levels are located in noncoding regions of the gene (Fig. 15.2). The first of these to be identified was the TAAAA(n) polymorphic repeat that is part of an *Alu* sequence positioned about 1 kb upstream from the transcription start site for the *SHBG* mRNA [119]. Variations in number of this pentanucleotide repeat per *SHBG* allele have been examined in relation to plasma SHBG levels in patients with a range of clinical conditions [120], and the emerging consensus is that men with low numbers of TAAAA repeats have lower SHBG levels and are at greater risk for the MetS [121].

The molecular explanation for how the variable TAAAA repeat number influences hepatic SHBG production remains to be fully elucidated, but studies using reporter genes driven by *SHBG* promoter sequences in HepG2 cells have demonstrated that the pentanucleotide repeat number may influence *SHBG* transcription through interactions with other downstream elements within the promoter including an SP1 binding site [119]. However, the effect of variable TAAAA repeats on *SHBG* transcription observed in these in vitro studies does not match what is observed in terms of differences in plasma SHBG levels in patients [122], and this may be due to either the transformed nature of HepG2 cells or the fact that reporter constructs act as naked DNA without assuming the complex chromatin structure that the *SHBG* promoter normally adopts in vivo. This has precluded further in depth studies of the molecular basis of how variations in the TAAAA repeat number influence *SHBG* transcription, but the recent introduction of genome editing techniques should allow this question to be addressed more directly.

Other common SNPs within the *SHBG* promoter or its first intron have been linked to plasma SHBG levels in genome-wide association studies (GWAS) of sex hormone dependent diseases (Fig. 15.2), including those associated with the MetS and T2DM. One of these SNPs (rs1799941) that is linked to individual differences in plasma SHBG levels, in men [123], women [124, 125],

and in children and adolescents [126], is located close (within 10 bp) to the *SHBG* transcription start site, with A and G alleles being associated with higher and lower plasma SHBG levels, respectively [127]. However it has also been noted that rs1799941 is in linkage disequilibrium (LD) with other genetic variations within the *SHBG* locus [128], including rs6295 and rs72829446 that is located ~15 kb downstream from the coding sequences for *SHBG* transcripts (Fig. 15.2). The rs1799941 is also in strong LD with rs12150660 located about 11.5 kb further upstream within the *SHBG* locus (Fig. 15.2), and which is also strongly associated with plasma testosterone concentrations [10].

A common SNP (rs6257) within intron 1 of the *SHBG* gene (Fig. 15.2) was originally associated with lower plasma SHBG levels and breast cancer risk [129] but has also been reported as a risk allele for T2DM [117]. This is in contrast to rs6295 that produces the SHBG D327 N variant with a prolonged plasma half-life, which is considered to be protective of risk for developing the MetS [104, 117, 118]. Recently, another SNP (rs3760213) linked to higher levels of plasma SHBG has been associated with a decreased risk for the MetS [118], and it may be directly involved in increasing *SHBG* expression because it is positioned close to a footprinted region (DNase1 footprint 6) ~200 bp upstream (Fig. 15.2) of the *SHBG* transcription start site [90]. Another SNP (rs727428) that is associated with plasma androgen and SHBG levels is positioned ~1 kb downstream of the most 3' *SHBG* exon [129], and is in LD with an SNP (rs858518) within the promoter that appears to promote *SHBG* expression in the liver (Fig. 15.2).

Apart from the SHBG D327 N variant (rs6295), there is only one other relatively common non-synonymous SNP (rs6258) within the *SHBG* coding sequence (Fig. 15.2) that appears to have the capacity to influence plasma testosterone levels. This polymorphism encodes SHBG P156L that has a reduced affinity for testosterone, and men with this variant have lower testosterone levels in their blood, presumably because of an increase in the metabolic clearance of testosterone [10]. Several other naturally occurring

SHBG variants have been identified recently with abnormalities in production or the ways they bind their sex steroids ligands, but these occur very rarely and their clinical significance is unknown [36]. However, one of them (SHBG G195E) with a secretion defect [36] has an amino acid substitution in the same position as another rare SHBG variant (SHBG G195R) recently identified in a man with no detectable SHBG in blood plasma [130].

Given the enormous numbers of plasma SHBG measurements performed worldwide for diagnostic reasons over several decades, it is remarkable that the young male adult patient homozygous for SHBG G195R represents the first verifiable case of a total absence of SHBG [130]. Like SHBG G195E, detailed molecular and biochemical analysis of SHBG G195R indicated that it is translated but is not secreted, most likely because of a folding defect [130]. As expected, the patient's plasma total testosterone concentration was well below the normal range, yet his free testosterone level was normal. Clinical assessments indicated fatigue, overt muscle weakness and low body weight, and other symptoms of hypoandrogenism, but gonadal development and sperm production and function appeared to be normal. Although this report provides an indication that plasma SHBG is not essential for male reproductive development and sperm production, the proband's clinical phenotype suggests a more direct role for SHBG in supporting the anabolic activities of androgens [130].

SHBG: Biomarker or Agent in Disease Etiology

Measurements of SHBG concentrations in blood samples have been used for decades as a biomarker of androgenicity in conjunction with total testosterone measurements, especially in women suffering from symptoms of androgen excess. In these patients, many of whom are diagnosed with

the polycystic ovarian syndrome (PCOS), the link between low plasma SHBG and elevated levels of free testosterone and clinical symptoms is easily drawn. There are several reports that the TAAAA repeat polymorphism in the SHBG promoter is associated with PCOS [120] but many other studies have failed to show consistent evidence for associations between any of the common variants in the *SHBG* gene and the development of PCOS, although they do confirm that many SHBG polymorphisms are associated with individual plasma SHBG levels [131]. The latter review also noted that discrepancies between studies examining the associations between *SHBG* polymorphism and risk of PCOS or T2DM may be explained by the genetic heterogeneity underlying both disorders, which may also be compounded by differences in ethnicity and variations in dietary preferences.

The most potent natural hormonal mediator of hepatic SHBG production is thyroid hormone, and very high plasma SHBG levels are observed in patients with hyperthyroidism or with poorly controlled exogenous thyroid hormone use [29]. In these cases, elevated plasma SHBG levels appears to be a biomarker of increased biologically active thyroid hormone, and it has been proposed that SHBG measurements may effectively discriminate between patients with thyrotoxicosis due to excessive thyroid hormone production/bioavailability and those with thyroid hormone resistance [132].

Increased SHBG levels in older men with osteoporosis have been associated with bone remodeling markers, hip bone mineral density and vertebral fracture risk, and serum SHBG measurements have been advocated as a useful biomarker for fracture risk in men [133], and especially in men with prostate cancer [134]. Given the established role that estrogen plays in maintaining bone mineral density, one interpretation is that increased plasma SHBG levels reduce the bioavailability of estradiol in both men and women [135]. However, under these circumstances, it should also be noted that

reductions in free testosterone will decrease its availability as a substrate for estradiol synthesis in bone, and this may be much more relevant in males in whom high plasma SHBG levels associated with SNPs in the *SHBG* locus are linked to osteoporosis risk [135, 136].

Many epidemiological studies have shown that low plasma testosterone and SHBG levels are strong risk factors for the MetS [13, 137, 138] and T2DM in men [139, 140]. While circulating testosterone levels in men are largely determined by the levels and activity of SHBG in the blood [10] it remains to be established if the health risks associated with low T are independent of SHBG. However, the association of free T levels and the MetS is much weaker, with substantial between-study heterogeneity [141]. Associations may differ according to age and BMI, as stronger associations have been reported in young [142] and non-obese men [4], and SHBG levels did not predict incipient diabetes among a group of subjects at high risk for developing diabetes [20].

On the other hand, while the inverse relationship between insulin resistance and reduced plasma SHBG levels is incontrovertible [143], the risk for T2DM in women with low SHBG levels is stronger than in men [19]. As discussed above, the molecular mechanisms responsible for this association clearly indicate that plasma SHBG production reflects hepatic metabolic state as well as the inflammatory conditions associated with insulin resistance. Moreover, it is apparent that SHBG measurements represent an independent predictive biomarker of these metabolic disturbances [13], as well as any responses to weight loss treatments [144].

New information from genetic studies linking SNPs with plasma SHBG levels and the relative risks for the MetS are beginning to raise questions of whether inherent differences in the hepatic production of SHBG, high versus low, protect against or predispose to the MetS in some individuals [117]. This is compatible with findings that higher testosterone and SHBG levels in aging males are associated with a reduced risk for the MetS, while the opposite hormonal profile increases risk, irrespective of body composition [8]. Furthermore, low plasma SHBG and

testosterone levels, in association with symptoms of clinical androgen deficiency, are associated with increased risk of developing the MetS over time, especially in middle-aged men of normal body mass index [4]. It is unlikely that SHBG is directly implicated in these responses, and a recent study suggested that a reduced plasma estradiol:testosterone (E2:T) ratio may be protective against developing the MetS in men [7]. While a lower E2:T ratio may reflect lower aromatase activity, it may be influenced by the level of SHBG in that SHBG binds T more strongly than E2 and the ratio will rise as SHBG declines in insulin resistance. Nevertheless, these findings are of particular interest in light of evidence that testosterone replacement therapies improve insulin resistance, visceral obesity, dyslipidemia and sexual dysfunction along with improved quality of life [5, 145]. Importantly, since testosterone replacement is being increasingly used in middle-aged and elderly men, measurements of SHBG provide important baseline assessments of free testosterone levels that could help personalize therapies, or a biomarker of any improvements in metabolic state that are achieved over time during androgen replacement therapies.

SHBG and Free Testosterone Measurements

The concentrations of SHBG in serum and heparinized plasma are usually measured using immunoassays, and are used in algorithms together with total testosterone levels to calculate plasma free testosterone levels. For instance, calculated free testosterone levels may be particularly useful in assessing men with suspected hypogonadal symptoms [146]. However, the identification of SHBG variants that may not be recognized appropriately in immunoassays, or have abnormalities in their steroid-binding properties [10, 36], highlights the need for sensitive and specific direct measurements of free testosterone measurement using mass spectrometric approaches. Such measurements should ideally be conducted after separation of the free hormone fraction under physiological conditions,

i.e. in undiluted serum or plasma samples at physiological temperatures, as has been conducted using radiolabeled steroids [147]. Although this presents technical challenges, relatively simple technologies exist that may allow this and they should be further developed.

Salivary steroid analysis have been used as a surrogate for measuring free steroid levels in the blood but have not been widely adopted because they are not easily adapted for routine clinical chemical laboratory use, and suffer from problems associated with plasma contamination of saliva from oral cavity wounds. However, as in the case of direct analyses of plasma free steroid levels, the interpretation of abnormal salivary steroid hormone levels is limited in the absence of knowledge of circulating SHBG or total testosterone levels. In addition, knowledge of changes in serum SHBG levels during the course of clinical conditions or in response to therapeutic interventions may be of value in of itself as a biomarker of improvements in metabolic state for instance. In the emerging era of personalized or precision medicine, knowledge of plasma SHBG levels, or SNP profiles that are associated with plasma SHBG levels and disease risk, could therefore be used to tailor individual hormone replacement treatments to optimize therapeutic dosages.

Conclusions

Plasma SHBG plays a central role in transporting and regulating the access of androgens and estrogens to their target tissues and cells. Production of SHBG by hepatocytes is regulated by hormones, cytokines, and dietary components that influence the metabolic state of the liver, and their effects are reflected in changes in plasma SHBG levels. Most of these effects are mediated by changes in levels of the transcription factor, HNF4 α , which acts in concert with COUP-TF1 as the main “on/off” controls of *SHBG* transcription, respectively. The levels of HNF4 α in the liver play a key role in regulating a network of genes involved in hepatic metabolism and homeostatic control mechanism, and it acts

together other related members of the NHR superfamily that also regulate metabolically important genes, including PPAR γ , which may all influence *SHBG* expression directly or indirectly in the liver. As such, plasma SHBG measurements serve as a sensitive surrogate biomarker of abnormalities in liver metabolism that are associated with the MetS and its associated diseases. Several recent GWAS of patients with these latter diseases or at risk for them have also indicated that genetic polymorphisms linked to either higher or lower plasma SHBG levels protect or increase the disease risk, respectively. This raises the question of whether the substantial interindividual differences in *SHBG* expression in the liver participate more directly in the etiology of diseases associated with the MetS: for instance, by changing the relative balance of plasma androgen and estrogens that many studies have implicated as disease promoting agents. If so, SHBG may also emerge as a therapeutic target that could be manipulated to modify exposures to these steroids in individuals at risk for the MetS.

References

1. Anderson JL, May HT, Lappe DL, et al. Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. *Am J Cardiol.* 2016;117(5):794–9.
2. Corona GG, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone replacement therapy and cardiovascular risk: A review. *World J Mens Health.* 2015;33(3):130–42.
3. Dimopoulou C, Ceausu I, Depypere H, et al. EMAS position statement: Testosterone replacement therapy in the aging male. *Maturitas.* 2016;84:94–9.
4. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. *J Clin Endocrinol Metab.* 2006;91(3):843–50.
5. Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. *Nat Rev Endocrinol.* 2013;9(8):479–93.
6. Kim C, Halter JB. Endogenous sex hormones, metabolic syndrome, and diabetes in men and

- women. *Curr Cardiol Rep.* 2014;16(4):467-014-0467-6.
7. Antonio L, Wu FC, O'Neill TW, et al. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. *J Clin Endocrinol Metab.* 2015;100(4):1396-404.
 8. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. *J Clin Endocrinol Metab.* 2005;90(5):2618-23.
 9. Faulds MH, Zhao C, Dahlman-Wright K, Gustafsson JA. The diversity of sex steroid action: regulation of metabolism by estrogen signaling. *J Endocrinol.* 2012;212(1):3-12.
 10. Ohlsson C, Wallaschofski H, Lunetta KL, et al. Genetic determinants of serum testosterone concentrations in men. *PLoS Genet.* 2011;7(10):e1002313.
 11. Hammond GL, Wu TS, Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. *Curr Opin Endocrinol Diabetes Obes.* 2012;19(3):183-9.
 12. Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. *Biol Reprod.* 2011;85(3):431-41.
 13. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. *Diabetes Care.* 2004;27(5):1036-41.
 14. Bhasin S, Jasjua GK, Pencina M, et al. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: The Framingham heart study. *Diabetes Care.* 2011;34(11):2464-70.
 15. Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP. Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. *J Clin Endocrinol Metab.* 1993;77(1):56-60.
 16. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. *Diabetes.* 1991;40(1):123-8.
 17. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes.* 1988;37(6):667-87.
 18. Vikan T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. *Eur J Endocrinol.* 2010;162(4):747-54.
 19. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA.* 2006;295(11):1288-99.
 20. Mather KJ, Kim C, Christophi CA, et al. Steroid sex hormones, sex hormone-binding globulin, and diabetes incidence in the diabetes prevention program. *J Clin Endocrinol Metab.* 2015;100(10):3778-86.
 21. Liu B, Xu Y, Liang JM, et al. Intrauterine insulin resistance in fetuses of overweight mothers. *J Obstet Gynaecol Res.* 2013;39(1):132-8.
 22. de Oya I, Schoppen S, Lasuncion MA, et al. Sex hormone-binding globulin levels and metabolic syndrome and its features in adolescents. *Pediatr Diabetes.* 2010;11(3):188-94.
 23. Krishnasamy SS, Chang C, Wang C, Chandiramani R, Winters SJ. Sex hormone-binding globulin and the risk for metabolic syndrome in children of South Asian Indian origin. *Endocr Pract.* 2012;18(5):668-75.
 24. Wang Q, Kangas AJ, Soininen P, et al. Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: Observational and causal effect estimates. *Int J Epidemiol.* 2015;44(2):623-37.
 25. Roberts CK, Croymans DM, Aziz N, Butch AW, Lee CC. Resistance training increases SHBG in overweight/obese, young men. *Metabolism.* 2013;62(5):725-33.
 26. Facchiano E, Scaringi S, Veltri M, et al. Age as a predictive factor of testosterone improvement in male patients after bariatric surgery: Preliminary results of a monocentric prospective study. *Obes Surg.* 2013;23(2):167-72.
 27. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. *Fertil Steril.* 1994;61(4):598-604.
 28. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. *J Clin Endocrinol Metab.* 1981;53(1):58-68.
 29. Anderson DC. Sex-hormone-binding globulin. *Clin Endocrinol (Oxf).* 1974;3(1):69-96.
 30. Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. *Clin Endocrinol (Oxf).* 1985;22(1):29-36.
 31. Nisker JA, Hammond GL, Davidson BJ, et al. Serum sex hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. A new biochemical basis for the association between obesity and endometrial carcinoma. *Am J Obstet Gynecol.* 1980;138(6):637-42.
 32. Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. *J Clin Invest.* 2002;109(7):973-81.
 33. Bartha JL, Comino-Delgado R, Romero-Carmona R, Gomez-Jaen MC. Sex hormone-binding globulin

- in gestational diabetes. *Acta Obstet Gynecol Scand.* 2000;79(10):839–45.
34. Hedderson MM, Ferrara A. Response to comment on Hedderson et al. Prepregnancy SHBG concentrations and risk for subsequently developing gestational diabetes mellitus. *Diabetes Care.* 2014;37:1296–1303. *Diabetes Care.* 2014;37(12):e280–1845.
 35. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.* 1999;84(10):3666–72.
 36. Wu TS, Hammond GL. Naturally occurring mutants inform SHBG structure and function. *Mol Endocrinol.* 2014;28(7):1026–38.
 37. Baker ME, French FS, Joseph DR. Vitamin K-dependent protein S is similar to rat androgen-binding protein. *Biochem J.* 1987;243(1):293–6.
 38. Gershagen S, Fernlund P, Edenbrandt CM. The genes for SHBG/ABP and the SHBG-like region of vitamin K-dependent protein S have evolved from a common ancestral gene. *J Steroid Biochem Mol Biol.* 1991;40(4–6):763–9.
 39. Joseph DR, Baker ME. Sex hormone-binding globulin, androgen-binding protein, and vitamin K-dependent protein S are homologous to laminin A, merosin, and Drosophila crumbs protein. *FASEB J.* 1992;6(7):2477–81.
 40. Evenas P, Dahlback B, Garcia de Frutos P. The first laminin G-type domain in the SHBG-like region of protein S contains residues essential for activation of the receptor tyrosine kinase sky. *Biol Chem.* 2000;381(3):199–209.
 41. Miguel-Queralt S, Knowlton M, Avvakumov GV, Al-Nouno R, Kelly GM, Hammond GL. Molecular and functional characterization of sex hormone binding globulin in zebrafish. *Endocrinology.* 2004;145(11):5221–30.
 42. Miguel-Queralt S, Avvakumov GV, Blazquez M, Piferrer F, Hammond GL. Sea bass (*Dicentrarchus labrax*) sex hormone binding globulin: molecular and biochemical properties and phylogenetic comparison of its orthologues in multiple fish species. *Mol Cell Endocrinol.* 2005;229(1–2):21–9.
 43. Beck K, Gruber TM, Ridgway CC, Hughes W, Sui L, Petra PH. Secondary structure and shape of plasma sex steroid-binding protein—comparison with domain G of laminin results in a structural model of plasma sex steroid-binding protein. *Eur J Biochem.* 1997;247(1):339–47.
 44. Avvakumov GV, Grishkovskaya I, Muller YA, Hammond GL. Crystal structure of human sex hormone-binding globulin in complex with 2-methoxyestradiol reveals the molecular basis for high affinity interactions with C-2 derivatives of estradiol. *J Biol Chem.* 2002;277:45219–25.
 45. Grishkovskaya I, Avvakumov GV, Sklenar G, Dales D, Hammond GL, Muller YA. Crystal structure of human sex hormone-binding globulin: Steroid transport by a laminin G-like domain. *EMBO J.* 2000;19(4):504–12.
 46. Grishkovskaya I, Avvakumov GV, Hammond GL, Catalano MG, Muller YA. Steroid ligands bind human sex hormone-binding globulin in specific orientations and produce distinct changes in protein conformation. *J Biol Chem.* 2002;277:32086–93.
 47. Grishkovskaya I, Avvakumov GV, Hammond GL, Muller YA. Resolution of a disordered region at the entrance of the human sex hormone-binding globulin steroid-binding site. *J Mol Biol.* 2002;318:621–6.
 48. Avvakumov GV, Grishkovskaya I, Muller YA, Hammond GL. Resolution of the human sex hormone-binding globulin dimer interface and evidence for two steroid-binding sites per homodimer. *J Biol Chem.* 2001;276:34453–7.
 49. Rosner W, Toppel S, Smith RN. Testosterone-estradiol-binding globulin of human plasma: denaturation and protection. *Biochim Biophys Acta.* 1974;351(1):92–8.
 50. Avvakumov GV, Muller YA, Hammond GL. Steroid-binding specificity of human sex hormone-binding globulin is influenced by occupancy of a zinc-binding site. *J Biol Chem.* 2000;275:25920–5.
 51. Bocchinfuso WP, Warmels-Rodenhisser S, Hammond GL. Expression and differential glycosylation of human sex hormone-binding globulin by mammalian cell lines. *Mol Endocrinol.* 1991;5:1723–9.
 52. Power SG, Bocchinfuso WP, Pallesen M, Warmels-Rodenhisser S, Van Baelen H, Hammond GL. Molecular analyses of a human sex hormone-binding globulin variant: evidence for an additional carbohydrate chain. *J Clin Endocrinol Metab.* 1992;75(4):1066–70.
 53. Strel'chyonok OA, Avvakumov GV, Survilo LI. A recognition system for sex-hormone-binding protein-estradiol complex in human decidua endometrium plasma membranes. *Biochim Biophys Acta.* 1984;802(3):459–66.
 54. Khan MS, Hryb DJ, Hashim GA, Romas NA, Rosner W. Delineation and synthesis of the membrane receptor-binding domain of sex hormone-binding globulin. *J Biol Chem.* 1990;265(30):18362–5.
 55. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. *Endocr Rev.* 1990;11(1):80–91.
 56. Rosner W, Hryb DJ, Kahn SM, Nakhla AM, Romas NA. Interactions of sex hormone-binding globulin with target cells. *Mol Cell Endocrinol.* 2010;316(1):79–85.
 57. Porto CS, Gunsalus GL, Bardin CW, Phillips DM, Musto NA. Receptor-mediated endocytosis of an extracellular steroid-binding protein (TeBG) in MCF-7 human breast cancer cells. *Endocrinology.* 1991;129(1):436–45.

58. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. *Cell*. 2005;122:751–62.
59. Ng KM, Catalano MG, Pinos T, et al. Evidence that fibulin family members contribute to the steroid-dependent extravascular sequestration of sex hormone-binding globulin. *J Biol Chem*. 2006;281(23):15853–61.
60. Berube D, Seralini GE, Gagne R, Hammond GL. Localization of the human sex hormone-binding globulin gene (SHBG) to the short arm of chromosome 17 (17p12–p13). *Cytogenet Cell Genet*. 1990;54(1–2):65–7.
61. Hammond GL, Underhill DA, Rykse HM, Smith CL. The human sex hormone-binding globulin gene contains exons for androgen-binding protein and two other testicular messenger RNAs. *Mol Endocrinol*. 1989;3:1869–76.
62. Nakhla AM, Hryb DJ, Rosner W, Romas NA, Xiang Z, Kahn SM. Human sex hormone-binding globulin gene expression—multiple promoters and complex alternative splicing. *BMC Mol Biol*. 2009;10:37.
63. Pinos T, Barbosa-Desongles A, Hurtado A, et al. Identification, characterization and expression of novel sex hormone binding globulin alternative first exons in the human prostate. *BMC Mol Biol*. 2009;10:59.
64. Selva DM, Hogeveen KN, Hammond GL. Repression of the human sex hormone-binding globulin gene in Sertoli cells by upstream stimulatory transcription factors. *J Biol Chem*. 2005;280(6):4462–8.
65. Selva DM, Bassas L, Munell F, et al. Human sperm sex hormone-binding globulin isoform: characterization and measurement by time-resolved fluorescence immunoassay. *J Clin Endocrinol Metab*. 2005;90(11):6275–82.
66. Joseph DR. Structure, function, and regulation of androgen-binding protein/sex hormone-binding globulin. *Vitam Horm*. 1994;49:197–280.
67. Hammond GL, Langley MS, Robinson PA. A liquid-phase immunoradiometric assay (IRMA) for human sex hormone binding globulin (SHBG). *J Steroid Biochem*. 1985;23(4):451–60.
68. Jänne M, Deol HK, Power SG, Yee SP, Hammond GL. Human sex hormone-binding globulin gene expression in transgenic mice. *Mol Endocrinol*. 1998;12(1):123–36.
69. Hong EJ, Sahu B, Janne OA, Hammond GL. Cytoplasmic accumulation of incompletely glycosylated SHBG enhances androgen action in proximal tubule epithelial cells. *Mol Endocrinol*. 2011;25(2):269–81.
70. Leinonen P, Hammond GL, Lukkarinen O, Vihko R. Serum sex hormone binding globulin and testosterone binding after estradiol administration, castration, and their combination in men with prostatic carcinoma. *Invest Urol*. 1979;17(1):24–7.
71. Cunningham SK, Loughlin T, Culliton M, McKenna TJ. The relationship between sex steroids and sex-hormone-binding globulin in plasma in physiological and pathological conditions. *Ann Clin Biochem*. 1985;22 (Pt 5):489–97.
72. Belgorosky A, Rivarola MA. Progressive decrease in serum sex hormone-binding globulin from infancy to late prepuberty in boys. *J Clin Endocrinol Metab*. 1986;63(2):510–2.
73. Belgorosky A, Rivarola MA. Changes in serum sex hormone-binding globulin and in serum non-sex hormone-binding globulin-bound testosterone during prepuberty in boys. *J Steroid Biochem*. 1987;27 (1–3):291–5.
74. Ibanez L, Potau N, Dunger D, de Zegher F. Precocious pubarche in girls and the development of androgen excess. *J Pediatr Endocrinol Metab*. 2000;13(Suppl 5):1261–3.
75. Pugeat M, Cousin P, Baret C, Lejeune H, Forest MG. Sex hormone-binding globulin during puberty in normal and hyperandrogenic girls. *J Pediatr Endocrinol Metab*. 2000;13(Suppl 5):1277–9.
76. Aydin B, Winters SJ. Sex Hormone Binding Globulin in Children and Adolescents. *J Clin Res Pediatr Endocrinol*. 2015;8(1):1–12.
77. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. *J Clin Endocrinol Metab*. 1996;81(5):1821–6.
78. Stomati M, Hartmann B, Spinetti A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. *J Endocrinol Invest*. 1996;19 (8):535–41.
79. Goto A, Chen BH, Song Y, et al. Age, body mass, usage of exogenous estrogen, and lifestyle factors in relation to circulating sex hormone-binding globulin concentrations in postmenopausal women. *Clin Chem*. 2014;60(1):174–85.
80. Karim R, Stanczyk FZ, Brinton RD, Rettberg J, Hodis HN, Mack WJ. Association of endogenous sex hormones with adipokines and ghrelin in postmenopausal women. *J Clin Endocrinol Metab*. 2015;100(2):508–15.
81. Brenta G, Schnitman M, Gurfinkiel M, et al. Variations of sex hormone-binding globulin in thyroid dysfunction. *Thyroid*. 1999;9(3):273–7.
82. Wang N, Zhai H, Zhu C, et al. Combined association of vitamin D and sex hormone binding globulin with nonalcoholic fatty liver disease in men and postmenopausal women: A cross-sectional study. *Medicine (Baltimore)*. 2016;95(4):e2621.
83. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. *J Clin Endocrinol Metab*. 1977;45(6):1211–9.
84. Estour B, Pugeat M, Lang F, Dechaud H, Pellet J, Rousset H. Sex hormone binding globulin in

- women with anorexia nervosa. *Clin Endocrinol (Oxf)*. 1986;24(5):571–6.
85. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. *J Clin Endocrinol Metab*. 1988;67(3):460–4.
 86. Holly JM, Dunger DB, Al-Othman SA, Savage MO, Wass JA. Sex hormone binding globulin levels in adolescent subjects with diabetes mellitus. *Diabet Med*. 1992;9(4):371–4.
 87. Daka B, Rosen T, Jansson PA, Rastam L, Larsson CA, Lindblad U. Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden. *Endocr Connect*. 2012;2(1):18–22.
 88. Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. *J Clin Invest*. 2007;117(12):3979–87.
 89. Weinberg ME, Manson JE, Buring JE, et al. Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women. *Metabolism*. 2006;55(11):1473–80.
 90. Janne M, Hammond GL. Hepatocyte nuclear factor-4 controls transcription from a TATA-less human sex hormone-binding globulin gene promoter. *J Biol Chem*. 1998;273(51):34105–14.
 91. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). *Nature*. 1996;384(6608):458–60.
 92. Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM. Identification of a binding motif specific to HNF4 by comparative analysis of multiple nuclear receptors. *Nucleic Acids Res*. 2012;40(12):5343–56.
 93. Winters SJ, Gogineni J, Karegar M, et al. Sex hormone-binding globulin gene expression and insulin resistance. *J Clin Endocrinol Metab*. 2014;99(12):E2780–8.
 94. Hertz R, Magenheim J, Berman I, Bar-Tana J. Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4alpha. *Nature*. 1998;392(6675):512–6.
 95. Dhe-Paganon S, Duda K, Iwamoto M, Chi YI, Shoelson SE. Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand. *J Biol Chem*. 2002;277(41):37973–6.
 96. Wisely GB, Miller AB, Davis RG, et al. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. *Structure*. 2002;10(9):1225–34.
 97. Petrescu AD, Hertz R, Bar-Tana J, Schroeder F, Kier AB. Ligand specificity and conformational dependence of the hepatic nuclear factor-4alpha (HNF-4alpha). *J Biol Chem*. 2002;277(27):23988–99.
 98. Sladek FM. What are nuclear receptor ligands? *Mol Cell Endocrinol*. 2011;334(1–2):3–13.
 99. Nayeem F, Nagamani M, Anderson KE, Huang Y, Grady JJ, Lu LJ. Dietary beta-tocopherol and linoleic acid, serum insulin, and waist circumference predict circulating sex hormone-binding globulin in premenopausal women. *J Nutr*. 2009;139(6):1135–42.
 100. Delarue J, Magnan C. Free fatty acids and insulin resistance. *Curr Opin Clin Nutr Metab Care*. 2007;10(2):142–8.
 101. Selva DM, Hammond GL. Thyroid hormones act indirectly to increase sex hormone-binding globulin production by liver via hepatocyte nuclear factor-4alpha. *J Mol Endocrinol*. 2009;43(1):19–27.
 102. Peter A, Kantartzis K, Machann J, et al. Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. *Diabetes*. 2010;59(12):3167–73.
 103. Shin JY, Kim SK, Lee MY, et al. Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. *Diabetes Res Clin Pract*. 2011;94(1):156–62.
 104. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest*. 2005;115(5):1343–51.
 105. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J Clin Invest*. 2006;116(7):1784–92.
 106. Simo R, Barbosa-Desongles A, Lecube A, Hernandez C, Selva DM. Potential role of tumor necrosis factor-alpha in downregulating sex hormone-binding globulin. *Diabetes*. 2012;61(2):372–82.
 107. Simo R, Barbosa-Desongles A, Hernandez C, Selva DM. IL1beta down-regulation of sex hormone-binding globulin production by decreasing HNF-4alpha via MEK-1/2 and JNK MAPK pathways. *Mol Endocrinol*. 2012;26(11):1917–27.
 108. Simo R, Saez-Lopez C, Lecube A, Hernandez C, Fort JM, Selva DM. Adiponectin upregulates SHBG production: molecular mechanisms and potential implications. *Endocrinology*. 2014;155(8):2820–30.
 109. Selva DM, Hammond GL. Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression. *Endocrinology*. 2009;150(5):2183–9.
 110. Mousavinab F, Tahtinen T, Jokelainen J, et al. The Pro12Aa polymorphism of the PPAR gamma 2 gene influences sex hormone-binding globulin level and its relationship to the development of the metabolic syndrome in young Finnish men. *Endocrine*. 2006;30(2):185–90.
 111. Regieli JJ, Jukema JW, Doevendans PA, et al. PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients. *Diabetes Care*. 2009;32(5):839–44.

112. Sridhar S, Walia R, Sachdeva N, Bhansali A. Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: A randomized double-blind placebo-controlled study. *Clin Endocrinol (Oxf)*. 2013;78(3):454–9.
113. Meikle AW, Stanish WM, Taylor N, Edwards CQ, Bishop CT. Familial effects on plasma sex-steroid content in man: Testosterone, estradiol and sex-hormone-binding globulin. *Metabolism*. 1982;31(1):6–9.
114. Gershagen S, Lundwall A, Fernlund P. Characterization of the human sex hormone binding globulin (SHBG) gene and demonstration of two transcripts in both liver and testis. *Nucleic Acids Res*. 1989;17:9245–58.
115. Gershagen S, Henningson K, Fernlund P. Subunits of human sex hormone binding globulin. Interindividual variation in size. *J Biol Chem*. 1987;262:8430–7.
116. Cousin P, Dechaud H, Grenot C, Lejeune H, Pugeat M. Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. *J Clin Endocrinol Metab*. 1998;83(1):235–40.
117. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. *N Engl J Med*. 2009;361:1152–63.
118. Pang XN, Yuan Y, Sun Y, Shen JP, Zha XY, Hu Y. The relationship of sex hormone-binding globulin (SHBG) gene polymorphisms with serum SHBG level and metabolic syndrome in Chinese Han males. *Aging Clin Exp Res*. 2014;26(6):583–9.
119. Hogeveen KN, Talikka M, Hammond GL. Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA) n repeat element within an Alu sequence. *J Biol Chem*. 2001;276(39):36383–90.
120. Xita N, Tsatsoulis A. Genetic variants of sex hormone-binding globulin and their biological consequences. *Mol Cell Endocrinol*. 2010;316(1):60–5.
121. Xita N, Milionis HJ, Galidi A, et al. The (TAAAA) n polymorphism of the SHBG gene in men with the metabolic syndrome. *Exp Clin Endocrinol Diabetes*. 2011;119(2):126–8.
122. Xita N, Tsatsoulis A, Chatzikiyriakidou A, Georgiou I. Association of the (TAAAA) n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. *J Clin Endocrinol Metab*. 2003;88(12):5976–80.
123. Perry JR, Weedon MN, Langenberg C, et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. *Hum Mol Genet*. 2010;19(3):535–44.
124. Riancho JA, Valero C, Zarrabeitia MT, Garcia-Unzueta MT, Amado JA, Gonzalez-Macias J. Genetic polymorphisms are associated with serum levels of sex hormone binding globulin in postmenopausal women. *BMC Med Genet*. 2008;9:112-2350-9-112.
125. Wickham EP, 3rd, Ewens KG, Legro RS, Dunaif A, Nestler JE, Strauss JF, 3rd. Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2011;96(4):E719–27.
126. White MJ, Eren F, Agirbasli D, Williams SM, Agirbasli M. SHBG gene polymorphism (rs1799941) associates with metabolic syndrome in children and adolescents. *PLoS ONE*. 2015;10(2):e0116915.
127. Eriksson AL, Lorentzon M, Mellstrom D, et al. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. *J Clin Endocrinol Metab*. 2006;91:5029–37.
128. Jin G, Sun J, Kim ST, et al. Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. *Hum Mol Genet*. 2012;21(23):5222–8.
129. Thompson DJ, Healey CS, Baynes C, et al. Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2008;17(12):3490–8.
130. Vos MJ, Mijnhout GS, Rondeel JM, Baron W, Groeneveld PH. Sex hormone binding globulin deficiency due to a homozygous missense mutation. *J Clin Endocrinol Metab*. 2014;99(9):E1798–802.
131. Chen C, Smothers J, Lange A, Nestler JE, Strauss JF, Wickham III EP. Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. *Minerva Endocrinol*. 2010;35(4):271–80.
132. Sarne DH, Refetoff S, Rosenfield RL, Farriaux JP. Sex hormone-binding globulin in the diagnosis of peripheral tissue resistance to thyroid hormone: the value of changes after short term triiodothyronine administration. *J Clin Endocrinol Metab*. 1988;66(4):740–6.
133. Legrand E, Hedde C, Gallois Y, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. *Bone*. 2001;29(1):90–5.
134. Varsavsky M, Reyes-Garcia R, Garcia-Martin A, Gonzalez-Ramirez AR, Aviles-Perez MD, Munoz-Torres M. SHBG levels are associated with bone loss and vertebral fractures in patients with prostate cancer. *Osteoporos Int*. 2013;24(2):713–9.
135. Vanderschueren D, Laurent MR, Claessens F, et al. Sex steroid actions in male bone. *Endocr Rev*. 2014;35(6):906–60.
136. Zha XY, Hu Y, Pang XN, Zhu JH, Chang GL, Li L. The association between sex hormone-binding globulin gene polymorphism with bone mineral density. *Steroids*. 2016;106:9–18.
137. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. *J Clin Endocrinol Metab*. 2007;92(9):3568–72.

138. Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. *Diabetes Care*. 2010;33(7):1618–24.
139. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. *Diabetes Care*. 1994;17(5):405–11.
140. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. *Diabetes Care*. 2000;23(4):490–4.
141. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. *Int J Epidemiol*. 2011;40(1):189–207.
142. Haring R, Volzke H, Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: Results from the study of health in Pomerania. *Diabetes*. 2009;58(9):2027–31.
143. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. *Clin Endocrinol (Oxf)*. 2013;78(3):321–9.
144. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. *Diabetes Obes Metab*. 2004;6(3):208–15.
145. Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. *Ther Adv Endocrinol Metab*. 2010;1(5):207–23.
146. Antonio L, Wu FC, O'Neill TW, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. *J Clin Endocrinol Metab*. 2016: jc20154106.
147. Hammond GL, Nisker JA, Jones LA, Siiteri PK. Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. *J Biol Chem*. 1980;255(11):5023–6.
148. Hammoud A, Gibson M, Hunt SC, et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. *J Clin Endocrinol Metab*. 2009;94(4):1329–32.
149. Pellitero S, Olaizola I, Alastrue A, et al. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. *Obes Surg*. 2012;22(12):1835–42.
150. Mora M, Aranda GB, de Hollanda A, Flores L, Puig-Domingo M, Vidal J. Weight loss is a major contributor to improved sexual function after bariatric surgery. *Surg Endosc*. 2013;27(9):3197–204.
151. Calderon B, Galdon A, Calanas A, et al. Effects of bariatric surgery on male obesity-associated secondary hypogonadism: comparison of laparoscopic gastric bypass with restrictive procedures. *Obes Surg*. 2014;24(10):1686–92.
152. Mihalca R, Copaescu C, Sirbu A, et al. Laparoscopic sleeve gastrectomy improves reproductive hormone levels in morbidly obese males—a series of 28 cases. *Chirurgia (Bucur)*. 2014;109(2):198–203.

An Ensemble Perspective of Aging-Related Hypoandrogenemia in Men

16

Peter Y. Liu MBBS, PhD, FRACP, Paul Takahashi MD
and Johannes D. Veldhuis MD

Contents

Overview	325
Role of Intrinsic GnRH Deficiency in Mediating Low-amplitude LH Secretion	326
Contribution of Primary Leydig-Cell Steroidogenic Failure	328
Alterations in Testosterone Feedback Restraint	329
Regulation of the Ensemble Hypothalamo-Pituitary-Leydig Cell Axis	331
Sampling and Counting of Pulses	332
Gonadotrope Responsiveness to GnRH	332
Accelerated LH Pulse Frequency in the Aging Male Monitoring Unobserved Gonadotropin Secretion	334
Regularity Analysis	337
Appraising Testosterone Signaling	337
Summary	340
References	340

Overview

Androgen deficiency in men is associated with reduced physical stamina, relative sarcopenia, osteopenia, visceral obesity, sexual dysfunction, depressed mood, reduced sense of well-being and detectable cognitive impairment [1–10]. Carefully titrated testosterone therapy to increase testosterone concentrations from low- to the mid-normal young eugonadal reference range moderately improves sexual desire in otherwise healthy aging men with and without symptomatic low libido [11]. Impoverished testosterone production in the older male has been affirmed by (i) direct sampling of the human spermatic vein; (ii) cross-sectional analysis, including meta-analysis, of epidemiological data from many geographically diverse but predominantly Caucasian populations; and (iii) longitudinal investigations in some of these healthy populations [12–20]. For example, the European SENIEUR and Massachusetts Male Aging Cohort studies inferred that bioavailable (nonSHBG-bound) testosterone concentrations decline by 0.8–1.3% annually [14, 21]; the European Male Aging cohort showed a 1.3% annual decline in free testosterone [19]; and, a 15-year prospective analysis in New Mexico observed that total testosterone concentrations fall by 110 ng/dL per decade in men after age 60 [15, 22]. The rate of fall in testosterone can vary by as much as fourfold

P.Y. Liu
Division of Endocrinology, Department of Medicine,
Harbor-UCLA Medical Center, 1000 West Carson
St., PO Box 446, Torrance, CA 90509, USA
e-mail: pliu@labiomed.org

P. Takahashi
Department of Medicine, Mayo Clinic, 200 First St
SW, Rochester, MN 55905, USA
e-mail: takahashi.paul@mayo.edu

J.D. Veldhuis (✉)
Department of Internal Medicine, Department of
Endocrinology, Endocrine Research Unit, Mayo
Clinic College of Medicine, Mayo Clinic Rochester,
200 First Street SW, Rochester, MN 55905, USA
e-mail: Veldhuis.Johannes@mayo.edu

when the same cohort is examined longitudinally, instead of cross-sectionally. This discrepancy is only partly explained by concurrent longitudinal changes in weight [17, 19, 20]. Surgery, trauma, stress, systemic illness, medication use, and chronic institutionalization are also associated with heightened androgen depletion in elderly individuals [6, 8, 14, 23–26]. A possible unifying mechanism underpinning these diverse associations is that inflammation, in particular interleukin-2, induces androgen depletion through enhanced feedback inhibition of LH secretion in older men [27]. However, the fundamental mechanisms that mediate waning testosterone secretion in aging men are only partly understood. Indeed, a unified physiological concept has been difficult to develop in this arena, partly due to confounding by obesity or factors associated with obesity such as insulin resistance.

Available data point to an array of contributing mechanisms underlying relative androgen depletion in the older male [28–39]. Primary (nonexclusive) considerations include reduced hypothalamic GnRH outflow, limited gonadotrope secretory capacity, impaired Leydig-cell steroidogenesis, and anomalous androgen-directed feedback control [39–44].

As a unifying approach, the male gonadal axis is viewed as an adaptive neuroendocrine ensemble. In this broader concept, testosterone availability is adjusted on a minute-by-minute basis by repeated decremental and incremental signaling interactions among GnRH, LH, and testosterone (Fig. 16.1). Simplified biomathematical simulations based on this network-like perspective predict that hypoandrogenemia and altered LH secretion in aging could arise singly or jointly by way of: (i) attenuated hypothalamic GnRH feedforward drive (albeit not acting alone); (ii) impaired Leydig-cell steroidogenesis; and/or (iii) reduced negative feedback by testosterone [45–47]. Figure 16.2 highlights the foregoing primary mechanistic considerations.

Model of GnRH-LH-Testosterone Ensemble





Fig. 16.1 Simplified schema of the GnRH-LH-testosterone (hypothalamo-pituitary-Leydig cell) axis with feedback (–, inhibitory) and feedforward (+, stimulatory) interactions mediated via specific interface (dose-response) functions

Role of Intrinsic GnRH Deficiency in Mediating Low-amplitude LH Secretion

Experiments in the male mouse and rat support an important (but not exclusive) role of GnRH-deficient hypogonadotropism in the hypoandrogenemia of aging [48–51]. Evidence to this end includes: (i) decreased castration-, naloxone-, and restraint stress-induced LH release in the older rodent [30, 49, 52–54]; (ii) diminished *in vivo* LH pulse amplitude in senescent animals [50, 55]; (iii) reduced *in vitro* hypothalamic GnRH secretion [56, 57]; (iv) altered GnRH neuronal synaptology [58]; (v) preservation of the stimulatory efficacy of GnRH [50, 59]; and (vi) restoration of sexual activity in the impotent animal by fetal

Fig. 16.2 Primary loci of postulated regulatory defects in the GnRH-LH-testosterone ensemble axis in aging men



hypothalamic neuronal transplantation [60]. Although such observations afford important clues for clinical investigation, the regulation of GnRH outflow in the laboratory animal is complex, multifactorial, incompletely defined, and not necessarily equivalent to that of the human male.

The intuition that hypothalamic GnRH deficiency subserves relative hypogonadism in elderly men has not been established or refuted [28, 32, 34, 61–64]. However, the notion is congruent with many clinical observations, as highlighted in Table 16.1. A necessary (but not sufficient) prediction is that GnRH action on gonadotropes is preserved. A recent prospectively randomized, interventional study used 14 days of pulsatile, i.v., infusion of GnRH

versus saline to stimulate LH and testosterone secretion. Older and young men treated with this regimen achieved an equivalent elevation of 24-h LH concentrations (Fig. 16.3a) consistent with retention of gonadotrope secretory responsiveness in the older male [34]. In young men, the increment in mean LH concentrations elicited a proportionate rise in testosterone production. On the other hand, the same average increase in LH immunoreactivity in aged individuals failed to augment total (Fig. 16.3b) as well as bioavailable and free testosterone concentrations equivalently. The latter age-related contrast would point to an abnormal pulsatile LH signal (of equivalent mean concentration only), relatively defective Leydig-cell responsiveness and/or accelerated testosterone metabolism in older men. The last

Table 16.1 Indirect evidence for impaired GnRH drive in the aging male

	Human	Rodent
1. Low-amplitude spontaneous LH pulses	[28, 29, 32–34, 45–47, 62]	[31, 48, 50, 51, 55, 57, 152]
2. Normal or increased LH secretory responsiveness to, i.v., GnRH pulses	[34, 54, 61, 113, 153]	[40, 43, 59, 154]
3. Blunted unleashing of pulsatile LH secretion by sex-hormone depletion, opiate-receptor blockade, androgen receptor blockade or stress	[63, 86–88]	[29, 30, 34, 49, 50, 52, 54, 56, 58–61, 91, 152, 153, 155–158]
4. Age-comparable LH bioactivity	[32, 40, 63, 74, 87, 159–163]	
5. Quantifiably disorderly LH release	[34, 36, 46, 47, 88–90, 137]	
6. Asynchrony of neurohormone outflow	[37, 38, 136, 139]	
7. Mathematical ensemble predictions	[45–47, 97]	




Fig. 16.3 **a** GnRH dose-response stimulation of (2-h mean) serum concentrations of LH (*top*), FSH (*middle*) and free (*uncombined*) alpha subunit (*bottom*) in young men (*interrupted lines*) and older volunteers (*solid lines*). Data are the mean \pm SEM. Adapted with permission from [113]. **b** Relationship between the increment in 24-h mean concentrations of LH (*x axis*) and testosterone (*y axis*) induced by 14 days of uninterrupted pulsatile, i.v., GnRH infusion (100 ng/kg every 90 min) compared with saline in young men (*upper interrupted curve and plus signs*). There is no correlation in older men (*lower continuous line and solid circles*). Adapted from [34]

(kinetic) consideration is excluded by the age-related fall in the metabolic clearance rate of testosterone that is partly due to higher SHBG concentrations [40, 42, 43, 65].

These earlier findings have been verified in a complementary experiment wherein 18 healthy men aged 23–72 years underwent graded

suppression of LH secretion through four escalating doses of ganirelix (0, 0.1, 0.3, and 1 mg/m²), a specific GnRH receptor antagonist [66]. Sixteen hours after subcutaneous administration of ganirelix, a submaximal dose of intravenous GnRH (100 ng/kg) was injected, and blood sampling was continued for a further 3 h. Increasing age attenuated the ability of ganirelix to decrease endogenous pulsatile LH secretion, but did not impact competitive interaction between ganirelix and injected GnRH. These joint outcomes suggest that age diminishes GnRH outflow without impairing GnRH action in healthy men. Further modeling confirmed that advanced age was associated with lower GnRH efficacy normalized to free testosterone and also revealed potentiated (maximal and graded) negative feedback by testosterone on hypothalamic GnRH secretion [67].

Contribution of Primary Leydig-Cell Steroidogenic Failure

Anatomical studies document an attrition of Leydig-cell number in the older male [68]. From a functional perspective, pharmacological stimulation with hCG does not induce maximal young-adult concentrations of testosterone in many elderly men [24, 28, 69–72]. Nonetheless, current hCG paradigms are difficult to interpret on experimental and physiological grounds; for example, (i) unequal concomitant (endogenous) LH concentrations among individuals may confound testicular responses to hCG [13, 24, 30, 71, 72]; (ii) the half-life of circulating hCG is approximately 20–30 h compared with 0.75–1.5 h for LH; indeed, the former kinetics abrogate normal intermittent stimulation of the testis [45, 73, 74]. This distinction is relevant, since each pulse of LH normally evokes a prompt burst of testosterone release, as monitored directly in the human spermatic vein [75, 76]; (iii) the nearly irreversible binding of hCG to the gonadal LH receptor downregulates steroidogenesis *in vitro* and *in vivo* [77, 78]; and (iv) the magnitude of hCG drive limits clinical evaluation to maximal Leydig-cell, responsiveness.

An equivalently sustained and potent lutropic stimulus is never achieved physiologically *in vivo*, except under maternal hCG exposure in the developing fetus [40, 42].

A second means of appraising Leydig-cell responsiveness is cross-correlation analysis of LH and (time-delayed) testosterone concentrations in paired hormone time series [79]. Comparisons by age disclose a young adult-like time lag of 30–40 min but significantly reduced feedforward coupling between LH and testosterone in older men. The latter distinction is reflected in a 50% reduction in the cross-correlation coefficient [33, 35].

A third experimental strategy to examine Leydig-cell steroidogenic capacity is to down-regulate gonadotropin secretion with a GnRH analog and then add back pulses of rh LH, *i.v.*, to emulate physiological patterns of gonadotropin stimulation. In this paradigm, LH withdrawal enforced by pituitary down-regulation impairs testosterone secretory responsiveness profoundly in both age groups, albeit twofold more in elderly men [80].

A fourth-interventional model (Fig. 16.4) is to administer a maximal dose of a selective GnRH receptor antagonist (ganirelix) to suppress all endogenous LH secretion, and then infuse successive, *i.v.*, pulses of rh LH to replicate normal LH on testosterone physiology [81–84]. Using this paradigm, pulsatile recombinant human (rh) LH infusions for 48 h designed to mimic both the pattern (every 2 h) and extent of young male LH secretion revealed lower mean and incremental and interpeak testosterone concentrations in 8 older (aged 60–73) compared with 13 young (aged 19–30) men [82]. These age relationships were confirmed in 15 healthy men aged 22–78 years across a tenfold range of amplitude varying, and not supraphysiological, pulses of rh LH administered across a 20-h period [83]. A further analysis of 92 healthy men aged 18–75 years who received various combinations of wide-ranging but not supraphysiological pulses of rh LH show that aging attenuates LH efficacy and testis sensitivity as well as augments Leydig cell downregulation [84].


Alterations in Testosterone Feedback Restraint

Whether or how sex-steroid negative feedback is altered in older men is controversial. For example, three clinical studies report heightened negative feedback by exogenous androgens in the aging male. These analyzes were based on short-term, *i.v.*, infusion of testosterone or dihydrotestosterone (over days), longer term trans-crotal delivery of testosterone (for 11 months), and transdermal supplementation with 5 alpha-dihydrotestosterone (for 15 months) [39, 44]. Two other investigations describe reduced androgen feedback efficacy in the older male after several weeks of intramuscular injection of a high dose of testosterone [61, 85]. Using a novel matched testosterone addback paradigm, experiments showed that aging may impair *both* positive and the negative actions of systemic testosterone on pulsatile LH secretion [86]. Specifically, stepwise testosterone repletion across the hypogonadal to eugonadal range in 23 men aged 19–71 years revealed that age attenuated both the ability for increasing testosterone concentration to increase LH secretory burst mass and to decrease LH secretory burst frequency.

Two interventional studies using an estrogen- or androgen-receptor antagonist, and one biomathematical construct, infer reduced LH secretory adaptations to muted sex-steroid feedback in elderly men [63, 87, 88]. Recent studies show that aging mutes unleashing of LH secretion by androgen-receptor blockade using a fourth-generation biomathematical construct [89, 90]. From another vantage, cross-correlation analysis of 24-h (paired) LH and testosterone concentration profiles identifies impaired negative feedback by *endogenous* androgen in older volunteers [35]. And based on immuno-cytochemical detection, androgen (and estrogen) receptors may decline in the brain and pituitary gland of aged rats, and in genital fibroblasts of older men [91, 92].

Prominent adaptations to experimental androgen depletion in young men are accelerated frequency and reduced incremental amplitude of LH


Fig. 16.4 Illustrative profiles of (paired) LH (*top*) and Te (*bottom*) concentrations sampled every 10 min for 24 h in a healthy young (*upper*) and older (*middle*) man on the second day of pulsatile iv infusion of rh LH and concomitant ganirelix administration [see text]. For comparison, LH and Te concentrations during ganirelix administration and iv addback of saline in a young subject are also shown (*lower*). Interrupted horizontal lines mark the lower 2.5% normal bounds of LH (2 IU/L) and Te (385 ng/dL) concentrations in young adults. Multiply Te values in ng/dL by 0.0347 to obtain units of nmol/L



pulses (Fig. 16.5a) and quantitatively irregular patterns of LH release [88, 93–95]. The neuroendocrine phenotype in older men includes each of the foregoing feedback adjustments [33, 34, 36, 37, 62]. Thus, a facile hypothesis is that lower bioavailable and free testosterone concentrations in the elderly male are the proximate cause of unleashing anomalous LH secretion patterns. However, quite unlike the feedback-deprived state, basal, pulsatile, and total LH secretion remain normal in many healthy older men [45, 46] (Fig. 16.5b). Accordingly, an important but unresolved mechanistic issue is how neuroendocrine disturbances in aging

individuals reflect expected feedback withdrawal due to hypoandrogenemia [43]. This question becomes important, inasmuch as testosterone repletion in androgen-deficient young men reverses each of rapid-frequency, diminutive-amplitude, and disorderly LH secretion [88, 93, 94].

One potential mechanism might relate to inflammation. Infusion of IL-2, which is an important inflammatory mediator, seems to potentiate the proportionate feedback inhibition of testosterone on LH in older men [27]. If verified, these data point to a possible interaction between age and concomitant comorbidities that



◀ **Fig. 16.5** Comparison of LH secretory attributes in young and older men based on a variable-waveform model that allows a freely varying basal secretion rate. **a** Impact of age on LH pulse frequency (events/day) and LH secretory burst mass (IU secreted per pulse per L of distribution volume). **b** Deconvolution estimates of basal (*top*), pulsatile (*middle*), and total (*bottom*) daily LH secretion in young and older men. Numerical values are the mean ± SEM (median). *P* values are estimated by the rank-sum test. *P* = NS denotes <0.05 . Adapted from [45]

cause inflammation. These data support the hypothesis that both age and comorbidities are associated with the age-related decline in testosterone.

Regulation of the Ensemble Hypothalamo-Pituitary-Leydig Cell Axis

An emergent thesis in neuroendocrine research is that early disruption of (negative) feedback and/or (positive) feedforward activation may occur without any demonstrable change in overall hormone production [34, 36, 41, 46, 47]. The foregoing insight is relevant to understanding early disarray of the hypothalamo-pituitary-gonadal axis in aging. Therein, we adopt the basic precept that repeated, dose-dependent, time-delayed adjustments among regulatory sites govern systemic androgen availability in a homeostatic fashion [45, 76, 96–103]. To aid intuition, we have formalized core feedback connections among GnRH, LH, and testosterone mathematically [45, 95–97]. A simplified model structure predicts that jointly impaired feedforward by LH, and feedback by testosterone (in part through aromatization to estradiol), would yield a high-frequency, low-amplitude, and disorderly pattern of LH release. A recent adaptation allows, but does not enforce, pulse-by-pulse hysteresis wherein the dose-response relationship during the ascending and descending phase of the response pulse peak is allowed to differ (Fig. 16.6) [104, 105]. On the other hand, isolated failure of GnRH outflow would explain only inappropriately low

Schema of Hysteretic Dose-Response Model




Fig. 16.6 Schema of dose-response hysteresis concept. Hormone (effector) concentrations within a pulse (*top left*) drive target-gland secretion rates (*top right*). The relationship between input (concentration) and output (secretion) is estimated as a dose-response logistic function (*below*). The onset (*solid arrows*) and recovery (*open arrows*) phases of the dose-response interface are estimated simultaneously with a hysteresis inflection point (delay time)

LH concentrations and attendant hypoandrogenemia, but not an elevated LH pulse frequency or irregular release patterns [46, 47]. Exploration of this ensemble concept requires more focused assessment of physiological regulation, as highlighted next.

Sampling and Counting of Pulses

The frequency and amplitude of LH pulses provide a window to signals from the brain and pituitary gland. Withdrawal of blood at 5 or 10-min intervals for 12–24 h will capture the majority of discrete LH release episodes in healthy men [40, 106–110]. Suitable monitoring paradigms define an accelerated frequency and attenuated amplitude of pulsatile LH release in older men by independent methods of pulse

detection, in separate gonadotropin assays and among different volunteer cohorts [34, 46, 47, 62, 111]. Figure 16.7 illustrates comparisons by age of immune-radiometric LH concentration times series collected every 10 min over 24 h [33]. Some, but not all, earlier analyzes using radioimmunoassay methods and/or less frequent (e.g., 20-min) blood-sampling protocols presaged the concept of lower amplitude and higher frequency LH peaks in older men [24, 40–42]. Recent biomathematical simulations establish that failure to detect either a loss of amplitude or a gain in frequency of LH pulses is a predictable technical artifact of insufficiently intensive blood sampling (Fig. 16.8).


Gonadotrope Responsiveness to GnRH

Viewed mechanistically, a 50% reduction in incremental (peak minus nadir) LH pulse amplitude in aging men could denote a diminished amount of hypothalamic GnRH secreted per burst, an abnormal GnRH waveform and/or impaired gonadotrope-cell responsiveness to GnRH. Recent GnRH dose-response analyzes conducted in randomly assigned order on separate days establish normal maximal, and enhanced submaximal, acute and short-term (14-day) stimulatory effects of GnRH in the elderly male [34, 112, 113]. Heightened sensitivity to small amounts of GnRH occur predictably in the presence of augmented pituitary LH stores in older individuals, as inferred post mortem. Furthermore, pituitary sensitivity to a wide 300-fold range of intravenously administered pulses of GnRH is age-invariant when testosterone exposure is matched at a physiological concentration, or when a single submaximal GnRH dose is assessed across matching graded degrees of androgen repletion [86, 114].

Accelerated LH Pulse Frequency in the Aging Male

A basic, unresolved mechanistic issue is whether aging causes a primary hypothalamic disturbance

Fig. 16.7 Diminution in LH secretory burst mass and acceleration of LH pulse frequency in aging when compared with young men inferred by two deconvolution methods [47]. LH concentration profiles (\pm sample SD's) measured in serum collected every 10 min for 24 h and analyzed by immuno-radiometric assays and variable-waveform (stochastic differential equation (SDE) based) deconvolution analysis (predicted continuous curve) [45]




that enforces a high frequency of GnRH pulses, and/or whether low bioavailable testosterone concentrations elevate LH pulse frequency via feedback withdrawal [33, 41–43, 47, 62]. This query is central to contemporary physiological assessments of aging, inasmuch as earlier investigations in healthy young men document that (i) infusion of testosterone or a nonaromatizable androgen suppress LH pulse frequency and elevate LH peak amplitude [30, 102, 115, 116]; and (ii) administration of ketoconazole (which depletes testosterone) or flutamide (which inhibits androgen-receptor binding) augments LH pulse frequency and reduces incremental LH peak (fractional) amplitude [93, 94, 117]. In the human, monkey, sheep and rat, a high frequency of GnRH stimuli reduces incremental (fractional)

LH pulse amplitude [43, 55]. In view of this reciprocal control mechanism (albeit not fully understood), diminished androgen bioavailability in older men could contribute in principle to both more rapid and lower amplitude LH pulses. What remains unknown is whether hypoandrogenemia in aging fully accounts for the observed neuroendocrine changes.

The time pattern of LH secretion within the physiological range is now directly known to influence testosterone response [118, 119]. Nineteen healthy men aged 18–49 years received four infusions in random order: saline, and continuous, hourly and second hourly rh LH matched for total dose infused over the entire 12-h period. Hourly, rh LH exposure resulted in higher testicular secretory sensitivity, greater rh

Fig. 16.8 Undersampling of LH release sensors detection of LH pulses (*top*) and inflates estimates of LH secretory burst mass. The resultant technical bias limits the identification of age-related contrasts in pulse frequency and size. 24 LH concentration time series were edited from original 10-min sampling sets to yield 30-min daughter series (simple subsets) in 11 young and 13 older men. Unpublished reanalysis of data in [34, 35, 62] (Bradford, Kuipers and Veldhuis)






LH potency, greater pulsatile testosterone secretion and faster half-time of appearance of peak testosterone. These data show that the time pattern of LH secretion enforces quantifiable differences in testosterone secretory dynamics, and suggests but does not prove that the increased frequency of LH pulses with age is an adaptive response to maintain testosterone output.

Monitoring Unobserved Gonadotropin Secretion

Lower incremental LH peak amplitude in older men can be dissected further mechanistically under the premise that fluctuating hormone concentrations are driven by specific (unobserved) secretion and kinetic processes. Deconvolution analysis is a family of computer-assisted methods designed to quantitate underlying secretion and/or elimination. Some deconvolution procedures allow one to determine the

following: (i) the frequency of secretory bursts; (ii) the amount of hormone released within each burst [mass of hormone discharged within the event normalized to unit distribution volume]; (iii) the subject- and condition-specific half-life of elimination of the hormone; and (iv) concomitant basal or (nonpulsatile) secretion.

There are several complementary deconvolution approaches to secretion analysis. Figure 16.9a illustrates one basic idea, wherein an unobserved Gaussian-shaped secretory burst creates each peak in serum hormone concentrations [120]. In this *waveform-dependent* concept, hormone concentrations increase rapidly due to the sharp onset of an underlying secretory burst, and then fall gradually after the burst, as the hormone is eliminated slowly from the circulation. The Gaussian-burst model allows one to calculate the number, location, duration, and amplitude of secretory bursts and predict the hormone half-life at the same time [121, 122]. Application of this methodology in healthy men quantitates a lower mass and higher frequency



◀ **Fig. 16.9** Concept of deconvolution analysis as a family of methods designed to quantitate unobserved secretion and/or kinetics from fluctuating hormone concentrations. **a** A *Gaussian* or slightly skewed *secretory burst model* (*top left*) provides estimates of time-delimited, burst-like discharge of molecules with individual release velocities driving a pulse. A secretory burst is defined by its position in time, maximum (amplitude), and half-duration (duration at half-maximal height) [120, 122]. The time integral of the convolution product of the secretory burst (*left*) and disappearance function (*middle*) yields the pulsatile hormone concentration (*right*). The reverse process of deducing underlying secretion and elimination from observed concentrations is termed deconvolution analysis. **b** A *waveform-independent approach* allows one to

calculate sample secretion rates (*bottom*) from measured hormone concentrations (*top*) based on a priori biexponential kinetics (*interrupted decay curves*). Experimental errors inherent in hormone measurements and the populational half-life estimate are combined to determine statistical confidence limits for each sample secretion rate [121, 123]. **c** Flexible deconvolution construct of a *generalized Gamma-density (variable) secretory-pulse waveform* is utilized to encapsulate burst timing, number, shape and size, basal secretion, and rapid and slow-phase hormone elimination kinetics simultaneously with random effects [95, 97]. Random effects arise from sampling uncertainty, assay error, stochastic admixture of secreted hormone in the bloodstream, unpredictable pulse times and varying effector-response interface properties [46, 96]

of LH secretory events in older than young men, but a comparable LH half-life [33, 41, 62]. The lower mass (IU) of LH released per secretory burst in the elderly male is due to attenuation of the amplitude (maximal secretion rate attained) rather than abbreviation of the duration (min) of release episodes.

A second-generation deconvolution technology defines secretion as an admixture of unknown basal output and superimposed events of any height, width, shape, and number [121] (Fig. 16.9b). This deconvolution construct is therefore defined as *waveform-independent*. For statistical reasons, optimal analysis in this methodology requires a priori knowledge of the two-component half-life of hormone elimination [123]. Because the true waveform of secretory bursts is (definitionally) unknown, definitive pulse counting is analytically difficult unless assumptions are made in fact about event shape, smoothness, location, or number [122]. However, this mathematical strategy likewise predicts lower peak rates of LH secretion in older men.

A third-generation deconvolution strategy uses coupled, stochastic differential equations to reconstruct simultaneously the number, shape, size, and timing of (unknown) secretory bursts, the basal release rate, biexponential disappearance kinetics and random effects driving hormone release [96, 97] (Fig. 16.9c). This comprehensive statistical platform predicts a lower mass and higher frequency of LH secretory bursts in older

than young men with no age difference in LH kinetics [45, 47, 95]. Estradiol but not age per se reduces LH bioactivity in vitro and prolongs LH metabolic clearance rate in vivo [73, 124]. The diminution in mass and acceleration in frequency of LH pulses tend to counterbalance closely, thus leaving the total and pulsatile daily LH secretion rate unchanged in aging individuals.

The fourth-generation deconvolution strategy allows for computer automation by comparing all possible pulse sets and objectively choosing the best model fit using mathematically validated criteria (e.g., Akaike Information Criterion) [105]. This method has been mathematically and empirically validated in three mammalian species [125, 126]. Future advances being investigated include allowing for pulse-by-pulse flexibility in pulse shape [105].

Contemporary secretion-based insights explain some earlier observations. For example, one method of discrete hormone peak detection, Cluster analysis, identifies a pulse simply as a statistical jump and drop in the hormone concentration [40, 127]. This approach is termed model-free, since few assumptions are made in defining a pulse. Deconvolution analysis illustrates that the peak increment is proportionate to the mass of hormone secreted in the burst *ceteris paribus* [122, 123, 128]. This point is important, since elderly men consistently exhibit a lower incremental LH peak amplitude compared with young counterparts [34, 95].

Regularity Analysis

Homeostasis within an endocrine axis requires repeated decremental and incremental adjustments in secretion [46, 96, 97] (Fig. 16.1). In the male gonadal axis, core homeostatic signals include (at least) GnRH, LH, and testosterone, which enforce adaptations over a rapid (minute-by-minute) time course [129]. Orderliness of the resultant subpatterns of hormone release can be quantitated objectively via a regularity statistic, approximate entropy (ApEn) [36, 130–132]. ApEn is calculated on a desktop computer as a single number, which exploits accurate probabilistic accounting to quantitate the reproducibility of successive measurements in a time series [133] (Fig. 16.10a). Higher ApEn denotes heightened irregularity of minute-by-minute hormone release, which in turn signifies deterioration or adaptation of feedback and feedforward adjustments [131, 134, 135].

In a clinical context, ApEn identifies disorderly patterns of hormone release, which denotes autonomy from normal regulatory adjustments [26, 131]. In addition, ApEn delineates irregular secretion of LH, testosterone, GH, ACTH, cortisol, and insulin in older compared with young individuals, thus defining age-related deterioration of adaptive control [34, 36–38, 41, 88, 136] (Fig. 16.10b). For example, elevated ApEn of LH and testosterone release patterns unmask disruption of one or more key signaling elements within the interlinked GnRH-LH-testosterone axis [36, 46, 47, 134]. Interventional studies are necessary to localize the individual and joint sites of statistically inferred regulatory defects. Under such a paradigm, aging attenuated the capability of graded testosterone addback to regularize LH secretion patterns under endogenous GnRH, but not under fixed exogenous GnRH [137]. Accordingly, these data point to impaired negative feedback at a hypothalamic locus.

The cross-ApEn statistic extends the concept of appraising single-hormone regularity to quantitating two-hormone (pairwise) synchrony [36]. Cross-ApEn unveils significant loss of bihormonal synchrony between LH and testosterone secretion in older men (Fig. 16.10c). This

measure further documents deterioration of coordinate patterns of LH release and oscillations of each of prolactin, FSH, nocturnal penile tumescence (NPT), and sleep stage [37, 46, 47]. According to this idea, brainstem regulatory centers oversee synchronous secretion of GnRH, LH, FSH, and prolactin, sleep-stage transitions and autonomic control of NPT cycles. Aging symmetrically erodes both feedback (testosterone on LH) and feedforward (LH on testosterone) linkages in the unperturbed state, as well as when perturbed by graded GnRH receptor blockade [138, 139]. Thus, the foregoing findings establish multilevel disruption of CNS-dependent neurohormone outflow in older men.

Appraising Testosterone Signaling

To date, the majority of clinical studies have utilized the total testosterone concentration to assess androgen-dependent negative feedback on the hypothalamo-pituitary unit [42, 43]. However, in men total testosterone is distributed in plasma as free (approximately 2%), weakly albumin-bound (50–55%) and tightly globulin-bound (40–45%) steroid [140, 141]. Rapid dissociation of testosterone from low-affinity albumin (nominal unidirectional half-time 0.2 s at 37 C) would favor effectual tissue uptake within a brief (2–10 s) capillary transit time, so long as reassociation is minimized [142]. On the other hand, slow release of testosterone from high-affinity sex-hormone binding globulin (SHBG) [half-time 3.3 s at 37 C] would putatively restrict access to cells, at least when reassociation is limited. Protein-binding effects are important, since SHBG concentrations increase as much as twofold, and bioavailable (nonSHBG-bound) testosterone concentrations fall by 30–50% in some older individuals [25, 143–146] (Fig. 16.11a). Advances in how SHBG should be measured and exactly how this binding should be modeled have occurred (see Chap. 15). Such modeling to determine calculated free testosterone will be increasingly important since recent epidemiological studies show that hypogonadism defined by dichotomization based on free, rather than total, testosterone is better






Fig. 16.10 **a** Notion of the approximate entropy (ApEn) statistic to quantitate relative regularity of serial (sample-by-sample) measurements. The bottom curve gives a cosine function (low ApEn) to illustrate a well reproduced pattern; the middle curve shows partial degradation of regularity (intermediate ApEn); and, the top frame depicts marked erosion of orderliness (high ApEn). **b** Increased ApEn of overnight (2.5-min) LH release profiles in healthy older compared with young men. Higher ApEn points to less orderly outflow of GnRH and/or LH, or disruption of the GnRH-LH feedforward

interface. Numerical values are the mean \pm SEM. **c** Cross-approximate entropy (cross-ApEn) differences in older and young men. Differences exceeding three SEM's (older minus young) denote significant deterioration of young-adult coupling between oscillations of LH and testosterone (*leftmost*), LH and FSH (*left middle*), LH and prolactin (PRL, *right middle*) and LH and nocturnal penile tumescence (NPT) (*rightmost*). *P* values denote the probability of falsely rejecting the null hypothesis of equivalent two-hormone synchrony in the two age groups. Unpublished compilation of data reported in [36–38, 111]

Fig. 16.11 **a** Comparison of serum total, nonSHBG (bioavailable) and percentage free testosterone measurements in two cohorts of men; viz., young ($N = 11$) and older ($N = 8$). Similar mean total testosterone concentrations by age (*top*) belie a reduction in bioavailable and percentage nonSHBG-bound (% free) testosterone (*middle* and *lower*) in older individuals. Adapted from [38]. **b** Schema of fate of secreted testosterone in plasma



associated with symptoms consistent with androgen deficiency [147]. However, current binding assumptions, analytical methods and models appear adequate when SHBG concentrations are within the normal male range [148–151]. Dynamic mechanisms of physiological control of free, SHBG- and albumin-bound testosterone are highlighted in the kinetic schema of Fig. 16.11b. Therefore, according to contemporary perspectives, carefully designed clinical studies will be needed to examine the age-dependence of free and bioavailable testosterone-mediated negative feedback on gonadotropin secretion [43].

Summary

Developing concepts of time-adaptive control of testosterone secretion incorporate interactions among GnRH, LH, and testosterone. Homeostasis requires reversible, recurrent, and reciprocal (feedback and feedforward) adjustments to external stress (e.g., food deprivation, trauma) and internal needs (e.g., anabolism, procreation). In this ensemble perspective, no single gland acts alone. Clinical studies in the healthy aging male point to regulatory failure of GnRH-driven pulsatile LH secretion, LH-stimulated Leydig-cell androgen biosynthesis, and testosterone-enforced feedback on GnRH/LH outflow. In addition, a variety of morbidities are known to affect the testis, and the hypothalamic-pituitary unit. Accordingly, hypoandrogenemia in the older male is the final common consequence of a matrix of primary and secondary deficits in the hypothalamo-pituitary-gonadal ensemble.

References

1. Stearns EL, MacDonald JA, Kaufman BJ, Padua R, Lucman T, Winter JSD, Faïman C. Declining testicular function with age, hormonal and clinical correlates. *Am J Med.* 1974;57:761–6.
2. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. *J Clin Endocrinol Metab.* 1983;57:71–7.

3. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men—A clinical research center study. *J Clin Endocrinol Metab.* 1996;81:3578–83.
4. Morley JE, Perry HM, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry HM Jr. Effects of testosterone on replacement therapy in old hypogonadal males: A preliminary study. *J Am Geriatr Soc.* 1993;41:149–52.
5. Urban RJ, Bodenbun YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. *Am J Physiol.* 1995;269:E280–6.
6. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. *J Clin Endocrinol Metab.* 1999;84:573–7.
7. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. *J Clin Endocrinol Metab.* 1999;84:3681–5.
8. Abbasi AA, Drinka PJ, Mattson DE, Rudman D. Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. *J Am Geriatr Soc.* 1993;41:975–82.
9. Tenover JS. Testosterone in the aging male. *J Androl.* 1997;18:103–6.
10. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. *J Clin Endocrinol Metab.* 2002;87:5001–7.
11. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER III, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Effects of testosterone treatment in older men. *N Engl J Med.* 2016;374:611–24.
12. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. *J Clin Epidemiol.* 1991;44:671–84.
13. Nieschlag E, Kley HK, Wiegelmann W, Solbach HG, Kruskemper HL. Age and endocrine function of the testes in adult man. *Dtsch Med Wochenschr.* 1973;98:1281–4.
14. Gray A, Feldman HS, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male

- aging study. *J Clin Endocrinol Metab.* 1991;73:1016–25.
15. Morley JE, Kaiser FE, Perry 3rd HM, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metab: Clin Exp.* 1997;46:410–13.
 16. Hollander N, Hollander VP. The microdetermination of testosterone in human spermatic vein blood. *J Clin Endocrinol Metab.* 1958;18:966–71.
 17. Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. *J Clin Endocrinol Metab.* 2004;89:4789–96.
 18. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010;363:123–35.
 19. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Keevil B, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: Longitudinal results from the European male ageing study. *Eur J Endocrinol.* 2013;168:445–55.
 20. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, Seibel MJ, Eisman JA, Handelsman DJ. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. *J Clin Endocrinol Metab.* 2007;92:3599–603.
 21. de Lignieres B. Transdermal dihydrotestosterone treatment of 'andropause'. *Ann Med.* 1993;25:235–41.
 22. Morley JE, Kaiser F, Raum WJ, Perry HM 3rd, Flood JF, Jensen J, Silver AJ, Roberts E. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor I to growth hormone. *Proc Natl Acad Sci USA.* 1997;94:7537–42.
 23. Blackman MR, Weintraub BD, Rosen SW, Harman SM. Comparison of the effects of lung cancer, benign lung disease, and normal aging on pituitary-gonadal function in men. *J Clin Endocrinol Metab.* 1988;66:88–95.
 24. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, lifestyle, residence, diet and activity. *J Clin Endocrinol Metab.* 1984;59:955–62.
 25. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. *J Clin Endocrinol Metab.* 1986;63:1418–20.
 26. Bergendahl M, Aloji JA, Iranmanesh A, Mulligan T, Veldhuis JD. Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances the orderliness of LH release in young but not older men. *J Clin Endocrinol Metab.* 1998;83:1967–75.
 27. Veldhuis JD, Yang RJ, Roelfsema F, Takahashi PY. Proinflammatory cytokine infusion attenuates LH's feedforward on testosterone secretion: modulation by age. *J Clin Endocrinol Metab.* 2016;101:539–49.
 28. Winters SJ, Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: Evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. *J Clin Endocrinol Metab.* 1982;55:560–5.
 29. Vermeulen A, Deslypere JP, De Meirleir K. A new look at the andropause: Altered function of the gonadotrophs. *J Steroid Biochem.* 1989;32:163–5.
 30. Baker HWG, Burger HG, de Kretser DM, Hudson B, O'Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC. Changes in the pituitary-testicular system with age. *Clin Endocrinol.* 1976;5:349–72.
 31. Mitchell R, Hollis S, Rothwell C, Robertson WR. Age-related changes in the pituitary-testicular axis in normal men; lower serum testosterone results from decreased bioactive LH drive. *Clin Endocrinol.* 1995;42:501–7.
 32. Urban RJ, Veldhuis JD, Blizzard RM, Dufau ML. Attenuated release of biologically active luteinizing hormone in healthy aging men. *J Clin Invest.* 1988;81:1020–9.
 33. Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: Possible Leydig cell desensitization to endogenous LH signaling—A clinical research center study. *J Clin Endocrinol Metab.* 1995;80:3025–31.
 34. Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig-cell) defects in the healthy aging male gonadotropic axis. *Eur J Endocrinol.* 1999;141:257–66.
 35. Mulligan T, Iranmanesh A, Johnson ML, Straume M, Veldhuis JD. Aging alters feedforward and feedback linkages between LH and testosterone in healthy men. *Am J Physiol.* 1997;273:R1407–13.
 36. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. *Proc Natl Acad Sci USA.* 1996;93:14100–5.

37. Veldhuis JD, Iranmanesh A, Godschalk M, Mulligan T. Older men manifest multifold synchrony disruption of reproductive neurohormone outflow. *J Clin Endocrinol Metab.* 2000;85:1477–86.
38. Veldhuis JD, Iranmanesh A, Mulligan T, Pincus SM. Disruption of the young-adult synchrony between luteinizing hormone release and oscillations in follicle-stimulating hormone, prolactin, and nocturnal penile tumescence (NPT) in healthy older men. *J Clin Endocrinol Metab.* 1999;84:3498–505.
39. Winters SJ, Sherins RJ, Troen P. The gonadotropin-suppressive activity of androgen is increased in elderly men. *Metab.* 1984;33:1052–9.
40. Urban RJ, Evans WS, Rogol AD, Kaiser DL, Johnson ML, Veldhuis JD. Contemporary aspects of discrete peak detection algorithms. I. The paradigm of the luteinizing hormone pulse signal in men. *Endocr Rev.* 1988;9:3–37.
41. Veldhuis JD. Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamo-pituitary-gonadal axis. *J Androl.* 1999;20:1–17.
42. Liu PY, Veldhuis JD. The hypothalamo-pituitary unit, testis and male accessory organs. In: Strauss JF, Barbieri RL, editors. *Yen and Jaffe's Reproductive Endocrinology: physiology, pathophysiology, and clinical management.* 7th edn. Philadelphia, PA, USA: Elsevier/Saunders; 2014; 272–86.
43. Veldhuis JD, Johnson ML, Keenan D, Iranmanesh A. The ensemble male hypothalamo-pituitary-gonadal axis. In: Timiras PS, editors. *Physiological basis of aging and geriatrics,* 3rd edn. Boca Raton: CRC Press; 2003; 213–31.
44. Winters SJ, Atkinson L. Serum LH concentrations in hypogonadal men during scrotal testosterone replacement through scrotal skin: further evidence that aging enhances testosterone negative feedback. *Clin Endocrinol.* 1997;47:317–22.
45. Keenan DM, Veldhuis JD, Yang R. Joint recovery of pulsatile and basal hormone secretion by stochastic nonlinear random-effects analysis. *Am J Physiol.* 1998;275:R1939–49.
46. Keenan DM, Veldhuis JD. Hypothesis testing of the aging male gonadal axis via a biomathematical construct. *Am J Physiol.* 2001;280:R1755–71.
47. Keenan DM, Veldhuis JD. Disruption of the hypothalamic luteinizing-hormone pulsing mechanism in aging men. *Am J Physiol.* 2001;281:R1917–24.
48. Chubb CE, Desjardins C. Testicular function and neuroendocrine activity in senescent mice. *Am J Physiol.* 1984;247:E410–5.
49. Shin SH, Howitt C. Effect of castration on luteinizing hormone and luteinizing hormone releasing hormone in the male rat. *J Endocrinol.* 1975;65:447–8.
50. Gruenewald DA, Naai MA, Hess DL, Matsumoto AM. The Brown Norway rat as a model of male reproductive aging: evidence for both primary and secondary testicular failure. *J Gerontol.* 1994;49:B42–50.
51. Bonavera JJ, Swerdloff RS, Leung A, Lue YH, Baravarian S, Superlano L, Sinha-hikim AP, Wang C. In the male Brown-Norway (BN) male rat reproductive aging is associated with decreased LH-pulse amplitude and area. *J Androl.* 1997;18:359–65.
52. Shaar CJ, Euker JS, Riegler GD, Meites J. Effects of castration and gonadal steroids on serum luteinizing hormone and prolactin in old and young rats. *Fed Proc.* 1974;66:45–51.
53. Mulligan T, Kuno HL, Vij S, Iranmanesh A, Veldhuis JD. Healthy older men show heightened LH secretory sensitivity and capacity to GnRH stimulation. Presented at the Annual Meeting of the American Geriatrics Society, Philadelphia, Pennsylvania, Abst #843. 1999.
54. Kaufman JM, Giri M, Deslypere JM, Thomas G, Vermeulen A. Influence of age on the responsiveness of the gonadotrophs to luteinizing hormone-releasing hormone in males. *J Clin Endocrinol Metab.* 1991;72:1255–60.
55. Karpas AE, Bremner WJ, Clifton DK, Steiner RA, Dorsa DM. Diminished luteinizing hormone pulse frequency and amplitude with aging in the male rat. *Endocrinol.* 1983;112:788–91.
56. Jarjour LT, Handelsman DJ, Swerdloff RS. Effects of aging on the in vitro release of gonadotropin-releasing hormone. *Endocrinol.* 1986;119:1113–7.
57. Coquelin AW, Desjardins C. Luteinizing hormone and testosterone secretion in young and old male mice. *Am J Physiol.* 1982;243:E257–63.
58. Witkin JW. Aging changes in synaptology of luteinizing hormone-releasing hormone neurons in male rat preoptic area. *Neuroscience.* 1987;22:1003–13.
59. Kaler LW, Critchlow V. Anterior pituitary luteinizing hormone secretion during continuous perfusion in aging male rats. *Mech Ageing Dev.* 1984;25:103–15.
60. Huang HH, Kissane JQ, Hawrylewicz EJ. Restoration of sexual function and fertility by fetal hypothalamic transplant in impotent aged male rats. *Neurobiol Aging.* 1987;8:465–72.
61. Deslypere JP, Kaufman JM, Vermeulen T, Vogelaers D, Vandalem JL, Vermeulen A. Influence of age on pulsatile luteinizing hormone release and responsiveness of the gonadotrophs to sex hormone feedback in men. *J Clin Endocrinol Metab.* 1987;64:68–73.
62. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML, Iranmanesh A. Attenuation of luteinizing hormone secretory burst amplitude is a proximate basis for the hypoandrogenism of healthy aging in men. *J Clin Endocrinol Metab.* 1992;75:707–13.
63. Veldhuis JD, Urban RJ, Dufau ML. Differential responses of biologically active LH secretion in

- older versus young men to interruption of androgen negative feedback. *J Clin Endocrinol Metab.* 1994;79:1763–70.
64. Vermeulen A, Deslypere JP, Kaufman JJ. Influence of antiopioids on luteinizing hormone pulsatility in aging men. *J Clin Endocrinol Metab.* 1989;68:68–72.
65. Tenover JS, Dahl KD, Hsueh AJ, Lim P, Matsumoto AM, Bremner WJ. Serum bioactive and immunoreactive follicle-stimulating hormone levels and the response to clomiphene in healthy young and elderly men. *J Clin Endocrinol Metab.* 1987;64:1103–8.
66. Takahashi PY, Liu PY, Roebuck PD, Iranmanesh A, Veldhuis JD. Graded inhibition of pulsatile LH secretion by a selective GnRH-receptor antagonist in healthy men: evidence that age attenuates hypothalamic GnRH outflow. *J Clin Endocrinol Metab.* 2005;90:2768–74.
67. Keenan DM, Clarke JJ, Veldhuis JD. Non-invasive analytical estimation of endogenous gonadotropin-releasing hormone (GnRH) drive: analysis using graded competitive GnRH-receptor antagonism and a calibrating pulse of exogenous GnRH. *Endocrinology.* 2011;152:4882–93.
68. Kaler LW, Neaves WB. Attrition of the human Leydig cell population with advancing age. *Anat Rec.* 1978;192:513–8.
69. Reubens R, Dhondt M, Vermeulen A. Further studies on Leydig cell response to human chorionic gonadotropin. *J Clin Endocrinol Metab.* 1976;39:40–5.
70. Nankin HR, Lin T, Muroso EP. The aging Leydig cell III. Gonadotropin stimulation in men. *J Androl.* 1981;2:181–6.
71. Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. *J Clin Endocrinol Metab.* 1980;51:35–40.
72. Longcope C. The effect of human chorionic gonadotropin on plasma steroid levels in young and old men. *Steroids.* 1973;21:583–92.
73. Veldhuis JD, Fraioli F, Rogol AD, Dufau ML. Metabolic clearance of biologically active luteinizing hormone in man. *J Clin Invest.* 1986;77:1122–8.
74. Veldhuis JD, Johnson ML, Dufau ML. Physiological attributes of endogenous bioactive luteinizing hormone secretory bursts in man: Assessment by deconvolution analysis and *in vitro* bioassay of LH. *Am J Physiol.* 1989;256:E199–207.
75. Winters SJ, Troen PE. Testosterone and estradiol are co-secreted episodically by the human testis. *J Clin Invest.* 1986;78:870–2.
76. Foresta C, Bordon P, Rossato M, Mioni R, Veldhuis JD. Specific linkages among luteinizing hormone, follicle stimulating hormone, and testosterone release in the peripheral blood and human spermatic vein: evidence for both positive (feed-forward) and negative (feedback) within-axis regulation. *J Clin Endocrinol Metab.* 1997;82:3040–6.
77. Glass AR, Vigersky RA. Resensitization of testosterone production in men after human chorionic gonadotropin-induced desensitization. *J Clin Endocrinol Metab.* 1980;51:1395–400.
78. Dufau ML, Catt KJ. Gonadotropin receptors and regulation of steroidogenesis in the testis and ovary. *Vitam Horm.* 1978;36:461–585.
79. Veldhuis JD, King JC, Urban RJ, Rogol AD, Evans WS, Kolp LA, Johnson ML. Operating characteristics of the male hypothalamo-pituitary-gonadal axis: Pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. *J Clin Endocrinol Metab.* 1987;65:929–41.
80. Mulligan T, Iranmanesh A, Veldhuis JD. Pulsatile intravenous infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. *J Clin Endocrinol Metab.* 2001;86:5547–53.
81. Veldhuis JD, Veldhuis NJ, Keenan DM, Iranmanesh A. Age diminishes the testicular steroidogenic response to repeated intravenous pulses of recombinant human LH during acute GnRH-receptor blockade in healthy men. *Am J Physiol.* 2005;288:E775–81.
82. Liu PY, Takahashi PY, Roebuck PD, Iranmanesh A, Veldhuis JD. Aging in healthy men impairs recombinant human LH-stimulated testosterone secretion monitored under a two-day intravenous pulsatile LH clamp. *J Clin Endocrinol Metab.* 2005;90:5544–50.
83. Takahashi PY, Votruba P, Abu-Rub M, Mielke K, Veldhuis JD. Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotropin inhibition in healthy men. *J Clin Endocrinol Metab.* 2007;92:3626–32.
84. Veldhuis JD, Liu PY, Keenan DM, Takahashi PY. Older men exhibit reduced efficacy of and heightened potency downregulation by intravenous pulses of recombinant human LH: a study in 92 healthy men. *Am J Physiol Endo Metab.* 2012;302:E117–22.
85. Gentili A, Mulligan T, Godschalk M, Clore J, Patrie J, Iranmanesh A, Veldhuis JD. Unequal impact of short-term testosterone repletion on the somatotrophic axis of young and older men. *J Clin Endocrinol Metab.* 2002;87:825–34.
86. Liu PY, Takahashi PY, Roebuck PD, Bailey JN, Keenan DM, Veldhuis JD. Testosterone's short-term positive effect on luteinizing-hormone secretory-burst mass and its negative effect on secretory-burst frequency are attenuated in middle-aged men. *J Clin Endocrinol Metab.* 2009;94:3978–86.
87. Veldhuis JD, Urban RJ, Dufau ML. Evidence that androgen negative-feedback regulates hypothalamic GnRH impulse strength and the burst-like secretion

- of biologically active luteinizing hormone in men. *J Clin Endocrinol Metab.* 1992;74:1227–35.
88. Veldhuis JD, Zwart A, Mulligan T, Iranmanesh A. Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. *J Clin Endocrinol Metab.* 2001;86:529–35.
 89. Takahashi PY, Liu PY, Veldhuis JD. Distinct roles of age and abdominal visceral fat in reducing androgen receptor-dependent negative feedback on LH secretion in healthy men. *J Androl.* 2014;2:588–95.
 90. Veldhuis JD, Takahashi PY, Keenan DM, Liu PY, Mielke KL, Weist SM. Age disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men. *Am J Physiol Endocrinol Metab.* 2010;299:E675–82.
 91. Haji M, Kato KI, Nawata H, Ibayashi H. Age-related changes in the concentrations of cytosol receptors for sex steroid hormones in the hypothalamus and pituitary gland of the rat. *Brain Res.* 1980;204:373–86.
 92. Roth GS, Heiss GI. Changes in the mechanisms of hormone and neurotransmitter action during aging: current status of the role of receptor and post-receptor alterations. *Mech Ageing Dev.* 1982;20:175–94.
 93. Veldhuis JD, Zwart AD, Iranmanesh A. Neuroendocrine mechanisms by which selective Leydig-cell castration unleashes increased pulsatile LH release in the human: an experimental paradigm of short-term ketoconazole-induced hypoandrogenemia and deconvolution-estimated LH secretory enhancement. *Am J Physiol.* 1997;272:R464–74.
 94. Zwart AD, Iranmanesh A, Veldhuis JD. Disparate serum free testosterone concentrations and degrees of hypothalamo-pituitary-LH suppression are achieved by continuous versus pulsatile intravenous androgen replacement in men: A clinical experimental model of ketoconazole-induced reversible hypoandrogenemia with controlled testosterone add-back. *J Clin Endocrinol Metab.* 1997;82:2062–9.
 95. Keenan DM, Sun W, Veldhuis JD. A stochastic biomathematical model of the male reproductive hormone system. *SIAM J Appl Math.* 2000;61:934–65.
 96. Keenan DM, Veldhuis JD. Stochastic model of admixed basal and pulsatile hormone secretion as modulated by a deterministic oscillator. *Am J Physiol.* 1997;273:R1182–92.
 97. Keenan DM, Veldhuis JD. A biomathematical model of time-delayed feedback in the human male hypothalamic-pituitary-Leydig cell axis. *Am J Physiol.* 1998;275:E157–76.
 98. Davies TF, Platzer M. The perfused Leydig cell: System characterization and rapid gonadotropin-induced desensitization. *Endocrinol.* 1981;108:1757–62.
 99. Chase DJ, Schanbacher B, Lunstra DD. Effects of pulsatile and continuous luteinizing hormone (LH) infusions on testosterone responses to LH in rams actively immunized against gonadotropin-releasing hormone. *Endocrinology.* 1988;123:816–26.
 100. Lincoln GA. Luteinizing hormone and testosterone in man. *Nature.* 1974;252:232–3.
 101. Rowe PH, Racey PA, Lincoln GA, Ellwood M, Lehane J, Shenton JC. The temporal relationship between the secretion of luteinizing hormone and testosterone in man. *J Endocrinol.* 1975;64:17–25.
 102. Bagatell CJ, Dahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. *J Androl.* 1994;15:15–21.
 103. Snyder PJ, Reitano JF, Utiger RD. Serum LH and FSH responses to synthetic gonadotropin-releasing hormone in normal men. *J Clin Endocrinol Metab.* 1975;41:938–45.
 104. Keenan DM, Iranmanesh A, Veldhuis JD. Analytical construct of reversible desensitization of pituitary-testicular signaling: Illustrative application in aging. *Am J Physiol Regul Integr Comp Physiol.* 2011;300:R349–50.
 105. Keenan DM, Veldhuis JD. Pulsatility of hypothalamo-pituitary hormones: a challenge in quantification. Review Article. *Physiology.* 2016;31:34–50.
 106. Veldhuis JD, Evans WS, Johnson ML, Rogol AD. Physiological properties of the luteinizing hormone pulse signal: impact of intensive and extended venous sampling paradigms on their characterization in healthy men and women. *J Clin Endocrinol Metab.* 1986;62:881–91.
 107. Partsch C-J, Abrahams S, Herholz N, Peter M, Veldhuis JD, Sippell WG. Variability of pulsatile LH secretion in young male volunteers. *Eur J Endocrinol.* 1994;131:263–72.
 108. Veldhuis JD, Evans WS, Rogol AD, Thorner MO, Drake CR, Merriam GR, Johnson ML. Intensified rates of venous sampling unmask the presence of spontaneous high-frequency pulsations of luteinizing hormone in man. *J Clin Endocrinol Metab.* 1984;59:96–102.
 109. Veldhuis JD, Evans WS, Rogol AD, Thorner MO, Drake CR, Merriam GR, Johnson ML. Performance of LH pulse detection algorithms at rapid rates of venous sampling in humans. *Am J Physiol.* 1984;247:554E–63E.
 110. Mulligan T, Delemarre-van de Waal HA, Johnson ML, Veldhuis JD. Validation of deconvolution analysis of LH secretion and half-life. *Am J Physiol.* 1994;267:R202–11.
 111. Veldhuis JD, Iranmanesh A, Demers LM, Mulligan T. Joint basal and pulsatile hypersecretory mechanisms drive the monotropic follicle-stimulating hormone (FSH) elevation in healthy older men: concurrent preservation of the

- orderliness of the FSH release process. *J Clin Endocrinol Metab.* 1999;84:3506–14.
112. Mulligan T, Iranmanesh A, Veldhuis JD. Pulsatile GnRH unmasks dual (hypothalamic and Leydig cell) defects in healthy older men. Presented at the American Geriatrics Society Annual Meeting, Philadelphia, Pennsylvania, 1999.
 113. Zwart AD, Urban RJ, Odell WD, Veldhuis JD. Contrasts in the gonadotropin-releasing dose-response relationships for luteinizing hormone, follicle-stimulating hormone, and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis. *Eur J Endocrinol.* 1996;135:399–406.
 114. Iranmanesh A, Mulligan T, Veldhuis JD. Age in men does not determine GnRH's dose-dependent stimulation of luteinizing hormone secretion under an exogenous testosterone clamp. *J Clin Endocrinol Metab.* 2010;95:2877–84.
 115. Veldhuis JD, Rogol AD, Samojlik E, Ertel N. Role of endogenous opiates in the expression of negative feedback actions of estrogen and androgen on pulsatile properties of luteinizing hormone secretion in man. *J Clin Invest.* 1984;74:47–55.
 116. Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. *J Clin Invest.* 1973;52:2616–8.
 117. Urban RJ, Davis MR, Rogol AD, Johnson ML, Veldhuis JD. Acute androgen receptor blockade increases luteinizing-hormone secretory activity in men. *J Clin Endocrinol Metab.* 1988;67:1149–55.
 118. Veldhuis JD, Liu PY, Takahashi PY, Keenan DM. Dynamic testosterone responses to near-physiological LH pulses are determined by the time pattern of prior intravenous LH infusion. *Am J Physiol Endocrinol Metab.* 2012;303:E720–8.
 119. Veldhuis JD, Liu PY, Takahashi PY, Weist SM, Wigham JR. Analysis of the impact of intravenous LH pulses versus continuous LH infusion on testosterone secretion during GnRH-receptor blockade. *Am J Physiol Regul Integr Comp Physiol.* 2012;303:R994–1002.
 120. Veldhuis JD, Carlson ML, Johnson ML. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. *Proc Natl Acad Sci USA.* 1987;84:7686–90.
 121. Veldhuis JD, Johnson ML. Deconvolution analysis of hormone data. *Meth Enzymol.* 1992;210:539–75.
 122. Veldhuis JD, Johnson ML. Specific methodological approaches to selected contemporary issues in deconvolution analysis of pulsatile neuroendocrine data. *Meth Neurosci.* 1995;28:25–92.
 123. Veldhuis JD, Moorman J, Johnson ML. Deconvolution analysis of neuroendocrine data: Waveform-specific and waveform-independent methods and applications. *Meth Neurosci.* 1994;20:279–325.
 124. Veldhuis JD, Dufau ML. Steroidal regulation of biologically active luteinizing hormone secretion in men and women. *Hum Reprod.* 1993;8(2):84–96.
 125. Chattopadhyay S, Keenan DM, Veldhuis JD. Probabilistic recovery of neuroendocrine pulsatile, secretory and kinetic structure: An alternating discrete and continuous schema. *Q Appl Math.* 2008;66:401–21.
 126. Liu PY, Keenan DM, Kok P, Padmanabhan V, O'Byrne KT, Veldhuis JD. Sensitivity and specificity of pulse detection using a new deconvolution method. *Am J Physiol Endo Metab.* 2009;297:E538–44.
 127. Veldhuis JD, Johnson ML. Cluster analysis: A simple, versatile and robust algorithm for endocrine pulse detection. *Am J Physiol.* 1986;250:E486–93.
 128. Veldhuis JD, Lassiter AB, Johnson ML. Operating behavior of dual or multiple endocrine pulse generators. *Am J Physiol.* 1990;259:E351–61.
 129. Veldhuis JD, Keenan DM, Clarke I, Alexandre S, Irvine CHG. Estimation of endogenous luteinizing hormone-testosterone secretory coupling in three mammalian species. Presented at 27th Annual Meeting of American Society of Andrology, Seattle, Washington, 24–27 Apr 2002.
 130. Pincus SM. Approximate entropy as a measure of system complexity. *Proc Natl Acad Sci USA.* 1991;88:2297–301.
 131. Pincus SM, Hartman ML, Roelfsema F, Thorner MO, Veldhuis JD. Hormone pulsatility discrimination via coarse and short time sampling. *Am J Physiol.* 1999;277:E948–57.
 132. Veldhuis JD, Johnson ML, Veldhuis OL, Straume M, Pincus S. Impact of pulsatility on the ensemble orderliness (approximate entropy) of neurohormone secretion. *Am J Physiol.* 2001;281:R1975–85.
 133. Pincus SM, Keefe DL. Quantification of hormone pulsatility via an approximate entropy algorithm. *Am J Physiol.* 1992;262:E741–54.
 134. Veldhuis JD, Straume M, Iranmanesh A, Mulligan T, Jaffe CA, Barkan A, Johnson ML, Pincus SM. Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. *Am J Physiol.* 2001;280:R721–9.
 135. Veldhuis JD, Pincus SM. Orderliness of hormone release patterns: a complementary measure to conventional pulsatile and circadian analyses. *Eur J Endocrinol.* 1998;138:358–62.
 136. Pincus SM, Veldhuis JD, Mulligan T, Iranmanesh A, Evans WS. Effects of age on the irregularity of LH and FSH serum concentrations in women and men. *Am J Physiol.* 1997;273:E989–95.
 137. Liu PY, Takahashi PY, Roebuck PD, Veldhuis JD. Age or factors associated with aging attenuate testosterone's concentration-dependent enhancement of the regularity of luteinizing hormone secretion in

- healthy men. *J Clin Endocrinol Metab.* 2006;91:4077–84.
138. Liu PY, Pincus SM, Keenan DM, Roelfsema F, Veldhuis JD. Analysis of bidirectional pattern synchrony of concentration-secretion pairs: implementation in the human testicular and adrenal axes. *Am J Physiol.* 2005;288:R440–6.
 139. Liu PY, Pincus SM, Takahashi PY, Roebuck PD, Iranmanesh A, Keenan DM, Veldhuis JD. Aging attenuates both the regularity and joint synchrony of LH and testosterone secretion in normal men: Analyses via a model of graded GnRH receptor blockade. *Am J Physiol.* 2006;290:E34–41.
 140. Veldhuis JD, Faunt LM, Johnson ML. Analysis of nonequilibrium dynamics of bound, free, and total plasma ligand concentrations over time following nonlinear secretory inputs: Evaluation of the kinetics of two or more hormones pulsed into compartments containing multiple variable-affinity binding proteins. *Meth Enzymol.* 1994;240:349–77.
 141. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem.* 1982;16:801–10.
 142. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. *J Clin Invest.* 1979;64:145–54.
 143. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. *J Clin Endocrinol Metab.* 1986;63:1418–23.
 144. Longcope C, Goldfield SRW, Brambilla DJ, McKinlay J. Androgens, estrogens, and sex hormone-binding globulin in middle-aged men. *J Clin Endocrinol Metab.* 1990;71:1442–6.
 145. Manni A, Pardridge WM, Cefalu W, Nisula BC, Bardin CW, Santner SJ, Santen RJ. Bioavailability of albumin-bound testosterone. *J Clin Endocrinol Metab.* 1985;61:705–10.
 146. Nahoul K, Roger M. Age-related decline of plasma bioavailable testosterone in adult men. *J Ster Biochem.* 1990;35:293–9.
 147. Antonio L, Wu FC, O'Neill TW, Pye SR, Ahern TB, Laurent MR, Huhtaniemi IT, Lean ME, Keevil BG, Rastrelli G, Forti G, Bartfai G, Casanueva FF, Kula K, Punab M, Giwercman A, Claessens F, Decallonne B, Vanderschueren D. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. *J Clin Endocrinol Metab.* 2016(in press); jc20154106.
 148. Veldhuis JD, Bondar OP, Dyer RB, Trushin SA, Klee EW, Singh RJ, Klee GG. Immunological and mass-spectrometric assays of SHBG: Consistent and inconsistent metabolic associations in healthy men. *J Clin Endocrinol Metab.* 2014;99:184–93.
 149. Zakharov MN, Bhasin S, Travison TG, Xue R, Ulloor J, Vasani RS, Carter E, Wu F, Jasuja R. A multi-step, dynamic allosteric model of testosterone's binding to sex hormone binding globulin. *Mol Cell Endocrinol.* 2015;399:190–200.
 150. Heinrich-Balard L, Zeinyeh W, Dechaud H, Rivory P, Roux A, Pugeat M, Cohen R. Inverse relationship between hSHBG affinity for testosterone and hSHBG concentration revealed by surface plasmon resonance. *Mol Cell Endocrinol.* 2015;399:201–7.
 151. Ohlsson C, Wallaschowski H, Lunetta KL, Stolk L, Perry JR, Koster A, Petersen AK, Eriksson J, Lehtimäki T, Huhtaniemi IT, Hammond GL, Maggio M, Coviello AD, Ferrucci L, Heier M, Hofman A, Holliday KL, Jansson JO, Kahonen M, Karasik D, Karlsson MK, Kiel DP, Liu Y, Ljunggren O, Lorentzon M, Lytikainen LP, Meitinger T, Mellstrom D, Melzer D, Miljkovic I, Nauck M, Nilsson M, Penninx B, Pye SR, Vasani RS, Reincke M, Rivadeneira F, Tajar A, Teumer A, Uitterlinden AG, Ulloor J, Viikari J, Volker U, Volzke H, Wichmann HE, Wu TS, Zhuang WV, Ziv E, Wu FC, Raitakari O, Eriksson A, Bidlingmaier M, Harris TB, Murray A, De Jong FH, Murabito JM, Bhasin S, Vandenput L, Haring R. Genetic determinants of serum testosterone concentrations in men. *PLoS Genet.* 2011;7:e1002313.
 152. Sortino MA, Aleppo G, Scapagnini U, Canonico PL. Different responses of gonadotropin-releasing hormone (GnRH) release to glutamate receptor agonists during aging. *Brain Res Bull.* 1996;41:359–62.
 153. Veldhuis JD, Iranmanesh A, Mulligan T. Age and testosterone feedback jointly control the dose-dependent actions of gonadotropin-releasing hormone in healthy men. *J Clin Endocrinol Metab.* 2005;90:302–9.
 154. Veldhuis JD, Iranmanesh A, Keenan DM. An ensemble perspective of aging-related hypoandrogenemia in men. In: Winters SJ, editor, *Male hypogonadism: Basic, clinical, and theoretical principles.* Totowa, NJ: Humana Press; 2004; 261–84.
 155. Goldman JM, Cooper RL, Rehnberg GL, Gabel S, McElroy WK, Hein J, Conn PM. Age-related alterations in the stimulated release in vitro of catecholamines and luteinizing hormone-releasing hormone from the male rat hypothalamus. *Neurochem Res.* 1987;12:651–7.
 156. Ellis GB, Desjardins C. Orchidectomy unleashes pulsatile luteinizing hormone secretion in the rat. *Bio Reprod.* 1984;30:619–27.
 157. Yahiro J, Glass AR, Fears WB, Ferguson EW, Vigersky RA. Exaggerated gonadotropin response to luteinizing hormone-releasing hormone in

- amenorrheic runners. *Am J Obstet Gynecol.* 1987;156:586–91.
158. Clarke IJ, Cummins JT. The significance of small pulses of gonadotropin-releasing hormone. *J Endocrinol.* 1987;113:413–8.
159. Veldhuis JD, Urban RJ, Beitins I, Blizzard RM, Johnson ML, Dufau ML. Pathophysiological features of the pulsatile secretion of biologically active luteinizing hormone in man. *J Steroid Biochem.* 1989;33:739–50.
160. Dufau ML, Veldhuis JD. Pathophysiological relationships between the biological and immunological activities of luteinizing hormone. In: Burger HG, editors, *Bailliere's clinical endocrinology and metabolism.* Philadelphia, Pennsylvania: W.B. Saunders; 1987; 1:153–76.
161. Veldhuis JD, Dufau ML. Estradiol modulates the pulsatile secretion of biologically active luteinizing hormone in man. *J Clin Invest.* 1987;80: 631–8.
162. Urban RJ, Veldhuis JD, Dufau ML. Estrogen regulates the gonadotropin-releasing-hormone stimulated secretion of biologically active luteinizing hormone in man. *J Clin Endocrinol Metab.* 1991;72:660–8.
163. Dufau ML, Veldhuis JD, Fraioli F, Johnson ML, Beitins IZ. Mode of secretion of bioactive luteinizing hormone in man. *J Clin Endocrinol Metab.* 1983;57:993–1000.

Giulia Rastrelli MD, PhD and Frederick C.W. Wu MD

Contents

Introduction.....	349
Testosterone and Aging.....	350
Morphological and Functional Alterations.....	350
Testosterone Declines with Age.....	350
Diagnosis of Late-Onset Hypogonadism (LOH) in Aging Men.....	350
Obesity-Related Testosterone Decline and Potential Underlying Mechanisms.....	355
HPT Axis Dysfunction.....	354
Leptin.....	356
TNF α	356
Insulin Resistance.....	357
Estrogens.....	357
The Role of Low Testosterone in Development of Obesity.....	357
Testosterone Treatment (TRT) and Obesity.....	358
Hypogonadism and Mortality.....	359
Conclusions.....	360
References.....	360

Introduction

It is well established that testosterone (T) deficiency is caused by pathologies affecting the hypothalamus or pituitary giving rise to secondary, AKA hypogonadotropic, hypogonadism (e.g., functioning or non-functioning pituitary adenomas, pituitary surgery, congenital GnRH deficiency, including Kallmann's syndrome), or the testis, resulting in primary, AKA hypergonadotropic, hypogonadism (e.g., Klinefelter syndrome, orchiectomy, chemotherapy, orchitis, testis injuries). During adult life, however, besides these pathological conditions of the hypothalamic–pituitary–testicular (HPT) axis, T levels can gradually decline with increasing age [1], usually to the borderline or low end of the reference range for young men, but in a small minority of older men, to the very low levels usually found in pathological hypogonadism. The mechanisms for this decline are not completely understood; they seem to involve dysfunction of the testis, such as depletion of Leydig cells and impaired testicular response to luteinizing hormone (LH), as well as the hypothalamus–pituitary GnRH/LH outflow and feedback response to testosterone (see Chaps. 1 and 15). Conditions closely linked to aging, such as chronic illnesses and medications, can also affect HPT axis function as men age. Obesity, independent of age, is also associated with low T from low SHBG (Chap. 15) and from down-regulation of hypothalamic–pituitary

G. Rastrelli (✉)
Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy
e-mail: giulia.rastrelli@gmail.com

F.C.W. Wu
University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Old St. Mary's Building Hathersage Road, Manchester M13 9WL, UK
e-mail: frederick.wu@manchester.ac.uk

gonadotropin secretion, the mechanisms for which may involve adipokines, pro-inflammatory cytokines, central insulin resistance, and a loss of GnRH- and inter-neurons. Insofar as the T decline with aging or obesity (so-called adult-onset, or late-onset hypogonadism, LOH) is generally relatively modest and its clinical consequences remain uncertain, the definition and criteria for the diagnosis of LOH are still under debate, with most guidelines recommending that low T be accompanied by cognate symptoms of androgen deficiency.

Testosterone and Aging

Morphological and Functional Alterations

It is recognized that the age-related progressive testicular dysfunction is underpinned by morphological derangements in the testis of aged men including a reduction in both number and function of Leydig cells [2, 3], germ cell degeneration, reduction in the number of Sertoli cells, thickening of basal membrane and appearance of areas of fibrosis [4]. Studies assessing Leydig cell steroidogenic capacity in healthy men pre-treated with GnRH-receptor agonists or antagonists showed that intravenous administration of exogenous LH in pulses can normalize T in younger men, whereas older men achieved T levels 30–50% lower than their younger counterparts [5, 6]. Furthermore, despite lower sperm quality with age [7, 8], most men can maintain a level of spermatogenesis sufficient for fertility during their entire life [9]. It is important to point out that the extent of testicular function impairment, in both the spermatogenic and steroidogenic compartments, associated with aging is often modest, partly due to the compensatory rise in gonadotrophins and somewhat variable due to the unpredictable consequences of comorbidities.

Although analysis of the pituitary found no specific morphological alteration attributable to aging, apart from interstitial fibrosis with high preservation of all cell types [10], several studies show that LH secretion in older men is blunted. Multiple concurrent mechanisms, including

reduced hypothalamic GnRH outflow, impaired secretion from the gonadotrope cells or altered feedback by androgens, have been hypothesized (for details, see Chap. 16).

Testosterone Declines with Age

Epidemiological studies in community dwelling men from different parts of the world showed a modest progressive decrease in T levels with increasing age [1, 11–14]. In the European Male Aging Study (EMAS), total T in the oldest (8th) decade was 8.6% lower than that in the youngest (4th) decade (Fig. 17.1) [1]. A more pronounced decline is observed for free T, with mean levels in the oldest decade being 33.1% lower than that in the youngest (Fig. 17.1) [1]. During a follow-up period of 4.4 years in EMAS, the subjects showed a small decline in T levels, with a mean decrease of 0.04 and 0.77% per year for total and free T, respectively [15]. Consistent with the cross-sectional data, the rates of T decline and LH rise were greatest for older men [15]. These data, in line with many other population-based studies from different parts of the world [11–13, 16–18], contrast with a few reports that did not find an age-related T decline [19–21]. The discrepancy may partly be explained by the health status of the subjects, since chronic diseases can abrogate HPT axis functions at multiple levels and accelerate the apparent aging-related fall in T [1, 22]. The loss of testicular function with aging in healthy men is moderated by the compensatory rise in LH such that the resultant pattern of a gradual but modest decline in T to the low physiological range over many decades stands in contradistinction with the relatively abrupt and inevitable loss of estradiol observed in women during the menopause. Hence, a real and universal “andropause” does not exist in men. However, in a small minority of elderly men (>70 year of age), T declines to the overtly hypogonadal range [12, 23–26], and if associated with symptoms, the term late-onset hypogonadism has been applied to describe this syndrome. In contrast, there is growing prevalence of symptomatic middle-aged men with obesity and insulin resistance [1, 15, 24, 27]




Fig. 17.1 Relationship between age and hormones. This figure shows mean hormone values at 5-year age bands with 95% confidence interval (shaded area) in 3220 European men. Mean hormone values with increasing age were interpolated to approximate the age trend. Total testosterone (T) and free T levels were significantly lower

and luteinizing hormone (LH) and sex hormone-binding globulin (SHBG) was significantly higher in the older age groups. There was an apparent inflection point around 70 years for LH. This figure is reproduced from Wu et al. [1] with permission from Endocrine Society

who present with low total T and sex hormone-binding globulin (SHBG) levels, but normal or only modestly low free T. This group of men is largely responsible for the explosion in testosterone prescriptions over the past decade [28].

Diagnosis of Late-Onset Hypogonadism (LOH) in Aging Men

Given the age-related decline in T levels, it is unfortunate that age-specific population reference ranges for T are not widely available. T thresholds for diagnosis are based on the reference intervals of healthy and young men [29], or their association with specific symptoms [30]. Hence, the cut-points for partitioning hypogonadal from eugonadal older men (and indeed eligibility for reimbursement) remain controversial, relying mostly on opined recommendations [31] and

consensus statements of various professional societies [32–34] that, not surprisingly, do not completely agree with each other (Table 17.1). For example, the International Society of Andrology (ISA), the International Society for the Study of Aging Male (ISSAM), the European Association of Urology (EAU), the European Academy of Andrology (EAA) and the American Society of Andrology (ASA) recommended the diagnosis of LOH when total T is below 8 nmol/L or within 8 and 12 nmol/L, if free T is below 225 pmol/L [32]. The EAU, however, suggests the threshold of 243 pmol/L for free T [34]. The Endocrine Society indicates a threshold between 9.8 and 10.4 nmol/L for total T, and for free T between 170 and 310 pmol/L while acknowledging that agreement on T thresholds is problematic and not truly evidence based [33]. There is agreement, however, on the requirement for two separate measurements of T for diagnosing

Table 17.1 Clinical features of androgen deficiency and guidelines of the International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), American Society of Andrology (ASA) [32], the Endocrine Society [33], and the EAU [34]

	ISA, ISSAM, EAU, EAA, and ASA [32]	Endocrine Society [33]	EAU [34]
<i>Testosterone thresholds</i>			
Total testosterone	8 nmol/L 8–12 nmol/L: measurement of free T is recommended	10.4 nmol/L	8 nmol/L 8–12 nmol/L: measurement of free T is recommended
Free testosterone	225 pmol/L	170–310 pmol/L: suggested in men with total T near to the lower limit of normal range and in those with suspected alterations of SHBG	243 pmol/L
<i>Symptoms and signs</i>			
Primary and secondary sexual characteristics		Gynecomastia and breast discomfort Testis hypotrophy Infertility Oligo-azoospermia	Gynecomastia Small testes Male-factor infertility
		Reduced body hair and frequency of shaving	
		Hot flushes, sweats	Decreased body hair
		Mild anemia	Hot flushes
Sexual	Low libido	Reduced sexual desire Reduced sexual activity	Reduced sexual desire Reduced sexual activity
	Erectile dysfunction		Erectile dysfunction
		Decreased spontaneous morning erections	Fewer and diminished nocturnal erections
Psychological	Decreased vitality	Decreased energy Decreased motivation Decreased initiative Decreased self-confidence	Fatigue
	Depressed mood	Depressed mood Feeling sad or blue Dysthymia Poor concentration and memory	Changes in mood
		Sleep disturbance Increased sleepiness	Sleep disturbances
			Anger Diminished cognitive function
Bone		Height loss	
		Low trauma fracture	Low trauma fractures
	Decreased bone mineral density Osteoporosis	Low bone mineral density	Decrease in bone mineral density (osteoporosis)
Body composition and metabolic disorders	Decreased muscle strength Decreased muscle mass	Reduced muscle bulk and strength Diminished physical or work performance	Decrease in lean body mass and muscle strength
	Increased body fat	Increased body fat	Visceral obesity Metabolic syndrome Insulin resistance and type 2 diabetes mellitus

SHBG Sex hormone-binding globulin

LOH, based on the finding that subnormal T levels are not confirmed in almost 30% of repeat measurements [35]. Moreover, morning T levels are recommended (7.00–11.00 am) [32–34] because serum T exhibits a diurnal rhythm with peak levels in the morning [36].

A further important issue is the method of T measurement. The most commonly used for clinical practice are platform-based immunoassays, but their accuracy and precision for T immunoassays have been questioned, especially at the low levels in children, women and severely hypogonadal men [37–40]. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) is now considered the gold standard for steroid measurement, but its costs and technical demands do not make it universally available for routine clinical practice. With improved quality control and methodological stringency, immunoassays are capable of providing T results in good agreement with LC-MS/MS in men [41]. Assessment of free T (non-protein-bound fraction of T) remains a controversial aspect of the biochemical evaluation of gonadal status, and its direct measurement is burdened with even more challenging analytical issues than for total T. The usefulness of evaluating free T arises from the “free hormone hypothesis” which suggests that only free unbound hormones are biologically active in target tissues. This hypothesis, though widely accepted in clinical practice, has not to date been corroborated by robust experimental evidence. In addition, there is also some evidence that T bound to SHBG can be internalized into cells by endocytosis through megalin protein [42], thus suggesting the possibility of a direct biological action also for protein-bound T. How to assess free T is also a matter of debate. The gold standard is measurement of free T by equilibrium dialysis, a technique that is expensive, time-consuming and not widely available. Alternative methods of measurement based on a labeled T analogue are unreliable and should not be used [43]. To circumvent these methodological issues, algorithms for calculating free T, based on the law of mass action and binding stoichiometry, have been introduced by Vermeulen [44], Södergård [45], Mazer [46] and Zakharov

[47]. Other equations, published by Nanjee [48], Ly [49] and Sartorius [50], are empirical estimates obtained through statistical extrapolation to laboratory FT measurements by equilibrium dialysis. The equations based on the law of mass action are strongly dependent on the association constant (K_a) for binding of T to SHBG and albumin. However, various K_a are used in different methods [44, 45, 51, 52], so that these equations carry intrinsic systematic errors based on their assumptions. Furthermore, their reliability is dependent on the accurate determination of total T and SHBG [53]. A study comparing the results of free T obtained by different equations based on the law of mass action (Vermeulen and Södergård) [44, 45] found that these equations systematically overestimate the value obtained by equilibrium dialysis [54]. The small overestimation of percentage free T may be attributed to errors in the measurement of T and SHBG with immunoassays, incorrect T-binding stoichiometry for SHBG, or the use of different K_a values [50]. Equations based on empirical assessment of free T may demonstrate better accuracy, but their applicability and transportability to different laboratories using different methods of hormone measurement is problematic. Despite the small systematic error associated with the mass action equations, a very high agreement between the calculated and the measured free hormone has been consistently found [44, 49, 55, 56]. Thus, despite the systematic, but nonetheless predictable, overestimation, the widespread application, accumulated credible clinical experience for more than 25 years, and convenience of the mass action calculations make it an acceptable method currently for evaluating free T in clinical practice until better alternatives are available. Accordingly, the U.S. Endocrine Society’s Expert Panel states that the use of equations based on the law of mass action provides the best approach for the estimation of free T concentration [57].

Based on these considerations, pending further studies demonstrating the clinical applicability of free T in the assessment of the androgenic status in men, total T measured by reliable methods, is still favored for the initial assessment and diagnosis of hypogonadism in men [57, 58].

However, recent data from EMAS showed that men with low total T levels do not have symptoms and signs of androgen deficiency if free T is normal, but when free T is low, even when total T is in the normal range, symptoms and signs of androgen deficiency are prevalent [59]. These results support the pivotal importance of measuring free T in conditions associated with alterations in SHBG levels, such as obesity or T2DM (low SHBG), or HepC or alcoholic liver cirrhosis, HIV infection or use of certain anticonvulsants (high SHBG) [32–34]. In these situations, the measurement of free T is essential for the accurate identification of LOH and to minimize its over-diagnosis [32–34].

Besides the uncertainty of T thresholds for hypogonadism in the elderly, the lack of precise knowledge on specific clinical features or consequences arising from pathologically low T levels in older men makes the diagnosis of LOH ever more challenging. Recommendations from professional societies require that the diagnosis of LOH requires low T levels together with androgen deficiency symptoms [32–34] (Table 17.1). However, symptoms of androgen deficiency are generally non-specific and overlap substantially with those of aging, depression and ill health. An attempt to create a working definition of LOH was based on the strength of the association between low T levels and the presence of symptoms [30]. After considering a large set of possible symptoms of hypogonadism, the presence of three sexual symptoms (i.e., erectile dysfunction, decreased sexual desire and impaired morning erections) was found to form a strong syndromic clustering with low T. Accordingly, LOH was defined as the simultaneous presence of erectile dysfunction, decreased sexual desire, and impaired morning erections in men with total and free T below 11 nmol/L and 220 pmol/L, respectively [30]. The specificity of sexual symptoms, but not physical and psychological ones, to low T, has been confirmed in the longitudinal extension of the EMAS, which showed that the fall of total T into the hypogonadal range during 4.3 years of follow-up is associated with the development of new sexual symptoms or the worsening of those already

present at baseline [60]. Interestingly, testosterone replacement therapy (TRT), compared to placebo in 800 older hypogonadal men in a randomized clinical trial (RCT), has recently been shown to improve sexual symptoms, with variable to negative results on physical and psychological outcomes [61]. Another RCT, involving more than 700 adult men (>18 years of age) receiving T gel or placebo for 3 months, showed that TRT improved sexual symptoms, but not energy level or mood [62].

LOH, as defined by low T and three sexual symptoms, has an overall population prevalence of 2.1% [30]. The prevalence increases with age, BMI, and comorbidity (Fig. 17.2) [30]. This prevalence is much lower than that reported (5.6 and 12%) in other surveys of similar populations [25, 63], presumably due to the inclusion of less stringent or specific clinical features.




Fig. 17.2 Prevalence of the late-onset hypogonadism (LOH) in EMAS, as defined by at least three sexual symptoms and total testosterone levels of <11 nmol/L and free testosterone of <220 pmol/L, overall and stratified by age (a), body mass index [BMI; Panel (b)] and comorbidity (c). The figure is reproduced from Wu et al. [30] with permission from Massachusetts Medical Society

Obesity-Related Testosterone Decline and Potential Underlying Mechanisms

HPT Axis Dysfunction

Obesity, independently of age, is probably the most important condition associated with low T in men. This is an increasingly common clinical problem due to the rapidly rising prevalence of obesity. In a number of population-based studies [1, 15, 24, 27], obesity, independently of age, was associated with a substantial decrease in both total and free T levels. In the EMAS population, the mean total and free T in obese (BMI ≥ 30) men was about 5 nmol/L and 55 pmol/L lower, respectively [1], compared to

the non-obese, approximating to a 15-year difference in age-stratified T distribution (Fig. 17.3). In contrast to the age-related decline, the fall in T in obese men is not accompanied by a compensatory rise in LH (Fig. 17.3) [1]. This pattern is consistent with secondary hypogonadism suggesting a derangement in HPT axis at the central level (hypothalamus-pituitary).

The finding of T rising after weight loss offers evidence supporting the causative role of obesity for hypogonadism rather than the reverse [15]. A meta-analysis of the available RCTs has shown that, in obese men, weight loss, obtained with either low calorie diet or bariatric surgery, was associated with a significant increase in total and free T levels as well as gonadotropins [64] (Table 17.2). The improvement in hormone




Fig. 17.3 Relationship between age, body mass index (BMI), and hormones. The EMAS cohort was stratified according to BMI into three groups: non-obese (BMI <25 kg/m²), overweight (BMI ≥ 25 to <30 kg/m²), and obese (BMI ≥ 30 kg/m²). Mean (95% confidence interval in shaded area and vertical lines) total and free testosterone (T) and sex hormone-binding globulin (SHBG) were significantly lower in the overweight and obese at all ages, compared with non-obese. The total T and SHBG age trends in the three BMI categories were

similar (indicating no interaction between BMI and age); the free T age trend in the obese group was less steep than in the other two groups (indicating an interaction between BMI and age). Mean LH was not significantly different among the three groups at the median age of 60 years. LH was higher in the older than 70 years non-obese, compared with the overweight and obese groups, due to a negative BMI age interaction. This figure is reproduced from Wu et al. [1] with permission from Endocrine Society

Table 17.2 Mean weighted differences and 95% confidence intervals of hormone levels before and after intentional weight loss obtained with low calorie diet or bariatric surgery

	Mean difference between post and pre-treatment	<i>p</i>
Total testosterone (nmol/L)		
Low calorie diet	2.87 (1.68–4.07)	<0.0001
Bariatric surgery	8.73 (6.51–10.95)	<0.0001
Free testosterone (pmol/L)	72.73 (41.86–103.60)	<0.0001
SHBG (nmol/L)	14.49 (10.04–18.94)	<0.0001
LH (U/L)	1.33 (0.75–1.91)	<0.0001

Data are derived from the meta-analysis of the available studies published in Corona et al. [64]

profile was proportionate to the extent of weight loss, thus demonstrating an apparent graded effect of weight loss on gonadal function [64]. Interestingly, the weight loss-related T increment was attenuated in older men [60, 64], exemplifying the multiple mechanisms at play in the aging HPT axis [vide supra]. Increased body fat and deterioration in health as well as age contribute to the suppression of HPT axis function at multiple levels, resulting in lower T in older men.

Obesity is not a mechanism, and the precise mechanism(s) by which obesity can suppress HPT axis function and induce hypogonadism is largely unknown. A preponderant role is attributed to the expansion of visceral adipose tissue, a source of many signaling molecules that can disrupt function and metabolism at multiple sites. Some of the most important are discussed below.

Leptin

Leptin is a peptide produced by adipose tissue (adipokine) whose circulating levels change according to nutritional status, being directly correlated with the amount of fat mass [65]. Leptin is involved in several functions, such as insulin sensitization, regulation of the balance between hunger and satiety, and hypothalamic–pituitary–gonadal function [66, 67]. Leptin signaling is one candidate to explain the link between nutritional status and gonadal function [68]. Animal models of leptin deficiency are characterized by hypogonadotropic hypogonadism with lack of pubertal development [69]. In women with hypothalamic amenorrhea

induced by excessive physical exercise, or the weight loss of anorexia nervosa, low leptin levels are associated with gonadotropin deficiency [70], and treatment with exogenous leptin is able to increase LH pulse frequency and amplitude as well as improve ovarian function [71]. However, in obese subjects, leptin is increased, in the presence of hypogonadotropic hypogonadism, suggesting possible leptin resistance [72–74]. GnRH neurons lack leptin receptors [75, 76], and the effect of leptin on GnRH secretion is thought to be mediated via kisspeptin neurons, which express leptin receptors [77]. In support of the role of Kiss1 neurons as mediators of leptin action, ob/ob mice (carrying inactivating mutations of the leptin gene) have a lower hypothalamic expression of kisspeptin mRNA that is increased by the administration of leptin [77]. Furthermore, the intra-cerebroventricular administration of kisspeptin in pubertal rats pre-treated with an anti-leptin antibody restored the secretion of LH [78]. Short-term kisspeptin administration increased LH pulse frequency and amplitude as well as testosterone levels, indicating functional reversibility at or proximal to hypothalamic GnRH neurons, in obese men with low T levels [78].

TNF α

Obesity is associated with chronic low-grade systemic inflammation with increased expression of pro-inflammatory cytokines. Circulating TNF α is increased in obese men, and is a possible candidate linking visceral obesity with

hypogonadotropic hypogonadism [79]. In an experimental model of high fat diet-induced metabolic syndrome, rabbits develop secondary hypogonadism and hypothalamic inflammation, with increased hypothalamic expression of IL-6, IL-8 and COX2 and a macrophage infiltrate that correlated with a reduction in circulating gonadotropins [80]. In this model, circulating TNF α is increased, and treatment with infliximab, an anti-TNF α mono-clonal antibody unable to cross brain-blood barrier, is associated with a decrease in hypothalamic inflammation [80]. Besides TNF α , other pro-inflammatory cytokines might be involved in the pathogenesis of obesity-related T decline. Recently, the acute administration of low to moderate doses of IL-2 reduced LH and T levels over a period of 24 h in 32 healthy volunteers, suggesting an inhibitory effect of this cytokine, involved in several systemic inflammatory conditions, on HPT at the hypothalamic/pituitary level [81].

Insulin Resistance

Another possible mechanism involved in the down-regulation of the HPT axis function in obese subjects is insulin resistance. Obesity is associated not only with peripheral but also with central insulin resistance [82]. Besides playing an essential role in glucose metabolism, insulin is involved in signaling satiety to the central nervous system [83]. Both GnRH neurons and kisspeptin neurons express insulin receptors [84, 85], and mice with a selective neuronal knockout for insulin receptors show an increased body mass and hypogonadotropic hypogonadism [86], suggesting a role for insulin in regulating the HPT axis. Accordingly, *in vivo* treatment of mice with increasing doses of insulin in hyperinsulinemic clamp studies was associated with an increase in circulating LH levels [87]. In addition, treatment of GnRH neurons with insulin *in vitro* induced a dose-dependent secretion of GnRH [88]. Obesity-related central insulin resistance could therefore negate the action of insulin on HPT axis, leading to secondary hypogonadism.

Estrogens

Estrogens have been, for a long time, the main candidate to explain the relationship between increased fat mass and down-regulation of the HPT. The hypothesis is that expanded adipose tissue in obese subjects leads to greater aromatase activity and thereby increased circulating estrogens, and an exaggerated feedback inhibition of GnRH-gonadotropin secretion. Accordingly, estrogen-antagonist [89] and aromatase inhibitor [90] treatment of overweight hypogonadal men increased LH and testosterone levels. However, the estrogen excess hypothesis is not entirely supported by data in obese diabetic [91, 92] and non-diabetic men [26], whose estradiol levels were low, rather than high, and showed a correlation with T but not with BMI. Only in cohorts of extremely obese men (candidates for bariatric surgery) estrogens are inappropriately high for the levels of T [93, 94] and show a positive correlation with BMI [95].

The Role of Low Testosterone in Development of Obesity

The relationship between T and obesity is complex and bidirectional. If a role of obesity in inducing hypogonadism is well recognized, some data also suggest that low androgen levels can lead to the development of obesity. Important information on the role of androgens in metabolism has been provided by the studies on androgen receptor (AR) knockout mice (ARKO). ARKO mice develop obesity with an increase in both subcutaneous and visceral fat, and they show a derangement in brown adipose tissue characteristics, which suggest a shift to the white adipose tissue profile [96]. Furthermore, ARKO mice display an increase in circulating triglycerides as well as in those stored within skeletal muscle and liver, and an impairment of glucose tolerance with hyperinsulinemia, hyperleptinemia, and hypoadiponectinemia [97]. *In vitro* studies demonstrated that androgens could inhibit the differentiation of pre-adipocytes in mice and in humans [98, 99]. Similar results have been

provided by in vivo studies [100, 101]. In addition, androgen treatment of pluripotent mesenchymal cells increased myogenic but inhibited adipogenic differentiation [102]. Taken together, these data suggest a role for androgens in regulating both central and peripheral insulin sensitivity and body composition, which is best shown when androgen action is abolished rather than diminished.

A human model for the metabolic derangements arising from chemical castration is represented by men with metastatic prostatic cancer who are treated with androgen deprivation therapy (ADT). Several prospective studies demonstrated that ADT for prostate cancer is associated with significant weight gain and changes in body composition from the first months of therapy [103]. A meta-analysis of longitudinal studies shows that ADT is associated with a mean increase of 7.7% in fat mass and a decrease of 2.8% in lean mass from baseline, befitting the clinical feature of “sarcopenic obesity” [104]. These changes in body composition were accompanied by impairment in lipid profile and insulin sensitivity [103], and patients are at higher risk for developing metabolic syndrome and diabetes [105]. The role of T and androgen deficiency in modifying body composition was assessed in a study conducted in more than 400 healthy young men aged 20–50 years in whom severe hypogonadism was experimentally induced by a GnRH analogue [106]. Volunteers were then randomly assigned to receive for 16 weeks placebo or different doses of T gel with or without an aromatase inhibitor. Results showed that experimental androgen deprivation is associated with a reduction in lean mass and leg-press strength as well as an increase in total and subcutaneous fat mass, *but no change in visceral fat* [106]. Testosterone replacement with aromatase inhibition (pure T effect) maintained lean mass and muscle strength, but not fat mass [106]. These data suggest that the adverse effects of severe hypogonadism on lean mass are mediated by testosterone, and in adipose tissue, by estrogen deficiency.

It should be highlighted that hypogonadism induced by GnRH analogues, as in ADT in men

with prostate cancer or experimental hypogonadism in eugonadal men [106], is associated with castrate T levels, which are much lower than those commonly found in LOH. A few longitudinal observational studies in the general population have evaluated the relationship between T and obesity with conflicting results. In the Rancho Bernardo study [107], a negative linear relationship between T or SHBG at baseline and waist-to-hip ratio at follow-up was found even for T levels within the eugonadal range (mean baseline total T of 18 nmol/L for those in the highest quartile of waist-to-hip ratio at follow-up). This observation is supported by a longitudinal study of 110 second-generation Japanese–American healthy male volunteers followed for 7.5 years [108]. In this study, the increase in intra-abdominal fat, as assessed by computed tomography, showed a linear negative relationship with total T at baseline, with a mean baseline total T of 14.8 nmol/L in the group with the highest increase in intra-abdominal fat [108]. More recently, longitudinal data from the EMAS showed that although low T at baseline is associated with incident metabolic syndrome, it was not associated with development of visceral obesity (determined by waist circumference) after 4.3 years [109]. Taken together, unlike the short-term changes associated with castration, chronic exposure over many years to moderately low T may predispose to abnormalities in central fat metabolism and body composition in men, but a causal relationship cannot be assumed from these observational data.

Testosterone Treatment (TRT) and Obesity

A number of uncontrolled registry studies appear to support the effect of TRT in improving body composition [110–115]. Several small RCTs of the metabolic outcomes of T therapy have been conducted. Meta-analysis of these results showed that T treatment was not associated with any change in BMI, body weight, or waist circumference [116]. However, a significant decrease in total fat mass and an increase in lean mass were

Table 17.3 Summary of the results from meta-analyses evaluating the effect of testosterone replacement therapy on body composition and metabolic outcomes as compared to placebo

Meta-analysis	Outcome	# Studies	# Subjects	Follow-up (weeks)	Age	Effect size used	Effect size and 95% confidence interval
Corona et al. [116]	Fat mass	11	715	12–168	52–77	Standardized difference in means	−0.39 (−0.61; −0.17)
	Lean mass	10	1000	12–168	52–71	Standardized difference in means	0.45 (0.26; 0.63)
Grossmann et al. [117]	HOMA index	7	833	12–48	44–64	Standardized difference in means	−0.34 (−0.51; −0.16)
	HbA1c	6	649	12–48	44–64	Difference in means (%)	−0.15 (−0.39; 0.10)

In order to allow a better comparison, for Corona et al. [116], the results from the meta-analysis of randomized clinical trials (RCTs) involving only hypogonadal men are reported, as shown in the original article. These results do not differ from those obtained from the meta-analysis of the RCTs enrolling men with both normal and low T levels [116]

consistently found in men treated with T, irrespective of their gonadal status [116] (Table 17.3). The improvement in body composition by treating hypogonadal men with TRT is not necessarily accompanied by a substantial improvement in insulin sensitivity. In another meta-analysis of double-blind RCTs conducted in hypogonadal men with metabolic syndrome and/or diabetes mellitus [117], TRT showed only a modest, although significant, improvement in HOMA-IR as compared to placebo, whereas the effect of TRT on glycated hemoglobin was not different from placebo (Table 17.3). A recent RCT of 44 men with type 2 diabetes mellitus and low free testosterone with normal or low LH levels showed that i.m. T treatment for 24 weeks improved insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamp and fasting glycemia, without any change in glycated hemoglobin [118].

In summary, currently available data suggest that TRT can improve body composition (total lean mass and fat mass) in hypogonadal men, but its benefits on insulin sensitivity and glycemic control remain uncertain. Based on available evidence, TRT is not recommended as a treatment for obesity, metabolic syndrome, or diabetes but is indicated only for the treatment hypogonadal men for the relief of symptoms of androgen deficiency.

Hypogonadism and Mortality

Several longitudinal studies showed that low T is associated with increased all-cause mortality [119]. Although low T did not predict incident cardiovascular (CV) events, it was associated with an increased CV mortality in several cohorts [119]. In the EMAS population, LOH, as defined by the presence of low free T levels and three sexual symptoms (see above), independently predicted overall and CV mortality [120].

The pathogenic mechanism(s) and cause-and-effect relationships underlying these associations are not clear. T is involved in vasomotion as well as in hemostasis and anti-inflammatory mechanisms, and its deficiency can alter these functions thus leading to atherosclerosis [121, 122]. In animal models, TRT was demonstrated to restrain fat storage in the arterial wall and to limit restenosis post-angioplasty [123, 124]. However, as discussed above, low T is associated with obesity and several related metabolic disorders, which may confound the apparent relationship between low T and CV mortality. The lack of association with incident CV events and the higher overall mortality suggest that low T is likely to be an epiphenomenon of poor health leading to mortality for different causes, rather than a factor with a direct or indirect detrimental

effect on CV health. These considerations may be relevant to the recent controversy regarding CV safety of TRT in elderly men with pre-existing comorbidities [<http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm>; 28].

Conclusions

Testosterone declines with increasing age due to depletion of Leydig cells and an impaired testicular response to LH, superimposed upon dysregulated GnRH/LH secretion. These changes are further aggravated by changes due to aging-related chronic illnesses. Obesity, independently of age, is associated with low T due to low SHBG, and from apparent down-regulation of hypothalamic–pituitary gonadotropin secretion. In contrast to classical pathological male hypogonadism, the T decline associated with aging/obesity (so-called LOH) is relatively modest, often in the borderline rather than the pathological range, and its clinical consequences are uncertain. According to current practice guidelines, LOH can be recognized when low T is accompanied by cognate symptoms of androgen deficiency. However, the threshold(s) for subnormal T (total or free) and the nature or severity of symptoms are not well defined. Among the common symptoms in aging men that potentially may arise from low T, sexual dysfunction is considered the most specific for hypogonadism, consistently occurring when T falls and while mounting evidence from recent RCTs confirmed that T replacement in older men with LOH is effective in improving sexual function. Although LOH is often associated with higher central fat mass and insulin resistance, particularly in type 2 diabetics, there is insufficient evidence that T treatment results in clinically significant improvements in glucose homeostasis or glycemic control. Low T, independent of obesity, is a predictor of increased overall and cardiovascular mortality, the most likely interpretation of which is that low T represents a marker of poor health, rather than an actual path variable leading to adverse clinical outcomes. This is an important caveat when

rationalizing T replacement as symptomatic treatment in older men among whom the underlying causes of low T should always be sought and managed.

References

1. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. *J Clin Endocrinol Metab.* 2008;93:2737–45.
2. Liao C, Reaven E, Azhar S. Age-related decline in the steroidogenic capacity of isolated rat Leydig cells: a defect in cholesterol mobilization and processing. *J Steroid Biochem Mol Biol.* 1993;46:39–47.
3. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, lifestyle, residence, diet and activity. *J Clin Endocrinol Metab.* 1984;59:955–62.
4. Huang R, Zhu WJ, Li J, Gu YQ. The changes of stage distribution of seminiferous epithelium cycle and its correlations with Leydig cell stereological parameters in aging men. *Pathol Res Pract.* 2014;210:991–6.
5. Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. *Eur J Endocrinol.* 1999;141:257–66.
6. Takahashi PY, Votruba P, Abu-Rub M, Mielke K, Veldhuis JD. Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotropin inhibition in healthy men. *J Clin Endocrinol Metab.* 2007;92:3626–32.
7. Stone BA, Alex A, Werlin LB, Marrs RP. Age thresholds for changes in semen parameters in men. *Fertil Steril.* 2013;100:952–8.
8. Johnson SL, Dunleavy J, Gemmel NJ, Nakagawa S. Consistent age-dependent declines in human semen quality: a systematic review and meta-analysis. *Ageing Res Rev.* 2015;19:22–33.
9. Belloc S, Hazout A, Zini A, Merviel P, Cabry R, Chahine H, Copin H, Benkhalifa M. How to overcome male infertility after 40: influence of paternal age on fertility. *Maturitas.* 2014;78:22–9.
10. Sano T, Kovacs KT, Scheithauer BW, Young WF Jr. Aging and the human pituitary gland. *Mayo Clin Proc.* 1993;68:971–7.

11. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. *J Clin Endocrinol Metab.* 2002;87:589–98.
12. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. *J Clin Endocrinol Metab.* 2001;86:724–31.
13. Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metabolism.* 1997;46:410–3.
14. Shi Z, Araujo AB, Martin S, O’Loughlin P, Wittert GA. Longitudinal changes in testosterone over five years in community-dwelling men. *J Clin Endocrinol Metab.* 2013;98:3289–97.
15. Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Keevil B, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC, EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European male ageing study. *Eur J Endocrinol.* 2013;168:445–55.
16. Travison TG, Araujo AB, Kupelian V, O’Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. *J Clin Endocrinol Metab.* 2007;92:549–55.
17. Lapauw B, Goemaere S, Zmierzak H, Van Pottelbergh I, Mahmoud A, Taes Y, De Bacquer D, Vansteelandt S, Kaufman JM. The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes. *Eur J Endocrinol.* 2008;159:459–68.
18. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, Seibel MJ, Eisman JA, Handelsman DJ. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. *J Clin Endocrinol Metab.* 2007;92:3599–603.
19. Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A, Allan CA, Ly LP, Conway AJ, McLachlan RI, Handelsman DJ. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. *Clin Endocrinol (Oxf).* 2012;77:755–63.
20. Kelsey TW, Li LQ, Mitchell RT, Whelan A, Anderson RA, Wallace WH. A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years. *PLoS ONE.* 2014;9:e109346.
21. Handelsman DJ, Sikaris K, Ly LP. Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan. *Ann Clin Biochem.* 2016;53:377–84.
22. Igaz P, Salvi R, Rey JP, Glauser M, Pralong FP, Gaillard RC. Effects of cytokines on gonadotropin-releasing hormone (GnRH) gene expression in primary hypothalamic neurons and in GnRH neurons immortalized conditionally. *Endocrinology.* 2006;147:1037–43.
23. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. *Diab Care.* 2000;23:490–4.
24. Mohr BA, Bhasin S, Link CL, O’Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts male aging study. *Eur J Endocrinol.* 2006;155:443–52.
25. Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab.* 2007;92:4241–7.
26. Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. *J Clin Endocrinol Metab.* 2010;95:1810–8.
27. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts male ageing study. *Clin Endocrinol (Oxf).* 2006;65:125–31.
28. Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and “age-related hypogonadism” – FDA concerns. *N Engl J Med.* 2015;373:689–91.
29. Morales A, Schulman CC, Tostain J, Wu FCW. Testosterone deficiency syndrome (TDS) needs to be named appropriately—the importance of accurate terminology. *Eur Urol.* 2006;50:407–9.
30. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, EMAS Group. Identification

- of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010;363:123–35.
31. Miner MM, Seftel AD. Testosterone and ageing: what have we learned since the institute of medicine report and what lies ahead? *Int J Clin Pract.* 2007;61:622–32.
 32. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. *J Androl.* 2009;30:1–9.
 33. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95:2536–59.
 34. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. Guidelines on male hypogonadism. Arnhem (The Netherlands): European Association of Urology; 2015. Available: <http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-Hypogonadism-2015.pdf>.
 35. Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. *Clin Endocrinol (Oxf).* 2007;67:853–62.
 36. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. *Clin Endocrinol (Oxf).* 2003;58:710–7.
 37. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab.* 2004;89:534–43.
 38. Moal V, Mathieu E, Reynier P, Malhiery Y, Gallois Y. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques. *Clin Chim Acta.* 2007;386:12–9.
 39. Rosner W, Vesper H, Endocrine Society, American Association for Clinical Chemistry, American Association of Clinical Endocrinologists, Androgen Excess/PCOS Society, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, et al. Toward excellence in testosterone testing: a consensus statement. *J Clin Endocrinol Metab.* 2010;95:4542–8.
 40. Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. *J Steroid Biochem Mol Biol.* 2010;121:513–9.
 41. Huhtaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Silman AJ, Vanderschueren D, Forti G, Wu FC, EMAS Group. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. *Eur J Endocrinol.* 2012;166:983–91.
 42. Hammes A, Andreassen TK, Spoelgen R, Raila J, Hubner N, Schulz H, Metzger J, Schweigert FJ, Lippa PB, Nykjaer A, Willnow TE. Role of endocytosis in cellular uptake of sex steroids. *Cell.* 2005;122:751–62.
 43. Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. *Clin Chem.* 2008;54:458–60.
 44. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.* 1999;84:3666–72.
 45. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem.* 1982;16:801–10.
 46. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. *Steroids.* 2009;74:512–9.
 47. Zakharov MN, Bhasin S, Travison TG, Xue R, Ulloor J, Vasani RS, Carter E, Wu F, Jasuja R. A multi-step, dynamic allosteric model of testosterone's binding to sex hormone binding globulin. *Mol Cell Endocrinol.* 2015;399:190–200.
 48. Nanjee MN, Wheeler MJ. Plasma free testosterone — is an index sufficient? *Ann Clin Biochem.* 1985;22:387–90.
 49. Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. *Eur J Endocrinol.* 2005;152:471–8.
 50. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. *Ann Clin Biochem.* 2009;46:137–43.
 51. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. *J Clin Endocrinol Metab.* 1981;53:58–68.
 52. Burke CW, Anderson DC. Sex-hormone-binding globulin is an oestrogen amplifier. *Nature.* 1972;240:38–40.

53. de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE, de Jong FH. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. *Clin Chem*. 2006;52:1777–84.
54. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, Handelsman DJ. Accuracy of calculated free testosterone formulae in men. *Clin Endocrinol (Oxf)*. 2010;73:382–8.
55. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, Neubauer G, Klibanski A. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. *J Clin Endocrinol Metab*. 2004;89:525–33.
56. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Riboli E, Toniolo P, Kaaks R. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. *Cancer Epidemiol Biomark Prev*. 2002;11:1065–71.
57. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab*. 2007;92:405–13.
58. Bhasin S, Zhang A, Coviello A, Jasuja R, Ulloor J, Singh R, Vesper H, Vasani RS. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. *Steroids*. 2008;73:1311–7.
59. Antonio L, Wu FC, O'Neill TW, Pye SR, Ahern TB4, Laurent MR, Huhtaniemi IT, Lean ME, Keevil BG, Rastrelli G, Forti G, Bartfai G, Casanueva FF, Kula K, Punab M, Giwercman A, Claessens F, Decallonne B, Vanderschueren D, EMAS Study Group. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. *J Clin Endocrinol Metab*. 2016;101:2647–57.
60. Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Keevil B, Maggi M, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC, EMAS Study Group. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. *J Clin Endocrinol Metab*. 2015;100:3172–82.
61. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli R, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS, Testosterone Trials Investigators. Effects of testosterone treatment in older men. *N Engl J Med*. 2016;374:611–24.
62. Brock G, Heiselman D, Maggi M, Kim SW, Rodriguez Vallejo JM, Behre HM, McGettigan J, Dowsett SA, Hayes RP, Knorr J, Ni X, Kinchen K. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. *J Urol*. 2016;195:699–705.
63. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. *J Clin Endocrinol Metab*. 2004;89:5920–6.
64. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E, Maggi M. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. *Eur J Endocrinol*. 2013;168:829–43.
65. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. *J Clin Endocrinol Metab*. 2003;88:1730–6.
66. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. *Int J Obes Relat Metab Disord*. 2002;26:1407–33.
67. Garcia-Galiano D, Allen SJ, Elias CF. Role of the adipocyte-derived hormone leptin in reproductive control. *Horm Mol Biol Clin Invest*. 2014;19:141–9.
68. Tena-Sempere M. Interaction between energy homeostasis and reproduction: central effects of leptin and ghrelin on the reproductive axis. *Horm Metab Res*. 2013;45:919–27.
69. Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. *Semin Reprod Med*. 2002;20:139–44.
70. Matejek N, Weimann E, Witzel C, Mölenkamp G, Schwidrigall S, Böhles H. Hypoleptinaemia in patients with anorexia nervosa and in elite gymnasts with anorexia athletica. *Int J Sports Med*. 1999;20:451–6.
71. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. *N Engl J Med*. 2004;351:987–97.
72. van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. *Obes Res*. 2003;11:377–86.
73. Banks WA. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. *Curr Pharm Des*. 2001;7:125–33.
74. Kwon O, Kim KW, Kim MS. Leptin signalling pathways in hypothalamic neurons. *Cell Mol Life Sci*. 2016;73:1457–77.

75. Finn PD, Cunningham MJ, Pau KY, Spies HG, Clifton DK, Steiner RA. The stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey. *Endocrinology*. 1998;139:4652–62.
76. Quennell JH, Mulligan AC, Tups A, Liu X, Phipps SJ, Kemp CJ, Herbison AE, Grattan DR, Anderson GM. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. *Endocrinology*. 2009;150:2805–12.
77. Smith JT, Acohido BV, Clifton DK, Steiner RA. KiSS-1 neurones are direct targets for leptin in the ob/ob mouse. *J Neuroendocrinol*. 2006;18:298–303.
78. George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. *Clin Endocrinol (Oxf)*. 2013;79:100–4.
79. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. *FEBS J*. 2009;276:5755–67.
80. Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, Rastrelli G, Maneschi E, Cellai I, Persani L, Adorini L, Vannelli GB, Maggi M. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. *Mol Cell Endocrinol*. 2014;382:107–19.
81. Veldhuis J, Yang R, Roelfsema F, Takahashi P. Proinflammatory cytokine infusion attenuates LH's feedforward on testosterone secretion: modulation by age. *J Clin Endocrinol Metab*. 2016;101:539–49.
82. Porte D Jr, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from *C. elegans* to humans. *Diabetes*. 2005;54:1264–76.
83. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. *Nature*. 2000;404:661–71.
84. Divall SA, Williams TR, Carver SE, Koch L, Brüning JC, Kahn CR, Wondisford F, Radovick S, Wolfe A. Divergent roles of growth factors in the GnRH regulation of puberty in mice. *J Clin Invest*. 2010;120:2900–9.
85. Qiu X, Dowling AR, Marino JS, Faulkner LD, Bryant B, Brüning JC, Elias CF, Hill JW. Delayed puberty but normal fertility in mice with selective deletion of insulin receptors from Kiss1 cells. *Endocrinology*. 2013;154:1337–48.
86. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. *Science*. 2000;289:2122–5.
87. Burcelin R, Thorens B, Glauser M, Gaillard RC, Pralong FP. Gonadotropin-releasing hormone secretion from hypothalamic neurons: stimulation by insulin and potentiation by leptin. *Endocrinology*. 2003;144:4484–91.
88. Gamba M, Pralong FP. Control of GnRH neuronal activity by metabolic factors: the role of leptin and insulin. *Mol Cell Endocrinol*. 2006;254–255:133–9.
89. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. *BJU Int*. 2016;117:677–85.
90. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. *Eur J Endocrinol*. 2008;158:741–7.
91. Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, Dandona P. Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. *Diab Care*. 2011;34:1854–9.
92. Dhindsa S, Batra M, Kuhadiya N, Dandona P. Oestradiol concentrations are not elevated in obesity-associated hypogonadotropic hypogonadism. *Clin Endocrinol (Oxf)*. 2014;80:464.
93. Aarts E, van Wageningen B, Loves S, Janssen I, Berends F, Sweep F, de Boer H. Gonadal status and outcome of bariatric surgery in obese men. *Clin Endocrinol*. 2014;81:378–86.
94. Pellitero S, Olaizola, Alastrue A, Martínez E, Granada ML, Balibrea JM, Moreno P, Serra A, Navarro-Díaz M, Romero R, Puig-Domingo M. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. *Obes Surg*. 2012;22:1835–42.
95. Hammoud A, Gibson M, Hunt SC, Adams TD, Carrell DT, Kolotkin RL, Meikle AW. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. *J Clin Endocrinol Metab*. 2009;94:1329–32.
96. Yanase T, Fan W, Kyoya K, Min L, Takayanagi R, Kato S, Nawata H. Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. *J Steroid Biochem Mol Biol*. 2008;109:254–7.
97. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. *Diabetes*. 2005;54:1717–25.
98. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. *Endocrinology*. 2006;147:141–54.
99. Gupta V, Bhasin S, Guo W, Singh R, Miki R, Chauhan P, Choong K, Tchkonja T, Lebrasseur NK, Flanagan JN, Hamilton JA, Viereck JC, Narula NS, Kirkland JL, Jasuja R. Effects of dihydrotestosterone

- on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. *Mol Cell Endocrinol*. 2008;296:32–40.
100. Maneschi E, Morelli A, Filippi S, Cellai I, Comeglio P, Mazzanti B, Mello T, Calcagno A, Sarchielli E, Vignozzi L, Saad F, Vettor R, Vannelli GB, Maggi M. Testosterone treatment improve metabolic syndrome-induced adipose tissue derangements. *J Endocrinol*. 2012;215:347–62.
 101. Maneschi E, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I, Comeglio P, Sarchielli E, Calcagno A, Mazzanti B, Vettor R, Vannelli GB, Adorini L, Maggi M. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. *J Endocrinol*. 2013;218(215):31.
 102. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. *Endocrinology*. 2003;144:5081–8.
 103. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. *Eur Urol*. 2015;67:825–36.
 104. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. *J Cancer Surviv*. 2010;4:128–39.
 105. Bosco C, Crawley D, Adolffson J, Rudman S, Van Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. *PLoS ONE*. 2015;10:e0117344.
 106. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med*. 2013;369:2457.
 107. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. *Ann Epidemiol*. 1992;2:675–82.
 108. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. *Int J Obes Relat Metab Disord*. 2000;24:485–91.
 109. Antonio L, Wu FC, O'Neill TW, Pye SR, Carter EL, Finn JD, Rutter MK, Laurent MR, Huhtaniemi IT, Han TS, Lean ME, Keevil BG, Pendleton N, Rastrelli G, Forti G, Bartfai G, Casanueva FF, Kula K, Punab M, Giwercman A, Claessens F, Decallonne B, Vanderschueren D, EMAS Study Group. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. *J Clin Endocrinol Metab*. 2015;100:1396–404.
 110. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klubanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab*. 1996;81:4358–65.
 111. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. *J Clin Endocrinol Metab*. 1996;81:3654–62.
 112. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. *J Clin Endocrinol Metab*. 1997;82:407–13.
 113. Schwarz ER, Willix RD Jr. Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men. *J Geriatr Cardiol*. 2011;8:201–6.
 114. Rodriguez-Tolrà J, TorremadéBarreda J, del Rio L, di Gregorio S, Franco Miranda E. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. *Aging Male*. 2013;16:184–90.
 115. Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. *Int J Obes (Lond)*. 2016;40:162–70.
 116. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M. Testosterone supplementation and body composition: results from a meta-analysis study. *Eur J Endocrinol*. 2016;174:R99–116.
 117. Grossmann M, Hoermann R, Wittert G, Yeap BB. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. *Clin Endocrinol (Oxf)*. 2015;83:344–51.
 118. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, Green K, Makdissi A, Hejna J, Chaudhuri A, Punyanitya M, Dandona P. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. *Diab Care*. 2016;39:82–91.
 119. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2011;96:3007–19.
 120. Pye SR, Huhtaniemi IT, Finn JD, Lee DM, O'Neill TW, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Rutter MK, Vanderschueren D,

- Wu FC, EMAS Study Group. Late-onset hypogonadism and mortality in aging men. *J Clin Endocrinol Metab.* 2014;99:1357–66.
121. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. *Best Pract Res Clin Endocrinol Metab.* 2011;25:337–53.
122. Wu FC, von Eckardstein A. Androgens and coronary artery disease. *Endocr Rev.* 2003;24:183–217.
123. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. *Circulation.* 2007;116:2427–34.
124. Tharp DL, Masseau I, Ivey J, Ganjam VK, Bowles DK. Endogenous testosterone attenuates neointima formation after moderate coronary balloon injury in male swine. *Cardiovasc Res.* 2009;82:152–60.

Androgen Replacement Therapy in Hypogonadal Men

18

Jonas Čeponis MD, PhD, Ronald S. Swerdloff MD
and Christina Wang MD

Contents

Introduction	369	Metabolic Parameters.....	376
Who Should Receive Androgen Replacement Therapy? How Is Male Hypogonadism Diagnosed?	370	Lipid Profile	376
What Are the Contraindications to Androgen Replacement Therapy in Hypogonadal Men?	372	Cardiovascular Disease Risk	377
What Safety Tests Should Be Done Before Start of Androgen Replacement?	372	Prostate Disease	382
What Are the Benefits and Risks of Androgen Replacement Therapy?	372	Hematocrit, Hemoglobin, and Liver Function Tests	383
Sexual Function	372	Other Possible Adverse Effects	384
Mood and Well-Being	373	What Are the Available Androgen Preparations?	384
Cognitive Function	374	Injectables	385
Bone Mineral Density (BMD).....	374	Oral.....	386
Body Composition.....	375	Transdermal Gels, Lotion, and Patches.....	387
		Transmucosal Preparations	388
		Implants.....	388
		Selective Androgen Receptor Modulators (SARMs)	388
		How Do We Monitor Androgen Replacement Therapy?	389
		Conclusions	389
		References	390

J. Čeponis
Department of Endocrinology, Lithuanian University
of Health Sciences, 2 Eiveniu St., 50009 Kaunas,
Lithuania
e-mail: jceponis@labiomed.org

R.S. Swerdloff
Harbor UCLA Medical Center Los Angeles,
Biomedical Research Institute, 1124 W. Carson St.,
Torrance, CA 905025, USA
e-mail: swerdloff@LABioMed.org

C. Wang (✉)
Harbor UCLA Medical Center and Los Angeles
Biomedical Research Institute, UCLA Clinical and
Translational Science Institute, 1000 W. Carson St.,
Torrance, CA 90509, USA
e-mail: wang@labiomed.org

Introduction

The preceding chapters have discussed the various etiologies of male hypogonadism. In this chapter, we will discuss the criteria for embarking on androgen replacement, the benefits and potential adverse effects of androgen replacement, and current and future treatment options. There has been significant progress in the field of androgen replacement for hypogonadal men in the past decade including a better understanding of who to treat, new and confirmed treatment targets, and new delivery systems, but there are also new controversies concerning long-term cardiovascular and prostate safety.

Who Should Receive Androgen Replacement Therapy? How Is Male Hypogonadism Diagnosed?

The T prescription rate for men over 40 years of age in the US tripled from 2001 to 2011. Of those receiving T therapy, only 74.7% had T levels measured, and the common diagnoses for T treatment included hypogonadism, erectile dysfunction and psychosexual dysfunction, and fatigue [1]. This increase in testosterone prescription may be due to increased awareness of hypogonadism and the benefits of T treatment by physicians and/or direct-to-consumer marketing of new T products. The United States Food and Drug Administration stated that T replacement therapy should be administered for men with classic hypogonadism that is caused by specific well-recognized medical conditions, and that available evidence does not support testosterone treatment for late onset, age-related, or idiopathic hypogonadism [2].

Men with androgen deficiency, defined as persistently low serum T concentrations, may present with decreased libido, impaired erectile function, decreased body and facial hair, easy fatigability, decreased muscle mass and strength, increased body fat, bone pain or fractures due to low bone mineral density (BMD), and increased negative mood parameters such as irritability, nervousness, inability to concentrate, and poor quality of life. Data from the European Male Aging Study (EMAS) and The Testosterone Trials (The T Trials), reveal that sexual symptoms including sexual activity, erectile dysfunction, loss of morning erections, and decreased sexual desire are best predictive of low T levels and are the commonest symptoms reported in middle-aged and older men [3, 4]. Because most of these symptoms are nonspecific, initiation of treatment should not be based on symptoms alone, but must include a persistently low serum T level [5].


For confirmation of the diagnosis of male hypogonadism, the total serum T should be measured in the morning because of the known diurnal variation of serum T concentrations with highest levels in the morning hours. It has been recognized

that there are large variations between methods and laboratories in measured serum T levels by direct immunoassays (radio-immunoassays, enzyme-linked immunosorbent assays, and chemiluminescent immunoassays) which are performed without sample extraction and chromatography. These assays are precise but not accurate, and some lack specificity and sensitivity. The preferred method for T assessment is by liquid chromatography–tandem mass spectrometry (LC-MS/MS) especially for samples in which low T concentrations are anticipated [6–8]. The Center for Disease Control in the United States established a program for harmonization of hormone assays. The program qualifies the laboratory and then provides continuous external testing to ensure that T results reported by the laboratories are accurate, irrespective of the methods used [9–11]. Similar hormone standardization programs exist in the European Union and Australia. The reference ranges for adults may differ for the various methods. Therefore, clinicians should carefully review the reference range quoted by each laboratory to make a diagnosis of hypogonadism based on serum T levels [7, 12]. The reference range should be based on serum values from healthy young adult men. Serum total T assays in which the reference ranges are significantly different from 300 to 1000 ng/dl (10.4–35 nmol/l) may need further validation by accuracy-based proficiency testing.

It is generally accepted that, based on a reference range of serum T levels in healthy adult young men of 300–1000 ng/dl (10.4–34.8 nmol/l), if the serum T level is <250 ng/dl (8.7 nmol/l) and there are symptoms suggestive of hypogonadism, the patient is most likely hypogonadal, and the cause for the hypogonadism should be identified (Fig. 18.1). If the serum T level is over 350 ng/dl (12.2 nmol/l), the patient is likely to be eugonadal and other causes of his symptoms should be investigated. If a morning total serum T level is in the lower normal or slightly below the normal range, a repeat test is suggested together with the measurement of free or bioavailable (non-SHBG bound) T [13–18].

Variations in sex hormone binding globulin (SHBG) gene polymorphisms and SHBG levels directly affect T levels (see Chap. 15). In

Fig. 18.1 Who should be treated with androgen replacement therapy?



genome-wide association studies, two single nucleotide polymorphisms were independently associated with serum T levels. One of the polymorphisms affects the ability of SHBG to bind T [19]. Most studies indicate that SHBG levels in men increase with age, which may mask hypogonadism because total T levels may be normalized by higher SHBG with aging [20]. In contrast, in overweight and/or insulin resistant men, total T may be low because the level of SHBG is low [21, 22]. Measuring free and/or bioavailable T in these situations is helpful.

Serum free T should be measured by equilibrium dialysis [16] which is available from most reference laboratories. If the free T measured by equilibrium dialysis is not available, the physician may request a measurement of sex hormone binding globulin (SHBG) and calculate the free T according to an established formula [23] (<http://www.issam.ch/freetesto.htm>). However, the applicability of mathematical estimation models to all patients has been questioned as it is based on a predefined affinity of SHBG to bind T, and this affinity may vary [24–26]. Many clinical laboratories continue to measure serum free T using analog displacement assays using automated platforms with chemiluminescent labeled reagents. Such assays of free T do not

accurately assess the free T fraction [27, 28], the levels are very low compared to measurements by equilibrium dialysis, and should not be used clinically [29]. Bioavailable T is the fraction of T in the serum that is the sum of free and albumin bound. This can be calculated or measured after ammonium sulfate treatment of the serum. The SHBG-bound hormone is precipitated and the supernatant containing the free and albumin bound fraction is quantitated by a serum T assay [14, 15]. Assays for bioavailable T are not available in many laboratories, and reference ranges have to be established by each laboratory.

If the repeat morning serum T level and/or the serum free T or bioavailable T levels are below the reference range of the laboratory, and the patient presents with symptoms consistent with hypogonadism, he may be considered for T replacement therapy if there are no contraindications; individuals with comorbid conditions that could produce transient stress may have treatment delayed, as treatment for the underlying condition should first be addressed. Next, the levels of LH and FSH should be determined. The finding of an elevated serum LH level is confirmatory for primary hypogonadism in men with low or borderline low serum T levels. Patients with functional or structural hypogonadotropic

hypogonadism will have low or inappropriately normal serum LH concentration coupled with low serum T concentrations. While the only therapeutic option for primary hypogonadism is testosterone replacement, patients with hypogonadotropic hypogonadism may have intact testicular function with appropriate gonadotropic stimulation, and they may benefit from alternative treatment modalities that stimulate testosterone secretion and sperm production such as gonadotropins and antiestrogens or aromatase inhibitors. Given the important function of estrogens in bone mass, fat accumulation, and perhaps sexual function in healthy men [30, 31], agents that decrease serum estrogens to low levels are probably not appropriate for the long-term management of hypogonadism [32].

What Are the Contraindications to Androgen Replacement Therapy in Hypogonadal Men?

The absolute contraindications to androgen replacement therapy are untreated or active prostate and breast cancer, as these are androgen-dependent tumors. The other contraindication is an elevated hematocrit or hemoglobin level (e.g., hematocrit >54%). Androgen treatment may cause fluid retention, and in unusual circumstances precipitate or aggravate heart failure. In older patients with symptoms or signs of moderate or of severe congestive heart failure, androgens should not be used until the heart failure has been treated.

While there is minimal evidence to implicate T in the development or aggravation of benign prostate hyperplasia (BPH), if a patient has significant lower urinary tract obstructive symptoms due to BPH then the symptoms should be controlled before instituting T replacement. Obese and older subjects who may be at risk of sleep apnea should be carefully questioned about their ventilatory disturbances during sleep. Patients with moderate or severe obstructive sleep apnea symptoms should be appropriately evaluated or treated before the start of T replacement therapy. On the other hand, recent studies also reveal that

testosterone deficiency is associated with obstructive sleep apnea especially in obese subjects [33].

What Safety Tests Should Be Done Before Start of Androgen Replacement?

A digital rectal examination and a serum prostate specific antigen test (PSA) should be performed to assess prostate abnormalities before a middle-aged or older patient is started on androgen treatment, or if the patient presents with a history of lower urinary tract symptoms. If the serum PSA level is elevated, or nodules or irregularities are found, the patient should be referred for Urological assessment. In general, a PSA concentration of >4 ng/ml indicates that the patient should be referred to an Urologist before considering androgen replacement. A complete blood count, liver function tests, HbA1C, and a lipid panel should be performed to ensure that the subject does not have an elevated hemoglobin or hematocrit and to assess the baseline liver enzymes and serum total, LDL and HDL-cholesterol since NAFLD, diabetes and dyslipidemia are common in men seeking treatment for adult onset hypogonadism.

What Are the Benefits and Risks of Androgen Replacement Therapy?

Androgen administration induces pubertal changes in patients who have not undergone puberty. In adult subjects, androgen maintains and restores secondary sex characters including facial, body, and pubic hair, the lower tone voice, external genitalia appearance, and the growth of the prostate. The risks and benefits of testosterone replacement therapy are summarized in Table 18.1 and described in the following sections.

Sexual Function

Androgen replacement has been shown to improve sexual function more in younger than in

Table 18.1 Benefits and risks of androgen therapy

Benefits	Risks
<ul style="list-style-type: none"> • Improves sexual function • Maintains secondary sex characters • ↑ Bone mass, muscle mass, and strength • Decreased fat mass (visceral adiposity) • Improves mood in hypogonadal men? • Cognitive function? • Metabolic benefits? • Coronary vasodilation? • Decrease cardiovascular disease risk? 	<ul style="list-style-type: none"> • Acne, oily skin • Decreased testis volume and suppressed spermatogenesis • ↑ Hematocrit/hemoglobin • Gynecomastia (with some preparations) • Weight gain, fluid retention • ↓ HDL, ↑ LDL: HDL ratio • Sleep apnea? • Increased cardiovascular disease risk? • Prostate dysfunction (benign prostatic hyperplasia, prostate cancer)?

older hypogonadal men. These include sexual desire (libido), sexual fantasies, sexual enjoyment and frequency of sexual thoughts, sexual activities, and erectile function in hypogonadal men. In younger hypogonadal men, sexual performance including erectile dysfunction is improved by androgen replacement therapy [34–38]. In older men, erectile dysfunction is frequently multifactorial, other causes such as vascular, neurogenic, psychogenic, medication-induced, and cavernosal problems may coexist. Therefore, improvement in erectile function following T treatment of androgen deficient older men may be less than in younger subjects [39, 40]; however, several controlled trials have shown some beneficial effects [41–43]. While objective data are limited and controversial, it is possible that androgen deficient older men whose erectile dysfunction has been improved by phosphodiesterase V inhibitors (e.g., Sildenafil, Vardenafil, Tadalafil), sexual performance may benefit from cotreatment with T through improvement in libido [42, 44]. When T was administered to older men with low or low normal T levels (<400 ng/dl, 13.9 nmol/l) for three years, there was no improvement in sexual desire, erectile dysfunction, or overall sexual function compared to placebo [45]. In a recent randomized, double-blind, placebo-controlled trial in hypogonadal older men with serum T levels <275 ng/dl (9.5 nmol/l), testosterone replacement resulting in physiological T concentrations moderately improved sexual activity, sexual desire, and erectile function scores as assessed by standardized questionnaires in both men with and without symptoms of sexual dysfunction. This is confirmed by the global impression of increase in

libido [43]. It should be noted that androgen replacement to restore serum T to the low normal range appears to induce maximum sexual function improvement in hypogonadal men [35, 36, 38, 46]. Once a threshold level of serum T is achieved with androgen replacement therapy, it has been suggested that further increase in serum T levels may not increase sexual motivation or performance [17, 47].

Mood and Well-Being

While there is no definitive answer whether quality of life improves after androgen replacement in young or older hypogonadal men, improvement in sexual function and mood, working in synchrony may improve quality of life in hypogonadal men. Anecdotal reports have indicated that androgen treatment may cause increased anger and “rage” attacks in men. Moreover, higher salivary T levels were found in athletes and other subjects who were engaged in competitive activities [48]. In a placebo-controlled study in normal men who were administered testosterone at a supra-physiological dose for up to 20 weeks, there was no significant change in aggression and mood parameters [49, 50]. Uncontrolled studies of hypogonadal men who were administered different T preparations have demonstrated enhanced positive mood parameters such as well-being, energy, friendliness, and a reduction in negative mood parameters including anger, fatigue, irritability, and nervousness [49, 51–53]. Thus, in contrast to anecdotal reports, T treatment in placebo-controlled and uncontrolled studies in hypogonadal and eugonadal men either has no effect or appears to improve mood [54];

however, the data remain conflicting. There are no data on beneficial effects in men with established clinical depression [41, 55]. Recently published results of randomized placebo-controlled trials of testosterone replacement (The Testosterone Trials) suggested slight improvement in mood and depressive symptoms in those receiving T replacement compared to placebo-treated older men [43].

Cognitive Function

Studies of cognitive function in hypogonadal younger men are lacking except for uncontrolled studies in men with Klinefelter syndrome in whom T replacement improved verbal skills [56–58]. In younger eugonadal men rendered hypogonadal by exogenous administration of a progestin, verbal memory was reduced, which corrected when T was coadministered with the progestin [59]. In older hypogonadal men, several well-controlled studies with limited numbers of subjects reported better performance on spatial ability, and in some studies, verbal memory also improved [60–63] after androgen replacement. Thus, whether T improves cognitive function remains unanswered.

Bone Mineral Density (BMD)

Androgens are required to achieve peak bone mass in adolescence, and are responsible for the higher BMD in men compared to women. Hypogonadism results in a progressive decrease in bone mass, and is one of the causes of osteoporosis in men. With aging, a progressive loss of BMD is associated with an increased fracture rate. Interestingly, BMD in older men is more strongly positively correlated with serum free estradiol than serum free testosterone levels [64, 65]. The few case reports of estrogen receptor mutations and aromatase deficiency in males all described the presence of severe osteoporosis [66–68]. Thus, the current hypothesis is that estrogens are required for maintaining peak BMD in men [69, 70]. A recent study in induced hypogonadism in which graded doses of

T replacement were administered in the presence or absence of an aromatase inhibitor showed a consistent decline in BMD when an aromatase inhibitor was coadministered with T, and this decline was independent of T replacement dose. While it is apparent that estrogen is the primary sex steroid regulator of bone mass in men [71], T also has positive effects on BMD possibly through both estrogen and androgen receptors [72]. The level of estrogen activity in the target tissues required to maintain BMD is not known, but in one study, serum estradiol >10 pg/ml (36.7 pmol/l) and testosterone levels >200 ng/dl (6.9 nmol/l) prevented increases in bone resorption and loss in BMD [71]. In the MrOs study of community dwelling older men, higher SHBG levels were associated with a higher likelihood of prevalent vertebral fracture, and men with serum estradiol levels equal to or less than 17 pg/ml (62.4 pmol/l) had a slightly higher likelihood of prevalent fracture than those with higher levels. Moreover, new or worsening vertebral fracture was associated with higher serum SHBG but not with serum T and estradiol [73].

Androgen replacement by injections, oral, or transdermal preparations have been shown to increase BMD in younger hypogonadal men [38, 74, 75]. The increase in BMD is accompanied by early elevations of bone formation markers and decreases in bone resorption markers [37, 38, 74, 76]. In older men, androgen administration resulted in increased BMD in some studies [77] but not others [78–80]. A randomized controlled trial in hypogonadal men older than age 50, with frailty and osteoporosis, showed significant improvement in lumbar and femoral neck BMD after 12 months of T replacement [81]. The peak increase in bone mineral density has been observed after 12–24 months of androgen replacement [75, 78]. In general, the lower the BMD and serum T level before treatment, the greater the improvement in BMD with T replacement [38, 78]. Though significant changes in BMD have occurred in hypogonadal men after long-term androgen replacement, randomized controlled studies to examine the effect of androgens on bone fractures have not been performed.

Body Composition

A meta-analysis of changes in body composition after T administration to middle-aged and older men including 29 randomized, controlled trials showed that T decreased fat mass (-6.2%), increased fat-free mass (+2.7%), but caused no change in overall body weight [82]. The conclusion is supported by a more recent meta-analysis of T treatment on body composition in 69 randomized placebo-controlled studies (Fig. 18.2) [83]. It is well established that androgens cause nitrogen retention in the body. Androgen treatment increases lean body mass and muscle mass by increasing muscle protein synthesis [84] to induce muscle fiber hypertrophy [85]. Androgens administered as sublingual tablets, injections or transdermal gels have increased muscle (lean) mass assessed by dual

energy X-ray absorptiometry (DEXA) scans in both younger and older hypogonadal men [37, 38, 74, 78, 86, 87]. The increase in muscle mass is associated with increased muscle strength in younger hypogonadal men in both the upper and lower limbs assessed by a number of different techniques [37, 38, 74, 78, 86]. Muscle strength is difficult to quantify in a standardized manner, especially in older men [88], but improvement in strength has recently been demonstrated [40, 77, 87]. Several randomized controlled trials have shown improvements in specific strength measurements after T therapy, such as isometric knee extension, gastrocnemius muscle thickness [89], leg press strength, chest press strength, and climbing power [90] but not in other measures such as grip strength [91, 92], carried load, or gait speed [90, 93]. The increase in muscle mass and strength is directly related to the amount of




Fig. 18.2 Effect of testosterone therapy on body composition and other metabolic parameters. Weighted mean differences (with 95% CI) of body weight, waist circumference, BMI, fat and lean mass, fasting glycemia, HOMA

index, total cholesterol, triglycerides, systolic (SBP), and diastolic (DBP) blood pressure at end point studies used in the meta-analysis. From Corona et al. [83]. Reprinted with permission from Bioscientifica Ltd.

testosterone administered and to serum T concentrations [46]. However, these increases in muscle mass and strength do not increase walk speed [43] or other daily activities of older men. The only study of T and coordination was in adolescent soccer players in whom serum T levels were positively correlated with soccer-specific performance laboratory tests [94].

Concomitant with increases in lean mass after androgen substitution in hypogonadal men, are consistent decreases in fat mass and percent body fat measured by DEXA, or visceral fat measured by abdominal CT or MRI scan. Decreases in subcutaneous fat, as well as adiponectin levels were observed in elderly men after six months of testosterone gel treatment [95]. Decrease in fat mass has been demonstrated with injectables and transdermal testosterone but not with sublingual T [37, 38, 74, 78, 86], and the effect of oral TU was less than that of intramuscular T injections [96] which may be related to the amount of T delivered and the serum T levels achieved. A dose-response study in normal men showed that the decrease in fat mass is directly related to the serum T level achieved and the dose of T administered [46]. Decreases in fat mass are also observed in middle-aged or older men receiving T [59, 77, 97]. The decrease in visceral fat observed in some studies has been suggested to result in decreased insulin resistance. A recent meta-analysis showed increases in lean mass and decreased fat mass while using either injectable or oral T formulations [98]. Another study showed a decrease in fat mass and increase in lean mass resulting in no net change in total body mass [99]. Similar positive effects were observed in patients with metabolic syndrome and type 2 diabetes [42, 100, 101].

Metabolic Parameters

A recent meta-analysis of 59 randomized controlled studies showed that T supplementation resulted in a reduction of fasting glucose and decreased insulin resistance (Fig. 18.2) [83]. T replacement has been reported to decrease insulin resistance and improve glycemic control

in some studies of hypogonadal men with diabetes [100, 102–104]; however, improvement has not been consistent across all studies [105]. A recent study in hypogonadal men with diabetes and/or metabolic syndrome reported a decrease in insulin resistance after 6 months with no further benefit after 12 months of T replacement using a testosterone gel [42]. While another study of testosterone treatment in patients with type 2 diabetes failed to show significant effects on insulin resistance, a very small but significant reduction in HbA1c was noted, with most improvement in poorly controlled patients [41].

Testosterone replacement also improved serum inflammation markers in patients with type 2 diabetes and metabolic syndrome [100, 106, 107]. The metabolic benefits of T treatment in obesity, type 2 diabetes and metabolic syndrome, and the impact on cardiovascular disease risks are complex [108]. This field remains controversial and the results are inconclusive, and large randomized controlled studies are needed in men with low T levels with close attention to covariates.

Lipid Profile

Supra-physiological doses of T esters administered to healthy men in male contraceptive trials resulted in significant suppression of serum HDL-cholesterol levels and a decrease in HDL to total cholesterol ratios [109]. On the other hand, serum HDL-cholesterol levels were not significantly changed in hypogonadal men administered transdermal T in patches or gels [38, 110–112]. A meta-analysis of 51 testosterone replacement studies has shown a slight decrease in HDL-cholesterol [113] while another meta-analysis of studies in men with total T <346 ng/dl (12 nmol/l) showed reduction of total cholesterol and triglycerides without any effect on HDL-cholesterol [83]. The decrease in serum HDL-cholesterol was dependent on the dose of T administered and the serum T level achieved [114]. Thus, during androgen replacement of hypogonadal men with near physiological doses of testosterone, significant changes in serum lipid

levels are uncommon. Moreover, the possible negative effect of a slight lowering of serum HDL-cholesterol levels needs to be considered together with effects of T on other lipoproteins, coagulation, and fibrinolytic factors. The role of HDL in cardiovascular disease has been recently revisited, and the levels of HDL-cholesterol may not be as important as the type and metabolism of HDL [115, 116].

Cardiovascular Disease Risk

Low T levels are associated with established cardiovascular risk factors, such as obesity, metabolic syndrome, and type 2 diabetes. In men undergoing coronary angiogram, men with demonstrable coronary artery disease had a significantly lower serum free androgen index and bioavailable T levels than those who did not have evident coronary artery disease [117, 118]. A number of studies have shown that testosterone replacement may improve risk factors for cardiovascular disease, such as fat mass, insulin resistance, inflammatory markers, and other features of metabolic syndrome (see Section “Metabolic Parameters,” Fig. 18.2). Other large epidemiological studies have shown that men with lower serum T levels have a higher risk of cardiovascular events and all-cause mortality [119–124] (Table 18.2).

In patients with cardiovascular disease, short term administration of T showed variable results. A study showed decreased ST segment depression and anginal symptoms in men with cardiovascular disease treated with T [125, 126]. Acute administration of T to men with exercise-induced myocardial ischemia reduced ST segment depression and increased exercise testing time compared to placebo [127, 128]. Because of this acute action of T, the effect may be ascribed to a direct coronary vasodilatory effect of the steroid. A subsequent study confirmed this hypothesis by showing acute T infusion increased coronary artery diameter and coronary blood flow in men with established coronary artery disease compared to vehicle administration [129]. However, others failed to demonstrate a beneficial effect on acute stress-induced myocardial ischemia [130].

Concerns that T replacement in hypogonadal men may increase adverse cardiovascular events were heightened when a randomized controlled trial in elderly hypogonadal men with mobility limitations and high prevalence of chronic disease was discontinued early due to higher incidence of cardiovascular adverse events in T-treated men compared to the placebo group [131]. These elderly men received 1% transdermal T gel up to 15 g/day. This study, however, was not designed nor powered to evaluate cardiovascular outcomes. The recorded cardiovascular adverse events were not adjudicated by independent committee and were highly variable. Included in the reported major cardiovascular adverse effects were: syncope, elevated blood pressure, tachycardia, and peripheral edema. Despite another randomized controlled study in older intermediate-frail men that did not demonstrate an increase in cardiovascular adverse events [89], the former study engendered a number of reports raising concerns about the cardiovascular safety of T replacement. These more recent reports included case-cohort studies, analyses of prescription data from large databases, and meta-analyses.

A retrospective cohort study in veterans with low T levels (<300 ng/ml) and a high burden of comorbidities who underwent a coronary angiography showed that T use was associated with increased mortality and myocardial infarction and stroke. The absolute difference in cardiovascular event rates was 5.8% higher at 3 year after the coronary angiogram in men who had filled at least one T prescription compared to those who were not treated. In this cohort, 82.4% of the men filled more than one prescription [132]. In another study also of veterans with low T, replacement with T was associated with lower mortality compared with no T treatment [133]. These authors showed in a longitudinal study that serum T and calculated free T were not significantly associated with cardiovascular disease or mortality, but serum dihydrotestosterone (DHT) and free DHT had significant curvilinear association with incident cardiovascular events [134]. In a large case-cohort study of older men, T therapy did not increase the risk of myocardial infarction, and in men at high risk for myocardial infarction, T use was moderately protective

Table 18.2 Cardiovascular outcomes in clinical studies

Study	Design	Treatment	No. of subjects	Age	T cutoff	Duration	CVD Outcomes	All-cause mortality
Shores et al. [124]	Retrospective analysis of VA database	None	858	>40	N/A	Avg. 4.3 years	No CVD data	Low T associated with ↑ all-cause mortality (HR 1.88 (1.34–2.63))
Khaw et al. [120]	Nested case control	None	825 died to 1489 alive of 11,606	40–79	N/A	Avg. 7 years	Lowest quartile versus highest ↑ CV mortality, OR 1.89 (1.16–3.13)	Lowest quartile versus highest ↑ all-cause mortality, OR 1.69 (1.18–2.38); ↑ in T by 6 nmol/l associated with OR 0.81 (0.71–0.92) for all-cause mortality
Laughlin et al. [119]	Prospective observational	None	794	50–91	N/A	Avg. 11.8 years	Low T ↑ CVD mortality, HR 1.38 (1.02–1.85)	Lowest quartile (<241 ng/dl) ↑ all-cause mortality, HR 1.4 (1.14–1.71)
Shores et al. [224]	Longitudinal cohort study	None	1032	66–97	N/A	Median 9 years	Low DHT but not T ↑ incident CVD when adjusted for other CV risk factors	Low DHT ↑ all-cause mortality
Shores et al. [225]	Retrospective VA database study	Various T formulations (88.6% IM)	1031 (TRT in 398)	>40	≤ 250 ng/dl (8.7 nmol/l)	Avg. TRT duration 20 months	N/A	TRT ↓ all-cause mortality, HR 0.61 (0.42–0.88). Significant effects in younger (41–59), with diabetes and without CVD
Muraleedharan et al. [226]	Retrospective cohort (TIMES2 follow up)	Various T formulations (93.8% gel)	64 on TRT versus 174 no TRT with Type 2 diabetes	Avg. 60.3 ± 11.5	T < 300 ng/dl (≤ 10.4 nmol/l)	Avg. TRT duration 41.6 months	N/A	TRT ↓ all-cause mortality, HR 0.43 (0.26–0.77)
Vigen et al. [132]	Retrospective analysis of VA database	Various T formulations (63.3% patches)	1223 started TRT, 7486 did not; undergoing coronary angiogram	Avg. 63.8 ± 9	T < 300 ng/dl	~10 months of TRT	TRT ↑ CVD, HR 1.29 (1.04, 1.58). Nonsignificant difference in absolute risk	

(continued)

Table 18.2 (continued)

Study	Design	Treatment	No. of subjects	Age	T cutoff	Duration	CVD Outcomes	All-cause mortality
Finkle et al. [136]	Health-care prescription database study	Various T formulations (most common—gel)	55 593 men prescribed TRT	Avg. 54.4		1 year pre versus 90 days post prescription	TRT ↑Post/pre-prescription rate ratio for MI—1.36 (1.03–1.81), in >65 years—2.19 (1.27–3.77), in <65 with CV history—2.9 (1.49–5.62)	
Baillargeon et al. [135]	Retrospective cohort Medicare database	IM T	6355 at least 1 T injection versus 19065 matched controls	>66	N/A	Avg. follow up 49.8 months	TRT not associated with MI, HR 0.84 (0.71–1.05)	Men in highest quartile for MI prognostic score TRT ↓MI risk HR 0.69 (0.53–0.92)
Basaria et al. [131]	RCT multicenter, 3 centers	Trans-dermal T titrated to 500–1000 ng/dl	209	>65 limited mobility	TT 100–350 ng/dl (3.5–12.1 nmol/l) or FT <50 pg/ml (173 pmol/l)	6 months	TRT ↑ CV related AE, HR 5.8 (2.0–16.8); highest T quartile versus others, HR 2.4	
Calof et al. [227]	Meta-analysis		1084 (651 in TRT and 433 placebo) in 19 trials			Avg. 10 months	No TRT effect on CV events, OR 1.14 (0.59–2.20)	
Haddad et al. [228]	Meta-analysis		CV events reported in 6 trials (161 TRT and 147 placebo)				No TRT effect on CV events, OR 1.82 (0.78–4.23)	
Fernández-Balsells et al. [229]	Meta-analysis		2679 in 51 trials			3mo-3 years	No TRT effect on MI, RR 0.91 (0.29–2.82)	No TRT effect on mortality, RR 1.12 (0.7–1.81)

(continued)

Table 18.2 (continued)

Study	Design	Treatment	No. of subjects	Age	T cutoff	Duration	CVD Outcomes	All-cause mortality
Corona et al. [121]	Meta-analysis	Cross-sectional studies	5153 patients with and 7513 without CVD in 54 studies				T ↓ in CVD patients. Low T associated with CVD, HR 1.31 (1.28–1.34) for 1 nmol/l ↓ in T	
		Longitudinal:	12,375 subjects in 10 studies				Baseline T ↓ in those with incident CVD; no T difference between case and controls	Baseline T ↓ in those with all-cause mortality
		RCTs in CHD patients	128 pts with CHD received T and 129 - placebo in 6 RCTs			Avg. 23 weeks	TRT ↑ treadmill test duration and time to ST depression	
Toma et al. [230]	Meta-analysis	RCTs in HF patients	198 men with HF in 4 studies			12–52 weeks	TRT ↑ 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption	
Xu et al. [137]	Meta-analysis		2994 in 27 trials			At least 12 weeks	TRT ↑ CV event risk 1.54 (1.09–2.18) overall, in pharma non-funded studies 2.06 (1.34–3.17) but not in pharma funded 0.89 (0.5–1.6)	
Corona et al. [138]	Meta-analysis		5464 in 74 trials (MACE in 26)			Avg. 34 weeks	TRT not associated with MACE incidence, OR = 1.01 (0.57–1.77); In men with metabolic disease ↓ CVD	

(continued)

Table 18.2 (continued)

Study	Design	Treatment	No. of subjects	Age	T cutoff	Duration	CVD Outcomes	All-cause mortality
Albert et al. [140]	Meta-analysis		5328 in 45 trials	63.3 ± 7.9		10.6 ± 8.6 months	TRT not associated with CV risk overall, RR 1.10 (0.86–1.41). ↑ rate during first 12 mos, 1.79 (1.13–2.83); >65 years, 2.9 (1.35–6.21). IM T–0.96 (0.462–1.98), oral 2.28 (0.60–8.59), transdermal 2.80 (1.38–5.68)	

HR Hazard ratio, *OR* Odds ratio, *TRT* Testosterone replacement therapy, *IM* Intramuscular, *CV* Cardiovascular, *CVD* CV disease, *CHD* Coronary heart disease, *MACE* Major CV event, *MACE* Major adverse cardiovascular event

[135]. Another cohort study, using a large health-care database, showed that men who received a T prescription have a higher rate of myocardial infarction in the 90 days following the prescription compared to the rate 12 months prior to the prescription. The increase in myocardial infarction rates was observed in men over the age of 65 years. The post/pre-prescription rate difference in myocardial infarction was not observed in men instead prescribed phosphodiesterase 5 inhibitors [136]. It should be noted that neither the patient diagnosis nor the reason for the prescription of T was known.

An older meta-analysis of randomized controlled trials found that T treatment of hypogonadal men was not associated with increased cardiovascular adverse events [113]. A more recent meta-analysis of 27 randomized, controlled trials found increased cardiovascular events risk in T-treated hypogonadal men. Interestingly, increased cardiovascular disease risk was only found in trials that were not funded by the pharmaceutical industry [137]. This was followed by another meta-analysis of T supplementation in men from 75 placebo randomized controlled trials which showed that T treatment was not related to cardiovascular adverse events [138] especially when hypogonadism is properly diagnosed and T replacement correctly performed [139]. Another meta-analysis of 45 trials showed that overall T supplementation was not associated with increased cardiovascular events risk, however, there was a slight increase in risk within the first 12 months of treatment, especially in men >65 years. Intramuscular T appeared to have no effect while oral or transdermal T treatments were associated with increased cardiovascular disease risk [140].

Despite the controversial results, major limitations, and questionable validity of these studies, such reports led the Food and Drug Administration to alert physicians to discuss cardiovascular disease risks with their patients before prescribing androgens (FDA January 2014) and required manufacturers to amend the product label to indicate a possible increased risk of heart attacks and strokes in patients treated with testosterone (FDA March, 2015) [2]. None

of the randomized, placebo-controlled testosterone studies to date including The Testosterone Trials were of sufficient power to evaluate cardiovascular adverse outcomes [93]. Thus, the FDA Drug Safety Communication March, 2015 stated “We are also requiring manufacturers of approved testosterone products to conduct a well-designed clinical trial to more clearly address the question of whether an increased risk of heart attack or stroke exists among users of these products.” (<http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm>)

In summary, there are no reliable data showing that T administration has either an adverse or beneficial effect on coronary artery disease risk, and further research in this area is necessary. There are no data to suggest that T replacement is contraindicated in certain groups of patients; however, when treating older men with multiple comorbidities who are at high cardiovascular risk, extreme care should be exercised. A recent AACE/ACE position statement recommends avoiding T treatment of the frail elderly [141], and risk versus benefits should be discussed with the older patient with testosterone deficiency. A large prospective, randomized, controlled intervention trial in older men with higher risk of major cardiovascular adverse events is being planned by the pharmaceutical companies in response to the request from the FDA to address the question whether T replacement in hypogonadal men changed their risk of cardiovascular disease.

Prostate Disease

Prostate growth and development are known to require the presence of androgens from childhood to adulthood. In younger hypogonadal men in whom prostate diseases are uncommon, androgen replacement results in an increase in the size of the prostate from the smaller volumes at baseline to the range observed in eugonadal men. Progressive increases in prostate volume do not occur with continued T replacement [142, 143]. Serum PSA levels may increase significantly with T replacement, but mostly remain

within the normal range [34, 77, 110, 143]. In middle-aged and older men, androgen replacement has resulted in few instances of lower urinary tract obstructive symptoms (LUTS) and increased serum PSA levels resulting in urological referral and ultrasound-guided prostate biopsy [38, 40]. In most of the reports, these prostate-related adverse events occurred early in the course of androgen replacement suggesting that androgen replacement may have unmasked an existing latent or histological cancer by increasing serum PSA levels to above the reference range triggering an early prostate biopsy and diagnosis. More recent studies, however, have not reported worsening of LUTS symptoms in patients with underlying symptoms at baseline [81, 91, 100, 144–146]. A recent meta-analysis of 14 testosterone replacement trials in which LUTS were evaluated by IPSS showed no significant difference between those receiving T and placebo [147]. Most Urologists agree that androgens do not induce BPH. Currently, we recommend that androgens should not be used in subjects with lower urinary tract obstructive symptoms until these symptoms have been assessed and treated.

There is no evidence in hypogonadal young or older men that androgen replacement induces formation of prostate cancer or converts a latent, histological prostate cancer to a clinically significant or metastatic cancer [148]. However, if a hypogonadal patient had a history of, or is at high risk of developing prostate cancer, then androgens should be avoided. Use of calculators to estimate risk of developing prostate cancer (such as <http://deb.uthscsa.edu/URORiskCalc/Pages/calcs.jsp>) has been recommended [5]. On the other hand, there are instances in which a patient with a distant completely resected intra-prostatic prostate cancer and long standing nearly undetectable PSA levels with severe symptoms and signs of T deficiency seeks T replacement. Treatment of such patients may be justified only with careful surveillance and well documented informed consent [149]. Coadministration of a 5 α -reductase inhibitor with testosterone appeared to spare the prostate from androgenic stimulation during T replacement in older, hypogonadal men with symptomatic benign prostatic hyperplasia [150].

Hematocrit, Hemoglobin, and Liver Function Tests

Androgens increase erythropoiesis by multiple mechanisms including: acting directly on bone marrow cells by increasing telomerase activity and extending the length of telomeres [151–153]; an action on the kidney to produce erythropoietin [154]; and by suppressing hepcidin leading to increased iron absorption and incorporation into red blood cells [155, 156]. Androgen therapy in hypogonadal and eugonadal men results in an elevation of hematocrit and hemoglobin. The effect of T to increase red cell indexes has been demonstrated in many androgen replacement studies [38, 86, 110]. The increase in hemoglobin and hematocrit occurs within three months which increase progressively if the dose of T is adjusted upwards. Direct dose-response relationships have been shown between T and hematocrit and hemoglobin concentrations [46]. A greater increase in hemoglobin was seen in older compared to young men with induced hypogonadism [157, 158]. A substantial increase in hemoglobin was found in men with obstructive sleep apnea [92] who are often polycythemic. Thus, androgen therapy must be used with caution in men with baseline hematocrit of 50% or over. When the hematocrit rises above 50%, the subject must be carefully monitored and the T replacement dose adjusted downwards to prevent hyperviscosity and increased risk of thrombosis. The Endocrine Society suggests stopping the therapy if hematocrit is >54% until it normalizes, and reinitiating with a reduced dose [5, 131]. Alternatively, phlebotomy may help decrease hematocrit to safe levels without compromising the treatment plan, and genetic testing for polycythemia vera should be considered.

Abnormal liver function tests have been reported with the use of 17 alkylated androgens [159, 160]. Modifications of the steroid ring were necessary to allow these 17 alkylated androgens to be active after oral administration. Because of the possibility of liver toxicity and the increase in LDL and decrease in HDL-cholesterol with oral 17 alkylated androgens, they are not recommended for use as androgen replacement. It should be noted

that native T and T esters administered as replacement therapy do not result in abnormalities of liver function [37, 38, 86, 110].

Other Possible Adverse Effects

Increased oiliness of the skin, and acne, are common complaints after T replacement, especially when high doses are administered. These conditions are treated by topical measures or by either changing the T preparation or reducing the T replacement dose. Because T esters, like native T, are aromatized to estrogens, changes in the androgen to estrogen balance may occur after T replacement which may cause gynecomastia. Testosterone replacement also causes fluid retention during the early weeks of treatment and should be used with caution in older patients with congestive heart failure or poor myocardial function. It has been recommended not to initiate T replacement in patients with poorly controlled heart failure [5]; however, no negative effect has been observed in patients with stable heart failure [161].

Earlier studies reported that sleep-related breathing disorders may be aggravated after T replacement [162]; however, a more recent randomized control study in aged obese men with untreated obstructive sleep apnea showed that while T replacement therapy did increase oxygen desaturation index and hypoxemic sleep time at seven weeks, no differences were observed at the study end point of 18 weeks, and there were no differences in apnea episodes [92]. In addition, no significant worsening of sleep apnea symptoms was observed in relatively healthy hypogonadal patients randomized to T treatment in other studies [144], thus the significance of sleep apnea as an adverse effect of T treatment should be reevaluated. A detailed history for symptoms of sleep apnea before and during T treatment should be obtained. High-risk patients (obese, elderly) should be investigated and treated for sleep apnea before commencement of androgen replacement therapy (see Chap. 19).

Testosterone administration suppresses gonadotropin secretion, and leads to reduced




Fig. 18.3 Kaplan-Meier observed plots showing recovery to sperm density thresholds of 3 (inverted triangle), 10 (triangle), 20 (circle) Mil/mL, and back to individual baseline (open circle). Median (95% CI) recovery times for each of the thresholds are shown. The number of subjects (n) remaining at 2.5, 5, 10, 15, and 20 months for each of the above thresholds are shown on the bottom of the graph. From Liu et al. [163] and the Hormonal Male Contraception Summit group. Reprinted with permission from Elsevier

intratesticular T levels and hypospermatogenesis. These changes are reversible after withdrawal of treatment. The rate of recovery of spermatogenesis depends on the type of androgen used (longer or shorter acting androgen), duration of treatment, sperm concentration at baseline, ethnicity, and age, as shown in healthy men administered androgens in male contraceptive trials (Fig. 18.3) [163]. Because suppression of spermatogenesis may be prolonged with long acting T undecanoate injections, men with hypogonadotropic hypogonadism seeking future fertility should instead be treated with gonadotropins.

What Are the Available Androgen Preparations?

Table 18.3 shows the currently available androgen preparations and those under development. Numerous new options have been developed and introduced into clinical practice in the past 15 years. The most popular methods are long

Table 18.3 Androgen preparations and delivery systems

	Currently available	Under development
Injectable	T enanthate T cypionate T undecanoate	T microspheres
Oral	T undecanoate (not available in the US)	T undecanoate (other formulations) Dimethandrolone Selective androgen receptor modulators (SARMS)
Transdermal	T nonscrotal patch T gels/lotions	Other T gels, creams DHT gel
Transmucosal	Trans-buccal T Intranasal T	
Implants	T pellets (available as 75 mg in US; 100 or 200 mg in Europe or Australia)	7 α methyl 19 nor-T (MENT)

acting intramuscular injections and transdermal gel preparations. Traditional intramuscular formulations are low cost; however, gels present a more convenient option for many patients. The long acting T undecanoate injection with one injection every 10–12 weeks is preferred by many patients and physicians. Gel tablets for buccal and nasal administration of testosterone have also been developed, but these have to be administered two to three times a day. Future goals of the pharmaceutical industry are to develop modified androgen and synthetic androgen receptor modulators to avoid potential adverse effects (for example, stimulatory effects of androgens on prostate growth) while maintaining the beneficial effects on bone, muscle mass, sexual function, and mood.

Injectables

Injectable intramuscular solutions have been the mainstay of T replacement therapy since the 1940s. Injectable T is usually esterified, which makes the molecule more oil soluble to extend the rate of resorption of T from the injection site so that a longer duration of action is achieved. Because testosterone is released from the injection site, the metabolism of T is not affected. Therefore, different T esters result in different durations of action. Testosterone enanthate and cypionate are T esters usually administered as a




Fig. 18.4 Graphical presentation of pharmacokinetic profiles of different testosterone preparations. *TE* Testosterone enanthate 200 mg IM once every three weeks; *TU* IM Testosterone undecanoate 750 mg IM once in ten weeks after 3 or 4 injections; *T patch* Trough levels after application of 5 mg T patch; *T gel* Trough levels after application of 10 g T gel; and *Oral TU* Levels after oral administration of TU 200 mg twice a day [170, 183, 222, 223]

deep intramuscular injection. The usual recommended dose is 200 mg in one mL oil administered every two weeks. The pharmacokinetics (PK) of TE is graphically shown in Fig. 18.4. Serum T levels peaked within 1–3 days after administration, and reached a trough after two weeks. In many subjects, the level of serum T achieved may reach a concentration which is higher than the normal adult male reference range for the first few days after an injection. The PK of T injections has been well studied [164, 165]. Most patients can be taught to self-administer injections. In some patients, the

high peaks and low troughs of serum T levels may result in mood swings and acne. In such patients, the dose may be decreased and the frequency of the injections increased, for example, T enanthate or cypionate may be administered at 100 mg every 7–10 days.

Testosterone undecanoate (TU) was developed and marketed initially in China for the treatment of hypogonadism [166]. The depot preparation (TU 250 mg/mL, 1000 mg per injection) is widely used in Europe, Middle East, South America, and Australia. The recommended regular dosing interval is 10–14 weeks; a booster dose at four to six weeks after the first injection helps to achieve steady state levels. After administration of 1000 mg TU, the serum T level peaked in the first or second week, and remained within the normal range for as long as 12 weeks [167, 168]. A lower dose formulation is available in the United States (250 mg/mL, 750 mg per 3 ml injection), is dosed approximately every 10 weeks, with the second booster injection administered 4 weeks after the first injection [169, 170].

The injectable preparations may pose a greater risk of polycythemia than with transdermal preparations, as the T concentration peak is higher, especially with shorter acting formulations [171]. There have been reports of bouts of coughing after IM injections, which has been ascribed to pulmonary oil microembolism, especially with depot TU, as well as rare possible anaphylactic reactions. These observations have led to a requirement in the United States that TU must be administered in a clinic or physician's office, and patients must be observed for 30 min after the injection. With the use of long acting T, it is recommended that serum T levels should be measured prior to an upcoming injection (trough level)—with a goal of serum T being within the lower normal range. In older men, it may be prudent to start with a lower T dose and use short acting preparations before transitioning to longer acting injectables in case adverse events occur [172].

T microspheres are T incorporated in biodegradable polylactide glycolide. When administered as a single injection, T

microspheres can maintain serum T levels within the normal range for 10 weeks in hypogonadal men [173]. Recent studies reaffirmed the long acting properties of T microsphere injections with a brief pronounced early peak of serum T followed by low normal T levels for 10–11 weeks [174]. Further development of such a formulation has not occurred.

Oral

Oral 17 alkylated T preparations are not recommended for long-term androgen replacement because of the potential adverse effects on liver function and on lipids. TU is a T ester with a long fatty acid side chain. TU is manufactured dissolved in castor oil. When TU is administered by mouth, it is absorbed mainly through the lymphatics, avoiding a first pass effect on the liver. Thus, absorption of TU is substantially influenced by the ingestion of food [175]. When TU is administered in the fasting state, serum T levels remained low. Serum T levels rose to peak levels 4–5 h after administration with food, and remained in the low normal range 8–12 h after oral administration [176–178]. The usual dose is TU 80 mg twice per day or 40 mg three times per day. There is large intra- and inter-subject variation in serum T levels mainly because absorption is dependent on ingestion of food and the fat content of the meal. Moreover, after oral TU (in castor oil) administration, serum T levels are often below the normal reference range prior to the next dose [179, 180]. TU has been used in many countries throughout the world except in the United States for many years, and has long-term safety data [181]. Several new formulations of TU are being developed, including a self-emulsifying drug delivery system which produces higher serum TU levels that result in higher and more consistent serum T levels [182]. However, as the 5 α -reductase enzyme is expressed in the intestine and liver, and converts TU to DHT undecanoate, the serum DHT to T ratio may be higher than with other formulations [183].

Transdermal Gels, Lotion, and Patches

Steady serum T levels in the normal range mimicking circadian variation are attained after T transdermal patch application (Fig. 18.3). A scrotal T patch was first to become available in the early 1990s. It was 60 mm in diameter, required shaving or clipping of scrotal skin hair, and produced high levels of DHT because of the higher activity of 5 α reductase in scrotal skin [184, 185]. This patch has been superseded by other transdermal preparations, and is not currently marketed in the US. The only transdermal patch currently available in the US is a permeation enhanced patch (Androderm[®]), which delivers 5 mg T per day, and produces serum T levels in the low normal range [184–188]. This patch is associated with skin irritation in up to 60% of subjects, leading to discontinuation in up to 10–15% of subjects [184–188]. Pre application of a corticosteroid cream may reduce the skin irritation. Another larger non-scrotal matrix patch (Testoderm TTS[®]) was developed, which produced much less skin irritation; however, poor adhesion to the skin and frequent patch dislodgement led to marketing discontinuation of this product.

Numerous transdermal T gels have been developed, and they are popular due to their convenience of use. They are currently the most common form of T replacement in the United States, United Kingdom, and many other countries [189]. The gel is applied to a wide area of skin (usually on the arms and shoulders), and is absorbed into *stratum corneum*, which, along with subcutaneous tissues, serve as a reservoir from which T is constantly absorbed for about 24 h. Only about 10% of the applied gel is absorbed into the systemic circulation during this period. Skin in different locations exhibits different absorption properties, which may result in different serum T levels [190]. Additionally, a study in older hypogonadal men showed large serum T fluctuations between applications and among patients which may be attributed to skin structural differences. This leads to difficulties in predicting treatment effect, as well as

determining the appropriate time for testing serum T levels and assessing the adequate treatment dose [191, 192].

Application of T gel results in dose-dependent increases in serum T levels, and as with other T preparations, positive effects on libido, mood, muscle size and strength, and body fat have been demonstrated in hypogonadal men treated with T gel. Additionally, there are positive effects on bone mineral density [193] that persist for over 3 years of treatment duration [194]. Because of the ease of application and flexibility of dosing, this method of T replacement is acceptable to many hypogonadal men. Most currently available formulations are T hydroalcoholic gels, which dry in a few minutes after application; however, they are flammable, therefore precautionary measures are recommended. A potential problem is the possibility of transfer of T to women and children during close contact of skin surfaces. This can be avoided by wearing clothing or removal of any residual T on the skin by showering before anticipated skin to skin contact. Washing clothes that patients wore after T gel application with other laundry resulted in only minimal transfer of T [195]. Skin irritation is the most common adverse event with transdermal gels; however, the irritation is much milder than that with T patches, and usually does not warrant discontinuation of treatment [196].

In addition to T gel, a gel containing the potent androgen, dihydrotestosterone (DHT) has been studied for treatment of younger [197] and older hypogonadal men [198–201]. DHT appeared to improve sexual dysfunction in older men with late onset hypogonadism but had minimal effect on muscle mass and strength [198, 200]. It is controversial whether DHT has any significant benefits over T as an androgen replacement therapy. Moreover, DHT is a nonaromatizable androgen, and unlike T is thus not converted to estradiol. Since some of the beneficial (as well as adverse) effects of T are attributed at least in part to its metabolite estradiol, it is not clear whether DHT will have any positive effects on bone mass, cognitive function, and fat mass [202] or be free from problems of T

induced gynecomastia. Two years of DHT gel treatment did not cause undesirable prostate effects; however, it resulted in a decreased spine but not hip bone mineral density [203].

Transmucosal Preparations

Transmucosal delivery systems for T have also been developed. As mucous membranes are more permeable than is skin, absorption rate is higher, and a lower dose is required to achieve the same serum T levels. Two formulations have been approved, and are currently marketed in the United States—an intranasal gel and a trans-buccal system. Due to its short duration of action, the intranasal gel has to be dosed 2–3 times per day, and results in somewhat fluctuating serum T levels. However, its noninvasive approach and avoidance of first pass metabolism in the liver may prove this to be a convenient alternative to currently available options [204]. A trans-buccal system is a tablet, which after application to the gum, forms a gel tablet, and delivers steady serum T levels for 8–12 h. Thus, it is administered twice per day [205]. A report of two years of continuous use of the system revealed that 62 percent of subjects had at least 80% of their T measurements within normal limits. Treatment was generally well tolerated, with local adverse events (gum edema, blistering, and gingivitis) leading to discontinuation in 4.3% of the patients [206].

Implants

Crystalline T pellets have been inserted into the abdominal subcutaneous fat for androgen replacement in hypogonadal men for some time. In Europe and Australia, where T pellets are available in 100 and 200 mg doses, they were frequently used to treat hypogonadal men before very long acting TU injections became available [207, 208]. Four 200 mg implants often maintain normal serum T levels for 16–20 weeks. Insertion of the pellets requires a minor surgical procedure under local anesthesia. Extrusion of the T

pellets has been observed in 8–11% of subjects [209], although with insertion by a very skilled operator, the extrusion rate is much lower. Implants are available commercially in the United States. This method for androgen replacement has not been widely used but is gaining popularity among some U.S. urologists.

Selective Androgen Receptor Modulators (SARMs)

SARMs are being developed as drugs for sarcopenia, cachexia, osteoporosis, and hypogonadism, among other indications. SARMs bind to androgen receptors, and may be agonistic or antagonistic in action depending on the target tissues and the modulating effects of coactivators or co-inhibitors of androgen receptor signaling [210]. An example of a steroid SARM is 7 α methyl 19 nor-testosterone (MENT). MENT can be aromatized to an active estrogen but is not 5 α reducible. In rodents and monkeys, MENT has a greater stimulatory effect on muscle relative to prostate [211, 212]. A clinical study showed that MENT could maintain sexual function and muscle mass in hypogonadal men. MENT is being developed as a long acting implant [52]. Production of non 5 α reductase reducible androgens through modification of the steroid ring may be clinically preferable as they might pose less prostate risks than with T. However, they may not be aromatized to active compounds, which raise long-term safety issues with regards to bone, fat mass, and perhaps sexual function. Other agents include 7 α -methyl-19-nortestosterone [213, 214] and dimethandrolone (7 α -11 β -dimethyl-19 nortestosterone) [215]. These modified androgens appear to be more potent than T, and exhibit no liver toxicity. Early phase 1 studies of dimethandrolone were reported [216]. These androgens may not be aromatizable to estrogenic compounds, and thus bone and fat mass, as well as sexual function must be monitored if they are used for long periods as androgen replacement therapy in hypogonadal men.

Nonsteroidal orally active SARMs, which have potent actions on muscle and the brain, but

little or markedly lower stimulatory effect on the prostate, are the goals of product development of a number of pharmaceutical companies [217, 218]. SARMs may suppress gonadotropin secretion and testosterone production, and it may be difficult to accurately assess the adequacy of androgen replacement. Some SARMs have less gonadotropin suppressive effect, and thus do not alter endogenous hormone levels. Current clinical studies have focused on the treatment of sarcopenia in patients with chronic comorbidities, cancer, and the elderly [90, 219, 220]. These drugs may prove to be advantageous in clinical practice [90, 213, 216, 221].

How Do We Monitor Androgen Replacement Therapy?

The goal of androgen replacement therapy is the alleviation of symptoms. In order to monitor and adjust the dose of T, serum T levels should be measured at an appropriate time after drug administration based on the pharmacokinetic characteristics of the specific preparation. For example, with T patches serum T levels peak at 12–16 h and return close to baseline by 24 h. Monitoring is recommended about 12 h after application, and levels should be in the mid normal range. Since serum T levels are maintained in a relatively steady state by transdermal gels, serum T can be measured at any time after the levels have plateaued, usually 3–4 days after initial application. In older men, considerable within-individual variation of serum T occurred when serum T was measured on different days. Serum levels of T 8–12 h after application of transdermal T gel appeared to best reflect average serum T over 24 h [191]. The injectable T preparations, T enanthate and cypionate result in peaks at 2–3 days and troughs at 10–14 days; serum T is measured before the next injection to ensure trough levels are near the lower end of the reference range for adult men, and that there is no accumulation of T. Serum T should be periodically measured at day 7 to ensure that serum T levels are within normal limits. Once a stable dose is determined, frequent measurement of

serum T levels is generally not necessary unless dose adjustments are made. In subjects using long acting TU injections, blood should be drawn prior to the next injection in order to establish the timing of further injections. If free or bioavailable T (either calculated or directly measured after equilibrium dialysis for free T and ammonium precipitation for bioavailable T) are used for the diagnosis of hypogonadism in men with low SHBG, monitoring should also use these parameters rather than total T. However, age-adjusted reference ranges for free and bioavailable T are not generally available, and the clinicians may use the range provided usually by reference laboratories.

Since administration of T may unmask histological prostate cancers by increasing serum PSA levels, measuring PSA early after treatment initiation, e.g., one to three months, is recommended. Thereafter, PSA should be checked on a yearly basis according to the urological practice applicable to each man. Hemoglobin and hematocrit should be checked at three months and then after each dose adjustment followed by yearly intervals. Subjects whose hemoglobin level is high before treatment should be monitored more carefully. As with other patients on replacement therapy, a yearly liver function test and lipid profile should be performed.

Conclusions

Androgen replacement therapy should be considered for all hypogonadal men with persistent low serum T levels and symptoms of T deficiency. Before commencement of replacement, contraindications to androgen treatment should be identified. In hypogonadal men, androgens improve sexual function, energy, and mood, increase muscle mass and strength, as well as bone mineral density. Androgen therapy can be tailored to each patient's needs and preferences. There have been many new androgen delivery systems introduced in the past few years, and many more are in development. Selective androgen receptor modulators may have the potential to optimize beneficial effects while

minimizing potential adverse effects. In older men, monitoring of prostate dysfunction and red cell indexes is necessary and important. With care, androgens can be used efficaciously and with minimal side effects.

Acknowledgements This work was supported by UCLA CTSI Grant UL1TR000124 to Los Angeles Biomedical Research Institute and Harbor UCLA Medical Center (CW) and NICHD Contract HHSN27520130024I (RSS and CW) and the Baltic American Freedom Foundation Research Scholar Program (JC).

References

- Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. *JAMA Int Med.* 2013;173(15):1465–6.
- Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and “age-related hypogonadism”—FDA concerns. *N Engl J Med.* 2015;373(8):689–91.
- Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010;363(2):123–35.
- Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. *J Clin Endocrinol Metab.* 2015;100(3):1146–55.
- Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95(6):2536–59.
- Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. *Clin Chem.* 2003;49(8):1381–95.
- Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine society position statement. *J Clin Endocrinol Metab.* 2007;92(2):405–13.
- Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab.* 2004;89(2):534–43.
- Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. *J Steroid Biochem Mol Biol.* 2010.
- Vesper HW, Botelho JC, Shacklady C, Smith A, Myers GL. CDC project on standardizing steroid hormone measurements. *Steroids.* 2008;73(13):1286–92.
- Vesper HW, Thienpont LM. Traceability in laboratory medicine. *Clin Chem.* 2009;55(6):1067–75.
- Steinberger E, Ayala C, Hsi B, Smith KD, Rodriguez-Rigau LJ, Weidman ER, et al. Utilization of commercial laboratory results in management of hyperandrogenism in women. *Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol.* 1998;4(1):1–10.
- Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.* 1999;84(10):3666–72.
- O'Connor S, Baker HW, Dulmanis A, Hudson B. The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation. *J Steroid Biochem.* 1973;4(4):331–9.
- Cumming DC, Wall SR. Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. *J Clin Endocrinol Metab.* 1985;61(5):873–6.
- Sinha-Hikim I, Arver S, Beall G, Shen R, Guerrero M, Sattler F, et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. *J Clin Endocrinol Metab.* 1998;83(4):1312–8.
- Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010;363(2):123–35.
- Zakharov MN, Bhasin S, Travison TG, Xue R, Ulloor J, Vasani RS, et al. A multi-step, dynamic allosteric model of testosterone's binding to sex hormone binding globulin. *Mol Cell Endocrinol.* 2015;399:190–200.
- Ohlsson C, Wallaschowski H, Lunetta KL, Stolk L, Perry JR, Koster A, et al. Genetic determinants of serum testosterone concentrations in men. *PLoS Genet.* 2011;7(10):e1002313.
- Vermeulen A. Clinical review 24: androgens in the aging male. *J Clin Endocrinol Metab.* 1991;73(2):221–4.
- Vermeulen A. Decreased androgen levels and obesity in men. *Ann Med.* 1996;28(1):13–5.
- Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. *J Clin Endocrinol Metab.* 1977;45(6):1211–9.

23. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem.* 1982;16(6):801–10.
24. de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. *Clin Chem.* 2006;52(9):1777–84.
25. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, et al. Accuracy of calculated free testosterone formulae in men. *Clin Endocrinol.* 2010;73:382–8.
26. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. *Ann Clin Biochem.* 2009;46(Pt 2):137–43.
27. Rosner W. Errors in the measurement of plasma free testosterone. *J Clin Endocrinol Metab.* 1997;82(6):2014–5.
28. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? *Clin Chem.* 1998;44(10):2178–82.
29. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. *J Clin Endocrinol Metab.* 2004;89(2):525–33.
30. Khosla S, Riggs BL. Androgens, estrogens, and bone turnover in men. *J Clin Endocrinol Metab.* 2003;88(5):2352–3.
31. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med.* 2013;369(11):1011–22.
32. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. *J Clin Endocrinol Metab.* 2009;94(12):4785–92.
33. Liu PY, Caterson ID, Grunstein RR, Handelsman DJ. Androgens, obesity, and sleep-disordered breathing in men. *Endocrinol Metab Clin North Am.* 2007;36(2):349–63.
34. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. *J Androl.* 1992;13(4):297–304.
35. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. *J Clin Endocrinol Metab.* 1979;48(6):955–8.
36. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. *Clin Endocrinol.* 1981;14(1):49–61.
37. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. *J Clin Endocrinol Metab.* 1996;81(10):3654–62.
38. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85(8):2839–53.
39. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. *J Clin Endocrinol Metab.* 1997;82(11):3793–6.
40. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab.* 1999;84(8):2647–53.
41. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. *J Sex Med.* 2014;11(3):840–56.
42. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). *Diab Care.* 2011;34(4):828–37.
43. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. *N Engl J Med.* 2016;374(7):611–24.
44. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). *J Sex Med.* 2011;8(1):284–93.
45. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. *JAMA.* 2015;314(6):570–81.
46. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. *Am J Physiol Endocrinol Metab.* 2001;281(6):E1172–81.
47. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab.* 2006;91(11):4335–43.

48. Dabbs JM Jr. Salivary testosterone measurements in behavioral studies. *Ann N Y Acad Sci.* 1993;694:177–83.
49. O'Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on cognitive function in men. *Neuropsychologia.* 2001;39(13):1385–94.
50. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. *J Clin Endocrinol Metab.* 1994;79(2):561–7.
51. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. *J Clin Endocrinol Metab.* 1992;75(6):1503–7.
52. Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. *J Clin Endocrinol Metab.* 1999;84(10):3556–62.
53. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. *J Clin Endocrinol Metab.* 1996;81(10):3578–83.
54. Tong SF, Ng CJ, Lee BC, Lee VK, Khoo EM, Lee EG, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. *Asian J Androl.* 2012;14(4):604–11.
55. Pope HG Jr, Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. *J Clin Psychopharmacol.* 2010;30(2):126–34.
56. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. *Horm Behav.* 1998;33(2):85–94.
57. Boone KB, Swerdloff RS, Miller BL, Geschwind DH, Razani J, Lee A, et al. Neuropsychological profiles of adults with Klinefelter syndrome. *J Int Neuropsychol Soc.* 2001;7(4):446–56.
58. Patwardhan AJ, Eliez S, Bender B, Linden MG, Reiss AL. Brain morphology in Klinefelter syndrome: extra X chromosome and testosterone supplementation. *Neurology.* 2000;54(12):2218–23.
59. Cherrier MM, Anawalt BD, Herbst KL, Amory JK, Craft S, Matsumoto AM, et al. Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. *J Clin Endocrinol Metab.* 2002;87(7):3090–6.
60. Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. *J Cogn Neurosci.* 2000;12(3):407–14.
61. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. *Behav Neurosci.* 1994;108(2):325–32.
62. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci.* 2002;57(5):M321–5.
63. Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. *J Am Geriatr Soc.* 2002;50(4):707–12.
64. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. *J Bone Miner Res.* 1997;12(11):1833–43.
65. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. *J Clin Endocrinol Metab.* 1998;83(7):2266–74.
66. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. *J Clin Endocrinol Metab.* 1995;80(12):3689–98.
67. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. *N Engl J Med.* 1994;331(16):1056–61.
68. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. *N Engl J Med.* 1997;337(2):91–5.
69. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. *J Clin Endocrinol Metab.* 2001;86(8):3555–61.
70. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, Mavilia C, Del MF, et al. Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. *J Clin Endocrinol Metab.* 2004;89(4):1808–16.
71. Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. *J Clin Invest.* 2016;126(3):1114–25.
72. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, et al. Identification of androgen receptors in normal human osteoblast-like cells. *Proc Natl Acad Sci U S A.* 1989;86(3):854–7.
73. Cawthon PM, Schousboe JT, Harrison SL, Ensrud KE, Black D, Cauley JA, et al. Sex hormones, sex hormone binding globulin, and vertebral fractures in older men. *Bone.* 2016;84:271–8.

74. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klubanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab.* 1996;81(12):4358–65.
75. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. *J Clin Endocrinol Metab.* 1997;82(8):2386–90.
76. Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. *Endocr Res.* 2000;26(2):153–68.
77. Tenover JL. Male senescence. In: Wang C, editor. *Male reproductive function.* Boston: Kluwer Academic Publishers; 1999. p. 139–56.
78. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85(8):2670–7.
79. Ishizaka K, Suzuki M, Kageyama Y, Kihara K, Yoshida K. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. *Asian J Androl.* 2002;4(2):117–21.
80. Medras M, Jankowska EA, Rogucka E. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism. *Andrologia.* 2001;33(1):47–52.
81. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. *J Am Geriatr Soc.* 2010;58(6):1134–43.
82. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. *Clin Endocrinol (Oxf).* 2005;63(3):280–93.
83. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al. THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. *Eur J Endocrinol.* 2016;174(3):R99–116.
84. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. *J Clin Endocrinol Metab.* 1996;81(10):3469–75.
85. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. *Am J Physiol Endocrinol Metab.* 2002;283(1):E154–64.
86. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. *J Clin Endocrinol Metab.* 1997;82(2):407–13.
87. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. *J Clin Endocrinol Metab.* 2005;90(3):1502–10.
88. Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. *Int J Androl.* 1999;22(4):261–5.
89. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab.* 2010;95(2):639–50.
90. Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Micek R, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. *J Gerontol A Biol Sci Med Sci.* 2013;68(1):87–95.
91. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab.* 2010;95(2):639–50.
92. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. *Eur J Endocrinol.* 2012;167(4):531–41.
93. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. *N Engl J Med.* 2016;374(7):611–24.
94. Vanttinen T, Blomqvist M, Hakkinen K. Development of body composition, hormone profile, physical fitness, general perceptual motor skills, soccer skills and on-the-ball performance in soccer-specific laboratory test among adolescent soccer players. *J Sports Sci Med.* 2010;9(4):547–56.
95. Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. *European journal of endocrinology/ European Federation of Endocrine Societies.* 2012;166(3):469–76.
96. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in

- hypogonadal men with metabolic syndrome. *J Endocrinol Invest.* 2010;33(11):776–83.
97. Marin P, Holmang S, Jonsson L, Sjöström L, Kvist H, Holm G, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. *Int J Obes Relat Metab Disord.* 1992;16(12):991–7.
 98. Neto WK, Gama EF, Rocha LY, Ramos CC, Taets W, Scapini KB, et al. Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. *Age (Dordr).* 2015;37(1):9742.
 99. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. *Diabetes Care.* 2016;39(1):82–91.
 100. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. *Clin Endocrinol (Oxf).* 2010;73(5):602–12.
 101. Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. *Diabetes Care.* 2014;37(8):2098–107.
 102. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. *J Androl.* 2009;30(6):726–33.
 103. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. *European journal of endocrinology/ European Federation of Endocrine Societies.* 2006;154(6):899–906.
 104. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. *Int J Endocrinol.* 2014;2014:527470.
 105. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. *J Clin Endocrinol Metab.* 2011;96(8):2341–53.
 106. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. *The journal of sexual medicine.* 2010;7(10):3495–503.
 107. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *J Clin Endocrinol Metab.* 2004;89(7):3313–8.
 108. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. *Diabetes Care.* 2011;34(7):1669–75.
 109. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. *J Clin Endocrinol Metab.* 1994;79(2):561–7.
 110. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. *Clin Endocrinol.* 1997;47(6):727–37.
 111. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. *J Clin Endocrinol Metab.* 2001;86(3):1026–33.
 112. Friedl KE, Hannan CJ Jr, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. *Metabolism.* 1990;39(1):69–74.
 113. Fernandez-Balsells MM, Murad MH, Lane M, Lampropoulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2010;95(6):2560–75.
 114. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. *J Clin Endocrinol Metab.* 2002;87(1):136–43.
 115. Arora S, Patra SK, Saini R. HDL-A molecule with a multi-faceted role in coronary artery disease. *Clinica chimica acta; international journal of clinical chemistry.* 2015;452:66–81.
 116. Barter PJ, Rye KA. Targeting High-Density Lipoproteins to Reduce Cardiovascular Risk: what Is the Evidence? *Clinical therapeutics.* 2015.
 117. Phillips GB, Pinkemell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. *Arterioscler Thromb.* 1994;14(5):701–6.
 118. Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. *Int J Cardiol.* 1998;63(2):161–4.
 119. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab.* 2008;93(1):68–75.

120. Khaw KT, Dowsett M, Folkard E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation*. 2007;116(23):2694–701.
121. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. *European journal of endocrinology/ European Federation of Endocrine Societies*. 2011;165(5):687–701.
122. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. *Circulation*. 1988;78(3):539–45.
123. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. *J Clin Endocrinol Metab*. 1997;82(2):682–5.
124. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. *Arch Intern Med*. 2006;166(15):1660–5.
125. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. *Br Heart J*. 1977;39(11):1217–22.
126. Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. *Chin Med J*. 1993;106(6):415–8.
127. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. *Eur Heart J*. 2000;21(11):890–4.
128. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. *Circulation*. 1999;99(13):1666–70.
129. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. *Circulation*. 1999;100(16):1690–6.
130. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. *Am Heart J*. 2002;143(2):249–56.
131. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. *N Engl J Med*. 2010;363(2):109–22.
132. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *JAMA*. 2013;310(17):1829–36.
133. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. *J Clin Endocrinol Metab*. 2012;97(6):2050–8.
134. Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. *J Clin Endocrinol Metab*. 2014;99(6):2061–8.
135. Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. *Ann Pharmacother*. 2014;48(9):1138–44.
136. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. *PLoS ONE*. 2014;9(1):e85805.
137. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med*. 2013;11:108.
138. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. *Expert Opin Drug Saf*. 2014;13(10):1327–51.
139. Corona GG, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone replacement therapy and cardiovascular risk: a review. *World J Men's Health*. 2015;33(3):130–42.
140. Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. *Clin Endocrinol (Oxf)*. 2016.
141. Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR. American association of clinical endocrinologists and American college of endocrinology position statement on the association of testosterone and cardiovascular risk. *Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol*. 2015;21(9):1066–73.
142. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. *Clin Endocrinol*. 1994;40(3):341–9.
143. Meikle AW, Arver S, Dobs AS, Adolphsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. *Urology*. 1997;49(2):191–6.
144. Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with

- low-normal testosterone levels. *J Clin Endocrinol Metab.* 2013;98(5):1891–900.
145. Del Fabbro E, Garcia JM, Dev R, Hui D, Williams J, Engineer D, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. *Support Care Cancer.* 2013;21(9):2599–607.
 146. Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. *BJU Int.* 2013;111(7):1130–40.
 147. Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. *Eur Urol.* 2016.
 148. Handelsman DJ. The safety of androgens: prostate and cardiovascular disease. In: Wang C, editor. *Male reproductive function.* Boston: Kluwer Academic Publishers; 1999. p. 173–89.
 149. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. *J Urol.* 2004;172(3):920–2.
 150. Page ST, Hirano L, Gilchrist J, Dighe M, Amory JK, Marck BT, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. *J Urol.* 2011;186(1):191–7.
 151. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. *Blood.* 2009;114(11):2236–43.
 152. Bar C, Huber N, Beier F, Blasco MA. Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres. *Haematologica.* 2015;100(10):1267–74.
 153. Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, et al. Danazol treatment for telomere diseases. *N Engl J Med.* 2016;374(20):1922–31.
 154. Rencricca NJ, Solomon J, Fimian WJ Jr, Howard D, Rizzoli V, Stohlman F Jr. The effect of testosterone on erythropoiesis. *Scand J Haematol.* 1969;6(6):431–6.
 155. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. *J Gerontol A Biol Sci Med Sci.* 2014;69(6):725–35.
 156. Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. *Aging Cell.* 2013;12(2):280–91.
 157. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. *J Clin Endocrinol Metab.* 2005;90(2):678–88.
 158. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. *J Clin Endocrinol Metab.* 2008;93(3):914–9.
 159. Delorimier AA, Gordan GS, Lowe RC, Carbone JV. Methyltestosterone, related steroids, and liver function. *Arch Intern Med.* 1965;116:289–94.
 160. Nadell J, Kosek J. Peliosis hepatis. Twelve cases associated with oral androgen therapy. *Arch Pathol Lab Med.* 1977;101(8):405–10.
 161. Stout M, Tew GA, Doll H, Zwierska I, Woodroffe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. *Am Heart J.* 2012;164(6):893–901.
 162. Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. *Clin Endocrinol.* 1985;22(6):713–21.
 163. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. *Lancet.* 2006;367(9520):1412–20.
 164. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. *J Clin Endocrinol Metab.* 1980;51(6):1335–9.
 165. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. *Fertil Steril.* 1982;37(3):425–30.
 166. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. *J Androl.* 1998;19(6):761–8.
 167. Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. *Eur J Endocrinol Eur Fed Endocr Soc.* 1999;140(5):414–9.
 168. Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. *Clin Endocrinol.* 1999;51(6):757–63.
 169. Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff RS, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. *J Urol.* 2008;180(6):2307–13.

170. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. *J Androl.* 2010;31(5):457–65.
171. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. *J Clin Endocrinol Metab.* 1999;84(10):3469–78.
172. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. *Aging Male.* 2009;12(1):5–12.
173. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. *J Clin Endocrinol Metab.* 1992;74(1):75–83.
174. Amory JK, Anawalt BD, Blaskovich PD, Gilchrist J, Nuwayser ES, Matsumoto AM. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viarel) in hypogonadal men. *J Androl.* 2002;23(1):84–91.
175. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. *Pharmacotherapy.* 2003;23(3):319–25.
176. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. The effect of food composition on serum testosterone levels after oral administration of Andriol testocaps. *Clin Endocrinol.* 2007;66(4):579–85.
177. Nieschlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. *Acta Endocrinol (Copenh).* 1975;79(2):366–74.
178. Schurmeyer T, Wickings EJ, Freischem CW, Nieschlag E. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. *Acta Endocrinol (Copenh).* 1983;102(3):456–62.
179. Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. *Eur J Endocrinol Eur Fed Endocr Soc.* 2009;160(5):821–31.
180. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. *JAMA.* 2008;299(1):39–52.
181. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. *J Androl.* 1994;15(3):212–5.
182. Yin A, Alfadhli E, Htun M, Dudley R, Faulkner S, Hull L, et al. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men. *J Androl.* 2012;33(6):1282–90.
183. Yin AY, Htun M, Swerdloff RS, Diaz-Arjonilla M, Dudley RE, Faulkner S, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. *J Androl.* 2012;33(2):190–201.
184. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. *JAMA.* 1989;261(17):2525–30.
185. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. *J Clin Endocrinol Metab.* 1989;68(2):369–73.
186. Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. *J Clin Pharmacol.* 1996;36(8):732–9.
187. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site—a clinical research center study. *J Clin Endocrinol Metab.* 1996;81(5):1832–40.
188. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. *J Clin Endocrinol Metab.* 1992;74(3):623–8.
189. Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. *J Clin Endocrinol Metab.* 2014;99(3):835–42.
190. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85(12):4500–10.
191. Swerdloff RS, Pak Y, Wang C, Liu PY, Bhasin S, Gill TM, et al. Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications. *J Clin Endocrinol Metab.* 2015;100(9):3280–7.
192. Muram D, Ni X. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men. *Curr Med Res Opin.* 2015;1–24.
193. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. *Clin Endocrinol.* 2001;54(6):739–50.

194. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab.* 2004;89(5):2085–98.
195. Satonin DK, Ni X, Mitchell MI, Joly H, Muram D, Small DS. Amount of testosterone on laundered clothing after use of testosterone topical 2% solution by healthy male volunteers. *J Sex Med.* 2016;13(2):187–93.
196. Muram D, Melby T, Alles Kingshill E. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. *Curr Med Res Opin.* 2012;28(5):761–6.
197. Schaison GNK, Couzinet B. Percutaneous dihydrotestosterone (DHT) treatment. In: Nieschlag EBH, editor. *Testosterone: action deficiency, substitution.* Berlin: Springer; 1990. p. 155–64.
198. de Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. *Ann Med.* 1993;25(3):235–41.
199. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. *J Clin Endocrinol Metab.* 2002;87(4):1467–72.
200. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. *J Clin Endocrinol Metab.* 2001;86(9):4078–88.
201. Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—a clinical research center study. *J Clin Endocrinol Metab.* 1998;83(8):2749–57.
202. Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? *J Clin Endocrinol Metab.* 2002;87(4):1462–6.
203. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. *Ann Intern Med.* 2010;153(10):621–32.
204. Rogol AD, Tkachenko N, Bryson N. Natesto™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. *Andrology.* 2016;4(1):46–54.
205. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. *J Clin Endocrinol Metab.* 2004;89(8):3821–9.
206. Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. *BJU Int.* 2012;110(2):162–9.
207. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. *J Clin Endocrinol Metab.* 1990;71(1):216–22.
208. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. An analysis of testosterone implants for androgen replacement therapy. *Clin Endocrinol.* 1997;47(3):311–6.
209. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ. Extrusion of testosterone pellets: a randomized controlled clinical study. *Clin Endocrinol.* 1999;51(4):469–71.
210. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. *J Med Chem.* 2009;52(12):3597–617.
211. Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7 α -methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. *J Clin Endocrinol Metab.* 1998;83(12):4212–9.
212. Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7 α -methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. *Endocrinology.* 1992;130(6):3677–83.
213. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7 α -Methyl-19-Nortestosterone in hypogonadal men. *J Clin Endocrinol Metab.* 2003;88(6):2784–93.
214. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, et al. A clinical trial of 7 α -methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. *J Clin Endocrinol Metab.* 2003;88(11):5232–9.
215. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. *Endocrinology.* 2006;147(6):3016–26.
216. Surampudi P, Page ST, Swerdloff RS, Nya-Ngatchou JJ, Liu PY, Amory JK, et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. *Andrology.* 2014;2(4):579–87.
217. Edwards JP, Zhi L, Pooley CL, Tegley CM, West SJ, Wang MW, et al. Preparation, resolution,

- and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. *J Med Chem.* 1998;41(15):2779–85.
218. Hamann LG, Higuchi RI, Zhi L, Edwards JP, Wang XN, Marschke KB, et al. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. *J Med Chem.* 1998;41(4):623–39.
219. Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. *Curr Opin Support Palliat Care.* 2013;7(4):345–51.
220. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. *Lancet Oncol.* 2013;14(4):335–45.
221. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. *J Cachexia Sarcopenia Muscle.* 2011;2(3):153–61.
222. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85(12):4500–10.
223. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. *Ferti Steril.* 1982;37(3):425–30.
224. Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth WT Jr, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. *J Clin Endocrinol Metab.* 2014;99(6):2061–8.
225. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. *J Clin Endocrinol Metab.* 2012;97(6):2050–8.
226. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol.* 2013;169(6):725–33.
227. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. *J Gerontol A Biol Sci Med Sci.* 2005;60(11):1451–7.
228. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. *Mayo Clin Proc.* 2007;82(1):29–39.
229. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2010;95(6):2560–75.
230. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementation in heart failure: a meta-analysis. *Circ Heart Fail.* 2012;5(3):315–21.

Androgen Therapy for Hypogonadism in Men with Chronic Illnesses

Wenyi Zhang MD, Moizza Shabbir BA
and Peter Y. Liu MBBS, PhD, FRACP

Contents

Introduction	399
Respiratory Diseases	400
Chronic Obstructive Pulmonary Disease	400
Obstructive Sleep Apnea	402
Heart Diseases	403
Systolic Heart Failure	403
Coronary Artery Disease	404
HIV/AIDS	406
Chronic Kidney Disease	410
Alcoholic Liver Disease	414
Muscle and Bone Disorders	415
Conclusions	415
References	416

Introduction

Mild androgen deficiency and inflammation are common features of many systemic illnesses, particularly metabolic disorders such as obesity, diabetes mellitus, and nonalcoholic fatty liver

disease [1–5]. Recent studies in humans now directly show that interleukin-2, a hallmark of inflammation, induces androgen depletion though enhanced feedback inhibition of LH secretion [6, 7]. These findings suggest a potential unifying mechanism whereby many diverse chronic illnesses could lead to mild androgen deficiency through low-grade inflammation.

In addition to mild androgen deficiency, many chronic illnesses also feature reduced energy, impaired sleep, sarcopenia, and osteopenia. This clinical picture is suggestive of male hypogonadism. Sufficiently prolonged or severe androgen deficiency could plausibly contribute to the clinical presentation of many chronic diseases. Accordingly, androgen therapy could ameliorate those features that are due to inadequate androgen exposure, most likely those features arising from dysfunction of organs that are unequivocally androgen-responsive such as bone, striated muscle, cardiac muscle, vascular smooth muscle, brain, and fat [8].

Recent studies in normal men have shown effects of testosterone therapy on erythropoiesis, skeletal muscle mass and strength, bone and fat mass, and sexual desire that are undeniably dose-related [9–11]. Applying these dose–response relationships from normal men to men with chronic illnesses is not prudent because coexisting inflammation or other factors may potentiate, retard, or invalidate these relationships, making decisions to treat that are benchmarked to eugonadal reference ranges in healthy individuals

W. Zhang · M. Shabbir · P.Y. Liu (✉)
Division of Endocrinology, Department of Medicine,
Harbor-UCLA Medical Center and Los Angeles
Biomedical Research Institute (LA BioMed), 1000
West Carson St., PO Box 446, Torrance, CA 90509,
USA
e-mail: pliu@labiomed.org

W. Zhang
e-mail: wzhang@labiomed.org

M. Shabbir
e-mail: mshabbir@labiomed.org

unreliable. For these reasons, simply assuming that testosterone therapy is indicated and can be titrated to maintain certain blood testosterone targets derived from reference ranges for eugonadal healthy individuals is presumptive. Instead, the efficacy of adjunctive androgen use in specific chronic illnesses should be firmly established by randomized placebo-controlled trials, first considering efficacy, and then establishing safety, within the limits imposed by the natural history of the underlying illness. Such an approach grounded in randomized controlled trials is the standard that would be required for any xenobiotic drug.

This review focuses on such high quality clinical studies, specifically those that assess effects on recognized androgen-sensitive tissues. Effects of androgens in acute illnesses (burns, surgery, trauma), psychiatric illnesses (schizophrenia, major depression), and in physiological processes (aging, growth, mood) are intentionally excluded due to space constraints. Certain chronic diseases such as cancer (including hematological malignancies and related conditions) and its treatment, and metabolic disorders, such as diabetes mellitus and nonalcoholic liver disease, are addressed elsewhere in this monograph.

Respiratory Diseases

Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is associated with weight loss and muscle wasting as well as decreased blood testosterone levels [12]. Reduced systemic testosterone exposure has been postulated to occur due to chronic systemic inflammation, glucocorticoid use, abdominal obesity, hypoxemia, hypercapnia, age, and smoking [13]. Cardiopulmonary rehabilitation is a core component of the management of COPD and associated congestive heart failure (CHF) [14], and androgen therapy could improve overall performance in either condition directly through increased skeletal muscle strength, or indirectly through increased respiratory muscle strength and oxygenation. Seven placebo-controlled, parallel

group studies examining the impact of androgen therapy on body composition, overall performance (walking) and respiratory specific parameters, including respiratory muscle strength and oxygenation in those with COPD, are summarized in Table 19.1 [15–21]. These studies of aromatizable (testosterone) and nonaromatizable (stanozolol and nandrolone) androgens show an increase in muscle mass with either androgen type, and a reduction in fat mass in two of the three studies of testosterone therapy, but generally no effect on total weight, physical performance (walking), respiratory function or oxygenation. These findings seem independent of underlying wasting and nutrition status and co-interventions such as cardiopulmonary rehabilitation, but the paucity of studies and small sample sizes limit generalizations. Moderate and inconsistent improvements in health related quality of life [21] and sexual quality of life [18] have been reported. These findings are consistent with a study of 122 adults, including 31 women, with chronic respiratory failure on long-term oxygen therapy or home ventilation [22]. The underlying cause for respiratory failure was COPD in 70–75% of those recruited; participants were randomized to receive home health education or a multimodal program consisting of health education, nutritional supplements, exercise, and oral testosterone decanoate (80 mg bid for men and 40 mg bid for women). Multimodal therapy increased weight and fat-free mass, but did not result in functional improvements in walking (6 min walking distance).

Two studies are notable [15, 19]. The first, by Schols et al. examined 217 adults with stable, moderate to severe, and bronchodilator-unresponsive pulmonary disease, and randomized them to receive placebo injections, nutritional supplementation plus placebo injections, or nutritional supplementation plus nandrolone injections [15]. Randomization was stratified according to baseline muscle depletion (ideal body weight <90% with or without lean mass <67%) and all subjects underwent a rehabilitation program (9 week blocks of no co-intervention, inspiratory muscle training, and then exercise training successively). Both nutritional supplementation with or without nandrolone increased body weight compared to placebo, with combined therapy also

Table 19.1 COPD

Study	N M/F	Inclusion criteria	Intervention	Co-intervention	Tx Dur Wks	Resp Muscle Strength	Oxy PaO ₂	Exercise Capacity (6MWT)	Body composition	
									Total	Muscle
Ferreira (1998) [*]	23	BMI < 20 P _{lmax} < 60%	T 250 mg IM once + St 12 mg qd	None [*] then IMT then ET	27	P _{lmax} ↔ FEV1 NR	NR	↔	↔	↔
Schols (1995) ^a (depleted)	110? ?	iBW < 90%	ND IM (50 mg M/25 mg F) q2wks	ET	8	P _{lmax} ↑ FEV1 ↔	NR	↔ ^b	↑ ^{***}	↓
Schols (1995) ^a (nondepleted)	107? ?	iBW ≥ 90%	ND IM (50 mg M/25 mg F) q2wks	ET	8	P _{lmax} ↔ FEV1 ↔	NR	↔	↑ ^{***}	↔
Creutzberg (2003)	63	BMI < 30	ND IM 50 mg q2wks	PR	8	P _{lmax} ↑ FEV1 NR	NR	NR	↔	↔
Svarterberg (2004)	29	BMI nml	T IM 250 mg q4wks	None	26	P _{lmax} NR FEV1 ↔	↔	↔	↔	↓
Casaburi (2004) ^{***}	53	75–130% iBW	TE IM 100 mg qwk	PRT	10	P _{lmax} ↔ FEV1 ↔	↑	NR	NR	↓
Sharma (2008)	16 9/7	BMI normal	ND IM (50 mg M/25 mg F) q2wks	PR nutrition ET	16	P _{lmax} ↔ FEV1 ↔	↔	↔	↔	↔
Daga (2014)	32	BMI normal	ND IM 25 mg qwk	nutrition	6	P _{lmax} NR FEV1 ↔	↔	↑	↔	NR ↑ arm circum

St Sianozolol, T Testosterone, TE Testosterone Enanthate, ND Nandrolone Decanoate

IMT inspiratory muscle training, ET exercise training, PR progressive resistance training BW body weight, iBW % of ideal body weight, BMI

Body Mass Index (kg/m²)

P_{lmax} maximal inspiratory pressure, FEV1 forced expiratory volume in 1 s, Oxy oxygenation, PaO₂ partial pressure oxygen, 6MWT 6 min walking test

NR No Result

^{*}Co-intervention consisted of none weeks 1–9, IMT weeks 9–18 then ET weeks 18–27

^{**}nutrition +ND vs placebo

^{***}Randomized to co-intervention of PRT in two-by-two factorial design

^arandomization was stratified to depleted and nondepleted groups a priori, and were randomized to 3 groups: placebo injections, placebo injections with nutrition and nandrolone injections with nutrition

^b12 min walk

increasing lean body mass in all individuals and respiratory muscle strength in depleted individuals. However, walking distance did not increase. In contrast, none of these parameters differed between those randomized to nutritional supplementation alone versus those who received nutritional supplementation plus nandrolone therapy. The lack of blinding with respect to the nutritional supplementation is a study limitation. After 4 years of follow-up, survival did not differ between those receiving nandrolone and nutritional supplementation, and either of the other two treatment groups [23]. One limitation of this study was that women were recruited, since the number, and whether there were gender differences in outcomes was not reported. The other study, from Casaburi et al. administered testosterone 100 mg or placebo every week to 47 male COPD patients, with or without progressive resistance training, 3 times each week for 10 weeks in a two-by-two factorial design, thereby allowing additive effects to be assessed [19]. Testosterone treatment was associated with a significant increase in body weight, increase in lean mass, and decrease in fat mass. Testosterone therapy with progressive resistance training (PRT) improved PaO₂ relative to placebo therapy with resistance training, but this was not observed between those randomized to testosterone or placebo in those who were not randomized to resistance training. Subjects receiving testosterone and resistance training tended to have a greater increase in lean mass, but this was not statistically significant. A small and significant increase in peak oxygen uptake, peak work rate, and lactic acidosis threshold was observed only in the testosterone and resistance training group (compared with the no exercise and no testosterone group). Generally, however, the combination of testosterone with PRT was no better than either alone. This study provides some evidence that supplemental testosterone might be utilized together with rehabilitation programs to improve muscle strength and improve respiratory function in COPD patients.

In conclusion, the management of COPD should be multidisciplinary. Nutrition should be optimized and combined with cardiopulmonary rehabilitation. Testosterone therapy increases

lean muscle mass, but this has not been demonstrated to translate into meaningful functional improvements thereby limiting widespread adoption. Further research in specific subgroups that are more likely to benefit from androgen therapy may be warranted.

Obstructive Sleep Apnea

Obstructive sleep apnea is associated with reduced blood testosterone, with lower blood testosterone concentrations being particularly related to greater degrees of hypoxemia [24]. The putative mechanisms underpinning reduced systemic testosterone exposure include hypoxemia-induced alterations in the hypothalamo-pituitary pulsatile secretion of luteinizing hormone [25–27], but detailed appraisal of the entire gonadal axis has not been systematically performed and direct testicular effects, from increased interleukin 2 or other factors, have not been excluded. Expert guidelines caution the use of androgen therapy in men with obstructive sleep apnea [28]. Two sets of two randomized controlled trials have examined the influence of testosterone therapy on sleep and/or breathing during sleep in young hypogonadal [29, 30] or older eugonadal men [31, 32]. In the first study [29], 11 hypogonadal men already receiving testosterone (testosterone enanthate 200–400 mg every two weeks) were studied, once approximately 3–7 (mean 3.5) days after a testosterone injection, and again at least 30 (mean 53) days after a testosterone injection in random order. Testosterone therapy increased the number of apneas and hypopneas by, on average, 9 events/h. In the other study [30], 10 men were rendered acutely hypogonadal with leuprolide, and were randomized to receive testosterone enanthate 200 mg or oil placebo every 2 weeks for 4 weeks. Testosterone only lengthened time in slow wave sleep, and effects on breathing were not reported.

In the other set of two studies performed in older eugonadal men, in the first study, 108 men were randomized to receive a dose-titrated testosterone patch (about 6 mg/day) or

matching placebo for three years [31]. Sleep breathing did not deteriorate, but the portable device was relatively insensitive, could only detect hypoxemia but not breathing, and sleep architecture was not examined. In the other study [32], 17 older men were randomized to receive either three injections of intramuscular testosterone esters at weekly intervals (500, 250 and 250 mg) or matching oil-based placebo, and then crossed-over to the other treatment after eight weeks washout. Polysomnography occurred 2–4 days after the last injection. Testosterone shortened sleep by an hour, induced sleep disordered breathing by 7 events/h, and increased the duration of hypoxemia by 2%. These studies in men without sleep disordered breathing suggest that high dose testosterone esters, but not lower dose more steady-state testosterone therapy, may have short-term effects on sleep and disordered breathing.

Only one study has purposely treated men with obstructive sleep apnea with testosterone, utilizing the hypothesis that lower dose more steady-state therapy may have time-dependent effects on sleep disordered breathing [33–36]. Sixty-seven middle-aged obese men with obstructive sleep apnea were placed on a hypocaloric diet and randomized to additionally receive three intramuscular injections of either testosterone undecanoate 1000 mg or matching placebo every 6 weeks. Testosterone therapy worsened the oxygen desaturation index by 10 events/h and the duration of hypoxemia by 6% after the second injection, but not after the third [33]. These data are consistent with putative time-dependent effects where adaptations in the hyperoxic ventilatory recruitment threshold to carbon dioxide reduced the propensity to sleep disordered breathing with time [35]. Despite these adverse effects on breathing during sleep, 18 weeks of testosterone therapy increased muscle mass, reduced liver fat, and improved insulin sensitivity and sexual desire compared with placebo therapy [34, 36]. Further studies examining the risks and benefits of testosterone therapy in men with obstructive sleep apnea over the longer term are required.

Heart Diseases

Systolic Heart Failure

Blood testosterone concentrations are reduced in men with severe systolic heart failure or coronary artery disease (CAD) irrespective of etiology [37]. The mechanisms by which this occurs are multifactorial. Cardiopulmonary rehabilitation is a key component of the care of men with systolic heart failure [14], and androgen therapy could improve overall performance either directly, through increased skeletal muscle strength and cardiac contractility, or indirectly, through improved systemic oxygenation and blood flow. Five randomized placebo-controlled trials of 12–52 weeks of testosterone therapy are summarized in Table 19.2 [38–43]. All these studies, except Stout et al.'s [42], show that testosterone improves physical performance (walking). On the other hand, cardiac function (Left Ventricle Ejection Fraction) and biochemical markers of congestive cardiac failure (brain natriuretic peptide) are consistently unaffected by testosterone therapy. Accordingly, the improved physical performance is presumably secondary to direct skeletal muscle effects that are independent of changes in cardiac contractility. One methodological issue is that these walking tests are volitional, and hence can be altered by a placebo effect. Although all of these studies (Table 19.2) are placebo-controlled, only Malkin's study utilized a matched placebo [40], with the remaining being possibly unblinded due to the use of a saline-based placebo [38, 39, 41–44]. Nevertheless, the unequivocally blinded study showed concordant findings [40], which were replicated in another unequivocally blinded trial of 36 women with CHF who were randomized to receive testosterone (300 µg) or placebo transdermal patch [45].

The one study (by Stout et al.) which failed to show improved physical performance, was also the only study to select men with a low testosterone level (<15 nmol/L) and to concurrently enforce an exercise program consisting of aerobic and resistance training two times each week [42]. In this small study, the baseline shuttle walk

Table 19.2 CHF

Study	N M/F	Trial type	Intervention	Co-intervention	Duration (weeks)	Performance measure	Cardiac Function (LVEF)	Biochemical (BNP)
Malkin (2003)/Pugh (2004)	20	PG	T* 100 mg IM q2wks	None	12	ISWT ↑	↔	↔
Malkin (2006)	76	PG	T patch 5 mg qd	None	52	ISWT ↑	↔	↔
Caminiti (2009)	70	PG	TU 1000 mg IM q6wks	None	12	6MWT ↑ Muscle Peak Torque ↑	↔	NR
Schwartz (2011)	58	PG	TU 1000 mg IM q6wks	None	12	NR	NR	NR
Stout (2012)	41	PG	T 100 mg IM q2wks	Exercise	12	ISWT ↔	↔	↔
Mirdamadi (2014)	50	PG	TE 250 mg IM q4wks	None	12	6MWT ↑	↔	NR

PG parallel group

T testosterone, TU Testosterone Undecanoate, TE Testosterone Enanthate

ISWT-incremental shuttle walk test, SWT-shuttle walk test, 6MWT-6 min walk test

NR no result, LVEF Left Ventricular Ejection Fraction, BNP Brain natriuretic peptide

*T ester mixture commercially available as Sustanon

distance of men randomized to receive testosterone was substantially lower than that of the placebo group, and 32% of subjects enrolled did not complete the study. Whether this really means that androgen therapy has no additional impact in men already undergoing an exercise program will require more and larger studies utilizing a two-by-two factorial design.

In addition to improvements in physical performance, two studies by Malkin et al. and Schwartz et al. have also shown beneficial electrocardiographic effects of testosterone therapy, namely on QT dispersion [38] and reduced QTc interval [41]. Both findings imply improved electrical conductance. Another study also examined immediate hemodynamic effects of testosterone therapy [46]. In this study, 12 men with CHF received 60 mg of buccal testosterone or matching placebo pills in random order on consecutive days. Testosterone therapy increased cardiac output measured by thermodilution, and reduced systemic vascular resistance 180 min after buccal application. Reduced systemic

vascular resistance with testosterone therapy within this time frame is suggestive of peripheral arterial vasodilation. Whether the changes in cardiac output are real, or secondary to reduced vascular resistance, is not clear. Even if real, these immediate changes do not appear to be sustained. The most parsimonious interpretation of this study in conjunction with the studies shown in Table 19.2 would be that improvements in physical performance due to testosterone do not seem to be mediated by improved cardiac function.

Coronary Artery Disease

Three studies in men with coronary artery disease show that testosterone can rapidly improve cardiac ischemia (see Table 19.3) [47–49]. Improved cardiac ischemia within this timeframe is most consistent with coronary vasodilation, and this is consistent with animal studies which show that testosterone causes endothelium-independent

Table 19.3 CAD

Study	N	Intervention	Design	Tx Dur	Washout Interval	Effect	Ischemia	Angina
Rosano (1999)	14	T 2.5 mg IV once	XO	5 min	2 days	I	↓	↔
Webb (1999)	14	T 2.3 mg IV once	XO	10 min	7 days	I	↓	↔
Thompson (2002)	32	T IV Titrated	XO	20 min	7 days	I	↔	↔
Jaffe (1977)	50	TC 200 mg IM qwk	PG	8 weeks		S	↓	↔
Wu and Weng (1993)	62	TU 120 mg qd for 2wk then 40 mg qd for 2 wk	XO	4 weeks	14 days	S	↓	↓
English (2000)	46	T patch 5 mg qd	PG	12 weeks		S	↓	↔*
Webb (2008)	22	TU 80 mg BID	XO	8 weeks	None	S	↓ ^a	↔
Cornoldi (2010)	87	TU 40 mg TID	PG	12 weeks		S	↓	↓

T Testosterone, TC Testosterone Cypionate, TE Testosterone Enanthate, TU Testosterone Undecanoate

PG parallel group, XO crossover

I immediate, S sustained

*Pain perception was improved by testosterone therapy

^aReduced ischemia only in myocardium supplied by non-obstructed arteries

coronary vasodilation through decreased smooth muscle tone. All studies were placebo-controlled, crossover in design, and objectively measured cardiac ischemia by stress ECG or imaging. Testosterone therapy improved cardiac ischemia in the first two studies by Rosano 1999 et al. and by Webb et al.; these studies also discontinued anti-anginal therapy prior to enrolment and were performed 10 or 30 min after IV doses which raised testosterone concentrations up to 22-fold higher than normal [47, 48]. The third study by Thompson et al. was the largest, but did not show improved cardiac ischemia. In this study, anti-anginal therapy was not discontinued and dose titration occurred to carefully raise testosterone 2 and sixfold higher than baseline [49]. Whether the discordant findings relate to dose or concomitant medications requires further investigation. Nevertheless, only intravenous testosterone infusions that result in very high

concentrations can acutely enhance brachial artery flow-mediated dilatation [50]. Not surprisingly, angina was not improved, likely owing to the short treatment duration.

Five randomized placebo-controlled trials show that testosterone therapy for 1–3 months results in sustained improvements in measured cardiac ischemia (see Table 19.3) [51–55]. Wu's and Cornoldi's studies both report reduced angina [52, 55], and English's study reports that perceived pain intensity, and physical role limitation measured by SF-36 questionnaire were improved by testosterone therapy [53]. These data, in combination with studies of immediate androgen action, suggest that improved cardiac ischemia can reduce symptoms when sustained. Blinding appeared to be adequate in all studies except possibly in one [52], in which another report inconsistently described the placebo treatment [56].

An unresolved issue is whether and how testosterone therapy would affect the process underlying coronary artery disease, and whether, over the longer term, such therapy would reduce, increase, or have no effect on cardiovascular events or mortality. Studies of androgen therapy of adequate duration in men with coronary artery disease are not available to address this issue, but data in men without coronary artery disease are available. In a study of 308 relatively healthy men over the age of 60, titrated testosterone gel therapy for 3 years did not increase common carotid artery intima media thickness or coronary calcification compared with placebo [57]. Although atherosclerosis progression was not demonstrated in this study that was adequately powered to do so, the possibility that effects may differ in those with preexisting or advanced atherosclerosis limits generalization to that population. Clinical trial data support this hypothesis. In one study that randomized 22 men to receive 8 weeks of testosterone undecylenate 80 mg bid or placebo pills in random order, imaging studies showed increased myocardial perfusion only in areas supplied by unobstructed coronary arteries [54]. Nonrandomized observational studies of men without known coronary artery disease also report that testosterone therapy decreases [58], increases [59, 60] or does not change [61] cardiovascular events. Findings from randomized controlled trials are also contradictory [62, 63], with one study showing an excess of cardiovascular events [62], but not the other slightly larger study [63], despite both studies being nearly identical in study design. Meta-analyses of randomized placebo-controlled trials also show contradictory results [64, 65]. The first reported that testosterone therapy increases cardiovascular events [64], but a later meta-analysis that included more studies [65] did not.

In conclusion, testosterone therapy decreases cardiac ischemia and improves symptoms when sustained. Effects on the underlying atherosclerotic process are ill-defined, and concern remains regarding long-term effects on cardiovascular events and morbidity. Until the cardiovascular safety in otherwise healthy individuals is

established, there does not appear to be a role for androgen therapy in those with coronary artery disease, given the many other treatment options that are disease modifying and/or anti-anginal.

HIV/AIDS

Hypogonadism is common in men with HIV especially in those with AIDS wasting. Testosterone production is adversely affected by HIV due to poor nutrition, opportunistic infections and the medications used to treat HIV/AIDS [66]. The availability of effective antiretroviral combinations has revolutionized the treatment and outcomes for patients with HIV/AIDS [67]. Both beginning therapy earlier, and effective preventative strategies, have reduced the progression of this disease so that wasting is much less common [68]. Randomized placebo-controlled trials of testosterone and the nonaromatizable androgens nandrolone, oxandrolone and oxymetholone are summarized in Tables 4 and 5, respectively [69–87]. These studies all showed that androgen therapy does not increase CD4 count or reduce viral load, except two studies showing either increased CD4 count [77] or reduced viral load [76], but not both. Nevertheless, androgen therapy for HIV/AIDS may still be useful to improve weight loss, weakness, mood, and quality of life. This is highly relevant because loss of fat-free mass [88], as well as cachexia in general [89], and specifically in those with HIV [90], predicts mortality. Accordingly, androgens or other agents such as megestrol or growth hormone that increase appetite and/or body weight may delay death, but no study has been designed to assess this outcome. Nevertheless, the degree of wasting may also be an important factor that modifies response.

Randomized placebo-controlled trials that examined the effect of testosterone, which is aromatizable (Table 19.4), or nonaromatizable androgens (Table 19.5) on weight, muscle mass, strength, and fat mass are summarized, showing wasting status. Most studies recruited men with wasting, and almost all studies recruited

exclusively men, except two non-testosterone studies that included women [78, 85]. Three studies are not included due to design issues: one because it randomized between nandrolone alone with or without progressive resistance training [75], meaning that nandrolone alone effects could only be assessed within group, another because all subjects received megestrol, which is known to induce hypogonadism and may have confounded results [91], and the third because it only compared megestrol with oxandrolone [92]. Some studies of testosterone, and all studies of other androgens, recruited men with any baseline testosterone level, and even those that specified an upper testosterone value [70–72, 79, 86, 87] included men with total testosterone concentrations of up to 400 ng/dL. Irrespective of baseline testosterone and wasting status, androgen therapy increases muscle mass, and more consistently so with nonaromatizable androgens. In this regard, the two studies by Grinspoon are particularly notable because both assessed muscle comprehensively by three modalities (fat-free mass by DEXA, lean mass by total body potassium and muscle mass by urinary creatinine excretion), and all three measures were increased by 6 months of testosterone therapy compared with placebo [71, 76]. Furthermore, these changes were sustained during the 6-month open-label extension of the study [93]. Two studies by Grinspoon 2000 and Bhasin 2000 of testosterone therapy have additionally examined specific peripheral muscle area [76, 79]. Both show an increase in CT or MRI measured leg and/or arm muscle area.

Effects on fat mass have been more difficult to demonstrate. First, no study of nandrolone, oxandrolone, or oxymetholone has shown a reduction in body fat (Table 19.5). However, this may be explained by the fact that these androgens are minimally aromatizable, and aromatization is important for body fat [10]. In contrast, the larger studies of testosterone therapy that have utilized accurate methods to measure fat have generally shown a reduction in fat mass. Bhasin's 2007 study is notable for three reasons: it treated the largest number of men with testosterone and placebo, men were specifically

recruited for abdominal obesity, and body fat was examined comprehensively by both DEXA and abdominal CT [86]. Testosterone gel therapy decreased total body fat, including trunk and extremity fat, as well as total abdominal subcutaneous fat, rather than visceral fat, compared to placebo. Since most studies examine men with HIV wasting, and no other study has recruited only abdominally obese men, it is not possible to determine if the lack of effect on visceral fat was specific to this population.

These improvements in body composition, namely increased muscle mass with (testosterone) or without (nonaromatizable androgens) reduced fat, have resulted in corresponding increases or no change in total weight (Tables 19.4 and 19.5). Despite demonstrating increased muscle mass in participants, most studies have failed to demonstrate an increase in muscle strength or other performance measurements. When measured, improvements in quality of life have either not been demonstrated or inconsistently improved [70, 72, 73, 79, 80].

Two studies by Gold et al. and Sardar et al. directly compared nandrolone with testosterone [83, 84], and a third study by Storer et al. compared testosterone with recombinant human growth hormone (rhGH) [81]. The first two studies randomized men to receive intramuscular injections of nandrolone decanoate 150 mg, testosterone 250 mg mixed esters as Sustanon[®], or oil-based placebo every two weeks for 12 weeks, and assessed body fat only by bioimpedance, which is a relatively inaccurate method. In the smaller study by Sardar et al. 104 men were randomized 42:42:20 (nandrolone: testosterone: placebo). Nandrolone was superior to testosterone for increasing BMI, but was not significantly different for total body weight, waist circumference, triceps skinfold thickness, or any other anthropometric measurement. In the larger study by Gold et al. 303 men were randomized 157:66:80, and nandrolone was superior to testosterone for both BMI and total body weight. The lack of reliable body composition information, particularly for muscle, is a major limitation. The third study by Storer et al. randomized 82 men with HIV-associated weight loss to

Table 19.4 HIV aromatizable androgens

Study	N	T status (ng/dL)	Wasting (Y/N)	Androgen intervention	Co-intervention	Weeks	Strength	Body Composition		Biochem
								Total	muscle	
Coodley (1997) ^{a*}	39	Any	Y WL > 5%	TC 200 mg IM q2wk	None	12	↔	NR	NR	CD4 ↔ Viral NR
Bhasin (1998)	41	<400	N	T patch 5 mg qd	None	12	UE ↔ LE ↔	↔	↓	CD4 ↔ Viral ↔
Grinspoon (1998)	51	Any ^a	Y iBW < 90% ± WL > 10%	TE 300 mg IM q3wk	None	24	6MWT ↔	↑	↔	CD4 ↔ Viral ↔
Dobs (1999)	133	<400 ^b	Y WL 5-20%	T scrotal patch 6 mg qd	None	12	NR	NR	NR	CD4 ↔ Viral ↔
Bhasin (2000)	61	<350	Y WL ≥ 5%	TE 200 mg IM qwk	PRT thrice weekly [*]	16	UE ↔ LE ↔	↔	↔	CD4 ↔ Viral ↔
Grinspoon (2000)	54	Any	Y iBW < 90% ± WL > 10%	TE 200 mg IM qwk	PRT thrice weekly [*]	12	UE ↑ LE ↔	↑	↑ arm (CT) ↑ leg (CT) ↑	CD4 ↔ Viral ↓
Bhasin (2007)	88	<400 ^c	N Abdominal obesity	T 1% gel 10 g qd	None	24	NR	↔	↑	CD4 ↔ Viral ↔
Knaapp (2008)	61	<400	Y BMI < 20 ± WL ≥ 5%	TE 300 mg IM qwk	None	16	LE ↔ Physical function ↔	↔	↑	CD4 ↔ Viral ↔
Sardar (2010)	104	Any	Y BMI < 20 ± WL 5-10%	ND 150 mg IM or T 250 mg IM q2wk (2:2:1)	None	12	NR	↑	NR	CD4 ↔ Viral NR

TC Testosterone Cypionate, T Testosterone, TE Testosterone Enanthate, ND Nandrolone Decanoate

NR no result

iBW ideal Body weight, WL weight loss, BMI body mass index (kg/m²), PRT progressive resistance training

^a6MWT 6 min walk test, LE lower extremity, UE upper extremity; (CT) measured by CAT scan; (MRT) measured by MRT scan; Viral serum viral load

^{*}also randomized to co-intervention in two-by-two factorial design

^{**}Crossover design with no washout period

^aand free T < 12 pg/ml

^bor free T < 16 pg/mL

^cor free T < 40 pg/mL or bioavailable T < 115 nd/dL

Table 19.5 HIV nonaromatizable androgens

Study	N M/F	T status	Wasting (Y/N)	Androgen Intervention	Co-intervention	Duration (weeks)	Strength	Body Composition		Biochem
								Total	Muscle	
Berger (1996)	63	Any	Y WL ≥ 10%	Ox 5 mg or 15 mg qd	None	16	↔	↑	NR	CD4 ↑ Viral NR
Strawford (1999)	24	>225	Y WL ≥ 5%	Ox 20 mg qd	PRT + T 100 mg qwk	8	UE ↑ LE ↔	↑	↔	CD4 ↔ Viral ↔
Batterham (2001) ^a	15	Any	Y WL ≥ 5%	ND 100 mg IM q2wk	None	12	N/A	↑	↓	CD4 NR viral NR
Hengge (2003)	89 79/10	Any	Y WL 5–10%	Oxymetholone 50 mg BID or TID	None	16	NR	↑	↔	CD4 NR Viral NR
Shevitz (2005) ^a	50 35/15	Any	Y WL 5–10% ±BMI < 20	Ox 10 mg BID	Nutrition	12	6MWT ↔ UE ↔ LE ↑	NR	↔	CD4 NR Viral NR
Storer (2005) ^{**}	82	Any	Y WL 5–15% ±BMI 17–19	ND 150 mg IM q2wk	None	12	↔	NR	↑	CD4 ↔ viral ↔
Grunfeld (2006)	262	Any	Y WL 10–20% ±BMI ≤ 20	Ox 20, 40 or 80 mg qd (1:1:1:1)	None	12	↔	↑	↔	CD4 ↔ Viral ↔
Gold (2006)	303	Any	Y WL 5–15% ±BMI 17–19	ND 150 mg or T 250 mg IM q2wk (2:1:1)	None	12	N/A	↑	↔	CD4 ↔ Viral ↔
Saha (2009) ^b	73	Any	Y WL 5–10%	ND 150 mg IM q2wk	None	12	NR	↔	↔	CD4 ↔ Viral NR
Sardar (2010)	104	Any	Y WL 5–10% ± BMI < 20	ND 150 mg or T 250 mg IM q2wk	None	12	N/A	↑	NR arm circumference ↑	CD4 ↔ viral NR

WL weight loss

T Testosterone; Ox Oxandrolone, ND Nandrolone Decanoate

NR no result

viral load, PRT progressive resistance training

UE upper extremity, LE lower extremity

^a randomized to oxandrolone, placebo or progressive resistance training

^{**} randomized to nandrolone, placebo or growth hormone, BMI body mass index (kg/m²)

^a randomized to nandrolone, medroxyprogesterone or dietary counseling

^b randomized to nandrolone or no treatment

receive intramuscular injections of nandrolone decanoate 150 mg, matching placebo every 2 weeks, or daily subcutaneous rhGH for 12 weeks. Both nandrolone and rhGH increased muscle and decreased fat (both determined by DEXA) compared with placebo. However, nandrolone was inferior to rhGH for fat loss, but equivalent for muscle gains. Despite these body compositional changes, muscular strength and insulin sensitivity measured by minimal model were no different from placebo.

Five studies incorporated a standard progressive resistance training (PRT) program three times per week into the study design [74–76, 78, 79]. A placebo for PRT was not used in any of these studies, and subsequently this intervention should be considered unblinded. In the first study by Shervitz et al. 50 adults with AIDS wasting all received a personalized and intensive nutrition program, and were additionally randomized to receive placebo tablets, oxandrolone 20 mg daily, or PRT for 12 weeks [78]. Oxandrolone was not directly compared against PRT in this study so that the relative benefits of androgen therapy versus PRT were not assessed. The additional effect of combination therapy has been examined in the remaining four studies [76, 79]. The first two studies by Grinspoon et al. [76] and Bhasin et al. [79] utilized a two-by-two factorial design, and reported that the combination either did not promote further gains [79], or neglected to report the effect of combination therapy [76] over testosterone therapy or PRT alone (see Table 19.4). In the third study, 30 men with stable weight were treated with supraphysiological weekly doses of intramuscular nandrolone decanoate (200 mg for the first dose, 400 mg for the second dose and 600 mg for all subsequent doses), and then randomized to additionally receive PRT or not for 12 weeks [75]. Combination therapy augmented gains in muscular strength and lean body mass measured by DEXA and bioimpedance, but not total body weight, perhaps because supraphysiological doses of nandrolone were administered. In the final study by Strawford et al. (see Table 19.5), 24 men with HIV-associated weight loss were all treated with PRT and testosterone enanthate 100 mg weekly

“to suppress endogenous testosterone production” and then randomized to also receive oxandrolone 20 mg each day or placebo tablets for 8 weeks [74]. The addition of oxandrolone increased muscle and upper limb strength, but the lack of a no-treatment control and the concurrent use of two androgens limit interpretation.

Together, these studies indicate that androgen therapy increases muscle and that aromatizable androgens probably reduce fat, with corresponding effects on total weight. Only inconsistent effects on muscle strength and quality of life have resulted from these body compositional improvements. The separate and adjunctive roles of exercise and rhGH have been inadequately studied.

Chronic Kidney Disease

Hypogonadism is common in men with chronic kidney disease, and is likely to contribute to their low libido, anemia, sarcopenia, and low bone mass [94]. The underlying mechanisms are multifactorial in origin, and include suppression of gonadotropins due to elevated prolactin arising from decreased renal clearance, comorbidities, and concurrent medications. Hypogonadism rarely improves with dialysis but typically does so after renal transplantation. Direct renotropic effects of androgens have been suspected for decades [8]; however, data in humans showing that androgens can directly improve renal function in those with impaired renal function either did not report benefit [95, 96], or were uncontrolled and therefore unreliable [97]. On the other hand, sarcopenia and anemia are recognized features of end stage renal failure, and muscle and erythropoiesis are recognized androgen targets.

Five randomized placebo-controlled trials consistently showed that weekly intramuscular injections of 100–200 mg of nandrolone for 3 months [98] or 6 months [99], or 6 months of oral oxymethenolone 50 mg bid [100–102] increases DEXA-measured lean body mass, compared with placebo (Table 19.6). Of these, the three largest studies, (Johansen’s study [98],

Table 19.6 Renal

Study	N M/F	Study group Dialysis	Wasting (Y/N)	Intervention	Co-intervention	Tx Dur (Weeks)	Strength	Body composition		
								total	muscle	fat
Johansen (1999)	29 23/6	HD or PD	Y	ND 100 mg IM qwk	None	24	Walk/stair climb ↓ Treadmill ↔	↔	↑	↔
Johansen (2006)	79 49/30	HD	N	ND 200 mg IM qwk (male) 100 mg IM qwk (female)	Resistance training	12	Walk/stair climb ↔ LE ↔	↑	↑	↓
Aramwit (2009)	44 25/19	HD	N	Oxymetholone 50 mg BID	None	24	NR	↑	↑	↓
Aramwit (2010)	24 20/4	PD	N	Oxymetholone 50 mg BID	EPO	24	NR	↔	↑	NR
Supasyndh (2013)	41 25/16	HD	NR	Oxymetholone 50 mg BID	None	24	Handgrip ↑ muscle area ↑	↔	↑	↓

HD hemodialysis; PD peritoneal dialysis

ND Nandrolone Decanoate, EPO recombinant human erythropoietin, NR no results

Aramwit's study [100], and Supasyndh's study [102]), also reported a reduction in fat mass [98, 100, 102]. These body compositional changes translated into functional improvements. Oxymethenolone therapy increased handgrip strength in 41 dialysis patients, including 16 women [102], increased insulin sensitivity by HOMA in 44 patients (including 19 females) [100], and improved global nutritional status in 24 adults, including 4 women [101]. Significant elevations in liver enzymes with oxymethenolone compared to placebo were highlighted in all three reports [100–102], although Aramwit's study in 2010 [101] may actually be from a subset of a larger study [100].

The increase in lean body mass with nandrolone therapy also translated into modest functional improvements. In Johansen's study [99], weekly intramuscular injections of nandrolone 100 mg for 6 months in 29 patients, including six women, improved some measures of physical performance when compared with saline placebo injections, including timed walking and stair climbing and self-reported fatigue, but not treadmill testing time and oxygen consumption or handgrip strength [99]. Given these improvements, the authors conducted a study to assess the synergistic effect of exercise in a two-by-two factorial design [98]. Seventy-nine adults, including 30 women, were randomized to 3 months of weekly intramuscular injections of nandrolone, lower limb exercise three times each week, both interventions simultaneously, or matched placebo injections supplied by the nandrolone manufacturer. Each injection of nandrolone was 200 mg for men and 100 mg for women. The main effects analyses showed increases in lower limb strength with exercise in a training-specific manner, but not with nandrolone therapy. Quadriceps muscle cross-sectional area increased with exercise and with nandrolone, without interaction between the two main effects. In these two studies, excess elevation of liver enzymes was not observed in those who received nandrolone. However, women did become virilized.

All five studies of nandrolone and oxymethenolone showed increases in lean muscle

mass. Two other studies of nandrolone therapy confirm this finding: one in those not yet requiring dialysis [95], and the other which utilized a no-treatment control group consisting of those who declined to participate in the randomized dose-finding trial [103]. In these studies, however, increased lean muscle mass was not always associated with increased muscle strength, and treatment improved some, but not all, measures of physical function. Non-pharmacological interventions, such as exercise training or nutritional supplementation, may be as, or more, effective. There is a paucity of studies looking at combination therapy.

The anemia of end stage renal failure has multiple contributing factors such as micronutrient deficiency (iron, folate, pyridoxine), blood loss and hemolysis, reduced red cell survival, EPO or androgen deficiency, and impaired EPO or androgen action [104]. A link between androgens and erythropoiesis has been suspected for over 75 years [105]. Recent physiological studies establish a linear dose–response relationship across the hypogonadal and eugonadal range that is augmented in older men [9]. Potential mechanisms include increased erythropoietin and reduced hepcidin [106], although effects on erythropoietin may be transitory [9, 107, 108]. Whether effects on hepcidin are mediated through recently identified master regulators such as erythroferrone requires further investigation [109].

It is well established that androgen therapy increases hemoglobin concentrations in men with end stage renal failure. The three largest randomized placebo-controlled studies have shown that nandrolone treatment (100–200 mg weekly) for 3–5 months increases hemoglobin concentration by 10–15 g/L [110–112] and decreases transfusion requirements [110]. These findings contrast with three smaller studies that failed to show an increase in hemoglobin in patients with end stage renal failure which may be explained by inadequate dosing and dropouts from the study [96, 113, 114]. Two other randomized controlled crossover trials concluded that injectable androgens were superior to oral androgens in supporting erythrocytosis [115], and that

erythrocytosis occurred only in those with remnant renal function [116]; however, methodological problems make these findings less convincing. There was a large proportion of dropouts in both studies, and neither study was blinded due to a lack of an appropriate placebo drug. The finding that remnant renal function was required was based on a subgroup analysis in anephric and non-anephric patients that appeared to be decided post hoc [116], and the differences between injectable and oral androgens may have been due to inadequate oral dosing: testosterone enanthate (4 mg/kg/wk) and nandrolone decanoate (3 mg/kg/wk) versus oxymetholone (1 mg/kg/day) and fluoxymesterone (0.4 mg/kg/day).

Current guidelines recommend recombinant human erythropoietin and analogues (EPO) but not androgen replacement [117], despite two randomized placebo-controlled trials showing equivalence between nandrolone and EPO [118, 119]. However, those two trials were small, each recruiting less than 30 men over 50 years of age, so that only large differences between therapies could have been recognized. Combination therapy with both androgen and EPO is also not recommended [117], but the hemoglobin targets on which these guidelines were based have been criticized and hence, these recommendations can be challenged [120, 121]. Three randomized controlled trials examined the combination of nandrolone with EPO versus EPO alone [122–124]. The first study was underpowered with only 12 adults in total, and up to only 4 months in treatment duration [122]. The other two studies were comparable, but only one showed that the combination was superior [123]. In that study, 19 adults, including eight women, were randomized to receive nandrolone (100 mg weekly) plus EPO (4500 U/wk) or EPO alone for 6 months. The addition of nandrolone to low dose EPO resulted in a significantly greater rise in hematocrit. However, a larger study in which 32 adults, including 12 women, were randomized to receive the same total dose of nandrolone (50 mg twice weekly) for the same duration of time (6 months) with or without a lower dose of EPO (3000 U/wk) showed no significant

differences in hematocrit or hemoglobin [124]. How the different doses of EPO affected these contradictory findings depends on the effect of androgen therapy on EPO deficiency and/or action. However, circulating EPO is neither consistently increased by androgens nor related to the resultant increases in hemoglobin [125]. On the other hand, the mean ages in the combined treatment groups were 54 [12] and 44 [124] years; this could conceivably account for these differences, since the induction of erythropoiesis by androgens is enhanced in older men [9]. In both studies, baseline hematocrit (23–25%) and the proportion of women (37–42%) were comparable. Virilization resulted in half of all women in the combination arm discontinuing from the study [124].

Two other randomized studies examined the combined effects of 6 months of androgen therapy with EPO, and also reported divergent results [101, 126]. Unlike the studies utilizing nandrolone, these two studies utilized placebo controls. The first study utilized an inadequate dose of transdermal testosterone, which only modestly and inconsistently increased serum testosterone or DHT in 40 uremic men with low testosterone levels, of whom 22 discontinued by the end of the 6-month treatment period [126]. The second study took 24 adults, including 4 women, on a stable dose of EPO and randomized them to oxymetholone 50 mg bid or placebo tablets [101]. Combined therapy further increased hematocrit from 0.32 to 0.38 and hemoglobin from 10.8 to 12.9 g/dL, with highly significant between group differences at 6 months, and no changes in EPO dose. In contrast with the earlier studies using nandrolone [123, 124], these individuals had much less anemia, were treated with a much higher EPO dose (on average 4000 U/wk), and included fewer women. The use of this 17 α -alkylated androgen was also associated with a significant increase in liver enzymes, although no subject discontinued for this reason or developed transaminitis that exceeded 5 times the upper limit of normal.

Together, these five randomized controlled trials provide contrasting and complementary information regarding the utility of combining

EPO with androgen therapy for the anemia of end stage renal disease [101, 122–124, 126]. Although androgen therapy is considerably cheaper than EPO, it should not be used in women and children, and 17 α -alkylated androgens may result in hepatotoxicity. One area of potential usage could be in older men [118, 127] who respond poorly to EPO, or for whom EPO is contraindicated or unavailable. Restricting use to non-17 α alkylated androgens, particularly in older men [9, 118, 127], may avoid most of the hazards. Other than anemia, testosterone deficiency in men with CKD may also contribute to low bone mass, increased cardiac disease, and increased mortality. Studies are needed to establish these potential benefits in this population, even in those who would appear to be unequivocally hypogonadal.

Alcoholic Liver Disease

Men with alcoholic liver disease show features of hypogonadism including small testes, gynecomastia, soft smoother skin, and reduced bone and muscle mass. Direct hepatotrophic effects of androgens have been described [8, 128]; however, the systematic use of androgens in alcoholic liver disease is now of historical interest, and information on the use of androgens in non-alcoholic fatty liver disease is very limited (see Chap. 11). The effects of androgen therapy could differ when applied acutely for alcoholic liver disease [129–132], compared with more prolonged therapy for those with alcoholic cirrhosis [133–135].

Three studies have examined whether one month of oxandrolone 80 mg daily during acute alcoholic hepatitis can improve short or long-term survival or other clinical endpoints. The first study separately randomized 132 men with moderate disease and 131 men with severe disease to 30 days of oxandrolone, prednisolone (60 mg daily initially) or placebo [129]. There were no statistically significant differences in short-term (30 day) or long-term survival among the three treatment groups, irrespective of disease severity.

Recent data indirectly strengthen this finding by showing no statistically significant difference in short-term (28 day) or long-term (90 days or 12 month) mortality between men and women treated with prednisolone (40 mg daily) or placebo for 28 days [136]. A second study showed no overall survival benefit in the intention-to-treat analysis amongst 271 undernourished men with severe alcoholic hepatitis randomized to combined oxandrolone with high calorie enteral supplementation, although a post hoc subgroup analysis showed a survival benefit with combined therapy in those with moderate malnutrition [130]. In any case, the study design did not allow for separation of effects due to improved nutrition from those due to oxandrolone. This is relevant because improved nutrition alone may reduce mortality [137]. The third study did not include placebo controls and only examined biochemical endpoints [131, 132].

Systematic studies in men with alcoholic cirrhosis are equally sparse and also now of mainly historical interest. Findings from small short-term studies treating <50 men with androgens for <1 month are inconclusive [133, 134], and there is only one relevant study, which was conducted by the Copenhagen Study Group for Liver Disease and powered to detect a 35% decrease in mortality. In this randomized parallel group study, micronized testosterone (200 mg tid, $n = 134$) compared with placebo ($n = 87$) administered for 3 years did not improve mortality [135], liver histology [138], liver function [139], or sexual dysfunction [140]. These studies of oral testosterone and oxandrolone resulted in proportionally higher hepatic than systemic exposure. Overdosage presumably resulting in detrimental effects, including portal vein thrombosis occurred [141].

Together, these studies show little benefit of adjunctive androgen use in men with alcoholic hepatitis or cirrhosis, although it is possible that overdosage to the liver may have adversely affected overall outcome. These data should not be extrapolated to non-alcoholic fatty liver disease, where other biological processes may be more androgen-responsive.

Muscle and Bone Disorders

Although skeletal muscle and bone are known androgen targets, the use of androgen therapy in disorders of muscle and bone is limited. Conceptually, simply increasing the mass of dysfunctional muscle or bone may not be beneficial. Randomized placebo-controlled trials of androgen therapy in bone disorders such as osteoporosis, osteomalacia, or other metabolic bone diseases are not available. On the other hand, androgen therapy may be useful for idiopathic osteoporosis where there is no underlying abnormality in bone architecture. Two randomized controlled trials are available [142, 143], but neither was adequately powered to examine fracture rates, and neither showed consistent or sustained improvements in bone mineral density. The largest study involved 327 patients treated with methandienone 2.5 mg daily or matching placebo for 9 months with 1 year of follow-up [142], and the other study randomized only 21 men to receive either weekly injections of nandrolone decanoate 50 mg or no treatment for 12 months [143]. Neither androgen utilized is aromatizable, which is problematic since aromatization is critical for action on bone [11].

Randomized controlled trials have examined the role of androgen therapy in men with muscular dystrophies such as myotonic dystrophy [144] and Duchenne muscular dystrophy [145]. In the first study, 40 men were randomized to receive intramuscular injections of testosterone enanthate (3 mg/kg) or placebo each week for 12 months [144]. In the other study, 51 boys aged 5–10 years were randomly assigned to receive oxandrolone (0.1 mg/kg/day) or placebo for 6 months [145]. Neither study showed consistent improvements in functional measures of performance such as skeletal or respiratory muscle strength, or walking.

Conclusions

The wide-ranging effects of androgens on multiple key organs important for survival and quality of life have long been recognized.

Striated muscle, cardiac muscle, respiratory muscle, bone, fat, hemopoietic tissue, vascular smooth muscle, and neurological tissues are all androgen-responsive. By improving function, androgen therapy could plausibly ameliorate the morbidity associated with many chronic illnesses that arise from sarcopenia, low energy, impaired sleep, and osteopenia. These improvements could plausibly impact both the natural history and outcome of many non-gonadal disorders.

Despite over 50 randomized controlled studies in multiple organ systems, androgen therapy has not increased survival or altered the natural history of any chronic illness. Increased lean muscle mass (with any androgen) and decreased fat mass (particularly with aromatizable androgens) has been universally observed in various lung diseases, heart diseases, renal diseases, and in HIV/AIDS with and without wasting. However, specific improvements in respiration, cardiac contractility or muscular strength have been much more difficult to show. Despite this, subjective functional improvements have often been demonstrated in the absence of objective changes in performance. Relaxation of vascular smooth muscle leading to improved circulation has been documented, but the impact on atherosclerosis and on cardiovascular morbidity and mortality are safety concerns that need to be addressed once efficacy is established.

Cardiopulmonary rehabilitation is a core component of the management of chronic obstructive pulmonary disease and congestive heart failure, and would seem to be important for at least some wasted individuals with kidney disease or HIV/AIDS. Careful clinical trials are required to properly establish the role of androgen therapy, but can be, and have been, performed in other settings such as aging [146]. Renotropic and hepatotropic effects are plausible, but have not been demonstrated with androgen therapy. Further research for these indications has been essentially abandoned because of the development of renal and liver transplantation. An adjunctive role for appropriately dosed androgen therapy to prolong the survival or function of renal and liver transplants is plausible, but would require careful

investigation since the immunomodulatory effects of androgens could be harmful. Androgen therapy for renal anemia, although once a standard therapy, has long been supplanted by modern erythropoietin analogues. However, an adjunctive role could be considered as new therapies based on new molecular targets (such as erythroferrone) are developed. Combining new with long established agents such as androgens that have a well-characterized mechanism of action and wide-ranging targets may be advantageous in certain clinical settings. As this review highlights, androgen therapy remains promising, even as new drugs come to market.

References

1. Abbasi AA, Drinka PJ, Mattson DE, Rudman D. Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. *J Am Geriatr Soc.* 1993;41(9):975–82.
2. Blackman MR, Weintraub BD, Rosen SW, Harman SM. Comparison of the effects of lung cancer, benign lung disease, and normal aging on pituitary-gonadal function in men. *J Clin Endocrinol Metab.* 1988;66(1):88–95.
3. Liu PY, Swerdloff RS, Veldhuis JD. Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: Future research and current practice recommendations. *J Clin Endocrinol Metab.* 2004;89(10):4789–96.
4. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: Longitudinal results from the European male ageing study. *Eur J Endocrinol.* 2013;168(3):445–55.
5. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010;363(2):123–35.
6. Veldhuis J, Yang R, Roelfsema F, Takahashi P. Proinflammatory cytokine infusion attenuates LH's feedforward on testosterone secretion: Modulation by age. *J Clin Endocrinol Metab.* 2016;101(2):539–49.
7. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. *Immunol Rev.* 2008;226:19–28.
8. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. *Endo Rev.* 1987;8(1):1–28.
9. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. *J Clin Endocrinol Metab.* 2008;93(3):914–9.
10. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallas JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med.* 2013;369(11):1011–22.
11. Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. *J Clin Invest.* 2016;126(3):1114–25.
12. Atlantis E, Fahey P, Cochrane B, Wittert G, Smith S. Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis. *BMJ Open.* 2013;3(8).
13. Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. *Eur Respir J.* 2009;34(4):975–96.
14. Vogiatzis I, Zakyntinos S. The physiological basis of rehabilitation in chronic heart and lung disease. *J Appl Physiol* (1985). 2013;115(1):16–21.
15. Schols AM, Soeters PB, Mostert R, Pluyms RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. *Am J Respir Crit Care Med.* 1995;152(4 Pt 1):1268–74.
16. Ferreira IM, Verreschi IT, Nery LE, Goldstein RS, Zamel N, Brooks D, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. *Chest.* 1998;114(1):19–28.
17. Creutzberg EC, Wouters EF, Mostert R, Pluyms RJ, Schols AM. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. *Chest.* 2003;124(5):1733–42.
18. Svartberg J, Aasebo U, Hjalmarson A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. *Respir Med.* 2004;98(9):906–13.
19. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2004;170(8):870–8.
20. Sharma S, Arneja A, McLean L, Duerksen D, Leslie W, Sciberras D, et al. Anabolic steroids in COPD: a review and preliminary results of a randomized trial. *Chronic Respir Dis.* 2008;5(3):169–76.
21. Daga MK, Khan NA, Malhotra V, Kumar S, Mawari G, Hira HS. Study of body composition, lung function, and quality of life following use of anabolic steroids in patients with chronic

- obstructive pulmonary disease. *Nutr Clin Pract: Official Publ Am Soc Parenter Enteral Nutr.* 2014;29(2):238–45.
22. Pison CM, Cano NJ, Cherion C, Caron F, Court-Fortune I, Antonini MT, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: A randomised controlled trial. *Thorax.* 2011;66(11):953–60.
 23. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1998;157(6 Pt 1):1791–7.
 24. Liu PY, Gooren LJ, Handelsman DJ. Impact of systemic disease on male sexual function. In: Kandeel FR, editor. *Male sexual dysfunction: Pathophysiology and treatment.* 1st ed. New York, NY: Informa Healthcare USA; 2007. p. 155–76.
 25. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. *J Clin Endocrinol Metab.* 2002;87(7):3394–8.
 26. Luboshitzky R, Lavie L, Shen-Orr Z, Lavie P. Pituitary-gonadal function in men with obstructive sleep apnea. The effect of continuous positive airways pressure treatment. *Neuroendocrinol Lett.* 2003;24(6):463–7.
 27. Liu PY, Yee BJ, Phillips CL, Grunstein RR. Sleep apnea and neuroendocrine function. *Sleep Med Clin.* 2007;2:225–36.
 28. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2010;95(6):2536–59.
 29. Schneider BK, Pickett CK, Zwillich CW, Weil JV, McDermott MT, Santen RJ, et al. Influence of testosterone on breathing during sleep. *J Appl Physiol.* 1986;61:618–23.
 30. Leibenluft E, Schmidt PJ, Turner EH, Danaceau MA, Ashman SB, Wehr TA, et al. Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men. *J Clin Endocrinol Metabol.* 1997;82(10):3203–7.
 31. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab.* 1999;84(8):2647–53.
 32. Liu PY, Yee BJ, Wishart SM, Jimenez M, Jung DG, Grunstein RR, et al. The short-term effects of high dose testosterone on sleep, breathing and function in older men. *J Clin Endocrinol Metab.* 2003;88(8):3605–13.
 33. Hoyos CM, Killick R, Yee BJ, Grunstein RR, Liu PY. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnea: A randomised placebo-controlled trial. *Clin Endocrinol (Oxf).* 2012;77:599–607.
 34. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnea: A randomised placebo-controlled trial. *Eur J Endocrinol.* 2012;167:531–41.
 35. Killick R, Wang D, Hoyos CM, Yee BJ, Grunstein RR, Liu PY. The effects of testosterone on ventilatory responses in men with obstructive sleep apnoea: A randomized placebo-controlled trial. *J Sleep Res.* 2013;22:331–6.
 36. Melehan KL, Hoyos CM, Yee BJ, Wong KK, Buchanan PR, Grunstein RR, et al. Increased sexual desire with exogenous testosterone administration in men with obstructive sleep apnea: A randomized placebo-controlled study. *Andrology.* 2016;4(1):55–61.
 37. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. *Endocr Rev.* 2003;24(3):313–40.
 38. Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy on QT dispersion in men with heart failure. *Am J Cardiol.* 2003;92(10):1241–3.
 39. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. *Heart.* 2004;90(4):446–7.
 40. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. *Eur Heart J.* 2006;27(1):57–64.
 41. Schwartz JB, Volterrani M, Caminiti G, Marazzi G, Fini M, Rosano GM, et al. Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure. *Int J Androl.* 2011;34(5 Pt 2):e415–21.
 42. Stout M, Tew GA, Doll H, Zwierska I, Woodroffe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: A double-blind randomized controlled feasibility study. *Am Heart J.* 2012;164(6):893–901.
 43. Mirdamadi A, Garakyaraghi M, Pourmoghaddas A, Bahmani A, Mahmoudi H, Gharipour M. Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure. *BioMed Res Int.* 2014;2014:392432.
 44. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. *J Am Coll Cardiol.* 2009;54(10):919–27.

45. Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. *J Am Coll Cardiol*. 2010;56(16):1310–6.
46. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. *Eur Heart J*. 2003;24(10):909–15.
47. Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. *Circulation*. 1999;99:1666–70.
48. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. *Am J Cardiol*. 1999;83(3):437–9, A9.
49. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. *Am Heart J*. 2002;143(2):249–56.
50. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. *Am J Cardiol*. 2000;85(2):269–72.
51. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. *Br Heart J*. 1977;39(11):1217–22.
52. Wu S, Weng X. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. *Chin Med J*. 1993;106:415–8.
53. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. *Circulation*. 2000;102(16):1906–11.
54. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. *Am J Cardiol*. 2008;101(5):618–24.
55. Cornoldi A, Caminiti G, Marazzi G, Vitale C, Patrizi R, Volterrani M, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. *Int J Cardiol*. 2010;142(1):50–5.
56. Wu S, Weng X. Therapeutic effect of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients. *Chin Med Sci J*. 1992;7(3):137–41.
57. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: A randomized clinical trial. *J Am Med Assoc*. 2015;314(6):570–81.
58. Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. *Eur Heart J*. 2015.
59. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *J Am Med Assoc*. 2013;310(17):1829–36.
60. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. *PLoS ONE*. 2014;9(1):e85805.
61. Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. *Ann Pharmacother*. 2014;48(9):1138–44.
62. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. *N Engl J Med*. 2010;363(2):109–22.
63. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab*. 2010;95(2):639–50.
64. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med*. 2013;11:108.
65. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: A systematic review and meta-analysis. *Expert Opin Drug Saf*. 2014;13(10):1327–51.
66. Rochira V, Guaraldi G. Hypogonadism in the HIV-infected man. *Endocrinol Metab Clin North Am*. 2014;43(3):709–30.
67. Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. *N Engl J Med*. 2014;371(3):248–59.
68. Piot P, Quinn TC. Response to the AIDS pandemic—A global health model. *N Engl J Med*. 2013;368(23):2210–8.
69. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. *Am J Physiol Endocrinol Metab*. 2001;281(6):E1172–81.
70. Dobs AS, Cofrancesco J, Noltzen WE, Danoff A, Anderson R, Hamilton CD, et al. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to

- human immunodeficiency virus infection. *Am J Med.* 1999;107(2):126–32.
71. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 1998;129(1):18–26.
72. Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. *J Clin Endocrinol Metab.* 1998;83(9):3155–62.
73. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. *Aids.* 1997;11(11):1347–52.
74. Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial. *J Am Med Assoc.* 1999;281(14):1282–90.
75. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. *J Clin Endocrinol Metab.* 1999;84(4):1268–76.
76. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. *Ann Intern Med.* 2000;133(5):348–55.
77. Berger JR, Pall L, Hall CD, Simpson DM. Oxandrolone in AIDS-wasting myopathy. *AIDS.* 1996;10(14):1657–62.
78. Shevitz AH, Wilson IB, McDermott AY, Spiegelman D, Skinner SC, Antonsson K, et al. A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting. *J Acquir Immune Defic Syndr.* 2005;38(4):399–406.
79. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. *J Am Med Assoc.* 2000;283(6):763–70.
80. Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: A randomized, double-blind, placebo-controlled study. *J Acquir Immune Defic Syndr.* 2006;41(3):304–14.
81. Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder ET, Beck K, et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. *J Clin Endocrinol Metab.* 2005;90(8):4474–82.
82. Saha B, Rajadhyaksha GC, Ray SK. Beneficial effects of nandrolone decanoate in wasting associated with HIV. *J Indian Med Assoc.* 2009;107(5):295–9.
83. Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TB, Helmyr PM, et al. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. *HIV Med.* 2006;7(3):146–55.
84. Sardar P, Jha A, Roy D, Majumdar U, Guha P, Roy S, et al. Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): A randomized, double-blind, placebo-controlled trial. *HIV Clin Trials.* 2010;11(4):220–9.
85. Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. *Aids.* 2003;17(5):699–710.
86. Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. *J Clin Endocrinol Metab.* 2007;92(3):1049–57.
87. Knapp PE, Storer TW, Herbst KL, Singh AB, Dzekov C, Dzekov J, et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. *Am J Physiol Endocrinol Metab.* 2008;294(6):E1135–43.
88. Graf CE, Herrmann FR, Spoerri A, Makhlof AM, Sorensen TI, Ho S, et al. Impact of body composition changes on risk of all-cause mortality in older adults. *Clin Nutr.* 2016.
89. Kotler DP. Cachexia. *Ann Intern Med.* 2000;133(8):622–34.
90. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. *Am J Clin Nutr.* 1989;50:444–7.
91. Mulligan K, Zackin R, Von Roenn JH, Chesney MA, Egorin MJ, Sattler FR, et al. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: A randomized, double-blind, placebo-controlled, multicenter trial. *J Clin Endocrinol Metab.* 2007;92(2):563–70.
92. Mwamburi DM, Gerrior J, Wilson IB, Chang H, Scully E, Saboori S, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: Similar results in 2 months. *Clin Infect Dis.* 2004;38(6):895–902.
93. Grinspoon S, Corcoran C, Anderson E, Hubbard J, Stanley T, Basgoz N, et al. Sustained anabolic effects of long-term androgen administration in men

- with AIDS wasting. *Clin Infect Dis.* 1999;28(3):634–6.
94. Dousdampanis P, Trigka K, Fourtounas C, Bargman JM. Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease. *Ther Apher Dial.* 2014;18(3):220–30.
 95. Eiam-Ong S, Buranaosot S, Wathanavaha A, Pansin P. Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease. *J Ren Nutr: Official J Counc Ren Nutr Natl Kidney Found.* 2007;17(3):173–8.
 96. van Coevorden A, Stolear JC, Dhaene M, Herweghem JLv, Mockel J. Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. *Clin Nephrol.* 1986;26(1):48–54.
 97. Wilkey JL, Barson LJ, Kest L, Bragagni A. The effect of testosterone on the azotemic patient: An intermediary report. *J Urol.* 1960;83:25–9.
 98. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. *J Am Soc Nephrol: JASN.* 2006;17(8):2307–14.
 99. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. *J Am Med Assoc.* 1999;281(14):1275–81.
 100. Aramwit P, Kobpipat N, Satirapoj B, Kopple JD, Supasyndh O. Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. *Clin Nephrol.* 2009;71(4):413–22.
 101. Aramwit P, Palapinyo S, Wiwatniwong S, Supasyndh O. The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. *Int J Clin Pharmacol Ther.* 2010;48(12):803–13.
 102. Supasyndh O, Satirapoj B, Aramwit P, Viroonudomphol D, Chaiprasert A, Thanachatwej V, et al. Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. *Clin J Am Soc Nephrol: CJASN.* 2013;8(2):271–9.
 103. Macdonald JH, Marcora SM, Jibani MM, Kumwenda MJ, Ahmed W, Lemmey AB. Nandrolone decanoate as anabolic therapy in chronic kidney disease: A randomized phase II dose-finding study. *Nephron Clin Pract.* 2007;106(3):c125–35.
 104. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, et al. Anemia in chronic renal failure. *Acta Endocrinol.* 1985;suppl 271:80–6.
 105. Shahidi NT. Androgens and erythropoiesis. *N Engl J Med.* 1973;289(2):72–80.
 106. Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, et al. Testosterone suppresses hepcidin in men: A potential mechanism for testosterone-induced erythrocytosis. *J Clin Endocrinol Metab.* 2010;95(10):4743–7.
 107. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. *Eur J Endocrinol.* 2010;162(2):385–90.
 108. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point. *J Gerontol A Biol Sci Med Sci.* 2014;69(6):725–35.
 109. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. *Nat Genet.* 2014;46(7):678–84.
 110. Hendler ED, Goffinet JA, Ross S, Longnecker RE, Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. *N Engl J Med.* 1974;291:1046–51.
 111. Williams JS, Stein JH, Ferris TF. Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. *Arch Intern Med.* 1974;134(2):289–92.
 112. Buchwald D, Argyres S, Easterling RE Jr, Oelshlegel FJ, Brewer GJ, Schoemaker EB, et al. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. *Nephron.* 1977;18(4):232–8.
 113. Bock EL, Fulle HH, Heimpel H, Pribilla W. Die Wirkung von Mesterolol bei Panmyelopathien und renalen Anaemien. *Med Klin.* 1976;71(13):539–47.
 114. Naik RB, Gibbons AR, Gyde OH, Harris BR, Robinson BH. Androgen trial in renal anaemia. *Proc Eur Dial Trans Assoc.* 1978;15:136–43.
 115. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, et al. A comparison of androgens for anemia in patients on hemodialysis. *N Engl J Med.* 1981;304(15):871–5.
 116. Cattran DC, Fenton SS, Wilson DR, Oreopoulos D, Shimizu A, Richardson RM. A controlled trial of nandrolone decanoate in the treatment of uremic anemia. *Kidney Int.* 1977;12(6):430–7.
 117. Group. KDIGO KAW. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int Suppl.* 2012;2:279–335.
 118. Gascon A, Belvis JJ, Berisa F, Iglesias E, Estopinan V, Teruel JL. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. *Geriatr Nephrol Urol.* 1999;9(2):67–72.
 119. Navarro JF, Mora C, Macia M, Garcia J. Randomized prospective comparison between erythropoietin

- and androgens in CAPD patients. *Kidney Int.* 2002;61(4):1537–44.
120. Klinger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. *Am J Kidney Dis.* 2013; 62(5):849–59.
 121. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, et al. Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. *Am J Kidney Dis.* 2013;62(5):860–73.
 122. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. *Clin Nephrol.* 1992;37(5):264–7.
 123. Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. *Am J Kidney Dis.* 1997;30(4):495–500.
 124. Sheashaa H, Abdel-Razek W, El-Husseini A, Selim A, Hassan N, Abbas T, et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. *Nephron Clinical practice.* 2005;99(4):c102–6.
 125. Teruel JL, Marcen R, Navarro JF, Villafruela JJ, Fernandez Lucas M, Liano F, et al. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. *Nephron.* 1995;70(3):282–6.
 126. Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. *Am J Kidney Dis.* 2006;47(2):251–62.
 127. Teruel JL, Aguilera A, Marcen R, Antolin JN, Otero GG, Ortuno J. Androgen therapy for anaemia of chronic renal failure. *Scand J Urol Nephrol.* 1996;30:403–8.
 128. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. *Gastroenterology.* 2008;135(3):947–55, 55 e1–5.
 129. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. *N Engl J Med.* 1984;311:1464–70.
 130. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis. *Hepatology.* 1993;17(4):564–76.
 131. Bonkovsky HL, Singh RH, Jafri IH, Fiellin DA, Smith GS, Simon D, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition. *Am J Gastroenterol.* 1991;86(9):1209–18.
 132. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. *Am J Gastroenterol.* 1991;86(9):1200–8.
 133. Wells R. Prednisolone and testosterone propionate in cirrhosis of the liver: A controlled trial. *Lancet.* 1960;ii:1416–9.
 134. Fenster LF. The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease. *Ann Intern Med.* 1966;65:738–44.
 135. Gluud C. Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: A double-blind study. *Hepatology.* 1986;6:807–13.
 136. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med.* 2015;372(17):1619–28.
 137. Cabre E, Rodriguez-Iglesias P, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial. *Hepatology.* 2000;32(1):36–42.
 138. Gluud C, Christoffersen P, Eriksen J, Wantzin P, Knudsen BB. Copenhagen Study Group for Liver Diseases. No effect of long-term oral testosterone treatment on liver morphology in men with alcoholic cirrhosis. *Am J Gastroenterol.* 1987;82:660–4.
 139. Gluud C, Henriksen JH. Copenhagen study group for liver diseases. Liver haemodynamics and function in alcoholic cirrhosis. *J Hepatol.* 1987;4:168–73.
 140. Gluud C, Wantzin P, Eriksen J. Copenhagen study group for liver diseases. No effect of oral testosterone treatment on sexual dysfunction in alcoholic cirrhotic men. *Gastroenterology.* 1988;95:1582–7.
 141. Gluud C, Dejgard A, Bennett P, Svenstrup B. Androgens and oestrogens before and following oral testosterone administration in male patients with and without alcoholic cirrhosis. *Acta Endocrinol.* 1987;115:385–91.
 142. Inkovaara J, Gothoni G, Halttula R, Heikinheimo R, Tokola O. Calcium, vitamin D and anabolic steroid in treatment of aged bones: Double-blind placebo-controlled long-term clinical trial. *Age Ageing.* 1983;12:124–30.
 143. Hamdy RC, Moore SW, Whalen KE, Landy C. Nandrolone decanoate for men with osteoporosis. *Am J Ther.* 1998;5(2):89–95.

144. Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, et al. Randomized controlled trial of testosterone in myotonic dystrophy. *Neurology*. 1989;39(2 Pt 1):219–22.
145. Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. *Neurology*. 2001;56(8):1075–9.
146. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. *N Engl J Med*. 2016;374(7):611–24.

Stimulation of Spermatogenesis in Hypogonadotropic Men

20

Julia Rohayem and Eberhard Nieschlag

Contents

Introduction	423
Pretreatment Diagnostic Workup in Male Hypogonadotropic Hypogonadism.....	423
Hormone Substitution Modalities for Stimulation of Spermatogenesis in HH.....	424
GnRH Replacement.....	424
Gonadotropin (hCG/FSH) Replacement.....	425
Monitoring	430
Caveats During Hormone Replacement.....	430
Therapeutic Outcome of Central Hormone Replacement Strategies.....	431
Efficacy of Spermatogenic Induction: Comparison GnRH Versus Gonadotropins.....	431
Factors Influencing Response to Gonadotropins or GnRH	431
Pregnancy Outcomes	432
Inheritance of Congenital Hypogonadotropic Hypogonadism	433
References	433

Introduction

The hypothalamic–pituitary–gonadal (HPG) axis coordinates two functions essential for male reproductive capacity: synthesis and secretion of sex steroid hormones, primarily testosterone, and production of spermatozoa. Gonadotropin-releasing hormone (GnRH), a decapeptide produced in hypothalamic GnRH neurons, is released into the portal blood in discrete pulses, binds to specific receptors on gonadotrophs in the anterior pituitary, where it elicits gonadotropin secretion. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are glycoprotein hormones that control the development, maturation and function of the gonads [1]. To induce and maintain quantitatively and qualitatively normal spermatogenesis, both gonadotropins are required [2]. While LH binds to the LHCG receptor of Leydig cells, thereby stimulating testosterone synthesis and secretion, FSH binds to its receptor on Sertoli cells and induces spermatid maturation (spermiogenesis) during spermatogenesis [1].

Knowledge of the impact of the patient's genetic background and our understanding of the physiologic principles of male reproductive health have substantially increased in recent years, enabling physicians not only to identify causes of hypospermatogenesis among a wide spectrum of possible disorders affecting maleness and reproductive capacity, but also to establish therapeutic strategies. Men with hypothalamic or pituitary

J. Rohayem · E. Nieschlag (✉)
Centre of Reproductive Medicine and Andrology,
University of Münster, Domagkstraße 11,
48129 Münster, Germany
e-mail: Eberhard.Nieschlag@ukmuenster.de

J. Rohayem
e-mail: julia.rohayem@ukmuenster.de

disorders have an excellent prognosis for fertility restoration and for paternity by natural intercourse or using assisted reproductive techniques.

Pretreatment Diagnostic Workup in Male Hypogonadotropic Hypogonadism

Hypogonadotropic hypogonadism (HH) is suspected in teenage boys with delayed, absent or partial (and then arrested) puberty which needs to be distinguished from the far more common constitutional pubertal delay (see Chap. 4). In adulthood, suspicion is raised by symptoms of androgen deficiency and/or infertility. The diagnosis of permanent HH has to be based upon a meticulous pretreatment diagnostic workup.

Previous medical history should include the presence of an undescended testis at birth (with age at possible orchidopexies) and previous diseases, including eating disorders, chronic diseases leading to weight loss, malignancies with chemo- and/or radiotherapy, inflammatory diseases (meningitis, orchitis) and testicular trauma or surgery. Inquiries should be made into the ability to smell and on somatic features that may be associated with various causes of congenital HH/Kallmann syndrome, including visual disturbances, renal agenesis, dental and digital anomalies, cleft lip and palate, coloboma, synkinesia/mirror movements and ataxia. In addition, information on exercise, recent medication (including opioids) and drug abuse (including anabolic steroids) should be sought.

Family history ought to assess the parent's age at entering puberty, age at maternal menarche and signs of hypogonadism or infertility in relatives.

Physical examination includes auxological measurements and pubertal Tanner staging with measurement of testicular volumes using a Prader orchidometer or ultrasound.

While *hormone investigations* of the hypothalamo–pituitary–gonadal axis focus on LH, FSH and testosterone levels, measurement of TSH, free T4, GH, IGF1, IGFBP3, prolactin,

and cortisol enables investigation of associated pituitary and adrenal hormone deficiencies.

Other laboratory analyses and function tests with measurement of inhibin-B levels and GnRH agonist testing (buserelin) may help to differentiate HH from CDGP (see Chap. 4).

Further diagnostic workup includes imaging procedures, such as magnetic resonance imaging (MRI) of the hypothalamo–pituitary region to rule out intracranial malformations, neoplasms or infiltrating diseases. Scrotal ultrasound provides information on parenchymal structure and testicular size [3]. Determination of bone age according to Greulich and Peyle [4] by a left-hand carporadiogram is used to estimate residual longitudinal growth potential in adolescents with absent or arrested puberty. Semi-quantitative olfactometry [University of Pennsylvania Smell Identification Test (UPSIT) or Sniffin'sticks] may be performed to distinguish between normal, partially or totally defective olfaction. Semen analysis is relevant to evaluate spermatogenesis and function of accessory glands, especially if paternity is desired. Karyotyping (+FISH) may be undertaken to rule out associated chromosomal anomalies. Sequencing of candidate genes in subjects with CHH (see Chap. 6) with description of mutations or polymorphisms is indicated for investigation of the genetic origin of HH. Results may also be helpful for genetic counselling prior to hormone replacement for fertility induction.

Hormone Substitution Modalities for Stimulation of Spermatogenesis in HH

GnRH Replacement

GnRH is effective therapy in men with hypothalamic GnRH deficiency provided that no additional pituitary pathologies are present [5–8], and that there is no GnRH-R mutation. The latter condition cannot be distinguished from GnRH deficiency unless genetic testing is done. GnRH has to be delivered in a pulsatile fashion by a

portable mini-pump to successfully stimulate gonadotropin secretion, and consequently testosterone secretion and spermatogenesis. Continuous application of GnRH results in downregulation of pituitary GnRH receptors and blockade of signal transduction [9]. GnRH replacement is costly and inconvenient for patients as they have to carry a mini-pump and subcutaneous catheter for an extended period. Therefore, this modality—although physiologically appealing—is reserved for very motivated patients [10]. The needle of a catheter linked to the portable GnRH mini-pump is placed into the patient's abdominal subcutaneous tissue. It has to be changed every 2 days. The pump is programmed to deliver GnRH boluses every 120 min, as this frequency was shown to be most effective [11]. After a starting dose of 4 µg per pulse, increases of 2 µg may be performed every 4 weeks, aiming to produce testosterone levels in the normal adult range after 3–12 months (depending on the maturity of the testes achieved previously). Dosages necessary to induce spermatogenesis vary considerably between individuals with HH, ranging from 5 to 20 µg GnRH per bolus (or 25–600 ng/kg GnRH per bolus). To induce spermatogenesis sufficient to induce a pregnancy, 1–3 years of treatment may be required. Patients with previously undescended testes may require considerably longer treatment for induction of spermatogenesis than patients with scrotal testes [5].

Gonadotropin (hCG/FSH) Replacement

In patients with hypogonadism of either hypothalamic or pituitary origin, subcutaneous or intramuscular hCG/FSH replacement is most often successful in stimulating endocrine and spermatogenic testicular functions and growth of previously immature testes.

Effective regimens of subcutaneous injections of hCG and FSH have been developed (Table 20.1).

Human chorionic gonadotropin (hCG) purified from the urine of pregnant women has been used to replace LH since 1952 [12]. It contains

almost exclusively LH-like bioactivity [13], and effectively stimulates testosterone production by Leydig cells.

Follicle-stimulating hormone (FSH) is required for spermatid maturation (spermiogenesis) during initiation and for maintenance of quantitatively normal spermatogenesis at puberty and thereafter [2, 14, 15]. *Urinary human menopausal gonadotropin (hMG)* has been used as a source of FSH since 1966 [16], *highly purified urinary FSH* has been available since 1997/98 [17, 18] and *recombinant FSH (rFSH)* since 1995 [19–22]. The putative risks of transmission of prion disease from urinary-derived gonadotropin preparations have not been documented in over 50 years of use. rFSH, not being of human or animal origin, harbours no such risk; however, a minor risk of infection transmission remains, as foetal calf serum is used in the cell culture media in rFSH production [23, 24]. Currently, there are no data concerning the efficiency of *recombinant LH (rLH)* or *recombinant chorionic gonadotropin (rCG)* for stimulation of spermatogenesis in male HH patients, as these substances are licensed only for assisted reproductive techniques in women. Likewise, *corifollitropin alfa*, a long-acting recombinant FSH-like substance, necessitating only one injection every two weeks to achieve therapeutic levels (instead of thrice weekly FSH injections), is licensed only for use in women [25]. However, this long-acting follicle 'FSH-CTP' (Org 36286) [consisting of the α -subunit of human FSH and a β -subunit composed of the beta-subunit of human FSH and the C-terminus (CTP) of the β -subunit of hCG to prolong its half-life] was found to increase inhibin-B levels in hypogonadotropic males [26], but has not been studied further.

Gonadotropin treatment is generally initiated by administering hCG for 3–6 months [27] to stimulate the synthesis of testosterone (and potentially other Leydig cell products) which is the pre-requisite for spermatogenic induction. In some patients with partially preserved gonadotropin secretion, hCG alone may initiate spermatogenesis [28]. Intramuscular (i.m.), as well as subcutaneous (s.c.), hCG injections are possible,

Table 20.1 Therapeutic options licensed for puberty induction and fertility treatment in male HH

Drug	Trade name	Application	Dose
Human chorionic gonadotropin (hCG)	Brevactid ^{®a} Pregnyl ^b Novarel ^b	s.c. or i.m.	1000–2500 IU twice weekly (on Mondays and Fridays)
Recombinant FSH (rFSH)	Gonal F ^{®a} , Puregon ^{®a} Follistim ^b	s.c. or i.m.	75–150 IU three times weekly (on Mondays, Wednesdays, Fridays)
Pulsatile GnRH	LutrePulse [®]	Mini-pump s.c.	4–20 µg per pulse every 120 min

^aTrade names of drugs marketed in Europe

^bTrade names of drugs marketed in the US

the latter allow for self-injection. If men remain azoospermic, FSH is added. To induce physiologic adult FSH levels, doses of 75–150 IU per injection are required [29]. Large studies using combined hCG/FSH treatment in adult male patients with HH are listed in Table 20.2.

In recent years, the question has been raised whether the sequence of gonadotropin stimulation should be reversed, and replacement should begin with FSH. This notion was triggered by the hypothesis that Sertoli cells may proliferate better upon FSH stimulation if not previously exposed to testosterone [30, 31]. In a recent trial, rFSH administration for 4 months prior to the initiation of pulsatile GnRH treatment resulted in spermatogenesis in 7/7 HH patients after 24 months at which time only 4/6 subjects treated with pulsatile GnRH alone had sperm in their ejaculates [32]. The groups were too small for a definite conclusion, and larger trials are required before this regimen may become routine. It should also be remembered that in HH adolescents presenting primarily for induction of puberty, use of FSH without hCG will not stimulate testosterone secretion or induce pubertal virilisation in contrast to protocols beginning with hCG. As rFSH is costly, the sequential approach starting with hCG has also been preferred for financial reasons.

Hormone Replacement in Prepubertal-Onset HH

A treatment regimen beginning with testosterone for induction of puberty stimulates normal linear growth, pubertal virilization and psycho-sexual maturation in congenital HH. However, this

traditional approach neglects testicular growth and the acquisition of fertility as components of normal puberty. The testes remain immature and small, i.e. in a prepubertal state, and spermatogenesis is not initiated. Meanwhile, there is sufficient evidence that complete male puberty, comprising pubertal virilisation in concert with testicular growth and initiation of spermatogenesis, can be successfully achieved during adolescence by replacement with gonadotropins (hCG/FSH) [7, 8, 30, 33–36] (Table 20.3).

Gonadotropin treatment may be suggested for pubertal induction, even if fertility is a matter for the future. Even though rFSH is costly, normalization of testicular size and initiation of spermatogenesis at a peer-related time may positively affect body image and fertility concerns, and thus provide self-assurance and confidence for the future in teenage boys with HH [36, 37]. In addition, spermatogenesis, once driven to full maturation, can be re-stimulated much faster when fertility is desired later in life [5, 38]. Subsequent treatment with testosterone does not seem to jeopardize the outcome of later stimulation therapy [36]. This is important for prepubertal boys who are unwilling to commit to five s.c. injections per week for 2–3 years. However, some of these young patients may be more agreeable to gonadotropin stimulation once pubertal induction with testosterone is accomplished [39].

In adolescent patients with open epiphyses (i.e. with a bone age < 16 years), the dose of hCG should be escalated in small increments over the first year (until serum testosterone levels are in the normal adult range). The goal is a pubertal growth spurt and attainment of final height in the range of

Table 20.2 Studies using hCG/FSH treatment for spermatogenic induction in adults with hypogonadotropic hypogonadism

Studies using hCG/FSH treatment in more than 20 adult HH patients	Number of adult HH patients	Age (years)	Gonadotropin preparations and sequence of applications	Duration of substitution (months) mean or median (range)	Previous gonadotropin exposure (endogenous or exogenous) or previous TRT	Mean \pm median (range) final single TV (ml) reached	Spermatogenesis achieved	Time to first sperm (months) from start FSH	Sperm concentr. achieved (mill/ml) mean \pm SD or median (range)	Time to sperm plateau (months)
Burgués and Calderón [17]	60	18–45	hCG \rightarrow hCG + purified FSH	hCG: 1 hCG + FSH: 6 (+3)	47 (78%) previous TRT 8 (13%) post-pubertal-onset HH 36 (60%) previous gonadotropins	11 \pm 1	48/60 (80%)	47% sperm positive after 6 months combined tx	25 \pm 8	n.a.
European Metrodin HP study group [18]	28	17–42	hCG + purified FSH	hCG: 3–6 hCG + FSH: 18	11 (39%) previous TRT 4 hCG 1 hCG/MHG	10 \pm 4	89% after 18 month FSH	ca. 20% sperm + after 6 months combined tx	16 \pm 21	n.a.
Liu et al. [68]	26	26–52	hCG \rightarrow hCG + rFSH or uFSH (+further cycles)	hCG: 3–6 hCG + FSH: 4 (0–10)	26 no previous gonadotropins 9 post-pubertal HH 19 no TRT 6 with sperm at start of hCG 16 with more than one cycle	n.a.	n.a.	Median: in first cycles: 7 median in further cycles: 3.5	12 (0–238)	Median (\pm SE): 29 \pm 2
Bouloux et al. [20]	49	31 \pm 7 (18–60)	hCG, hCG \rightarrow hCG + rFSH	hCG: 4 hCG + FSH: \geq 11	7 GnRH 19 hCH/FSH 8 no previous tx	12 \pm 7	23/49 (47%); 9/49 (18%) on hCG alone 14/30 (47%) after additional 6 months FSH	Median: 5.5	n.a. (ca. 1–10)	ca. 10
Matsumoto et al. [22]	36	18–55	hCG \rightarrow hCG + rFSH	hCG: 3–6 hCG + FSH: 18	5 hCG 2 hCG/FSH 5 GnRH 32 TRT	15 \pm 4 13 (7–28)	22/29 (76%)	n.a.; 19/29 (65%) at 6 months	10 \pm 15 5.2 (0–70)	n.a.
Warne et al. [21]	100	16–48	hCG \rightarrow hCG + rFSH	hCG: 3–6 hCG + FSH: 18	n.a.	12 (15) \pm 5	68/81 (84%)	Median: 6–9 (3–18)	n.a. (69% > 1.5)	n.a.
Rohayem et al. [60]	51	22–47	hCG \rightarrow hCG + FSH (urinary derived or purified or rFSH)	hCG: 11 \pm 8 hCG + FSH: 9 \pm 7	10 with pubertal arrest 10 post-pubertal HH 0 with previous hCG/rFSH 42 with previous TRT	27 \pm 15	50/51 (98%)	9 \pm 7	15 \pm 29 2.5 (0–156)	hCG/FSH: 24 \pm 16

Table 20.3 Studies using hCG/FSH in adolescent patients with HH, with assessment of puberty (incl. increase in testicular volume (TV)) and spermatogenesis

Studies using hCG/FSH in adolescent patients with HH, with assessment of puberty (incl. increase in TV) and spermatogenesis	Number of adolescent HH patients	Age (years)	Gonadotropin preparations and sequence of applications	Duration of substitution (months)	Virilisation/adult T levels achieved (%)	Mean ± median (range) final single TV (ml) reached	Spermatogenesis achieved	Time to first sperm (months) from start FSH	Sperm concentration achieved (mill/ml) mean ± SD median (range)	Time to sperm plateau (months)
Liu et al. [7]	3 (subset of cohort)	16–17	hCG/HMG		100	9 ± 1	n.a., total cohort: 80%		<5	
Schopohl [8]	9 (subset of cohort)	18–24	hCG/MHM	20 ± 2	100	n.a. (8–30)	n.a., total cohort: 47%		n.a., total cohort: (2–26)	20 ± 2
Barrio et al. [33]	14 (IHH: 7 panhypopit: 7)	13–21	hCG + rFSH	31	100	IHH: 10 ± 4 panhypo: 15 ± 5	7/8 (87%) IHH: 4/5 panhypo: 3/3		n.a. (1.5–80)	
Raivio et al. [30]	14	10–18	rFSH → rFSH + hCG	rFSH: 2–34 hCG + FSH: n.a.	100	6 (2–37)	6/7 (86%)		8.5 (2.9–92)	
Sinsi et al. [34]	10 (subset of cohort)	11–25	hCG → hCG + rFSH	hCG/rFSH: 12 (–24)	100	10 (7–15)	n.a. total cohort: 81%		29 (2.6–96)	
Zacharin et al. [35]	7 (subset of cohort)	16–22	hCG → hCG + rFSH	hCG/rFSH: 9	100	12 ± 7 10 (5–27)	7/7(100%)		1.2 (0.2–15) 4.6 ± 6 after 9 months	
Rohayem et al. [36]	60 A: 34 B: 26	14–22	A: hCG → hCG + rFSH B: Testis → hCG → hCG + rFSH	A: hCG: 31 ± 6 hCG/FSH: 25 ± 9 B: hCG: 30 ± 7 hCG/FSH: 25 ± 9	A: 100 B: 100	A: 17 ± 3; 15 (8–40) B: 16 ± 3 17.5 (2–30)	A: 21/23 (91%) B: 18/19 (95%)	A: n.a. B: 11 ± 6	A: 17 (0.2–337) 40 ± 73 B: 3.5 (0.1–158) 19 ± 38	A: 31 ± 6 B: 30 ± 7

mid-parental expectations. Adverse effects, including severe acne or gynecomastia, can generally be avoided by this regimen. Subsequent combined hCG/rFSH replacement over two to three years is required for testicular growth and to fully activate the individual's spermatogenic potential. Over 70% of adolescents will thereby reach normal adult testicular size, and sperm will appear in semen in over 90% of patient [35, 36].

In view of the challenging differential diagnosis of constitutional delay of puberty (CDGP), this regimen bears an important further advantage: low hCG doses have only weak suppressive effects at the hypothalamic or pituitary level; therefore, the pubertal GnRH pulse generator may activate in cases of unrecognized CDGP. Patients misdiagnosed as HH may thus be recognized if special attention to a potential rise in serum LH levels is given during the first phase of gonadotropin replacement.

In patients with lack of pubertal development but a late diagnosis of CHH in adulthood, or those with previous testosterone treatment, final height may already have been attained. In these adult men, higher initial hCG replacement doses and faster dose escalations can be applied than in HH boys with open epiphyses/immature growth plates. Success rates for spermatogenic induction in adults are slightly below those of adolescents, ranging from 65 to 90% [5, 17, 18, 40].

Treatment Protocol for Testosterone-Naïve Prepubertal Patients

A starting dose of (250–) 500 IU hCG, injected subcutaneously on Mondays and Fridays, with increments of 250–500 IU hCG per injection every 6 months, to a maximum of 3×2500 IU hCG s.c./week, is recommended. The aim is to achieve pubertal levels [serum testosterone ≥ 1.5 ng/ml, (5.2 nmol/l)] after approximately 6 months, and levels in the mid-normal adult range [testosterone > 3.5 ng/ml, (12 nmol/l)] by one year. rFSH (follitropin alpha) $3 \times (75\text{--})150$ IU s.c./week (injected Mondays, Wednesdays and Fridays) is added when pubertal serum testosterone levels

(>5.2 nmol/l) are reached. Subsequent rFSH dosage modifications above 150 IU per injection are not recommended as they do not further stimulate spermatogenesis.

Treatment Protocol for Testosterone-Virilized Adolescents with Prepubertal-Onset HH

A full hCG starting dose of 1500 IU s.c. may initially be applied twice weekly. hCG dose reduction is recommended if polycythemia, gynecomastia or excessive acne occur. If testosterone levels remain below the normal adult range (<12 nmol/l) after 6–9 months, the hCG dose can be increased by increments of 500–1000 IU per injection (to a maximum of 3×2500 IU s.c./week). rFSH (follitropin alpha) $3 \times (75\text{--})150$ IU is additionally injected thrice weekly after 3–6 months of hCG without subsequent dose modifications.

Hormone Replacement in Post-pubertal-Onset HH

In patients with HH acquired post-pubertally, testicular maturation has already been completed, as indicated by adult testicular size. If the patient has been gonadotropin deficient for a prolonged period, however, paused spermatogenesis may have led to a reduction in testicular volume. Hormone replacement can be initiated either with testosterone or gonadotropins. Since gonadotropins are costly, this therapeutic investment is justified only if paternity is desired. In all other cases, testosterone is the preferred modality for replacement. When stimulation therapy for fertility induction is initiated in patients with previously accomplished testicular maturation, Leydig cell response (as indicated by a rise in serum testosterone levels to the adult range) to hCG occurs within 1–3 months. In some cases this is sufficient for initiation of spermatogenesis [27]. However, prolonged treatment with hCG alone will suppress endogenous residual FSH secretion. Therefore, addition of FSH is often required. Spermatozoa appear in semen after 3–9 months of combined hCG/FSH replacement. Stimulation of spermatogenesis will not proceed further when

the sperm concentration in the ejaculate reaches a plateau that is indicative of the individual's spermatogenic capacity. Once spermatogenesis is fully activated by combined hCG/FSH replacement, sperm production may be maintained with hCG alone for several months (in patients with residual endogenous gonadotropin secretion) [41, 42].

It has been proposed that extended periods of hCG replacement could predispose to the development of hCG antibodies with loss of its effectiveness [43–45], as well as a risk for hypothyroidism [46] due to the structural homology between hCG and TSH. However, this concern has not been substantiated in clinical practice. Nevertheless, recombinant LH (rLH), so far not licensed for use in males, might be used as a therapeutic “rescue strategy” for restimulation of spermatogenesis in such cases.

Treatment Protocol for Adult-Onset HH

A full hCG starting dose of 1500 IU s.c. is applied twice weekly. HCG dose reduction is recommended in cases of polycythemia, gynecomastia or excessive acne. If testosterone levels remain below the normal adult range (<12 nmol/l) after 3–6 months, the hCG dose can be increased by increments of 500–1000 IU per injection every (3)–6 months to a maximum of 3×2500 IU s.c./week. In the great majority of patients who remain azoospermic on hCG alone after 6 months, rFSH (follitropin alpha) 3×150 IU is additionally injected thrice weekly after 6 months of hCG, without subsequent dose modifications.

Monitoring

Measurement of serum LH, FSH, testosterone levels and testicular volumes (via Prader orchidometer and/or ultrasound) ought to be performed at 3–6 monthly intervals during gonadotropin substitution, along with annual bone age estimations in adolescents until a bone age of 16 years (and thus near final height) is reached.

Special attention should be given to LH levels, as a spontaneous increase above >1 U/L would indicate spontaneous HPG axis activation during gonadotropin substitution, which would question the diagnosis of persistent HH. In such cases, cessation of hormone replacement is indicated. Regular measurement of serum testosterone levels (e.g. every three months) is useful not only to monitor the Leydig cell response, but also, along with FSH levels, adherence to treatment. Once maturity for semen analysis is attained in previously prepubertal subjects, ejaculates can be collected and analysed according to WHO guidelines [47] after at least 48 h of sexual abstinence. Thereafter, semen analyses may be repeated every three months until a plateau of sperm concentrations is documented in at least two follow-up visits or until pregnancy is achieved. Sperm cryopreservation may be offered before gonadotropin replacement is stopped and patients are switched to testosterone replacement. However, restimulation of the testes with gonadotropins by a second treatment cycle is known to be successful in most subjects, and spermatogenic induction is achieved faster than during the initial phase of gonadotropin stimulation, even after a long period of testosterone substitution [5]. Therefore, sperm cryopreservation is recommended only in patients with a very poor primary spermatogenic response or in subjects necessitating assisted reproductive techniques for impregnation of their partners.

Caveats During Hormone Replacement

Misdiagnosis of CDGP and CHH Reversal

Lifelong hormone replacement is indicated in nearly all cases of congenital hypogonadotropic hypogonadism. Once gonadotropin substitution (in adult doses) is begun, the GnRH pulse generator is suppressed, making spontaneous activity of the GnRH pulse generator improbable. Because of clinical overlap between CHH and constitutionally delayed puberty, however, CDGP might be misdiagnosed as HH. Moreover, GnRH deficiency seems to resolve in approxi-

mately 5% of patients with Kallmann syndrome or CHH (with *CHD7*, *FGFR1*, *GNRHR*, *TACR* mutations) [48–52]. Therefore, continuous attention should be given to LH levels (the parameter reflecting the patient's endogenous HPG axis activity), in order to recognize spontaneous GnRH pulse generator activation. However, during hCG/FSH replacement, an LH surge is probable only in patients regularly omitting injections. Of note, if reversal of HH occurs, it may not be sustained [51, 52]. The vulnerability and plasticity of the reproductive axis emphasizes the need for lifelong attention to symptoms of androgen deficiency and surveillance of HPG axis hormones.

HPG Axis Suppression/Inhibition: Drug-Induced Hypogonadotropic Hypogonadism

Prolonged abuse of anabolic androgenic steroids (AAS) (including testosterone preparations) suppresses the HPG axis [53, 54]. As shown in clinical trials of testosterone-based hormonal male contraception, suppression is reversible if androgen administration ceases [55]; however, reactivation of the GnRH pulse generator may be delayed up to 3–24 months [56]. In these cases, cessation of exogenous hormone administration or abuse is the primary recommendation. In clinical practice, a variety of approaches have been described to overcome AAS-induced hypogonadism, such as hCG or antiestrogens [53]. However, these may produce unwanted side effects such as gynecomastia and liver dysfunction so that the best advice is to expect spontaneous recovery of HPG axis function after cessation of abuse.

GnRH secretion is also suppressed with the use of morphine, heroin and methadone, each of which activates hypothalamic inhibitory neurons [57–59]. Iatrogenic HPG axis downregulation also occurs as a result of GnRH agonist treatment (for precocious puberty in boys and during anti-androgenic treatment of metastatic prostate cancer in adults). Therefore, inquiries on recent medication use and drug abuse are essential to recognize this potentially reversible cause of HH.

Therapeutic Outcome of Central Hormone Replacement Strategies

Efficacy of Spermatogenic Induction: Comparison GnRH Versus Gonadotropins

Pulsatile GnRH replacement mimics physiology by stimulating the pituitary to release endogenous pulses of LH and FSH. In contrast, subcutaneously administered hCG induces two, and FSH injections produce three peaks per week in the patient's bloodstream. Nonetheless, the efficacy




Fig. 20.1 Maximal final bi-testicular volumes (BTVs) achieved by gonadotropin replacement: Testicular growth reflects the putative onset and severity of HPG axis functional impairment in different HH subgroups, with better results in patients with post-pubertally acquired hypogonadotropic disturbances compared to those with congenital or early-onset HH. MPHD congenital/infancy = multiple pituitary hormone deficiencies, either congenital or acquired during infancy or childhood; CHH absent puberty = congenital hypogonadotropic hypogonadism with absent pubertal development; CHH pubertal arrest = congenital hypogonadotropic hypogonadism with spontaneous initiation of pubertal development, but subsequent pubertal arrest; MPHD postpubertal = multiple pituitary hormone deficiencies, acquired after puberty. From Rohayem et al. [60]. Reprinted with permission from John Wiley and Sons

of spermatogenic induction is comparable with both therapeutic strategies [5, 7]. Success rates in adults range from 65 to 90% [5, 16, 18, 40].

Factors Influencing Response to Gonadotropins or GnRH

GnRH and gonadotropin substitution regimens are more successful in cases without additional testicular damage. Testicular growth and full spermatogenic activation are achieved less quickly, and less effectively in patients with Kallmann syndrome or CHH with absent puberty, compared to those with arrested puberty or HH that is acquired after puberty [60] (Fig. 20.1). Likewise, the time needed to achieve adult testosterone levels following Leydig cell stimulation with hCG is longer in these groups. The pretreatment serum level of the Sertoli cell marker inhibin B, and baseline testicular volumes both mirror the degree of seminiferous tissue development and

endogenous maturation, with low values in subjects with severely impaired maturation and higher values in less severe cases [61, 62]. Cryptorchidism, known to induce changes in the germinal epithelium [63], is a negative predictor of outcomes in HH patients seeking fertility who are treated with GnRH or gonadotropins [5, 21, 38, 63–65]. Kallmann syndrome patients have a high prevalence of undescended testes at birth [60, 66]. Nevertheless, a history of previously cryptorchid testes does not preclude fertility, especially in unilateral cases, but testicular responses require longer stimulation [5]. Patients with congenital multiple pituitary hormone defects also tend to have poorer semen quality in response to treatment [60, 67].

Pregnancy Outcomes

Pregnancies are achieved in 40–55% of partners of HH men wishing paternity who have




Fig. 20.2 Sperm concentrations at the time of achievement of pregnancy in different HH subgroups are plotted over months of hCG/FSH treatment to conception in successful patients. In those unsuccessful, maximal sperm concentrations are plotted over months of hCG/FSH until treatment was terminated. The majority of conceptions occurred despite subnormal sperm concentrations (<15mill/ml) in the ejaculate. MPHD congenital/infancy = multiple pituitary hormone deficiencies, either

congenital or acquired during infancy or childhood; CHH absent puberty = congenital hypogonadotropic hypogonadism with absent pubertal development; CHH pubertal arrest = congenital hypogonadotropic hypogonadism with spontaneous initiation of pubertal development, but subsequent pubertal arrest; MPHD post-pubertal = multiple pituitary hormone deficiencies, acquired after puberty. From Rohayem et al. [60]. Reprinted with permission from John Wiley and Sons

undergone central hormone replacement [5, 38, 60, 68]. Spontaneous pregnancies can occur with subnormal sperm counts, as spermatozoa have an excellent fertilizing potential [5, 33, 60, 64, 65, 68] (Fig. 20.2). However, in 1/5 to 1/8 patients, assisted reproductive techniques (ART), i.e. in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), are required to achieve conception [60, 68, 69]. Even if no sperm appear in the ejaculate after prolonged treatment, testicular sperm extraction (TESE) may provide viable spermatozoa. However, pregnancies via TESE-ICSI in partners of HH patients have not been reported in the current literature, except for a HH patient also suffering from adrenal hypoplasia due to *DAX-1 (NROB1)* mutation [70].

Inheritance of Congenital Hypogonadotropic Hypogonadism

Patients with CHH are usually infertile; therefore most cases occur sporadically, as a result of de novo mutations or—in case of recessive inheritance—from heterozygous (often consanguineous) parents. With successful fertility treatments, vertical disease transmission may increase, especially in case of dominant heredity. Given that the genetic basis of the majority (around 70%) of HH patients remains unknown, even if molecular genetic testing is performed, it is difficult to provide accurate counselling. Nevertheless, information on the risk of disease transmission to the patient's offspring should be given prior to fertility treatment and genetic counselling provided to all subjects with identified mutations. Pre-implantation diagnostics (PID)/pre-implantation genetic diagnosis (PGD) and foetal ultrasound [71] may be options for the future to select embryos without disease-causing mutation.

References

- Weinbauer GF, Luetjens CM, Simoni M, Nieschlag E. Physiology of testicular function. In: Nieschlag E, Behre HM, Nieschlag S, editors. *Andrology: male reproductive health and dysfunction*. 3rd ed. Berlin: Springer; 2010. p. 11–59.
- Nieschlag E, Simoni M, Gromoll J, Weinbauer GF. Role of FSH in the regulation of spermatogenesis: clinical aspects. *Clin Endocrinol*. 1999;51:139–46.
- Behre HM, Zitzmann M. Imaging diagnosis. In: Nieschlag E, Behre HM, Nieschlag S, editors. *Andrology: male reproductive health and dysfunction*. 3rd ed. Berlin: Springer; 2010. p. 101–7.
- Greulich WW, Pyle SI (Hrsg). *Radiographic atlas of skeletal development of hand and wrist*. 2nd ed. California: Stanford University Press; 1959.
- Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. *Eur J Endocrinol*. 1998;139:298–303.
- Morris DV, Adeniyi-Jones R, Wheeler M, Sonksen P, Jacobs HS. The treatment of hypogonadotropic hypogonadism in men by the pulsatile infusion of luteinising hormone-releasing hormone. *Clin Endocrinol*. 1984;21:189–200.
- Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 1988;67:1140–5.
- Schopohl J. Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. *Hum Reprod*. 1993;8:175–9.
- Conn PM, Crowley JR. Gonadotropin-releasing hormone and its analogues. *N Engl J Med*. 1991;324:93–103.
- Delemarre-van de Waal HA. Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism—diagnostic and therapeutic aspects. *Eur J Endocrinol*. 2004;151(Suppl 3):U89–94.
- Whitcomb RW, Crowley WF. Clinical review 4: diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men. *J Clin Endocrinol Metab*. 1990;70:3–7.
- Maddock WO, Nelson WO. The effects of chorionic gonadotropin in adult men: increased estrogen and 17-ketosteroid excretion, gynecomastia, Leydig cell stimulation and seminiferous tubule damage. *J Clin Endocrinol Metab*. 1952;12:985–1014.
- Siris ES, Nisula BC, Catt KJ, Horner K, Birken S, Canfield RE, Ross GT. New evidence for intrinsic follicle-stimulating hormone-like activity in human chorionic gonadotropin and luteinizing hormone. *Endocrinology*. 1978;102:1356–61.
- Matsumoto AM, Karpas AE, Bremner WJ. Chronic human chorionic gonadotropin administration in normal men: Evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man. *J Clin Endocrinol Metab*. 1986;62:1184–92.
- Tapanainen JS, Aittomaki K, Min J, Vaskivuo T, Huhtaniemi IT. Men homozygous for an inactivating

- mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. *Nat Genet.* 1997;15:205–6.
16. Lytton B, Kase N. Effects of human menopausal gonadotrophin on a eunuchoidal male. *N Engl J Med.* 1966;274:1061–4.
 17. Burgués S, Calderón MD. Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotropic hypogonadism. *Hum Reprod.* 1997;12:980–6.
 18. European Metrodin HP Study Group EMHSG. Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotrophin for treating men with isolated hypogonadotropic hypogonadism. *European Metrodin HP Study Group. Fertil Steril.* 1998;70:256–62.
 19. Kliesch S, Behre HM, Nieschlag E. Recombinant human follicle-stimulating hormone and human chorionic gonadotrophin for induction of spermatogenesis in a hypogonadotropic male. *Fertil Steril.* 1995;63:1326–8.
 20. Bouloux PM, Nieschlag E, Burger HG, Skakkebaek NE, Wu FC, Handelsman DJ, Baker GH, Ochsenukuehn R, Syska A, McLachlan RI, Giwercman A, Conway AJ, Turner L, van Kuijk JH, Voortman G. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotrophin alone. *J Androl.* 2003;24:604–11.
 21. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotrophin. *Fertil Steril.* 2009;92:594–604.
 22. Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, Spratt D, Brentzel J, O'Dea L. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f[®]): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. *Fertil Steril.* 2009;92:979–90.
 23. The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotrophin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. *J Clin Endocrinol Metab.* 2001;86:2607–18.
 24. Debate group: “Bye-bye urinary gonadotropins?” Matorra R, Rodriguez-Escudero F. “The use of urinary gonadotropins should be discouraged”. Crosignani PG. “Risk of infection is not the main problem”. Balen A. “Is there a risk of prion disease after the administration of urinary-derived gonadotropins?”. Dyer J. “The conflict between effective and affordable health care—a perspective from the developing world”. *Hum Reprod* 2002;17:1675–83.
 25. Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. *Cochrane Database Syst Rev.* 2015;7:CD009577.
 26. Bouloux PM, Handelsman DJ, Jockenhövel F, Nieschlag E, Rabinovici J, Frasa WL, de Bie JJ, Voortman G, Itskovitz-Eldor J. FSH-CTP study group. First human exposure to FSH-CTP in hypogonadotropic hypogonadal males. *Hum Reprod.* 2001;16:1592–97.
 27. Finkel DM, Phillips BA, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. *N Engl J Med.* 1985;313:651–5.
 28. Vicari E, Mongioi A, Calogero AE, Moncada ML, Sidoti G, Polosa P, D'Agata R. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotropic hypogonadism—long-term follow-up. *Int J Androl.* 1992;15:320–9.
 29. Mannaerts B, Fauser B, Lahlou N, Harlin J, Shoham Z, Bennink HC, Bouchard P. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism. *Fertil Steril.* 1996;65:406–10.
 30. Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. *Eur J Endocrinol.* 2007;156:105–11.
 31. Rey RA, Musse M, Venara M, Chemes HE. Ontogeny of the androgen receptor expression in the fetal and postnatal testis: its relevance on Sertoli cell maturation and the onset of adult spermatogenesis. *Microsc Res Tech.* 2009;72:787–95.
 32. Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, Dym M, Sluss PM, Crowley WF Jr, Pitteloud N. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2013;98:E1790–5.
 33. Barrio R, De Luis D, Alonso M, Lamas A, Moreno JC. Induction of puberty with human chorionic gonadotrophin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. *Fertil Steril.* 1999;71:244–8.
 34. Sinesi AA, Esposito D, Maione L, Quinto MC, Visconti D, De Bellis A, Bellastella A, Conzo G, Bellastella G. Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. *Hum Reprod.* 2008;23:1029–34.
 35. Zacharin M, Sabin MA, Nair VV, Dagabdhao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotrophin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular

- growth and may promote early spermatogenesis. *Fertil Steril*. 2012;98:836–42.
36. Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M, and the “German Adolescent Hypogonadotropic Hypogonadism Study Group”. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? A multicentre prospective study of hCG/hFSH treatment outcomes during adolescence. *Clin Endocrinol (Oxf)*. 2017;86:75–87.
 37. Shiraiishi K, Oka S, Matsuyama H. Assessment of quality of life during gonadotrophin treatment for male hypogonadotropic hypogonadism. *Clin Endocrinol (Oxf)*. 2014;81:259–65.
 38. Liu PY, Baker HWG, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. *J Clin Endocrinol Metab*. 2009;94:801–8.
 39. Rogol AD. Pubertal androgen therapy in boys. *Pediatr Endocrinol Rev*. 2005;3:383–90.
 40. Bouloux P, Warne DW, Loumaye E. Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. *Fertil Steril*. 2002;77:270–3.
 41. Johnsen SG. Maintenance of spermatogenesis induced by hMG treatment by means of continuous hCG treatment in hypogonadotropic men. *Acta Endocrinol*. 1978;89:763–9.
 42. Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with hCG alone. *Eur J Endocrinol*. 2002;147:617–24.
 43. Sokol RZ, McClure RD, Peterson M, Swerdloff RS. Gonadotropin therapy failure secondary to human chorionic gonadotropin-induced antibodies. *J Clin Endocrinol Metab*. 1981;52:929–33.
 44. Claustrat B, David L, Faure A, Francois R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. *J Clin Endocrinol Metab*. 1983;57:1041–7.
 45. Thau RB, Goldstein M, Yamamoto Y, Burrow GN, Phillips D, Bardin CW. Failure of gonadotropin therapy secondary to chorionic gonadotropin-induced antibodies. *J Clin Endocrinol Metab*. 1988;66:862–7.
 46. Ogura T, Mimura Y, Otsuka F, Kishida M, Yokota K, Suzuki J, Nagai A, Hirakawa S, Makino H, Tobe K. Hypothyroidism associated with anti-human chorionic gonadotropin antibodies secondarily produced by gonadotropin therapy in a case of idiopathic hypothalamic hypogonadism. *J Endocrinol Invest*. 2003;26:1128–35.
 47. World Health Organisation. (WHO) Laboratory Manual for the Examination and Processing of Human Semen. 5th ed. Geneva, Switzerland: World Health Organization; 2010.
 48. Quinton R, Cheow HK, Tymms DJ, Bouloux PM, Wu FC, et al. Kallmann’s syndrome: is it always for life? *Clin Endocrinol (Oxf)*. 1999;50:481–5.
 49. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, et al. Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med*. 2007;357:863–73.
 50. Laitinen EM, Tommiska J, Sane T, Vaaralahti K, Toppari J, Raivio T. Reversible congenital hypogonadotropic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations. *PLoS One*. 2012;7:e39450.
 51. Tommiska J, Jørgensen N, Christiansen P, Juul A, Raivio T. A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as reversal of hypogonadotropic hypogonadism and late-onset hypogonadism. *Clin Endocrinol (Oxf)*. 2013;78:316–7.
 52. Sidhoum VF, Chan YM, Lippincott MF, Balasubramanian R, Quinton R, et al. Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system. *J Clin Endocrinol Metab*. 2014;99:861–70.
 53. Nieschlag E, Vorona E. Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. *Eur J Endocrinol*. 2015;173:47–58.
 54. Tenforde AS, Barrack MT, Nattiv A, Fredericson M. Parallels with the female athlete triad in male athletes. *Sports Med*. 2015. (Epub ahead of print).
 55. Nieschlag E. Clinical trials in male hormonal contraception. *Contraception*. 2010;82:457–70.
 56. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Hormonal Male Contraception Summit Group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. *Lancet*. 2006;367:1412–20.
 57. Cicero TJ, Meyer ER, Bell RD, Wiest WG. Effects of morphine on the secondary sex organs and plasma testosterone levels of rats. *Res Commun Chem Pathol Pharmacol*. 1974;7:17–24.
 58. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. *J Pain*. 2002;3:377–84.
 59. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. *Cancer*. 2004;100:851–8.
 60. Rohayem J, Sinthofen N, Nieschlag E, Kliesch S, Zitzmann M. Causes of hypogonadotropic hypogonadism predict response to gonadotropin substitution in adults *Andrology*. 2016;4:87–94.
 61. Pitteloud N, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, Crowley WF Jr. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2002;87:152–60.
 62. Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with

- isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. *J Endocrinol Metab.* 1988;66:1144–51.
63. Mengel W, Hienz HA, Sippe WG, Hecker WC. Studies on cryptorchidism: a comparison of histological findings in the germinative epithelium before and after the second year of life. *J Pediatr Surg.* 1974;9:445–50.
 64. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2002;87:4128–36.
 65. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, Takeyama M, Fujioka H, Takada S, Koide T, Okuyama A. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. *J Urol.* 2005;173:2072–5.
 66. Jones TH, Darne JF. Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotropic hypogonadism. *Clin Endocrinol (Oxf).* 1993;38:203–8.
 67. Ley SB, Leonard JM. Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. *J Clin Endocrinol Metab.* 1985;61:746–52.
 68. Liu PY, Gebiski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. *Hum Reprod.* 2002;17:625–33.
 69. Bakircioglu ME, Erden HF, Ciray HN, Bayazit N, Bahçeci M. Gonadotrophin therapy in combination with ICSI in men with hypogonadotropic hypogonadism. *Reprod Biomed Online.* 2007;15:156–60.
 70. Frapsauce C, Ravel C, Legendre M, Sibony M, Mandelbaum J, Donadille B, Achermann JC, Siffroi JP, Christin-Maitre S. Birth after TESE-ICSI in a man with hypogonadotropic hypogonadism and congenital adrenal hypoplasia linked to a DAX-1 (NR0B1) mutation. *Hum Reprod.* 2011;26:724–8.
 71. Sarfati J, Bouvattier C, Bry-Gauillard H, Cartes A, Bouligand J, Young J. Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life. *Orphanet J Rare Dis.* 2015;10:71.

Index

Note: Page numbers followed by *f* and *t* refer to figures and tables respectively

A

- Absent testis, 199
- Acquired cryptorchidism, 199
- Acquired hypogonadotropic hypogonadism, non-tumorous causes of
 - diagnosis, 182
 - physiopathology of
 - aneurysms, 181
 - arachnoid cyst, 181
 - empty sella, 181
 - head trauma, 182
 - mucocoeles, 181
 - non-neoplastic diseases, 180
 - pituitary apoplexy results, 181
 - therapy, 182
- Acromegaly
 - diagnosis, 174
 - dopamine agonists, 175
 - hypogonadism, physiopathology of, 173
 - Lanreotide Autogel, 175
 - medical therapy, classes of, 175
 - pegvisomant, 175
 - radiation therapy, 175
 - SRS, 175
 - trans-sphenoidal adenomectomy, 175
- Acute lymphoblastic leukaemia (ALL), 239
- Acute myeloid leukaemia (AML), 239
- Adolescence, 100
- Adrenocorticotrophic hormone (ACTH), 33
- Adult Leydig cells, 28
- Aging, 34–36
- Aging-related hypoandrogenemia, men
 - androgen deficiency, 325
 - hypothalamo-pituitary Leydig cell axis
 - accelerated LH pulse frequency, 332–334
 - appraising testosterone signaling, 337, 340
 - GnRH, gonadotrope responsiveness, 332
 - monitoring unobserved gonadotropin secretion, 334–336
 - pulses, sampling and counting of, 332
 - regularity analysis, 337
 - mediating low-amplitude LH secretion, GnRH deficiency in, 326–328
 - primary Leydig-cell steroidogenic failure, 328–329
 - testosterone feedback restraint alterations in, 329–331
 - Alcoholic liver disease (ALD)
 - bidirectional nature of, 223
 - categories, 223
 - ethanol, 224
 - histologic stages, 222
 - periphery, 224
 - risk factor, 222
- American Association for the Study of Liver Diseases (AASLD), 225
- Anabolic-androgenic steroids (AAS)
 - actions, mechanism of, 270
 - anabolic substances, 272–273
 - anti-catabolic actions, 270
 - drug-testing programs, 273
 - erythropoietic effects, 270–271
 - organic androgen deficiency, 273–274
 - physiologic adaptation and exercise performance, 269–270
 - psychological effects, 271
 - steroid hormone receptors, 270
 - usage
 - prevalence of, 272
 - side effects of, 271–272
 - WADA, 273, 274
- Androgen-binding protein, 311
- Androgen deprivation therapy (ADT), 358
- Androgen receptor knockout mice (ARKO), 357
- Androgen receptors (AR), 11, 61
- Androgen replacement therapy
 - androgen preparations
 - and delivery systems, 383*t*
 - implants, 386
 - injectables, 383–384
 - lotion and patches, 385–386
 - oral, 384
 - SARMs, 386–387
 - transdermal gels, 385–386
 - transmucosal preparations, 386
 - benefits and risks
 - BMD, 372
 - body composition, 373
 - cardiovascular disease risk, 375–380
 - cognitive function, 372
 - hematocrit, 381–382

hemoglobin, 381–382
 lipid profile, 374–375
 liver function tests, 381–382
 metabolic parameters, 374
 mood and well-being, 371
 possible adverse effects, 382
 prostate disease, 380–381
 sexual function, 370–371
 bioavailable T, 369
 contraindications, 370
 digital rectal examination and PSA, 370
 goal of, 387
 serum free T, 369
 SHBG levels, 368–369
 T prescription rate, 368
Androgen synthesis
 alternative pathway, 30
 canonical pathway, 29
Aneuploidy, 193
Anogenital distance (AGD), 292
Anorchia, 199
Anosmia, 99
Anti-Müllerian hormone (AMH), 32, 97
Aromatase inhibitors (AIs), 87
Ascended testis, 198–199
Assisted reproductive techniques (ART), 164, 240
Athletes and anabolic-androgenic steroids
 actions, mechanism of, 270
 anabolic substances, 272–273
 anti-catabolic actions, 270
 drug-testing programs, 273
 erythropoietic effects, 270–271
 organic androgen deficiency, 273–274
 physiologic adaptation and exercise performance, 269–270
 psychological effects, 271
 steroid hormone receptors, 270
 usage
 prevalence of, 272
 side effects of, 271–272
 WADA, 273, 274
Autoimmune disease, 191, 192
Azoospermia, 189

B

Bariatric surgery, 64
Benefits and risks, of androgen replacement therapy
 BMD, 372
 body composition, 373
 cardiovascular disease risk, 375–380
 cognitive function, 372
 hematocrit, 381–382
 hemoglobin, 381–382
 lipid profile, 374–375
 liver function tests, 381–382
 metabolic parameters, 374
 mood and well-being, 371
 possible adverse effects, 382

 prostate disease, 380–381
 sexual function, 370–371
Bilateral adrenalectomy, 178
Blood–testis barrier (BTB), 52–53
Bone disorders, 415
Bone mineral density (BMD), 228, 372
Bromocriptine mesylate, 172

C

Cancer treatment
 genetic damage, cytotoxic therapy, 244
 and gonadal function, 237
 and hypothalamic-pituitary function, 238
 Leydig cell function
 chemotherapy, 241–242
 clinical impact of, 243–244
 radiotherapy and, 242–243
 males fertility preservation for
 ex vivo techniques, 246–248
 hormonal therapy for, 245–246
 male germ cell differentiation in vitro, 248–249
 semen cryopreservation and assisted reproduction, 244–245
 and spermatogenesis, 238
 chemotherapy-induced damage, 238–239
 irradiation-induced damage to, 241–242
 spermatogenetic failure, 239–240
Cardiovascular disease, 305
Catastrophic effects, 285
Central precocious puberty (CPP), 79
Chemical exposures, 283, 294
Chicken Ovalbumin Upstream Promoter-TF1 (COUP-TF1), 313
Chronic kidney disease
 EPO, 412, 413
 hypogonadism, 410
 nandrolone therapy, 412
 non-pharmacological interventions, 412
 oxymethenolone therapy, 412
 physiological studies, 412
 quadriceps muscle, 412
Chronic liver disease (CLD), 219
Chronic obstructive pulmonary disease (COPD), 400–402
Coloboma, Heart defects, choanal Atresia, Retardation of
 growth and development, Gonadal defects, and
 Ear/hearing abnormalities (CHARGE syndrome), 98, 112, 114, 115
 gonadal defect in, 112
Compensated Leydig cell failure, 293, 294
Computerized tomography (CT), 171
Congenital adrenal hyperplasia (CAH) males
 genetics, 154–155
 hypogonadism
 hypergonadotropic, 162
 hypogonadotropic, 161–162
 males, fertility in
 21-hydroxylase deficiency, 155
 subfertility in, causes of, 155

- presentation and diagnosis, 154
 - prevalence, 154
 - subfertility, causes of
 - compliance, 163
 - psychological factors, 163
 - testicular abnormalities, 162
 - testicular volume in, 162
 - transition, 163
 - subfertility, treatment of
 - genetic counseling, 164
 - hypogonadism, 163
 - testicular adrenal rest tumors (*see also* Testicular adrenal rest tumors (TART))
 - diagnosing, 156–157
 - histopathology, 157–158
 - influence, 161
 - origin of, 159–160
 - prevalence of, adult, 156
 - steroid production, 158–159
 - testicular tumors in, 161
 - therapeutic control, 161
 - Congenital cryptorchidism, 198
 - Congenital hypogonadotropic hypogonadism (CHH)
 - complex syndromic forms of, 114–115
 - congenital KS and NCHH, genetics of
 - anosmin-1, 105, 106
 - CCDC141, 107, 108
 - CHARGE syndrome, 112
 - CHD7, 112, 113
 - EMX1, 113
 - FEZF1, 107, 108
 - FGF8, 111
 - FGF17, 111–112
 - FGFR1, 111
 - GNRH1 gene, 109
 - GNRHR, 108, 109
 - HS6ST1, 112
 - IL17RD, 107
 - inheritance, patterns of, 104–105
 - KISS1, 110
 - KISS1R, 109–110
 - NSMF, 114
 - Plexin D1-dependent, 108
 - PROK2/PROKR2 mutations, 113–114
 - semaphorin 3A, 106–107
 - semaphorin 3E, 108
 - SOX10, 106
 - TAC3/TACR3 pathway, 109–110
 - WDR11, 113
 - WS, 106
 - X-KS, 105
 - evaluation of, 116–117
 - GnRH deficiency, 98, 99
 - hypogonadotropic hypogonadism
 - critical illness, 116
 - functional cause of, 115
 - human male, normal sexual development in
 - GnRH secretion, ontogeny of, 95–97
 - normal gonadal development, 97–98
 - idiopathic hypogonadotropic hypogonadism
 - clinical features, 99
 - definition and incidence, 99
 - Kallmann syndrome, 98
 - non-reproductive features of, 101
 - pathophysiology of
 - biochemical studies, 102–103
 - GnRH secretion, patterns of, 103–104
 - reproductive features of
 - adolescence, 100
 - neonatal period, 99–100
 - variant forms of
 - adult-onset, 102
 - fertile eunuch syndrome, 101–102
 - reversal of, 102
 - Congestive heart failure (CHF), 400
 - Constitutional delay of puberty (CDGP), 429
 - Coronary artery disease (CAD), 403
 - Cortisol, 158
 - Cryptorchidism
 - definitions, 198–199
 - evaluation and treatment guideline, 205
 - germ cell counts, 208
 - hormone production and sexual development, 206–207
 - incidence of, 199
 - infertility, 208
 - paternity and related factors, 209–210
 - prevalence of, 199
 - spermatogenesis, 208–209
 - treatment and fertility, age of, 208
 - C-terminal peptide, 310
 - GnRH, 1 (*see also* Gonadotropin-releasing hormone (GnRH))
 - intracellular tail, 4
 - Cushing's disease
 - bilateral adrenalectomy, 178
 - diagnosis, 176–177
 - hypogonadism, physiopathology of, 176
 - medical therapies, 178
 - TCS, 177
 - trans-sphenoidal adenomectomy, 177
 - Cyclic adenosine monophosphate (cAMP), 130
- D**
- Decellularized testicular matrix (DTM), 249
 - Decontamination strategies, 248
 - Dehydroepiandrosterone (DHEA), 8, 9, 272
 - Delayed puberty (DP)
 - diagnosis, 84–85
 - HH, 83–84
 - hypergonadotropic hypogonadism, 84
 - male
 - AIs, 87
 - epiphyseal closure, 86
 - ISS, 86, 87
 - low-dose testosterone, 85
 - medications, 85, 86f

therapeutic indications, 85
 presentation, 82
 self-limited, 82–83
 Desert Hedgehog (DHH), 31
 Diacylglycerol (DAG), 6
 Dibromochloropropane (DBCP), 285, 286
 Dihydrotestosterone (DHT), 10, 221
 Disordered sex development (DSD), 30
 Doping, 258
 Dual energy X-ray absorptiometry (DEXA), 375
 Dynorphin (DYN), 3

E

Ectopic testis, 199
 Endocrine signals, 15
 Endocrine-disrupting chemicals (EDCs), 76
 Epidermal growth factor receptor (EGFR), 33
 Erythropoietin (EPO), 412–414
 Estradiol-17 β , 61, 62
 Estrogens, 357
 Ethane dimethane sulfonate (EDS), 38
 Exercise

- athletes and anabolic-androgenic steroids
 - AAS usage, prevalence of, 272
 - actions, mechanism of, 270
 - anabolic substances, 272–273
 - anti-catabolic actions, 270
 - drug-testing programs, 273
 - erythropoietic effects, 270–271
 - organic androgen deficiency, 273–274
 - physiologic adaptation and exercise performance, 269–270
 - psychological effects, 271
 - steroid hormone receptors, 270
 - usage, side effects of, 271–272
 - WADA, 273, 274
- characteristics, 258
- endocrine reproductive disturbance, 258
- exercise-hypogonadal males
 - athletes, low testosterone levels in, 266–268
 - basal hormonal responses, 262–263
 - cortisol, 266
 - gonadotropins, 263–264
 - mechanistic studies, 264–265
 - reproductive hormones, 263–264
 - testosterone, 263–264
- factors affecting circulating testosterone
 - cardiovascular factors, 260
 - hypothalamic-pituitary-testicular axis, 259–260
 - physiological and non-physiological factors, 260
- normal men, exercise responses
 - gonadotrophins, 262
 - pituitary hormone, prolactin, 262
 - testosterone, 260–262
- overtraining syndrome
 - consequences and symptoms of, 268, 268*t*
 - EHMC, 268, 269
- physiological system, 258

testosterone, physiological actions of

- anabolic effects, 259
- androgenic effects, 259
- categories, 259

 Exercise-hypogonadal male condition (EHMC), 258
 Extracellular matrix (ECM), 54

F

Familial male-limited precocious puberty (FMPP), 139
 Fertile eunuch syndrome, 101–102
 Fetal Leydig cells, 27
 Follicle stimulating hormone (FSH), 34, 425

- β subunit (*see* FSH β subunit (FSHB))
- regulate spermatogenesis, 59

 Follicle-stimulating hormone receptor (FSHR)

- activating mutations, 142–143
- inactivating mutations, 140–142
- polymorphisms, 143–144

 FOS proto-oncogenes, 16
 Free hormone hypothesis, 353
 FSH β subunit (FSHB)

- mutations, 136–137
- polymorphisms, 137–138

G

G protein-coupled receptors (GPCRs), 129
 Genetic polymorphism, 318
 Genome-wide association studies (GWAS), 315
 Germ cells, 50
 Glucocorticoid therapy, 163
 Golgi region, 58
 Gonadal-suppressive therapy, 246
 Gonadotropin

- receptors, 129–131
 - activating receptor mutations, 138
 - FSHR mutations, 140–143
 - inactivation, 138
 - LHCGR mutations, 138–140
 - polymorphisms, 143–144
- secretion and actions, 131–132
- subunits, 128–129
 - CGA, 132
 - CGB, 134
 - FSHB polymorphisms, 137–138
 - FSHB, mutations, 136–137
 - LHB mutations, 134–135
 - LHB polymorphisms, 135–136

 Gonadotropin-inhibiting hormone (GnIH), 4
 Gonadotropin-releasing hormone (GnRH)

- activin, 12–13
- α -subunits, 5
- C-terminal intracellular tail, 4
- FSH, 14–15
- gonadotropic hormones, 6–7
- gonadotropin secretion, testicular control of
 - estradiol treatment, 11, 12*f*
 - kisspeptin neurons, 12

LH and FSH levels, 11
 negative feedback control, 10, 11f
 homologous desensitization, 6
 inhibin, 13–15
 LH- β and FSH- β gene expression, 15–16
 long-term stimulatory effects of, 5
 males, estrogens in, 9–10
 mediating low-amplitude LH secretion, 326–328
 ontogeny of, 95–97
 I2PP2A, 6
 puberty, central control of
 glial cells, 80
 KISS1, 79
 kisspeptin signals, 79–80
 neurokinin B, 80
 NPY, 81
 pulsatile gonadotropin secretion, 7–8
 synthesis and secretion
 axons, 1
 GnIH, 4
 GnRH mRNA levels, 2
 GnRH pulse generator, 2
 hypophysiotropic peptides, 2
 kisspeptin neurons, 2, 3
 KNDy, synchronous activity of, 3
 testosterone synthesis, LH control of
 cAMP-dependent PKA, 9
 17 α -hydroxypregnenolone, 8
 intratesticular testosterone concentrations, 9
 Leydig cells, 9
 StAR, 9
 Growth hormone (GH), 82, 173
 -releasing hormone (GH-RH), 173
 Gynecomastia, 187, 190

H

Heart diseases
 coronary artery disease, 404–406
 systolic heart failure, 403–404
 Hematopoietic stem cell transplantation (HSCT), 237
 Hepatocyte nuclear factor4 α (HNF4 α), 313
 HIV/AIDS
 aromatizable androgens, 406, 408t
 nonaromatizable androgens, 406, 409t
 randomized placebo-controlled trials, 406
 testosterone
 gel therapy, 407
 production, 406
 Hodgkin's disease (HD), 236
 Human chorionic gonadotropin (hCG), 127, 132–134, 220, 425
 Human Leydig cell
 clinical aspects
 aging of, 34–36
 toxicology, 38
 tumors, 36–38
 development
 adult, 28

 fetal, 27
 fetal population, 26
 neonatal, 27–28
 post-natal testosterone surge, 27
 predominant cytoplasmic organelle, 26
 testosterone levels, 26
 regulation of
 activity, 32–34
 development, 31–32
 steroidogenic function of
 androgen secretion, 30–31
 androgen synthesis, 29–30
 estrogen synthesis, 30
 INSL3, 31
 principal function, 30
 Human spermatogenesis
 AR, 61
 cellular events, 49
 epithelial cycle of, 58–59
 estrogen, 62–62
 FSH, 59
 hormonal regulation, 59
 ITT microenvironment, 60–61
 LH, 59–60
 obesity
 bariatric surgery, 64
 disruptive effects of, 63
 SHBG level, 63
 seminiferous epithelium, structure and composition of
 BTB, 52–53
 germ cells, 50
 Sertoli cells, 50–53
 spermatids and spermiogenesis, 58
 spermatocytes and meiosis, 56–58
 spermatogonia and self-renewal, 54–56
 testis, cell–cell interactions in, 53–54
 sncRNAs, 62–63
 Human testicular function, 132
 11-Hydroxylated steroids, production of, 159
 17-Hydroxyprogesterone, 159
 Hyperglycemia, 313
 Hypogonadism, 4
 Hypogonadotropic hypogonadism (HH), 81, 83–84
 CAH males, 161–162
 central hormone replacement strategies, therapeutic
 outcome of
 factors influencing response, 432
 GnRH vs. gonadotropins, 431–432
 pregnancy outcomes, 432–433
 CHH (*see* Congenital hypogonadotropic hypogonadism (CHH))
 critical illness, 116
 functional cause of, 115
 pretreatment diagnostic workup, 424
 spermatogenesis, stimulation of
 caveats during hormone replacement, 430–431
 GnRH replacement, 424–425
 gonadotropin (hCG/FSH) replacement, 425–430
 monitoring, 430

- Hypothalamic-pituitary-testicular (HPT) axis, 201, 357
dysfunction, 355–356
- Hypothalamo-pituitary Leydig cell axis
accelerated LH pulse frequency, 332–334
appraising testosterone signaling, 337, 340
GnRH, gonadotrope responsiveness, 332
monitoring unobserved gonadotropin secretion
deconvolution procedures, 334
fourth-generation deconvolution strategy, 336
second-generation deconvolution technology, 336
third-generation deconvolution strategy, 336
waveform-dependent concept, 334
pulses, sampling and counting of, 332
regularity analysis, 337
- Hypothalamus–pituitary–gonadal (HPG) axis, 77, 95, 220
- I**
- Idiopathic hypogonadotropic hypogonadism (IHH), 83
- Idiopathic short stature (ISS), 86
- Inhibin-B, 14–15, 77–78
- Insulin-like growth factor (IGF)-1, 259
- Insulin resistance, 357
- Interleukin (IL), 220
- Intracytoplasmic sperm injection (ICSI), 193, 244
- Intratesticular testosterone (ITT) microenvironment, 60–61
- I2PP2A. *See* Proto-oncogene SET
- J**
- JUN proto-oncogenes, 16
- K**
- Kallmann syndrome (KS), 98, 99, 432
X-KS, 105
- Kisspeptin, 79
neurons, 2, 3, 12
signals, 79–80
- Klinefelter syndrome (KS), 30
clinical features of, 190–191
diagnosis of, 192
historical description of, 188
and infertility, 193
morbidity associated, 191–192
pathophysiology of
chromosomal analysis, 188
hormonal axis, 189
microarray analysis, 189
testicular biopsy specimens, 189
primary hypogonadism, forms of, 193–194
primary testicular failure, 187
testosterone therapy, 192–193
- KNDy neurons, 80
- L**
- Lacto-bacillus reuteri*, 290
- Late-onset hypogonadism (LOH), 132
hypogonadism and mortality, 359–360
obesity-related testosterone decline and potential underlying mechanisms
ARKO mice, 357
estrogens, 357
HPT axis dysfunction, 355–356
insulin resistance, 357
leptin, 356
prostate cancer, ADT for, 358
sarcopenic obesity, 358
TNF α , 356–357
- testosterone and aging
diagnosis of, 351–354
morphological and functional alterations, 350
testosterone declines, 350–353
TRT and obesity, 358–359
- Leptin, 356
- Leydig cell
adult, 28
clinical aspects
age-related declines, 35–36
tumors, 36–38
toxicology, 38
fetal, 27
fetal population, 26
neonatal, 27–28
post-natal testosterone surge, 27
predominant cytoplasmic organelle, 26
regulation
activity, 32–34
adult Leydig cell differentiation, 32
androgen receptors, 32
DHH and PDGFA, 31
LH receptor, 32
Sertoli cells, 31, 32
steroidogenic function of
androgen secretion, 30–31
androgen synthesis, 29–30
estrogen synthesis, 30
INSL3, 31
principal function, 30
testosterone levels, 26
- Leydig cell function
chemotherapy, 241–242
clinical impact of, 243–244
radiotherapy and, 242–243
- Leydig cell hyperplasia, 38–39
- Leydig cell tumors (LCTs), 139
- LH β subunit (LHB)
mutations, 134–135
polymorphisms, 135–136
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS), 353

- Liver disease
 alcoholic liver disease
 bidirectional nature of, 223
 categories, 223
 ethanol, 224
 histologic stages, 222
 periphery, 224
 risk factor, 222
 diagnosis, 228–229
 end-stage, hypogonadism in
 BMD, 228
 cirrhosis, 227
 testosterone levels, 228
 hemochromatosis
 C282Y polymorphism, 222
 HH, 221
 iron deposition, 222
 phlebotomy, 222
 hepatitis B/C, 224–225
 NAFLD
 aromatase, 226
 Leydig cell function, 226
 metabolic syndrome, 226
 TNF α and IL1 β , 227
 pathophysiology, 220–221
 testosterone treatment, 229–230
 Loss-of-function (LOF), 107
 Lower urinary tract obstructive symptoms (LUTS), 381
 Luteinizing hormone (LH), 32
 differential control of, neuroendocrine mechanisms, 15–16
 testosterone
 production, 59–60
 synthesis, control of, 8–9
 Luteinizing hormone/choriogonadotropin receptor (LHCGR) mutations, 59
 activating mutations, 139–140
 inactivating mutations, 138–139
- M**
 Magnetic resonance (MR), 171
 Male
 CHH (*see* Congenital hypogonadotropic hypogonadism (CHH))
 exercise (*see* Exercise)
 HH (*see* Hypogonadotropic hypogonadism (HH))
 hypogonadism and liver disease (*see* Liver disease)
 hypogonadism (*see* Androgen replacement therapy)
 CAH (*see* Congenital adrenal hyperplasia (CAH))
 fertility preservation for
 ex vivo techniques, 246–248
 hormonal therapy for, 245–246
 male germ cell differentiation in vitro, 248–249
 semen cryopreservation and assisted reproduction, 244–245
 Masculinization programming window (MPW), 292
 Mediobasal hypothalamus (MBH), 2
 Metabolic clearance rate (MCR), 260
 Metabolic syndrome (MetS), 317
 prevalence of, 305
 risk factor for, 306
 Methyl 19 nor-testosterone (MENT), 386
 Microbiome, 290
 Mineralocorticoids, 163
 Muscle disorders, 415
- N**
 National Health and Nutrition Examination Survey (NHANES), 219
 Nelson's syndrome, 178
 Neonatal Leydig cells, 27–28
 Neurokinin B (NKB), 110
 Neuropeptide Y (NPY), 81
 Neuropeptides neurokinin B (NKB), 3
 Nonalcoholic fatty liver disease (NAFLD), 225–227, 314
 Non-functioning/gonadotroph adenomas
 diagnosis, 178
 gonadotropin therapy, 179
 hypogonadism, physiopathology of, 178
 trans-sphenoidal resection, 179
 Non-Hodgkin lymphoma (NHL), 239
 Non-obstructive azoospermia (NOA), 58, 61
 Non-pituitary sellar and parasellar tumors
 diagnosis, 180
 hypogonadism, physiopathology of, 179–180
 radiotherapy, 180
 Normal puberty
 clinical markers of, 73
 endocrine changes
 GnRH upstream pathways, 78–82
 gonadotropin-releasing hormone and gonadotropins, 77
 sex steroids and inhibin-B, 77–78
 physiology, 73
 timing of
 EDCs, 76
 epigenetic regulators, 76
 near-normal distribution, 74
 nutritional changes, 75
 PHV, 74
 Normosmic CHH (nCHH), 99. *See also* Congenital hypogonadotropic hypogonadism (CHH)
 N-terminal peptide, 105, 113, 129, 310
- O**
 Obesity
 bariatric surgery, 64
 disruptive effects of, 63
 SHBG level, 63
 Obstructive azoospermia (OA), 61
 Obstructive sleep apnea, 402–403
 Oligozoospermia, 245
 Orchidopexy, 199, 205
 Organic androgen deficiency, 273
 Oxymethenolone therapy, 412

Overtraining syndrome
 consequences and symptoms of, 268, 268r
 EHMC, 268, 269

P

Paternity, 209
 Peak height velocity (PHV), 74
 Periodic acid Schiff's reaction (PAS), 58
 Pharmacokinetics (PK), 383
 Pituitary adenylate cyclase-activating polypeptide (PACAP), 16
 Platelet-derived growth factor- α (PDGFA), 31
 Polycystic ovarian syndrome (PCOS), 316
 Pregnenolone, 29
 Pre-treatment testicular dysfunction
 HD, 236
 paediatric malignancies, 236–237
 testicular cancer, 236
 Primordial germ cells (PGCS), 200
 Progressive resistance training (PRT), 402, 410
 Prolactinomas
 bromocriptine mesylate, 172
 cabergoline, 172
 diagnosis, 171
 hypogonadism, physiopathology of, 169–171
 quinagolide, 172
 transsphenoidal/endoscopic transnasal approach, 172
 Prostate specific antigen test (PSA), 370
 Proto-oncogene SET, 6
 Puberty
 central control of
 glial cells, 80
 KISS1, 79
 kisspeptin signals, 79–80
 neurokinin B, 80
 NPY, 81
 DP (*see* Delayed puberty (DP))
 normal (*see* Normal puberty)

Q

Quality of life, 187, 243, 371, 410
 androgen therapy in HIV/AIDS, 406
 sexual, 400

R

Randomized clinical trial (RCT), 354
 Rathke's cleft cysts, 179
 Reactive oxygen species (ROS), 225
 Recovery, 239
 Reinke's crystals, 36
 Reproduction, 9, 13
 Respiratory diseases
 COPD, 400–402
 obstructive sleep apnea, 402–403
 Retinoic acid (RA), 56
 Retractable testis, 199

S

Sarcopenic obesity, 358
 Scrotal cooling, 287
 Sedentary lifestyle, 288
 Selective androgen receptor modulators (SARMs), 386–387
 Sertoli cells
 ARs, 54, 61
 Dicer, deletion of, 63
 diphtheria toxin receptor, 54
 FSH, 59
 Leydig cell function, 53
 phases, 50
 P-Mod-S, 54
 Sex hormone binding globulin (SHBG), 30, 63, 173
 androgen and estrogen action, regulator of
 healthy adults, 312
 hyperglycemia, 313
 NAFLD, 314
 NHR family, 314
 plasma levels of, 307
 plasma, reductions in, 311, 312
 PPAR γ , 314
 structure and function of, 308–311
 tissue specific expression, 310–311
 transcription unit, 313–314
 clinical and epidemiological studies, 306
 disease etiology, biomarker/agent, 316–317
 free testosterone measurements, 317
 IR, 306
 polymorphism, 314–315
 Sex-steroid negative feedback, 329
 Short stature homeobox (SHOX), 190
 Single nucleotide polymorphisms (SNPs), 62
 Small non-coding RNAs (sncRNAs), 62–63
 Smooth endoplasmic reticulum (SER), 26
 Sperm counts, 208, 284
 Spermatogenesis, stimulation of
 caveats during hormone replacement
 CDGP and CHH reversal, misdiagnosis of, 430–431
 HPG axis suppression/inhibition, 431
 GnRH replacement, 424–425
 hCG/FSH replacement
 adult-onset, 430
 post-pubertal-onset, hormone replacement in, 429–430
 prepubertal-onset, hormone replacement in, 426, 429
 prepubertal-onset, testosterone-virilized adolescents with, 429
 testosterone-naive prepubertal patients, 429
 monitoring, 430
 Spermatogenesis
 spermatogenetic failure
 after testicular cancer, 240
 haematological malignancy, after treatment of, 239–240
 germinal epithelium
 chemotherapy-induced damage, 238–239

irradiation-induced damage to, 241–242
 Spermatogonial stem cells (SSCs), 238
 Stem cell factor (SCF), 54
 Stereotactic radiation surgery (SRS), 175
 Steroid acute regulator (STAR), 29
 Steroidogenesis
 androgen secretion, Leydig cells/testis, 30–31
 androgen synthesis
 alternative pathway, 30
 canonical pathway, 29
 estrogen synthesis, 30
 Steroidogenic acute regulatory (StAR), 9
 Stress, 258, 274
 Subfertility, in CAH males
 causes of
 compliance, 163
 psychological factors, 163
 testicular abnormalities, 162
 testicular volume in, 162
 transition, 163
 treatment of
 genetic counseling, 164
 hypogonadism, 163
 Suprachiasmatic nuclei (SCN), 114

T
 Taurodontism, 192
 Testicular adrenal rest tumors (TART)
 diagnosing, 156–157
 histopathology, 157–158
 influence, 161
 origin of, 159–160
 prevalence of
 adult, 156
 children and adolescents, 156
 steroid production, 158–159
 testicular tumors in, 161
 therapeutic control, 161
 Testicular dysfunction
 adult male, environmental/lifestyle effects on
 DBCP, 285
 DDT/DDE, 286
 Lacto-bacillus reuteri, 290
 obesity, 289
 occupational effects, 284–285, 287
 pesticide exposure and sex hormone levels, 286
 psychological stress, 291
 scrotal temperature, 288
 seasonal effects, 283–284
 underweight and overweight, 289
 vigorous exercise, 291
 visceral obesity, 290
 western style diet, 290
 endocrine disruptors, 282
 falling sperm counts, 282
 TDS and masculinization programming window
 AGD, 293

 endocrine-active, 294
 Leydig cell function, 293
 MPW, 292
 negative findings, 295
 pesticides, 295, 296
 Testicular dysgenesis syndrome (TDS), 236
 Testis, 14, 30–31
 Testis-sparing surgery, 36
 Testosterone, 159
 Testosterone replacement therapy (TRT), 273, 354, 358–359
 Testosterone undecanoate (TU), 384
 Testotoxicosis, 139
 Thyrotroph-stimulating hormone (TSH), 6, 128
 Trans-buccal system, 386
 Transcranial surgery (TCS), 177
 Tumor necrosis factor (TNF), 314
 alpha (TNF α), 356–357
 Type 2 diabetes mellitus (T2DM), 305

U

Undescended testis
 ascended testis, 203–204
 clinical evaluation
 laboratory testing, 205
 physical examination, 204–205
 cryptorchidism, consequences of
 germ cell counts, unilateral and bilateral, 208
 hormone production and sexual development, 206–207
 infertility, 208
 paternity and related factors, 209–210
 spermatogenesis, 208–209
 treatment and fertility, age of, 208
 definitions, 198–199
 epidemiology, 199–200
 germ cell development and congenitally cryptorchid testis, 202–203
 hormonal treatment, 206
 normal development and descent
 hormonal role, 201–202
 PGCS, 200
 Sertoli cells, 200
 testicular descent, 200–201
 testicular development, 200
 surgical treatment, 205
 testicular cancer
 case-control study, 211
 meta-analysis, 211
 orchidopexy, tumors and age, 211
 risk, 210, 211

V

Very small embryonic-like stem cells (VSELs), 247
 Visceral obesity, 290

W

Waardenburg syndrome (WS), [106](#)
Western style diet, [290](#)
White adipose tissue (WAT), [80](#)
Whole exome sequencing (WES), [107](#)
Wild-type (WT) receptor, [127](#)
Wilm's tumor gene (WT1), [31](#)
World Anti-Doping Association (WADA), [273](#)

X

X chromosome, additional, [188](#), [189](#)
X-linked ANOS1 mutations, [111](#)
X-linked recessive inheritance, [105–106](#)

Y

Young children, mini puberty, [77](#)
Young men, with HH, [283](#), [291](#)